<SEC-DOCUMENT>0001077183-22-000173.txt : 20221108
<SEC-HEADER>0001077183-22-000173.hdr.sgml : 20221108
<ACCEPTANCE-DATETIME>20221108164251
ACCESSION NUMBER:		0001077183-22-000173
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221108
DATE AS OF CHANGE:		20221108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEOGENOMICS INC
		CENTRAL INDEX KEY:			0001077183
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-TESTING LABORATORIES [8734]
		IRS NUMBER:				742897368
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35756
		FILM NUMBER:		221369560

	BUSINESS ADDRESS:	
		STREET 1:		9490 NEOGENOMICS WAY
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33912
		BUSINESS PHONE:		2397680600

	MAIL ADDRESS:	
		STREET 1:		9490 NEOGENOMICS WAY
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN COMMUNICATIONS ENTERPRISES INC
		DATE OF NAME CHANGE:	19990120
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>neo-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2d7a6b14-636e-498a-9bb1-3c76242be649,g:a2221670-aa14-4f97-b400-5f284572b74c,d:b12970009bdf4a5493f36f07a1369fa4--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:neo="http://neogenomics.com/20220930" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>neo-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV8zLTEtMS0xLTEyNjYyOA_31f5b906-49c3-41ff-8bd2-81925b108c48">0001077183</ix:nonNumeric><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV80LTEtMS0xLTEyNjYyOA_f5da2ad5-d462-4391-8127-93118be1f632">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV81LTEtMS0xLTEyNjYyOA_30d8d38f-f6a3-4103-b0aa-eb164e1acd5e">2022</ix:nonNumeric><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV82LTEtMS0xLTEyNjYyOA_b63d9db4-9052-4793-9e2f-8476e4bb496d">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV83LTEtMS0xLTEyNjYyOA_9080c953-5fbf-4de9-b7d7-65fecaa43ed0">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="neo-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9648e920d3546c49f4130aefa7f79ff_I20221104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i83580aae10c642e8968c0f73731cc216_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic8321097bff14046a282e8abcc199611_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7160abe114438ea10e14d931ab82b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd4ac9e3d6c4f07b201d7d092bbaa5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedad137938d1409a9e8fbc5c4f397c9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6690cf98ad3d4222abbea100fb427703_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if597821897f345c99cbbeebab1378c50_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529f30ec7dff4e9b85a9c64c0c6dc63f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9c30d1bc7c04d6ebec2ff027f47d17c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5831a61214043b5a99770b3ea06868d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if71720d4e7b844b096debe1ed180ea82_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f993779fd3b4952a907b9dd4f4b3d4d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dea28d0e93949f5aefc5a14f49c8485_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c1c0ca88b04fc9862f5dd8242e69fd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894e20df066b4a5988b63308c44592af_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icac541c50198437baeb6432443c98ca9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d90e116c7a466cba2f377d4f8ca18a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44fa76d75a604e91bc3f64022a394556_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b81d3b93d874a9db542449b4531b9ab_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17cd1a8aeece46c2965383c6ff51f141_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i818d019ce1c04ff989dc836cb55d44ec_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if54a2cabacf746aaa21fa48bec9ae3b1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad9898a18252459abeaaa2287043243d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf24d4d87dae432094313f13b0433e46_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29cb3ad0f407462c9898cd940c1d37f7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id315e694cb304a8dbb920f3d1bca41dc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd47353cc04d40d487c363e58d6cd0d8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1530977a71d4f31a22fb39f5d0e7492_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d8c97e16ec459e907fcfda4a1c55d2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27adbda67be34d02b60f48394e1038b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48785c4f7e124415b6108ca28afcff05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2eb88896ee74655baa3b18785a707ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i245eb6ec3baa4df3b5146a6e6b182283_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia78d78a3c9db493697ca176e09b7aa91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i595026d5245f4feeafe415ec5546194b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1264117696a4469a67e0ec136421d1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbbb19f83f1e4ad79e3dc7bea4c0e730_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1bf40a8250f436ba33bacfac6825360_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i405da8647b38440ebba559d212b5dd7c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc37ab8dceb2404d8981b679d85008ed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52b9deb5b5e412c986b3a960ef6ec52_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cb2d646d0b14c8c9d1612c5c39524e8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee2a6c9923d645828b82bac68cf565f0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8d80520822e4942b1b02b3aede5033c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8a738d631c488c8a6d2ef8b1207ad6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e83cb2ada244e87863fccb0435f1caa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b87d5129c424480b7bca5c7de9631c3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d53da225c7543cc8626b67085ff1039_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292a317c53d4440db036498f37a42c80_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63a18efae1e24ac0a0f14cc9cb60d3d6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d66426c727144e6a0ed073ec7de01aa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab400f484a364301b9f34d240511f761_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic547475396b745199691ec6a3e16bdbc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b5778ebf6a4a509905cb89051df5f5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b48692e0ad44bfa45dab1bc766eee5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b574e55d4754f55a7a02ba000cdea51_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5524fa47c894252b50792cf5bfb8a1e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i634952822d8f47419d1fb60b6c946c77_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0254e4cf16114941859a750438514071_D20210407-20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-07</xbrli:startDate><xbrli:endDate>2021-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff7308f890e64260ae7552498699b417_I20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c2a0a7992f4f9c87c6ec0df05f6881_I20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47dac90fa672439484bfb0a011afa79b_I20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb74da8b2fb46a5bb928c2ae920bddb_D20210407-20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-07</xbrli:startDate><xbrli:endDate>2021-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i752263ab04214611a5770e4027948a06_D20210407-20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-07</xbrli:startDate><xbrli:endDate>2021-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9000f1ccba54fd19804e3f40e0611cb_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a29368d78684750a6b47e75d93b5fe5_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie866a05c754c4aea88ba72656f3dfaf1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447890f585a7488ca3884eedd5e3f87b_D20210930-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f304bd718a4345825da30d39801aa4_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19602c53e9f24c5e9c34e6540ce4ce9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia684065582284ea892447e0db574adc0_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972519f375d24149b066529619e13c9d_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0bbfe44413e450596641e770fb62e42_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddea112c263e4efd98f07f82c1942c43_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc7e8245487f4f58b121fa84f4613dc4_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc78548fd43f4d83ac64d4a4b191d44e_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec4e93a323ef4cc3a8b43b840cbbf66c_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb7a81052f8342aaaa4c62d41e183a9e_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b166ff4628f47a6a659a300bfe3a6bd_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57af656e837042e79c7838e6547334dc_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7214014d96a45c489ea60bba444a28e_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865870f7a6e3486b94e11d31cbf92518_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1bbf95ea8de4373bbdc6c8c9dfb2a77_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5190e0e6e6094a9aba5a2f9550f41b08_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a24c5b482d4c868eb1ce13b760dbe9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbdaab51178b41529b740316e578e1d9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18fb7d36fca64200a81888dd0251b185_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54101ba639b4d8da6ecd576e651fccd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766ee8715c984f5a91d4e9e5957aa027_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e89a70008f0452185c38f35f5c3160f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i449f2af14b0146a5a78576a510536145_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45be316a68fd49828e355ae260885a25_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdae249624a24acd9b708eff8cd37977_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06d8161afc2042ec9e387fdb20260efb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i270d8802e355431a87805141beb22e21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0387bd97bb24097a69a3236c020cbf9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a59efcaaa54315abd137625d2903be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6004076cc7944a468953c8b1ff560f34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i836abb9e08624532bd3983b006965c8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i836132e570fa408799f2204a799b968a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75847b6fd90245879f447b248c88a3c6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib63051c22ad4419daca3d275e18517da_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743caf65823d4bd1958a8cbb299c0895_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51799610f4064775a69dfb0cac87a703_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6bf0ff21f364dc0a684dbf075b53b37_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae95464f5ee74284b6ae32d61d93ce73_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1af9878ff27e4d028b3550392083c7b2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ea5826458e41d99aa352a497ffafd4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118589658cf34ed5b9ddf840fb4e46c8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i604eda05df5c4b31b29a38fc217c0cbb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6936f18c703b4b55a0cdedf5a286c9e3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bbc37daa8d04bef9ffd619049eca18d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf405aba888440c491e4e49e02bde83d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2698d44ba514d578ea6e059ae78c719_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibac99a06e90442119500a802935b5fc5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id067a8d27c5e4dde917550297727f471_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8dbf4d41b6a462f9551daf656d6df24_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i200b62a58197422faf0e93c36a17fcf2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f5e669517d4caf99147dede75e60cd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia425bc11b6e14936bb3bb334c3fcd38d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5eb1da66af64627bcc27ca09542053d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59406768d67448cb2b65eb67fed6dd0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dc03daff727488d8a6291b702771aaa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa480d457354319b83badeb66ffb82a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0f765f52554a9c8dd28422846ea647_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e9885cc6a7e41a58d60dbb43b197069_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8cb448cee344b8bf8f9dd3f02aecf6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie81bbebaf499410a8b2e96ff47a6f837_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10649a3764d48f99a112b7824cbe5ee_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea910074ae8048cb9c2564fc116234c3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2be2fd21f9148e0b393eeafdff75ecf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf8ac5a2c2b446f397a0b928f822a84c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d7ac3af4f1f4aba835faf1dec1ae2d7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7758f3fc5d2843889d3dccc581512940_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f5b2b00f414b6cb866b819f1811ee6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecbb10c34a5e40a192afaea2596f4d4b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea762de04e3247bd84d1cc134af37b04_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3c9ac9f23540ddbfd3c2431b55c0cb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacdf3ffa20844c33b3b4b233621d3bda_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12a6b55ac524499facd15cc496171051_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75652f68da664faa9631192fcc0b0756_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i542bc1cf4cff4dbf8c06c801299e4c0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195050c8c9bc4002b86ccce162741c31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if242353c50be44199306bd42b828c140_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e94869d91d484ba640ce057070111e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic977ba257bc74ed0ac2c4dcf4afc8570_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8311a90b3b424cac6df4bef4c4fbdf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3004fdeeb1e74b4ca1d1b3699743ba6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d3e0ab7458409591d23b08216cb230_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a655c1539e343408dda30ab3e70fe06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b4e60329fa940689159d4dd319eb066_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc756c44664b43f4b23fb38f1e93addd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e9f544c88447d2a59495913c96164d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc93136cd934c7ebd896d313b7290a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c789341c8e4a58bd9ab39f1bf6644b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e98456b3d846289512b6de773624bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe8bbfc732445e9aceeb47b5e0c3c5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc990a87d7a472183c3ef562e4fdfc4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f5ddba725f1440e874eacac1370e4dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibedaa1c912184478b0503bfd2e5d722b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e72e0725a14c9ca1b8b6e1a39fc880_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4319725e3601450bad41434e87073ac6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fbddcccd95b4981920388808f6beba8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62f94087a2cb4149929f3d7ce3682734_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105dd178cd01422fa6a4e525c0693dae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62854311ca47485eae6a22edb90202c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e5dd926f964588ba31f770c52749a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia89899f69b9044c0a9086495bace3ae2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f7167428b0340b584497251fb87718a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321e7755d58a4125b1abe353704933f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4822392b9ab44df6b413f0f3ac8e55be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b09d8a7a9546a1bddda55ed781ae42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb1d46b14a944988aae7942c987d7d5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e4ee5f830e74fdc9b4bbb24f9d53418_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i472970cdec304f53a5e8cd5cd075b4bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia93e0b2a1e3d464f8e6df2d0e9f52148_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib40d6f4a0a5143328f21dd179932836c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d9995d5167f4c7bb2a4f642fe88981d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e0361f10ac4f76b5eba47b82775cbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75670d9ce45547bc99a81d6754f3d28c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ae39a4495a641b8aa5ccb48e1ae2a5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb880a76146242968e6bfd45a3fcc254_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b823d3747b4ba79fe123db7bc136cb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i549421f861aa49dc823adf1f4747dd6d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79e1457052954b8b8b8d8d0bbe2ac708_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d4e012e5ff04c92ba9762ee777b5ee0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i797aec3fed494b6da15b5b1d78e7afaf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie84a64cf52bf488aa8c4b5c32b37ab49_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd5d3b7d14541ccb4c98224679c859c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac8a4996bb34043b19229ddcdd8fcf5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfbdc2914bf44ebf9369d82276e58d62_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106e8545ca314dd797829120c72a1131_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idede4c70818e4ec8b5e2e8f0405ddf00_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361720e05c8e458d9eda92fc5388b6e8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef158959bfb4e7f9623bff4b4a573cb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib216f20bf24c458d809516016332ecd5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6c3992b5294ed89c00bb7e4387a2ff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib759ebff98dd441ca6275338c855db76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e053abf65147d29a5dd6a6ac867b9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd8360c0431e46e48e0c165b0287f029_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19cd4a991b204018b122a75e5768a87f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c8ecbf116e841a9b4dfffda832ac632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b5bb4b553741e0bed88b54c12490b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i240234cbd1b048a88a80ecfb7db9b243_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9cf7af964324575b1e90a208499969a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2acb703fa2e4b3d8f2adf8f1ccf8251_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7474ff176c7846c0acef3250e51c454e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1287835862df47c8bc96b7ec0def19bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4649c38cd34257bb5c56cd8d83cd45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e071a65fde4540a8f2f69263d43769_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic77b4f7ab7454a149dc9bb68b7337a50_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac78e36d8f94115b39886bb71273081_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac44e2ebca3469bb5add1f5bc673f54_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8950ddf7dc73426abd2e59bb9e3428cd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5b9002c6c54807843802a2269d680c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985788d5c071467d85f2f33e2f2e2fe3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613c8ef800af4acbb247578aff04da3d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e078001d1454b3cbc7f7d7b83568f2e_I20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>neo:day</xbrli:measure></xbrli:unit><xbrli:context id="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e9577a5d34442988876254f1f4de500_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09ab64c3de5a4744a9608181e3687f96_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2b7a7f93dbb4b1ca8195ad0d4023f57_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf3c51ab90a4a2898937c535e682135_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf48e559e728411498f7b81a86313e8e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5639e39468f41488a1252639d4ef0c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766de052b6724a39ac4cff4bcdcc1a5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8696c4831ac447f91dae99b16f092c2_I20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied71922b6fb843699775ee25dc037112_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia865031156044a7dbb6c87daac4c70d7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ca9c808340f4bfcb031c666d2d97909_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1edd2c29bc214bb28b0e32e7fd84ca23_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cc7c64aab7049d8bf4e97fd24d8055d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dfff7d2e5c04e57a4f8de1a51fac23f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2582f1fdaa5d4fd58b8edb349ee79064_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23b5d383d9e84db6b635cdcd0c0f9d95_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62713aa84dd049d68dc66b6a1fe200e6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id36af2f403f24cf7b4525fc88fa61cb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9abed8a09c214319a4423cf3fb5ecb73_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idda8fd6e0a664803b84d581d6ad6b27a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae752c4884e4e67ad202713d68fe1b2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b69f5ad10b449dac5c4fc387dfccf0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0739f9f5cb43425cb2d6fc5c3d1947da_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a3daea84f54e7bbfd7da40f557227c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i403368f4b4754ed4b335bff0b80a92da_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65fbf7f2c924f07a648c17a334c7c42_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402c8314c37b4397a60a9dc5100ead32_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915d2ee33bfe41828d288f2c9e850276_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2983b693db614e67a0385420d6fe04db_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8422c990601641b9923d741a1879f6f6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie06ce2ae770d4cf98f1c70856a4ca493_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>neo:segment</xbrli:measure></xbrli:unit><xbrli:context id="i12404422705e4e5db442f2c6fa044950_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c4daaae4c144b64bf090d8b0ec28bde_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ce6ba5e4be4b41adb542d8cc8b71c4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c9f8f865eca4dee9704f9ae41b2c4a2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4e564189e94f8da0931134c08f04e2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9077f666a17a48f3b7bc80bc791c4661_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11e2ed3be0744fb0a5fa17de9fd64cb8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i518f32fbbb6149f08c71ce0cf09bfa3e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6531ec4b2bd491d919cb52b975afca2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idadb4a2ecea94787888cba5a2ec1fdf4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e676b3f14974a14b21ed4e1353a4970_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0430c68b11e441a1932ef5b6bf20883e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f4d4146b09f46f8bae21fa55af4e603_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c17f0a685d4b4bb4ac9262b0409185_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4359f136a8724314ae74fdfcb5cf1ddb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31361b8430c34cb1a61a5212cab1d7e4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4429118382147fe986ee5dbfc122521_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c42bc6f38d647e19f5951ebd7219933_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c5815174fc465484a397d6b8310ed5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ee7ce21290e41ef94470a95e2d94830_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05bf8eb6bc645cd9e362b07a66b1d8c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3db9446bf9344b45b0f702886c5f0051_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69da659e90044db1a544a5bde21c110c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a46098d95ff4c398528d14d94cf1462_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f31d48f948140049d3ec9c0b3ce5eb3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i277bb1a3397c493eab6081211ecad60e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2147cc98bb480fb457363bd7cdaef9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce2989799cb43159de5d33b523a462c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ab618a9f5c4dd0a3656bbe96c190ad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i242b0a5a38704451a6823784364be43c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ad372323184dde948139f6d77bc2bd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf08791a42c4b12b704b3c8c21f8f15_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05e8201ba8544204b7f58c994e8ac179_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50746063c011499591f6bd542aedaab2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f0500c13d24ac7bcf932ec6cb56213_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94151c90de104b8dbe11dec588578819_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96522c45dcd84160880608c828bd86b3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic226270fce13411aaa7fde2cdeb1e234_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i953f791557df441a893456e3ce3c860a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62cba84218e84f778d2010e7be8c7e0d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5b26bbdce64c3ca2829078807c061f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia40344f3d7174e60be2e0dbaf9533460_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd0bf6f3fb647c1a101a318ce23fbad_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e63a0f57c2427c9d3b54f1c162de3c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bbde1a0788e4d5e98970b3bd2cb180a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346de9f05ee645788bff3412f862de33_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i879e090b3f4e4e71bc92de7e2ad882b2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4d31e5c09604f229766351b8ba0d0fc_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68c2a2f8b6bc4a8f9ea7991d94b969f2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54a7a7e84624ef48b6fa7119e60f286_D20210120-20210120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:PatentInfringementComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-20</xbrli:startDate><xbrli:endDate>2021-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>neo:patent</xbrli:measure></xbrli:unit><xbrli:context id="idbe5ba6b460e48cea499cfd288684c3c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c663a25f6742dea0c2944423d3ba66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ee0320473e4c25be7915c5434f0efe_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:StrategicAllianceWithInivataLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eb774483c5d44a88b442c3a493331f4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServiceContractsWithCytomXTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2b85ad77a2443083ab566f9d503e37_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServiceContractsWithCytomXTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3640c3db5b114ab3997daf6009f1e121_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServiceContractsWithCytomXTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ce9041f492249c4a99391bfbb0cddc4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServiceContractsWithCytomXTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6637559ec6a04ab5b9435cf6158fd0c4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f4bd7a8247d417ea28e862e1cf803db_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i250039242aab493dabb7b5413e5f5a41_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb967b231404449cb3a51eadf05ece29_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19908e283dc94d0d945d062e4df46a9a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">neo:COVID19PCRTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib12970009bdf4a5493f36f07a1369fa4_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl84NA_1f066c47-e003-40dd-b863-5a23b457b07b">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6N2M2Y2VmMGM2MmYyNDc4YzlmMDAzNGEwMDM0MTkwODIvdGFibGVyYW5nZTo3YzZjZWYwYzYyZjI0NzhjOWYwMDM0YTAwMzQxOTA4Ml8wLTAtMS0xLTEyNjYyOA_f36c487a-92aa-4f79-bc35-c8040623bb2f">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8xMjA_2b629b26-b996-4932-989d-b4a11acd9e77">September 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center;text-indent:42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6YjQ1YjgyNDJmMGE5NDE4Yzk2ZWQ5MDU5NGM5YmE3YTAvdGFibGVyYW5nZTpiNDViODI0MmYwYTk0MThjOTZlZDkwNTk0YzliYTdhMF8wLTAtMS0xLTEyNjYyOA_8d51c65a-6d93-45b9-b4a1-c063fe67aa8a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8yMTQ_333f6a57-0447-415c-8462-a44c3a9585a6">001-35756</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8yMTc_606a9227-cedd-4957-b3c4-57b4b44c848d">NEOGENOMICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:28.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl8wLTAtMS0xLTEyNjYyOA_63eafb76-3833-4aea-a9bb-8e99003c449d">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl8wLTMtMS0xLTEyNjYyOA_2d341abb-0e53-4cd3-9b06-09c79f053b80">74-2897368</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl8zLTAtMS0xLTEyNjYyOA_8513d8db-260e-4124-b7aa-b0f6cf36cb52">9490 NeoGenomics Way,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl8zLTEtMS0xLTEyNjYyOA_6e80ab77-f04c-4f44-b7cc-f0941970389d">Fort Myers,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl80LTAtMS0xLTEyNjYyOA_93cc1b1d-b5ad-4199-8909-207ebab4709d">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl80LTMtMS0xLTEyNjYyOA_05e6008c-4b94-4bbd-8263-54cbc4b9a19a">33912</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8yODA_c52f5e71-87af-4ee4-81ed-6a546cb3e65e">(239)</ix:nonNumeric> <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8yODM_82135441-d69b-469b-9e43-90c0463016fe">768-0600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:29.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MDBjNjBkMzY5ZDhmNDQ2NGFlZjgxNGU2NTA2MDE3N2MvdGFibGVyYW5nZTowMGM2MGQzNjlkOGY0NDY0YWVmODE0ZTY1MDYwMTc3Y18xLTAtMS0xLTEyNjYyOA_0429a6ac-5206-473f-9166-9450ff0dc0e4">Common stock ($0.001 par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MDBjNjBkMzY5ZDhmNDQ2NGFlZjgxNGU2NTA2MDE3N2MvdGFibGVyYW5nZTowMGM2MGQzNjlkOGY0NDY0YWVmODE0ZTY1MDYwMTc3Y18xLTItMS0xLTEyNjYyOA_aa874f76-5b65-42bf-ab8b-cccc191a52b2">NEO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MDBjNjBkMzY5ZDhmNDQ2NGFlZjgxNGU2NTA2MDE3N2MvdGFibGVyYW5nZTowMGM2MGQzNjlkOGY0NDY0YWVmODE0ZTY1MDYwMTc3Y18xLTQtMS0xLTEyNjYyOA_16e3bab1-92c0-4255-8b64-937d749cfa36">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl83NTA_ed4c803d-e4be-4a78-bd2c-8092b3f3178a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">No&#160;&#160;&#9744;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;<ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8xMDc0_afa21a17-348d-4cb9-8c2e-20be0f40e013">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MjI4YTU5YjE4MTFkNDM4ZGE1OGY5ZDhhNzczYTZjOGEvdGFibGVyYW5nZToyMjhhNTliMTgxMWQ0MzhkYTU4ZjlkOGE3NzNhNmM4YV8wLTAtMS0xLTEyNjYyOA_fbf1b7c8-f176-40fc-bf01-fc5b3e15d6d8">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">S</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MjI4YTU5YjE4MTFkNDM4ZGE1OGY5ZDhhNzczYTZjOGEvdGFibGVyYW5nZToyMjhhNTliMTgxMWQ0MzhkYTU4ZjlkOGE3NzNhNmM4YV8xLTQtMS0xLTEyNjYyOA_46a98cd7-c5c7-48d2-9243-9bc01461d4ef">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MjI4YTU5YjE4MTFkNDM4ZGE1OGY5ZDhhNzczYTZjOGEvdGFibGVyYW5nZToyMjhhNTliMTgxMWQ0MzhkYTU4ZjlkOGE3NzNhNmM4YV8yLTQtMS0xLTEyNjYyOA_d9a5abee-27a1-43e9-99b7-6fbb63051b1a">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8xOTE3_c5411440-df28-417a-98a6-2b8ba93889d1">S</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of November&#160;4, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="if9648e920d3546c49f4130aefa7f79ff_I20221104" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8xODQ5_510748ed-d6cc-4ec3-8123-5650c203fa84">126,303,261</ix:nonFraction> shares of Common Stock, par value $0.001 per share outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:90.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_13">PART I FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_16">Item 1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_94">Item 2. Management&#8217;s Discussion and Analysis of&#160;&#160;Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_94">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_130">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_130">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_133">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_133">43</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_136">PART II OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_139">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_139">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_142">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_142">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_145">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_145">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_148">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_148">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_151">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_151">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_154">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_154">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_157">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_157">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib12970009bdf4a5493f36f07a1369fa4_160">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib12970009bdf4a5493f36f07a1369fa4_160">47</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements generally can be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements address various matters, including the Company&#8217;s strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, projected costs, prospects and plans and objectives of management. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the risks set forth in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 25, 2022, and in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to respond to rapid scientific change;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The risk of liability in conducting clinical trials and providing research services and the sufficiency of our insurance to cover such claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to implement our business strategy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The potential impact to our business operations, customer demand and supply chain due to the ongoing global COVID-19 coronavirus pandemic and its related variants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The expected reimbursement levels from governmental payers and private insurers and proposed changes to those levels;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The application, to our business and the services we provide, of existing laws, rules and regulations, including without limitation, Medicare laws, anti-kickback laws, Health Insurance Portability and Accountability Act of 1996 regulations, state medical privacy laws, international privacy laws, federal and state false claims laws and corporate practice of medicine laws;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Regulatory developments in the United States including downward pressure on health care reimbursement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to maintain our license under the Clinical Laboratory Improvement Amendments of 1988 (&#8220;CLIA&#8221;);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Food and Drug Administration, or FDA regulation of Laboratory Developed Tests (&#8220;LDTs&#8221;);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Failure to timely or accurately bill for our services;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to expand our operations and increase our market share;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to expand our service offerings by adding new testing capabilities and overcome capacity constraints;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to develop or acquire licenses for new or improved testing technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to meet our future capital requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to manage our indebtedness;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to manage the quality of our investment portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our expectations regarding the conversion of our outstanding 1.25% Convertible Senior Notes due May 2025 (the &#8220;2025 Convertible Notes&#8221;) or our outstanding 0.25% Convertible Senior Notes due January 2028 (the &#8220;2028 Convertible Notes&#8221;) in the aggregate principal amount of $201.3 million and $345.0 million, respectively, and our ability to make debt service payments under the 2025 Convertible Notes or 2028 Convertible Notes if such notes are not converted;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to have sufficient cash to pay our obligations under the 2025 Convertible Notes or the 2028 Convertible Notes;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The dilutive impact of the conversion of the 2025 Convertible Notes or the 2028 Convertible Notes;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to protect our intellectual property from infringement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to integrate acquisitions and costs related to such acquisitions;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The effects of seasonality on our business;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to maintain service levels and compete with other diagnostic laboratories;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to hire and retain sufficient managerial, sales, clinical and other personnel to meet our needs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to successfully scale our business, including expanding our facilities, our backup systems and infrastructure;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our handling, storage and disposal of biological and hazardous materials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The accuracy of our estimates regarding reimbursement, expenses, future revenues and capital requirements; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to manage expenses and risks associated with international operations, including anti-corruption and trade sanction laws and other regulations, and economic, political, legal and other operational risks associated with foreign jurisdictions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements included in this Quarterly Report on Form 10-Q speak only as of the date of this report, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time and it is not possible for management to predict all of such factors, nor can it assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_13"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8212; FINANCIAL INFORMATION</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:67.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022<br/>(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMy0yLTEtMS0xMjY2Mjg_1eb98a78-1049-4648-aaf2-25c8d082ce54">266,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMy00LTEtMS0xMjY2Mjg_1ae62197-76f0-4879-acfa-834fffc777b3">316,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNS0yLTEtMS0xMjY2Mjg_89f9f3a7-31c3-4901-b0ef-12bccfcffa90">177,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNS00LTEtMS0xMjY2Mjg_5a020ddc-ac68-4d2d-b1cf-716babeed906">198,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNi0yLTEtMS0xMjY2Mjg_869ee3d9-5f7a-4038-9ceb-75b86ece5e3f">111,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNi00LTEtMS0xMjY2Mjg_296e42ae-9514-45f9-9d97-7a37a7ec507c">112,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNy0yLTEtMS0xMjY2Mjg_29987d86-b7da-4c60-b436-ae9ca8a52a34">23,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNy00LTEtMS0xMjY2Mjg_b7841bf8-aae4-4a13-b8ff-e646909fddc5">23,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfOC0yLTEtMS0xMjY2Mjg_f9dd14f7-5dc1-4f6f-83d1-5c7ba15ef0f8">16,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfOC00LTEtMS0xMjY2Mjg_aad4f64e-83ad-4129-aa8a-d22bd1816e2e">12,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfOS0yLTEtMS0xMjY2Mjg_602ed40d-feac-44b3-8b57-53d6d82801f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfOS00LTEtMS0xMjY2Mjg_ca50e6c0-8cf6-4a1c-889c-14e5a4f67a87">10,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTAtMi0xLTEtMTI2NjI4_dd61b276-6d23-46d6-a70d-354775504f91">7,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTAtNC0xLTEtMTI2NjI4_8491878b-e154-4210-8ea1-8ee4a9d26c6f">8,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTEtMi0xLTEtMTI2NjI4_d9a45aaa-f425-4dc6-9727-f0e5c84f83c0">603,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTEtNC0xLTEtMTI2NjI4_81f4109b-49f0-473e-b8b4-8dd7682591a3">681,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment (net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTItMC0xLTEtMTI2NjI4L3RleHRyZWdpb246NTcxMDFkMzQxOGY0NGU5MDliYThjNDA4NjU3YWE2M2JfNjM_f4b78064-200f-4d72-99c1-21b9e9e8da70">125,018</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTItMC0xLTEtMTI2NjI4L3RleHRyZWdpb246NTcxMDFkMzQxOGY0NGU5MDliYThjNDA4NjU3YWE2M2JfNzA_3d064a2a-22c5-45b4-8375-15e2227f446a">109,952</ix:nonFraction>, respectively)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTItMi0xLTEtMTI2NjI4_1e57dfc0-63f4-4722-a19f-cc3279f783f9">106,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTItNC0xLTEtMTI2NjI4_26502944-faa9-4c9b-91a2-e5f8dce5f7a9">109,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTMtMi0xLTEtMTI2NjI4_fd8d6e03-20ae-43a9-8d7c-f8709ee5387b">98,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTMtNC0xLTEtMTI2NjI4_db6b1305-f001-427a-bf5a-b53221d851f0">102,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTUtMi0xLTEtMTI2NjI4_3dabe311-08fd-4127-a448-a17ba25f8ace">416,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTUtNC0xLTEtMTI2NjI4_c882c2ec-1fb8-4f10-af5c-6c59bb2de4a9">442,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTYtMi0xLTEtMTI2NjI4_a0981086-da7b-422d-b1e8-20db375e8aa5">522,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTYtNC0xLTEtMTI2NjI4_8ad9498f-f3c5-4af1-92a6-e8108b5aef90">527,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjEtMi0xLTEtMTI2NjI4_02ba34e6-433b-483c-a33c-ce0d4ff0b16a">6,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjEtNC0xLTEtMTI2NjI4_f51e13d8-2c92-43bc-9026-1fae381af0ab">7,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjItMi0xLTEtMTI2NjI4_c2c1f80a-b000-4741-836a-958d1823cbd4">1,152,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjItNC0xLTEtMTI2NjI4_11e99869-3311-4d0c-8291-022bc9e58396">1,188,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjMtMi0xLTEtMTI2NjI4_ae0532da-f047-4abd-b83b-0cd8eb2cbd09">1,755,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjMtNC0xLTEtMTI2NjI4_2793bca3-6e6f-4faa-bfcd-865e06d0e996">1,869,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjYtMi0xLTEtMTI2NjI4_a3d360fe-3d38-4ed6-915c-0f93aca80789">13,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjYtNC0xLTEtMTI2NjI4_36f0c0b7-2387-45b2-ae10-fab458c858d0">17,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjctMi0xLTEtMTI2NjI4_791e0ac6-f82d-4115-abeb-d56e02dfe9f4">37,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjctNC0xLTEtMTI2NjI4_b02bf8a6-d415-4bf2-b335-616f62fd0545">38,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjgtMi0xLTEtMTI2NjI4_662b1548-3312-4caa-900b-78ba2a7c9441">20,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjgtNC0xLTEtMTI2NjI4_c63bca46-0f95-4938-b6f4-20f62e77d4ec">17,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of equipment financing obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjktMi0xLTEtMTI2NjI4_12ac546c-a4ee-4d06-834c-2e09fcee5515">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjktNC0xLTEtMTI2NjI4_9bb89f2c-f7f2-4580-b1fd-f272d7f4aff5">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzAtMi0xLTEtMTI2NjI4_f9c2e54b-6c79-44e2-8fd8-83b05f1f7214">6,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzAtNC0xLTEtMTI2NjI4_c0fcf666-e129-44b0-8dae-bcc5cadb43ca">6,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharma contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzMtMi0xLTEtMTI2NjI4_f280e7f2-1247-4750-a88d-d24af6159940">6,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzMtNC0xLTEtMTI2NjI4_7c3fa6ea-666e-40bd-a553-945d111e613e">5,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzQtMi0xLTEtMTI2NjI4_c3aa069f-6fb5-436e-8b36-5143c74a4eeb">85,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzQtNC0xLTEtMTI2NjI4_62eb747d-725a-4aba-862c-df132980e435">87,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzYtMi0xLTEtMTI2NjI4_b38cf00e-a73c-4a7c-9563-27f389254680">534,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzYtNC0xLTEtMTI2NjI4_85f5a05b-61d8-4ad4-8e4a-52265c02c394">532,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzgtMi0xLTEtMTI2NjI4_9149ad8c-d63f-4f60-8e07-bf8b306050a6">70,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzgtNC0xLTEtMTI2NjI4_2a35355c-4ce3-47ea-8d81-18f53d406f99">72,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDEtMi0xLTEtMTI2NjI4_612cc89a-b7fa-4201-adaf-3a8bf544ab87">38,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDEtNC0xLTEtMTI2NjI4_3277d20b-7d6f-4090-b6a4-aa4ea6f0bb94">55,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDItMi0xLTEtMTI2NjI4_20394cef-2682-44f4-99d8-5788b55bb8e4">14,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDItNC0xLTEtMTI2NjI4_b5e1f766-dd0b-4923-90eb-d9b228816d08">14,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDMtMi0xLTEtMTI2NjI4_4fc3e00a-e1ef-44ac-8334-3f2e7ac3e625">657,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDMtNC0xLTEtMTI2NjI4_b9d425e2-d70a-43da-99e2-9d9fc1fe9b60">674,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDQtMi0xLTEtMTI2NjI4_73ddc341-a573-4af3-bac8-f00c890f4ca3">742,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDQtNC0xLTEtMTI2NjI4_fa3b0e12-d8ad-4a5f-b7ac-cd733bb97409">761,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDUtMi0xLTEtMTI2NjI4_22a96c79-e846-4d6b-81d4-d69da3409d10"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDUtNC0xLTEtMTI2NjI4_faaadb24-d901-4612-8a0f-3e101e671cae"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfMTg_14d98f18-bf64-4d1f-93e8-acd9f14e5f88"><ix:nonFraction unitRef="usdPerShare" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfMTg_b423a05e-4a54-472d-af6b-42c1831204e9">0.001</ix:nonFraction></ix:nonFraction> par value, (<ix:nonFraction unitRef="shares" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfMzM_046a56d7-707d-41a3-aaef-c20b7da75be5"><ix:nonFraction unitRef="shares" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfMzM_70c229f9-4960-436e-8b85-380dcabc19ce">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfNTU_004b4ef1-02ce-4ac2-8ce6-99034807207b"><ix:nonFraction unitRef="shares" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfNTU_24b27d84-a760-4014-a399-60bfcc2eec07">126,562,037</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfNjI_deeab515-be88-4679-8583-afd9bceccb8a"><ix:nonFraction unitRef="shares" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfNjI_fdaf90b2-d4ce-421b-a08f-ca128bc8191e">124,107,500</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMi0xLTEtMTI2NjI4_07bedd65-e127-4029-832d-4952ce6c2e6b">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctNC0xLTEtMTI2NjI4_13fdf742-b61b-46bf-837e-a486ff13e38a">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDgtMi0xLTEtMTI2NjI4_5b8265d6-d427-4096-8c1d-6e7a27a25aaa">1,154,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDgtNC0xLTEtMTI2NjI4_3808e484-942b-4620-a77c-b4fdda600886">1,123,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDktMi0xLTEtMTI2NjI4_d982dc43-bd49-487a-926a-c442cb5b6b02">5,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDktNC0xLTEtMTI2NjI4_b212cb2b-0eeb-4575-bf30-455faca32d18">638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTAtMi0xLTEtMTI2NjI4_6d878d6a-aaf2-4114-a1ca-4e2e9aa0dc69">136,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTAtNC0xLTEtMTI2NjI4_20226bf3-5808-447a-9a13-0306b734ccd8">14,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTEtMi0xLTEtMTI2NjI4_b85f9da8-2117-4f84-9bd4-40f14a89c4f1">1,012,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTEtNC0xLTEtMTI2NjI4_b25c9890-7bcc-4236-80d4-3d6f1b472a77">1,108,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTItMi0xLTEtMTI2NjI4_8d4df16e-aab7-4a76-9885-67bc22b10d33">1,755,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTItNC0xLTEtMTI2NjI4_e5a0a51d-7b4b-4448-82e4-c2a069a1d945">1,869,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements. </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET REVENUE</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMy0xLTEtMS0xMjY2Mjg_9a2cc4fa-9e32-424a-a450-691c06abf9ac">106,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMy0zLTEtMS0xMjY2Mjg_9ab0de20-2fd6-477b-92d0-7573d0d23cdd">102,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMy01LTEtMS0xMjY2Mjg_43f7c95c-a4b4-40b4-92c1-8c74aede0936">310,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMy03LTEtMS0xMjY2Mjg_8803075b-1692-4a2c-ab2c-8e34f07fc106">300,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNC0xLTEtMS0xMjY2Mjg_81bd774e-960c-4efb-bd24-510e2e81d0a5">22,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNC0zLTEtMS0xMjY2Mjg_5bf12147-4d3c-4bdf-ba00-9c54aeca807f">19,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNC01LTEtMS0xMjY2Mjg_d46df4bf-935b-4c8f-8e6b-61503179b08e">60,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNC03LTEtMS0xMjY2Mjg_527f22d9-9280-4c33-acf6-f8a1129050c4">58,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNS0xLTEtMS0xMjY2Mjg_cd1b9f4f-07c1-4add-b468-ecaab3b7f2e0">128,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNS0zLTEtMS0xMjY2Mjg_7df3e5bf-3e4e-4d69-a382-5885e9d8baf3">121,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNS01LTEtMS0xMjY2Mjg_9df75f0f-b565-4545-94a0-baf36ea9fc54">371,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNS03LTEtMS0xMjY2Mjg_037ef3ea-3020-43a6-9427-8dc39429fde3">358,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COST OF REVENUE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNy0xLTEtMS0xMjY2Mjg_ed4ba55c-952a-4cb7-958a-03b548771652">79,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNy0zLTEtMS0xMjY2Mjg_3355f19f-537a-46d1-bde7-ed9b729d6e68">74,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNy01LTEtMS0xMjY2Mjg_9b04607c-c51a-4905-ba85-ddb0d5f821dd">239,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNy03LTEtMS0xMjY2Mjg_3dca421f-5fd2-491b-9158-3d701a285d93">216,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GROSS PROFIT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfOS0xLTEtMS0xMjY2Mjg_f37ecd72-46cb-4da3-9ddb-4fe3d933d58f">48,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfOS0zLTEtMS0xMjY2Mjg_30e22ab3-643a-489c-b425-ea37f9b04440">47,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfOS01LTEtMS0xMjY2Mjg_8afcad4a-f6a1-402a-bea5-0c4cc6084dd0">131,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfOS03LTEtMS0xMjY2Mjg_5be7a455-0f57-405d-8548-b0feec695fcf">141,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTEtMS0xLTEtMTI2NjI4_c4082697-a0b7-4b52-afc0-2192acf2c2cd">64,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTEtMy0xLTEtMTI2NjI4_1c325530-3c79-4cc0-8607-c75fe2f68d3f">63,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTEtNS0xLTEtMTI2NjI4_79fffba6-477c-4b1f-ae15-65c5967a37ff">188,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTEtNy0xLTEtMTI2NjI4_9164d045-f1ad-4b10-8b47-8289550f3c4e">158,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTItMS0xLTEtMTI2NjI4_551104e5-6f57-4805-ad7a-777c6f94d833">7,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTItMy0xLTEtMTI2NjI4_d4f8aeac-9cee-4ad5-befc-3f9c54693f61">7,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTItNS0xLTEtMTI2NjI4_a9e786b0-6aaa-4b8d-91a3-3e18cba07c32">23,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTItNy0xLTEtMTI2NjI4_c923e8c9-389c-4cd7-bffe-5cbf32ebb314">13,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTMtMS0xLTEtMTI2NjI4_78a780f8-a163-4d3a-b2ba-b776bd22a4d3">16,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTMtMy0xLTEtMTI2NjI4_52d294c6-789c-4ca2-b740-19d44dcc0e1e">15,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTMtNS0xLTEtMTI2NjI4_9af2bf22-06b0-4dae-be48-177ac62ddb8f">50,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTMtNy0xLTEtMTI2NjI4_c83c2fe9-05ed-4bb8-ad4c-1f5a7b592c84">46,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTQtMS0xLTEtMTI2NjI4_5ba20da2-c3f2-4dc3-aff4-5e5c991c2405">88,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTQtMy0xLTEtMTI2NjI4_b4aded1e-f679-46fa-81a4-cb86f4b04b02">86,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTQtNS0xLTEtMTI2NjI4_4c63d2e9-f620-4d3e-a754-8fe2159f813a">262,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTQtNy0xLTEtMTI2NjI4_e04ab56f-cf42-47a4-8b60-e5afc61fea7f">218,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LOSS FROM OPERATIONS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTUtMS0xLTEtMTI2NjI4_45bb2265-86b9-4ca0-a66f-09be4e6d0a5d">39,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTUtMy0xLTEtMTI2NjI4_af6bde4d-aa1d-415e-b26b-5b9fedd48259">39,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTUtNS0xLTEtMTI2NjI4_0208bb73-6303-43a2-a45b-0b1203a3f233">131,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTUtNy0xLTEtMTI2NjI4_3440e5df-6e1d-413a-9c1b-b640b2e19a0e">77,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTYtMS0xLTEtMTI2NjI4_1edf6ce3-87a4-43e7-b3d8-5d90e46565fd">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTYtMy0xLTEtMTI2NjI4_5eac69e9-32fd-46f1-8f00-11973560ca52">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTYtNS0xLTEtMTI2NjI4_f955101e-5cea-48fd-9508-39b59846a05c">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTYtNy0xLTEtMTI2NjI4_54de532a-20d7-4911-bb2e-7efa64c352da">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTctMS0xLTEtMTI2NjI4_59494f84-dd39-4eca-a934-9c7b6311c695">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTctMy0xLTEtMTI2NjI4_0dfe6f22-3fd4-4d23-9c46-af0034d0ec99">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTctNS0xLTEtMTI2NjI4_c58ae205-a078-4c05-bb92-5bcd0ee42167">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTctNy0xLTEtMTI2NjI4_1632bca7-1dc1-4346-b6af-1c8636025866">431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTgtMS0xLTEtMTI2NjI4_5fbfc9fe-f555-4bbd-a12b-aa8d9ec844be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTgtMy0xLTEtMTI2NjI4_f804ae8c-d4a0-4883-823e-d58313a7c93e">17,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTgtNS0xLTEtMTI2NjI4_39c57ffa-d93c-49bf-83ca-9a502b64b870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTgtNy0xLTEtMTI2NjI4_8064233c-4c95-486f-96c1-899662da96f4">109,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjEtMS0xLTEtMTI2NjI4_5b9f5329-19ed-4b72-a235-627ce993a3d4">39,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjEtMy0xLTEtMTI2NjI4_e93e42fa-f381-4223-89d0-e4ff36216a0d">23,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjEtNS0xLTEtMTI2NjI4_1d8306f1-55a4-4053-af13-fcea23e8c492">133,818</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjEtNy0xLTEtMTI2NjI4_8a1ed9ed-fb6b-4d4c-9f25-96da7eea4cb6">29,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjItMS0xLTEtMTI2NjI4_395cbcfe-5d08-40bb-bbd8-345e825375dc">2,772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjItMy0xLTEtMTI2NjI4_56148a96-7735-4a8d-9988-a912efe74584">2,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjItNS0xLTEtMTI2NjI4_ede2cd7a-5b9c-4367-a7a2-1191dd0cf260">12,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjItNy0xLTEtMTI2NjI4_0ee21359-c7aa-4ad9-a9fc-1fa6956a77e7">4,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjMtMS0xLTEtMTI2NjI4_c67aa505-967f-4847-9be5-cce9be584bb8">36,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjMtMy0xLTEtMTI2NjI4_fbda78ce-c9b8-40ec-b0b9-f62670b5e34a">20,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjMtNS0xLTEtMTI2NjI4_7b4a013d-f17f-467a-b937-e6a602833f2b">121,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjMtNy0xLTEtMTI2NjI4_fb274829-f6a7-41d5-9eaa-8fb53045746e">33,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME PER SHARE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzEtMS0xLTEtMTI2NjI4_856697ab-326b-44f1-9409-19bf01f4a7f7">0.30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzEtMy0xLTEtMTI2NjI4_4f3a887d-ead4-4fd5-bb79-af9307b6c46f">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzEtNS0xLTEtMTI2NjI4_4b9826d6-d9b7-4b43-b2f1-84563e717ef8">0.98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzEtNy0xLTEtMTI2NjI4_4abb32fa-fcdd-411a-8dc1-de46d237297c">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzItMS0xLTEtMTI2NjI4_a6f9a2e3-2f70-4ff9-bb97-86f26520b865">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzItMy0xLTEtMTI2NjI4_5e65e33f-50b1-4e54-a942-28b69750c3e0">0.17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzItNS0xLTEtMTI2NjI4_bbb2304b-e04d-4d1b-bd99-20ac14037a8f">0.98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzItNy0xLTEtMTI2NjI4_0a5ceb70-d73d-4dcd-8b3e-0e5b1378415d">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzUtMS0xLTEtMTI2NjI4_b63b3d8c-d5b3-4da4-a6f7-580ad08acd65">124,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzUtMy0xLTEtMTI2NjI4_16610e0f-6641-41b3-922c-7a0e46078323">122,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzUtNS0xLTEtMTI2NjI4_07928ebd-171d-41b5-b5df-8e1e17adaf3f">124,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzUtNy0xLTEtMTI2NjI4_0c461b4c-fb63-4795-830b-1d5fb8350e87">119,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzYtMS0xLTEtMTI2NjI4_0ba81adc-e937-47c6-9095-664160d3c526">124,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzYtMy0xLTEtMTI2NjI4_7387ff57-beba-4320-bb9a-38fc5e3ac98c">122,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzYtNS0xLTEtMTI2NjI4_ac233831-a47b-4fe2-a3c4-06264d5a9fb2">124,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzYtNy0xLTEtMTI2NjI4_414dbf98-ae1e-4967-b711-ed56d872f911">121,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:46.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMi0yLTEtMS0xMjY2Mjg_b7185dda-ef27-42f9-aae1-d0aba5df6155">36,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMi00LTEtMS0xMjY2Mjg_772094ab-d114-419e-909f-81b7214f27b8">20,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMi02LTEtMS0xMjY2Mjg_b1f99eb4-a88d-4a9b-b185-64f51e7b97ad">121,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMi04LTEtMS0xMjY2Mjg_d2bd0094-4d59-4040-bf21-22dfa8d81e4d">33,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER COMPREHENSIVE LOSS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfNi0yLTEtMS0xMjY2Mjg_b6dd4c85-50b1-4931-88e2-d41cb6ecc1f9">1,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfNi00LTEtMS0xMjY2Mjg_81f41edd-48ce-4fc1-9c07-981b59653bfc">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfNi02LTEtMS0xMjY2Mjg_2a5ecc77-abaf-43ed-91fd-62147b0b7948">4,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfNi04LTEtMS0xMjY2Mjg_87728f24-e9d4-4faa-9890-7466607652e8">400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfOS0yLTEtMS0xMjY2Mjg_b6dd1dd7-4ef6-41d9-a948-b6f66f65eb5e">1,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfOS00LTEtMS0xMjY2Mjg_1c5ca160-fc05-4546-b0c5-9f6a79fbdfff">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfOS02LTEtMS0xMjY2Mjg_641ede91-4e60-4180-9ab5-613e0399c295">4,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfOS04LTEtMS0xMjY2Mjg_e12c713f-ae34-4de6-8299-a77316db2f86">400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMPREHENSIVE (LOSS) INCOME</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMTAtMi0xLTEtMTI2NjI4_cb36fbd5-ad3a-4f1a-a220-96ca070a78f7">37,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMTAtNC0xLTEtMTI2NjI4_b67606d6-38e9-400c-b24e-b1d5d13b6311">20,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMTAtNi0xLTEtMTI2NjI4_6c260a39-7e16-4c7b-8c50-a59167c0646d">126,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMTAtOC0xLTEtMTI2NjI4_06c8901e-7f63-48a3-96f4-89d316c49012">33,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd7160abe114438ea10e14d931ab82b3_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi02LTEtMS0xMjY2Mjg_0d781019-a744-45fd-8fd6-abc1c20d0d0d">124,107,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7160abe114438ea10e14d931ab82b3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi04LTEtMS0xMjY2Mjg_baeb671c-8eb9-489e-bd75-635d7020ca13">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd4ac9e3d6c4f07b201d7d092bbaa5a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi0xMC0xLTEtMTI2NjI4_5a2bfc56-f21d-47b4-92a5-f5d87806e22c">1,123,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedad137938d1409a9e8fbc5c4f397c9d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi0xMi0xLTEtMTI2NjI4_58242688-df27-4555-b335-f42b7c25b109">638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6690cf98ad3d4222abbea100fb427703_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi0xNC0xLTEtMTI2NjI4_37f66b27-14e7-4f3f-9b03-02acd6a98c8b">14,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi0xNi0xLTEtMTI2NjI4_17077d5c-a56b-47a3-b333-096be3aff1d4">1,108,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock issuance ESPP Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if597821897f345c99cbbeebab1378c50_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMy02LTEtMS0xMjY2Mjg_4887ede7-a5d1-4dba-9b0d-d7ff79f9e53c">47,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMy0xMC0xLTEtMTI2NjI4_a072a80e-35eb-46dd-b885-b3a20617cba2">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMy0xNi0xLTEtMTI2NjI4_efd857fa-fb80-4f1f-93b5-56375d67269f">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if597821897f345c99cbbeebab1378c50_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNC02LTEtMS0xMjY2Mjg_31a2eb02-bf52-4a76-b71c-aba0abed0f50">100,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNC0xMC0xLTEtMTI2NjI4_853fcf7f-d8b1-47e6-bcd7-f47f9b320222">1,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNC0xNi0xLTEtMTI2NjI4_51b3eabc-5dfd-4825-abff-bc731779bba2">1,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if597821897f345c99cbbeebab1378c50_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNS02LTEtMS0xMjY2Mjg_ea80db57-bd4b-4aef-b876-4535f17ebc63">466,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if597821897f345c99cbbeebab1378c50_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNS04LTEtMS0xMjY2Mjg_c61cf23e-509f-4895-81da-344f1e1e1d8a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNS0xMC0xLTEtMTI2NjI4_622ba250-04b3-419c-86a5-22a64a388283">6,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNS0xNi0xLTEtMTI2NjI4_cce720be-96a0-4d31-8708-4c70ffb7ca5f">6,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ESPP expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNy0xMC0xLTEtMTI2NjI4_5fa3dcd1-3940-431b-8be8-653f96792be7">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNy0xNi0xLTEtMTI2NjI4_ffa2c1e1-cc14-4915-a8d6-f5bc42d96311">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfOC0xMC0xLTEtMTI2NjI4_b470a3bc-4731-4bb7-a6d1-f33488b3906c">11,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfOC0xNi0xLTEtMTI2NjI4_10f92068-f833-4e71-b55a-6f1c756af714">11,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i529f30ec7dff4e9b85a9c64c0c6dc63f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfOS0xMi0xLTEtMTI2NjI4_d43e8dfb-12ca-4726-a7dd-a2265f70d047">2,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfOS0xNi0xLTEtMTI2NjI4_ca7be6e0-c44c-4673-83eb-a2e600b60d13">2,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9c30d1bc7c04d6ebec2ff027f47d17c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTAtMTQtMS0xLTEyNjYyOA_b13c19c1-1103-442d-8153-0fe537644085">49,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTAtMTYtMS0xLTEyNjYyOA_d8cf4266-fd74-4a5f-a05e-c481a4e8ba86">49,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5831a61214043b5a99770b3ea06868d_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtNi0xLTEtMTI2NjI4_3aad99b0-f190-4417-923b-6136ba632cbf">124,722,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5831a61214043b5a99770b3ea06868d_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtOC0xLTEtMTI2NjI4_48017c01-e448-43a7-81b9-f0543d7097cf">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71720d4e7b844b096debe1ed180ea82_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtMTAtMS0xLTEyNjYyOA_087cd864-ea7c-4710-abcf-b7af3a2b218c">1,142,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f993779fd3b4952a907b9dd4f4b3d4d_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtMTItMS0xLTEyNjYyOA_efd8adde-c4a9-49bd-953b-c340b658307c">3,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dea28d0e93949f5aefc5a14f49c8485_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtMTQtMS0xLTEyNjYyOA_d861ddfe-2983-4331-94b5-17ab31604028">64,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c1c0ca88b04fc9862f5dd8242e69fd_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtMTYtMS0xLTEyNjYyOA_774bd9a7-55c4-4c1e-81aa-0972c6da7c2e">1,075,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock issuance ESPP Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i894e20df066b4a5988b63308c44592af_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTItNi0xLTEtMTI2NjI4_7ab27c27-3b15-4750-90d7-313afdd57f09">89,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTItMTAtMS0xLTEyNjYyOA_ba6b766a-1465-43f5-a9de-c0c38c58a3cc">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTItMTYtMS0xLTEyNjYyOA_6079f849-4a88-4a69-adde-992f7a98aa3d">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i894e20df066b4a5988b63308c44592af_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTMtNi0xLTEtMTI2NjI4_215fe1bf-b974-44cb-bd95-ba10b8665435">773,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894e20df066b4a5988b63308c44592af_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTMtOC0xLTEtMTI2NjI4_b925f8d1-7042-437e-be5c-07514c429914">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTMtMTAtMS0xLTEyNjYyOA_fd9457d3-9236-47a6-8ebc-d8c3df2f1fa1">311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTMtMTYtMS0xLTEyNjYyOA_f02cdb16-d9fa-47dc-88df-e3db565d10cf">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i894e20df066b4a5988b63308c44592af_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTQtNi0xLTEtMTI2NjI4_b8ec7b54-8171-4d0b-bd0f-cf0288a6275f">94,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTQtMTAtMS0xLTEyNjYyOA_61db2c1f-bb1a-4fe7-9cba-aaeeb219d948">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTQtMTYtMS0xLTEyNjYyOA_a7789582-b7e7-4732-b2d9-8091b048f7a2">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ESPP expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTgtMTAtMS0xLTEyNjYyOA_c387b3c5-9d43-4c67-b866-4aeec438db76">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTgtMTYtMS0xLTEyNjYyOA_845f070b-635e-4fe8-b027-06caa0fb032f">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTktMTAtMS0xLTEyNjYyOA_1a10ed7f-973b-4e46-a318-585db33afebd">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTktMTYtMS0xLTEyNjYyOA_8449a90f-35ff-485c-a4d8-22c50f3fad07">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d90e116c7a466cba2f377d4f8ca18a_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjAtMTItMS0xLTEyNjYyOA_dba69f9c-76e3-4aa2-9a79-49e885afda91">1,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjAtMTYtMS0xLTEyNjYyOA_6712d004-a4e3-4870-9a58-ba72ee53c37e">1,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44fa76d75a604e91bc3f64022a394556_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjEtMTQtMS0xLTEyNjYyOA_e6697497-3012-4051-8bd2-4b191e221e18">35,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjEtMTYtMS0xLTEyNjYyOA_be534fc4-a844-49ed-972c-001a492518b2">35,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b81d3b93d874a9db542449b4531b9ab_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItNi0xLTEtMTI2NjI4_f6e82416-7cd6-4ebd-aceb-a64694ea2acc">125,679,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b81d3b93d874a9db542449b4531b9ab_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItOC0xLTEtMTI2NjI4_cd8e8d5f-e4a9-4d2b-8739-ec34b6dadade">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17cd1a8aeece46c2965383c6ff51f141_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItMTAtMS0xLTEyNjYyOA_5fad572e-b559-4cb9-901d-3ba12ea4854e">1,146,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i818d019ce1c04ff989dc836cb55d44ec_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItMTItMS0xLTEyNjYyOA_62f428c8-df9a-4c20-bd54-8a4863b34b9b">4,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if54a2cabacf746aaa21fa48bec9ae3b1_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItMTQtMS0xLTEyNjYyOA_0727ba17-67f7-44ac-a3b1-c0d16f4949d8">99,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9898a18252459abeaaa2287043243d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItMTYtMS0xLTEyNjYyOA_1857bf70-1642-4eea-b2f7-d3cb465ffd60">1,043,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock issuance ESPP Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjMtNi0xLTEtMTI2NjI4_e69cc0ee-72e9-4360-b69c-44f794d85576">150,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjMtMTAtMS0xLTEyNjYyOA_a3281aeb-58e3-47f7-a397-41d5107d74e5">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjMtMTYtMS0xLTEyNjYyOA_32f350ee-cd39-4e6f-b9c2-8707d0589c07">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjQtNi0xLTEtMTI2NjI4_c0b1bc60-ad5b-4fda-9ddc-058d4fd6d83d">493,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjQtOC0xLTEtMTI2NjI4_b48a4c4a-f55c-41c1-9314-df0b0b58f9a1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjQtMTAtMS0xLTEyNjYyOA_69e14ee6-a80b-4c72-9175-f4e2d783d656">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjQtMTYtMS0xLTEyNjYyOA_ff7ee7f0-1328-4e69-a9c5-bf9d4ebe9771">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjUtNi0xLTEtMTI2NjI4_4897b7fd-ddaf-406b-ad4c-664485816af5">237,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjUtMTAtMS0xLTEyNjYyOA_3ce09657-c5b6-49ba-86b3-03182ddcc905">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjUtMTYtMS0xLTEyNjYyOA_fee07ce9-e128-4b4f-b9f5-3a3be0a753ac">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ESPP expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjctMTAtMS0xLTEyNjYyOA_24edbc42-72bf-4a1c-8c7d-ce47e3c609bc">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjctMTYtMS0xLTEyNjYyOA_37779f67-d437-4199-8bba-66bced9ca30b">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjgtMTAtMS0xLTEyNjYyOA_28004288-7a20-4c31-8df7-1c50876d6f07">4,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjgtMTYtMS0xLTEyNjYyOA_c182561c-6ca0-4ec3-a42d-80dd519e8974">4,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf24d4d87dae432094313f13b0433e46_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjktMTItMS0xLTEyNjYyOA_e627b7ac-5bef-4d57-b816-00b5112fb923">1,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjktMTYtMS0xLTEyNjYyOA_d5f7f607-ad6f-4d39-9237-f49aeb703c3c">1,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29cb3ad0f407462c9898cd940c1d37f7_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzAtMTQtMS0xLTEyNjYyOA_7116ea8a-49cd-4ff0-a8ce-3c2e0eef8aeb">36,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzAtMTYtMS0xLTEyNjYyOA_90b6c609-07d1-47a7-b07c-4d5e8ecd84bd">36,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id315e694cb304a8dbb920f3d1bca41dc_I20220930" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtNi0xLTEtMTI2NjI4_7bd999a2-8890-44b1-877a-3bde0589fa9c">126,562,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id315e694cb304a8dbb920f3d1bca41dc_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtOC0xLTEtMTI2NjI4_eaefea55-9fb3-43fa-84cc-f271f02573e4">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd47353cc04d40d487c363e58d6cd0d8_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtMTAtMS0xLTEyNjYyOA_a86f9807-2e63-49d7-bd1e-51d996815790">1,154,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1530977a71d4f31a22fb39f5d0e7492_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtMTItMS0xLTEyNjYyOA_25641720-e698-4d84-a105-b53012be41c7">5,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08d8c97e16ec459e907fcfda4a1c55d2_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtMTQtMS0xLTEyNjYyOA_24b4c946-8700-4aff-a154-ea20adafa16e">136,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtMTYtMS0xLTEyNjYyOA_7cc41c6e-aa2c-4bad-9a3a-a244a2ae5501">1,012,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(Accumulated Deficit) Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27adbda67be34d02b60f48394e1038b2_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi02LTEtMS0xMjY3NTQ_96a82123-35d3-4601-b59a-d4c77bb5304b">112,075,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27adbda67be34d02b60f48394e1038b2_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi04LTEtMS0xMjY3NTQ_84570591-314e-44dd-a9ec-6f7bee78edeb">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48785c4f7e124415b6108ca28afcff05_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi0xMC0xLTEtMTI2NzU0_f672ddc2-393f-4339-bfa8-736a776b51c7">701,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2eb88896ee74655baa3b18785a707ba_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi0xMi0xLTEtMTI2NzU0_935dfb11-69b0-429f-aa38-777d1e55d801">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245eb6ec3baa4df3b5146a6e6b182283_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi0xNC0xLTEtMTI2NzU0_cb2c73a0-6396-4110-a34f-c72246524eaa">7,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia78d78a3c9db493697ca176e09b7aa91_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi0xNi0xLTEtMTI2NzU0_19812104-590d-4ba8-b06b-86cd23118632">694,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative-effect adjustment from change in accounting principle</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i595026d5245f4feeafe415ec5546194b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMy0xMC0xLTEtMTI2NzU0_6cf3d127-75cf-4509-a278-ea028cf10038">23,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1264117696a4469a67e0ec136421d1c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMy0xNC0xLTEtMTI2NzU0_6bee881d-e750-44e7-acf1-472c0dee6600">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbbb19f83f1e4ad79e3dc7bea4c0e730_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMy0xNi0xLTEtMTI2NzU0_c2ef9308-de17-4672-8ea5-104b626d6e03">22,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Premiums paid for capped call confirmations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331" decimals="-3" name="neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNC0xMC0xLTEtMTI2NzU0_974cccb4-f88d-49dc-9383-f0bcd9de947c">29,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" name="neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNC0xNi0xLTEtMTI2NzU0_19f48263-56af-4fbb-946c-17a7b4b13e4e">29,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock issuance ESPP Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNS02LTEtMS0xMjY3NTQ_80c675c2-596f-4906-9c35-39b119508b62">23,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNS0xMC0xLTEtMTI2NzU0_46f1ce03-9989-48b3-a271-aef771114693">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNS0xNi0xLTEtMTI2NzU0_8e5b0299-3c17-4987-84f1-632f4299a114">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNi02LTEtMS0xMjY3NTQ_42dfcb08-2177-4c7b-80d5-10c139c98fdc">83,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNi0xMC0xLTEtMTI2NzU0_0e5f5acb-dbe3-4110-9b5e-90fcf6322dad">614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNi0xNi0xLTEtMTI2NzU0_34cf15e9-7dac-453b-b66f-7f59bf64cfcf">614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNy02LTEtMS0xMjY3NTQ_71392f29-b914-4e20-807e-2dc03aabadac">260,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNy0xMC0xLTEtMTI2NzU0_9a02ae34-4851-4fb6-9a18-79c674448d24">2,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNy0xNi0xLTEtMTI2NzU0_4ddf9f9b-2edd-4d94-811a-f1d0ccb124d6">2,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock - public offering, net of underwriting discounts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOC02LTEtMS0xMjY3NTQ_60c62bc7-1e8f-46e2-8759-4b6317190e6a">4,693,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOC04LTEtMS0xMjY3NTQ_36e111aa-40d3-4306-950e-9c2c2683bf40">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOC0xMC0xLTEtMTI2NzU0_276070dd-02ba-4186-81fa-3720c2dbbe99">218,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOC0xNi0xLTEtMTI2NzU0_e6d3bd37-5232-4418-ad78-0b8c8e978d93">218,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock issuance fees and expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOS0xMC0xLTEtMTI2NzU0_d7461d80-2219-4dc0-9dcb-0efb3a5ecbe0">242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOS0xNi0xLTEtMTI2NzU0_a856fc2f-7afa-4477-8b28-550aba8503e3">242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ESPP expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTAtMTAtMS0xLTEyNjc1NA_06ba91e5-3da1-4ee5-b638-f4ebe71aa3d4">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTAtMTYtMS0xLTEyNjc1NA_a1978341-893e-490f-968c-6fdbbbe0b8a2">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTEtMTAtMS0xLTEyNjc1NA_edce5704-c6a0-40d6-97f9-24f85205eead">2,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTEtMTYtMS0xLTEyNjc1NA_03366364-4a0a-4dc7-a500-b04f1ac8d933">2,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1bf40a8250f436ba33bacfac6825360_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTItMTItMS0xLTEyNjc1NA_10102210-9cad-4427-a48b-b14af7c467c0">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTItMTYtMS0xLTEyNjc1NA_7fff1d1e-b5af-4445-812e-184ce1ede0e4">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i405da8647b38440ebba559d212b5dd7c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTMtMTQtMS0xLTEyNjc1NA_359f9fb6-9bd5-4ca1-bcca-ed82ec3dc7f3">22,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTMtMTYtMS0xLTEyNjc1NA_5a6a0bd4-b1e0-4919-98d9-8e5a31554d8b">22,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc37ab8dceb2404d8981b679d85008ed_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtNi0xLTEtMTI2NzU0_1dc8db8b-6c19-43d0-b48e-13a827c9fbf5">117,136,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc37ab8dceb2404d8981b679d85008ed_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtOC0xLTEtMTI2NzU0_33930528-c3d3-4f4b-a1fb-b093102e138f">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52b9deb5b5e412c986b3a960ef6ec52_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtMTAtMS0xLTEyNjc1NA_fd9c448c-1a19-4e2b-8eee-24634d4a2b67">872,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cb2d646d0b14c8c9d1612c5c39524e8_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtMTItMS0xLTEyNjc1NA_a39d15ef-1197-40cc-8368-fa44d4fe071c">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee2a6c9923d645828b82bac68cf565f0_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtMTQtMS0xLTEyNjc1NA_c6c12911-8f24-4ba9-aaf3-5927f0973747">28,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d80520822e4942b1b02b3aede5033c_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtMTYtMS0xLTEyNjc1NA_8368ae8f-8bfe-492c-83f2-89469ef7a7d5">843,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock issuance ESPP Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTUtNi0xLTEtMTI2NjI4_de8dcd3e-d6cc-436e-80b7-24b0d39c9232">31,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTUtMTAtMS0xLTEyNjYyOA_500d1358-dacd-4a67-93f7-971ac9cb8ef1">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTUtMTYtMS0xLTEyNjYyOA_a7beafb2-d8b2-42c7-9b48-5d26fe5ff836">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTYtNi0xLTEtMTI2NjI4_73d2c755-ad86-4134-b195-54ac5b6ac860">146,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTYtMTAtMS0xLTEyNjYyOA_47eeff40-c3e8-4fab-ace2-ec2d6b6facdc">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTYtMTYtMS0xLTEyNjYyOA_76dff0ea-ae5d-43e5-aeca-0f5a764cbb1a">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTctNi0xLTEtMTI2NjI4_e4ce2d34-1428-4776-bee4-832ea243153a">354,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTctOC0xLTEtMTI2NjI4_31a85044-02d9-4fa4-bbb7-9a7945b24c31">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTctMTAtMS0xLTEyNjYyOA_01acbf10-1657-4cc2-af70-cc8886201787">4,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTctMTYtMS0xLTEyNjYyOA_4e6149c7-80d1-41a6-b124-51f646aa2d2d">4,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock - private placement, net of private placement fees</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTgtNi0xLTEtMTI2NjI4_6d81556a-e7e6-47a1-8bb6-e8ca2ea8e9e7">4,444,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTgtOC0xLTEtMTI2NjI4_aadda407-4c00-451a-8fd1-b68c1e569b13">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTgtMTAtMS0xLTEyNjYyOA_fb9886b9-9316-4a3c-be23-b361d5828386">189,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTgtMTYtMS0xLTEyNjYyOA_499d862c-0b73-4f04-a2ee-57eec662b1e5">189,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for acquisition</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTktNi0xLTEtMTI2NjI4_f96eb9ce-1121-4265-80d9-29fc19089781">597,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTktOC0xLTEtMTI2NjI4_c1c26b17-43eb-4e34-b948-a179a83b11b4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTktMTAtMS0xLTEyNjYyOA_fe994823-c00a-4481-828e-b5a1fbc92545">29,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTktMTYtMS0xLTEyNjYyOA_6b7d8227-2aec-43da-91b3-4b87869a9f8a">29,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock issuance fees and expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjAtMTAtMS0xLTEyNjYyOA_b7061d55-0dfc-49a0-ae0b-779ccd5c7120">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjAtMTYtMS0xLTEyNjYyOA_281d4fef-b049-47fa-87f4-4e4770d67a5a">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ESPP expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjEtMTAtMS0xLTEyNjYyOA_c1c18117-3a04-4847-821f-c6421f4ae595">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjEtMTYtMS0xLTEyNjYyOA_bc4cc8ed-193e-4b93-9887-7a714e17a5d6">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjItMTAtMS0xLTEyNjYyOA_3edcfd9d-eba0-4259-b1ae-b2a94ca7b9ee">4,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjItMTYtMS0xLTEyNjYyOA_16cd6c69-0ecc-4f31-9c21-c2cd57a0d95c">4,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c8a738d631c488c8a6d2ef8b1207ad6_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjMtMTItMS0xLTEyNjYyOA_ec1dd5e9-9ec9-458f-a585-fb1c83d8da12">183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjMtMTYtMS0xLTEyNjYyOA_02c98190-a4bc-4817-890e-0317af8159b8">183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e83cb2ada244e87863fccb0435f1caa_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjUtMTQtMS0xLTEyNjYyOA_c7d7556f-ed09-4e71-a939-f8bac830ac88">75,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjUtMTYtMS0xLTEyNjYyOA_163e7191-8359-4783-8058-7354957ff0e1">75,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b87d5129c424480b7bca5c7de9631c3_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtNi0xLTEtMTI2NjI4_96f28377-93b5-4d69-a017-1ba073094a3c">122,711,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b87d5129c424480b7bca5c7de9631c3_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtOC0xLTEtMTI2NjI4_c678c7e6-10a6-4c71-aebf-f23546aab6b9">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d53da225c7543cc8626b67085ff1039_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtMTAtMS0xLTEyNjYyOA_c239039b-5a29-4fb4-96b6-f13c655ddbe9">1,101,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a317c53d4440db036498f37a42c80_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtMTItMS0xLTEyNjYyOA_40b4b77f-6ba7-4988-86bc-c4f33296561b">333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a18efae1e24ac0a0f14cc9cb60d3d6_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtMTQtMS0xLTEyNjYyOA_c11f98c3-a270-46b5-a3a1-e2326c67e170">47,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d66426c727144e6a0ed073ec7de01aa_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtMTYtMS0xLTEyNjYyOA_970584a3-997f-49a3-807a-5ef6c0eeb57a">1,148,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock issuance ESPP Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzEtNi0xLTEtMTI2NjI4_53992fa1-3638-4858-8f48-205fd13f2226">27,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzEtMTAtMS0xLTEyNjYyOA_5bc02182-f81c-44fd-863a-565d2b51f422">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzEtMTYtMS0xLTEyNjYyOA_bc4d6af6-ff57-4305-a394-45afa33e01f5">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzItNi0xLTEtMTI2NjI4_0bea63ae-0922-4a6d-865f-73db647b9085">160,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzItMTAtMS0xLTEyNjYyOA_dd0a9df8-1873-42b0-a41c-dcda8cef1414">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzItMTYtMS0xLTEyNjYyOA_e264d1d1-d2b7-4554-a967-d45ebd69f882">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzMtNi0xLTEtMTI2NjI4_3ae19eba-5574-4d5e-8df3-a244b6b10d52">317,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzMtOC0xLTEtMTI2NjI4_c0c83c92-07bc-4265-a14c-9e3b09df2595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzMtMTAtMS0xLTEyNjYyOA_71fad3a6-27fe-48de-a311-0f6fe9cd1b82">3,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzMtMTYtMS0xLTEyNjYyOA_daccac5f-cbe3-4cf0-a73a-1a8f37ceb799">3,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock issuance fees and expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzQtMTAtMS0xLTEyNjYyOA_6a7a1fab-1afb-41f7-93c6-2a4f3c54e17c">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzQtMTYtMS0xLTEyNjYyOA_4ddb0fa7-b133-42a0-b7c6-b0fe584494e3">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ESPP expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzUtMTAtMS0xLTEyNjYyOA_a1123e90-711e-4383-9a60-8e19d76906ba">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzUtMTYtMS0xLTEyNjYyOA_b6093c5d-aa7f-46f2-894f-3a0a7d84cb9e">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock based compensation expense - options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzYtMTAtMS0xLTEyNjYyOA_d5aef946-c0c8-4004-ad66-07867b42da34">5,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzYtMTYtMS0xLTEyNjYyOA_851e4eec-59bc-420a-9a36-73ba0ff65bfa">5,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab400f484a364301b9f34d240511f761_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzktMTItMS0xLTEyNjYyOA_e5f0427a-2a7a-4f9d-9889-bec0bd034f59">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzktMTYtMS0xLTEyNjYyOA_07cf4d5e-12a2-4716-ade1-fabf4f264567">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic547475396b745199691ec6a3e16bdbc_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDAtMTQtMS0xLTEyNjYyOA_7a070df3-ea0b-46bd-989d-8d2f64a5a260">20,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDAtMTYtMS0xLTEyNjYyOA_ecb8442d-bf82-4dc1-b273-fa6abbca250f">20,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6b5778ebf6a4a509905cb89051df5f5_I20210930" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtNi0xLTEtMTI2NjI4_779f8709-1c0b-43f3-a1e3-f775d5242a55">123,217,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b5778ebf6a4a509905cb89051df5f5_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtOC0xLTEtMTI2NjI4_07f7dc7e-1109-486b-b7cf-9e1b747c1602">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b48692e0ad44bfa45dab1bc766eee5_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtMTAtMS0xLTEyNjYyOA_908446c0-3e0d-4c7b-b891-124dd5737624">1,110,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b574e55d4754f55a7a02ba000cdea51_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtMTItMS0xLTEyNjYyOA_408f3cec-cced-4e34-b732-845f871d62a4">390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5524fa47c894252b50792cf5bfb8a1e_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtMTQtMS0xLTEyNjYyOA_ba1367a1-5b77-47dc-a8c5-2815d7233428">26,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtMTYtMS0xLTEyNjYyOA_294ae5a2-e861-4e02-a684-9637c4a0d999">1,137,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_31"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMy0yLTEtMS0xMjY2Mjg_e1e2f3df-8e60-4ff0-9be5-c811e859195c">121,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMy00LTEtMS0xMjY2Mjg_115f6a1a-6e34-4752-88d6-0b5f5b95fcba">33,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net&#160;cash&#160;used in operating&#160;activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNS0yLTEtMS0xMjY2Mjg_8b53bbbd-3ad9-43a0-a1ef-21c34f8449bb">25,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNS00LTEtMS0xMjY2Mjg_bb74b4b9-721f-450d-8781-e1ee7e8003b7">21,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNi0yLTEtMS0xMjY2Mjg_f7bc6995-c9d8-4f06-9431-ee5fcdba0b2a">25,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNi00LTEtMS0xMjY2Mjg_2c15956d-babd-45a8-82bb-9bb7d7dbb6ce">14,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNy0yLTEtMS0xMjY2Mjg_22401d1a-909e-49c9-b969-8b667299ce44">20,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNy00LTEtMS0xMjY2Mjg_425ac436-89a1-4afe-90d7-7df2e0ff844c">12,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfOC0yLTEtMS0xMjY2Mjg_27746265-0961-490f-a923-680b38115bed">7,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfOC00LTEtMS0xMjY2Mjg_ffc6e88e-448a-44be-9668-745354e68861">6,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of convertible debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfOS0yLTEtMS0xMjY2Mjg_af17ae6e-7499-44fd-964b-7b3b4be15079">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfOS00LTEtMS0xMjY2Mjg_abb9406b-1181-4090-9eb2-e3eca10124e9">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issue costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTAtMi0xLTEtMTI2NjI4_ce868b5b-99ab-49ed-8656-8adc0c8dd136">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTAtNC0xLTEtMTI2NjI4_5fe952c2-7903-4d55-bf56-048ad5230862">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="neo:GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTItMi0xLTEtMTI2NjI4_4743eafe-3872-4c1d-acf9-dbe5639ea2ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="neo:GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTItNC0xLTEtMTI2NjI4_32415722-8877-4a29-8c5b-ae2b7569da3f">109,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest receivable on loan receivable from non-consolidated affiliate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="neo:ReceivableWithImputedInterestNonConsolidatedAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTMtMi0xLTEtMTI2NjI4_c646b500-9a2c-4034-a8fe-536a32d924d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="neo:ReceivableWithImputedInterestNonConsolidatedAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTMtNC0xLTEtMTI2NjI4_b240b638-42c0-4b15-b862-719f02104490">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTQtMi0xLTEtMTI2NjI4_6a3e4d67-a18d-4928-bcf4-08c51c89b1df">3,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTQtNC0xLTEtMTI2NjI4_01bcf2c9-f7a1-45bb-bf0e-a22cbab865ef">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTUtMi0xLTEtMTI2NjI4_2386dc1c-f16c-4873-8a91-9afb0e91023a">2,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTUtNC0xLTEtMTI2NjI4_d5c174ba-dda4-495e-b606-6c68b1775bbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of COVID-19 PCR testing inventory and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="neo:PolymeraseChainReactionTestingExitCostsCOVID19" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTYtMi0xLTEtMTI2NjI4_c1a39d64-f7b6-4582-9630-f431d797327d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="neo:PolymeraseChainReactionTestingExitCostsCOVID19" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTYtNC0xLTEtMTI2NjI4_6dc9473e-b4ed-45f0-8596-e2f96582eda3">6,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTctMi0xLTEtMTI2NjI4_e76e520b-5870-4dc3-a446-926673b6d671">1,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTctNC0xLTEtMTI2NjI4_39dfa289-b1ed-4c04-a0ad-a26e316390a9">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTktMi0xLTEtMTI2NjI4_b37e51ce-8ce6-4d10-a6e9-38b5ef89720d">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTktNC0xLTEtMTI2NjI4_16797310-4895-4f3a-ba2d-d98f7b22b177">2,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjAtMi0xLTEtMTI2NjI4_c7dd3e62-b9a1-42f9-92f7-2126bfb89634">403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjAtNC0xLTEtMTI2NjI4_20e69472-ac2b-41d4-be2f-3af4c99994db">3,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid lease asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="neo:IncreaseDecreaseInPrepaidConstruction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjEtMi0xLTEtMTI2NjI4_9e3f1ced-02a8-4088-8fd2-87cfbba03ea7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="neo:IncreaseDecreaseInPrepaidConstruction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjEtNC0xLTEtMTI2NjI4_bc7eacd2-6355-4315-a7dc-2a3555c15e18">4,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjItMi0xLTEtMTI2NjI4_2d9ebcf1-3e29-4493-a167-8a234137f7a8">3,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjItNC0xLTEtMTI2NjI4_ced1dfee-41bd-4248-9309-1d1464552caa">11,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, operating lease liabilities, deferred taxes, accrued and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjQtMi0xLTEtMTI2NjI4_28972b05-7702-497f-92fb-da9c8620edbc">20,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjQtNC0xLTEtMTI2NjI4_01d6cb45-df42-40ba-8083-79cdce0d8133">15,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjUtMi0xLTEtMTI2NjI4_39b557ec-6c36-4426-b960-99d97d58c91d">62,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjUtNC0xLTEtMTI2NjI4_24070676-c804-450d-890a-553a8be41b42">6,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjctMi0xLTEtMTI2NjI4_622193f2-d35e-4a97-a1ff-68a9623ef3ff">73,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjctNC0xLTEtMTI2NjI4_c955a585-694d-4cfe-acb9-62f1ec2e875c">180,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjgtMi0xLTEtMTI2NjI4_92dd89b8-04db-4dab-bd1e-a3ec533f6dda">89,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjgtNC0xLTEtMTI2NjI4_114e6ec5-129a-4983-afc4-0d21289b5cca">44,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjktMi0xLTEtMTI2NjI4_36119863-794e-42aa-8c7f-d5dce8cfdb38">26,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjktNC0xLTEtMTI2NjI4_4aade9bd-c133-416f-a382-9b16dce2eeef">52,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzAtMi0xLTEtMTI2NjI4_f0fdd85b-555a-4c35-adcd-49f39a0c0b1d">12,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzAtNC0xLTEtMTI2NjI4_8fa750d7-69f7-4856-b21a-4fef097fa8ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzEtMi0xLTEtMTI2NjI4_63cd9655-129b-4f7f-93d4-bfafcc8a458e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzEtNC0xLTEtMTI2NjI4_6004d738-a971-4c6a-b263-6ec2c68f7064">419,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loan receivable from non-consolidated affiliate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzItMi0xLTEtMTI2NjI4_88a2b237-9abf-45fa-869f-ea63bf9a5389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzItNC0xLTEtMTI2NjI4_ce8b4bda-0d9d-4b91-9317-f10707dd7983">15,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzMtMi0xLTEtMTI2NjI4_c788272a-0200-4e7f-a0e3-2e3ad8c7d7a7">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzMtNC0xLTEtMTI2NjI4_3f911a74-085e-4d6d-aacf-8f07c9a32618">622,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of equipment financing obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="neo:RepaymentsOfEquipmentAndOtherFinanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzUtMi0xLTEtMTI2NjI4_01559249-a8a5-4421-8b5e-2d87c87fc35b">706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="neo:RepaymentsOfEquipmentAndOtherFinanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzUtNC0xLTEtMTI2NjI4_f2b2b326-a14c-425f-9183-87fe1b25a57e">2,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzYtMi0xLTEtMTI2NjI4_7c58247e-1255-489f-a337-e2c1bf89f7ee">10,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzYtNC0xLTEtMTI2NjI4_cd6639fb-f73d-45a5-94f9-ab01bd912443">12,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of convertible debt, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzgtMi0xLTEtMTI2NjI4_39aea022-fb4b-4c3e-b619-3a1337ced828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzgtNC0xLTEtMTI2NjI4_89f18a6c-4f7d-410d-992d-d60d623f3004">334,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premiums paid for capped call confirmations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="neo:PaymentsOfPremiumsForCappedCallConfirmations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzktMi0xLTEtMTI2NjI4_18f4d4a8-b2d2-4de8-a396-4c3e132baa47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="neo:PaymentsOfPremiumsForCappedCallConfirmations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzktNC0xLTEtMTI2NjI4_4b932962-1bd9-4794-92c8-39e2e7892d27">29,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from equity offering, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="neo:ProceedsFromEquityOfferingNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDAtMi0xLTEtMTI2NjI4_f2ede77f-b3fa-4ceb-ac97-10f818187fa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="neo:ProceedsFromEquityOfferingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDAtNC0xLTEtMTI2NjI4_8cc45c25-194c-475e-a8f2-75216a97a816">408,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDEtMi0xLTEtMTI2NjI4_1d8614e2-c88c-4c45-a470-6efd7b887f48">10,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDEtNC0xLTEtMTI2NjI4_dd066714-fc1d-49e0-9746-0a290592e34c">722,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDMtMi0xLTEtMTI2NjI4_8253cc8e-4595-4a89-a973-4330aa468b10">50,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDMtNC0xLTEtMTI2NjI4_912b55cc-1e80-4442-8cab-cbe96a0ef423">93,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDQtMi0xLTEtMTI2NjI4_149257a1-0249-4990-a37e-4e0a989ff346">316,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia78d78a3c9db493697ca176e09b7aa91_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDQtNC0xLTEtMTI2NjI4_72310d58-c0a4-430a-9d68-c2bdec24fef0">250,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDUtMi0xLTEtMTI2NjI4_008bde98-86b7-4964-bfd9-3536a4f2967f">266,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDUtNC0xLTEtMTI2NjI4_87439082-f9a1-4149-987a-1e6519ded2db">343,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:66.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.321%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMy0yLTEtMS0xMjY2Mjg_4668af27-050b-4e11-9ee0-11bc08e84cf2">266,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMy00LTEtMS0xMjY2Mjg_d0b0e35c-35aa-43eb-bcc1-fe0cc58caf23">340,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfNS0yLTEtMS0xMjY2Mjg_dac8c76a-7bcc-4c98-af6d-640256727d60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfNS00LTEtMS0xMjY2Mjg_f9c57355-5974-4053-bc38-9fb5b9aef921">3,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfNi0yLTEtMS0xMjY2Mjg_0988d961-ca90-40d1-9e67-1957d31e9539">266,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfNi00LTEtMS0xMjY2Mjg_b6359c02-3067-47c6-af5d-ff36e6fb0811">343,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfOS0yLTEtMS0xMjY2Mjg_4b6d9236-6551-4139-882b-520aa054da84">2,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfOS00LTEtMS0xMjY2Mjg_d96097d5-a66a-4642-9afd-34772908228a">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTAtMi0xLTEtMTI2NjI4_e5fdccf4-31db-42d9-863e-cdba060aefb2">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTAtNC0xLTEtMTI2NjI4_a951b61f-5dd3-4977-9f48-09f1bbece95d">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of common stock issued to fund business acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="neo:FairValueOfCommonStockIssuedToFundAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTItMi0xLTEtMTI2NjI4_b26ff0cd-4178-4c94-9ebf-97e79f3ae4c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="neo:FairValueOfCommonStockIssuedToFundAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTItNC0xLTEtMTI2NjI4_d990d403-acd2-4884-aaa1-2327641bceca">29,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTYtMi0xLTEtMTI2NjI4_29f3a57b-9667-4e55-ac79-6e08840c27a7">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTYtNC0xLTEtMTI2NjI4_48f8373e-434a-4111-bf3c-3c0470aa58f9">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMzExNA_9d79862a-c8ff-4782-843f-367aa8fd6c34" continuedAt="id72cc1f115da438a8fe65848d6738164" escape="true">Nature of the Business</ix:nonNumeric></span></div><ix:continuation id="id72cc1f115da438a8fe65848d6738164"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Nature of the Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeoGenomics, Inc., a Nevada corporation (the &#8220;Company,&#8221; or &#8220;NeoGenomics&#8221;), and its subsidiaries, operate as a certified, high complexity clinical laboratory in accordance with the federal government&#8217;s CLIA, as amended, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">COVID-19 Pandemic Update</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact from the COVID-19 pandemic, including recent COVID-19 variants, and the related disruptions had a significant adverse impact on the Company&#8217;s results of operations, volume growth rates and test volumes in 2020, 2021, and in the first three quarters of 2022. The full extent to which the COVID-19 outbreak will impact the Company&#8217;s business, results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#8217;s results of operations, financial condition, and cash flows may continue to be materially adversely affected, particularly if the pandemic continues to persist for a significant amount of time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the cash on hand, marketable securities, and expected cash collections are sufficient to fund near-term capital and operating needs for at least the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the first quarter 2021, due to the broad roll-out of the COVID-19 vaccine and a sharp decline in COVID-19 polymerase chain reaction (&#8220;PCR&#8221;) testing demand, the Company made the decision to exit COVID-19 PCR testing and the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-5" name="neo:PolymeraseChainReactionTestingExitCostsCOVID19" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMTkxMw_60d33c39-8e25-4e5b-9ad1-4890d4ff057a">6.1</ix:nonFraction>&#160;million expense related to the exit from COVID-19 PCR testing. This amount consisted of write-offs of $<ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-5" name="neo:PolymeraseChainReactionTestingWriteOffsCOVID19" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjAxMA_03342667-7368-4b87-8d66-e15d198520d5">5.3</ix:nonFraction>&#160;million for all remaining COVID-19 PCR testing inventory recorded to cost of revenue and $<ix:nonFraction unitRef="usd" contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331" decimals="-5" name="neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjA5NA_bd637d32-4478-42b6-86fc-b2e0279d4466">0.8</ix:nonFraction>&#160;million for all remaining COVID-19 PCR testing laboratory equipment recorded to general and administrative expenses </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Consolidated Statements of Operations for the nine months ended September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There were <ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="INF" name="neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjI5MA_3ead02cf-3aa4-4a83-b560-8b6522267ac7"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="INF" name="neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjI5MA_45391a91-6af9-4cae-b744-e28b3a732dd6"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="INF" name="neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjI5MA_e80ebe3b-55ac-4c9f-a620-1870a3a85fff">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> COVID-19 PCR testing laboratory equipment or COVID-19 PCR testing inventory write-offs recorded for the three months ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the three and nine months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal government passed legislation that the President of the United States signed into law on March 27, 2020, known as the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). The CARES Act permits the deferral of payment of the employer portion of social security taxes between March 27, 2020 and December 31, 2020. Fifty percent of the deferred amount was due on December 31, 2021 and the remaining 50% is due on December 31, 2022. As of September 30, 2022 and December 31, 2021, the total accrued deferred social security taxes related to the CARES Act was $<ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-5" name="neo:SocialSecurityTaxEmployerDeferralCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjE5OTAyMzI1ODY3MA_292c1bd8-d095-4b1f-ba8c-2cc4abd239ec"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-5" name="neo:SocialSecurityTaxEmployerDeferralCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjE5OTAyMzI1ODY3MA_607f5132-2b97-43d0-90c0-2a7d88108d26">3.0</ix:nonFraction></ix:nonFraction>&#160;million. This amount was recorded in accrued expenses and other liabilities on the Consolidated Balance Sheets.</span></div></ix:continuation><div id="ib12970009bdf4a5493f36f07a1369fa4_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTc_740e5b44-f9f9-44be-81f1-5413bf7fcb66" continuedAt="i642762a59ed740d198e40642df07fce0" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i642762a59ed740d198e40642df07fce0" continuedAt="i466cf988ef414fa8900e17ef94870300"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTI_b76e01d7-63f4-4082-8860-7271efa7b592" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with GAAP for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, except for new accounting standards discussed under Recent Accounting Pronouncements.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in the Company&#8217;s annual audited Consolidated Financial Statements and accompanying notes have been condensed or omitted in these accompanying interim Consolidated Financial Statements and footnotes. Accordingly, the accompanying interim unaudited Consolidated Financial Statements included herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations presented in this Quarterly Report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited Consolidated Financial Statements include all adjustments and accruals, consisting only of normal, recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i466cf988ef414fa8900e17ef94870300" continuedAt="i02115e96669f4f57a600f2b582b7588b"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTU_d044246a-c7b3-474a-837a-7372a03caaa9" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#8217;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="neo:AssetsHeldForSalePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTM_1efc7e67-fe02-4915-ab57-adf76ab1ccd2" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Assets Held for Sale</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned <ix:nonFraction unitRef="sqft" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="INF" name="neo:AssetHeldForSaleSquareFeetOfFacilityOwned" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMzg4Mg_2b82ad74-62cf-4bb5-b679-b3dfe8b76761">43,560</ix:nonFraction> square feet of its Carlsbad, California facility. During the third quarter of 2021, the Company committed to selling this property and the associated land and concluded that these assets met the held for sale criteria. As of December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfNDExNA_b199ca71-5dd9-485d-a53b-a5778bfe8ca3">10.1</ix:nonFraction>&#160;million was recorded as assets held for sale within current assets on the Consolidated Balance Sheets for this property and associated land and reflected its carrying value which was lower than its fair value less costs to sell. The Company sold this property and associated land for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfNDQwNQ_343d70f9-7434-4e1e-bace-5da052af4748">12.1</ix:nonFraction>&#160;million, net of closing costs, in the first quarter of 2022. For the nine months ended September 30, 2022, a net gain on the sale of this property and associated land of $<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfNDU0Mg_4abaed85-0da1-43c0-8127-8ea1d272daf0">2.0</ix:nonFraction>&#160;million is included in general and administrative expenses on the Consolidated Statements of Operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTg_368ae80a-ad61-4d23-9e80-ae13d1012d10" continuedAt="i6ce1244baefd4e2dbf73a559560d2de0" escape="true">Goodwill</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ce1244baefd4e2dbf73a559560d2de0">The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#8217;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#8217; data.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2022, the Company performed a qualitative assessment to determine whether it was more likely than not that the fair values of its reporting units were less than their carrying values. Such qualitative factors included macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. As a result of the qualitative assessment, the Company determined that there were indicators that it was more likely than not that the fair values of its reporting units were less than their carrying values. Accordingly, the Company performed a quantitative analysis and determined the reporting units&#8217; fair values exceeded the reporting units&#8217; carrying values and there was <ix:nonFraction unitRef="usd" contextRef="iad9898a18252459abeaaa2287043243d_I20220630" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfNjYzMg_3090e1a6-a522-4cba-ba49-022a4c3f3e40">no</ix:nonFraction> impairment of the recorded goodwill as of June 30, 2022.</span></div><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMjE5OTAyMzI3NzI1OA_c123767c-649c-4310-ae51-35ff6e786827" continuedAt="i60b31fbcedda4e8dabd95f215cfe9dc9" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of payroll and payroll related costs for the Company&#8217;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, gains or losses on disposals of assets, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i02115e96669f4f57a600f2b582b7588b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i60b31fbcedda4e8dabd95f215cfe9dc9">segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three and nine months ended September 30, 2022 and 2021.</ix:continuation></span></div><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTA_2a5b053f-7e8d-4233-aea8-a9b2780d9d6c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-10&#8221;). This update requires business entities to disclose information annually about certain government assistance they receive. Such annual disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this new accounting standard in its Annual Report on Form 10-K for the year ended December 31, 2022 and does not expect the adoption of this standard to have a material impact on its Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-08</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating its adoption date of this standard and the impact of the standard on its Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIBOR</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of September 30, 2022, there was no impact to the Company&#8217;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.</span></div></ix:nonNumeric></ix:continuation><div id="ib12970009bdf4a5493f36f07a1369fa4_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTE3MjM_a5038404-4d6a-4410-aea9-defda5ea15e5" continuedAt="id96e8f4c91114bc6ae33dc514fe56f22" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="id96e8f4c91114bc6ae33dc514fe56f22" continuedAt="i656bbeeb964d42b585398b16186259a8"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Trapelo Health</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2021 (the &#8220;Trapelo Acquisition Date&#8221;), the Company completed the acquisition of a <ix:nonFraction unitRef="number" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTM1_8ed1afec-d1c8-4b9c-808a-a01b4e4bcd99">100</ix:nonFraction>% ownership interest in Intervention Insights, Inc. d/b/a Trapelo Health (&#8220;Trapelo&#8221;), an information technology company focused on precision oncology. The purchase price consisted of (i) cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMzQ1_df2a7b78-06fc-4768-83e4-514324e90b9f">35.6</ix:nonFraction>&#160;million, which included a net adjustment of $<ix:nonFraction unitRef="usd" contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407" decimals="-5" name="neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMzg0_575382f9-7636-46ac-a2ea-7183f03ee0fe">0.6</ix:nonFraction>&#160;million for estimated cash on hand of Trapelo and estimated working capital adjustments on the Trapelo Acquisition Date, and (ii) equity consideration of $<ix:nonFraction unitRef="usd" contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNTMz_7324f63f-82a4-45de-bfe4-1a0d32daf246">29.2</ix:nonFraction>&#160;million, consisting of <ix:nonFraction unitRef="shares" contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNTUx_284ee773-fd5a-4625-ab90-1b9ed12d20a7">597,712</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iff7308f890e64260ae7552498699b417_I20210407" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjAy_3f48ea66-1870-4fa8-a79d-113ebdbce6e0">0.001</ix:nonFraction> per share, valued at $<ix:nonFraction unitRef="usdPerShare" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjI2_3567624f-4047-4117-909b-fbd5d4474146">48.81</ix:nonFraction> per share. The Company acquired control of Trapelo on the Trapelo Acquisition Date; therefore, the fair value of the common stock issued as part of consideration was determined on the basis of the closing market price of the Company&#8217;s common stock immediately prior to the Trapelo Acquisition Date. The Trapelo acquisition enhances the Company&#8217;s ability to provide customers clinical decision support to help answer complex questions related to precision oncology biomarker testing and treatment options as part of the Company&#8217;s comprehensive oncology offerings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Trapelo was determined to be a business combination and has been accounted for using the acquisition method. The purchase price and purchase price allocation were based upon management&#8217;s best estimates and assumptions and were considered final as of March 31, 2022. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTE3MjQ_74c0742c-1004-478f-824a-457103f6afe3" continuedAt="i4888db2fded64faf8ef000b5e56b5bf5" escape="true">The following table summarizes the purchase consideration recorded for the acquisition of Trapelo, the fair value of the net assets acquired and liabilities assumed, and the calculation of goodwill based on </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i656bbeeb964d42b585398b16186259a8" continuedAt="i2b727ab818004d4c98b91616f3e4709d"><ix:continuation id="i4888db2fded64faf8ef000b5e56b5bf5" continuedAt="ib64b74bf398341c787ca24ce61926f12"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the excess of the consideration transferred over the fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:74.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued as consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMi0yLTEtMS0xMjY2Mjg_0abe8c60-b779-45af-8000-ed3ea2f50936">597,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share value of common stock issued as consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMy0yLTEtMS0xMjY2Mjg_be2a8e7d-3509-4874-80f2-d51d74897b3a">48.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of common stock at Trapelo Acquisition Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfNC0yLTEtMS0xMjY2Mjg_d8f241c3-2782-4340-afc8-05a5d01c2fe8">29,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Cash paid at closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfNS0yLTEtMS0xMjY2Mjg_3f9e9b88-3567-4ffe-90cc-b829f55c0174">35,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfNi0yLTEtMS0xMjY2Mjg_a36f864d-638d-428c-9b31-644b67e9db95">64,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of the purchase consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfOS0yLTEtMS0xMjY2Mjg_b98d1a6a-b888-4f23-a20e-6edbd370b948">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTAtMi0xLTEtMTI2NjI4_119507c9-7304-4320-b4f8-78fc9f84b2cc">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - marketing assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c2a0a7992f4f9c87c6ec0df05f6881_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTEtMi0xLTEtMTI2NjI4_72b0e08f-9ad5-473c-bb8d-6d0b7037035d">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dac90fa672439484bfb0a011afa79b_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTItMi0xLTEtMTI2NjI4_446387b0-2302-4e60-ac18-814ee85a0440">19,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTMtMi0xLTEtMTI2NjI4_f213a43d-bf49-41f0-a025-08fa0cdd376e">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTQtMi0xLTEtMTI2NjI4_ed18fd73-391e-489e-904f-2bed8da73648">20,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTUtMi0xLTEtMTI2NjI4_cd141179-cf22-4b0d-970e-47b3273a91ef">751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTYtMi0xLTEtMTI2NjI4_43e7b797-c19d-4b38-8378-1eb6de78cb00">20,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTctMi0xLTEtMTI2NjI4_c423f751-5808-4a8a-89e1-ea91272b2560">44,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTgtMi0xLTEtMTI2NjI4_cc69279f-2d70-4261-a0dc-6e8b6c4b4a16">64,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identified developed technology and marketing intangible assets are being amortized over <ix:nonNumeric contextRef="i2fb74da8b2fb46a5bb928c2ae920bddb_D20210407-20210407" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTk2NQ_978040dc-b765-4d28-8d0f-9206923f9a17">ten years</ix:nonNumeric> and <ix:nonNumeric contextRef="i752263ab04214611a5770e4027948a06_D20210407-20210407" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTk3Mg_41a7fe8b-7f9a-49fb-a823-032f11269b63">four years</ix:nonNumeric>, respectively, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Trapelo acquisition is <ix:nonNumeric contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMjE0OA_06eb4398-b1dd-4f3d-8a79-515cafd71dbb">9.8</ix:nonNumeric> years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The marketing intangible assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the marketing intangible assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the marketing intangible assets had the intangible assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#8217;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized, all of which was assigned to the Clinical Services segment, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. <ix:nonFraction unitRef="usd" contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMzMwNQ_d5cec33f-c442-4f5a-b716-c1708eeb3a65">No</ix:nonFraction>ne of the goodwill resulting from the acquisition of Trapelo is expected to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of Trapelo are included in the Company&#8217;s unaudited Consolidated Financial Statements beginning on the Trapelo Acquisition Date. No pro forma information has been included relating to the Trapelo acquisition, as this acquisition was not deemed to be material to the Company&#8217;s revenue or net loss on a pro forma basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Inivata Limited</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021 (the &#8220;Inivata Acquisition Date&#8221;), the Company completed the acquisition of the remaining equity interests in Inivata Limited, a private limited company incorporated in England and Wales (&#8220;Inivata&#8221;). Inivata is a global, commercial stage, liquid biopsy platform company. The acquisition follows a $<ix:nonFraction unitRef="usd" contextRef="id9000f1ccba54fd19804e3f40e0611cb_I20200531" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNDA5NA_14faea51-da3b-4c7c-bf89-b26707a22718">25.0</ix:nonFraction>&#160;million minority equity investment by the Company in Series C1 Preference Shares (the &#8220;Preference Shares&#8221; or &#8220;previously-held equity interest&#8221;) in Inivata in May 2020, at which time the Company also acquired a fixed price option to purchase the remainder of equity interests in Inivata for $<ix:nonFraction unitRef="usd" contextRef="i6a29368d78684750a6b47e75d93b5fe5_D20210618-20210618" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNDM3OQ_c6ef601a-c985-48ff-81d1-bbf483e80191">390.0</ix:nonFraction>&#160;million (the &#8220;Purchase Option&#8221;). The Company and Inivata also entered into a line of credit agreement in the amount of $<ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNDQ5Mw_9a1b27f9-8754-45d6-b361-104c755e00f5">15.0</ix:nonFraction>&#160;million (the &#8220;Line of Credit&#8221;) in May 2020. In the first quarter of 2021, prior to the Inivata Acquisition Date, an observable transaction of an identical investment in Inivata Preference Shares occurred which resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Company recorded a net unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="ie866a05c754c4aea88ba72656f3dfaf1_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNDg0Mg_a6db4fcc-a882-470b-ac6e-b310f5f2defd">5.0</ix:nonFraction>&#160;million on investment in non-consolidated affiliate for this remeasurement for the three months ended March 31, 2021 in other expense (income), net on the Consolidated Statements of Operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i2b727ab818004d4c98b91616f3e4709d" continuedAt="i2c2db3c148374fbba96d72de7db3f2cf"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inivata acquisition adds liquid biopsy platform technology, including minimal residual disease testing capabilities, to the Company&#8217;s comprehensive portfolio of oncology testing solutions. The purchase price consisted of cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNTI3OA_e2f5383c-b646-4858-ab6a-94097d3ee1f7">398.6</ix:nonFraction>&#160;million, which included a net adjustment of $<ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-5" name="neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNTMxNw_14e4ad8b-7023-48dd-978e-e1e903082a12">8.6</ix:nonFraction>&#160;million for estimated cash on hand of Inivata and other adjustments on the Inivata Acquisition Date, and was funded through cash on hand and a private placement of equity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the acquisition of the remaining equity interests in Inivata, the Company accounted for its previously-held equity interest and the Purchase Option in Inivata as equity securities without a readily determinable fair value. The equity interests were recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Therefore, the Company&#8217;s acquisition of control of Inivata on the Inivata Acquisition Date was accounted for as a business combination achieved in stages under the acquisition method. Accordingly, the Company used a discounted cash flow to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#8217;s previously-held equity interest and Purchase Option in Inivata. To determine the fair value of the previously-held equity interest, the fair value of Inivata&#8217;s total equity was allocated to its various classes of equity based on the respective rights and privileges of each class of stock in liquidation. The business enterprise value and a Black-Scholes model were then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at the fair value at the Inivata Acquisition Date based on its settlement value. This resulted in fair values of $<ix:nonFraction unitRef="usd" contextRef="i447890f585a7488ca3884eedd5e3f87b_D20210930-20210930" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjkxOA_bd3909f1-1e30-4be8-843d-532a350a2212">64.9</ix:nonFraction> million in Preference Shares and a $<ix:nonFraction unitRef="usd" contextRef="i447890f585a7488ca3884eedd5e3f87b_D20210930-20210930" decimals="-5" name="neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjk0OA_b35a8e08-3934-47c7-8206-087f55da6737">74.3</ix:nonFraction> million Purchase Option, immediately prior to the acquisition. On the Inivata Acquisition Date, the $<ix:nonFraction unitRef="usd" contextRef="i42f304bd718a4345825da30d39801aa4_I20210618" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNzA0Mw_fc0639c7-99eb-4d86-87ec-133a80d0c263">10.3</ix:nonFraction>&#160;million outstanding under the Line of Credit extended by the Company to Inivata was effectively settled as part of the acquisition of Inivata at the $<ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNzE4Nw_9a1b27f9-8754-45d6-b361-104c755e00f5">15.0</ix:nonFraction>&#160;million principal amount and was recorded as part of the consideration transferred in the acquisition. The Company recorded a gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#8217;s Consolidated Statements of Operations of $<ix:nonFraction unitRef="usd" contextRef="i19602c53e9f24c5e9c34e6540ce4ce9a_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNzQ1MA_c6cc9fc8-2b5e-4cdf-a343-08e9c4964770">109.3</ix:nonFraction>&#160;million for the year ended December 31, 2021 for the excess of the acquisition-date fair value of the Company&#8217;s previously-held equity interest, Purchase Option, and Line of Credit over their carrying values.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ib64b74bf398341c787ca24ce61926f12" continuedAt="i56870de6757a473383a9568d9e2bf723">The purchase price and purchase price allocation were based upon management&#8217;s best estimates and assumptions and were considered final as of June 30, 2022. The following table summarizes the calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit, and the estimated fair value of the previously-held equity interest and Purchase Option, over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):</ix:continuation></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i2c2db3c148374fbba96d72de7db3f2cf" continuedAt="i8dd5b7de2d2f4fedbe0c7c10c506d641"><ix:continuation id="i56870de6757a473383a9568d9e2bf723"><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:33.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.709%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 18, 2021<br/>(as initially reported)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Measurement Period Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 18, 2021 <br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMi0yLTEtMS0xMjY2Mjg_a5d79d72-b0b4-4831-9f13-b3e80dd10dcf">398,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMi02LTEtMS0xMjY2Mjg_8d4d4842-9d95-40dc-8803-5d939f8a23b5">398,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of Line of Credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMy0yLTEtMS0xMjY2Mjg_55fbf7fd-3bfd-4a77-a3c9-f84021e8b136">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMy02LTEtMS0xMjY2Mjg_9a7cccff-a635-41e3-a5de-8453c154d71a">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNC0yLTEtMS0xMjY2Mjg_9fc70217-b722-4eb7-bc04-d67080eabaec">413,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNC02LTEtMS0xMjY2Mjg_8b3b93b5-c2fb-49f5-9bba-4db2d21cf969">413,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of previously-held equity interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNS0yLTEtMS0xMjY2Mjg_a52fd8b9-f254-4717-8800-539f951cb68e">62,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNS00LTEtMS0xMjY2Mjg_601344ff-fa5e-45bd-8282-30700aba0c7c">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNS02LTEtMS0xMjY2Mjg_9956b854-d642-4089-a654-f6f81fffe603">64,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of Purchase Option</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNi0yLTEtMS0xMjY2Mjg_55a8b881-904e-4b51-a560-478b4d252898">58,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNi00LTEtMS0xMjY2Mjg_165cf1be-25fd-4724-a4fe-b4f924732a88">15,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNi02LTEtMS0xMjY2Mjg_eb0f76fb-1b05-48dc-b070-1b36a945bc91">74,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNy0yLTEtMS0xMjY2Mjg_8fa03851-c9b1-49f2-806b-70bf1c81f80f">535,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNy00LTEtMS0xMjY2Mjg_ec604ac7-84a2-4870-a4d9-71960b35518c">17,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNy02LTEtMS0xMjY2Mjg_8afba7f1-abc3-4e8f-a0ac-8f0417e231b2">552,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allocation of the fair value business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTAtMi0xLTEtMTI2NjI4_4ea8a3c3-52f3-4949-9051-2b74685ea7f0">14,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTAtNi0xLTEtMTI2NjI4_d0819efb-44d1-427d-9072-6e2074d1abe2">14,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTEtMi0xLTEtMTI2NjI4_279f34c7-c4b9-4d42-9d3e-af1e480b9539">5,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTEtNC0xLTEtMTI2NjI4_c957f9f1-5898-47e9-8002-962fd9292776">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTEtNi0xLTEtMTI2NjI4_bd51afbe-9179-4806-9e97-966ccf709923">5,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTItMi0xLTEtMTI2NjI4_c9b3dc00-fc2b-46e3-9ff8-2f24d5cf06ef">1,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTItNi0xLTEtMTI2NjI4_47013880-a382-4efe-b942-f53139cb2e5f">1,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets - developed technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddea112c263e4efd98f07f82c1942c43_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTMtMi0xLTEtMTI2NjI4_1fe5c121-1b0b-4b24-87a6-0f8b2a33db2c">302,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc7e8245487f4f58b121fa84f4613dc4_D20210618-20210618" decimals="-3" sign="-" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTMtNC0xLTEtMTI2NjI4_b96b3e66-7884-4149-95d1-ed104dd8b05d">11,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc78548fd43f4d83ac64d4a4b191d44e_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTMtNi0xLTEtMTI2NjI4_92a3edf6-d639-4c9e-8741-01747ad51e91">291,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets - trademarks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec4e93a323ef4cc3a8b43b840cbbf66c_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTQtMi0xLTEtMTI2NjI4_0e7b5308-5f0a-4478-9c0e-99c0a4d7020f">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb7a81052f8342aaaa4c62d41e183a9e_D20210618-20210618" decimals="-3" sign="-" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTQtNC0xLTEtMTI2NjI4_29699294-4704-4542-aeef-935e31a4d649">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b166ff4628f47a6a659a300bfe3a6bd_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTQtNi0xLTEtMTI2NjI4_6c084a91-459a-49a7-b079-c8cb0c9a6a81">31,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible asset - trade name</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57af656e837042e79c7838e6547334dc_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTUtMi0xLTEtMTI2NjI4_7790b956-99ec-46cc-82d5-474eb96e4ef8">2,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7214014d96a45c489ea60bba444a28e_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTUtNC0xLTEtMTI2NjI4_59665c77-6453-414a-8374-df853c6081d1">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865870f7a6e3486b94e11d31cbf92518_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTUtNi0xLTEtMTI2NjI4_77f6ecae-e88c-4a6c-a225-ef22d08817ab">2,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTYtMi0xLTEtMTI2NjI4_1cd29656-b0ae-42ff-a98c-d9e021aeb13c">6,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTYtNi0xLTEtMTI2NjI4_a8e9d0bd-d45e-498f-aa93-18609e48c0f8">6,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTctMi0xLTEtMTI2NjI4_794d0b6a-dfd3-4487-a576-4bf838d18f85">364,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" sign="-" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTctNC0xLTEtMTI2NjI4_f9afad84-1f63-4d62-9af1-9195a79cd1a8">11,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTctNi0xLTEtMTI2NjI4_25fa4297-a069-46ef-941c-0e5b827c5c9a">353,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTgtMi0xLTEtMTI2NjI4_8a604847-152c-4198-a2c1-d499fbb4b652">4,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" sign="-" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTgtNC0xLTEtMTI2NjI4_06a832bd-c1e6-4eec-b4be-e74392b5009b">1,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTgtNi0xLTEtMTI2NjI4_c3b702ad-f9cc-4b2a-ac18-e073396ab2d6">5,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTktMi0xLTEtMTI2NjI4_12f2a622-781c-4900-acb1-aa2205990cc5">64,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTktNC0xLTEtMTI2NjI4_dc2618dd-b0ba-4ed9-b897-9684b913d100">3,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTktNi0xLTEtMTMzNTUw_aa19667e-52b4-47c8-a58a-31567a652800">4,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTktNi0xLTEtMTI2NjI4_5d0b5a22-af7b-4d51-9c5a-418175303015">56,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjAtMi0xLTEtMTI2NjI4_2d0f7ccb-fe39-4999-aa48-ae1d1261036f">4,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjAtNi0xLTEtMTI2NjI4_64dbee58-a4c1-4140-8984-7a6540ce5a41">4,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net identifiable assets acquired </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjEtMi0xLTEtMTI2NjI4_eb2a9b25-2ac1-4391-a739-4f04299498b2">290,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" sign="-" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjEtNC0xLTEtMTI2NjI4_ffe9ade8-164f-4f37-81f1-c2cbf8b6e922">9,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjEtNi0xLTEtMTMzNTUw_e4bbd36b-b17d-4d1b-8187-1d0b0228adb8">4,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjEtNi0xLTEtMTI2NjI4_3c6c4f67-8c32-4c79-8969-3411acd2a551">285,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjItMi0xLTEtMTI2NjI4_69875333-f0d5-46fe-bbd2-a84fc8677c6c">244,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjItNC0xLTEtMTI2NjI4_9f5e12bb-8095-44f7-a0c4-462368d17969">27,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618" decimals="-3" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjItNi0xLTEtMTMzNTUw_f7423bdb-3782-4f4b-8f45-45a43ae81e4b">4,349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjItNi0xLTEtMTI2NjI4_f3a66e8d-4e86-4937-bb84-cbc63f70c928">267,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972519f375d24149b066529619e13c9d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjMtMi0xLTEtMTI2NjI4_75a6e17b-91b2-4217-af6e-42cda4d0d2cd">535,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjMtNC0xLTEtMTI2NjI4_1dc67d84-9355-40ad-bafc-fd0f421509c3">17,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjMtNi0xLTEtMTI2NjI4_7c63fe5b-0242-4ff4-89ae-528683bfa9bd">552,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangibles assets and related future amortization.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2022, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618" decimals="-5" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjU5NzA2OTc3ODkzMQ_c8d2244d-959c-4fc6-8199-cc50cb66f35c">4.3</ix:nonFraction>&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identified developed technology intangible assets and the trademark intangible assets are both being amortized over <ix:nonNumeric contextRef="ieb7a81052f8342aaaa4c62d41e183a9e_D20210618-20210618" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfODkyNQ_6e290fb7-a61d-4007-b1bb-0cd437cb1d31"><ix:nonNumeric contextRef="icc7e8245487f4f58b121fa84f4613dc4_D20210618-20210618" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfODkyNQ_83a6c351-b08c-4275-a2c7-86deb47594ce">fifteen years</ix:nonNumeric></ix:nonNumeric>, and the trade name intangible asset is being amortized over <ix:nonNumeric contextRef="id7214014d96a45c489ea60bba444a28e_D20210618-20210618" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfODk4OQ_f78f78b4-307a-4401-b338-d8cc4391dcec">five years</ix:nonNumeric>, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Inivata acquisition is <ix:nonNumeric contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfOTE1MQ_dc4b29e5-e9b3-4fc4-b7ab-396fa1644354">14.9</ix:nonNumeric> years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The trademarks and trade name assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the trademarks and trade name assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the trademarks and trade name assets had the assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#8217;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized, of which $<ix:nonFraction unitRef="usd" contextRef="ie1bbf95ea8de4373bbdc6c8c9dfb2a77_D20210618-20210618" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMjE5OTAyMzI2NzI4MA_1c47cc09-930f-4fba-8787-3651a6e70073">234.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5190e0e6e6094a9aba5a2f9550f41b08_D20210618-20210618" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMjE5OTAyMzI2NzI5Ng_6abd8650-1aec-4291-a36a-dd5e4a350f86">32.4</ix:nonFraction>&#160;million was assigned to the Clinical Services and Pharma Services segments, respectively, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of liquid biopsy technology for oncology testing. The recording of amortizable intangibles has given rise to a deferred tax liability upon the acquisition of Inivata which increased goodwill by $<ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTA1MTQ_7bcd1d8b-0b1f-414d-a8a1-4179bff342f9">56.6</ix:nonFraction> million. <ix:nonFraction unitRef="usd" contextRef="if0bbfe44413e450596641e770fb62e42_I20210618" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTA1MTg_ee05f9dd-7418-4161-b00f-ea51358ec0a4">No</ix:nonFraction>ne of the goodwill resulting from the acquisition of Inivata is expected to be deductible for income tax purposes.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i8dd5b7de2d2f4fedbe0c7c10c506d641"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTE3MjY_cc62615f-71f9-42d3-996a-6884b7543e5f" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:40.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.499%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30, 2021 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjM4ZmQ5MDNhYWIxNTQwNjc5ZDQ4ZjhhY2VhYjJkYWQxL3RhYmxlcmFuZ2U6MzhmZDkwM2FhYjE1NDA2NzlkNDhmOGFjZWFiMmRhZDFfMi0yLTEtMS0xMjY2Mjg_89464edc-b8bc-4fcc-bc8d-47fe21c6164f">121,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a24c5b482d4c868eb1ce13b760dbe9_D20210101-20210930" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjM4ZmQ5MDNhYWIxNTQwNjc5ZDQ4ZjhhY2VhYjJkYWQxL3RhYmxlcmFuZ2U6MzhmZDkwM2FhYjE1NDA2NzlkNDhmOGFjZWFiMmRhZDFfMi00LTEtMS0xMjY2Mjg_ad2a354a-2130-480d-88f5-20dcf49ceb17">358,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjM4ZmQ5MDNhYWIxNTQwNjc5ZDQ4ZjhhY2VhYjJkYWQxL3RhYmxlcmFuZ2U6MzhmZDkwM2FhYjE1NDA2NzlkNDhmOGFjZWFiMmRhZDFfMy0yLTEtMS0xMjY2Mjg_61a95e3e-e5c6-4282-9729-7f5ce109858a">37,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42a24c5b482d4c868eb1ce13b760dbe9_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjM4ZmQ5MDNhYWIxNTQwNjc5ZDQ4ZjhhY2VhYjJkYWQxL3RhYmxlcmFuZ2U6MzhmZDkwM2FhYjE1NDA2NzlkNDhmOGFjZWFiMmRhZDFfMy00LTEtMS0xMjY2Mjg_0da32486-dcf4-4ab5-becc-6bdffea1578e">88,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These unaudited pro forma results represent the combined results of operations of the Company and Inivata, on an unaudited pro forma basis, for the period in which the acquisition of Inivata occurred and the prior reporting period as though the companies had been combined as of the beginning of the earliest period presented. Therefore, the unaudited pro forma consolidated results have been prepared by adjusting the Company&#8217;s historical results to include the acquisition of Inivata as if it occurred on January 1, 2020. These unaudited pro forma consolidated historical results exclude, $<ix:nonFraction unitRef="usd" contextRef="ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930" decimals="-5" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMjE5OTAyMzI2Nzc1Mg_46b327a8-b719-4d2c-bf67-442656971e47">17.8</ix:nonFraction>&#160;million of measurement period adjustments recorded in the three months ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and $<ix:nonFraction unitRef="usd" contextRef="i42a24c5b482d4c868eb1ce13b760dbe9_D20210101-20210930" decimals="-5" name="neo:GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTE2NDM_51ba488c-f914-47da-b284-841e01dfb5b2">109.3</ix:nonFraction>&#160;million of gain on investment in and loan receivable from non-consolidated affiliate, net, recorded in the nine months ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></ix:continuation><div id="ib12970009bdf4a5493f36f07a1369fa4_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNDIxNg_a0f5e073-d8c1-4a26-afed-cd37af61c4c1" continuedAt="i613587cdfaa444688cbcdff56f347639" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i613587cdfaa444688cbcdff56f347639" continuedAt="ib194f63bc24b4e8588405760d2b121a6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.&#160;These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly.&#160;These are typically obtained from readily-available pricing sources for comparable instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs, where there is little or no market activity for the asset or liability.&#160;These inputs reflect the reporting entity&#8217;s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNDIxOA_af02a8e7-b99d-4e66-b5ef-ba6c9d9e1904" continuedAt="ief47b0f8f16a4d6fbdd781ebd143f8b6" escape="true">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#8217;s marketable securities accounted for as available-for-sale securities as of September 30, 2022 and December 31, 2021.</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="ib194f63bc24b4e8588405760d2b121a6" continuedAt="iddf3007b34984edc92b91651d7a88c3e"><ix:continuation id="ief47b0f8f16a4d6fbdd781ebd143f8b6"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNC0yLTEtMS0xMjY2Mjg_c1c1f383-c277-4f0e-83ae-aca43ffbe8c4">52,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNC00LTEtMS0xMjY2Mjg_4b55da8d-82bc-47d8-b148-0e0670d2a3f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNC02LTEtMS0xMjY2Mjg_b6153226-bed7-42f4-927f-1e19e34b658f">889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNC04LTEtMS0xMjY2Mjg_29bce335-564b-4ae4-b723-3085aafdd349">51,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNi0yLTEtMS0xMjY2Mjg_8e5a3c65-ad85-4c2a-92d3-c8eab0778ded">8,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNi00LTEtMS0xMjY2Mjg_f3e6dc69-4797-4913-9a44-a03c66b5175e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNi02LTEtMS0xMjY2Mjg_9d2bbe77-bb96-4409-9479-8ff4cd121de3">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNi04LTEtMS0xMjY2Mjg_098adc57-f04e-4db3-88cc-c0d2bcdfaf90">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNy0yLTEtMS0xMjY2Mjg_fe81abb1-63e1-4b9c-98f7-bb5788b55d87">8,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNy00LTEtMS0xMjY2Mjg_82c74d76-5497-44bb-8fc2-8904a799ab9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNy02LTEtMS0xMjY2Mjg_c2a10525-26e4-4e50-b217-5d147b29717d">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNy04LTEtMS0xMjY2Mjg_2f1230b4-8445-4e22-83d3-5c9fdf05d402">8,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOC0yLTEtMS0xMjY2Mjg_dfd2f2dc-3baf-4c44-b8bf-c7f3ee50e409">12,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOC00LTEtMS0xMjY2Mjg_fa1beaa3-657c-46db-8ee8-5ab26d955492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOC02LTEtMS0xMjY2Mjg_5e48de74-cae0-42b4-bbba-cb8e67aff26e">1,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOC04LTEtMS0xMjY2Mjg_01d8e009-8c27-4677-b11b-bb426e28e91f">11,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOS0yLTEtMS0xMjY2Mjg_4462562a-94f3-4fa7-a2b0-f74d1666458a">6,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOS00LTEtMS0xMjY2Mjg_b650549e-3087-433d-97ff-73862625776e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOS02LTEtMS0xMjY2Mjg_57f72003-ea31-4e52-a460-a88df3366814">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOS04LTEtMS0xMjY2Mjg_a021f1a0-e24a-4601-8c98-a3f6573448d3">6,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449f2af14b0146a5a78576a510536145_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTAtMi0xLTEtMTI2NjI4_ad131a0d-8177-482e-b734-54a10f6c046f">30,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449f2af14b0146a5a78576a510536145_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTAtNC0xLTEtMTI2NjI4_16274a9f-aa16-4d1e-b148-bb8c4ebf22ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i449f2af14b0146a5a78576a510536145_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTAtNi0xLTEtMTI2NjI4_5fb8b5d4-114b-4044-99fe-2f9bbde6613c">510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449f2af14b0146a5a78576a510536145_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTAtOC0xLTEtMTI2NjI4_286bda2c-1c82-44be-925a-86e41939d967">29,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45be316a68fd49828e355ae260885a25_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTEtMi0xLTEtMTI2NjI4_c4fa156e-4caf-4f7b-bb28-3e0945907ad1">62,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45be316a68fd49828e355ae260885a25_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTEtNC0xLTEtMTI2NjI4_c0caffa3-ac42-43b5-a6c2-57f252a344ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45be316a68fd49828e355ae260885a25_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTEtNi0xLTEtMTI2NjI4_94572b87-41da-410b-a0f4-57dc8ccaa748">2,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45be316a68fd49828e355ae260885a25_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTEtOC0xLTEtMTI2NjI4_4a3ffa55-2a39-4ad6-967f-4c1d1f8212cf">60,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTItMi0xLTEtMTI2NjI4_bfce9b60-bf2b-49f1-997e-fb2a0ed61bb3">182,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTItNC0xLTEtMTI2NjI4_028a3a99-6417-4ada-a5a6-bcb291fe5e16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTItNi0xLTEtMTI2NjI4_d52dff00-6201-42e6-943f-ac73e250153f">5,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTItOC0xLTEtMTI2NjI4_a46a0ae1-e2b4-4595-8489-1ad9ad4aca8a">177,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNC0yLTEtMS0xMjY2Mjg_92862a99-4079-402b-825a-46607af9b014">52,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNC00LTEtMS0xMjY2Mjg_3a6dc5f9-5918-4fdf-bc3f-41c9e182502a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNC02LTEtMS0xMjY2Mjg_eb568ef7-bdee-485b-abcc-6b2dd3840397">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNC04LTEtMS0xMjY2Mjg_96d02fc0-4a6b-4ae9-aafd-28c3cf118316">52,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNS0yLTEtMS0xMjY2Mjg_bedf2389-8cf7-4f02-a9c3-7174f4e700c0">6,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNS00LTEtMS0xMjY2Mjg_886df41c-a899-406e-9c4d-3e4c96a492db">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNS02LTEtMS0xMjY2Mjg_5ac1ab60-40c4-4fda-b442-f3a00220ec6c">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNS04LTEtMS0xMjY2Mjg_e3d3003f-7382-436f-9a66-c8fcbcda838b">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270d8802e355431a87805141beb22e21_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNi0yLTEtMS0xMjY2Mjg_a27d917b-5205-4393-9f4e-f6e2997b35b3">17,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270d8802e355431a87805141beb22e21_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNi00LTEtMS0xMjY2Mjg_385bd7d4-33bc-4161-93a1-5bbc486054be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i270d8802e355431a87805141beb22e21_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNi02LTEtMS0xMjY2Mjg_e5e79ffb-3a25-4098-ac1e-8e91af8bb739">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270d8802e355431a87805141beb22e21_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNi04LTEtMS0xMjY2Mjg_45d9baea-9bda-4350-a1bd-ab66c3a5d7d7">17,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNy0yLTEtMS0xMjY2Mjg_eb6f6667-3ecb-45da-9307-39224f3969d0">12,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNy00LTEtMS0xMjY2Mjg_36cf9660-2c27-4953-a6b8-4f8d3690e939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNy02LTEtMS0xMjY2Mjg_1aee5ef4-9b45-443e-b7ab-fb97561d3f74">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNy04LTEtMS0xMjY2Mjg_a7fa1e57-8b12-4038-a6b4-4c0491149639">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a59efcaaa54315abd137625d2903be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOC0yLTEtMS0xMjY2Mjg_231a5a19-9214-48cb-ad68-34be3b7adf64">17,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a59efcaaa54315abd137625d2903be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOC00LTEtMS0xMjY2Mjg_cfba5961-2103-4275-8d78-cac683200b49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67a59efcaaa54315abd137625d2903be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOC02LTEtMS0xMjY2Mjg_73755d9c-cefd-4e0b-9c63-6107db2490f2">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a59efcaaa54315abd137625d2903be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOC04LTEtMS0xMjY2Mjg_3e1c0673-9f18-4e3a-90ae-183baec86504">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOS0yLTEtMS0xMjY2Mjg_454ea7e7-a434-4210-a232-64c8bfd4d411">27,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOS00LTEtMS0xMjY2Mjg_0ad3f98a-32c5-47cb-afdd-d08622da1e7e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOS02LTEtMS0xMjY2Mjg_9f835e02-fe8b-4ae2-a478-2cdbbaf77b85">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOS04LTEtMS0xMjY2Mjg_194bdb2e-f3cd-4dbd-90e5-e3cbf4fbd475">27,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836abb9e08624532bd3983b006965c8c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTAtMi0xLTEtMTI2NjI4_636c3c68-b83c-4aaa-9c2e-c909f32593bb">65,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836abb9e08624532bd3983b006965c8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTAtNC0xLTEtMTI2NjI4_a76ca4e3-713d-4cdb-9d88-134555d27ffc">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i836abb9e08624532bd3983b006965c8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTAtNi0xLTEtMTI2NjI4_aadb3a82-1b93-4e5c-9b03-277957fa285a">452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836abb9e08624532bd3983b006965c8c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTAtOC0xLTEtMTI2NjI4_272ec6e8-2b82-4b30-b75c-d1d54090e1ac">64,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTEtMi0xLTEtMTI2NjI4_33753d90-5831-444b-bd08-fe38129f93c8">199,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTEtNC0xLTEtMTI2NjI4_80fdb4a6-b7bc-4791-ac62-2351baf06760">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTEtNi0xLTEtMTI2NjI4_cc37d36f-e7c5-42ce-99a6-e81e2fe5b0bf">923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTEtOC0xLTEtMTI2NjI4_5995788c-2839-45a3-954b-c7e23b776727">198,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $<ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfMjU5Mw_2c5b26af-7eba-40d6-b7db-5fa5b7ff5a2d">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNzE0NjgyNTU4NDc5Mw_6db2b0bd-7821-4540-83cc-113b3ee59390">0.6</ix:nonFraction>&#160;million of accrued interest receivable at September 30, 2022 and December 31, 2021, respectively, included in other current assets on its Consolidated Balance Sheets related to its marketable securities. Realized gains or losses on marketable securities for the three and nine months ended September 30, 2022 and September 30, 2021 were immaterial. </span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNDIxOQ_c73c4de1-a6ba-46ee-b6bf-f2b50e3aa304" continuedAt="i4bf1163e75ef42d7aa2fbf272bd885bf" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at September 30, 2022 and December 31, 2021. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNC0yLTEtMS0xMjY2Mjg_cdc71392-5ce1-42ae-b926-b52cc85c40ed">36,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNC00LTEtMS0xMjY2Mjg_28675706-d5d4-42c1-946e-5b524e717ffa">15,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNC02LTEtMS0xMjY2Mjg_91adde8f-f3c9-4642-8c44-36c857c1c157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNC04LTEtMS0xMjY2Mjg_68bae6fd-60e2-4d8b-8f70-7b1b13d8ab50">51,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNi0yLTEtMS0xMjY2Mjg_04a13086-934b-41ed-a4fd-62e714a6b471">5,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNi00LTEtMS0xMjY2Mjg_bc4c1059-335c-4793-a393-0c76dc042851">2,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNi02LTEtMS0xMjY2Mjg_5725203d-a706-4f74-aca4-4beeae8c6870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNi04LTEtMS0xMjY2Mjg_f525a1b2-c561-454a-b10f-1a00a57c3b2c">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNy0yLTEtMS0xMjY2Mjg_97ddbe84-6ba9-4135-8fbd-46e19fa87fdb">6,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNy00LTEtMS0xMjY2Mjg_8a4cf146-7af2-4587-a911-e03a2507738b">2,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNy02LTEtMS0xMjY2Mjg_84fe4a36-3749-4aff-a375-67b160382a67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNy04LTEtMS0xMjY2Mjg_48001487-cb70-4f81-b45b-08364a25d3de">8,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOC0yLTEtMS0xMjY2Mjg_81d72989-ebbf-404e-aa21-3b94670e2b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOC00LTEtMS0xMjY2Mjg_83a0560b-09ac-4e98-bd58-43137dedc5ce">11,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOC02LTEtMS0xMjY2Mjg_e8201655-96af-49ec-bf46-f0e2d62abd99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOC04LTEtMS0xMjY2Mjg_84bfe423-f191-44f1-aa50-3d623f9f8ee6">11,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOS0yLTEtMS0xMjY2Mjg_241a486d-2497-4740-9b6e-511a2567328b">6,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOS00LTEtMS0xMjY2Mjg_29a6030d-71b8-4b61-b3df-6526e911d1b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOS02LTEtMS0xMjY2Mjg_1c4b06c7-4c4b-4292-a48d-64c08a45e579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOS04LTEtMS0xMjY2Mjg_074cc363-8c85-47d1-86f6-f10838ac1a77">6,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449f2af14b0146a5a78576a510536145_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTAtMi0xLTEtMTI2NjI4_5257eafd-6ed4-46f9-b437-9fc847991940">25,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449f2af14b0146a5a78576a510536145_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTAtNC0xLTEtMTI2NjI4_d51ade99-cc2c-425f-b30f-7fb844a07c26">4,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449f2af14b0146a5a78576a510536145_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTAtNi0xLTEtMTI2NjI4_34846408-cf93-497f-87ff-4c4dc4d48e9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449f2af14b0146a5a78576a510536145_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTAtOC0xLTEtMTI2NjI4_16f10b39-2c3b-49d4-b192-f67dad288334">29,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45be316a68fd49828e355ae260885a25_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTEtMi0xLTEtMTI2NjI4_861137c6-9704-4020-8948-287e0e3cd416">31,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45be316a68fd49828e355ae260885a25_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTEtNC0xLTEtMTI2NjI4_2d06f4ef-3957-4998-a7e3-3265699eeafc">28,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45be316a68fd49828e355ae260885a25_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTEtNi0xLTEtMTI2NjI4_116abc53-317a-49ae-a7b6-e43d85b4a481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45be316a68fd49828e355ae260885a25_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTEtOC0xLTEtMTI2NjI4_89af6f91-99dc-4bab-9747-44c0f8b903a7">60,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTItMi0xLTEtMTI2NjI4_21cd9ee4-cacf-4280-af85-efc43e70cfc1">112,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTItNC0xLTEtMTI2NjI4_bf79ca43-d845-4a75-8b98-24325b9b904c">65,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTItNi0xLTEtMTI2NjI4_0f5c4778-21ba-456c-903b-c2df03556492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTItOC0xLTEtMTI2NjI4_354f6b4f-529e-4130-ab35-41cb1e373375">177,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="iddf3007b34984edc92b91651d7a88c3e" continuedAt="i6234a78412cb42368326cef1af5468eb"><div style="text-align:justify"><ix:continuation id="i4bf1163e75ef42d7aa2fbf272bd885bf"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNC0yLTEtMS0xMjY2Mjg_3bf8f8f2-82f9-4c29-aaab-56710f28461d">22,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNC00LTEtMS0xMjY2Mjg_3fbf498a-a0ed-47f0-b587-5f86ea6498f8">30,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNC02LTEtMS0xMjY2Mjg_b0e66497-5274-49bf-bf10-36dad55fa7ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNC04LTEtMS0xMjY2Mjg_a383d53c-ff42-4021-80bb-8cc0e797a435">52,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNS0yLTEtMS0xMjY2Mjg_fb0d7e02-7380-470c-ad06-05be63a8bfa9">4,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNS00LTEtMS0xMjY2Mjg_ce21ac4d-f9b8-4966-9b8a-fb497133323c">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNS02LTEtMS0xMjY2Mjg_2c4f5c49-0e65-4174-a91e-fb97bdda1e77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNS04LTEtMS0xMjY2Mjg_a2f524a4-3d68-4d9b-b146-8414a74559ec">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270d8802e355431a87805141beb22e21_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNi0yLTEtMS0xMjY2Mjg_955128c6-69dd-4ad3-bd56-0997349faccf">14,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270d8802e355431a87805141beb22e21_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNi00LTEtMS0xMjY2Mjg_fa9f9917-2df5-4d6f-83e1-a7e527373935">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270d8802e355431a87805141beb22e21_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNi02LTEtMS0xMjY2Mjg_3c6aa5fc-d8d9-473b-a671-6454e0a83ec7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270d8802e355431a87805141beb22e21_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNi04LTEtMS0xMjY2Mjg_965464c7-3dce-41b6-b492-ce23e563e1b8">17,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNy0yLTEtMS0xMjY2Mjg_4e402f4d-7e01-4deb-9f81-290b120632e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNy00LTEtMS0xMjY2Mjg_c5d72f0a-64cd-43c2-b099-80111f224cc0">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNy02LTEtMS0xMjY2Mjg_d5552e49-33cf-4f1f-aa52-18d8e491c218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNy04LTEtMS0xMjY2Mjg_5bb54a98-c492-45eb-af74-85e94c11b141">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a59efcaaa54315abd137625d2903be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOC0yLTEtMS0xMjY2Mjg_42f136dc-c86b-4234-aaf7-bc28067f106e">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a59efcaaa54315abd137625d2903be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOC00LTEtMS0xMjY2Mjg_82dd2504-a762-4707-abf5-a0dbc6d980a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a59efcaaa54315abd137625d2903be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOC02LTEtMS0xMjY2Mjg_cf2c0dff-6531-4015-86b1-d7fc26da7be7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a59efcaaa54315abd137625d2903be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOC04LTEtMS0xMjY2Mjg_ef5a2334-5b3f-4dac-8c84-28c04ffb2784">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOS0yLTEtMS0xMjY2Mjg_07d2ce72-32a5-44ca-8d17-b24c98da6255">20,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOS00LTEtMS0xMjY2Mjg_35c111a6-6ed8-42e0-a535-6fd9e9a87400">6,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOS02LTEtMS0xMjY2Mjg_5340088d-8fe9-4977-94c2-1e5d9712e28e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOS04LTEtMS0xMjY2Mjg_b33674a3-049a-4d12-9d0b-657750f79dc7">27,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836abb9e08624532bd3983b006965c8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTAtMi0xLTEtMTI2NjI4_a1ca8097-e1f8-4f00-9fa7-92f583b72e61">25,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836abb9e08624532bd3983b006965c8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTAtNC0xLTEtMTI2NjI4_6d887b73-f66f-46b2-a3a7-eb2d6aad6966">39,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836abb9e08624532bd3983b006965c8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTAtNi0xLTEtMTI2NjI4_242dfc57-59a0-46fc-8aa9-7e158a483fe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836abb9e08624532bd3983b006965c8c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTAtOC0xLTEtMTI2NjI4_5a722ed9-8482-4702-b8c4-05c12e5220df">64,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTEtMi0xLTEtMTI2NjI4_8d691535-c54a-47e6-9531-bbc9f63c45f2">104,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTEtNC0xLTEtMTI2NjI4_2ec68817-7ec4-4c33-882d-fe67c1fb51a8">93,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTEtNi0xLTEtMTI2NjI4_0972d31c-3f66-4b87-bfe0-0252b6aacaaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTEtOC0xLTEtMTI2NjI4_bad522da-8592-4298-bae6-ef60a2304836">198,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNDIxNQ_fe5ce4f8-c2a7-4aa5-bf3b-1ba2a68f4941" continuedAt="idf733f2f049d4fb0b74aed9b9d1d2a5b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of September 30, 2022 and December 31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836132e570fa408799f2204a799b968a_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNC0yLTEtMS0xMjY2Mjg_d49bc950-34fb-4ca8-8b23-9345594155e4">197,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75847b6fd90245879f447b248c88a3c6_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNC00LTEtMS0xMjY2Mjg_e2b55926-fd85-4837-bdeb-e4ab13b468c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63051c22ad4419daca3d275e18517da_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNC02LTEtMS0xMjY2Mjg_e15bd135-e19b-48b6-b0ec-9ae62aca550b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743caf65823d4bd1958a8cbb299c0895_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNC04LTEtMS0xMjY2Mjg_82323a86-8248-4a2a-9fcb-c8d49eb833c5">197,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51799610f4064775a69dfb0cac87a703_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNi0yLTEtMS0xMjY2Mjg_aacd0840-b2f0-4195-a69d-b5e5a7ad1814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6bf0ff21f364dc0a684dbf075b53b37_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNi00LTEtMS0xMjY2Mjg_81fc82e1-971e-4ec4-bf20-927a6da3eef9">35,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae95464f5ee74284b6ae32d61d93ce73_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNi02LTEtMS0xMjY2Mjg_cc44c3bb-3730-4a26-aa0a-8ff181678258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af9878ff27e4d028b3550392083c7b2_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNi04LTEtMS0xMjY2Mjg_4a8af484-a95a-4ccb-a16a-d7af3bd94380">35,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ea5826458e41d99aa352a497ffafd4_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfOC0yLTEtMS0xMjY2Mjg_63a97300-fda6-4d45-b0ba-779472589bbf">51,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118589658cf34ed5b9ddf840fb4e46c8_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfOC00LTEtMS0xMjY2Mjg_5bcbcdd6-0e39-4245-9a94-25657e0a72b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i604eda05df5c4b31b29a38fc217c0cbb_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfOC02LTEtMS0xMjY2Mjg_b49b4d31-de8b-40d9-909a-e6ae71590620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6936f18c703b4b55a0cdedf5a286c9e3_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfOC04LTEtMS0xMjY2Mjg_ebcd697a-3006-4a0d-aec9-9608010a5d7e">51,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bbc37daa8d04bef9ffd619049eca18d_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTAtMi0xLTEtMTI2NjI4_f4e28cfc-fbdf-4205-9110-e93532613f82">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf405aba888440c491e4e49e02bde83d_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTAtNC0xLTEtMTI2NjI4_43ffc22a-f560-406d-adcd-c493206177e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2698d44ba514d578ea6e059ae78c719_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTAtNi0xLTEtMTI2NjI4_f5ace403-1bf3-4b5f-a4a9-51cb50bd5549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac99a06e90442119500a802935b5fc5_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTAtOC0xLTEtMTI2NjI4_49da276a-1f68-48a9-a6d1-4161d0f59337">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id067a8d27c5e4dde917550297727f471_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTEtMi0xLTEtMTI2NjI4_6344b2c6-7d37-47be-a6ed-766fa2b2194d">8,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8dbf4d41b6a462f9551daf656d6df24_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTEtNC0xLTEtMTI2NjI4_3afd3889-b45f-4a7d-ba62-5e222c1acc2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i200b62a58197422faf0e93c36a17fcf2_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTEtNi0xLTEtMTI2NjI4_bb165c3c-5417-46fb-bf7d-a535dd973ed7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f5e669517d4caf99147dede75e60cd_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTEtOC0xLTEtMTI2NjI4_2d2e4e72-dcb4-4e6a-be03-ee1bca617318">8,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia425bc11b6e14936bb3bb334c3fcd38d_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTItMi0xLTEtMTI2NjI4_bdc2603f-8da8-4984-a2ca-9b3b342ee504">11,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eb1da66af64627bcc27ca09542053d_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTItNC0xLTEtMTI2NjI4_798a94c9-9208-4e15-8370-6e47024c144e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59406768d67448cb2b65eb67fed6dd0_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTItNi0xLTEtMTI2NjI4_2d1d4efb-6a3f-4dcb-ab44-66edeaaf0e26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc03daff727488d8a6291b702771aaa_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTItOC0xLTEtMTI2NjI4_3cb08f1a-48c4-4ccb-a9aa-93c6d61a760e">11,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aa480d457354319b83badeb66ffb82a_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTMtMi0xLTEtMTI2NjI4_7eb3afa4-d438-41bd-8dd4-a0a11659afe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0f765f52554a9c8dd28422846ea647_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTMtNC0xLTEtMTI2NjI4_ba74d2f1-975b-4e97-ba79-02a5f8251df5">6,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e9885cc6a7e41a58d60dbb43b197069_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTMtNi0xLTEtMTI2NjI4_73a10434-c25d-4196-b289-55a8aa1beab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8cb448cee344b8bf8f9dd3f02aecf6_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTMtOC0xLTEtMTI2NjI4_99dac6ba-9082-4958-9490-456240d72508">6,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81bbebaf499410a8b2e96ff47a6f837_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTQtMi0xLTEtMTI2NjI4_4a61c0ac-f0c9-46c6-b14b-45bcb909d920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10649a3764d48f99a112b7824cbe5ee_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTQtNC0xLTEtMTI2NjI4_e08b2b55-f262-4b87-b020-5dc2d9f6514a">29,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea910074ae8048cb9c2564fc116234c3_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTQtNi0xLTEtMTI2NjI4_2042bedf-87a7-4e58-945a-1f570e63109a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2be2fd21f9148e0b393eeafdff75ecf_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTQtOC0xLTEtMTI2NjI4_74275c9f-45ca-4a01-be18-adf9a4416a3e">29,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf8ac5a2c2b446f397a0b928f822a84c_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTUtMi0xLTEtMTI2NjI4_7573acfa-ff53-4a56-87c9-3651999196ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d7ac3af4f1f4aba835faf1dec1ae2d7_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTUtNC0xLTEtMTI2NjI4_be2c7627-3abc-4634-9c6f-509dd096dacd">60,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7758f3fc5d2843889d3dccc581512940_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTUtNi0xLTEtMTI2NjI4_d92d1722-4fd6-4b13-a274-66a87cd4b936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f5b2b00f414b6cb866b819f1811ee6_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTUtOC0xLTEtMTI2NjI4_2b7e86a2-03df-47d0-bc57-fe97ce268578">60,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecbb10c34a5e40a192afaea2596f4d4b_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTYtMi0xLTEtMTI2NjI4_a04a4c75-77b9-43ad-b619-511d63f4a4b9">278,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea762de04e3247bd84d1cc134af37b04_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTYtNC0xLTEtMTI2NjI4_737e23f8-9a42-4981-8cd9-95ca0647fffe">132,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c9ac9f23540ddbfd3c2431b55c0cb_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTYtNi0xLTEtMTI2NjI4_a8c00e2b-7ad4-4906-8f2b-96eb96e38d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacdf3ffa20844c33b3b4b233621d3bda_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTYtOC0xLTEtMTI2NjI4_c5ce32d9-9ca1-4865-95bf-9797364ca348">411,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i6234a78412cb42368326cef1af5468eb"><div style="text-align:justify"><ix:continuation id="idf733f2f049d4fb0b74aed9b9d1d2a5b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6b55ac524499facd15cc496171051_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNC0yLTEtMS0xMjY2Mjg_18db9e58-4076-4098-b7ee-4309194d36f6">254,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75652f68da664faa9631192fcc0b0756_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNC00LTEtMS0xMjY2Mjg_2ad6827f-377d-487d-a0b3-b8aea5713ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i542bc1cf4cff4dbf8c06c801299e4c0e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNC02LTEtMS0xMjY2Mjg_27b190c8-fcd2-443f-9625-09302b9caf61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195050c8c9bc4002b86ccce162741c31_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNC04LTEtMS0xMjY2Mjg_2f848ced-e000-40ce-a2dc-e86f3a156b9b">254,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if242353c50be44199306bd42b828c140_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNi0yLTEtMS0xMjY2Mjg_a67f732f-08d1-49fb-b016-06c16ea96ec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e94869d91d484ba640ce057070111e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNi00LTEtMS0xMjY2Mjg_d1377a5e-193c-4290-aed1-ec5b261a0b73">22,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic977ba257bc74ed0ac2c4dcf4afc8570_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNi02LTEtMS0xMjY2Mjg_b973be81-589e-4a52-8b5d-2303a838ac19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8311a90b3b424cac6df4bef4c4fbdf_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNi04LTEtMS0xMjY2Mjg_059f7ce7-a248-4a6b-bb4a-cb38ddca349c">22,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3004fdeeb1e74b4ca1d1b3699743ba6c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOC0yLTEtMS0xMjY2Mjg_625ba7ee-2123-4edc-bac6-d14e1064e6b5">52,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d3e0ab7458409591d23b08216cb230_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOC00LTEtMS0xMjY2Mjg_79c5ce5f-3a25-4ae3-97a6-76a462e62b30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a655c1539e343408dda30ab3e70fe06_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOC02LTEtMS0xMjY2Mjg_adebf61b-0f7c-476b-8572-4ee9e5adbea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4e60329fa940689159d4dd319eb066_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOC04LTEtMS0xMjY2Mjg_ea5c0fd7-17c1-48f1-a745-9471f2019ba0">52,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc756c44664b43f4b23fb38f1e93addd_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOS0yLTEtMS0xMjY2Mjg_7b15da64-4807-43eb-ba98-40d2410e0750">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e9f544c88447d2a59495913c96164d_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOS00LTEtMS0xMjY2Mjg_056ad70f-411e-4d5a-a72b-9f789d7f59ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc93136cd934c7ebd896d313b7290a1_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOS02LTEtMS0xMjY2Mjg_6e351b29-418f-416a-bb77-5ba471b2850f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c789341c8e4a58bd9ab39f1bf6644b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOS04LTEtMS0xMjY2Mjg_ed12aedd-32c3-40a9-86a4-bbc5d8b7ef76">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e98456b3d846289512b6de773624bf_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTAtMi0xLTEtMTI2NjI4_a2ac27cb-bfb5-4461-9856-82e7c633125a">17,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe8bbfc732445e9aceeb47b5e0c3c5a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTAtNC0xLTEtMTI2NjI4_056d8d3a-bfa0-438f-9a78-51ee1e815a78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc990a87d7a472183c3ef562e4fdfc4_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTAtNi0xLTEtMTI2NjI4_c5576ac7-f9e6-40b0-ba1b-ad37a3d36244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5ddba725f1440e874eacac1370e4dd_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTAtOC0xLTEtMTI2NjI4_018ed82a-ce8e-4581-b2e4-95a8000efbaf">17,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedaa1c912184478b0503bfd2e5d722b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTEtMi0xLTEtMTI2NjI4_7d7a8ec4-dbe2-45cc-9046-f659d1bfb81b">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e72e0725a14c9ca1b8b6e1a39fc880_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTEtNC0xLTEtMTI2NjI4_75d684ae-1bc6-495a-83c8-e48d1c40f9f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4319725e3601450bad41434e87073ac6_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTEtNi0xLTEtMTI2NjI4_b644bce8-2d87-497c-88ed-b39a55eaed83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbddcccd95b4981920388808f6beba8_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTEtOC0xLTEtMTI2NjI4_ca55ee35-8e3d-4862-9d2c-7e44c1a0354f">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f94087a2cb4149929f3d7ce3682734_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTItMi0xLTEtMTI2NjI4_38f26e58-8f0c-4dd4-be0b-728fbb92c47a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105dd178cd01422fa6a4e525c0693dae_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTItNC0xLTEtMTI2NjI4_13b6355c-f19b-42e8-9004-72c60c1fd426">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62854311ca47485eae6a22edb90202c9_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTItNi0xLTEtMTI2NjI4_29bec136-7073-47fc-95f0-6f7f21c093af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e5dd926f964588ba31f770c52749a9_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTItOC0xLTEtMTI2NjI4_17dda7ac-271a-4fec-8ac0-ed222954d490">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89899f69b9044c0a9086495bace3ae2_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTMtMi0xLTEtMTI2NjI4_c53421b6-e931-487c-ba51-abe89f5c313f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f7167428b0340b584497251fb87718a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTMtNC0xLTEtMTI2NjI4_1e570515-8abe-4679-bfe3-e0adce8bdf8d">27,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i321e7755d58a4125b1abe353704933f9_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTMtNi0xLTEtMTI2NjI4_46a1cdd5-6af7-4b43-9055-760532436d65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4822392b9ab44df6b413f0f3ac8e55be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTMtOC0xLTEtMTI2NjI4_3a77758e-7eaa-4daf-bb4f-19e3cfe57c6d">27,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b09d8a7a9546a1bddda55ed781ae42_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTQtMi0xLTEtMTI2NjI4_2f0eb354-e4c9-4bf9-952a-18883e7a055d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1d46b14a944988aae7942c987d7d5a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTQtNC0xLTEtMTI2NjI4_98eb814d-b547-4a1e-8745-cddb07e62ef2">64,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e4ee5f830e74fdc9b4bbb24f9d53418_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTQtNi0xLTEtMTI2NjI4_87b6f72e-1237-48f8-b671-7e0f6a731188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472970cdec304f53a5e8cd5cd075b4bd_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTQtOC0xLTEtMTI2NjI4_56774ec2-dad3-4394-84e5-fee14881d215">64,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia93e0b2a1e3d464f8e6df2d0e9f52148_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTUtMi0xLTEtMTI2NjI4_d15e877c-008e-4a53-8143-121f19017520">342,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib40d6f4a0a5143328f21dd179932836c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTUtNC0xLTEtMTI2NjI4_ff4a888b-8f7f-4f2f-aa7d-9ba4600cbcad">132,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d9995d5167f4c7bb2a4f642fe88981d_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTUtNi0xLTEtMTI2NjI4_a6cb99c5-42b4-4123-b127-3a32edcfddc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e0361f10ac4f76b5eba47b82775cbb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTUtOC0xLTEtMTI2NjI4_99543ab2-9970-4e1b-9466-c8b7e41ab784">475,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the three and nine months ended September 30, 2022 and September 30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other liabilities, and other current assets and liabilities, are considered reasonable estimates of their respective fair values at September 30, 2022 and December 31, 2021 due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, and long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and, as such, these are considered Level 3 fair value measurements.</span></div></ix:continuation><div id="ib12970009bdf4a5493f36f07a1369fa4_52"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjI2_0edf7d94-71fb-4132-b688-2c300174f54e" continuedAt="i617f0a56b7e54822bb1d5090bf5d4fe2" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i617f0a56b7e54822bb1d5090bf5d4fe2" continuedAt="i0ec254bab9b44f579de6f9e6527e7c69"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjI3_5fb6ba84-d026-44aa-8d41-ce8dff5c8b53" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amounts of goodwill by segment at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pharma Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75670d9ce45547bc99a81d6754f3d28c_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMS0xLTEtMS0xMjY2Mjg_7ea79b19-c5c4-446b-9439-333af23afce6">462,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae39a4495a641b8aa5ccb48e1ae2a5b_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMS0zLTEtMS0xMjY2Mjg_47d798e6-ff96-4311-9869-d0b1f1f7d9ec">64,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMS01LTEtMS0xMzI0OTU_59e57e92-8b25-4ee1-884d-72c6536b5527">527,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMi0xLTEtMS0xMjY2Mjg_14286854-8d6c-4d9f-88a3-2f6079972f3a">3,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMi0zLTEtMS0xMjY2Mjg_aa725a09-2f54-47e3-8137-6c4f2b723d67">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMi01LTEtMS0xMzI0OTU_69eb0db8-fa6b-4bed-a0d9-270305a235ef">4,349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb880a76146242968e6bfd45a3fcc254_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMy0xLTEtMS0xMjY2Mjg_3de8eeb3-e534-4e47-ae72-7ddc79c675ea">458,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b823d3747b4ba79fe123db7bc136cb_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMy0zLTEtMS0xMjY2Mjg_238ed0d5-c043-4eb8-85ae-559f7affec23">63,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMy01LTEtMS0xMzI0OTU_9f819c5a-8fcb-41ca-9f89-f51a90d3f6fb">522,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2022, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618" decimals="-5" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfMTA5OTUxMTYzMDA4OQ_c8d2244d-959c-4fc6-8199-cc50cb66f35c">4.3</ix:nonFraction>&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjI5_e7c87311-23ef-4f96-81e4-3e355aba90b5" continuedAt="i7b7afff5660d44d598a0adfad198bcff" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:41.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i549421f861aa49dc823adf1f4747dd6d_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjo2OTNiMWMwMGQwZjY0MWRiODIwM2Q0YTAxNmFkZTRmYl80_e07eb0e4-4f5a-4a85-a003-9b09b8c6ae32">7</ix:nonNumeric> - <ix:nonNumeric contextRef="i79e1457052954b8b8b8d8d0bbe2ac708_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjo2OTNiMWMwMGQwZjY0MWRiODIwM2Q0YTAxNmFkZTRmYl85_d002fbe8-eb54-4616-8fcf-5d0c2d3cbe30">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4e012e5ff04c92ba9762ee777b5ee0_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC00LTEtMS0xMjY2Mjg_8d1e48df-3383-49c5-8a69-a3d8b952192e">143,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4e012e5ff04c92ba9762ee777b5ee0_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC02LTEtMS0xMjY2Mjg_edd9b9fd-09fc-4897-a175-0f095037d05f">53,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4e012e5ff04c92ba9762ee777b5ee0_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC04LTEtMS0xMjY2Mjg_6bf40eef-f768-49e8-b5fe-d6e22a7ae439">89,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i797aec3fed494b6da15b5b1d78e7afaf_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjo4Mzc5NzNiZTlhMGI0YThiOTgxODA0MzQ1N2IwNDE1YV80_e616d492-1a6a-42d1-9e24-e24ab0741b64">10</ix:nonNumeric> - <ix:nonNumeric contextRef="ie84a64cf52bf488aa8c4b5c32b37ab49_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjo4Mzc5NzNiZTlhMGI0YThiOTgxODA0MzQ1N2IwNDE1YV85_a387bf9e-d6e6-4a82-ba0a-5e8bac4da138">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd5d3b7d14541ccb4c98224679c859c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS00LTEtMS0xMjY2Mjg_a7b52449-cb4e-498f-ada4-ce5da131ec47">310,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd5d3b7d14541ccb4c98224679c859c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS02LTEtMS0xMjY2Mjg_76afb3cc-98a0-41ca-b7fd-ade6334f5625">27,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd5d3b7d14541ccb4c98224679c859c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS04LTEtMS0xMjY2Mjg_da96f2af-70f4-4cb9-96a7-54299336fea4">282,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ac8a4996bb34043b19229ddcdd8fcf5_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNi0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjpkYzdiZDA5ZjI2ZWI0ZTM4YjliOWM3Y2Q1OWFkNmI5YV80_f1440b6a-4dd7-4030-8a9b-82218aac7bde">4</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbdc2914bf44ebf9369d82276e58d62_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNi00LTEtMS0xMjY2Mjg_09bd4642-6e34-4921-8108-2d89c643bb6a">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbdc2914bf44ebf9369d82276e58d62_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNi02LTEtMS0xMjY2Mjg_f2f4926d-518e-4f42-81a1-d3246c973ff5">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbdc2914bf44ebf9369d82276e58d62_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNi04LTEtMS0xMjY2Mjg_6900a2ba-1c65-49eb-9aaf-9d687e5f8674">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i106e8545ca314dd797829120c72a1131_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNy0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoyMGY5M2Y4ODMwNzQ0ZDU4YjI2ZjcxZDA1NDFjZTRiN180_4bfc326d-3642-4380-b19f-51c75a84603d">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idede4c70818e4ec8b5e2e8f0405ddf00_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNy00LTEtMS0xMjY2Mjg_78140d47-27c4-45fe-b10b-fe1bb519ad9c">31,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idede4c70818e4ec8b5e2e8f0405ddf00_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNy02LTEtMS0xMjY2Mjg_6fc05ee4-cb46-47f6-b6c0-6dea5ef31628">2,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idede4c70818e4ec8b5e2e8f0405ddf00_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNy04LTEtMS0xMjY2Mjg_075896ce-67ed-4c97-8df0-c25c16355e63">28,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i361720e05c8e458d9eda92fc5388b6e8_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOC0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjpiNzZkYmQxN2E5MWM0NzVjODM0YzI0ZTdiNmUwNjk3Nl80_eec72bdb-be3e-4890-929a-c00b439b77ce">5</ix:nonNumeric> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef158959bfb4e7f9623bff4b4a573cb_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOC00LTEtMS0xMjY2Mjg_b85a1b4e-3a96-4f1e-88fb-dca4f2b6ff2a">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef158959bfb4e7f9623bff4b4a573cb_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOC02LTEtMS0xMjY2Mjg_b387ee7c-6350-42c1-b2d7-0f193f711cdf">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef158959bfb4e7f9623bff4b4a573cb_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOC04LTEtMS0xMjY2Mjg_967f00c5-cb8a-4610-8e1f-33eaeefc403f">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib216f20bf24c458d809516016332ecd5_I20220930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOS00LTEtMS0xMjY2Mjg_81c7ec18-9774-4c91-b80f-251feb06b136">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib216f20bf24c458d809516016332ecd5_I20220930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOS04LTEtMS0xMjY2Mjg_52ba6073-3ec3-41b2-9ba8-31d24e9d58d0">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfMTAtNC0xLTEtMTI2NjI4_c3eb874a-287a-4a90-9d14-689ca886e5cb">501,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfMTAtNi0xLTEtMTI2NjI4_19831e19-4c00-4190-ba54-ab4ea64d2e8c">84,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfMTAtOC0xLTEtMTI2NjI4_4fa410fd-34d5-44db-85dc-03e1209c9dfa">416,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i0ec254bab9b44f579de6f9e6527e7c69"><div><ix:continuation id="i7b7afff5660d44d598a0adfad198bcff"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:41.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifd6c3992b5294ed89c00bb7e4387a2ff_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjplNjdmNzExYjNhMWQ0M2UyYTU5YmZlYmQxOTRkMWM4Y180_e1f8fe5f-8e76-41c2-bb20-848909051ce4">7</ix:nonNumeric> - <ix:nonNumeric contextRef="ib759ebff98dd441ca6275338c855db76_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjplNjdmNzExYjNhMWQ0M2UyYTU5YmZlYmQxOTRkMWM4Y185_9bf72115-254f-4f84-aa0b-a29d33b3c48f">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e053abf65147d29a5dd6a6ac867b9b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi00LTEtMS0xMjY2Mjg_5a663323-0c5a-4023-803e-9bd2444dd429">143,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e053abf65147d29a5dd6a6ac867b9b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi02LTEtMS0xMjY2Mjg_f565c846-81fd-4b91-aeb9-3b7f96faa918">45,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e053abf65147d29a5dd6a6ac867b9b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi04LTEtMS0xMjY2Mjg_723b078d-5fce-415b-b4b6-a7de0cf247ac">97,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd8360c0431e46e48e0c165b0287f029_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjphZDdkNzM2ODZlNzE0YmRkYWY4NmRjYmIxNjY1MTY1Ml80_cec7dbb9-a4a7-420b-84c5-ebdb69387e4e">10</ix:nonNumeric> - <ix:nonNumeric contextRef="i19cd4a991b204018b122a75e5768a87f_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjphZDdkNzM2ODZlNzE0YmRkYWY4NmRjYmIxNjY1MTY1Ml85_e9d40ede-d6f6-4a5d-8bb0-7dc8242717cd">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8ecbf116e841a9b4dfffda832ac632_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy00LTEtMS0xMjY2Mjg_9b8f6f67-6177-42dc-bc14-e246a79673ca">310,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8ecbf116e841a9b4dfffda832ac632_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy02LTEtMS0xMjY2Mjg_503f5d41-bd96-4935-b90f-2c6bb4d066b6">11,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8ecbf116e841a9b4dfffda832ac632_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy04LTEtMS0xMjY2Mjg_0815cad9-a58c-40bb-9b1b-294258c52e88">298,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic0b5bb4b553741e0bed88b54c12490b9_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNC0yLTEtMS0xMjY2Mjg_e5b8983c-9f5d-4e49-8f93-f273df680f16">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240234cbd1b048a88a80ecfb7db9b243_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNC00LTEtMS0xMjY2Mjg_ff684808-741b-40ed-a010-2c09f7ab38e6">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240234cbd1b048a88a80ecfb7db9b243_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNC02LTEtMS0xMjY2Mjg_8872021f-f05d-4231-8bc3-c76d74ad823c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240234cbd1b048a88a80ecfb7db9b243_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNC04LTEtMS0xMjY2Mjg_e0f63a80-0e50-4fa9-8c3a-1a8ff4bba5d8">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if9cf7af964324575b1e90a208499969a_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNS0yLTEtMS0xMjY2Mjg_6db8dd58-3658-4abb-9f1c-d7d9e4220962">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2acb703fa2e4b3d8f2adf8f1ccf8251_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNS00LTEtMS0xMjY2Mjg_b853a09b-fe97-4b0b-8d4f-6d0c04ae42a8">31,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2acb703fa2e4b3d8f2adf8f1ccf8251_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNS02LTEtMS0xMjY2Mjg_bfb1825d-8294-4a08-8990-b7e73a146074">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2acb703fa2e4b3d8f2adf8f1ccf8251_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNS04LTEtMS0xMjY2Mjg_c9ce8b52-f493-4c3c-a595-b7a19c38d487">30,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7474ff176c7846c0acef3250e51c454e_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNi0yLTEtMS0xMjY2Mjg_9e686c45-ac4d-476d-82de-cb3cd1eb76d0">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1287835862df47c8bc96b7ec0def19bc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNi00LTEtMS0xMjY2Mjg_79a4d75b-853e-429b-953f-29f8ff036777">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1287835862df47c8bc96b7ec0def19bc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNi02LTEtMS0xMjY2Mjg_5229b6d3-8ef7-4076-aed9-eb4de722e92f">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1287835862df47c8bc96b7ec0def19bc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNi04LTEtMS0xMjY2Mjg_a93dc951-63cd-4ffc-9b4e-6bba0cce3d15">2,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4649c38cd34257bb5c56cd8d83cd45_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNy00LTEtMS0xMjY2Mjg_00d2dd70-2505-484b-b7f9-8084c4c02d44">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4649c38cd34257bb5c56cd8d83cd45_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNy04LTEtMS0xMjY2Mjg_d68ecf0b-01df-4287-b968-aea03623115a">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfOC00LTEtMS0xMjY2Mjg_69da2d62-ced3-41cf-8001-55ea1efbc8c7">501,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfOC02LTEtMS0xMjY2Mjg_d7141966-60de-4576-acbc-0aa967c9a1b0">59,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfOC04LTEtMS0xMjY2Mjg_860d8373-f0e7-48c7-91ef-0a0ee6c7f6e5">442,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amortization expense within cost of revenue and general and administrative expense on the Consolidated Statement of Operations. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="neo:ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjMw_ae767995-6430-4a17-a317-8bb6caa2b719" continuedAt="i703402d948a74157aeade87c4a05fc77" escape="true">The following table summarizes the amortization expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:justify"><ix:continuation id="i703402d948a74157aeade87c4a05fc77"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e071a65fde4540a8f2f69263d43769_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMi0yLTEtMS0xMjY2Mjg_b37323cc-f092-4486-958f-61f78a22d09f">4,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77b4f7ab7454a149dc9bb68b7337a50_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMi00LTEtMS0xMjY2Mjg_8d22955b-c040-408a-9cf0-77ef5bbc2eb6">4,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac78e36d8f94115b39886bb71273081_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMi02LTEtMS0xMjY2Mjg_76a0af93-b8ab-475d-a2e0-f5b9b1fb06f6">14,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ac44e2ebca3469bb5add1f5bc673f54_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMi04LTEtMS0xMjY2Mjg_0758480a-f6f5-4827-ae18-31759da58a09">5,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8950ddf7dc73426abd2e59bb9e3428cd_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMy0yLTEtMS0xMjY2Mjg_198f9bd3-4ded-4016-94bc-fa7888d518a4">3,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5b9002c6c54807843802a2269d680c_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMy00LTEtMS0xMjY2Mjg_3fd32613-fed4-42e7-af44-ba706dfeac85">3,649</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i985788d5c071467d85f2f33e2f2e2fe3_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMy02LTEtMS0xMjY2Mjg_1dab857c-adfa-48e1-bacb-2c5aea07cce3">10,911</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613c8ef800af4acbb247578aff04da3d_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMy04LTEtMS0xMjY2Mjg_9fc73013-53bb-4cd8-8167-3c384627a6b4">9,129</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfNC0yLTEtMS0xMjY2Mjg_4cf4d426-5767-41da-bace-c778d4f97764">8,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfNC00LTEtMS0xMjY2Mjg_5103bfae-77bd-4c7b-acd6-e42bbb595df5">8,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfNC02LTEtMS0xMjY2Mjg_225b3602-4347-445b-b40c-9cf5056da81b">25,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfNC04LTEtMS0xMjY2Mjg_9fc79694-3a1b-40b5-9111-d7aaeb8c5cf1">14,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjI1_d8b48d99-6448-4fa1-8cf4-f10c782eaa1b" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense related to amortizable intangible assets for each of the following periods as of September 30, 2022 is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfMC0xLTEtMS0xMjY2Mjg_5700a991-6c3b-49ab-abd6-5ec70a02a8c5">8,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfMS0xLTEtMS0xMjY2Mjg_a2296f66-9b90-4506-b113-99d5e038cf6e">33,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfMi0xLTEtMS0xMjY2Mjg_cccac90e-9074-4adb-8034-d6d2be95741d">33,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfMy0xLTEtMS0xMjY2Mjg_9186ff62-55f9-4fb5-af67-8aa61cd06da2">33,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfNC0xLTEtMS0xMjY2Mjg_26268379-9692-42ba-884e-9a4e163e68f5">33,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="neo:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfNi0xLTEtMS0xMjY2Mjg_6a2f56b1-a9d3-45b5-ab1f-cf347619db0b">259,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfNy0xLTEtMS0xMjY2Mjg_146bc85a-32a6-44c6-9e62-aadf6398c749">403,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_58"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTU0MQ_0b99d3cc-3c02-4dec-87fb-7c0a210a44fa" continuedAt="ifdae8e9c58d34b7db509ff129cf01e4d" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="ifdae8e9c58d34b7db509ff129cf01e4d" continuedAt="i1e5e0354f3fa4b5eae4a7e13974fade3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2028 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, the Company completed the sale of $<ix:nonFraction unitRef="usd" contextRef="i2e078001d1454b3cbc7f7d7b83568f2e_I20210111" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTA0_008ac48d-abed-477f-a424-e4d1217eeacc">345.0</ix:nonFraction>&#160;million of Convertible Senior Notes with a stated interest rate of <ix:nonFraction unitRef="rate" contextRef="i2e078001d1454b3cbc7f7d7b83568f2e_I20210111" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTY2_11476341-951e-40c4-b326-d7a007d96a59">0.25</ix:nonFraction>% and a maturity date of January 15, 2028 (the &#8220;2028 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzg2_696b8471-2274-4743-b64f-0a7c467d2d10">130.0</ix:nonFraction>% of the conversion price of the 2028 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDU1_85743f2d-8a47-44c0-996a-546d1dfccd8f">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDcw_e83c119a-67a1-4f84-a049-8e774be41014">30</ix:nonFraction> consecutive trading days of the quarter ended June 30, 2022. Based on the terms of the 2028 Convertible Notes, the holders could not have converted all or a portion of their 2028 Convertible Notes in the third quarter of 2022. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNzk1_63573127-89bf-44b4-8107-7754152e2709">130.0</ix:nonFraction>% of the conversion price of the 2028 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjE5OTAyMzI2MTY1Nw_3e2252e6-5ec9-4140-8e44-786bc48a266b">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjE5OTAyMzI2MTY2MQ_563cd2a4-c376-4a41-a804-08c6b5d173c9">30</ix:nonFraction> consecutive trading days of the quarter ended September 30, 2022. Based on the terms of the 2028 Convertible Notes, the holders cannot convert all or a portion of their 2028 Convertible Notes in the fourth quarter of 2022. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7e9577a5d34442988876254f1f4de500_I20220930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjM2NQ_aa42a5dc-cd0a-4115-bede-13b34ab4f703">8.61</ix:nonFraction> on September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2028 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i09ab64c3de5a4744a9608181e3687f96_D20220701-20220930" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTMwNg_e45575a9-f151-4957-be72-649981d8fb91">0.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i09ab64c3de5a4744a9608181e3687f96_D20220701-20220930" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTMxMA_502ea91a-1d0d-415d-8088-a5bd0ac19c10">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i09ab64c3de5a4744a9608181e3687f96_D20220701-20220930" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTMxNw_0d09b64a-4825-4898-a859-59dd9408b78f">8,500</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2022. The interest expense recognized on the 2028 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTU2MA_e4efd3e0-8f81-41c0-9a4e-aa0c5f66e228">0.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTU2NA_be0bd2dc-f739-4672-88a3-12ef8f52f97d">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTU3MQ_bca77a08-d949-4ac0-9a22-fea3f1841ef3">25,300</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2022. The interest expense </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i1e5e0354f3fa4b5eae4a7e13974fade3" continuedAt="ie554b4a7e9ab4de6bb624bb2312206ea"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized on the 2028 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="ie2b7a7f93dbb4b1ca8195ad0d4023f57_D20210701-20210930" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTgxMQ_383a40a6-c830-495a-9ec1-4dcdcaa75b59">0.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ie2b7a7f93dbb4b1ca8195ad0d4023f57_D20210701-20210930" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjM1MQ_3025c639-1e9a-4dc8-be27-c37c710c1d87">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie2b7a7f93dbb4b1ca8195ad0d4023f57_D20210701-20210930" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTgyMg_896ba063-338c-4b58-98f4-05d9b50dc9fa">8,400</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2021. The interest expense recognized on the 2028 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i6cf3c51ab90a4a2898937c535e682135_D20210101-20210930" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjQ2OA_c1742ef6-8e0f-4f82-8ed2-c7b8f1dff48b">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i6cf3c51ab90a4a2898937c535e682135_D20210101-20210930" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjQ4Mg_6528ea08-fe42-4def-92d3-7691324a0e32">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6cf3c51ab90a4a2898937c535e682135_D20210101-20210930" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjQ5Ng_52122e2d-d31e-42c2-8ef5-34c48c65a120">23,700</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2021. The effective interest rate on the 2028 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjMwNg_58d5f3f8-6ace-4150-b40d-b167f97e1035">0.70</ix:nonFraction>%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="rate" contextRef="i7e9577a5d34442988876254f1f4de500_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjQ4NQ_25b43761-d1a1-471d-aaff-fe081b95bb23">0.25</ix:nonFraction>% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the estimated fair values (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="i7e9577a5d34442988876254f1f4de500_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjY1MA_0bd62494-9e38-4e53-931b-9912ba2a18eb">0.25</ix:nonFraction>% Convertible Senior Notes due 2028 was $<ix:nonFraction unitRef="usd" contextRef="ibf48e559e728411498f7b81a86313e8e_I20220930" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjY5MQ_6dd907cd-5856-40ac-bad6-9a09b9b83787">217.4</ix:nonFraction>&#160;million. At December 31, 2021, the estimated fair value (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="ie5639e39468f41488a1252639d4ef0c1_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTA5OTUxMTYzMzMyNQ_ace924fe-787a-47a6-a0f3-152de2d1fe57">0.25</ix:nonFraction>% Convertible Senior Notes due 2028 was $<ix:nonFraction unitRef="usd" contextRef="i766de052b6724a39ac4cff4bcdcc1a5b_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjc4NQ_a7b01116-be8a-47e8-8387-88be483955f7">297.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2025 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2020, the Company completed the sale of $<ix:nonFraction unitRef="usd" contextRef="ib8696c4831ac447f91dae99b16f092c2_I20200504" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjg2OQ_2eaed371-8fdf-4005-abde-e07ac46a94e6">201.3</ix:nonFraction>&#160;million of Convertible Senior Notes with a stated interest rate of <ix:nonFraction unitRef="rate" contextRef="ib8696c4831ac447f91dae99b16f092c2_I20200504" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjkzMQ_6469d668-4f93-443b-b928-db947b998c9f">1.25</ix:nonFraction>% and a maturity date of May 1, 2025 (the &#8220;2025 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzE0Nw_02dab045-44b8-4ee0-9855-6797ba44ced4">130.0</ix:nonFraction>% of the conversion price of the 2025 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzIxNg_7b2c8aba-3832-43fb-8a2e-9b219b8ecad3">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzIzMQ_3ff12317-df7c-43d2-b659-6663073aa477">30</ix:nonFraction> consecutive trading days of the quarter ended June 30, 2022. Based on the terms of the 2025 Convertible Notes, the holders could not have converted all or a portion of their 2025 Convertible Notes in the third quarter of 2022. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzU1NQ_d21353b4-63d6-4e7a-8e71-953e42954941">130.0</ix:nonFraction>% of the conversion price of the 2025 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzYyNA_4d769948-314b-4d52-a1c5-c557486e2e33">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzYzOQ_9c33464e-630f-43ae-85b9-d9f79078f646">30</ix:nonFraction> consecutive trading days of the quarter ended September 30, 2022. Based on the terms of the 2025 Convertible Notes, the holders cannot convert all or a portion of their 2025 Convertible Notes in the fourth quarter of 2022. The value of the 2025 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ied71922b6fb843699775ee25dc037112_I20220930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTA5OTUxMTYzMzg5NQ_ba67998c-a4f7-4a84-837b-6bbf7f3002be">8.61</ix:nonFraction> on September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2025 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="ia865031156044a7dbb6c87daac4c70d7_D20220701-20220930" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDA1NQ_632b796d-dd55-4c6b-9570-2fb05ef1288f">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ia865031156044a7dbb6c87daac4c70d7_D20220701-20220930" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDA1OQ_7732e983-07f1-42f0-bc8f-9211eac865e7">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia865031156044a7dbb6c87daac4c70d7_D20220701-20220930" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDA2Ng_a5aa7a65-39c0-4635-860d-9fe20a105f22">37,200</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2022. The interest expense recognized on the 2025 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDMwOQ_ce802196-674f-4bc0-94e7-c8d33ac2d4c4">1.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDMxMw_19e8034b-29a2-4a89-80a9-26eb51d95748">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930" decimals="-5" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDMyMA_76bcb89b-c42a-4c0c-909f-b9697590754a">0.1</ix:nonFraction>&#160;million for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2022. The interest expense recognized on the 2025 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i5ca9c808340f4bfcb031c666d2d97909_D20210701-20210930" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjYyMg_4a230e5e-d82b-4978-ae12-dc6cb984735b">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i5ca9c808340f4bfcb031c666d2d97909_D20210701-20210930" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjYzNg_89200620-b4a1-4005-9126-84c22a314f94">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5ca9c808340f4bfcb031c666d2d97909_D20210701-20210930" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjY1MA_bdfd6e5c-dd32-4b0e-8cf0-31cd544bdf3c">36,500</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2021. The interest expense recognized on the 2025 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i1edd2c29bc214bb28b0e32e7fd84ca23_D20210101-20210930" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjcxOA_1215688a-7c7c-49c2-bafa-3304576a225e">1.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i1edd2c29bc214bb28b0e32e7fd84ca23_D20210101-20210930" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjczMg_82bb63f1-4bf4-4525-9cb0-dc5c8c502caa">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1edd2c29bc214bb28b0e32e7fd84ca23_D20210101-20210930" decimals="-5" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3Mjc0Ng_4184032b-6e96-4f21-90e1-904fa8d23428">0.1</ix:nonFraction>&#160;million for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2021. The effective interest rate on the 2025 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTA1NQ_24327bcd-48b9-4e93-8440-a8491a1faa0f">1.96</ix:nonFraction>%, which includes the interest on the 2025 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2025 Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="ied71922b6fb843699775ee25dc037112_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTIzNA_9116bc40-13b7-4610-b5dd-bdcbd00a3a28">1.25</ix:nonFraction>% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, which began on November 1, 2020.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie554b4a7e9ab4de6bb624bb2312206ea">At September 30, 2022, the estimated fair values (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="ied71922b6fb843699775ee25dc037112_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTQwMg_9d46d718-5706-417e-bd5a-9241f42db5a4">1.25</ix:nonFraction>% Convertible Senior Notes due 2025 was $<ix:nonFraction unitRef="usd" contextRef="i5cc7c64aab7049d8bf4e97fd24d8055d_I20220930" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTQ0Mw_a9635228-8eb9-47cd-bc08-f9b71a2816a2">171.1</ix:nonFraction>&#160;million. At December 31, 2021, the estimated fair value (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="i8dfff7d2e5c04e57a4f8de1a51fac23f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTA5OTUxMTYzMzMzOA_796fd56f-465e-469f-8ab6-3e97e03d24a4">1.25</ix:nonFraction>% Convertible Senior Notes due 2025 was $<ix:nonFraction unitRef="usd" contextRef="i2582f1fdaa5d4fd58b8edb349ee79064_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTUzNw_60803a75-8304-42d1-98ee-bb0ddca1a1e7">238.9</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjczNA_6668be74-a656-462f-85e1-a8ba0a7e56fb" continuedAt="i5f432dcb34414f728c0bd0949469dcc3" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i5f432dcb34414f728c0bd0949469dcc3" continuedAt="i8dd7e59247a140be8956d64f4f03beac"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfNzM_b372c9c6-2549-48a1-9adf-0482b217daee">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfODA_b52f60be-f358-482c-9a47-c71d3b59ac6f">5.2</ix:nonFraction> million for stock-based compensation in general and administrative expenses </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended September 30, 2022 and 2021, respectively, and approximately $<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjY2_e8b6edc9-c709-44e8-894c-74c0167362e1">20.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjcz_27fe82bd-9c26-4b65-a721-653d46ba4fe6">12.4</ix:nonFraction> million for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjczNQ_26b3606f-af08-4d35-ab9d-adef1d1b6823" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s plans for the nine months ended September 30, 2022 is as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfMS0yLTEtMS0xMjY2Mjg_5e33e973-b164-4678-8691-bf4d951d279b">2,961,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfMS00LTEtMS0xMjY2Mjg_1d9bec14-9fcd-42f0-a891-56643ef5ef2b">25.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfMi0yLTEtMS0xMjY2Mjg_c8ee9190-bf51-48f4-a3a9-857de6b5190f">3,849,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfMi00LTEtMS0xMjY2Mjg_e583f629-c29d-447f-bb8c-5d7b1680609b">14.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNC0yLTEtMS0xMjY2Mjg_6d343e12-0280-4e26-bd9e-cc8a75862912">804,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNC00LTEtMS0xMjY2Mjg_8cc03ed2-72d0-4c44-a546-125122ce9c46">11.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNS0yLTEtMS0xMjY2Mjg_aa1fe4c3-606d-4fdf-95c1-4321f9004832">1,758,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNS00LTEtMS0xMjY2Mjg_464c54b3-07d4-4aae-a788-b909b49f4169">28.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNi0yLTEtMS0xMjY2Mjg_c08256d3-71dd-4fad-a57d-19a260fb31f0">4,247,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNi00LTEtMS0xMjY2Mjg_f930fe95-3ad5-4ae3-b514-b824affdc778">17.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNy0yLTEtMS0xMjY2Mjg_41a3670d-a630-4323-8a2f-cf65aad12925">1,019,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNy00LTEtMS0xMjY2Mjg_b018aaf8-518d-4fde-a6f6-d38a036faf28">24.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjczNg_db61b4e9-0903-4528-bc17-328df55477fe" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award granted during the nine months ended September 30, 2022 was estimated as of the grant date using a Black-Scholes model with the following assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23b5d383d9e84db6b635cdcd0c0f9d95_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMS0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoxMWU4YzU4NDYxY2Y0ZjA1YTQwZTAzODNlOGQxNTY1OV80_2f8c618f-85d6-4ceb-b2fb-14efb8154935">3.0</ix:nonNumeric> - <ix:nonNumeric contextRef="i62713aa84dd049d68dc66b6a1fe200e6_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMS0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoxMWU4YzU4NDYxY2Y0ZjA1YTQwZTAzODNlOGQxNTY1OV85_37d3858b-495d-41c1-85f0-68b3586005fb">5.5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23b5d383d9e84db6b635cdcd0c0f9d95_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMi0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoyMzVlZDM0MTc3YWM0MGJlOTUxZjAyYTk2YjRjMTU3YV83MTQ2ODI1NTgwNTQ4_b90d5278-5591-439e-83b5-a29fe753c92b">1.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i62713aa84dd049d68dc66b6a1fe200e6_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMi0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoyMzVlZDM0MTc3YWM0MGJlOTUxZjAyYTk2YjRjMTU3YV83MTQ2ODI1NTgwNTU0_00368dc2-f9ef-4c4b-88ad-6d9f9ce25e1c">3.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (%)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23b5d383d9e84db6b635cdcd0c0f9d95_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMy0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjozODBjZGEwOGQzMjc0M2Y2YWY4YTAwZDYwMDlkMmViN180_ba2aea4d-5846-4295-81d1-ca7fa69d8ea3">42</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i62713aa84dd049d68dc66b6a1fe200e6_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMy0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjozODBjZGEwOGQzMjc0M2Y2YWY4YTAwZDYwMDlkMmViN185_0988f48a-9cd4-49fe-a730-b377769c7624">60</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfNC0xLTEtMS0xMjY2Mjg_8c41a856-a597-42ef-af55-7f743d25f864">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfNS0xLTEtMS0xMjY2Mjg_dbf00ba2-871c-4656-8251-7c95b8477762">6.51</ix:nonFraction></span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfNjc4_bc0bee19-0b62-45d7-b000-66f8cb6fcc4e">14.8</ix:nonFraction> million of unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfODI3_d597099b-7973-4fa5-a9fa-975da891fbfc">2.2</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Awards</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjczMg_cad5753d-1824-4ed2-a38f-d38f0a4ea282" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted stock activity under the Company&#8217;s plans for the nine months ended September 30, 2022 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id36af2f403f24cf7b4525fc88fa61cb6_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMS0yLTEtMS0xMjY2Mjg_c456645c-1abb-4176-a34b-d1d2b9fe1785">851,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id36af2f403f24cf7b4525fc88fa61cb6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMS00LTEtMS0xMjY2Mjg_29180fcf-8b6c-4d7a-baf4-e41fcd760212">36.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMi0yLTEtMS0xMjY2Mjg_eb36217b-8864-4370-b371-fffe7a9087df">2,477,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMi00LTEtMS0xMjY2Mjg_de029c86-626a-456b-b308-0f9a5edc7dd2">14.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMy0yLTEtMS0xMjY2Mjg_bc2feba8-9c89-49bc-84f4-cf472408c1a2">311,055</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMy00LTEtMS0xMjY2Mjg_3f89c6ce-f3e6-4920-96f3-2bcdd6dbf60b">36.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfNC0yLTEtMS0xMjY2Mjg_8aad2480-c347-4bd2-8f8a-b12964d47519">1,022,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfNC00LTEtMS0xMjY2Mjg_65f00ca4-28e0-4b1e-b676-66aa5bf37ba3">27.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9abed8a09c214319a4423cf3fb5ecb73_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfNS0yLTEtMS0xMjY2Mjg_78efc1a3-ac96-4a7d-85b1-012676b5b993">1,994,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9abed8a09c214319a4423cf3fb5ecb73_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfNS00LTEtMS0xMjY2Mjg_cd5414da-8b55-493a-8f26-a15f6f279ab1">13.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i9abed8a09c214319a4423cf3fb5ecb73_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTAwNw_7c247f69-ed7a-4fb1-a979-408d8fffa0f9">19.8</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to restricted stock that will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTE1OQ_5106472c-5a69-488f-838e-9162bd1c46b8">2.2</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Modification of Stock Option and Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, upon the Chief Legal Officer&#8217;s departure from the Company and in accordance with the terms of the Chief Legal Officer&#8217;s employment agreement, <ix:nonFraction unitRef="shares" contextRef="idda8fd6e0a664803b84d581d6ad6b27a_D20220401-20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTM5OA_4e388902-8cb7-4601-822a-59996ed851fe">41,487</ix:nonFraction> previously granted time-based vesting stock option awards and <ix:nonFraction unitRef="shares" contextRef="i7ae752c4884e4e67ad202713d68fe1b2_D20220401-20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTQ2Mw_d03f62c7-0c2e-4878-9d68-d9de9c5ad053">76,138</ix:nonFraction> previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $<ix:nonFraction unitRef="usd" contextRef="i79b69f5ad10b449dac5c4fc387dfccf0_D20220101-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTY2NA_f51f3ead-d8f7-4671-91ca-a8718b180e2f">2.2</ix:nonFraction> million of incremental stock-based compensation which consisted of $<ix:nonFraction unitRef="usd" contextRef="i0739f9f5cb43425cb2d6fc5c3d1947da_D20220101-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTcyNg_52cf68ce-8395-4e6b-8543-27bca42b7ab6">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i90a3daea84f54e7bbfd7da40f557227c_D20220101-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTczMw_a796d0f9-c880-47fc-abfe-e87465095a16">1.9</ix:nonFraction> million for the acceleration of stock option awards and restricted stock </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8dd7e59247a140be8956d64f4f03beac" continuedAt="iccbba906e0724b2c9e9ebe9eeadad9fa">awards, respectively, within general and administrative expenses on the Consolidated Statements of Operations for the nine months ended September 30, 2022. There were <ix:nonFraction unitRef="usd" contextRef="i403368f4b4754ed4b335bff0b80a92da_D20220701-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfNjU5NzA2OTc2OTUyNQ_722f828a-0dcc-4f91-a96a-f5029bf1bd64"><ix:nonFraction unitRef="usd" contextRef="if65fbf7f2c924f07a648c17a334c7c42_D20220701-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfNjU5NzA2OTc2OTUyNQ_a0869991-73a9-4bb5-aa37-79f029b65b3e">no</ix:nonFraction></ix:nonFraction> such amounts for the three months ended September 30, 2022. </ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iccbba906e0724b2c9e9ebe9eeadad9fa">In the first quarter of 2022, upon the Chief Executive Officer&#8217;s departure from the Company and in accordance with the terms of the Chief Executive Officer&#8217;s separation agreement, <ix:nonFraction unitRef="shares" contextRef="i402c8314c37b4397a60a9dc5100ead32_D20220101-20220331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjEzMg_20d8a466-5e76-4c2b-b364-38b4466c25dc">237,960</ix:nonFraction> previously granted time-based vesting stock option awards and <ix:nonFraction unitRef="shares" contextRef="i915d2ee33bfe41828d288f2c9e850276_D20220101-20220331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjE5Nw_848e59b5-bcd4-4de9-a123-86da5a312075">142,302</ix:nonFraction> previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $<ix:nonFraction unitRef="usd" contextRef="i2983b693db614e67a0385420d6fe04db_D20220101-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjM5OA_9fc7a306-1719-4169-aede-31588d980ec1">5.9</ix:nonFraction> million of incremental stock-based compensation which consisted of $<ix:nonFraction unitRef="usd" contextRef="i8422c990601641b9923d741a1879f6f6_D20220101-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjQ2MA_69c48160-1b60-4a3f-a63b-632535203990">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie06ce2ae770d4cf98f1c70856a4ca493_D20220101-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjQ2Nw_9549315e-a98e-419d-8caf-792c9de020c9">3.6</ix:nonFraction> million for the acceleration of stock option awards and restricted stock awards, respectively, within general and administrative expenses on the Consolidated Statements of Operations for the nine months ended September 30, 2022. There were <ix:nonFraction unitRef="usd" contextRef="i403368f4b4754ed4b335bff0b80a92da_D20220701-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjY4NQ_722f828a-0dcc-4f91-a96a-f5029bf1bd64"><ix:nonFraction unitRef="usd" contextRef="if65fbf7f2c924f07a648c17a334c7c42_D20220701-20220930" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjY4NQ_a0869991-73a9-4bb5-aa37-79f029b65b3e">no</ix:nonFraction></ix:nonFraction> such amounts for the three months ended September 30, 2022.</ix:continuation> </span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_70"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzI4Nw_f10c84fe-56cd-4875-8650-ff4bbe9124d6" continuedAt="ibdc601579d3443b6b3490551adf95f53" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="ibdc601579d3443b6b3490551adf95f53" continuedAt="i77edfb76a58c43b3a3e6e63a680b561e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s <ix:nonFraction unitRef="segment" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNDc_b1b33c91-6dc9-481b-9797-74039dcd76ba">two</ix:nonFraction> reportable segments for which it recognizes revenue are (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience and other anticipated adjustments, including anticipated payer denials. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzI5MA_e3645028-6a79-43b1-a420-74a414728921">Collection of consideration the Company expects to receive typically occurs within 90 to 120 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharma Services segment generally enters into contracts with pharmaceutical customers as well as other CROs to provide research and clinical trial services ranging in duration from one month to several years.&#160;The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, and/or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is usually recognized over time based on the number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to the sponsor(s) at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics is the sale of de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected in advance of services being provided are deferred as contract liabilities on the Consolidated Balance Sheets. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. Contract assets are established for revenue recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets. All others are classified as non-current assets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customers, either immediately or according to advance notice terms specified within the contracts.&#160;All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i77edfb76a58c43b3a3e6e63a680b561e"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzI5MQ_87e9e30b-e2fe-45da-82f3-e9f49afa7081" continuedAt="i8d619e5f81cf445e8b492e267478674a" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMS0xLTEtMS0xMjY2Mjg_a1232c06-a07e-4974-be20-db3b03325dde">2,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMS0zLTEtMS0xMjY2Mjg_837bb79b-622b-4658-8109-f6f5aca073c9">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMi0xLTEtMS0xMjY2Mjg_c621cdf6-6e08-431e-bfd5-3624d70400d2">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMi0zLTEtMS0xMjY2Mjg_2a8474e3-a40b-4ba7-9d57-a9429606bf1d">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMy0xLTEtMS0xMjY2Mjg_2bf8351e-ddb0-4b1d-a213-d6ce408227ba">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMy0zLTEtMS0xMjY2Mjg_957435f7-a0ef-4546-95d5-4d4ddfd83002">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:CapitalizedContractCostNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfNi0xLTEtMS0xMjY2Mjg_24b95e12-f5b9-4a05-9526-531fcc8c4df4">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfNi0zLTEtMS0xMjY2Mjg_36bec197-9658-4618-95e3-0a79673e1767">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfNy0xLTEtMS0xMjY2Mjg_90155ed4-4396-4e98-baf7-a985a169cce3">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfNy0zLTEtMS0xMjY2Mjg_7e9961ce-e652-461d-9238-1ffcf5287dc8">882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma capitalized commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:CapitalizedContractCostGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfOC0xLTEtMS0xMjY2Mjg_9addba89-1209-49ec-91f8-2dc15064096b">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfOC0zLTEtMS0xMjY2Mjg_d0bef946-da6f-463f-84f2-092bac80e9d2">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTEtMS0xLTEtMTI2NjI4_5925c5a6-7325-4abb-b8b6-7e4f01fe918b">6,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTEtMy0xLTEtMTI2NjI4_7f1e0941-a161-42d5-b148-f8af0836a8e1">5,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTItMS0xLTEtMTI2NjI4_d8ed20b7-f708-49a5-8bda-1caab30c1e5e">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTItMy0xLTEtMTI2NjI4_6932a18e-948c-49e2-8ad6-2d4b5b138223">917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83580aae10c642e8968c0f73731cc216_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTMtMS0xLTEtMTI2NjI4_2b82e3ae-ed91-4cbe-87b0-7d8061a082b3">7,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8321097bff14046a282e8abcc199611_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTMtMy0xLTEtMTI2NjI4_0bd2eb03-e80e-4359-aa8c-16d5623fe5a1">6,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets. </span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i8d619e5f81cf445e8b492e267478674a" continuedAt="i6e04096bb7e540acb1037f647033bae3">(3)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6e04096bb7e540acb1037f647033bae3"> Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized for the three and nine months ended September 30, 2022 related to Pharma contract liability balances outstanding at the beginning of the period was $<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODA4Nw_4c3482fe-19b3-4a38-b250-2c2d29e4032a">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODEwNw_4abca97f-d75f-4367-876c-cd44cea5a810">4.8</ix:nonFraction>&#160;million, respectively. Revenue recognized for the three and nine months ended September 30, 2021 related to Pharma contract liability balances outstanding at the beginning of the period was $<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNjU5NzA2OTc3NDA3Ng_21ab1910-e5d8-426b-afc3-9f4bb7998207">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODA0OA_6f25b2c8-1995-4145-8e39-d49defde65a5">4.2</ix:nonFraction> million, respectively. Amortization of capitalized commissions for the three and nine months ended September 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODEzMw_83f4c497-779e-49f1-b3fe-e72b8de92713">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODE0OA_44f44a2f-9872-4b00-8156-2797e4a4ef23">0.6</ix:nonFraction>&#160;million, respectively. Amortization of capitalized commissions for the three and nine months ended September 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNjU5NzA2OTc3NDA1Mw_f96c3b78-6524-4874-a003-fad8ffb3e7e2">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNjIxMQ_9a02ea77-f48a-4ae7-8047-62830b3e6a98">0.9</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered various factors for both its Clinical Services and Pharma Services segments in determining appropriate levels of homogeneous data for its disaggregation of revenue; including the nature, amount, timing, and uncertainty of revenue and cash flows. Clinical Services categories align with the types of customers due to similarities of billing method, level of reimbursement, and timing of cash receipts. Unbilled amounts are accrued and allocated to payer categories based on historical experience. In future periods actual billings by payer category may differ from accrued amounts. Pharma Services relate to contracts with large pharmaceutical and biotech customers as well as other CROs. Because the nature, timing, and uncertainty of revenue and cash flows are similar and primarily driven by individual contract terms Pharma Services revenue is not further disaggregated.</span></div><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzI5NA_e8ae24e2-a348-4fc9-ac08-e521014ef6cb" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Client direct billing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12404422705e4e5db442f2c6fa044950_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfMy0yLTEtMS0xMjY2Mjg_24304682-1d6e-4c0c-8213-5372b9e54b0b">73,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4daaae4c144b64bf090d8b0ec28bde_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfMy00LTEtMS0xMjY2Mjg_e027b787-9be6-4430-b864-15b3cd2767fd">64,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ce6ba5e4be4b41adb542d8cc8b71c4_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfMy02LTEtMS0xMjY2Mjg_fb7815f0-6b3c-49cf-bcee-e240f348710a">208,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9f8f865eca4dee9704f9ae41b2c4a2_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfMy04LTEtMS0xMjY2Mjg_700053ce-3006-45f0-9faa-ecfb74d52e6d">188,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial Insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e564189e94f8da0931134c08f04e2_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNC0yLTEtMS0xMjY2Mjg_91faad14-22ed-4494-9a4c-77f57124115b">17,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9077f666a17a48f3b7bc80bc791c4661_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNC00LTEtMS0xMjY2Mjg_71e91d49-5b60-4894-9bc0-58ef5d25b46f">19,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e2ed3be0744fb0a5fa17de9fd64cb8_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNC02LTEtMS0xMjY2Mjg_7a8c9b94-7e1d-4555-bffa-ba4b5d1737c6">53,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i518f32fbbb6149f08c71ce0cf09bfa3e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNC04LTEtMS0xMjY2Mjg_7dcebcf2-3acc-457e-b27c-9afb2ae05002">58,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Medicare and Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6531ec4b2bd491d919cb52b975afca2_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNS0yLTEtMS0xMjY2Mjg_57bafffd-3f40-40b4-9fa3-23081f161d00">15,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idadb4a2ecea94787888cba5a2ec1fdf4_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNS00LTEtMS0xMjY2Mjg_bc980fc7-6b6a-4e0a-b7d3-19f1c7cce5d5">18,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e676b3f14974a14b21ed4e1353a4970_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNS02LTEtMS0xMjY2Mjg_4fd13de7-0cf0-41dc-aa17-6582f2bce3de">48,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0430c68b11e441a1932ef5b6bf20883e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNS04LTEtMS0xMjY2Mjg_caff1756-521d-403c-9852-9fa248a24886">52,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Self-Pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4d4146b09f46f8bae21fa55af4e603_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNi0yLTEtMS0xMjY2Mjg_0ce6a544-111b-469e-83d6-3792e5e05d43">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c17f0a685d4b4bb4ac9262b0409185_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNi00LTEtMS0xMjY2Mjg_78bebe64-c325-45d8-ad58-4129ee3e5635">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4359f136a8724314ae74fdfcb5cf1ddb_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNi02LTEtMS0xMjY2Mjg_93bdf433-ffe0-4d82-90d0-adf2c7da683d">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31361b8430c34cb1a61a5212cab1d7e4_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNi04LTEtMS0xMjY2Mjg_ca0b186b-e0fb-4e86-9a28-2bfded5ffbdd">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Clinical Services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNy0yLTEtMS0xMjY2Mjg_a44b4c1e-e229-49df-8e1c-6e73403e0a03">106,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNy00LTEtMS0xMjY2Mjg_c8f3eb1c-5124-4d24-bec1-fe45f8be22a5">102,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNy02LTEtMS0xMjY2Mjg_274cba14-d15e-4db8-83f1-2b4d7a3779fb">310,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNy04LTEtMS0xMjY2Mjg_d19c27aa-f5e1-41de-92b9-54bc771684e5">300,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOC0yLTEtMS0xMjY2Mjg_26ad7a9b-3abd-4d2d-8bd1-b1ed56faaef8">22,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOC00LTEtMS0xMjY2Mjg_c4a1cd17-c9aa-437a-8500-89f0f47464f6">19,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOC02LTEtMS0xMjY2Mjg_8c9fccee-5ba4-4ff5-b5d0-0103c72c6d50">60,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOC04LTEtMS0xMjY2Mjg_de9685d5-ab68-4949-8872-7e5bdbc100ed">58,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOS0yLTEtMS0xMjY2Mjg_b61adb8d-0238-4b5e-81db-80049c75101e">128,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOS00LTEtMS0xMjY2Mjg_3e54f943-a372-4169-905c-80f1c987ba8c">121,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOS02LTEtMS0xMjY2Mjg_7b844cd5-be92-4d24-9a15-83313d6cea25">371,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOS04LTEtMS0xMjY2Mjg_380756c7-621a-4848-a8a4-7cdb63bcbf2f">358,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_73"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83My9mcmFnOjNkY2M0ZjAyNDFmZjQzNWQ5ZTg1M2M3NWQ0ZDFhOTg4L3RleHRyZWdpb246M2RjYzRmMDI0MWZmNDM1ZDllODUzYzc1ZDRkMWE5ODhfMjAzMA_ad89a897-5956-48ad-8412-cf22f337cd6e" continuedAt="i4901d2351ea740d3b30c90770af4dffd" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i4901d2351ea740d3b30c90770af4dffd"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of each interim period, management estimates the annual effective tax rate based on forecasted pre-tax results of the Company&#8217;s global operations and applies such rate to its ordinary quarterly earnings to calculate income tax expense related to ordinary income. The tax effects of items significant, unusual and infrequent in nature are discretely calculated and recognized in the period during which they occur. These discrete items often relate to changes in tax laws, excess tax benefits/deficiencies related to share-based compensation or adjustments to previously reported tax expense/benefits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing available positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred income tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome. Cumulative loss in recent years is commonly defined as a three-year cumulative loss position. As of September 30, 2022, the Company&#8217;s U.S. ongoing operations were in a three-year cumulative loss position. Management determined that sufficient objectively verifiable positive evidence did not exist to overcome the negative evidence of the Company&#8217;s U.S. cumulative loss position. Accordingly, the Company&#8217;s estimated annual effective tax rate applied to the Company&#8217;s pre-tax loss for the three and nine months ended September 30, 2022, includes the unfavorable impact of a valuation allowance against the Company&#8217;s deferred income tax assets expected to be created in 2022 for additional U.S. net operating loss and tax credit carryforwards.</span></div></ix:continuation><div id="ib12970009bdf4a5493f36f07a1369fa4_76"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjQxNg_49be0063-ba48-4edc-8881-aff14ba8a487" continuedAt="ib2ff61b4842f415fbcd1766427013e7f" escape="true">Net (Loss) Income Per Share</ix:nonNumeric></span></div><ix:continuation id="ib2ff61b4842f415fbcd1766427013e7f" continuedAt="i68a7b639b83d41a8b8c1ad56d8db1a14"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents both basic earnings per share (&#8220;EPS&#8221;) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised and if the 2028 Convertible Notes and 2025 Convertible Notes were converted. The potential dilution from stock awards is accounted for using the treasury stock method based on the average market value of the Company&#8217;s common stock. The potential dilution from conversion of the 2028 Convertible Notes and 2025 Convertible Notes is accounted for using the if-converted method, which requires that all of the shares of the Company&#8217;s common stock issuable upon conversion of the 2028 Convertible Notes and the 2025 Convertible Notes will be included in the calculation of diluted EPS assuming conversion of the 2028 Convertible Notes and the 2025 Convertible Notes at the beginning of the reporting period (or at time of issuance, if later).</span></div><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjQxOA_6acab686-e3ed-4191-a836-924ab66fdb55" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculations (in thousands, except net loss per share amounts):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMy0yLTEtMS0xMjY2Mjg_56157c20-520b-41c7-9b39-c7e3e2dd77c6">36,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMy00LTEtMS0xMjY2Mjg_f9ab7c1c-41f0-4d2e-81af-15716cf97d31">20,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMy02LTEtMS0xMjY2Mjg_febbc9f5-e29f-4652-93bf-ec99c5752559">121,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMy04LTEtMS0xMjY2Mjg_52338472-0085-456b-9de9-d4cbf2180cba">33,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOC0yLTEtMS0xMjY2Mjg_476cc719-9464-4152-8de0-f086b107e42b">124,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOC00LTEtMS0xMjY2Mjg_8e78f3c2-8247-43a6-931f-58a2cb8a9309">122,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOC02LTEtMS0xMjY2Mjg_d75e4545-8430-44b1-8b9b-6caf4c71059d">124,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOC04LTEtMS0xMjY2Mjg_3851f783-34d3-4dd5-906e-92d3ba189dbd">119,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4429118382147fe986ee5dbfc122521_D20220701-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOS0yLTEtMS0xMjY2Mjg_bf9f1cfa-577f-4cfe-8e33-67e91edd777b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c42bc6f38d647e19f5951ebd7219933_D20210701-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOS00LTEtMS0xMjY2Mjg_5696d87e-d4c4-48c2-8225-367733f21f67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36c5815174fc465484a397d6b8310ed5_D20220101-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOS02LTEtMS0xMjY2Mjg_931e6791-d834-4bee-bbf5-be8191807820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ee7ce21290e41ef94470a95e2d94830_D20210101-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOS04LTEtMS0xMjY2Mjg_8c4281ee-0439-486a-9bab-75afd9e4bb6a">2,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if05bf8eb6bc645cd9e362b07a66b1d8c_D20220701-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTAtMi0xLTEtMTI2NjI4_afc8249a-45c1-4bf3-8ee1-b8e1d97ad410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3db9446bf9344b45b0f702886c5f0051_D20210701-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTAtNC0xLTEtMTI2NjI4_8c198c59-2c32-4f8f-8df0-73be464051c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTAtNi0xLTEtMTI2NjI4_12019192-1ea0-4144-abca-ec9570387bc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69da659e90044db1a544a5bde21c110c_D20210101-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTAtOC0xLTEtMTI2NjI4_c1dbc5fd-cf82-419b-882f-5b2fc273cf98">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of Convertible Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a46098d95ff4c398528d14d94cf1462_D20220701-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTEtMi0xLTEtMTI2NjI4_13c93acc-2389-4352-9fab-311495639767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f31d48f948140049d3ec9c0b3ce5eb3_D20210701-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTEtNC0xLTEtMTI2NjI4_a1b9217e-0b0d-4879-bcdb-51ab7a670548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i277bb1a3397c493eab6081211ecad60e_D20220101-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTEtNi0xLTEtMTI2NjI4_4e572bb9-077b-4e4f-9f77-ee629044a3e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d2147cc98bb480fb457363bd7cdaef9_D20210101-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTEtOC0xLTEtMTI2NjI4_b914ab0e-20f7-40ca-9313-fc6499f8093a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of Convertible Notes due 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ce2989799cb43159de5d33b523a462c_D20220701-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTItMi0xLTEtMTI2NjI4_8b44a15e-880d-4e54-ba0d-7ed353e280b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75ab618a9f5c4dd0a3656bbe96c190ad_D20210701-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTItNC0xLTEtMTI2NjI4_43e7dc31-0100-40ee-a1a6-0836dfc2d780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i242b0a5a38704451a6823784364be43c_D20220101-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTItNi0xLTEtMTI2NjI4_e4e8e4b8-07b4-43fd-a490-75e8f6489130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86ad372323184dde948139f6d77bc2bd_D20210101-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTItOC0xLTEtMTI2NjI4_eff263b6-46db-41f7-8196-98f5624a96d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTMtMi0xLTEtMTI2NjI4_fad47ad5-71d4-4e58-88a3-a745d3d0e173">124,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTMtNC0xLTEtMTI2NjI4_decc7e11-bf97-4475-92ef-26d655c3e303">122,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTMtNi0xLTEtMTI2NjI4_9b443f42-16ad-496c-9001-54bcd1aa5147">124,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTMtOC0xLTEtMTI2NjI4_822030fd-234e-4cb4-903e-6fffb67c11b0">121,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTUtMi0xLTEtMTI2NjI4_7e1c41ad-b1ba-4ec5-bdfa-9076e4dd6ee9">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTUtNC0xLTEtMTI2NjI4_36b6883a-69e2-4421-887f-11b3ceb786aa">0.17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTUtNi0xLTEtMTI2NjI4_4e30efea-d0d7-4be6-91db-c8a29db1d997">0.98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTUtOC0xLTEtMTI2NjI4_595c93a6-e4e7-4313-b172-039ef9452933">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTYtMi0xLTEtMTI2NjI4_50edaecc-0805-48d9-a37c-513083a8d8ef">0.30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTYtNC0xLTEtMTI2NjI4_cc005134-e69f-4e01-b6c8-2be21f69c921">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTYtNi0xLTEtMTI2NjI4_57668e3e-3f00-4e1d-9cbf-765d9100d486">0.98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTYtOC0xLTEtMTI2NjI4_75854070-f2a5-49e9-850c-15a708e89d5b">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjQxOQ_fb95adbf-9aed-43b1-a938-828697476fd2" continuedAt="i187f5e79d2ff4a72a69191db3a71c1a1" escape="true">The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i68a7b639b83d41a8b8c1ad56d8db1a14"><div style="text-align:center"><ix:continuation id="i187f5e79d2ff4a72a69191db3a71c1a1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:37.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cf08791a42c4b12b704b3c8c21f8f15_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMi0yLTEtMS0xMjY2Mjg_970dc9fe-0cec-4d4a-b4ff-7f2ed88e5171">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05e8201ba8544204b7f58c994e8ac179_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMi00LTEtMS0xMjY2Mjg_b15483d3-b0bf-4a8e-8768-6e7f1d61eb7a">1,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50746063c011499591f6bd542aedaab2_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMi02LTEtMS0xMjY2Mjg_bb6621bf-9ad9-48a7-9916-ad811aa196b9">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72f0500c13d24ac7bcf932ec6cb56213_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMi04LTEtMS0xMjY2Mjg_36a56cb1-2df5-4b75-932e-624cbe3cea27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94151c90de104b8dbe11dec588578819_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMy0yLTEtMS0xMjY2Mjg_3836470d-c241-42e2-b8bc-36972c6929bc">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96522c45dcd84160880608c828bd86b3_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMy00LTEtMS0xMjY2Mjg_c02ffcab-88cc-4e6f-80f6-b3c7efb62926">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic226270fce13411aaa7fde2cdeb1e234_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMy02LTEtMS0xMjY2Mjg_872c2580-a0fc-4b04-a124-e797948a29b8">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i953f791557df441a893456e3ce3c860a_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMy04LTEtMS0xMjY2Mjg_54332540-7736-4115-be46-e4e58f44b2d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62cba84218e84f778d2010e7be8c7e0d_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNC0yLTEtMS0xMjY2Mjg_232ddc73-17ae-4cda-9123-2af7d0278138">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e5b26bbdce64c3ca2829078807c061f_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNC00LTEtMS0xMjY2Mjg_1bae88bf-8e4e-43dd-bdf6-f5a6c15f5841">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia40344f3d7174e60be2e0dbaf9533460_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNC02LTEtMS0xMjY2Mjg_df112064-157a-4c8d-ae4d-f04a467530f8">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dd0bf6f3fb647c1a101a318ce23fbad_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNC04LTEtMS0xMjY2Mjg_3ce213f2-c072-4b9d-973a-ebf542e71f92">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98e63a0f57c2427c9d3b54f1c162de3c_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNS0yLTEtMS0xMjY2Mjg_533444d7-873f-4370-8127-5349c2a919c3">5,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bbde1a0788e4d5e98970b3bd2cb180a_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNS00LTEtMS0xMjY2Mjg_85e1aeb4-a219-4f5a-b2be-e84f7bc6ef6d">5,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i346de9f05ee645788bff3412f862de33_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNS02LTEtMS0xMjY2Mjg_ae12d1fe-505a-4b50-8a0b-16ec9fb0a84d">5,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i879e090b3f4e4e71bc92de7e2ad882b2_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNS04LTEtMS0xMjY2Mjg_8bfa0257-82d0-4e23-8bcb-62cf16fb303b">5,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the &#8220;Capped Call Transactions&#8221;) with option counterparties pursuant to capped call confirmations at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="ib4d31e5c09604f229766351b8ba0d0fc_D20210111-20210111" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjA3NA_e3f4de7e-c2e9-44da-a21d-9e7e1a4c993f">29.3</ix:nonFraction>&#160;million. The potential effect of the Capped Call Transactions were excluded from the calculation of diluted net loss per share in the three and nine months ended September 30, 2022 as the Company&#8217;s closing price on September 30, 2022 did not exceed the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i68c2a2f8b6bc4a8f9ea7991d94b969f2_I20220930" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjI5OA_852d0a61-75a4-49fc-923f-262c8241ed12">85.75</ix:nonFraction> per share. The Capped Call Transactions are not reflected in diluted net loss per share as they are anti-dilutive.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_82"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84Mi9mcmFnOmUwZGE3ZmU4ZDZiODQ3ZTY4MWJmY2EyMTdlZjA5ZTRkL3RleHRyZWdpb246ZTBkYTdmZThkNmI4NDdlNjgxYmZjYTIxN2VmMDllNGRfMjc2OQ_11e2d1a1-034a-40ff-b2bf-ebf2f06e7410" continuedAt="ia19324f07736485da556256ff151451d" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ia19324f07736485da556256ff151451d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceeding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2021, Natera, Inc. filed a patent infringement complaint against the Company&#8217;s newly-acquired subsidiary Inivata Limited and its subsidiary Inivata, Inc. in United States District Court for the district of Delaware, alleging Inivata&#8217;s InVisionFirst-Lung&#8482; cancer diagnostic test of infringing <ix:nonFraction unitRef="patent" contextRef="ie54a7a7e84624ef48b6fa7119e60f286_D20210120-20210120" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84Mi9mcmFnOmUwZGE3ZmU4ZDZiODQ3ZTY4MWJmY2EyMTdlZjA5ZTRkL3RleHRyZWdpb246ZTBkYTdmZThkNmI4NDdlNjgxYmZjYTIxN2VmMDllNGRfMzY4_c3abcafd-7955-42f3-9a1c-bedd3ee638d2">two</ix:nonFraction> patents. The litigation is presently in the pleadings stage. The Company believes that it has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. At the time of filing, the outcome of this matter is not estimable or probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, the Company is voluntarily conducting an internal investigation that focuses on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;) of the Company&#8217;s internal investigation in November 2021. The Company&#8217;s review of this matter is ongoing. The Company has a reserve of $<ix:nonFraction unitRef="usd" contextRef="idbe5ba6b460e48cea499cfd288684c3c_I20220930" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84Mi9mcmFnOmUwZGE3ZmU4ZDZiODQ3ZTY4MWJmY2EyMTdlZjA5ZTRkL3RleHRyZWdpb246ZTBkYTdmZThkNmI4NDdlNjgxYmZjYTIxN2VmMDllNGRfMTI2MQ_6d334721-3436-4a31-98fc-f244a48a6e30"><ix:nonFraction unitRef="usd" contextRef="i72c663a25f6742dea0c2944423d3ba66_I20211231" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84Mi9mcmFnOmUwZGE3ZmU4ZDZiODQ3ZTY4MWJmY2EyMTdlZjA5ZTRkL3RleHRyZWdpb246ZTBkYTdmZThkNmI4NDdlNjgxYmZjYTIxN2VmMDllNGRfMTI2MQ_91f7790a-807f-414c-ab3b-1d2cacdaf93c">11.2</ix:nonFraction></ix:nonFraction> million in other long-term liabilities as of September 30, 2022 and December 31, 2021 on the Consolidated Balance Sheets for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#8217;s best estimate of the minimum probable loss associated with this matter. As a result of the ongoing investigation and interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. The Company was notified on June 30, 2022 that the Department of Justice (&#8220;DOJ&#8221;) will be participating in the investigation of this matter. At this time, the Company is unable to predict the duration, scope, result or related costs associated with any further investigation, including by the OIG, DOJ, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Any determination that the Company&#8217;s operations or activities are not in compliance with existing laws or regulations, however, could result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, or other losses or conduct restrictions, which could be material to the Company&#8217;s financial results or business operations.</span></div></ix:continuation><div><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_85"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfMTU3Ng_2f974b07-e933-48d0-8bac-386d2d484fbd" continuedAt="i2d16fe38719e4a4aad0a50941603fe19" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i2d16fe38719e4a4aad0a50941603fe19" continuedAt="i0aa4ee8d1cd5482b9d7e627301f1d057"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company formed a strategic alliance with Inivata and entered into a Strategic Alliance Agreement and Laboratory Services Agreement whereas Inivata, prior to the Inivata Acquisition Date, would render and perform certain laboratory testing which the Company made available to customers. In connection with this agreement, Inivata provided $<ix:nonFraction unitRef="usd" contextRef="i79ee0320473e4c25be7915c5434f0efe_D20210101-20210930" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNDAw_719d581f-3d53-4067-9506-ab417609e459">0.8</ix:nonFraction> million of testing services to the Company recorded in cost of revenue in the Consolidated Statements of Operations for the nine months ended September 30, 2021 through the Inivata Acquisition Date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company completed its acquisition of all remaining equity interest in Inivata by exercising its Purchase Option. Beginning June 18, 2021, Inivata is a wholly-owned consolidated subsidiary of the Company. As of the Inivata Acquisition Date, Inivata&#8217;s financial statement activity is being consolidated within the Company&#8217;s unaudited Consolidated Financial Statements. For further details on the acquisition of Inivata, please refer to Note 3. Acquisitions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has Pharma Services contracts with CytomX Therapeutics, Inc., an entity with whom a director of the Company, Dr. Alison L. Hannah, was an officer at until September 2022, and the Company&#8217;s former Chief Legal Officer, Halley E. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0aa4ee8d1cd5482b9d7e627301f1d057" continuedAt="if0bf0d6372ea42ac8d6a39c94e0ae610">Gilbert, is a director. In connection with these contracts, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i6eb774483c5d44a88b442c3a493331f4_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc3MDI3Nw_805be543-9cdc-4b47-b368-bede53a39bba">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3d2b85ad77a2443083ab566f9d503e37_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfMTM3Ng_6ebd5a5a-fa0d-480c-a755-5c4b6c553b78">0.5</ix:nonFraction>&#160;million of revenue in the Consolidated Statements of Operations for the three and nine months ended September 30, 2022, respectively. For the three and nine months ended September 30, 2021, the Company recognized revenue in the Consolidated Statements Operations of $<ix:nonFraction unitRef="usd" contextRef="i3640c3db5b114ab3997daf6009f1e121_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfMTUwMw_3770857d-3dff-439d-be35-70afd852504a">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9ce9041f492249c4a99391bfbb0cddc4_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfMTUxMA_e96edfa9-f9b9-4cef-aafe-92559f9b8995">0.4</ix:nonFraction>&#160;million, respectively.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if0bf0d6372ea42ac8d6a39c94e0ae610">The Company has Pharma Services contracts with HOOKIPA Pharma, Inc., an entity with whom a director of the Company, Michael A. Kelly, is a director. In connection with these contracts, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i6637559ec6a04ab5b9435cf6158fd0c4_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc2OTk1NQ_e63a3af8-2e3d-4aa9-b4d3-4b723aa696a3"><ix:nonFraction unitRef="usd" contextRef="i6f4bd7a8247d417ea28e862e1cf803db_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc2OTk1NQ_f64d7f96-5321-49f4-941f-421aea2be3d2">0.3</ix:nonFraction></ix:nonFraction>&#160;million of revenue in the Consolidated Statements of Operations for both the three and nine months ended September 30, 2022. For the three and nine months ended September 30, 2021, the Company recognized revenue in the Consolidated Statements of Operations of $<ix:nonFraction unitRef="usd" contextRef="i250039242aab493dabb7b5413e5f5a41_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc2OTk2OQ_8bbd2195-3f86-4b9a-8a68-e70e01b6b2a0">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ieb967b231404449cb3a51eadf05ece29_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc2OTk4Mw_099c6a2c-1055-409a-8a41-c7aefdd88db6">0.4</ix:nonFraction>&#160;million, respectively.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTk1MQ_2e49ebd6-b2ac-462d-b243-f0efb4e10cd2" continuedAt="i6c6836c2c9cb49b48dec007b03827d4b" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="i6c6836c2c9cb49b48dec007b03827d4b" continuedAt="i82eaf6a4fc7a46629c7276d6cea19297"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under <ix:nonFraction unitRef="segment" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfNzE_022f5384-de9c-4d1c-84c2-20946c310f5c">two</ix:nonFraction> reportable segments, (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology and oncology practices, hospital pathology labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and self-pay patients. The Pharma Services segment supports pharmaceutical firms&#8217; drug development programs by assisting with various clinical trials and research as well as providing informatics related services often supporting pharmaceutical commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) includes revenues, cost of revenue, and gross profit for both reportable segments.&#160;Assets are not presented at the segment level as that information&#160;is not used by the CODM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTk1Mg_2ed1f6d4-f978-41a3-a575-8fa0a905e01f" continuedAt="i1121586130424d0c801bcc833a46271f" escape="true">The following table summarizes the segment information (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i82eaf6a4fc7a46629c7276d6cea19297" continuedAt="i38a463d4f21a43b4bcf008ff8db5fe43"><ix:continuation id="i1121586130424d0c801bcc833a46271f" continuedAt="id354e870887543c5813b7374f612ff97"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMy0yLTEtMS0xMjY2Mjg_463cf27a-25f2-4346-a1dd-9dd755c337f5">106,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMy00LTEtMS0xMjY2Mjg_d12374ea-3485-4ddc-82ca-63e6af13108b">102,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMy02LTEtMS0xMjY2Mjg_8300b3c7-cdbc-4bc3-b438-b21e12dcd446">310,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMy04LTEtMS0xMjY2Mjg_49289a1a-5ea9-47bf-b8a9-06b69fb04c64">300,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNC0yLTEtMS0xMjY2Mjg_9cdcc7fe-05f4-4cea-b489-245d6a9c061f">22,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNC00LTEtMS0xMjY2Mjg_0f68ab0e-998f-4c30-bf31-26f7b7bdf7ab">19,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNC02LTEtMS0xMjY2Mjg_a783dc9f-1e9f-4abb-a8fc-ba932fb1b1ce">60,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNC04LTEtMS0xMjY2Mjg_d861f3ae-e615-442d-8197-7947b781715f">58,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNS0yLTEtMS0xMjY2Mjg_29983672-5e6a-4ce3-b098-58c8a888079f">128,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNS00LTEtMS0xMjY2Mjg_046c1b09-d37c-4f50-9163-f954aeef7284">121,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNS02LTEtMS0xMjY2Mjg_b252c63e-81be-404b-a7d5-9cc2c186115d">371,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNS04LTEtMS0xMjY2Mjg_d0fbabcb-65b0-4359-b85e-0fb76997d5b7">358,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOC0yLTEtMS0xMjY2Mjg_ff4ae6aa-669b-49a3-929d-44a03a2f5a1f">65,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOC00LTEtMS0xMjY2Mjg_020bee0a-ffa4-4249-9db8-a9b35d50bc1d">59,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOC02LTEtMS0xMjY2Mjg_167f1604-0e22-4780-bd9d-43e149bc9da1">197,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOC04LTEtMS0xMjY2Mjg_e5d78ea9-38c4-4a00-aeba-d964a12fa5d7">178,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOS0yLTEtMS0xMjY2Mjg_8bb532e5-d996-4193-b94e-64909359dee4">14,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOS00LTEtMS0xMjY2Mjg_bc5916b9-44a5-40fe-857d-aaf4ef9782d5">14,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOS02LTEtMS0xMjY2Mjg_f010d984-2210-4c56-9863-bbec58479618">42,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOS04LTEtMS0xMjY2Mjg_443983c4-6219-4c13-b155-1a5d0224cd29">38,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTAtMi0xLTEtMTI2NjI4_761f5bcb-56c0-4148-92b0-c6231a42f09d">79,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTAtNC0xLTEtMTI2NjI4_712ce54e-aa08-426f-94a4-bd5f1277a02b">74,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTAtNi0xLTEtMTI2NjI4_7d4ff51f-4bbc-416c-a9bd-cb7199f4166e">239,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTAtOC0xLTEtMTI2NjI4_35cf7e1a-bb11-4619-8a29-e33f3c348653">216,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTMtMi0xLTEtMTI2NjI4_dba24db3-358b-43ba-9841-86cae43a64d6">40,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTMtNC0xLTEtMTI2NjI4_f6cbb544-1771-4be9-8192-07b26d7eaab3">42,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTMtNi0xLTEtMTI2NjI4_9860646f-5d11-4e38-a111-0edbd079f39e">113,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTMtOC0xLTEtMTI2NjI4_c755e4f1-8cfc-432b-a275-a4ff62396a14">121,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTQtMi0xLTEtMTI2NjI4_5b967ec8-844e-4e54-ad4a-75399efc812d">7,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTQtNC0xLTEtMTI2NjI4_c1aea550-703b-48b9-8565-00bdfa3e3321">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTQtNi0xLTEtMTI2NjI4_9eeef420-2535-4f35-a9ba-0fbc1ab3ad89">18,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTQtOC0xLTEtMTI2NjI4_ef0f1856-760c-4fdb-b809-3ed0c27e3fb3">20,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTUtMi0xLTEtMTI2NjI4_d3266411-5332-4a61-9893-443cdc8ea955">48,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTUtNC0xLTEtMTI2NjI4_a9d19a5c-b027-4c41-9cfa-d0c9fa087027">47,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTUtNi0xLTEtMTI2NjI4_fd8936fb-9dc8-4fcc-aa0e-770613f77a23">131,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTUtOC0xLTEtMTI2NjI4_d0dad8e1-64ac-42dd-a96b-660d57d1babf">141,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTgtMi0xLTEtMTI2NjI4_6006fc89-f42b-4481-a350-5fdece3c9fec">64,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTgtNC0xLTEtMTI2NjI4_264112a7-0f6d-45e0-a819-fd29e1675b29">63,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTgtNi0xLTEtMTI2NjI4_ef7fcde3-cf32-4e20-812f-732fb144e95b">188,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTgtOC0xLTEtMTI2NjI4_cdc869d5-bf22-4dc0-8208-1ece2e55f601">158,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTktMi0xLTEtMTI2NjI4_a03d9e1f-282b-47e1-9e19-7c7d29e9c49c">7,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTktNC0xLTEtMTI2NjI4_9ef55631-eaec-4882-bef0-a8fddd09ff7d">7,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTktNi0xLTEtMTI2NjI4_f3bbee5a-dd84-4875-b475-e7d37f4df3aa">23,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTktOC0xLTEtMTI2NjI4_a5689e21-c798-47a3-854c-3f634ff20db2">13,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjAtMi0xLTEtMTI2NjI4_4b0270ff-2eb7-4add-beba-4dadd971a97e">16,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjAtNC0xLTEtMTI2NjI4_79574a96-8dca-4087-9b00-504c3512b152">15,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjAtNi0xLTEtMTI2NjI4_7ecb5b13-bb54-4c98-b246-17a150ffadc9">50,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjAtOC0xLTEtMTI2NjI4_9c178638-e4fd-4979-98d3-1fe93c744d0f">46,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjEtMi0xLTEtMTI2NjI4_0faf1ee1-f56a-43c1-912e-a90d0ffc29b3">88,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjEtNC0xLTEtMTI2NjI4_b6a43f3b-de6c-4e61-845d-e72d461843b2">86,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjEtNi0xLTEtMTI2NjI4_6c996615-8499-45de-bfa7-c1b1180e99e0">262,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjEtOC0xLTEtMTI2NjI4_ec420888-774a-404d-93cc-7cd098b6ab30">218,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjItMi0xLTEtMTI2NjI4_aa83a8df-a3d7-4062-bc17-a182d6eedd3c">39,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjItNC0xLTEtMTI2NjI4_01a41e6c-4045-43af-bc0f-05ee72cfb887">39,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjItNi0xLTEtMTI2NjI4_db33029c-e7b1-425d-bbbb-5504a19d0779">131,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjItOC0xLTEtMTI2NjI4_1635cf42-cf89-4c9e-b258-45d45d971193">77,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjMtMi0xLTEtMTI2NjI4_9d6774e7-83b2-446d-9007-68e8b98de745">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjMtNC0xLTEtMTI2NjI4_03b41ac8-ad15-42eb-aa04-3a4fdf257237">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjMtNi0xLTEtMTI2NjI4_b90f45fb-bab3-4e35-bac5-f3451fdfd794">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjMtOC0xLTEtMTI2NjI4_f2936577-5dd0-420d-988b-dd6c246f8193">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjQtMi0xLTEtMTI2NjI4_1ce5b7ff-bd0b-427c-830e-b1870d0688b9">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjQtNC0xLTEtMTI2NjI4_d0048053-9c2a-41db-ab56-49cf11b6fb8a">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjQtNi0xLTEtMTI2NjI4_9ecff3c8-ec1e-41f4-bcc8-9288473a8ee6">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjQtOC0xLTEtMTI2NjI4_f36bbc2b-5585-4680-9ef1-3add4c82eaa0">431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjUtMi0xLTEtMTI2NjI4_c628212c-1f95-481d-bd37-243754e88534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjUtNC0xLTEtMTI2NjI4_8e0343e8-9324-4763-b8dc-35ac2f8cbef2">17,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjUtNi0xLTEtMTI2NjI4_00a6af7b-9a19-4e54-b17a-f26d35e4305e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjUtOC0xLTEtMTI2NjI4_5af65693-1464-4c6f-bc90-3fdfb17e5092">109,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjgtMi0xLTEtMTI2NjI4_b8186eb3-7240-44ba-ac4e-01eaa3f3e34d">39,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjgtNC0xLTEtMTI2NjI4_a33d9137-4fd7-4785-bde2-1a10857cdf10">23,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjgtNi0xLTEtMTI2NjI4_fb00f796-f4b2-4996-a155-2d550f5a482c">133,818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjgtOC0xLTEtMTI2NjI4_b1ddf957-6a0d-4767-932a-3ef1cef0e130">29,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjktMi0xLTEtMTI2NjI4_47e61b3b-14fb-46d0-bac7-3005caed2c2a">2,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjktNC0xLTEtMTI2NjI4_b850c355-7850-45f8-949f-eeb98f6ea59b">2,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjktNi0xLTEtMTI2NjI4_21c4cf54-b642-4dca-840b-2a3189753bfd">12,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjktOC0xLTEtMTI2NjI4_de7c8cb5-fa71-4f8e-a0c8-0eed7d3cdcb2">4,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMzAtMi0xLTEtMTI2NjI4_b9e9fb3c-79df-4e33-a3f4-8e22477d98e7">36,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMzAtNC0xLTEtMTI2NjI4_cf6744ce-f51b-412c-a6f2-7d982356ea74">20,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMzAtNi0xLTEtMTI2NjI4_855d03a2-888b-412b-a77e-067705766df5">121,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMzAtOC0xLTEtMTI2NjI4_cb848e7f-9a0c-4703-85b4-166d2a03fc9e">33,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTEzMQ_1bb7898f-ff68-4a87-85ef-224f8b195eeb"><ix:nonFraction unitRef="usd" contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTEzMQ_40291b43-93e6-4031-bb8c-f830b762796e">4.3</ix:nonFraction></ix:nonFraction>&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2022 include $<ix:nonFraction unitRef="usd" contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTMxMw_8fedcc8c-9794-4883-b441-3f60b147c567">12.8</ix:nonFraction>&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2021 include write-offs of $<ix:nonFraction unitRef="usd" contextRef="i19908e283dc94d0d945d062e4df46a9a_D20210101-20210930" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTQ3Ng_6d47a5c0-aaa5-48ee-a8a1-8c15d63271e3">5.3</ix:nonFraction>&#160;million for COVID-19 PCR testing inventory and $<ix:nonFraction unitRef="usd" contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTUxOA_28bef9f5-6d55-4c40-84da-5c9d04dd9516">5.0</ix:nonFraction>&#160;million of amortization of acquired Inivata developed technology intangible assets.</span></div></ix:continuation></ix:continuation><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i38a463d4f21a43b4bcf008ff8db5fe43" continuedAt="i4e1dd031335f4411bb5dd1472cf49cf8"><ix:continuation id="id354e870887543c5813b7374f612ff97" continuedAt="if69b80dc3b9a492e84c9919ecd72224d">(2) </ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e1dd031335f4411bb5dd1472cf49cf8"><ix:continuation id="if69b80dc3b9a492e84c9919ecd72224d">Pharma Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 include $<ix:nonFraction unitRef="usd" contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTY3Mg_a35197d7-d68d-4a5d-8bf7-58b704e83fa9"><ix:nonFraction unitRef="usd" contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTY3Mg_c002247e-69e3-4b91-985b-d954d797ee9d">0.6</ix:nonFraction></ix:nonFraction>&#160;million of amortization of acquired Inivata developed technology intangible assets. Pharma Services cost of revenue for the nine months ended September 30, 2022 and September 30, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTgxOQ_4bebb2be-9607-480d-874e-61d5f646b291">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfOTg5NTYwNDY1MjE0Ng_80042df8-6b59-488d-b1d7-ca0a99296d4b">0.6</ix:nonFraction>&#160;million of amortization, respectively, of acquired Inivata developed technology intangible assets.</ix:continuation></ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_94"></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_97"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NeoGenomics, Inc., a Nevada corporation (referred to individually as the &#8220;Parent Company&#8221; or collectively with its subsidiaries as &#8220;NeoGenomics,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221; in this Quarterly Report) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;NEO&#8221;.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included herein. The information contained below includes statements of the Company&#8217;s or management&#8217;s beliefs, expectations, hopes, goals and plans that, if not historical, are forward-looking statements subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion on forward-looking statements, see the information set forth in the introductory note to this Quarterly Report on Form 10-Q under the caption &#8220;Forward-Looking Statements,&#8221; which information is incorporated herein by reference.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the COVID-19 pandemic is materially adversely affecting the Company&#8217;s employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 pandemic will impact the Company&#8217;s business, results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#8217;s results of operations, financial condition and cash flows are likely to continue to be materially adversely affected, particularly if the pandemic persists for a significant amount of time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact from the COVID-19 pandemic and the related disruptions have had a significant adverse impact on our results of operations, volume growth rates and test volumes in 2021 and in the first three quarters of 2022. For example, our Pharma Services customers are facing challenges in recruiting patients and in conducting clinical trials for which our tests could be utilized. Demand may fluctuate depending on the duration and severity of the COVID-19 pandemic, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business disruption, reduced revenues and a decreased number of tests, any of which could materially affect our business, financial condition, and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on risk factors related to the pandemic or other risks that could impact our results, please refer to the Company&#8217;s Form 10-K under Item 1A, &#8220;Risk Factors&#8221; for the year ended December 31, 2021, as filed with the SEC on February 25, 2022, and in Part II, Item 1A. &#8220;Risk Factors&#8221; in the Quarterly Report on Form 10-Q.</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_100"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a network of cancer-focused testing laboratories in the United States, Europe and Asia. Our mission is to improve patient care through exceptional cancer-focused testing services. Our vision is to be the world&#8217;s leading cancer testing and information company by delivering uncompromising quality, exceptional service and innovative solutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo and Carlsbad, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Rolle, Switzerland; Singapore and China. We currently offer the following types of testing services:</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cytogenetics (&#8220;karyotype analysis&#8221;) &#8211; the study of normal and abnormal chromosomes and their relationship to disease. Cytogenetics involves analyzing the chromosome structure to identify changes from patterns seen in normal chromosomes. Cytogenetic studies are often performed to provide diagnostic, prognostic and occasionally predictive information for patients with hematological malignancies.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fluorescence In-Situ Hybridization (&#8220;FISH&#8221;) &#8211; a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes. The technique uses fluorescent probes that bind to only those parts of the chromosome with which they show a high degree of sequence similarity. Fluorescence microscopy is used to visualize the fluorescent probes bound to the chromosomes. FISH can be used to help identify numerous types of gene alterations, including amplifications, deletions, and translocations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Flow cytometry &#8211; a technique utilized to measure the characteristics of cell populations. Typically performed on liquid samples such as peripheral blood and bone marrow aspirate, it may also be performed on solid tissue samples </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as lymph nodes following additional processing steps. Cells are labeled with selective fluorescent antibodies and analyzed as they flow in a fluid stream through a beam of light. The properties measured in these antibodies include the relative size, relative granularity or internal complexity, and relative fluorescence intensity. These fluorescent antibodies bind to specific cellular antigens and are used to identify abnormal and/or malignant cell populations. Flow cytometry is typically utilized in diagnosing a wide variety of hematopoietic and lymphoid neoplasms. Flow cytometry is also used to monitor patients during the course of therapy to identify extremely low levels of residual malignant cells, known as minimal residual disease (&#8220;MRD&#8221;) monitoring.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Immunohistochemistry (&#8220;IHC&#8221;) and Digital Imaging &#8211; the process of localizing cellular proteins in tissue sections and relies on the principle of antigen-antibody binding. IHC is widely used in the diagnosis of abnormal cells such as those found in cancer. Specific surface membrane, cytoplasmic, or nuclear markers may be identified. IHC is also widely used to understand the distribution and localization of differentially expressed proteins. Digital imaging allows clients to visualize scanned slides and also perform quantitative analysis for certain stains. Scanned slides are received online in real time and can be previewed often a full day before the glass slides can be shipped back to clients.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Molecular testing &#8211; a rapidly growing field which includes a broad range of laboratory techniques utilized in cancer testing. Most molecular techniques rely on the analysis of DNA and/or RNA, as well as the structure and function of genes at the molecular level. Molecular testing technologies include: liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases; DNA fragment length analysis; polymerase chain reaction (&#8220;PCR&#8221;) analysis; reverse transcriptase polymerase chain reaction (&#8220;RT-PCR&#8221;) analysis, real-time (or quantitative) polymerase chain reaction (&#8220;qPCR&#8221;) analysis; bi-directional Sanger sequencing analysis; and next-generation sequencing (&#8220;NGS&#8221;) analysis.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Morphologic analysis &#8211; the process of analyzing cells under the microscope by a pathologist, usually for the purpose of diagnosis. Morphologic analysis may be performed on a wide variety of samples, such as peripheral blood, bone marrow, lymph node, and from other sites such as lung, breast, etc. The services provided at NeoGenomics may include primary diagnosis, in which a sample is received for processing and our pathologists provide the initial diagnosis; or may include secondary consultations, in which slides and/or tissue blocks are received from an outside institution for a second opinion. In the latter setting, the expert pathologists at NeoGenomics assist our client pathologists on some of their most difficult and complex cases.</span></div><div style="margin-bottom:5pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Segment </span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical cancer testing services we offer to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. We believe our relationship as a non-competitive partner to community-based pathology practices, hospital pathology labs, reference labs, and academic centers can empower them to expand their breadth of testing to provide a menu of services that could match or exceed the level of service found in any center of excellence around the world. Community-based pathology practices and hospital pathology labs may order certain testing services on a technical component only (&#8220;TC&#8221; or &#8220;tech-only&#8221;) basis, which allows them to participate in the diagnostic process by performing the professional component (&#8220;PC&#8221;) interpretation services without having to hire laboratory technologists or purchase the sophisticated equipment needed to perform the technical component of the tests. We also support our pathology clients with interpretation and consultative services using our own specialized team of pathologists for difficult or complex cases and we provide overflow interpretation services when requested by clients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading provider of Molecular and NGS testing for oncology. These tests are interpreted by NeoGenomics&#8217; team of Molecular experts and are often ordered in conjunction with other testing modalities. NGS panels are one of our fastest growing testing areas and clients can often receive a significant amount of biomarker information from very limited samples. These comprehensive panels can allow for faster treatment decisions for patients as compared to a series of single-gene molecular tests being ordered sequentially. We have one of the broadest Molecular menus in the industry and our targeted NeoTYPE panels include genes relevant to a particular cancer type, as well as other complementary tests such as IHC and FISH. In addition, we offer molecular-only NGS targeted and comprehensive panels which combine DNA and RNA into a single work stream in order to report a full spectrum of genomic alterations, including mutation, fusions, copy number variations, and gene expression. This comprehensive menu means that NeoGenomics can be a &#8220;one-stop shop&#8221; for our clients who can get all of their oncology testing needs satisfied by our laboratory. This is attractive to our clients as patient samples do not need to be split and then managed across several laboratories. The acquisition of Inivata provided us with oncology Liquid Biopsy technology capabilities. InVisionFirst&#174;-Lung is a highly sensitive, targeted plasma-based assay for patients with non-small cell lung cancer, and RaDaR&#8482; is an industry-leading liquid biopsy assay designed to detect residual disease and recurrence in plasma samples from patients with solid tumor malignancies. We expect our Molecular laboratory and NGS capabilities to be a key growth driver in the coming years. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we directly serve oncology, dermatology and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic testing services. We typically serve these types of clients with a comprehensive service offering where we perform both the technical and professional components of the tests ordered. In certain instances, larger clinician practices have begun to internalize pathology interpretation services, and our tech-only service offering allows these larger clinician practices to also participate in the diagnostic process by performing the PC interpretation services on TC testing performed by us.&#160;In these instances, we will typically provide all of the more complex, molecular testing services.</span></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Segment</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services revenue consists of three revenue streams:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Clinical trials and research;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Validation laboratory services; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Informatics.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research.&#160;This portion of our business often involves working with the pharmaceutical firms (&#8220;sponsors&#8221;) on study design as well as performing the required testing.&#160;Our medical team often advises the sponsor and works closely with them as specimens are received from the enrolled sites.&#160;We also work on developing tests that will be used as part of a companion diagnostic to determine patients&#8217; response to a particular drug.&#160;As studies unfold, our clinical trials team reports the data and often provides key analysis and insights back to the sponsors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services segment provides comprehensive testing services in support of our pharmaceutical clients&#8217; oncology programs from discovery to commercialization.&#160;In biomarker discovery, our aim is to help our customers discover the right content.&#160;We help our customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing our discovery tools with the informatics to capture meaningful data.&#160;In other pre-clinical and non-clinical work, we can use our platforms to characterize markers of interest.&#160;Moving from discovery to development, we seek to help our customers refine their biomarker strategy and, if applicable, develop a companion diagnostic pathway using the optimal technology for large-scale clinical trial testing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether serving as the single contract research organization or partnering with one, our Pharma Services team provides significant technical expertise, working closely with our customers to support each stage of clinical trial development.&#160;Each trial we support comes with rapid turnaround time, dedicated project management and quality assurance oversight. We have experience in supporting submissions to the Federal Drug Administration (&#8220;FDA&#8221;) for companion diagnostics. Our Pharma Services strategy is focused on helping bring more effective oncology treatments to market through providing world-class laboratory services in oncology to key pharmaceutical companies in the industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we are well positioned to service Pharma sponsors across the full continuum of the drug development process. Our Pharma Services team can work with them during the basic research and development phase as compounds come out of translational research departments as well as work with clients from Phase 1 clinical trials through Phases II and III as the sponsors work to prove the efficacy of their drugs. The laboratory biomarker tests that are developed during this process may become companion diagnostic (&#8220;CDx&#8221;) tests, that will be used on patients to determine if they could respond to a certain therapy. We are able to offer these CDx tests to the market immediately after FDA approval as part of our Day 1 readiness program. This ability helps to speed the commercialization of a drug and can enable Pharma sponsors to reach patients through our broad distribution channel in the Clinical Services segment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to connecting patients with life-altering therapies and trials. In carrying out these commitments, we aim to provide transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and have invested in leading technologies to seek to ensure the data we maintain is secured at all times. We are continuing to develop and broaden our informatics and data-related tools to leverage our unique market position and oncology expertise to help our stakeholders solve real-world problems such as identifying patients for clinical trials or providing clinical decision support tools for physicians and providers. We also offer testing and informatics tools to help health care professionals in the rapidly evolving field of precision medicine, such as Trapelo&#8482;. Trapelo&#8482; is an end-to-end, clinical decision-support platform designed to resolve the complexities of precision oncology &#8211; from test ordering to therapy selection to navigating prior authorization. Trapelo&#8482; helps oncologists determine which biomarkers to test and in selecting the appropriate tests from laboratory offerings, and then assists with interpreting test results to identify appropriate, evidence-based treatment options. Trapelo&#8482; also collaborates with health plans to embed plan policy at the &#8220;point of decision&#8221; and streamline prior authorization to optimize the efficient delivery of precision care for better patient outcomes.</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Focus Areas: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to sustainable growth while transforming patient care by being an innovative leader in our industry. Our focus for 2022 is to sustain a purpose driven culture that maintains excellence in service and performance while growing through innovation. We expect the following initiatives to allow the Company to continue on its path to become one of the world&#8217;s leading cancer testing and information companies:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Growth through Innovation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successfully launch new test offerings and secure reimbursement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expand development of new cancer treatments; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerate precision medicine in the community.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Excellence in Service and Performance</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Achieve turnaround time targets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Grow consolidated revenue and profitability; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Design next-generation Laboratory Information Management System (&#8220;LIMS&#8221;) platform.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purpose Driven Culture</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drive an engaged and committed workforce; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foster inclusive and effective leadership by expanding our culture of inclusion and developing our future leaders.</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_106"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Strengths</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the competitive strengths discussed below, we believe that our superior testing technologies and instrumentation, laboratory information system, client education programs, and broad domestic and growing international presence also differentiate NeoGenomics from its competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Turnaround Times</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to provide industry leading turnaround times for test results to our clients nationwide, both in the Clinical Services and Pharma Services segments. By providing information to our clients in a rapid manner, physicians can begin treating their patients as soon as possible. Rapid turnaround times allow for the performance of other adjunctive tests within an acceptable diagnosis window in order to augment or confirm results and more fully inform treatment options. Additionally, we believe that our rapid turnaround time on testing and our project milestones are a key differentiator in our Pharma Services segment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">World-class Medical and Scientific Team</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our team of medical professionals and PhDs are specialists in the field of genetics, oncology and pathology.&#160;As of September 30, 2022, we employed or contracted with approximately 180 MDs and PhDs. We have many nationally and world-renowned pathologists on staff, which is a key differentiator from many smaller laboratories.&#160;Our clinical customers look to our staff and their expertise and they often call our medical team on challenging cases.&#160;For our Pharma Services segment, many sponsors work with our medical team on their study design and on the interpretation of results from the studies.&#160;Our medical team is a key differentiator as we have a depth of medical expertise that many other laboratories cannot offer to pharmaceutical companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Innovative Service Offerings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we currently have the most extensive menu of tech-only FISH services in the country as well as extensive and advanced tech-only flow cytometry and IHC testing services. These types of testing services allow the professional interpretation component of a test to be performed and billed separately by our physician clients. Our tech-only services are designed to give pathologists the option to choose, on a case by case basis, whether they want to order just the technical information and images relating to a specific test so they can perform the professional interpretation, or order &#8220;global&#8221; services and receive a comprehensive test report which includes a NeoGenomics pathologist&#8217;s interpretation of the test results. Our clients appreciate the flexibility to access NeoGenomics&#8217; medical staff for difficult or complex cases or when they are otherwise unavailable to perform professional interpretations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a comprehensive suite of technical and interpretation services, to meet the needs of those clients who are not credentialed and trained in interpreting genetic tests and who require pathology specialists to interpret their testing results. In our global service offerings, our lab performs the technical component of the tests and our MDs and PhDs provide the service of interpreting the results of those tests. Our professional staff is also available for post-test consultative services. Clients using our global service offering rely on the expertise of our medical team to give them the answers they need in a timely manner to help inform their diagnoses and treatment decisions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have one of the broadest Molecular and NGS test menus in the world. Clients have the ability to order single gene molecular tests, targeted NeoTYPE panels that include the relevant actionable genes for a particular cancer type as well as large NGS panels. Our Pharma Services segment offers a full range of sequencing testing including whole exome and whole genome sequencing. Our menu enables us to be a true &#8220;one-stop shop&#8221; for our clients as we can meet all of their oncology testing needs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Direct Sales Force</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our direct sales force has been trained extensively in cancer genetic testing and consultative selling skills to service the needs of clients. Our sales team for the clinical cancer testing services is organized into five regions &#8211; Northeast, Southeast, North Central, South Central, and West. Our Pharma Services segment has a dedicated team of business development specialists who are experienced in working with pharma sponsors and helping them with the testing needs of their research and development projects as well as Phase I, II and III studies. These sales representatives utilize our custom Customer Relationship Management System (&#8220;CRM&#8221;) to manage their territories, and we have integrated the key customer care functionality within our Laboratory Information Services (&#8220;LIS&#8221;) into the CRM so that our sales representatives can stay informed of emerging issues and opportunities within their regions. Our in-house customer care team is aligned with our field sales team to serve the needs of our clients by utilizing the same LIS and CRM. Our field teams can see in real-time when a client calls the laboratory, the reason for the call, the resolution, and if face-to-face interaction is needed for follow-up. Our sales force educates clients on new test offerings and their proper utilization and our representatives are often seen as trusted advisors by our clients.</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_109"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our clinical testing volume is dependent on patients being treated by hematology/oncology professionals and other healthcare providers. The volume of our testing services generally declines modestly during the summer vacation season, year-end holiday periods and other major holidays, particularly when those holidays fall during the middle of the week. In addition, the volume of our testing tends to decline due to extreme adverse weather conditions, such as excessively hot or cold spells, heavy snow, hurricanes or tornadoes in certain regions, consequently reducing revenues and cash flows in any affected period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Pharma Services segment, we enter into both short-term and long-term contracts, ranging from one month to several years. While the volume of this testing is not as directly affected by seasonality as described above, the testing volume does vary based on the terms of the contract. Our volumes are often based on how quickly sponsors can get patient enrollees for their trials and seasonality can impact how quickly they can get patients enrolled. Many of our long-term contracts contain specific performance obligations where the testing is performed on a specific schedule. This results in revenue that is not consistent among periods. In addition, this results in backlog that can be significant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_112"></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three and Nine Months Ended September 30, 2022 as Compared to the Three and Nine Months Ended September 30, 2021</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Consolidated Statements of Operations as a percentage of net revenue:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue for the three months ended September 30, 2022 and September 30, 2021 includes $4.9 million and $4.8 million, respectively, of amortization of acquired Inivata developed technology intangible assets. Cost of revenue for the nine months ended September 30, 2022 includes $14.6 million of amortization of acquired Inivata developed technology intangible assets. Cost of revenue for the nine months ended September 30, 2021 includes $5.6 million of amortization of acquired Inivata developed technology intangible assets and write-offs of $5.3 million for COVID-19 PCR testing inventory.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical and Pharma Services net revenues for the periods presented are as follows ($ in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,597&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated revenues increased $7.4&#160;million, or 6.1%, year-over-year. Clinical Services revenue for the three and nine months ended September 30, 2022 increased $3.9 million and $10.5 million, respectively, when compared to the same periods in 2021. Increases in Clinical Services revenue reflects an increase in average unit price due to strategic reimbursement initiatives and a more favorable test mix.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma Services revenue for the three and nine months ended September 30, 2022 increased $3.5 million and $2.0 million, respectively, compared to the same periods in 2021 due to the timing of project billings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Revenue and Gross Profit</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payroll and payroll related costs for performing tests, maintenance and depreciation of laboratory equipment, rent for laboratory facilities, laboratory reagents, probes and supplies, and delivery and courier costs relating to the transportation of specimens to be tested.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated cost of revenue and gross profit metrics are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,889&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,952&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue as a % of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,803&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 includes $4.3 million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2022 includes $12.8 million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2021 includes write-offs of $5.3 million for COVID-19 PCR testing inventory and $5.0 million of amortization of acquired Inivata developed technology intangible assets.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharma Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 includes $0.6 million of amortization of acquired Inivata developed technology intangible assets. Pharma Services cost of revenue for the nine months ended September 30, 2022 and September 30, 2021 includes $1.8 million and $0.6 million, respectively, of amortization of acquired Inivata developed technology intangible assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated cost of revenue increased for the three and nine months ended September 30, 2022 when compared to the same periods in 2021 primarily due to higher payroll and payroll-related costs and the amortization of acquired Inivata developed technology intangible assets. The cost of revenue in the first quarter of 2021 included write-offs of $5.3 million for inventory due to the exit from COVID-19 PCR testing. There were no such inventory write-offs for the three months ended September 30, 2021 and the three and nine months ended September 30, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit margin for the three and nine months ended September 30, 2022 was 38.0% and 35.3%, respectively, compared to 38.9% and 39.5%, respectively, in the same periods of 2021. The decreases of 0.9% and 4.2% for the three and nine months ended September 30, 2022, respectively, are primarily due to amortization of acquired Inivata developed technology intangible assets and higher payroll and payroll-related costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of payroll and payroll related costs for our executive, billing, finance, human resources, information technology, and other administrative personnel, as well as stock-based compensation. We also allocate professional services, facilities expense, IT infrastructure costs, depreciation, amortization and other administrative-related costs to general and administrative expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated general and administrative expenses are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As a % of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $0.4 million for the three months ended September 30, 2022, when compared to the same period in 2021. This increase was primarily due to $4.4 million of higher payroll and payroll-related costs, $2.8 million of net loss on disposal of assets, $2.2 million of consulting fees related to Project Catalyst (our value capture program), and $2.1 million of relocation costs for our new Chief Executive Officer. These increases in general and administrative expenses for the three months ended September 30, 2022 were partially offset by a decrease when compared to the same period in 2021 of $10.5 million of loss contingency for a regulatory matter and $0.8 million of facilities costs. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $29.5 million for the nine months ended September 30, 2022, when compared to the same period in 2021. This increase was partially due to $10.8 million for the Inivata and Trapelo Health subsidiaries which were acquired in the second quarter of 2021 and a net increase in non-cash stock-based compensation expenses of $7.6 million, which included incremental stock-based compensation for the acceleration of stock option and restricted stock awards upon the Chief Executive Officer and Chief Legal Officer&#8217;s departures. Excluding the increase in general and administrative expenses for the Inivata and Trapelo Health subsidiaries, general and administrative expenses also increased by $6.7 million of payroll and payroll-related costs, $5.5 million of professional fees, $4.1 million of investments in technology, $2.9 million of severance costs primarily related to the prior Chief Executive Officer and Chief Legal Officer&#8217;s departures, $2.2 million in consulting fees related to Project Catalyst (our value capture program), $2.1 million of relocation costs for our new Chief Executive Officer, $1.8 million of depreciation, $1.7 million of net loss on disposal of assets, and $1.5 million of facilities costs. These increases in general and administrative expenses for the nine months ended September 30, 2022 were partially offset by a decrease when compared to the same period in 2021 of $10.5 million of loss contingency for a regulatory matter and $11.4 million of acquisition transaction costs related to the acquisitions of Inivata and Trapelo that occurred in the second quarter of 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses relate to costs of developing new proprietary and non-proprietary genetic tests, including payroll and payroll related costs, maintenance of laboratory equipment, laboratory supplies (reagents), and outside consultants and experts assisting our research and development team.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated research and development expenses for the periods presented are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a % of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were flat for the three months ended September 30, 2022 when compared to the same period in 2021 and primarily include research and development expenses for the Inivata subsidiary which was acquired in June of 2021. Research and development expenses increased $10.3 million for the nine months ended September 30, 2022 when compared to the same period in 2021. This increase primarily reflects an increase in research and development expenses for the Inivata subsidiary which was acquired in June of 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate research and development expenditures will increase in future quarters as we continue to invest in development costs for innovation projects and bringing new tests to market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales and marketing expenses for the periods presented are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a % of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales and marketing expenses increased $1.1 million and $3.5 million for the three and nine months ended September 30, 2022, respectively, when compared to the same periods in 2021.&#160;These increases primarily reflect an increase in payroll and payroll-related costs due to the expansion of our precision medicine sales team. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect higher commissions expense in the coming quarters as our sales representatives continue generating new business in both of our business segments. We expect our sales and marketing expenses over the long term to align with changes in revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net interest expense decreased $1.2 million and $1.0 million for the three and nine months ended September 30, 2022, respectively, compared to the same periods in 2021. Interest expense reflects the effective interest rate on the 2028 Convertible Notes and the 2025 Convertible Notes which is 0.70% and 1.96%, respectively. Interest on the 2028 Convertible Notes and 2025 Convertible Notes began accruing upon issuance and is payable semi-annually. For further details regarding the convertible notes, please refer to Note 6. Debt, in the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gain on Investment In and Loan Receivable from Non-Consolidated Affiliate, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#8217;s Consolidated Statements of Operations of $17.8 million and $109.3 million in the three and nine months ended September 30, 2021, respectively, for the excess of the acquisition-date fair value of the Company&#8217;s previously-held equity interest, Purchase Option, and Line of Credit over their carrying values. There were no such amounts for the three and nine months ended September 30, 2022. For further details regarding the previously-held equity investment, purchase option in Inivata and the related gain, please refer to Note 3. Acquisitions, in the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net (Loss) Income Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides consolidated net (loss) income for each period along with the computation of basic and diluted net (loss) income per share for the three and nine months ended September 30, 2022 and 2021 (in thousands, except net (loss) income per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,852)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,348)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,563)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_115"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Non-GAAP Financial Measures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide greater transparency regarding our operating performance, the financial results and financial guidance include the use of certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to the Company&#8217;s core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of the Company&#8217;s core test-level operating results across reporting periods and when comparing those same results to those published by our peers. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results, should not be considered measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures used by other companies.&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definitions of Non-GAAP Measures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-GAAP Adjusted EBITDA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Adjusted EBITDA&#8221; is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest expense, (ii) tax (benefit) or expense, (iii) depreciation and amortization expense, (iv) non-cash stock-based compensation expense, and, if applicable in a reporting period, (v) acquisition and integration related expenses, (vi) write-off of COVID-19 PCR testing inventory and equipment, (vii) gain on investment in and loan receivable from non-consolidated affiliate, net, (viii) CEO transition costs, (ix) loss contingency for regulatory matter, and (x) other significant or non-operating (income) or expenses, net.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of GAAP net (loss) income to Non-GAAP EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income (GAAP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,852)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,348)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,563)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to net (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA (non-GAAP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,088)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Further adjustments to EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of COVID-19 PCR testing inventory and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEO transition costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss contingency for regulatory matter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other significant (income) expenses, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA (non-GAAP)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,558)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,113)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,842)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> For the three months ended September 30, 2022, other significant (income) expenses, net, includes consulting fees related to Project Catalyst (our value capture program), fees related to a regulatory matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and other non-recurring items. For the three months ended September 30, 2021, other significant (income) expenses, net, includes strategic deal costs, moving costs and other non-recurring items. For the nine months ended September 30, 2022, other significant (income) expenses, net, includes fees related to a regulatory matter, consulting fees related to Project Catalyst (our value capture program), moving costs, a gain on the sale of a building and other non-recurring items. For the nine months ended September 30, 2021, other significant (income) expenses, net, includes strategic deal costs, moving costs, and other non-recurring items.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_118"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through cash generated from operations, public and private sales of debt and equity securities, and bank debt borrowings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of our consolidated cash flows for operating, investing and financing activities for the nine months ended September 30, 2022 and 2021 as well balances of cash and cash equivalents and working capital:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,947)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(622,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,701)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working Capital </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, end of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518,357&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,193&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Defined as current assets less current liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Operating Activities</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, cash used in operating activities was $62.3 million compared to $6.9 million in the same period in 2021. This $55.4 million increase was primarily driven by our operating results (net loss adjusted for depreciation, amortization of intangibles, and other non-cash charges) which resulted in $26.5 million of higher cash used by operating activities year-over-year, as well as a $28.8 million year-over-year increase in cash used to fund net operating assets. The increase in cash used by operating activities in the nine months ended September 30, 2022 compared to the same period in 2021 reflects cash used to fund the operating activities of our Inivata subsidiary which was acquired in June of 2021 and higher payroll and payroll-related costs to support our strategic growth initiatives. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Investing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, cash provided by investing activities was $1.6 million compared to $622.8 million of cash used in investing activities in the same period in 2021. This change was primarily due to a $419.4 million decrease in net cash used in business acquisitions, a $107.0 million decrease in purchases of marketable securities and a $45.1 million increase in sales and maturities of marketable securities year-over-year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Financing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, cash provided by financing activities was $10.0 million compared to $722.8 million in the same period in 2021. The cash provided by financing activities during the nine months ended September 30, 2022 consisted of $10.7 million for the net issuance of common stock offset by $0.7 million used for the repayment of equipment financing obligations. The primary reason for the decrease in cash provided by financing activities year-over-year was that there were no convertible debt or equity offerings in the nine months ended September 30, 2022. Comparatively, the nine months ended September 30, 2021 had convertible debt net proceeds of $334.4 million and equity offering net proceeds of $408.1 million, partially offset by $29.3 million of premiums paid for capped call confirmations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Outlook</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $266.1 million in unrestricted cash and cash equivalents as of September 30, 2022 in addition to $177.4&#160;million of marketable securities available to support current operational liquidity needs. We anticipate that the cash on hand, marketable securities and cash collections are sufficient to fund our near-term capital and operating needs for at least the next 12 months. Operating needs include, but are not limited to, the planned costs to operate our business, including amounts required to fund working capital and capital expenditures, continued research and development efforts, and potential strategic acquisitions and investments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that the cash on hand, marketable securities and cash collections are sufficient to fund our near-term capital and operating needs for at least the next 12 months. Operating needs include, but are not limited to, the planned costs to operate our business, including amounts required to fund working capital and capital expenditures, continued research and development efforts, and potential strategic acquisitions and investments. </span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_121"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Capital Expenditures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We forecast capital expenditures in order to execute on our business plan and maintain growth; however, the actual amount and timing of such capital expenditures will ultimately be determined by the volume of business. We currently anticipate that our capital expenditures for the year ending December 31, 2022 will be in the range of $30.0 million to $40.0 million. During the nine months ended September 30, 2022, we purchased, with cash, approximately $26.4 million of capital equipment, software and leasehold improvements. We have funded and plan to continue funding these capital expenditures with cash and financing.</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_124"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with United States generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our management routinely makes judgments and estimates about the effects of matters that are inherently uncertain. Please refer to our critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 and Note 2. Summary of Significant Accounting Policies, in the accompanying notes to the unaudited Consolidated Financial Statements for a complete description of our significant accounting policies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. We first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#8217;s fair value. We estimate the fair values of our reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#8217; data. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 we performed a qualitative assessment to determine whether it was more likely than not that the fair values of our reporting units were less than their carrying values. Such qualitative factors included macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. As a result of the qualitative assessment, we determined that due to changes in executive leadership and the sustained decline in our stock price of $12.15 per share as of March 31, 2022 to $8.15 per share as of June 30, 2022, there were indicators that it was more likely than not that the fair values of the reporting units were less than their carrying values. Accordingly, we performed a quantitative analysis and compared our reporting units&#8217; fair values to their carrying values to determine whether goodwill was impaired. We determined the fair values of our reporting units using a combination of the income approach using discounted cash flows and the market approach utilizing comparable companies&#8217; data. The assumptions and estimates, including management's estimated future revenue growth rates, estimated future margins and discount rates, used in the quantitative analysis were based on management&#8217;s best estimate about current and future conditions including projected net revenue from emerging market technologies acquired through the June 2021 acquisition of Inivata. The results of the quantitative analysis showed that the reporting units&#8217; fair values exceeded their carrying values and there was no impairment of the recorded goodwill as of June 30, 2022. However, to the extent we continue to experience declines in our stock price or experience other indicators, such as industry and market considerations or declines in financial performance, that the fair values of our reporting units are less than their carrying values, there could be a risk of goodwill impairment of our reporting units in future periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks, including changes in interest rates and foreign currency exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued $201.3 million aggregate principal amount of the 2025 Convertible Notes. The 2025 Convertible Notes have a fixed annual interest rate of 1.25%; therefore, we do not have economic interest rate exposure with respect to the 2025 Convertible Notes. In January 2021, we issued $345.0 million aggregate principal amount of the 2028 Convertible Notes. The 2028 Convertible Notes have a fixed annual interest rate of 0.25%; therefore, we do not have economic interest rate exposure with respect to the 2028 Convertible Notes. However, the fair value of the 2025 Convertible Notes and 2028 Convertible Notes is exposed to interest rate risk. Generally, the fair market value will increase as interest rates fall and decrease as interest rates rise. In addition, the fair value is affected by our common stock price. The fair value will generally increase as our common stock price increases and will generally decrease as our common stock price declines. We carry the 2025 Convertible Notes and 2028 Convertible Notes at face value less unamortized debt discount and debt issuance costs on our balance sheet, and we present the fair value for required disclosure purposes only.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid and high-quality U.S. government and other highly credit rated debt securities. Our investments are exposed to market risk due to fluctuations in interest rates, which may affect our interest income and the fair market value of our investments. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term securities with short maturities. If a 1% change in interest rates were to have occurred on September 30, 2022, this change would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we do not believe that we have a material financial market risk exposure and do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates. While we believe our marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in Cambridge, United Kingdom; Rolle, Switzerland; Suzhou, China; and Singapore. Our international revenues and expenses denominated in foreign currencies (primarily British Pounds, Swiss Francs, Chinese Renminbi and Singapore Dollars) expose us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. We do not </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hedge foreign currency exchange risks and do not currently believe that these risks are significant.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_133"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosure Controls and Procedures</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule 15d-15, our management carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this report.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8212; OTHER INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_139"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time the Company is engaged in legal proceedings in the ordinary course of business. For further information on legal proceedings, please refer to Note 11. Commitments and Contingencies, in the notes to the unaudited Consolidated Financial Statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider each of the risk factors described in Part I, Item 1A, &#8220;Risk Factors&#8221; contained in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on February 25, 2022, as well as the other information set forth in this Quarterly Report on Form 10-Q. In addition, we are supplementing such risk factors with the following disclosure:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If goodwill and intangible assets that we recorded in connection with our acquisitions become impaired, we may have to take significant charges against earnings. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the accounting for our completed acquisitions, we recorded a significant amount of goodwill and intangible assets. Goodwill and indefinite-lived intangible assets are evaluated for impairment annually, or more frequently if conditions warrant, by comparing the carrying value of a reporting unit to its estimated fair value. Intangible assets with definite lives are reviewed for impairment when events or circumstances indicate that their carrying value may not be recoverable. Declines in operating results, sustained market declines and other factors that impact the fair values of our reporting units could result in an impairment of goodwill or intangible assets and a charge against earnings, which could materially adversely affect our results of operations or financial condition in future periods. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None for the quarterly period ended September 30, 2022 that have not previously been included in a Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning our purchases of common stock for the periods indicated:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;text-decoration:underline">Period of Repurchase</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:700;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2022 - July 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1, 2022 - August 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1, 2022 - September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36.82pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Equity Incentive Plan, as amended on May 27, 2021, allows participants to surrender already-owned shares having a fair market value equal to the required withholding tax related to the vesting of restricted stock. Pursuant to a share withholding election made by participants in connection with the vesting of such awards, all of which were outside of a publicly-announced repurchase plan, we acquired from such participants the shares noted in the table above to satisfy tax withholding obligations related to the vesting of their restricted stock. The average prices listed in the above table are averages of the fair market prices at which we valued shares withheld for purposes of calculating the number of shares to be withheld.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_148"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_151"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ib12970009bdf4a5493f36f07a1369fa4_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:6.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NO.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a10-1retentionagreementcin.htm">Retention Agreement, dated October 19, 2022, by and between NeoGenomics, Inc. and Cynthia Dieter.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a10-2amendedemploymentagre.htm">Amendment to Employment Agreement, dated August 15, 2022, by and between NeoGenomics, Inc. and Christopher Smith.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718322000124/a10-1csmithemploymentagree.htm">Employment Agreement, executed July 20, 2022, by and between NeoGenomics, Inc. and Christopher Smith. (Incorporated by reference to the Company's Current Report on Form 8-K as filed with the SEC on July 21, 2022).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718322000120/ex10-1settlementagreementf.htm">Settlement Agreement, dated as of July 11, 2022, by and between Inivata Limited and Clive Morris.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718322000120/ex10-1settlementagreementf.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718322000120/ex10-1settlementagreementf.htm">(Incorporated by reference to the Company's Current Report on Form 8-K</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718322000120/ex10-1settlementagreementf.htm">/A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718322000120/ex10-1settlementagreementf.htm"> as filed with the SEC on July </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718322000120/ex10-1settlementagreementf.htm">18</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718322000120/ex10-1settlementagreementf.htm">, 2022).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a09302022neo-ex311.htm">Certification by Principal Executive Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a09302022neo-ex312.htm">Certification by Principal Financial Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a09302022neo-ex321.htm">Certification by Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive File (formatted as inline XBRL and contained within Exhibit 101)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denotes a management contract or compensatory plan or arrangement.</span></td></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="ib12970009bdf4a5493f36f07a1369fa4_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date: November 8, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Christopher M. Smith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher M. Smith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ William B. Bonello</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William B. Bonello</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a10-1retentionagreementcin.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3678acf7a7ab47d6b4c43835a54997ba_1"></div><div style="min-height:130.32pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:174px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"></div></div><div style="margin-top:4.6pt;padding-left:6.95pt;padding-right:397.1pt;text-align:justify"><font><br></font></div><div style="padding-right:397.1pt;text-align:justify"><font><br></font></div><div style="padding-right:397.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">October 19, 2022 </font></div><div style="padding-right:397.1pt;text-align:justify"><font><br></font></div><div style="padding-right:397.1pt;text-align:justify"><font><br></font></div><div style="padding-right:397.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cindy Dieter</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Cindy,</font></div><div><font><br></font></div><div style="padding-left:6.95pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To incentivize you to remain with and committed to the success of the Company, we are pleased to offer you a special retention bonus (the &#8220;Retention Bonus&#8221;), subject to the terms and conditions of this letter. You will be eligible to receive a cash bonus in a total amount equal to $150,000 (less applicable withholdings and deductions). The bonus will be payable in two instalments as outlined below (each date representing a &#8220;Vesting Date&#8221;)&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:43pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.2pt">$75,000 on March 31, 2023 if you are actively </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">employed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">by the Company on the Vesting Date.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:43pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.2pt">$75,000 on May 31, 2023, if you are actively </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">employed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">by the Company on the Vesting Date.</font></div><div><font><br></font></div><div style="margin-top:9.55pt;padding-left:6.95pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To the extent earned, the Retention Bonus will be payable as soon as administratively practicable, and not more than 30 days, after the Vesting Date (or termination of employment without Cause, if applicable). Other terms, including terms in the event of the termination of your employment, are contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit</font></div><div style="padding-left:6.95pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. You will be solely and exclusively liable for any taxable event resulting from the payment of the sums referenced above. Further, to receive such payment, you must agree to the terms contained in this letter and its Exhibit A, including your agreement to hold harmless and indemnify the Company for any tax liability, interest, and&#47;or penalties arising out of any failure by you to pay taxes.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6.95pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to the Retention Bonus, you will be awarded an LTI Grant of approximately $100,000. This LTI Grant is subject to the Vesting Schedule in the Restricted Stock Award Agreement. The Restricted Stock Award Agreement will be uploaded to Solium for your review and signature. If for some reason, you do not see the award in Solium within 30 days, please let Kathryn McKenzie know.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6.95pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I want to thank you for your hard work, dedication, achievements, and your personal contribution to our culture and our company&#8217;s continuing success. As a result of efforts by you and our teams, we are making great strides in becoming be the leading oncology diagnostics services company in the world.</font></div><div><font><br></font></div><div style="padding-left:6.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  &#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Chris Smith</font></div><div style="margin-top:10.4pt;padding-left:6.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chris Smith</font></div><div style="padding-left:6.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chief Executive Officer</font></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:130.32pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:174px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:94.92pt;padding-right:94.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exhibit A</font></div><div style="padding-left:94.97pt;padding-right:94.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Retention Bonus &#8211; Additional Terms</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:7pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If, before the Vesting Date, you terminate your employment with NeoGenomics, Inc. (the &#8220;Company&#8221;) or the Company terminates your employment with Cause, no Retention Bonus paid to you. If the Company terminates you for any reason other than Cause before the Vesting Date (including due to your death or disability), then you will still be entitled to the Retention Bonus to the extent it has not already been paid.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:7pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this letter agreement, &#8220;Cause&#8221; means the Company&#8217;s good faith determination of any of the following&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:5.75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:25.68pt">your willful and continued failure to perform your material duties with the Company (other than such failure resulting due to death or disability), or</font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:5.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.58pt">any breach by you of the material provisions of your employment or other agreements with the Company&#59; or</font></div><div style="padding-left:61pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.58pt">gross misconduct by you which results in serious damage to the Company&#59; or</font></div><div style="margin-top:1.85pt;padding-left:61pt;padding-right:5.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:20.18pt">felony conviction involving your personal dishonesty or moral turpitude&#59; or a determination by the Company, after consideration of available information, that you have violated the Company policies or procedures involving compliance with law, including laws prohibiting discrimination, harassment, or workplace violence&#59; or</font></div><div style="padding-left:61pt;padding-right:5.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:23.23pt">engagement in illegal drug use or alcohol abuse that prevents you from performing your duties in any manner, or</font></div><div style="margin-top:0.1pt;padding-left:61pt;padding-right:5.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:20.18pt">your misappropriation, embezzlement, or conversion of the Company&#8217;s opportunities or property.</font></div><div><font><br></font></div><div style="margin-top:8.7pt;padding-left:6.95pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The terms contained in this letter and its Exhibit A constitute the entire understanding and agreement between you and the Company with respect to the retention bonus payments referenced in this letter and the terms and conditions associated with those payments. This Agreement supersedes and terminates all prior oral or written promises, representations, understandings, and agreements regarding this subject matter. The terms contained in this letter and its Exhibit A may not be changed, amended, or modified orally and no modification, amendment, or waiver of any term contained herein, or any future representation, promise, or condition in connection with the subject matter referenced above, shall be binding upon any party hereto unless memorialized in a written agreement between you and the Company that expressly references this letter and its Exhibit A and identifies the terms herein that are to be changed, amended, or modified. Such change, amendment, or modification must be signed by you and duly authorized officers or representatives of the Company. Notwithstanding this provision, this letter and its Exhibit A shall not in any way diminish any obligation, duty, or undertaking owed by you to the Company because of any other contract, agreement, or law on a different subject matter. The terms contained in this letter and its Exhibit A will be in addition to, and not in place of, any and all other rights held by the Company by virtue of any other contract, agreement, or undertaking, and to that extent, your other obligations to the Company are not altered, changed, or superseded by this letter or its Exhibit A.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:130.32pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:174px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"></div></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95.42pt;padding-right:95.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EMPLOYEE ACKNOWLEDGEMENT AND AGREEMENT</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:7pt;padding-right:5.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By signing below, I acknowledge and agree to the terms contained in this letter and its Exhibit A for purposes of the retention bonus payments referenced above. I further acknowledge that I have read, carefully reviewed, and considered this letter and its Exhibit A, that I understand those documents and freely and voluntarily agrees to all of their terms and conditions, that I have had the opportunity to consult with an attorney of my choice, and that I enter into this Agreement voluntarily without coercion and with full knowledge of its contents and effect.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:42.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cindy Dieter</font></div><div style="margin-top:0.35pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:264px"></div><div style="margin-top:0.05pt;padding-left:43pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Printed Name</font></div><div style="margin-top:0.05pt;padding-left:43pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:43pt"><font><br></font></div><div style="padding-left:42.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Cindy Dieter</font></div><div style="margin-top:0.35pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:264px"></div><div style="margin-top:0.05pt;padding-left:43pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Employee Signature</font></div><div style="margin-top:0.05pt;padding-left:43pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a10-2amendedemploymentagre.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib8bde3bf9e064f6d8204a0e0516c47fb_1"></div><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">Exhibit 10.2</font></div></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:110.69pt;padding-right:110.69pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMENDMENT TO EMPLOYMENT AGREEMENT</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This AMENDMENT TO EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made and entered into by and between NeoGenomics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Christopher Smith (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and is effective as of August 15, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the Employment Agreement by and between the Company and the Executive, dated as of August 15, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:8.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company and the Executive desire to modify certain terms and conditions of the Executive&#8217;s employment.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:8.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants contained herein and intending to be legally bound hereby, the parties hereby agree to amend the Employment Agreement on the terms set forth in this Amendment.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:41pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.05pt;text-decoration:underline">Relocation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2(d) of the Employment Agreement shall be amended to remove &#8220;$400,000.00&#8221; from the second sentence of such Section and replace it therein with a reference to &#8220;$1,200,000.00&#8221;.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.05pt;text-decoration:underline">Restricted Stock Unit Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2(c) of the Employment Agreement shall be amended to&#58;</font></div><div><font><br></font></div><div style="padding-left:60.25pt;text-indent:-19.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Add the following sentence immediately after the first sentence of such Section&#58;</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:43.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;In addition, subject to approval by the Board or the Compensation Committee, the Executive will receive an additional one-time inducement grant of restricted stock with an aggregate target value equal to approximately $3,350,000.00 (the &#8216;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sign-on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8217;)&#8221;&#59; and</font></div><div style="padding-right:43.85pt;text-align:justify"><font><br></font></div><div style="padding-left:60.25pt;text-indent:-19.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.32pt">Add the following language to the third sentence of such Section (after giving effect to subsection (a) above) immediately following &#8220;on an annual basis over a period of four years from the date of grant&#8221;&#58;</font></div><div style="padding-left:24.25pt;text-indent:-1.3pt"><font><br></font></div><div style="padding-left:41pt;padding-right:22.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(or, with respect to the Sign-On Grant, as to 100% of the restricted stock, on the fourth anniversary of the grant date).&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Executive acknowledges and agrees that the Employment Agreement, as amended by this Amendment, constitutes the entire agreement between the</font></div><div><font><br></font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee and the Company with respect to the terms and conditions of his employment and supersedes all other agreements and understandings, whether written or oral.</font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, this Amendment has been executed by the Company, by its duly authorized representative, and by Executive as of the date first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.853%"><tr><td style="width:1.0%"></td><td style="width:42.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTIVE&#58; </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE COMPANY&#58; </font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Chris Smith</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Lynn Tetrault</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Christopher Smith</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Lynn Tetrault</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Chair and Interim CEO</font></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.794%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:0.411%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.795%"></div></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a09302022neo-ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9637257d6a32483484c497d83e358ab0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher M. Smith, certify that&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of NeoGenomics, Inc.&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Christopher M. Smith</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher M. Smith</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a09302022neo-ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia3306eb6adb740a5bc58399fc003c0cd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William B. Bonello, certify that&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of NeoGenomics, Inc.&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; William B. Bonello</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William B. Bonello</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a09302022neo-ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1635342402a449c58966cb403ed3d8f6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Quarterly Report of NeoGenomics, Inc. (the &#8220;Company&#8221;) on Form 10-Q as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the dates indicated below, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his or her knowledge&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Christopher M. Smith</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher M. Smith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; William B. Bonello</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William B. Bonello</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>neo-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2d7a6b14-636e-498a-9bb1-3c76242be649,g:a2221670-aa14-4f97-b400-5f284572b74c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:neo="http://neogenomics.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://neogenomics.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://neogenomics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusiness" roleURI="http://neogenomics.com/role/NatureoftheBusiness">
        <link:definition>0000008 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://neogenomics.com/role/Acquisitions">
        <link:definition>0000010 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://neogenomics.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000012 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://neogenomics.com/role/Debt">
        <link:definition>0000013 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://neogenomics.com/role/StockBasedCompensation">
        <link:definition>0000014 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://neogenomics.com/role/RevenueRecognition">
        <link:definition>0000015 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://neogenomics.com/role/IncomeTaxes">
        <link:definition>0000016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShare" roleURI="http://neogenomics.com/role/NetLossIncomePerShare">
        <link:definition>0000017 - Disclosure - Net (Loss) Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://neogenomics.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://neogenomics.com/role/RelatedPartyTransactions">
        <link:definition>0000019 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://neogenomics.com/role/SegmentInformation">
        <link:definition>0000020 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://neogenomics.com/role/AcquisitionsTables">
        <link:definition>0000022 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://neogenomics.com/role/FairValueMeasurementsTables">
        <link:definition>0000023 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000024 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://neogenomics.com/role/StockBasedCompensationTables">
        <link:definition>0000025 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://neogenomics.com/role/RevenueRecognitionTables">
        <link:definition>0000026 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareTables" roleURI="http://neogenomics.com/role/NetLossIncomePerShareTables">
        <link:definition>0000027 - Disclosure - Net (Loss) Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://neogenomics.com/role/SegmentInformationTables">
        <link:definition>0000028 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessNarrativeDetails" roleURI="http://neogenomics.com/role/NatureoftheBusinessNarrativeDetails">
        <link:definition>0000029 - Disclosure - Nature of the Business - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://neogenomics.com/role/AcquisitionsNarrativeDetails">
        <link:definition>0000031 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsScheduleofProvisionalInformationDetails" roleURI="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails">
        <link:definition>0000032 - Disclosure - Acquisitions - Schedule of Provisional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsProFormaInformationDetails" roleURI="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails">
        <link:definition>0000033 - Disclosure - Acquisitions - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAmortizedCostDetails" roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails">
        <link:definition>0000034 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValuebyContractualMaturityDetails" roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails">
        <link:definition>0000035 - Disclosure - Fair Value Measurements - Fair Value by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails">
        <link:definition>0000036 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofGoodwillDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails">
        <link:definition>0000037 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails">
        <link:definition>0000038 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1">
        <link:definition>0000038 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails">
        <link:definition>0000039 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails">
        <link:definition>0000040 - Disclosure - Goodwill and Intangible Assets - Estimated Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://neogenomics.com/role/DebtDetails">
        <link:definition>0000041 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000042 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>0000043 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails">
        <link:definition>0000044 - Disclosure - Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRestrictedStockActivityDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails">
        <link:definition>0000045 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://neogenomics.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>0000046 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractAssetsandLiabilitiesDetails" roleURI="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails">
        <link:definition>0000047 - Disclosure - Revenue Recognition - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>0000048 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails" roleURI="http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails">
        <link:definition>0000049 - Disclosure - Net (Loss) Income Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareScheduleofAntidilutiveSharesDetails" roleURI="http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails">
        <link:definition>0000050 - Disclosure - Net (Loss) Income Per Share - Schedule of Antidilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000051 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://neogenomics.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000052 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://neogenomics.com/role/SegmentInformationDetails">
        <link:definition>0000053 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="neo_PolymeraseChainReactionTestingWriteOffsCOVID19" abstract="false" name="PolymeraseChainReactionTestingWriteOffsCOVID19" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_AssetsHeldForSalePolicyPolicyTextBlock" abstract="false" name="AssetsHeldForSalePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PharmaServicesMember" abstract="true" name="PharmaServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_InivataMember" abstract="true" name="InivataMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" abstract="true" name="PharmaServicesContractsWithHOOKIPAPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_GainLossOnInvestmentAndLoanReceivable" abstract="false" name="GainLossOnInvestmentAndLoanReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_TrapeloHealthMember" abstract="true" name="TrapeloHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_FederalHealthcareProgramRevenueMember" abstract="true" name="FederalHealthcareProgramRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" abstract="false" name="ReceivableWithImputedInterestNonConsolidatedAffiliates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" abstract="false" name="GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_InterestExpenseDebtContractualCouponInterest" abstract="false" name="InterestExpenseDebtContractualCouponInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ChiefLegalOfficerMember" abstract="true" name="ChiefLegalOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PatentInfringementComplaintMember" abstract="true" name="PatentInfringementComplaintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_StrategicAllianceWithInivataLimitedMember" abstract="true" name="StrategicAllianceWithInivataLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_YankeeBondsMember" abstract="true" name="YankeeBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ContractualObligationTable" abstract="true" name="ContractualObligationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" abstract="true" name="ZeroPointTwoFivePercentConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_AssetHeldForSaleSquareFeetOfFacilityOwned" abstract="false" name="AssetHeldForSaleSquareFeetOfFacilityOwned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="neo_SocialSecurityTaxEmployerDeferralCARESAct" abstract="false" name="SocialSecurityTaxEmployerDeferralCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" abstract="false" name="CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" abstract="false" name="ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="neo_ClientDirectBillingMember" abstract="true" name="ClientDirectBillingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_PaymentsOfPremiumsForCappedCallConfirmations" abstract="false" name="PaymentsOfPremiumsForCappedCallConfirmations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_IntangibleAssetsAcquiredAmortizationExpense" abstract="false" name="IntangibleAssetsAcquiredAmortizationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate" abstract="false" name="GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" abstract="false" name="PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" abstract="false" name="InterestExpenseDebtAmortizationOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_MedicareAndOtherGovernmentalMember" abstract="true" name="MedicareAndOtherGovernmentalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_ClinicalServicesMember" abstract="true" name="ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_FairValueOfCommonStockIssuedToFundAcquisition" abstract="false" name="FairValueOfCommonStockIssuedToFundAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_InterestExpenseDebtAccretionOfDebtDiscount" abstract="false" name="InterestExpenseDebtAccretionOfDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" abstract="false" name="BusinessCombinationStepAcquisitionPurchaseOptionFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ContractualObligationLineItems" abstract="true" name="ContractualObligationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="neo_COVID19PCRTestingMember" abstract="true" name="COVID19PCRTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract" abstract="true" name="SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="neo_CommercialInsuranceMember" abstract="true" name="CommercialInsuranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract" abstract="true" name="SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="neo_ProceedsFromEquityOfferingNet" abstract="false" name="ProceedsFromEquityOfferingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_IncreaseDecreaseInPrepaidConstruction" abstract="false" name="IncreaseDecreaseInPrepaidConstruction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember" abstract="true" name="PharmaServiceContractsWithCytomXTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_PolymeraseChainReactionTestingExitCostsCOVID19" abstract="false" name="PolymeraseChainReactionTestingExitCostsCOVID19" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_CappedCallTransactionsMember" abstract="true" name="CappedCallTransactionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_RepaymentsOfEquipmentAndOtherFinanceObligation" abstract="false" name="RepaymentsOfEquipmentAndOtherFinanceObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_SelfPayServicesMember" abstract="true" name="SelfPayServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" abstract="true" name="OnePointTwoFivePercentConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>neo-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2d7a6b14-636e-498a-9bb1-3c76242be649,g:a2221670-aa14-4f97-b400-5f284572b74c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f6d366a4-4d19-493d-ad95-c7fa4276b818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_21bb9b77-25cc-4a26-a4df-aa1b53297584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f6d366a4-4d19-493d-ad95-c7fa4276b818" xlink:to="loc_us-gaap_AssetsCurrent_21bb9b77-25cc-4a26-a4df-aa1b53297584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_c5206918-86ba-4706-a687-8dbeb5316edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f6d366a4-4d19-493d-ad95-c7fa4276b818" xlink:to="loc_us-gaap_AssetsNoncurrent_c5206918-86ba-4706-a687-8dbeb5316edb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1cfdc1fb-1306-4a69-b47f-7de044d47e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_99779a21-ce6d-4d17-9a15-51bbcbfb0995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1cfdc1fb-1306-4a69-b47f-7de044d47e56" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_99779a21-ce6d-4d17-9a15-51bbcbfb0995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2fe582e9-2cd3-4e1c-8d89-43fcbed79f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1cfdc1fb-1306-4a69-b47f-7de044d47e56" xlink:to="loc_us-gaap_Goodwill_2fe582e9-2cd3-4e1c-8d89-43fcbed79f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a189a00-a319-4cfd-ac62-4d8cb86c3b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1cfdc1fb-1306-4a69-b47f-7de044d47e56" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a189a00-a319-4cfd-ac62-4d8cb86c3b07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c2c942a0-5c73-41f5-b66e-698f5926f172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1cfdc1fb-1306-4a69-b47f-7de044d47e56" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c2c942a0-5c73-41f5-b66e-698f5926f172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5adf9275-a228-424c-9162-5c929202d4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1cfdc1fb-1306-4a69-b47f-7de044d47e56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5adf9275-a228-424c-9162-5c929202d4a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c285843d-5a49-4caf-89a1-aac4e1afa1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_681d3ee0-9666-45be-9449-d08cc1342e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c285843d-5a49-4caf-89a1-aac4e1afa1b8" xlink:to="loc_us-gaap_Liabilities_681d3ee0-9666-45be-9449-d08cc1342e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f03b5cee-c2c1-4f1d-bfbe-f13a4bca5a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c285843d-5a49-4caf-89a1-aac4e1afa1b8" xlink:to="loc_us-gaap_StockholdersEquity_f03b5cee-c2c1-4f1d-bfbe-f13a4bca5a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e4dacee5-c0e1-439f-af9e-41932b74879f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c285843d-5a49-4caf-89a1-aac4e1afa1b8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e4dacee5-c0e1-439f-af9e-41932b74879f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_81308d90-50e4-4c53-8cd6-ab170272bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3765bf02-215f-434b-8e4c-dba904fc9b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_81308d90-50e4-4c53-8cd6-ab170272bbd7" xlink:to="loc_us-gaap_AccountsPayableCurrent_3765bf02-215f-434b-8e4c-dba904fc9b57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de8b90e8-996b-45e3-9d99-7225eedce2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_81308d90-50e4-4c53-8cd6-ab170272bbd7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de8b90e8-996b-45e3-9d99-7225eedce2c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_34ddb92e-e4ef-4fb2-bdd4-de5af481da7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_81308d90-50e4-4c53-8cd6-ab170272bbd7" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_34ddb92e-e4ef-4fb2-bdd4-de5af481da7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f5372dd2-ff34-4301-8f8d-2fccd3049871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_81308d90-50e4-4c53-8cd6-ab170272bbd7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f5372dd2-ff34-4301-8f8d-2fccd3049871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e7d18998-3361-46aa-8372-b39acf0a64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_81308d90-50e4-4c53-8cd6-ab170272bbd7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e7d18998-3361-46aa-8372-b39acf0a64ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_82b54c60-b9ad-4a60-9ca5-c02ba022c576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_81308d90-50e4-4c53-8cd6-ab170272bbd7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_82b54c60-b9ad-4a60-9ca5-c02ba022c576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b9aa09ed-c405-4469-a601-49df924614b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_582d1ad5-17b6-4d43-b7bb-a6b4f84845ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b9aa09ed-c405-4469-a601-49df924614b6" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_582d1ad5-17b6-4d43-b7bb-a6b4f84845ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b6ceabf4-50de-4f98-bca2-8503fd6a02e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b9aa09ed-c405-4469-a601-49df924614b6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b6ceabf4-50de-4f98-bca2-8503fd6a02e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7361d679-7d83-4246-aa29-c037470f4fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b9aa09ed-c405-4469-a601-49df924614b6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7361d679-7d83-4246-aa29-c037470f4fd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e4ea0804-c15d-4838-bc82-07e54b8f3590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b9aa09ed-c405-4469-a601-49df924614b6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e4ea0804-c15d-4838-bc82-07e54b8f3590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_880a935f-3825-4026-8a35-80d41cf7585e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_47628f4b-3909-4060-9505-f0b4a2f51655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_880a935f-3825-4026-8a35-80d41cf7585e" xlink:to="loc_us-gaap_LiabilitiesCurrent_47628f4b-3909-4060-9505-f0b4a2f51655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a8f4d85a-7244-4f1c-8850-3d76a769c256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_880a935f-3825-4026-8a35-80d41cf7585e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_a8f4d85a-7244-4f1c-8850-3d76a769c256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_915bfb35-a191-4946-96fd-55acb6363a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa0f55ef-28e7-42df-9d4a-43d6f11eb3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_915bfb35-a191-4946-96fd-55acb6363a26" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa0f55ef-28e7-42df-9d4a-43d6f11eb3e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_8bb66b6e-8756-4e15-ab6f-c191a9386e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_915bfb35-a191-4946-96fd-55acb6363a26" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_8bb66b6e-8756-4e15-ab6f-c191a9386e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f9afcdcf-347a-4e23-b7d8-c9e8efb2e26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_915bfb35-a191-4946-96fd-55acb6363a26" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f9afcdcf-347a-4e23-b7d8-c9e8efb2e26f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0ddcbb29-1db6-499c-89a4-3216aaa0dd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_915bfb35-a191-4946-96fd-55acb6363a26" xlink:to="loc_us-gaap_InventoryNet_0ddcbb29-1db6-499c-89a4-3216aaa0dd0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_997127a5-fd5c-4c71-849c-8b5e54c686b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_915bfb35-a191-4946-96fd-55acb6363a26" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_997127a5-fd5c-4c71-849c-8b5e54c686b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0f6c6b1c-888a-4060-b594-0c2e5e46b054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_915bfb35-a191-4946-96fd-55acb6363a26" xlink:to="loc_us-gaap_OtherAssetsCurrent_0f6c6b1c-888a-4060-b594-0c2e5e46b054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_c07299b4-21cc-4930-a403-928f7b600052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_915bfb35-a191-4946-96fd-55acb6363a26" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_c07299b4-21cc-4930-a403-928f7b600052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36da01d8-7a60-45cf-8320-013ee240a8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_e6ff5842-1b5d-4eb8-b67f-06fdfa6de7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36da01d8-7a60-45cf-8320-013ee240a8e8" xlink:to="loc_us-gaap_CommonStockValueOutstanding_e6ff5842-1b5d-4eb8-b67f-06fdfa6de7b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c62d3f1-c201-4ab3-8f25-eee503dc90b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36da01d8-7a60-45cf-8320-013ee240a8e8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c62d3f1-c201-4ab3-8f25-eee503dc90b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0089c4c9-e903-49a7-bc8e-073ab74c712c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36da01d8-7a60-45cf-8320-013ee240a8e8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0089c4c9-e903-49a7-bc8e-073ab74c712c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_055fa3cd-47b1-4b30-b8f9-2f5c8412ed79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36da01d8-7a60-45cf-8320-013ee240a8e8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_055fa3cd-47b1-4b30-b8f9-2f5c8412ed79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_56e430b3-0638-4d5f-a464-31d56950ec15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_33e1448c-155f-4fff-ab02-9c1d186f3152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_56e430b3-0638-4d5f-a464-31d56950ec15" xlink:to="loc_us-gaap_GrossProfit_33e1448c-155f-4fff-ab02-9c1d186f3152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_abc67b99-bfb0-4f36-a228-1faf566f4328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_56e430b3-0638-4d5f-a464-31d56950ec15" xlink:to="loc_us-gaap_OperatingExpenses_abc67b99-bfb0-4f36-a228-1faf566f4328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a6842c05-a874-4d81-a1e9-944e0bc0b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a04701e5-9de7-423b-a03f-330e89a96329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a6842c05-a874-4d81-a1e9-944e0bc0b39e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a04701e5-9de7-423b-a03f-330e89a96329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8b199b27-6c3e-4714-82f4-6b80c6fe5e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a6842c05-a874-4d81-a1e9-944e0bc0b39e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8b199b27-6c3e-4714-82f4-6b80c6fe5e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8eb67a33-4f8e-464f-8671-63d643257f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f30e48ce-0b60-46b9-a2cb-d4ec5c672a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8eb67a33-4f8e-464f-8671-63d643257f91" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f30e48ce-0b60-46b9-a2cb-d4ec5c672a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e6c59052-b815-484a-a2a2-e8c937572f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8eb67a33-4f8e-464f-8671-63d643257f91" xlink:to="loc_us-gaap_OperatingIncomeLoss_e6c59052-b815-484a-a2a2-e8c937572f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable_9dbd184f-6c3c-4dd8-9092-ce531f15f00f" xlink:href="neo-20220930.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8eb67a33-4f8e-464f-8671-63d643257f91" xlink:to="loc_neo_GainLossOnInvestmentAndLoanReceivable_9dbd184f-6c3c-4dd8-9092-ce531f15f00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_eec3b28f-45ee-410d-96de-de30751411cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8eb67a33-4f8e-464f-8671-63d643257f91" xlink:to="loc_us-gaap_InterestExpense_eec3b28f-45ee-410d-96de-de30751411cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b03fdb3e-6e1d-4f43-b4e6-00713727b598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aed75a99-01c1-4364-bec1-7a6624b56eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b03fdb3e-6e1d-4f43-b4e6-00713727b598" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aed75a99-01c1-4364-bec1-7a6624b56eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d148fdf4-f226-426a-91ae-ff177b289319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b03fdb3e-6e1d-4f43-b4e6-00713727b598" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d148fdf4-f226-426a-91ae-ff177b289319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_aa852907-b290-4171-b172-f921d1b5a60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1e1b2995-d631-4bfe-94e1-39f40b943aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aa852907-b290-4171-b172-f921d1b5a60c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1e1b2995-d631-4bfe-94e1-39f40b943aae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_88a848e7-cd94-48cd-a188-f473a3750d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aa852907-b290-4171-b172-f921d1b5a60c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_88a848e7-cd94-48cd-a188-f473a3750d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_f7daf625-e452-4de3-af3b-3a51dd36dfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aa852907-b290-4171-b172-f921d1b5a60c" xlink:to="loc_us-gaap_SellingAndMarketingExpense_f7daf625-e452-4de3-af3b-3a51dd36dfea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c2fe26e9-3ef3-4596-af87-9a859f3102f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ccafe924-0229-486b-8e0b-4c335da5cb78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c2fe26e9-3ef3-4596-af87-9a859f3102f4" xlink:to="loc_us-gaap_NetIncomeLoss_ccafe924-0229-486b-8e0b-4c335da5cb78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_851937c0-2d97-46ff-b3e5-56f7fba9281d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c2fe26e9-3ef3-4596-af87-9a859f3102f4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_851937c0-2d97-46ff-b3e5-56f7fba9281d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_91318c42-9c62-49cb-83ca-3d9f33a6e871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_162a825c-da1a-406e-aa47-5644d98bf281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_91318c42-9c62-49cb-83ca-3d9f33a6e871" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_162a825c-da1a-406e-aa47-5644d98bf281" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a77a02ed-38f5-4bf1-b644-7c32a2401c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f6ec5f2d-7843-4b4b-801a-aacf8ea65e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a77a02ed-38f5-4bf1-b644-7c32a2401c59" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f6ec5f2d-7843-4b4b-801a-aacf8ea65e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8297f3ac-bf48-49ee-af16-12f7cf380ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a77a02ed-38f5-4bf1-b644-7c32a2401c59" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8297f3ac-bf48-49ee-af16-12f7cf380ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_7d5571d7-b97c-4236-9139-ac48117bf8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a77a02ed-38f5-4bf1-b644-7c32a2401c59" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_7d5571d7-b97c-4236-9139-ac48117bf8ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_a06509e5-7c41-4adc-86fe-7f1d78694645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a77a02ed-38f5-4bf1-b644-7c32a2401c59" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_a06509e5-7c41-4adc-86fe-7f1d78694645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0ac12b85-02e0-4a89-8093-633f5d975d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a77a02ed-38f5-4bf1-b644-7c32a2401c59" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0ac12b85-02e0-4a89-8093-633f5d975d70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e3e08fe3-fc17-4919-92b3-442a90f0e032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a77a02ed-38f5-4bf1-b644-7c32a2401c59" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e3e08fe3-fc17-4919-92b3-442a90f0e032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62145fdb-51ca-42a1-ad5d-92bcd01a4f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49fc11a1-bc6f-4561-a89b-ea78bb29a290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62145fdb-51ca-42a1-ad5d-92bcd01a4f1b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49fc11a1-bc6f-4561-a89b-ea78bb29a290" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_62def773-3737-4233-9f1c-684f48310f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62145fdb-51ca-42a1-ad5d-92bcd01a4f1b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_62def773-3737-4233-9f1c-684f48310f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52d5152b-a50d-4d33-8c4d-804bdcf58d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2c1e8680-0f00-4365-9af2-edd7880c9db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52d5152b-a50d-4d33-8c4d-804bdcf58d4f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2c1e8680-0f00-4365-9af2-edd7880c9db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fcb4b6b-174b-4200-8f1c-6bd88f65242a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52d5152b-a50d-4d33-8c4d-804bdcf58d4f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fcb4b6b-174b-4200-8f1c-6bd88f65242a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4662cf96-ec71-4bad-9d29-cd71f15287be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52d5152b-a50d-4d33-8c4d-804bdcf58d4f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4662cf96-ec71-4bad-9d29-cd71f15287be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47b00c40-4652-48fc-a77f-119ecf23699e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_NetIncomeLoss_47b00c40-4652-48fc-a77f-119ecf23699e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_26050d8f-da46-4baa-9cf4-aa2e32410652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_26050d8f-da46-4baa-9cf4-aa2e32410652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncreaseDecreaseInPrepaidConstruction_3e038fb5-c3a1-41ae-9f6f-126d0213e12d" xlink:href="neo-20220930.xsd#neo_IncreaseDecreaseInPrepaidConstruction"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_neo_IncreaseDecreaseInPrepaidConstruction_3e038fb5-c3a1-41ae-9f6f-126d0213e12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_37097622-3680-419d-93a0-aebe4293dd06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_37097622-3680-419d-93a0-aebe4293dd06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_fcbbe9b5-d480-414b-a9b9-62bfa4827fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_fcbbe9b5-d480-414b-a9b9-62bfa4827fcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet_4095bde0-ea00-4218-8423-fc5a08d83c12" xlink:href="neo-20220930.xsd#neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet_4095bde0-ea00-4218-8423-fc5a08d83c12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d7bb9312-2273-4fc2-a233-a645d8aa794a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d7bb9312-2273-4fc2-a233-a645d8aa794a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_695de0a5-5044-4f4a-a89c-bd00b4485553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_ShareBasedCompensation_695de0a5-5044-4f4a-a89c-bd00b4485553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3cd85951-ce0f-451f-81b0-8b8546b5edde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_Depreciation_3cd85951-ce0f-451f-81b0-8b8546b5edde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_bf0d7a29-ca7a-4ecf-a6c9-d02121fe494f" xlink:href="neo-20220930.xsd#neo_ReceivableWithImputedInterestNonConsolidatedAffiliates"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_bf0d7a29-ca7a-4ecf-a6c9-d02121fe494f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_bb70ac54-2e8b-4c4a-bdf5-17a43fcba223" xlink:href="neo-20220930.xsd#neo_PolymeraseChainReactionTestingExitCostsCOVID19"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_bb70ac54-2e8b-4c4a-bdf5-17a43fcba223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_5b0c787f-ea3f-4ab7-8dea-3d649f4ef605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_5b0c787f-ea3f-4ab7-8dea-3d649f4ef605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_000c70a8-b75d-4d71-ac3f-6d7d5d868cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_000c70a8-b75d-4d71-ac3f-6d7d5d868cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8122b5df-94eb-42c1-bde5-82c5fd0b355e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8122b5df-94eb-42c1-bde5-82c5fd0b355e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9d996e12-9033-4d89-ae42-f6ae642c54ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_OperatingLeaseExpense_9d996e12-9033-4d89-ae42-f6ae642c54ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_47f04a15-694b-4c22-8356-6f38cba86565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_47f04a15-694b-4c22-8356-6f38cba86565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_7a67f6fc-d4d3-4b22-8dcc-fae81edd694d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_7a67f6fc-d4d3-4b22-8dcc-fae81edd694d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_818616b9-aa7f-45c2-aeed-9ff53b1adf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3840507a-a4dc-4522-a2ba-f25aa947cb3c" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_818616b9-aa7f-45c2-aeed-9ff53b1adf8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c29e753-d5bb-415d-bf7a-aca719c9340f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_50977198-9b67-423f-aef6-a2b4cd28b2a3" xlink:href="neo-20220930.xsd#neo_RepaymentsOfEquipmentAndOtherFinanceObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c29e753-d5bb-415d-bf7a-aca719c9340f" xlink:to="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_50977198-9b67-423f-aef6-a2b4cd28b2a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b30979e2-951f-47ae-a9c1-f07755139b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c29e753-d5bb-415d-bf7a-aca719c9340f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b30979e2-951f-47ae-a9c1-f07755139b3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_28733971-e8bc-421d-8b61-c28a9adb62ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c29e753-d5bb-415d-bf7a-aca719c9340f" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_28733971-e8bc-421d-8b61-c28a9adb62ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations_838b1451-af59-4625-9308-99f098187e85" xlink:href="neo-20220930.xsd#neo_PaymentsOfPremiumsForCappedCallConfirmations"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c29e753-d5bb-415d-bf7a-aca719c9340f" xlink:to="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations_838b1451-af59-4625-9308-99f098187e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ProceedsFromEquityOfferingNet_fc64c27c-a15d-4178-af41-8a20618da47d" xlink:href="neo-20220930.xsd#neo_ProceedsFromEquityOfferingNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c29e753-d5bb-415d-bf7a-aca719c9340f" xlink:to="loc_neo_ProceedsFromEquityOfferingNet_fc64c27c-a15d-4178-af41-8a20618da47d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#AcquisitionsScheduleofProvisionalInformationDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_69505a62-7ce0-4734-95c8-ead48461cb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_524f8579-d383-45cf-abd3-1da5c6e4e823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_69505a62-7ce0-4734-95c8-ead48461cb8c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_524f8579-d383-45cf-abd3-1da5c6e4e823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_45a9e9f7-8e89-42cc-8d26-2980d9c859f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_69505a62-7ce0-4734-95c8-ead48461cb8c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_45a9e9f7-8e89-42cc-8d26-2980d9c859f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_754cbda9-a06d-43df-8356-f18e4b8ff6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_69505a62-7ce0-4734-95c8-ead48461cb8c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_754cbda9-a06d-43df-8356-f18e4b8ff6a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e062231a-3a9f-48e9-bc27-bcf45a38de2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_69505a62-7ce0-4734-95c8-ead48461cb8c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e062231a-3a9f-48e9-bc27-bcf45a38de2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_38bf58d5-39ee-46da-b00e-6f2a2d773f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_af327df8-3a48-4086-9367-602a86b174d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_38bf58d5-39ee-46da-b00e-6f2a2d773f9d" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_af327df8-3a48-4086-9367-602a86b174d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_12140544-726c-4776-8d7d-de4f4de9d3e7" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_38bf58d5-39ee-46da-b00e-6f2a2d773f9d" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_12140544-726c-4776-8d7d-de4f4de9d3e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_54471ca1-abaf-46b2-9dc0-97d49b56aa57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52a419c-4dc2-4dc6-83af-1758bb11144d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_54471ca1-abaf-46b2-9dc0-97d49b56aa57" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52a419c-4dc2-4dc6-83af-1758bb11144d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c92402ec-8083-4c29-b760-b6b1f290d416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_54471ca1-abaf-46b2-9dc0-97d49b56aa57" xlink:to="loc_us-gaap_Goodwill_c92402ec-8083-4c29-b760-b6b1f290d416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a7139e51-16ba-47a6-ae4c-3206c7182d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_fa39521e-85b6-44db-a205-4019a3479d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a7139e51-16ba-47a6-ae4c-3206c7182d11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_fa39521e-85b6-44db-a205-4019a3479d37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a1a3ac18-c9f4-4e5a-884a-6ccf5aec0c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a7139e51-16ba-47a6-ae4c-3206c7182d11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a1a3ac18-c9f4-4e5a-884a-6ccf5aec0c2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_547d71e8-8d32-4129-995f-58b9f5218d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a7139e51-16ba-47a6-ae4c-3206c7182d11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_547d71e8-8d32-4129-995f-58b9f5218d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_b38f5aec-ed1b-4d51-969b-d0cadd6784d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a7139e51-16ba-47a6-ae4c-3206c7182d11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_b38f5aec-ed1b-4d51-969b-d0cadd6784d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_0399c587-d557-4681-813f-0cec805dcb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a7139e51-16ba-47a6-ae4c-3206c7182d11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_0399c587-d557-4681-813f-0cec805dcb3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1b1f6d9d-0637-4758-9be8-69ba06941063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b9477e9a-97a8-479a-9595-aeadee5a955d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1b1f6d9d-0637-4758-9be8-69ba06941063" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b9477e9a-97a8-479a-9595-aeadee5a955d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2a2c5035-8819-4245-8e8f-d830ef783a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1b1f6d9d-0637-4758-9be8-69ba06941063" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2a2c5035-8819-4245-8e8f-d830ef783a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_f8c7fdc3-353d-43ac-9de6-78415edca49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1b1f6d9d-0637-4758-9be8-69ba06941063" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_f8c7fdc3-353d-43ac-9de6-78415edca49b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_5a66f07d-e8e9-495c-a3cb-291c69959666" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities_830c2e68-a6cc-488d-ba62-73d882f46150" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_5a66f07d-e8e9-495c-a3cb-291c69959666" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities_830c2e68-a6cc-488d-ba62-73d882f46150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent_a1b34d56-b87e-4011-be00-d0f37d01ba77" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_5a66f07d-e8e9-495c-a3cb-291c69959666" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent_a1b34d56-b87e-4011-be00-d0f37d01ba77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_c1a8d74e-f5bd-4841-8131-9e3966eb3f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_5a66f07d-e8e9-495c-a3cb-291c69959666" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_c1a8d74e-f5bd-4841-8131-9e3966eb3f17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_352ec88d-8e6b-4117-a733-b46c84c45137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_f3b231db-b477-49fd-b844-48c2556be4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_352ec88d-8e6b-4117-a733-b46c84c45137" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_f3b231db-b477-49fd-b844-48c2556be4b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_dc50fb89-ad78-48b9-affb-f649fb3bbab5" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_352ec88d-8e6b-4117-a733-b46c84c45137" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_dc50fb89-ad78-48b9-affb-f649fb3bbab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_0f617a60-6226-461d-a5ee-0be2df7b7250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c9472e2f-f639-462d-8dce-8917fe64ed8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_0f617a60-6226-461d-a5ee-0be2df7b7250" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c9472e2f-f639-462d-8dce-8917fe64ed8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_e1f4a838-0b0c-42f8-80a5-95596d788353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_0f617a60-6226-461d-a5ee-0be2df7b7250" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_e1f4a838-0b0c-42f8-80a5-95596d788353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_a6d2970e-6ca9-4b75-88f8-1d0e5abff27f" xlink:href="neo-20220930.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_0f617a60-6226-461d-a5ee-0be2df7b7250" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_a6d2970e-6ca9-4b75-88f8-1d0e5abff27f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsScheduleofAmortizedCostDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_41660af4-0e4b-4550-8b61-9dbec3955e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1715d440-de07-4d0f-b540-f991836074f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_41660af4-0e4b-4550-8b61-9dbec3955e6a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1715d440-de07-4d0f-b540-f991836074f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_badee82f-f4bf-4f71-9642-0f9c3c86fbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_41660af4-0e4b-4550-8b61-9dbec3955e6a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_badee82f-f4bf-4f71-9642-0f9c3c86fbc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_16c397b0-7912-4b4f-be5a-77a84d740bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_41660af4-0e4b-4550-8b61-9dbec3955e6a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_16c397b0-7912-4b4f-be5a-77a84d740bd1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsFairValuebyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_bf52124f-3e25-499f-a089-2e5770d980aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8f9b6096-f2d4-4c5d-9dee-15cfc7081e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_bf52124f-3e25-499f-a089-2e5770d980aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8f9b6096-f2d4-4c5d-9dee-15cfc7081e9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1e81479e-c15b-4ea4-9d61-2aa69732f395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_bf52124f-3e25-499f-a089-2e5770d980aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1e81479e-c15b-4ea4-9d61-2aa69732f395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4585c8cc-9fad-4a57-8b31-e33cb15a4b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_bf52124f-3e25-499f-a089-2e5770d980aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4585c8cc-9fad-4a57-8b31-e33cb15a4b96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fb511964-ff0b-4c2e-b0c6-3aa53c6ee47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11689d21-0e05-4db7-a550-be51ecdf899f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_fb511964-ff0b-4c2e-b0c6-3aa53c6ee47c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11689d21-0e05-4db7-a550-be51ecdf899f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_c38655f0-0d4c-41d6-9256-a87f4e896974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_fb511964-ff0b-4c2e-b0c6-3aa53c6ee47c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_c38655f0-0d4c-41d6-9256-a87f4e896974" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ee49874-282c-4f54-a683-13c7d082f763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a34bfc09-2ff3-4002-9415-3eb64e245a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ee49874-282c-4f54-a683-13c7d082f763" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a34bfc09-2ff3-4002-9415-3eb64e245a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8c458b87-b0d7-4732-9cb1-1ec94e814de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ee49874-282c-4f54-a683-13c7d082f763" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8c458b87-b0d7-4732-9cb1-1ec94e814de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4f3433b0-7a12-4f69-9374-6d75e96dd477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0479e96d-19ca-4f86-a780-c21afffc7a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4f3433b0-7a12-4f69-9374-6d75e96dd477" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0479e96d-19ca-4f86-a780-c21afffc7a7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50174040-3ae6-4f2a-b324-781806aefdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4f3433b0-7a12-4f69-9374-6d75e96dd477" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50174040-3ae6-4f2a-b324-781806aefdc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_735e5e0f-d8be-45a7-a067-e2a9ca62977d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_167deac1-fdca-4fdb-b9c4-cec11a39e78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_735e5e0f-d8be-45a7-a067-e2a9ca62977d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_167deac1-fdca-4fdb-b9c4-cec11a39e78b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_14387c69-3181-4696-b8f4-c3d1ed6dd581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_735e5e0f-d8be-45a7-a067-e2a9ca62977d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_14387c69-3181-4696-b8f4-c3d1ed6dd581" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36e4c005-b092-4c8d-a763-c0e2afab8fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_db92a29d-171c-443c-884e-e81bebc43b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36e4c005-b092-4c8d-a763-c0e2afab8fcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_db92a29d-171c-443c-884e-e81bebc43b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_13862c79-ebe9-4125-962d-319536152345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36e4c005-b092-4c8d-a763-c0e2afab8fcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_13862c79-ebe9-4125-962d-319536152345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d5b5221e-b794-46fc-985a-d743aaf38ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36e4c005-b092-4c8d-a763-c0e2afab8fcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d5b5221e-b794-46fc-985a-d743aaf38ee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49434e20-d935-4f4c-b9b0-2bf07b431861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36e4c005-b092-4c8d-a763-c0e2afab8fcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49434e20-d935-4f4c-b9b0-2bf07b431861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fffa7fb5-8fe8-47fe-a772-bc27ccc2a04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36e4c005-b092-4c8d-a763-c0e2afab8fcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fffa7fb5-8fe8-47fe-a772-bc27ccc2a04d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3d077225-b667-4f1f-9247-c0352b7e77a9" xlink:href="neo-20220930.xsd#neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36e4c005-b092-4c8d-a763-c0e2afab8fcf" xlink:to="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3d077225-b667-4f1f-9247-c0352b7e77a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#RevenueRecognitionContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_99fff1d0-f6cd-4e41-8b9d-87983fce8786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_2ee497ba-4061-4c6f-b5af-453fdeae6e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalizedContractCostGross_99fff1d0-f6cd-4e41-8b9d-87983fce8786" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_2ee497ba-4061-4c6f-b5af-453fdeae6e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_ffc1ecc5-9e01-41b9-b5aa-8baff4a93bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalizedContractCostGross_99fff1d0-f6cd-4e41-8b9d-87983fce8786" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_ffc1ecc5-9e01-41b9-b5aa-8baff4a93bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_420c086d-3860-44d6-a6ef-e62ce7cac82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_21001a1c-c1a1-4ac7-ab56-74b6c4529aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_420c086d-3860-44d6-a6ef-e62ce7cac82f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_21001a1c-c1a1-4ac7-ab56-74b6c4529aa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_5fe3ca73-dcf0-4091-8975-628028121367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_420c086d-3860-44d6-a6ef-e62ce7cac82f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_5fe3ca73-dcf0-4091-8975-628028121367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_95dc84e1-3b93-4549-a6db-177925096f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8a2509ef-5776-44d6-953a-791c6ed67c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_95dc84e1-3b93-4549-a6db-177925096f98" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8a2509ef-5776-44d6-953a-791c6ed67c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b96fddae-ae26-42be-a56f-1c2c21bcbbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_95dc84e1-3b93-4549-a6db-177925096f98" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b96fddae-ae26-42be-a56f-1c2c21bcbbdc" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>neo-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2d7a6b14-636e-498a-9bb1-3c76242be649,g:a2221670-aa14-4f97-b400-5f284572b74c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="idc8c97d27145490aa505feb8b4fb1ba1_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_271a5b1a-4298-42f0-9981-f6472a5dc4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_271a5b1a-4298-42f0-9981-f6472a5dc4da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9ea35ad1-d2ef-4525-99b4-cc78698e1030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9ea35ad1-d2ef-4525-99b4-cc78698e1030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_aae184c7-9276-40e8-afa9-6f455dcc39ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_GrossProfit_aae184c7-9276-40e8-afa9-6f455dcc39ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a0206d56-3a9c-4411-ba05-fe9615cafe32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a0206d56-3a9c-4411-ba05-fe9615cafe32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_33e02397-5a75-4ecd-ae00-55cdce522011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_33e02397-5a75-4ecd-ae00-55cdce522011" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_75a38153-ac36-45fe-b98e-64a276455e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:to="loc_us-gaap_SellingAndMarketingExpense_75a38153-ac36-45fe-b98e-64a276455e83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3247b6e9-947c-4812-8d3b-e63fcebb5b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:to="loc_us-gaap_OperatingExpenses_3247b6e9-947c-4812-8d3b-e63fcebb5b8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7f96bb13-389f-49c7-8243-537d9e18d10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_OperatingIncomeLoss_7f96bb13-389f-49c7-8243-537d9e18d10c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bb3bb6bd-78ef-42a7-ad54-c4e2ade90342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_InterestExpense_bb3bb6bd-78ef-42a7-ad54-c4e2ade90342" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_049ac324-d707-42cc-97de-d21f7af978c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_049ac324-d707-42cc-97de-d21f7af978c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable_42784afb-8a6a-48ea-b85c-a39633d292ca" xlink:href="neo-20220930.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_neo_GainLossOnInvestmentAndLoanReceivable_42784afb-8a6a-48ea-b85c-a39633d292ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2084d3f5-528e-4eca-b001-fda538d2796f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2084d3f5-528e-4eca-b001-fda538d2796f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1ea43b87-b6ef-451e-abfe-069c07c24b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1ea43b87-b6ef-451e-abfe-069c07c24b74" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de3ae97b-520c-48f0-beb0-88cdf439af77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_NetIncomeLoss_de3ae97b-520c-48f0-beb0-88cdf439af77" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_addb7a32-ceee-43da-a461-8f7fcb6a3b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_addb7a32-ceee-43da-a461-8f7fcb6a3b34" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_aa6ed8b6-0c6d-45d0-a691-8e9949f8a0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_addb7a32-ceee-43da-a461-8f7fcb6a3b34" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_aa6ed8b6-0c6d-45d0-a691-8e9949f8a0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_30f6e6dd-c7f6-4ddd-ba4f-be742d95a39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_addb7a32-ceee-43da-a461-8f7fcb6a3b34" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_30f6e6dd-c7f6-4ddd-ba4f-be742d95a39a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1b6fb153-f505-4b4d-a3eb-f12d4e17a794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1b6fb153-f505-4b4d-a3eb-f12d4e17a794" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfe31ef8-8b36-4b16-819f-f537987fcd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1b6fb153-f505-4b4d-a3eb-f12d4e17a794" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfe31ef8-8b36-4b16-819f-f537987fcd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_085626cf-240e-4f97-9437-bfa4a0b82333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1b6fb153-f505-4b4d-a3eb-f12d4e17a794" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_085626cf-240e-4f97-9437-bfa4a0b82333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1c9c03b4-761e-4b8b-93e5-aaf93c2f0411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_StatementTable_1c9c03b4-761e-4b8b-93e5-aaf93c2f0411" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e44e8ee5-519c-461c-b43c-c22b9b546cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1c9c03b4-761e-4b8b-93e5-aaf93c2f0411" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e44e8ee5-519c-461c-b43c-c22b9b546cce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e44e8ee5-519c-461c-b43c-c22b9b546cce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e44e8ee5-519c-461c-b43c-c22b9b546cce" xlink:to="loc_us-gaap_SegmentDomain_e44e8ee5-519c-461c-b43c-c22b9b546cce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae7c98a1-8af5-4633-99dd-e8450e945177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e44e8ee5-519c-461c-b43c-c22b9b546cce" xlink:to="loc_us-gaap_SegmentDomain_ae7c98a1-8af5-4633-99dd-e8450e945177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_85804291-d884-4f83-86e9-dd11b72d7186" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ae7c98a1-8af5-4633-99dd-e8450e945177" xlink:to="loc_neo_ClinicalServicesMember_85804291-d884-4f83-86e9-dd11b72d7186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_fe7a4e3c-781a-45ac-8992-4fba07eeea04" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ae7c98a1-8af5-4633-99dd-e8450e945177" xlink:to="loc_neo_PharmaServicesMember_fe7a4e3c-781a-45ac-8992-4fba07eeea04" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i73b952190aea4d14aa9099526b642e53_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b30db1a2-14eb-4905-a661-aa90483ae58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b30db1a2-14eb-4905-a661-aa90483ae58c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_57bee929-8c7d-4607-af0d-0558650c6898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_SharesOutstanding_57bee929-8c7d-4607-af0d-0558650c6898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1e264ed-4c13-4f1c-957b-cf4adb268f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockholdersEquity_b1e264ed-4c13-4f1c-957b-cf4adb268f22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_99b74f4d-0e23-4194-a095-b05d025aae86" xlink:href="neo-20220930.xsd#neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_99b74f4d-0e23-4194-a095-b05d025aae86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b91ac11a-a765-4dd8-9a3f-1c592a3be0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b91ac11a-a765-4dd8-9a3f-1c592a3be0c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9555c59b-baa2-418e-9401-90bf48d49f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9555c59b-baa2-418e-9401-90bf48d49f9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5f3c9591-96ca-49ff-8037-bb3c178b39e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5f3c9591-96ca-49ff-8037-bb3c178b39e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a4de90e9-ef27-4941-8a97-acba8caeda38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a4de90e9-ef27-4941-8a97-acba8caeda38" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12ec8768-6374-412a-9338-f1c5a2732cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12ec8768-6374-412a-9338-f1c5a2732cd0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d805af49-65d7-4e66-be79-ffd33d416d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d805af49-65d7-4e66-be79-ffd33d416d99" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_99ddf721-ee9a-4950-90ca-7d5ae5d36d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_99ddf721-ee9a-4950-90ca-7d5ae5d36d98" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c51e903b-d8ac-41b6-a8d5-de09696bf0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c51e903b-d8ac-41b6-a8d5-de09696bf0c1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_535b5585-2639-4f5c-86cc-b0e493e58a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_535b5585-2639-4f5c-86cc-b0e493e58a0f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_9067e3b9-9b5b-46d9-997c-e252537a372f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_9067e3b9-9b5b-46d9-997c-e252537a372f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_8934d9b2-17a3-467b-b49c-d261a3cd48c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_8934d9b2-17a3-467b-b49c-d261a3cd48c0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_59d57086-eefe-40f1-9883-b42348482e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_59d57086-eefe-40f1-9883-b42348482e7a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_46482d45-d69d-4bee-bb52-f7ee836ed478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_46482d45-d69d-4bee-bb52-f7ee836ed478" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a50fbbd7-76da-4d2b-abce-ec93efe80a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a50fbbd7-76da-4d2b-abce-ec93efe80a17" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8c5202d-f7dc-4885-a238-e04c1f766e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_NetIncomeLoss_c8c5202d-f7dc-4885-a238-e04c1f766e67" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_96a4aa0b-643e-4de9-a0ec-2ef51f401cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f9eb6d2b-c578-4df8-adac-36a507cf2b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c76a89bb-85b3-43c1-801c-fcfa06669d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b30db1a2-14eb-4905-a661-aa90483ae58c" xlink:to="loc_us-gaap_StatementTable_c76a89bb-85b3-43c1-801c-fcfa06669d04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ed051d2e-a750-445d-bdbe-d18bee12ba8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c76a89bb-85b3-43c1-801c-fcfa06669d04" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ed051d2e-a750-445d-bdbe-d18bee12ba8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ed051d2e-a750-445d-bdbe-d18bee12ba8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ed051d2e-a750-445d-bdbe-d18bee12ba8d" xlink:to="loc_us-gaap_EquityComponentDomain_ed051d2e-a750-445d-bdbe-d18bee12ba8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ed051d2e-a750-445d-bdbe-d18bee12ba8d" xlink:to="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c433c874-cb3c-4a2e-bfef-bcddb597801f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:to="loc_us-gaap_CommonStockMember_c433c874-cb3c-4a2e-bfef-bcddb597801f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_26393fbd-8914-43ec-98f6-18922dde45dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_26393fbd-8914-43ec-98f6-18922dde45dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bbdbfcb3-206e-422c-ba10-159ab80259ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bbdbfcb3-206e-422c-ba10-159ab80259ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9100948a-8f9c-4fd2-8731-9be310888a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:to="loc_us-gaap_RetainedEarningsMember_9100948a-8f9c-4fd2-8731-9be310888a34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_179a1cf8-2469-4034-b3f6-8e0e6fb1f5a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c76a89bb-85b3-43c1-801c-fcfa06669d04" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_179a1cf8-2469-4034-b3f6-8e0e6fb1f5a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_179a1cf8-2469-4034-b3f6-8e0e6fb1f5a0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_179a1cf8-2469-4034-b3f6-8e0e6fb1f5a0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_179a1cf8-2469-4034-b3f6-8e0e6fb1f5a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a99c8e5c-5972-4cde-b8b7-8b832d5ac2ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_179a1cf8-2469-4034-b3f6-8e0e6fb1f5a0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a99c8e5c-5972-4cde-b8b7-8b832d5ac2ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3c0bb4e4-b7b9-4f29-a86c-981f1f277e3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a99c8e5c-5972-4cde-b8b7-8b832d5ac2ac" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3c0bb4e4-b7b9-4f29-a86c-981f1f277e3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i94d1c4ea721e430db1b46df42df6b9a8_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2c63cc7e-d7c4-41a6-b36f-1f5431e08983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2c63cc7e-d7c4-41a6-b36f-1f5431e08983" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_76840247-ef9b-4de8-8fa2-808e074b1a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_76840247-ef9b-4de8-8fa2-808e074b1a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_e5ffd6ed-956c-46f1-8efa-5623b09d9bf0" xlink:href="neo-20220930.xsd#neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_e5ffd6ed-956c-46f1-8efa-5623b09d9bf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8ec130a3-b109-4a3f-8855-1d671f781fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8ec130a3-b109-4a3f-8855-1d671f781fe3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_027bfab2-70de-460c-b918-944a73f2415a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_027bfab2-70de-460c-b918-944a73f2415a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_885d42b6-d7c6-4a89-8c83-00bac053cef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_885d42b6-d7c6-4a89-8c83-00bac053cef7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_91e4d155-fecb-4e41-84f0-ed61a409b282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_91e4d155-fecb-4e41-84f0-ed61a409b282" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_57ca7941-5bcf-4c3c-9ebd-514b6652bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_57ca7941-5bcf-4c3c-9ebd-514b6652bc4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8657ccd7-b2d7-4185-81c8-673ba144ffbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8657ccd7-b2d7-4185-81c8-673ba144ffbf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_432589d7-acaf-4558-a693-20d6c9ba8d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_432589d7-acaf-4558-a693-20d6c9ba8d87" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_d92b87f7-fc65-4536-8b9a-56659a4911f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_d92b87f7-fc65-4536-8b9a-56659a4911f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_561242b9-ce41-4c63-b580-58488317e5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_561242b9-ce41-4c63-b580-58488317e5b1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_d156a65c-11e9-4e52-8e4c-7807c8087eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_d156a65c-11e9-4e52-8e4c-7807c8087eb2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_f5e51ced-fe75-493e-b70d-52c506f78fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_f5e51ced-fe75-493e-b70d-52c506f78fcf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_035ab4ab-45e6-4d47-b510-0782b5f3b455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_035ab4ab-45e6-4d47-b510-0782b5f3b455" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_6391e6df-de0d-4306-b1ed-a839eea7500e" xlink:href="neo-20220930.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_6391e6df-de0d-4306-b1ed-a839eea7500e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1c0374eb-2bfd-4f6a-81d1-caa529d18fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_LineOfCredit_1c0374eb-2bfd-4f6a-81d1-caa529d18fd2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_bb70b985-9f44-48f8-852f-095db9bfda94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_bb70b985-9f44-48f8-852f-095db9bfda94" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_304e35af-e914-4d74-8f75-5f06f7b30ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_304e35af-e914-4d74-8f75-5f06f7b30ceb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d154b16d-0194-4ced-8da9-bd433084b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d154b16d-0194-4ced-8da9-bd433084b2bb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_8f86b946-f7a6-4d2b-b0ae-b50cd6f2b90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_8f86b946-f7a6-4d2b-b0ae-b50cd6f2b90f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate_01b26fa1-cc06-4229-a518-01153a8d8eb8" xlink:href="neo-20220930.xsd#neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate_01b26fa1-cc06-4229-a518-01153a8d8eb8" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a59f6e30-8763-4f0f-a9fd-dbc008d85658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a59f6e30-8763-4f0f-a9fd-dbc008d85658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a59f6e30-8763-4f0f-a9fd-dbc008d85658_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a59f6e30-8763-4f0f-a9fd-dbc008d85658" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a59f6e30-8763-4f0f-a9fd-dbc008d85658_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e60e3864-0c10-45df-bc9b-4cbacbcd1d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a59f6e30-8763-4f0f-a9fd-dbc008d85658" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e60e3864-0c10-45df-bc9b-4cbacbcd1d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_9e4ac7ab-31ef-45a5-8ca7-f08ffb628b7b" xlink:href="neo-20220930.xsd#neo_TrapeloHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e60e3864-0c10-45df-bc9b-4cbacbcd1d77" xlink:to="loc_neo_TrapeloHealthMember_9e4ac7ab-31ef-45a5-8ca7-f08ffb628b7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_70fc79f4-0e7c-41c4-a061-5a5607abdb42" xlink:href="neo-20220930.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e60e3864-0c10-45df-bc9b-4cbacbcd1d77" xlink:to="loc_neo_InivataMember_70fc79f4-0e7c-41c4-a061-5a5607abdb42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_38f6ad2e-5088-4a5d-bfb9-8652e0cfa235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_38f6ad2e-5088-4a5d-bfb9-8652e0cfa235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_38f6ad2e-5088-4a5d-bfb9-8652e0cfa235_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_38f6ad2e-5088-4a5d-bfb9-8652e0cfa235" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_38f6ad2e-5088-4a5d-bfb9-8652e0cfa235_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_38f6ad2e-5088-4a5d-bfb9-8652e0cfa235" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_03972c14-4a9d-4d32-8374-39c30ace3d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_03972c14-4a9d-4d32-8374-39c30ace3d9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_d49285c0-5506-40e6-9785-1b7315196108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_d49285c0-5506-40e6-9785-1b7315196108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_0ab9f55c-6862-4bc8-b940-d5482839d22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:to="loc_us-gaap_TrademarksMember_0ab9f55c-6862-4bc8-b940-d5482839d22d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_456a07f8-ba30-4081-a031-0d86f35d6333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:to="loc_us-gaap_TradeNamesMember_456a07f8-ba30-4081-a031-0d86f35d6333" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_eb385ee2-bcab-47b7-af90-3192509d6ff9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_eb385ee2-bcab-47b7-af90-3192509d6ff9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_eb385ee2-bcab-47b7-af90-3192509d6ff9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_eb385ee2-bcab-47b7-af90-3192509d6ff9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_eb385ee2-bcab-47b7-af90-3192509d6ff9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ac33174a-ad45-4202-bab2-d1123c08b71a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_eb385ee2-bcab-47b7-af90-3192509d6ff9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ac33174a-ad45-4202-bab2-d1123c08b71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b53c8f4f-cc6c-4f18-963d-25649c642fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ac33174a-ad45-4202-bab2-d1123c08b71a" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b53c8f4f-cc6c-4f18-963d-25649c642fc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e444a24d-362f-44ef-8c02-3c0b9a319b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e444a24d-362f-44ef-8c02-3c0b9a319b79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e444a24d-362f-44ef-8c02-3c0b9a319b79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e444a24d-362f-44ef-8c02-3c0b9a319b79" xlink:to="loc_us-gaap_RelatedPartyDomain_e444a24d-362f-44ef-8c02-3c0b9a319b79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_373ef24b-29db-4e35-8e92-413690db7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e444a24d-362f-44ef-8c02-3c0b9a319b79" xlink:to="loc_us-gaap_RelatedPartyDomain_373ef24b-29db-4e35-8e92-413690db7ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_61747ab3-5c17-45db-a04d-090542d4a157" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_373ef24b-29db-4e35-8e92-413690db7ee0" xlink:to="loc_srt_AffiliatedEntityMember_61747ab3-5c17-45db-a04d-090542d4a157" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fa24f6c7-4cc2-4d7e-bcea-078e5ca58745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fa24f6c7-4cc2-4d7e-bcea-078e5ca58745" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fa24f6c7-4cc2-4d7e-bcea-078e5ca58745_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fa24f6c7-4cc2-4d7e-bcea-078e5ca58745" xlink:to="loc_us-gaap_SegmentDomain_fa24f6c7-4cc2-4d7e-bcea-078e5ca58745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_babd7ce5-2526-4713-aa4d-1d8c934b9216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fa24f6c7-4cc2-4d7e-bcea-078e5ca58745" xlink:to="loc_us-gaap_SegmentDomain_babd7ce5-2526-4713-aa4d-1d8c934b9216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_de775144-9b81-4fd2-9e04-147844052d34" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_babd7ce5-2526-4713-aa4d-1d8c934b9216" xlink:to="loc_neo_ClinicalServicesMember_de775144-9b81-4fd2-9e04-147844052d34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_9a11b076-3745-45d7-a9ea-c38b5d47e8ce" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_babd7ce5-2526-4713-aa4d-1d8c934b9216" xlink:to="loc_neo_PharmaServicesMember_9a11b076-3745-45d7-a9ea-c38b5d47e8ce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#AcquisitionsScheduleofProvisionalInformationDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="extended" id="ie4b0c80246b44345afbd151c90f7bd4a_AcquisitionsScheduleofProvisionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_837bae1b-0c36-4d9c-9c2e-aa89086fc0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_837bae1b-0c36-4d9c-9c2e-aa89086fc0e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1d8f1296-3b6c-47fb-9aa5-d4fb420111df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1d8f1296-3b6c-47fb-9aa5-d4fb420111df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e93cf150-9663-47eb-bc32-580d1c333f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e93cf150-9663-47eb-bc32-580d1c333f25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_562e0005-a169-4f11-a457-24e860cb7ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_562e0005-a169-4f11-a457-24e860cb7ace" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_d4a08b6c-cfa2-4b4c-bb5c-bb3de90b6a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_d4a08b6c-cfa2-4b4c-bb5c-bb3de90b6a72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7f71a480-2ad5-4f46-bdb1-451472821bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7f71a480-2ad5-4f46-bdb1-451472821bbe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_a96e7dd5-0c63-4572-8025-7c76289f77b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_a96e7dd5-0c63-4572-8025-7c76289f77b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a8d9f795-ef13-48d1-bf4c-e7f95a63e05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a8d9f795-ef13-48d1-bf4c-e7f95a63e05f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_69c09670-fe86-4916-9d4c-d4b996bd0049" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_69c09670-fe86-4916-9d4c-d4b996bd0049" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_667df282-d347-4ed1-a25f-a0d167c9e3a4" xlink:href="neo-20220930.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_667df282-d347-4ed1-a25f-a0d167c9e3a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_843c5b97-45b8-43e5-a8c8-14094edff8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_843c5b97-45b8-43e5-a8c8-14094edff8d7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_1a5d785e-a9aa-465b-96e3-5c05a2d8cd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_1a5d785e-a9aa-465b-96e3-5c05a2d8cd8f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1fc56941-25ab-4221-92db-b9f430e4873b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1fc56941-25ab-4221-92db-b9f430e4873b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_89bd6563-4332-4a5a-af5a-1d2f908d8c9e" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_89bd6563-4332-4a5a-af5a-1d2f908d8c9e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_14803819-e556-40b6-a750-4a882a25475d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_14803819-e556-40b6-a750-4a882a25475d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3c05cf92-aa8f-452f-92f4-0e581f3f50d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3c05cf92-aa8f-452f-92f4-0e581f3f50d3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_2e4a6633-5d2e-49e9-95a4-9e80c30263d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_2e4a6633-5d2e-49e9-95a4-9e80c30263d9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8dea726a-568f-4afc-9fd7-c971da567cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8dea726a-568f-4afc-9fd7-c971da567cff" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_ceb7afd6-ec04-43fa-ab5c-987532a7e28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_ceb7afd6-ec04-43fa-ab5c-987532a7e28b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_c5f26a6c-f252-4c59-ae8f-acab5c7812ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_c5f26a6c-f252-4c59-ae8f-acab5c7812ee" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_12721ebe-90e3-4d25-8ff9-5642913ad273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_12721ebe-90e3-4d25-8ff9-5642913ad273" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent_3a7cfdd6-1669-41e6-b42e-387d63f1f7b3" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent_3a7cfdd6-1669-41e6-b42e-387d63f1f7b3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_be77cb37-d4e7-4252-86b4-8987af27c639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_be77cb37-d4e7-4252-86b4-8987af27c639" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities_82d80409-7604-45bf-b5b9-598ead524391" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities_82d80409-7604-45bf-b5b9-598ead524391" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ba4cd153-c6b8-4347-a5a7-3bbe6f6e5700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ba4cd153-c6b8-4347-a5a7-3bbe6f6e5700" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_bd3dccfe-8097-4c58-afc5-eb749959bdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_bd3dccfe-8097-4c58-afc5-eb749959bdaa" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_b79d879d-9bf1-44b0-8ddb-72eb31a3420c" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_b79d879d-9bf1-44b0-8ddb-72eb31a3420c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b4c19920-56cb-472b-a165-0fe519ad6916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b4c19920-56cb-472b-a165-0fe519ad6916" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_04cd85da-f7a2-4da5-93bb-e538617b98f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_04cd85da-f7a2-4da5-93bb-e538617b98f8" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f1b33825-8938-4b2b-8197-cf430a17468e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_Goodwill_f1b33825-8938-4b2b-8197-cf430a17468e" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0f375296-9f41-4a8d-87d2-f40c2313ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0f375296-9f41-4a8d-87d2-f40c2313ddae" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7adf0cd5-f0dd-4971-8907-a2b106d7b82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7adf0cd5-f0dd-4971-8907-a2b106d7b82c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7adf0cd5-f0dd-4971-8907-a2b106d7b82c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7adf0cd5-f0dd-4971-8907-a2b106d7b82c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7adf0cd5-f0dd-4971-8907-a2b106d7b82c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b82345-55c8-46aa-a746-e38e99eeb7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7adf0cd5-f0dd-4971-8907-a2b106d7b82c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b82345-55c8-46aa-a746-e38e99eeb7fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_ff2fe900-9a2c-455a-ab57-1842012f9942" xlink:href="neo-20220930.xsd#neo_TrapeloHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b82345-55c8-46aa-a746-e38e99eeb7fb" xlink:to="loc_neo_TrapeloHealthMember_ff2fe900-9a2c-455a-ab57-1842012f9942" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_493bff56-5425-48f3-b5d3-18b461cc5517" xlink:href="neo-20220930.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b82345-55c8-46aa-a746-e38e99eeb7fb" xlink:to="loc_neo_InivataMember_493bff56-5425-48f3-b5d3-18b461cc5517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80181af4-cca9-431a-b14e-0d781b033bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80181af4-cca9-431a-b14e-0d781b033bbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80181af4-cca9-431a-b14e-0d781b033bbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80181af4-cca9-431a-b14e-0d781b033bbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80181af4-cca9-431a-b14e-0d781b033bbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80181af4-cca9-431a-b14e-0d781b033bbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_0c03cf4e-868c-49f0-be9b-0fd1ce57d268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_0c03cf4e-868c-49f0-be9b-0fd1ce57d268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e3e03d98-3944-45df-a38c-c8372de9b152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e3e03d98-3944-45df-a38c-c8372de9b152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_9aa1845d-d2e2-474d-aaa6-30a1948428e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:to="loc_us-gaap_TrademarksMember_9aa1845d-d2e2-474d-aaa6-30a1948428e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9caabda0-22a2-4dff-b40e-cd63456539fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:to="loc_us-gaap_TradeNamesMember_9caabda0-22a2-4dff-b40e-cd63456539fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_17397809-b25a-4b70-ae40-8fa6316416df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:to="loc_srt_RestatementAxis_17397809-b25a-4b70-ae40-8fa6316416df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_17397809-b25a-4b70-ae40-8fa6316416df_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_17397809-b25a-4b70-ae40-8fa6316416df" xlink:to="loc_srt_RestatementDomain_17397809-b25a-4b70-ae40-8fa6316416df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_3197ef12-b24b-405b-93bf-35d709b53d87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_17397809-b25a-4b70-ae40-8fa6316416df" xlink:to="loc_srt_RestatementDomain_3197ef12-b24b-405b-93bf-35d709b53d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_348cdc36-81fc-452c-bd61-30bb5bd5f051" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3197ef12-b24b-405b-93bf-35d709b53d87" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_348cdc36-81fc-452c-bd61-30bb5bd5f051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_d7d69ec2-6b3b-4a43-861c-8467a75d0a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_d7d69ec2-6b3b-4a43-861c-8467a75d0a06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_d7d69ec2-6b3b-4a43-861c-8467a75d0a06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_d7d69ec2-6b3b-4a43-861c-8467a75d0a06" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_d7d69ec2-6b3b-4a43-861c-8467a75d0a06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_a8970b6a-40f1-453f-8568-0c611a5b9e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_d7d69ec2-6b3b-4a43-861c-8467a75d0a06" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_a8970b6a-40f1-453f-8568-0c611a5b9e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionOtherMember_c9eac279-27b2-4154-ad4f-1a70246df170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_a8970b6a-40f1-453f-8568-0c611a5b9e18" xlink:to="loc_us-gaap_ErrorCorrectionOtherMember_c9eac279-27b2-4154-ad4f-1a70246df170" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#AcquisitionsProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="extended" id="ia9b388d216294717bf3d19bb82421bd1_AcquisitionsProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_261422c8-7fc6-4a0a-bc2a-1685c99f847f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4d410af2-f312-4783-b377-e6876edfee46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_261422c8-7fc6-4a0a-bc2a-1685c99f847f" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4d410af2-f312-4783-b377-e6876edfee46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_50c15e35-f4d9-48d4-971c-b81ea91163da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_261422c8-7fc6-4a0a-bc2a-1685c99f847f" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_50c15e35-f4d9-48d4-971c-b81ea91163da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b802d92-4b94-49ad-9427-d30ce238534b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_261422c8-7fc6-4a0a-bc2a-1685c99f847f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b802d92-4b94-49ad-9427-d30ce238534b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_697c9dbb-fb35-42de-841f-4d5e897c785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b802d92-4b94-49ad-9427-d30ce238534b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_697c9dbb-fb35-42de-841f-4d5e897c785f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697c9dbb-fb35-42de-841f-4d5e897c785f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_697c9dbb-fb35-42de-841f-4d5e897c785f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697c9dbb-fb35-42de-841f-4d5e897c785f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7b2f122-e8c4-4a42-a4ab-79ff89c8be71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_697c9dbb-fb35-42de-841f-4d5e897c785f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7b2f122-e8c4-4a42-a4ab-79ff89c8be71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_9c4a5d43-08d5-4135-b9e5-91489394d428" xlink:href="neo-20220930.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7b2f122-e8c4-4a42-a4ab-79ff89c8be71" xlink:to="loc_neo_InivataMember_9c4a5d43-08d5-4135-b9e5-91489394d428" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsScheduleofAmortizedCostDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="extended" id="i5d897510d171417a8daca011a976c897_FairValueMeasurementsScheduleofAmortizedCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_21bb05f8-69eb-4e88-a492-33c299e09d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_21bb05f8-69eb-4e88-a492-33c299e09d8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bf7d0de2-7593-4d83-bc1b-d5bc36bb59db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bf7d0de2-7593-4d83-bc1b-d5bc36bb59db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b2e3e847-c79d-4e5b-b973-00868343d76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b2e3e847-c79d-4e5b-b973-00868343d76e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_aae9eef8-ea05-4e02-acf6-6fcc52734a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_aae9eef8-ea05-4e02-acf6-6fcc52734a64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_0fe666e1-cbcc-4a8b-892a-945ca699af53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_0fe666e1-cbcc-4a8b-892a-945ca699af53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26e0b401-5da1-4387-a425-c4f953016ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26e0b401-5da1-4387-a425-c4f953016ec0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d1ba08b1-a342-4363-8132-dd41d8769320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26e0b401-5da1-4387-a425-c4f953016ec0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d1ba08b1-a342-4363-8132-dd41d8769320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1ba08b1-a342-4363-8132-dd41d8769320_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d1ba08b1-a342-4363-8132-dd41d8769320" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1ba08b1-a342-4363-8132-dd41d8769320_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d1ba08b1-a342-4363-8132-dd41d8769320" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_36b81d27-c58a-4083-bc15-438cc9122655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_36b81d27-c58a-4083-bc15-438cc9122655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_0baf7400-7e98-4662-9c24-500feb96ed1b" xlink:href="neo-20220930.xsd#neo_YankeeBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_neo_YankeeBondsMember_0baf7400-7e98-4662-9c24-500feb96ed1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_c759319c-db34-4c09-b6eb-3a5177186659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_AgencySecuritiesMember_c759319c-db34-4c09-b6eb-3a5177186659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_1d8283a9-469f-4ea8-9055-369bc3e078d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_MunicipalBondsMember_1d8283a9-469f-4ea8-9055-369bc3e078d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d488638a-e6ec-4e2e-a37b-649d380d7a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_CommercialPaperMember_d488638a-e6ec-4e2e-a37b-649d380d7a3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e3436e60-1799-40a7-88f6-972d67c06bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e3436e60-1799-40a7-88f6-972d67c06bab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_b6c54715-1731-48ea-8bce-40a541c0d057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_b6c54715-1731-48ea-8bce-40a541c0d057" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsFairValuebyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="extended" id="i7e597e26ba4e4737b004f7954a414ac1_FairValueMeasurementsFairValuebyContractualMaturityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a8a01b70-b1fd-4682-978c-8707105cddcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a8a01b70-b1fd-4682-978c-8707105cddcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_21df1c79-774d-43a6-bb3c-1ce04d700d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_21df1c79-774d-43a6-bb3c-1ce04d700d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_04281038-6615-4b03-a58c-26887d091fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_04281038-6615-4b03-a58c-26887d091fb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e18ad181-e5b0-494b-b181-9a81c050f2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e18ad181-e5b0-494b-b181-9a81c050f2f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b18a00e-d7d3-4437-aa64-65739bfc2e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b18a00e-d7d3-4437-aa64-65739bfc2e7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0bc668da-bd44-40c5-8ddc-41c5146e39db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b18a00e-d7d3-4437-aa64-65739bfc2e7a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0bc668da-bd44-40c5-8ddc-41c5146e39db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bc668da-bd44-40c5-8ddc-41c5146e39db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0bc668da-bd44-40c5-8ddc-41c5146e39db" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bc668da-bd44-40c5-8ddc-41c5146e39db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0bc668da-bd44-40c5-8ddc-41c5146e39db" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_9926d970-843b-4112-a2e0-506a7667e34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_9926d970-843b-4112-a2e0-506a7667e34a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_d21cef6b-1f12-4856-8f4e-a8a3dde9b59e" xlink:href="neo-20220930.xsd#neo_YankeeBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_neo_YankeeBondsMember_d21cef6b-1f12-4856-8f4e-a8a3dde9b59e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_60205c01-75e5-451b-93ed-f5d8575e39a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_AgencySecuritiesMember_60205c01-75e5-451b-93ed-f5d8575e39a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_f1aac5c1-b29b-4d4f-a7ec-28087bb4e1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_MunicipalBondsMember_f1aac5c1-b29b-4d4f-a7ec-28087bb4e1c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_98331023-c685-4e99-a34a-e1f7e390105c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_CommercialPaperMember_98331023-c685-4e99-a34a-e1f7e390105c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9d6f978e-65c3-4746-a3a2-d1825aab52aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9d6f978e-65c3-4746-a3a2-d1825aab52aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_521f82a0-69d2-4202-a0a8-8fccc1a8ae81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_521f82a0-69d2-4202-a0a8-8fccc1a8ae81" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="extended" id="idcbaf9c4bf554f1096848d0046080804_FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0eea4bca-24ab-4dc8-ad26-dccb03a7a7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0eea4bca-24ab-4dc8-ad26-dccb03a7a7a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e5506de1-4e2d-4556-9201-74c9b4849fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e5506de1-4e2d-4556-9201-74c9b4849fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a3bfadd3-348e-4f5d-80fa-15e853725823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a3bfadd3-348e-4f5d-80fa-15e853725823" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_be1ba742-dc94-4cf7-bd40-1fb0016ee60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_be1ba742-dc94-4cf7-bd40-1fb0016ee60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_be1ba742-dc94-4cf7-bd40-1fb0016ee60d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_be1ba742-dc94-4cf7-bd40-1fb0016ee60d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_be1ba742-dc94-4cf7-bd40-1fb0016ee60d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7577f4a4-2dfe-4316-844e-007b5cf748b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_be1ba742-dc94-4cf7-bd40-1fb0016ee60d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7577f4a4-2dfe-4316-844e-007b5cf748b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9181e46b-756a-4460-8e72-aa6d6c02a7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7577f4a4-2dfe-4316-844e-007b5cf748b8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9181e46b-756a-4460-8e72-aa6d6c02a7db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1cf68d83-631d-4a79-851a-6cfc8d903c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1cf68d83-631d-4a79-851a-6cfc8d903c90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1cf68d83-631d-4a79-851a-6cfc8d903c90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1cf68d83-631d-4a79-851a-6cfc8d903c90" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1cf68d83-631d-4a79-851a-6cfc8d903c90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1cf68d83-631d-4a79-851a-6cfc8d903c90" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9b654243-9b44-437b-b0fb-e28ae7491d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9b654243-9b44-437b-b0fb-e28ae7491d8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2d83c1af-36e2-4329-9b03-83c9531165d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2d83c1af-36e2-4329-9b03-83c9531165d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_15383b60-477c-468c-947a-89affa7751b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_15383b60-477c-468c-947a-89affa7751b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_36ef4f54-2a70-4347-be12-84e3c26cb6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_36ef4f54-2a70-4347-be12-84e3c26cb6b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36ef4f54-2a70-4347-be12-84e3c26cb6b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_36ef4f54-2a70-4347-be12-84e3c26cb6b0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36ef4f54-2a70-4347-be12-84e3c26cb6b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_36ef4f54-2a70-4347-be12-84e3c26cb6b0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f5b7265c-bf3b-4132-aa8d-b9a8db0dfed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f5b7265c-bf3b-4132-aa8d-b9a8db0dfed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_9b80cb50-72b4-4642-bc0a-5a7b67dfc58d" xlink:href="neo-20220930.xsd#neo_YankeeBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_neo_YankeeBondsMember_9b80cb50-72b4-4642-bc0a-5a7b67dfc58d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_ff12604a-8209-41d0-806f-f1db27d41f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_AgencySecuritiesMember_ff12604a-8209-41d0-806f-f1db27d41f50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_104c92d1-eab2-4ce8-9d7a-b692e6903ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_MunicipalBondsMember_104c92d1-eab2-4ce8-9d7a-b692e6903ec0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1c785258-57ff-480b-aa54-6c81bbe08c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_CommercialPaperMember_1c785258-57ff-480b-aa54-6c81bbe08c3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_76a52333-52e7-476a-a56f-0362e95d8ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_76a52333-52e7-476a-a56f-0362e95d8ee4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_931938d3-c207-4624-a6d2-bf440cc3478c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_931938d3-c207-4624-a6d2-bf440cc3478c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e45148fd-1840-4377-bd2a-cfefb072b80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e45148fd-1840-4377-bd2a-cfefb072b80e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e45148fd-1840-4377-bd2a-cfefb072b80e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e45148fd-1840-4377-bd2a-cfefb072b80e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e45148fd-1840-4377-bd2a-cfefb072b80e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77504af0-b540-4940-b1ae-dc4b38071b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e45148fd-1840-4377-bd2a-cfefb072b80e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77504af0-b540-4940-b1ae-dc4b38071b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_464f3cac-1b5c-4be6-b40a-46b4b5bdce64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77504af0-b540-4940-b1ae-dc4b38071b11" xlink:to="loc_us-gaap_MoneyMarketFundsMember_464f3cac-1b5c-4be6-b40a-46b4b5bdce64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4815f7f7-2e22-4014-9f4f-a95db9df253f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77504af0-b540-4940-b1ae-dc4b38071b11" xlink:to="loc_us-gaap_CommercialPaperMember_4815f7f7-2e22-4014-9f4f-a95db9df253f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="extended" id="i1e7870c9820841d5b367022687c6f571_GoodwillandIntangibleAssetsScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2dc23482-6f2b-4ab6-8d37-207edb689196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_474a66b3-422b-4ede-be13-e034facc9f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2dc23482-6f2b-4ab6-8d37-207edb689196" xlink:to="loc_us-gaap_GoodwillRollForward_474a66b3-422b-4ede-be13-e034facc9f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5c89c676-0e9b-40ce-9d14-c328a4d7023e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_474a66b3-422b-4ede-be13-e034facc9f4f" xlink:to="loc_us-gaap_Goodwill_5c89c676-0e9b-40ce-9d14-c328a4d7023e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_23643f6d-ec94-4eef-a5eb-06b057862fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_474a66b3-422b-4ede-be13-e034facc9f4f" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_23643f6d-ec94-4eef-a5eb-06b057862fe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0df4f277-75a0-45d6-966b-d256b02a516e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_d85381c8-0eb1-43d8-a197-040b678ccd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2dc23482-6f2b-4ab6-8d37-207edb689196" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_d85381c8-0eb1-43d8-a197-040b678ccd3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_2dc23482-6f2b-4ab6-8d37-207edb689196" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c7710433-67e2-443c-93b9-16bede76a8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c7710433-67e2-443c-93b9-16bede76a8d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7710433-67e2-443c-93b9-16bede76a8d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c7710433-67e2-443c-93b9-16bede76a8d9" xlink:to="loc_us-gaap_SegmentDomain_c7710433-67e2-443c-93b9-16bede76a8d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_44a1b9cd-fc4e-4660-aa5b-e7c841dc2f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c7710433-67e2-443c-93b9-16bede76a8d9" xlink:to="loc_us-gaap_SegmentDomain_44a1b9cd-fc4e-4660-aa5b-e7c841dc2f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_4c3b5bd7-4989-4613-a278-6fb0bb9883d0" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_44a1b9cd-fc4e-4660-aa5b-e7c841dc2f9d" xlink:to="loc_neo_ClinicalServicesMember_4c3b5bd7-4989-4613-a278-6fb0bb9883d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_5f5206fb-3147-482a-9ae4-90073d1d2fa8" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_44a1b9cd-fc4e-4660-aa5b-e7c841dc2f9d" xlink:to="loc_neo_PharmaServicesMember_5f5206fb-3147-482a-9ae4-90073d1d2fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a42bd6f4-a066-4eef-8618-77e87a7deb66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a42bd6f4-a066-4eef-8618-77e87a7deb66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a42bd6f4-a066-4eef-8618-77e87a7deb66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a42bd6f4-a066-4eef-8618-77e87a7deb66" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a42bd6f4-a066-4eef-8618-77e87a7deb66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53230274-dfb2-4a15-91e6-65ce0a925bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a42bd6f4-a066-4eef-8618-77e87a7deb66" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53230274-dfb2-4a15-91e6-65ce0a925bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_e4fd618c-3d6c-41ec-b783-14b3762343f8" xlink:href="neo-20220930.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53230274-dfb2-4a15-91e6-65ce0a925bf2" xlink:to="loc_neo_InivataMember_e4fd618c-3d6c-41ec-b783-14b3762343f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_e05108b4-3fc3-4b37-8e8e-b9b635d307bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_e05108b4-3fc3-4b37-8e8e-b9b635d307bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e05108b4-3fc3-4b37-8e8e-b9b635d307bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_e05108b4-3fc3-4b37-8e8e-b9b635d307bb" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e05108b4-3fc3-4b37-8e8e-b9b635d307bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_82ebd39f-a920-4404-8fbd-c6c4a2851c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_e05108b4-3fc3-4b37-8e8e-b9b635d307bb" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_82ebd39f-a920-4404-8fbd-c6c4a2851c15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionOtherMember_62d35d87-5b37-45df-90ac-4798f04aaf47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_82ebd39f-a920-4404-8fbd-c6c4a2851c15" xlink:to="loc_us-gaap_ErrorCorrectionOtherMember_62d35d87-5b37-45df-90ac-4798f04aaf47" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="extended" id="i983512cdf3a047d29da8fe5df33d461e_GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_12164fe9-de38-436c-a80a-015ac65ff318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_12164fe9-de38-436c-a80a-015ac65ff318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_19f47b73-ae8b-48b4-b5fb-64cd027fa434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_19f47b73-ae8b-48b4-b5fb-64cd027fa434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_46771c60-19e6-404d-86cb-2a92a1d7740c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_46771c60-19e6-404d-86cb-2a92a1d7740c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_20631fa7-1a25-4a9b-98d7-58dfdd2b9c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_20631fa7-1a25-4a9b-98d7-58dfdd2b9c13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_56a5d446-1d47-4d8d-bd6d-4eebfbccef0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_56a5d446-1d47-4d8d-bd6d-4eebfbccef0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_15acee90-9851-4366-8186-9acf015e4aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_15acee90-9851-4366-8186-9acf015e4aad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_aaa69cb5-50be-4104-8ff0-4ad6448b7d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_aaa69cb5-50be-4104-8ff0-4ad6448b7d19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2578e62c-b40c-415e-98f6-4eed195f7bf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:to="loc_srt_RangeAxis_2578e62c-b40c-415e-98f6-4eed195f7bf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2578e62c-b40c-415e-98f6-4eed195f7bf0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2578e62c-b40c-415e-98f6-4eed195f7bf0" xlink:to="loc_srt_RangeMember_2578e62c-b40c-415e-98f6-4eed195f7bf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bfe971e8-82da-487f-b2eb-bf285262140e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2578e62c-b40c-415e-98f6-4eed195f7bf0" xlink:to="loc_srt_RangeMember_bfe971e8-82da-487f-b2eb-bf285262140e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e146fc4-a412-4c90-a7cc-ed3f346083fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bfe971e8-82da-487f-b2eb-bf285262140e" xlink:to="loc_srt_MinimumMember_1e146fc4-a412-4c90-a7cc-ed3f346083fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b6efd4f9-831e-4669-bf0a-765428ee3b07" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bfe971e8-82da-487f-b2eb-bf285262140e" xlink:to="loc_srt_MaximumMember_b6efd4f9-831e-4669-bf0a-765428ee3b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3b15e8e0-798c-48a4-9862-924aad22a0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3b15e8e0-798c-48a4-9862-924aad22a0d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3b15e8e0-798c-48a4-9862-924aad22a0d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3b15e8e0-798c-48a4-9862-924aad22a0d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3b15e8e0-798c-48a4-9862-924aad22a0d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3b15e8e0-798c-48a4-9862-924aad22a0d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6047db93-1a8e-46ef-92c9-0ea318818729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6047db93-1a8e-46ef-92c9-0ea318818729" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6cf433a2-64ff-4dd2-84c3-b430632f72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6cf433a2-64ff-4dd2-84c3-b430632f72f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_c539b303-227c-46af-9183-53ec8374c8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_c539b303-227c-46af-9183-53ec8374c8f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_6ba4ae09-70f3-4394-8ef5-e5a788f33d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_TrademarksMember_6ba4ae09-70f3-4394-8ef5-e5a788f33d40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_125297df-b3b7-4c3a-aa5f-8731da3ab706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_TradeNamesMember_125297df-b3b7-4c3a-aa5f-8731da3ab706" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4addd612-52a4-41a2-90af-a9dc74b03119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4addd612-52a4-41a2-90af-a9dc74b03119" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4addd612-52a4-41a2-90af-a9dc74b03119_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4addd612-52a4-41a2-90af-a9dc74b03119" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4addd612-52a4-41a2-90af-a9dc74b03119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1886f355-8e69-4526-9852-938b135c8ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4addd612-52a4-41a2-90af-a9dc74b03119" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1886f355-8e69-4526-9852-938b135c8ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_e9280d12-9521-4b69-8b81-3a39094aab41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1886f355-8e69-4526-9852-938b135c8ce1" xlink:to="loc_us-gaap_TrademarksMember_e9280d12-9521-4b69-8b81-3a39094aab41" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended" id="i3dbd37f3a5654c3585978688278c53c8_GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b75f32a-ddda-462b-a197-0a9abbf7dc25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_52530f62-8d54-4ea7-8dc1-40d4b5a0ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b75f32a-ddda-462b-a197-0a9abbf7dc25" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_52530f62-8d54-4ea7-8dc1-40d4b5a0ff1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_74c36f8f-2e72-4726-930a-2024ec646fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b75f32a-ddda-462b-a197-0a9abbf7dc25" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_74c36f8f-2e72-4726-930a-2024ec646fad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_542652e0-1ef6-4302-bf25-ebd4ae992bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_74c36f8f-2e72-4726-930a-2024ec646fad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_542652e0-1ef6-4302-bf25-ebd4ae992bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_542652e0-1ef6-4302-bf25-ebd4ae992bda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_542652e0-1ef6-4302-bf25-ebd4ae992bda" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_542652e0-1ef6-4302-bf25-ebd4ae992bda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_add506a3-f396-4a89-8793-b2512d7c28af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_542652e0-1ef6-4302-bf25-ebd4ae992bda" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_add506a3-f396-4a89-8793-b2512d7c28af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b1d27142-66d9-4316-aa5a-c782d3100474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_add506a3-f396-4a89-8793-b2512d7c28af" xlink:to="loc_us-gaap_CostOfSalesMember_b1d27142-66d9-4316-aa5a-c782d3100474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8ade55b6-7686-4fbb-a12c-4193bdcdaa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_add506a3-f396-4a89-8793-b2512d7c28af" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8ade55b6-7686-4fbb-a12c-4193bdcdaa8d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/DebtDetails" xlink:type="extended" id="i938550ed52d34f51bb33ffff35543d46_DebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d3d999c6-317a-441b-a590-2a11954abbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d3d999c6-317a-441b-a590-2a11954abbd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c1956f81-154d-4e85-b146-002cca3a431e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c1956f81-154d-4e85-b146-002cca3a431e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f7931dad-28bc-48ec-b778-898f739b5481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f7931dad-28bc-48ec-b778-898f739b5481" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0aea8b49-ef8e-4615-a54f-a76fad6bcee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0aea8b49-ef8e-4615-a54f-a76fad6bcee9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_d6b119bd-0cc7-4b2c-9a27-fc23b9723d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_d6b119bd-0cc7-4b2c-9a27-fc23b9723d01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_dd1cb973-827a-41cb-b517-d8b27b879c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_dd1cb973-827a-41cb-b517-d8b27b879c7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtContractualCouponInterest_047b860d-7f7f-47e7-9fa7-5f9b2940c993" xlink:href="neo-20220930.xsd#neo_InterestExpenseDebtContractualCouponInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_neo_InterestExpenseDebtContractualCouponInterest_047b860d-7f7f-47e7-9fa7-5f9b2940c993" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_70c83543-db9a-403b-8ba5-c91584169c28" xlink:href="neo-20220930.xsd#neo_InterestExpenseDebtAccretionOfDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_70c83543-db9a-403b-8ba5-c91584169c28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_52167381-850f-4c05-8c4f-54e9113bec10" xlink:href="neo-20220930.xsd#neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_52167381-850f-4c05-8c4f-54e9113bec10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_9521a6bc-23b8-4c9d-af02-3c5a7ce3a335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_9521a6bc-23b8-4c9d-af02-3c5a7ce3a335" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_eb595733-e3a2-4a8c-a6cf-ab4f705bcae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentFairValue_eb595733-e3a2-4a8c-a6cf-ab4f705bcae4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7a95e1a8-43a2-41df-af3d-b5d7b712f288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:to="loc_us-gaap_DebtInstrumentAxis_7a95e1a8-43a2-41df-af3d-b5d7b712f288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7a95e1a8-43a2-41df-af3d-b5d7b712f288_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a95e1a8-43a2-41df-af3d-b5d7b712f288" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7a95e1a8-43a2-41df-af3d-b5d7b712f288_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ee5933fa-b664-4d85-b606-71f6c24a95e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a95e1a8-43a2-41df-af3d-b5d7b712f288" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ee5933fa-b664-4d85-b606-71f6c24a95e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_aef9bac4-34c3-4f33-a4df-a46b57c17579" xlink:href="neo-20220930.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee5933fa-b664-4d85-b606-71f6c24a95e2" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_aef9bac4-34c3-4f33-a4df-a46b57c17579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_d3849bb1-c122-4518-a337-747fbf7d9495" xlink:href="neo-20220930.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee5933fa-b664-4d85-b606-71f6c24a95e2" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_d3849bb1-c122-4518-a337-747fbf7d9495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b1a59ab9-d6a2-4aa3-825a-ff1cd276784a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b1a59ab9-d6a2-4aa3-825a-ff1cd276784a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1a59ab9-d6a2-4aa3-825a-ff1cd276784a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b1a59ab9-d6a2-4aa3-825a-ff1cd276784a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1a59ab9-d6a2-4aa3-825a-ff1cd276784a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ce4390cf-ad01-4292-8274-f0babb24bc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b1a59ab9-d6a2-4aa3-825a-ff1cd276784a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ce4390cf-ad01-4292-8274-f0babb24bc9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_f8de5183-e08e-40fd-9b82-bb5c0bf5874e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ce4390cf-ad01-4292-8274-f0babb24bc9a" xlink:to="loc_us-gaap_ConvertibleDebtMember_f8de5183-e08e-40fd-9b82-bb5c0bf5874e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b13f6415-a294-4cf6-8969-21f24803b298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b13f6415-a294-4cf6-8969-21f24803b298" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b13f6415-a294-4cf6-8969-21f24803b298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b13f6415-a294-4cf6-8969-21f24803b298" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b13f6415-a294-4cf6-8969-21f24803b298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1871f247-6e7f-4bdd-bf3e-266bbd692ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b13f6415-a294-4cf6-8969-21f24803b298" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1871f247-6e7f-4bdd-bf3e-266bbd692ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_bcda3b0f-ab97-43b5-a80e-9036e63e2d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1871f247-6e7f-4bdd-bf3e-266bbd692ac1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_bcda3b0f-ab97-43b5-a80e-9036e63e2d11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cce697b-8920-45d2-84e9-c056264d758b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cce697b-8920-45d2-84e9-c056264d758b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cce697b-8920-45d2-84e9-c056264d758b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cce697b-8920-45d2-84e9-c056264d758b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cce697b-8920-45d2-84e9-c056264d758b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d86d9ab-fdf8-45b6-a879-9eaabdb933d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cce697b-8920-45d2-84e9-c056264d758b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d86d9ab-fdf8-45b6-a879-9eaabdb933d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_01851902-98ad-48c4-be35-c792b7b1c24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d86d9ab-fdf8-45b6-a879-9eaabdb933d6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_01851902-98ad-48c4-be35-c792b7b1c24d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="icda147251b6c4a539f92baddfbde607b_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_895fe541-04ec-48e7-abe8-5a635ed8276f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_895fe541-04ec-48e7-abe8-5a635ed8276f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a741684d-d505-4650-a91f-a3d3b61d9cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a741684d-d505-4650-a91f-a3d3b61d9cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6c42b245-481d-42c6-9878-290afd020022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6c42b245-481d-42c6-9878-290afd020022" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_d76aee84-1ba3-437c-b14c-e73c98fd0af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_d76aee84-1ba3-437c-b14c-e73c98fd0af6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_68ae9196-fdb0-497c-b7c4-d68e39427758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchaseProgramAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_68ae9196-fdb0-497c-b7c4-d68e39427758" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23f7917d-4068-45ce-aecf-f38c60f28d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23f7917d-4068-45ce-aecf-f38c60f28d60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a624b806-ed33-4967-acea-7b0a4224b0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23f7917d-4068-45ce-aecf-f38c60f28d60" xlink:to="loc_us-gaap_AwardTypeAxis_a624b806-ed33-4967-acea-7b0a4224b0bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a624b806-ed33-4967-acea-7b0a4224b0bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a624b806-ed33-4967-acea-7b0a4224b0bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a624b806-ed33-4967-acea-7b0a4224b0bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8440418-f0fe-467d-b1c9-e647587c7590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a624b806-ed33-4967-acea-7b0a4224b0bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8440418-f0fe-467d-b1c9-e647587c7590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_af5c6d01-d3f0-4ff4-935b-e7bcc05ea571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8440418-f0fe-467d-b1c9-e647587c7590" xlink:to="loc_us-gaap_RestrictedStockMember_af5c6d01-d3f0-4ff4-935b-e7bcc05ea571" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f767f6fa-cf1c-433e-a151-d5fc19d1954e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8440418-f0fe-467d-b1c9-e647587c7590" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f767f6fa-cf1c-433e-a151-d5fc19d1954e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8352ec38-fc98-49ae-b010-351a04006d8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23f7917d-4068-45ce-aecf-f38c60f28d60" xlink:to="loc_srt_TitleOfIndividualAxis_8352ec38-fc98-49ae-b010-351a04006d8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8352ec38-fc98-49ae-b010-351a04006d8d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_8352ec38-fc98-49ae-b010-351a04006d8d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8352ec38-fc98-49ae-b010-351a04006d8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b801dc41-e445-451d-b4e9-9ceb1c94ad19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_8352ec38-fc98-49ae-b010-351a04006d8d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b801dc41-e445-451d-b4e9-9ceb1c94ad19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ChiefLegalOfficerMember_33d09320-20d7-4c3c-b85f-9485c80a45a5" xlink:href="neo-20220930.xsd#neo_ChiefLegalOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b801dc41-e445-451d-b4e9-9ceb1c94ad19" xlink:to="loc_neo_ChiefLegalOfficerMember_33d09320-20d7-4c3c-b85f-9485c80a45a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_0bcf6b01-8ade-4d05-b2e3-9290626c53d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b801dc41-e445-451d-b4e9-9ceb1c94ad19" xlink:to="loc_srt_ChiefExecutiveOfficerMember_0bcf6b01-8ade-4d05-b2e3-9290626c53d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" xlink:type="extended" id="id692d9eb365c4a138ca47fa5724ff7eb_StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cf45bd11-f43d-4db5-baf8-51fd14ae1429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cf45bd11-f43d-4db5-baf8-51fd14ae1429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b4780397-f5ae-4850-91c0-456874ccec86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b4780397-f5ae-4850-91c0-456874ccec86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_56a787ce-192c-4dd2-a639-5d6ae05d8d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_56a787ce-192c-4dd2-a639-5d6ae05d8d41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c4e84622-54d5-470c-bc30-0c814c42a983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c4e84622-54d5-470c-bc30-0c814c42a983" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3d7c98de-a4e0-432a-9193-00920207f951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3d7c98de-a4e0-432a-9193-00920207f951" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b1488b-189e-4136-9a6c-c0b5ed754113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b1488b-189e-4136-9a6c-c0b5ed754113" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb9d5440-c2b2-48ef-8e33-4e2a690a7cdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b1488b-189e-4136-9a6c-c0b5ed754113" xlink:to="loc_srt_RangeAxis_eb9d5440-c2b2-48ef-8e33-4e2a690a7cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb9d5440-c2b2-48ef-8e33-4e2a690a7cdd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eb9d5440-c2b2-48ef-8e33-4e2a690a7cdd" xlink:to="loc_srt_RangeMember_eb9d5440-c2b2-48ef-8e33-4e2a690a7cdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ad675e9-0179-4da7-a8f5-15cf794914c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eb9d5440-c2b2-48ef-8e33-4e2a690a7cdd" xlink:to="loc_srt_RangeMember_8ad675e9-0179-4da7-a8f5-15cf794914c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fabff48-653e-4102-b953-a6ea28efc9b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8ad675e9-0179-4da7-a8f5-15cf794914c9" xlink:to="loc_srt_MinimumMember_8fabff48-653e-4102-b953-a6ea28efc9b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ee1da91-2f76-431f-8806-442b4e94fb42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8ad675e9-0179-4da7-a8f5-15cf794914c9" xlink:to="loc_srt_MaximumMember_1ee1da91-2f76-431f-8806-442b4e94fb42" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended" id="i4a8df52e6dc94853bc70185efb88e5cb_StockBasedCompensationSummaryofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2621252-e0c8-4da0-ab1a-a468e1101d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2621252-e0c8-4da0-ab1a-a468e1101d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6c9eaae8-0acf-46a2-8a62-5bc355a95ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6c9eaae8-0acf-46a2-8a62-5bc355a95ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6e7ffde-4a95-4cb4-8681-8e838cb91742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6e7ffde-4a95-4cb4-8681-8e838cb91742" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_14a8d1bc-f1de-44bf-bd76-42a2fa885b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_14a8d1bc-f1de-44bf-bd76-42a2fa885b55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4fdc21e3-0def-470c-83fa-de3b1866dd62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4fdc21e3-0def-470c-83fa-de3b1866dd62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_13358a69-1c5a-43c2-a64a-1fbf164d3c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2621252-e0c8-4da0-ab1a-a468e1101d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7efd6b9c-e894-4e8f-b469-a7e5663a091d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7efd6b9c-e894-4e8f-b469-a7e5663a091d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0306bba9-50e7-4968-bbe3-9a01aa750c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0306bba9-50e7-4968-bbe3-9a01aa750c44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_caf3efc1-a98c-4ea9-aa74-1a7b171b5521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_caf3efc1-a98c-4ea9-aa74-1a7b171b5521" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a55da3e-a0d8-4d12-92ef-aa6f57285df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a55da3e-a0d8-4d12-92ef-aa6f57285df5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a4d7d83-4465-4eb3-ab74-6af4345b93f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b426dd7-ca0b-473b-a5e8-716ca9399031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2621252-e0c8-4da0-ab1a-a468e1101d7c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b426dd7-ca0b-473b-a5e8-716ca9399031" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5f7a6f5a-08f6-4cb9-a6f6-25e0866f6442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b426dd7-ca0b-473b-a5e8-716ca9399031" xlink:to="loc_us-gaap_AwardTypeAxis_5f7a6f5a-08f6-4cb9-a6f6-25e0866f6442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f7a6f5a-08f6-4cb9-a6f6-25e0866f6442_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5f7a6f5a-08f6-4cb9-a6f6-25e0866f6442" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f7a6f5a-08f6-4cb9-a6f6-25e0866f6442_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b4185a7-4254-44ce-9cb3-dcee08b634ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5f7a6f5a-08f6-4cb9-a6f6-25e0866f6442" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b4185a7-4254-44ce-9cb3-dcee08b634ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c8a55461-a125-4884-86d0-948e8ca39230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b4185a7-4254-44ce-9cb3-dcee08b634ff" xlink:to="loc_us-gaap_RestrictedStockMember_c8a55461-a125-4884-86d0-948e8ca39230" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="ia0563317bb3342a6acd9536553262d70_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_777119c2-4caf-4852-9220-50eac95b3df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0d7978ec-a722-4fcd-a4c1-c33f8698ca37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_777119c2-4caf-4852-9220-50eac95b3df3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0d7978ec-a722-4fcd-a4c1-c33f8698ca37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_252c5da8-07ec-492d-948a-2b9d735d3f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_777119c2-4caf-4852-9220-50eac95b3df3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_252c5da8-07ec-492d-948a-2b9d735d3f65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_baa2351f-e4c5-47c7-b3ae-f3b6e8e01ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_252c5da8-07ec-492d-948a-2b9d735d3f65" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_baa2351f-e4c5-47c7-b3ae-f3b6e8e01ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_baa2351f-e4c5-47c7-b3ae-f3b6e8e01ca9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_baa2351f-e4c5-47c7-b3ae-f3b6e8e01ca9" xlink:to="loc_us-gaap_SegmentDomain_baa2351f-e4c5-47c7-b3ae-f3b6e8e01ca9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3a5b80d9-41ee-4fe6-b1e8-216f228f6cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_baa2351f-e4c5-47c7-b3ae-f3b6e8e01ca9" xlink:to="loc_us-gaap_SegmentDomain_3a5b80d9-41ee-4fe6-b1e8-216f228f6cd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_e11b481e-eeb1-4116-9fe9-a1b507de3e78" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3a5b80d9-41ee-4fe6-b1e8-216f228f6cd5" xlink:to="loc_neo_ClinicalServicesMember_e11b481e-eeb1-4116-9fe9-a1b507de3e78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_07022680-9934-4e1b-aef0-687f19c27281" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3a5b80d9-41ee-4fe6-b1e8-216f228f6cd5" xlink:to="loc_neo_PharmaServicesMember_07022680-9934-4e1b-aef0-687f19c27281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_585dc2f3-93aa-4612-9680-67879f21ac8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_252c5da8-07ec-492d-948a-2b9d735d3f65" xlink:to="loc_srt_ProductOrServiceAxis_585dc2f3-93aa-4612-9680-67879f21ac8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_585dc2f3-93aa-4612-9680-67879f21ac8e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_585dc2f3-93aa-4612-9680-67879f21ac8e" xlink:to="loc_srt_ProductsAndServicesDomain_585dc2f3-93aa-4612-9680-67879f21ac8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_585dc2f3-93aa-4612-9680-67879f21ac8e" xlink:to="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClientDirectBillingMember_99fe6fef-9623-4b68-beab-f90a4fa98e60" xlink:href="neo-20220930.xsd#neo_ClientDirectBillingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:to="loc_neo_ClientDirectBillingMember_99fe6fef-9623-4b68-beab-f90a4fa98e60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommercialInsuranceMember_0e3e304a-add0-406a-90df-cd7ca585a658" xlink:href="neo-20220930.xsd#neo_CommercialInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:to="loc_neo_CommercialInsuranceMember_0e3e304a-add0-406a-90df-cd7ca585a658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_MedicareAndOtherGovernmentalMember_14857c1f-c33f-41f1-8668-b4da64b70f22" xlink:href="neo-20220930.xsd#neo_MedicareAndOtherGovernmentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:to="loc_neo_MedicareAndOtherGovernmentalMember_14857c1f-c33f-41f1-8668-b4da64b70f22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SelfPayServicesMember_5073e24a-8575-4a8a-90cd-80df3c0a6812" xlink:href="neo-20220930.xsd#neo_SelfPayServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:to="loc_neo_SelfPayServicesMember_5073e24a-8575-4a8a-90cd-80df3c0a6812" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails" xlink:type="extended" id="ibbf297aa31e640d9a96f1eaa1d6609f1_NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_93ea6e36-4edb-4869-bf42-5863a03556cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_93ea6e36-4edb-4869-bf42-5863a03556cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_2a05549c-8c36-49e4-a90b-b300089e44b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_2a05549c-8c36-49e4-a90b-b300089e44b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_077f7cdc-b4c2-439a-bcdc-3c488811589a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_077f7cdc-b4c2-439a-bcdc-3c488811589a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_e25203f5-40d1-486a-9280-4fbf92736b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_e25203f5-40d1-486a-9280-4fbf92736b44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4edd45ac-760e-496e-b3a0-5678148a122b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4edd45ac-760e-496e-b3a0-5678148a122b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_30329e0f-7e18-469a-bccd-efc31320d639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_30329e0f-7e18-469a-bccd-efc31320d639" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_306db56d-85d0-4642-b008-3bb9a4ae6b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_306db56d-85d0-4642-b008-3bb9a4ae6b3e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_ea3d0684-65b3-4055-abfb-c4d3f08a83c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_ea3d0684-65b3-4055-abfb-c4d3f08a83c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a9b1b74-07be-444f-acf8-5a88f8450ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_ea3d0684-65b3-4055-abfb-c4d3f08a83c4" xlink:to="loc_us-gaap_AwardTypeAxis_6a9b1b74-07be-444f-acf8-5a88f8450ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9b1b74-07be-444f-acf8-5a88f8450ee2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6a9b1b74-07be-444f-acf8-5a88f8450ee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9b1b74-07be-444f-acf8-5a88f8450ee2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a543e09-d38c-4af6-afa7-12dff76ac743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6a9b1b74-07be-444f-acf8-5a88f8450ee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a543e09-d38c-4af6-afa7-12dff76ac743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cd167bae-f1f8-42b4-8dc3-ed71e34746dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a543e09-d38c-4af6-afa7-12dff76ac743" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cd167bae-f1f8-42b4-8dc3-ed71e34746dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b5059d6f-3fc5-4789-99c2-58c25ed584ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a543e09-d38c-4af6-afa7-12dff76ac743" xlink:to="loc_us-gaap_RestrictedStockMember_b5059d6f-3fc5-4789-99c2-58c25ed584ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a8715c2f-3310-4e60-891b-6f1f768407a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_ea3d0684-65b3-4055-abfb-c4d3f08a83c4" xlink:to="loc_us-gaap_DebtInstrumentAxis_a8715c2f-3310-4e60-891b-6f1f768407a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a8715c2f-3310-4e60-891b-6f1f768407a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a8715c2f-3310-4e60-891b-6f1f768407a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a8715c2f-3310-4e60-891b-6f1f768407a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_969fe21a-764f-40b4-9c9e-705cac64a041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a8715c2f-3310-4e60-891b-6f1f768407a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_969fe21a-764f-40b4-9c9e-705cac64a041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_f2ddc774-4b7a-4907-a3e7-da2899d50d79" xlink:href="neo-20220930.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_969fe21a-764f-40b4-9c9e-705cac64a041" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_f2ddc774-4b7a-4907-a3e7-da2899d50d79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_08e65145-fd75-4bc8-ac38-79b8e0c0f7b7" xlink:href="neo-20220930.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_969fe21a-764f-40b4-9c9e-705cac64a041" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_08e65145-fd75-4bc8-ac38-79b8e0c0f7b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails" xlink:type="extended" id="i155f0165f0d94304a7e1f909dae68743_NetLossIncomePerShareScheduleofAntidilutiveSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3cfe9f0c-39ba-4645-bb0f-8e4cda4d4223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3cfe9f0c-39ba-4645-bb0f-8e4cda4d4223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_8e9cf793-36ea-4037-a6c3-6231883d76c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_8e9cf793-36ea-4037-a6c3-6231883d76c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c812cc98-794d-479f-83f6-5ef2f2389f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c812cc98-794d-479f-83f6-5ef2f2389f9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_89c67956-e2f7-4c60-8639-fc6a2c016848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_89c67956-e2f7-4c60-8639-fc6a2c016848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89c67956-e2f7-4c60-8639-fc6a2c016848_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_89c67956-e2f7-4c60-8639-fc6a2c016848" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89c67956-e2f7-4c60-8639-fc6a2c016848_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_89c67956-e2f7-4c60-8639-fc6a2c016848" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a4c699a-a622-4a3e-b5a4-4f83b15eed32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a4c699a-a622-4a3e-b5a4-4f83b15eed32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_881a78ec-eadd-44cc-bfdb-fe988a704c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:to="loc_us-gaap_RestrictedStockMember_881a78ec-eadd-44cc-bfdb-fe988a704c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_6c01f208-a307-4354-88bf-b2a2b845bc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_6c01f208-a307-4354-88bf-b2a2b845bc1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_712ecde4-2acf-4a1b-b929-3862bd16e952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_712ecde4-2acf-4a1b-b929-3862bd16e952" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_712ecde4-2acf-4a1b-b929-3862bd16e952_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_712ecde4-2acf-4a1b-b929-3862bd16e952" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_712ecde4-2acf-4a1b-b929-3862bd16e952_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fcd72def-ec79-40cc-9ba1-943ddd2780aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_712ecde4-2acf-4a1b-b929-3862bd16e952" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fcd72def-ec79-40cc-9ba1-943ddd2780aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_284dcfe8-bb05-4c9f-8876-c7c0a52d64b2" xlink:href="neo-20220930.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fcd72def-ec79-40cc-9ba1-943ddd2780aa" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_284dcfe8-bb05-4c9f-8876-c7c0a52d64b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_97fa4dcf-39e2-45f6-9eb6-49663a135991" xlink:href="neo-20220930.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fcd72def-ec79-40cc-9ba1-943ddd2780aa" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_97fa4dcf-39e2-45f6-9eb6-49663a135991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d48a55be-74f7-414c-a9f0-5c21a74d1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d48a55be-74f7-414c-a9f0-5c21a74d1e58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d48a55be-74f7-414c-a9f0-5c21a74d1e58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d48a55be-74f7-414c-a9f0-5c21a74d1e58" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d48a55be-74f7-414c-a9f0-5c21a74d1e58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_431b60bc-2f9a-497a-93e6-38e4de1ffe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d48a55be-74f7-414c-a9f0-5c21a74d1e58" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_431b60bc-2f9a-497a-93e6-38e4de1ffe79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember_57af0161-6c10-4918-9de3-17d41c218388" xlink:href="neo-20220930.xsd#neo_CappedCallTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_431b60bc-2f9a-497a-93e6-38e4de1ffe79" xlink:to="loc_neo_CappedCallTransactionsMember_57af0161-6c10-4918-9de3-17d41c218388" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i0a332eca656a400aac4b392cd722db6d_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationLineItems_6842d6db-96fc-4ac0-bc5a-c8a8a6d09049" xlink:href="neo-20220930.xsd#neo_ContractualObligationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_362aa612-c7ae-418e-b1c7-0a4d7d556adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ContractualObligationLineItems_6842d6db-96fc-4ac0-bc5a-c8a8a6d09049" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_362aa612-c7ae-418e-b1c7-0a4d7d556adc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_320d95fc-fd8a-4d63-be3b-d7b91cbf7908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ContractualObligationLineItems_6842d6db-96fc-4ac0-bc5a-c8a8a6d09049" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_320d95fc-fd8a-4d63-be3b-d7b91cbf7908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationTable_74aab52f-cc30-4b4a-8945-38b9973eeac2" xlink:href="neo-20220930.xsd#neo_ContractualObligationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_neo_ContractualObligationLineItems_6842d6db-96fc-4ac0-bc5a-c8a8a6d09049" xlink:to="loc_neo_ContractualObligationTable_74aab52f-cc30-4b4a-8945-38b9973eeac2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1f5f8144-eb7c-4c25-a825-3d7741857356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_ContractualObligationTable_74aab52f-cc30-4b4a-8945-38b9973eeac2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1f5f8144-eb7c-4c25-a825-3d7741857356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1f5f8144-eb7c-4c25-a825-3d7741857356_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1f5f8144-eb7c-4c25-a825-3d7741857356" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1f5f8144-eb7c-4c25-a825-3d7741857356_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b127abc7-70cb-4f32-88a8-16a9b711003a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1f5f8144-eb7c-4c25-a825-3d7741857356" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b127abc7-70cb-4f32-88a8-16a9b711003a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PatentInfringementComplaintMember_2554a8e5-8dcf-4ec3-830a-cabb1ab40fde" xlink:href="neo-20220930.xsd#neo_PatentInfringementComplaintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b127abc7-70cb-4f32-88a8-16a9b711003a" xlink:to="loc_neo_PatentInfringementComplaintMember_2554a8e5-8dcf-4ec3-830a-cabb1ab40fde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FederalHealthcareProgramRevenueMember_fd8fe2e0-7953-4ae0-8542-7fadc2addff3" xlink:href="neo-20220930.xsd#neo_FederalHealthcareProgramRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b127abc7-70cb-4f32-88a8-16a9b711003a" xlink:to="loc_neo_FederalHealthcareProgramRevenueMember_fd8fe2e0-7953-4ae0-8542-7fadc2addff3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="ic66b4d1d751f48a880708300890ef0d1_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3a59d0e0-e9e6-4ac3-bae1-2da03c93d591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_fa9647c1-f80b-44ef-a743-00b2b8b3f7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3a59d0e0-e9e6-4ac3-bae1-2da03c93d591" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_fa9647c1-f80b-44ef-a743-00b2b8b3f7b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_6afe108a-3722-4930-bfcb-150d33a3ac7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3a59d0e0-e9e6-4ac3-bae1-2da03c93d591" xlink:to="loc_us-gaap_RevenueFromRelatedParties_6afe108a-3722-4930-bfcb-150d33a3ac7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d90743c-afe3-437d-8271-77ca1922665b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3a59d0e0-e9e6-4ac3-bae1-2da03c93d591" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d90743c-afe3-437d-8271-77ca1922665b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef71507e-e493-4835-b178-0ac2aca0217e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d90743c-afe3-437d-8271-77ca1922665b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef71507e-e493-4835-b178-0ac2aca0217e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ef71507e-e493-4835-b178-0ac2aca0217e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef71507e-e493-4835-b178-0ac2aca0217e" xlink:to="loc_us-gaap_RelatedPartyDomain_ef71507e-e493-4835-b178-0ac2aca0217e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0311bba9-fdfe-4c2c-8285-f5a3771825f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef71507e-e493-4835-b178-0ac2aca0217e" xlink:to="loc_us-gaap_RelatedPartyDomain_0311bba9-fdfe-4c2c-8285-f5a3771825f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_18374068-faa8-4de7-b3b7-6653404c86fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0311bba9-fdfe-4c2c-8285-f5a3771825f5" xlink:to="loc_srt_AffiliatedEntityMember_18374068-faa8-4de7-b3b7-6653404c86fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_182bff63-953f-4f6a-9948-a51398cb7378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d90743c-afe3-437d-8271-77ca1922665b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_182bff63-953f-4f6a-9948-a51398cb7378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_182bff63-953f-4f6a-9948-a51398cb7378_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_182bff63-953f-4f6a-9948-a51398cb7378" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_182bff63-953f-4f6a-9948-a51398cb7378_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_182bff63-953f-4f6a-9948-a51398cb7378" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StrategicAllianceWithInivataLimitedMember_739c8441-943d-4f85-924f-a57f6a2c8e5e" xlink:href="neo-20220930.xsd#neo_StrategicAllianceWithInivataLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:to="loc_neo_StrategicAllianceWithInivataLimitedMember_739c8441-943d-4f85-924f-a57f6a2c8e5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember_513601bb-b9db-4f6e-8a98-448102900f77" xlink:href="neo-20220930.xsd#neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:to="loc_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember_513601bb-b9db-4f6e-8a98-448102900f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_75807202-c1a0-417b-ab7e-c2336b5a9249" xlink:href="neo-20220930.xsd#neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:to="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_75807202-c1a0-417b-ab7e-c2336b5a9249" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#SegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="extended" id="if9e24e186df24c08ac0ac82573e42add_SegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6ae85353-7507-4732-8bb7-94364b4f6dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6ae85353-7507-4732-8bb7-94364b4f6dba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_529f3444-d8d1-49ba-bbff-501133c784dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_529f3444-d8d1-49ba-bbff-501133c784dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_dc42976b-5398-4788-99f0-9a3e21e85f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_GrossProfit_dc42976b-5398-4788-99f0-9a3e21e85f66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7d779e14-93e5-4b84-881b-441459377f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7d779e14-93e5-4b84-881b-441459377f10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8baf65b6-05d3-46dc-9d38-8a5f6d95c977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8baf65b6-05d3-46dc-9d38-8a5f6d95c977" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_0170c5c0-8e18-4f1e-8381-db3cf2c595da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_SellingAndMarketingExpense_0170c5c0-8e18-4f1e-8381-db3cf2c595da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_56e3426f-ce4c-486f-8b17-b77d55a70aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_OperatingExpenses_56e3426f-ce4c-486f-8b17-b77d55a70aee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6fa3c83c-f963-4018-a459-73a877321640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_OperatingIncomeLoss_6fa3c83c-f963-4018-a459-73a877321640" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3ed5fee7-bc55-4c26-927a-44a6c7083b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_InterestExpense_3ed5fee7-bc55-4c26-927a-44a6c7083b84" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_556b29eb-da81-412a-9179-0c75a5014198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_556b29eb-da81-412a-9179-0c75a5014198" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_f2e50eb1-bf31-4831-947c-64a449120589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_GainLossOnInvestments_f2e50eb1-bf31-4831-947c-64a449120589" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d8ed012-59f9-4b21-8f8d-ce2002256419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d8ed012-59f9-4b21-8f8d-ce2002256419" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a7bb9a62-d84f-4f26-b3c7-1f32d1d0f1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a7bb9a62-d84f-4f26-b3c7-1f32d1d0f1cd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_251fde62-acc6-4b28-9af0-ba0fc98b027e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_NetIncomeLoss_251fde62-acc6-4b28-9af0-ba0fc98b027e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IntangibleAssetsAcquiredAmortizationExpense_777ba963-2ad8-4d6b-bcbc-f7a50a85c4f3" xlink:href="neo-20220930.xsd#neo_IntangibleAssetsAcquiredAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_neo_IntangibleAssetsAcquiredAmortizationExpense_777ba963-2ad8-4d6b-bcbc-f7a50a85c4f3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_09ceef32-52be-4641-b95f-eb19f99e825e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_InventoryWriteDown_09ceef32-52be-4641-b95f-eb19f99e825e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c73fd5c-9628-4744-a554-4fb3db3de79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c73fd5c-9628-4744-a554-4fb3db3de79b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0d4ad3f3-0c7b-4719-b016-13c20f4a4d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c73fd5c-9628-4744-a554-4fb3db3de79b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0d4ad3f3-0c7b-4719-b016-13c20f4a4d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0d4ad3f3-0c7b-4719-b016-13c20f4a4d9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0d4ad3f3-0c7b-4719-b016-13c20f4a4d9b" xlink:to="loc_us-gaap_SegmentDomain_0d4ad3f3-0c7b-4719-b016-13c20f4a4d9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f77e3e53-53da-4931-a7df-fa043195ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0d4ad3f3-0c7b-4719-b016-13c20f4a4d9b" xlink:to="loc_us-gaap_SegmentDomain_f77e3e53-53da-4931-a7df-fa043195ce29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_5f4070d5-b0e1-4fd9-9d90-858e305f3ab4" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f77e3e53-53da-4931-a7df-fa043195ce29" xlink:to="loc_neo_ClinicalServicesMember_5f4070d5-b0e1-4fd9-9d90-858e305f3ab4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_bc255b3c-d732-4c6e-a623-ebe9c28744e5" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f77e3e53-53da-4931-a7df-fa043195ce29" xlink:to="loc_neo_PharmaServicesMember_bc255b3c-d732-4c6e-a623-ebe9c28744e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_36a92e45-8a28-440a-b93b-2c608d4cfb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c73fd5c-9628-4744-a554-4fb3db3de79b" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_36a92e45-8a28-440a-b93b-2c608d4cfb8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_36a92e45-8a28-440a-b93b-2c608d4cfb8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_36a92e45-8a28-440a-b93b-2c608d4cfb8e" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_36a92e45-8a28-440a-b93b-2c608d4cfb8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_14c42ecc-7472-42e2-b760-75c8091acf81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_36a92e45-8a28-440a-b93b-2c608d4cfb8e" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_14c42ecc-7472-42e2-b760-75c8091acf81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_COVID19PCRTestingMember_08aac5c1-bb23-449b-beae-a8ac1486d165" xlink:href="neo-20220930.xsd#neo_COVID19PCRTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_14c42ecc-7472-42e2-b760-75c8091acf81" xlink:to="loc_neo_COVID19PCRTestingMember_08aac5c1-bb23-449b-beae-a8ac1486d165" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>neo-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2d7a6b14-636e-498a-9bb1-3c76242be649,g:a2221670-aa14-4f97-b400-5f284572b74c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_850a5e63-f2db-474c-aa47-a3c9ea18997e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Year or Less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8d4aed24-e4af-47f6-b556-4cfe37158448_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_453cf4aa-41d5-44b9-9060-59aa0f82889b_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_352c97e0-6bfb-45f5-962a-4a2479f869ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_44f0d950-43a7-4154-b1a3-6c9e78217741_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_4d9f1ad5-bd9a-4e4e-8a17-14012c4f880f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investment in and loan receivable from non-consolidated affiliate, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PatentInfringementComplaintMember_fb34814b-751a-40e5-9770-d4a17785bfb6_terseLabel_en-US" xlink:label="lab_neo_PatentInfringementComplaintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Complaint</link:label>
    <link:label id="lab_neo_PatentInfringementComplaintMember_label_en-US" xlink:label="lab_neo_PatentInfringementComplaintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Complaint [Member]</link:label>
    <link:label id="lab_neo_PatentInfringementComplaintMember_documentation_en-US" xlink:label="lab_neo_PatentInfringementComplaintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Complaint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PatentInfringementComplaintMember" xlink:href="neo-20220930.xsd#neo_PatentInfringementComplaintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PatentInfringementComplaintMember" xlink:to="lab_neo_PatentInfringementComplaintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_f59b30d4-9fc6-4994-8f5b-ef4f85235883_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days (in days)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_371af5f6-a0c1-4090-90ea-5b0c788a0672_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_07f82053-cbeb-4460-9953-6c9b9a2f9c65_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_e3897243-733c-4509-baa7-2b7ca965dc2c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_0a018b05-ec14-4271-b803-9684d56aeef9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue payment terms</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8fce5571-b41f-402b-bb2d-52ee14fc3819_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over Five Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b79ebcc0-4d85-4d41-a40f-cb7ac3c60c41_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_15c3d436-4d19-4cba-96f5-a6c60ed9ce7d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d5b1beb3-0b87-4bb3-821d-1cbe7d3c02d7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8977f635-800e-4af3-a59e-c13e50bf8567_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_84748ced-0633-4676-93e4-9aa58822f37c_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_db188ee9-c1db-4589-ae24-866a004df042_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_650db482-b6af-45dd-8d57-27b119ffc87b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_4d55c0fd-8b4a-4c9d-8dc3-7dcd50fc6df2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2682a244-f363-486b-97bb-4d44693c65e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_2db9d0ca-50a0-473b-9731-c6b1878df229_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_b1b6c771-383c-4f57-aefa-0694f05447b3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_d122f985-edce-48ce-bec3-14ce4419b040_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value/share at grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_7f2ef52f-91d0-483c-8b47-5e615b322736_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_51a48ba0-fdd9-4f89-b458-051868ead421_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_38df84f6-9806-4041-87ca-263dee6c7f1d_terseLabel_en-US" xlink:label="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business, adjustments</link:label>
    <link:label id="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_label_en-US" xlink:label="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired From Acquisition And Working Capital Adjustments</link:label>
    <link:label id="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_documentation_en-US" xlink:label="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired From Acquisition And Working Capital Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:href="neo-20220930.xsd#neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:to="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ce89b926-1abb-4604-b7e7-09c6a851443f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET (LOSS) INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_574145b4-836b-4dda-b28f-a878fe9fce12_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET (LOSS) INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1ef36120-4100-4690-9337-c0ce7586d15c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c695cbdf-cc3d-4d18-967b-11d9f7f4fcf0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_b202a63a-e77f-4884-bedd-02f8c7251831_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Each Stock Option Award Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_854ebf48-d8da-41fe-8d59-8ea6f5e3fcbf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a1851508-a37a-42fc-b10e-9791a4159b18_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over One Year Through Five Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_a9f01559-b2ee-4dfd-b646-deff7464d34c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_IntangibleAssetsAcquiredAmortizationExpense_35b8681a-1440-4f2b-84b6-2b88cfdf89a8_terseLabel_en-US" xlink:label="lab_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_neo_IntangibleAssetsAcquiredAmortizationExpense_label_en-US" xlink:label="lab_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Acquired, Amortization Expense</link:label>
    <link:label id="lab_neo_IntangibleAssetsAcquiredAmortizationExpense_documentation_en-US" xlink:label="lab_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Acquired, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:href="neo-20220930.xsd#neo_IntangibleAssetsAcquiredAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:to="lab_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_de431bf5-e424-4703-ae19-0c91d3b4ba06_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_653fddd2-b7e7-4f8e-92eb-1b3e02a1551c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_85bd80d9-8df9-490e-8cdb-b794e9fd2dda_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_bacdfc34-d30e-470e-9f42-9cd50fc2d82e_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pharma contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_7e5a9ede-c5a2-40af-8f5b-b0f27720fbac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price per share on closing date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_07a84473-9ba7-4e24-8dde-294f6c8e2eb5_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share value of common stock issued as consideration (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3e57d3d6-21ac-42f0-a027-4b3ceca00095_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9388700f-bf95-4938-9b1a-dbee0b4d5c65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_59db9e95-3a3f-4a8b-9b01-0822d3642552_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (loss) per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60bbc914-59cf-46eb-b77e-eaad642775c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_04f0a3e7-4e12-4697-94cc-f638b5514bd5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_390bcfed-7889-485a-a67c-4e107011c961_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_a1b47f9f-65e8-43f3-8980-0e73c9fd7bde_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_862b9afd-9d69-42ff-964e-759cbc6f0375_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_c4a15e4f-b3f5-4d32-ab4a-93822707b8da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, (250,000,000 shares authorized; 126,562,037 and 124,107,500 shares issued and outstanding, respectively)</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9a211f04-3249-41ba-8554-129b8df4aaec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_77f01dc7-5dac-432c-b223-35c654972d2d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_25b98964-df93-46eb-ab66-b507f5a3e82d_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of Convertible Notes (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_c3d35fd4-2575-4ec8-af5d-84cd47ebbf4e_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, other current assets</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract_e91ff67b-5952-429d-ba50-1417081e2001_terseLabel_en-US" xlink:label="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract_label_en-US" xlink:label="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Reductions in Options Outstanding [Abstract]</link:label>
    <link:label id="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Reductions in Options Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract" xlink:href="neo-20220930.xsd#neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract" xlink:to="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_83881521-3114-49db-a0d0-e770e649dd4d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE LOSS:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_79f4a2fe-11cc-43d4-92e6-7a2690967439_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_02278dac-431f-4099-9227-15864cd031d9_verboseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5afe3b7-ba4a-46b7-a9ee-42ce2bfb4efd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition_d46384a6-f779-466b-aa10-11959e3ba465_terseLabel_en-US" xlink:label="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock issued to fund business acquisition</link:label>
    <link:label id="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition_label_en-US" xlink:label="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Common Stock Issued To Fund Acquisition</link:label>
    <link:label id="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition_documentation_en-US" xlink:label="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Common Stock Issued To Fund Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:href="neo-20220930.xsd#neo_FairValueOfCommonStockIssuedToFundAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:to="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_1ef0fa31-9709-4d78-b479-a4896f3e8e2f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_858d50af-4c67-48ea-84e5-213d07385550_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5394ae40-ef7b-4242-8a63-0cdcc8e55489_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember_e840e88f-7742-4b9a-b2b4-ea9d1cc52df7_terseLabel_en-US" xlink:label="lab_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Service Contracts with CytomX Therapeutics, Inc.</link:label>
    <link:label id="lab_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember_label_en-US" xlink:label="lab_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Service Contracts with CytomX Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember_documentation_en-US" xlink:label="lab_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Service Contracts with CytomX Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember" xlink:href="neo-20220930.xsd#neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember" xlink:to="lab_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_80359ad4-ad2f-4dcd-955a-18c89658f405_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b8310379-8e81-4d8d-9257-6d8f0cdeba15_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bb93ae08-c6fc-4bac-a900-b2e65a576876_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_55c47e65-e5d1-4bd8-ab8f-27c10b3b7189_terseLabel_en-US" xlink:label="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="neo-20220930.xsd#neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3c0766c3-4fa4-48c9-96e9-578a76136615_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_3fdaf6a3-36cb-4112-b312-f00c8a565ce2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from assets held for sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e55f4830-eea6-4a80-a7ab-d3574c74ff9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_01c1f955-a03f-4d3e-bf1a-af0d44c43717_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_2e0d95e5-dde0-47b5-8fbb-bd41f6a6ad34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_ba3061da-5c2f-475f-a7e1-55ac361420a3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_2730fdd3-57b6-4a13-9c12-8725f4a4500a_negatedLabel_en-US" xlink:label="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of equipment financing obligations</link:label>
    <link:label id="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_label_en-US" xlink:label="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Equipment and Other Finance Obligation</link:label>
    <link:label id="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_documentation_en-US" xlink:label="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Equipment and Other Finance Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:href="neo-20220930.xsd#neo_RepaymentsOfEquipmentAndOtherFinanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:to="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e02f2940-361a-4442-a1ca-0e1d87b02c1b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests acquired (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_bf1eb917-6841-4c04-a96f-c3e57a04fc70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ccb79a22-c50f-49ac-806d-bdc3c8203746_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock - public offering, net of underwriting discounts &amp; private placement, net of private placement fees</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2a340e96-a87c-47b0-9a5c-836d1855329e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0daddeb2-67b6-4c50-a321-a4b0a0d806b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f7aceb23-992f-49b1-8f65-2b37dfea31de_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b83b8e4-aaa8-4dcf-85fb-c99b0ccdd79d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2564608-a6bb-4296-b19e-c1088ec3ea65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Restricted Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5223f4a9-b52e-4fff-bc38-14c9b979d4f3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48141659-d1df-4324-8735-736d95d81e03_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9e139da2-dd9a-492d-91dd-60bec71e5c7d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2736cefd-84ca-4c4e-adfa-9e81caed4659_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_97c619ea-7cf0-4076-98d1-dee7e4a23f49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_d17f724e-cf3f-4466-98bf-0718148f78c3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e2fce9a7-1cfe-4f5c-a84c-0ff55b03a840_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a72fe29e-50dd-47f0-b7f3-885b0dc7d9bb_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_2a24933e-32b1-4502-98cd-2dfb33ec3919_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing Assets</link:label>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c9246cca-759c-412c-8a2a-2f39d96d1ba0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued as consideration (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_770e92cd-5205-44de-bf41-2849f98cbfc6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_6739bf52-0d95-49ff-82b1-76270953bebe_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_4d22c248-cf09-4669-8c94-d9fff266f385_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_c52fb840-5622-4ae7-8c0b-c826e112f264_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_c6bb085a-2fdf-456b-87b6-373d4318c0f0_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inivata Limited</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_50ce00c3-18bf-4177-927d-331c5b1e3933_verboseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d5ddf76f-b106-461e-ad2b-1ef1bd10ebdb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contract Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_83587b4d-79eb-499b-acb1-9b304347c3bc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_9bf881ca-095c-4828-9d92-e048c639e877_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance fees and expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_745d2053-ded6-4460-88b6-069a31e29510_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_50c6a456-4285-4890-908b-0f2915dec3d9_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_f2f6c7b6-619e-43ab-bd01-f3d2e517ccd9_terseLabel_en-US" xlink:label="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services contracts with HOOKIPA Pharma, Inc</link:label>
    <link:label id="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_label_en-US" xlink:label="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services contracts with HOOKIPA Pharma, Inc [Member]</link:label>
    <link:label id="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_documentation_en-US" xlink:label="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services contracts with HOOKIPA Pharma, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:href="neo-20220930.xsd#neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:to="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3f84ab66-a180-43c0-8910-afbaed95729d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ChiefLegalOfficerMember_6b33171c-2d2f-4bdf-babc-d9b2c6239db4_terseLabel_en-US" xlink:label="lab_neo_ChiefLegalOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Legal Officer</link:label>
    <link:label id="lab_neo_ChiefLegalOfficerMember_label_en-US" xlink:label="lab_neo_ChiefLegalOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Legal Officer [Member]</link:label>
    <link:label id="lab_neo_ChiefLegalOfficerMember_documentation_en-US" xlink:label="lab_neo_ChiefLegalOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Legal Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ChiefLegalOfficerMember" xlink:href="neo-20220930.xsd#neo_ChiefLegalOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ChiefLegalOfficerMember" xlink:to="lab_neo_ChiefLegalOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_67f15b92-e07b-4fdd-bcfc-383350e848f2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET (LOSS) INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_edb39d42-4cb7-4d73-83d1-bc1ba84685c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d009c083-8386-478f-b12c-7a9e2f6d9b67_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_76b52bb7-cab7-44c4-8e06-28c9b38d65e4_totalLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, net identifiable assets acquired</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_02c438dc-3f9c-46e7-b906-9abd5ff82487_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental stock-based compensation for accelerated vesting</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Program, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchaseProgramAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:to="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_2615d374-917d-4531-8f3f-9d200c2fca82_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_25eb1867-02a0-4d94-b674-1af39aee12ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a96d844c-5137-4304-9c7d-313a5242fecb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate_31aacb58-daae-4dfd-973e-10148d8fe689_terseLabel_en-US" xlink:label="lab_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investment in and loan receivable from non-consolidated affiliate, net</link:label>
    <link:label id="lab_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate_label_en-US" xlink:label="lab_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Investments And Loan Receivable From Non-Consolidated Affiliate</link:label>
    <link:label id="lab_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate_documentation_en-US" xlink:label="lab_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Investments And Loan Receivable From Non-Consolidated Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate" xlink:href="neo-20220930.xsd#neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate" xlink:to="lab_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_654f97cb-6131-449d-aa2c-db83b9e072b4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_9e7370c3-e56f-4572-83e5-e57bc1f95c17_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b8a154a-d073-4dfe-a66d-d72c43f03678_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0a747083-fd1e-484c-b807-56d51857ee68_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_1921f58f-507c-478e-a304-7bffc72aee55_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_0da1d751-5147-4177-b9d3-9386a8aa1474_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_8c36cae7-5784-456c-a002-a6903214e82a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f75646be-9f6e-45ff-bd9e-d248b8ae7d92_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_6833b8a3-7797-45d0-916b-00ea49eeedd5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_b63f25df-1259-4ce9-91e1-2a78d87918dd_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_37a9a4d6-1ee4-4f10-90b1-33e61041c693_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, operating lease liabilities, deferred taxes, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_993e02e0-f806-4e66-af35-acd2f49039c2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62e03eda-b895-4082-97ac-53ed121232b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2c1f589-4f0b-48fe-a488-876482193398_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_20c4a160-81c8-45e9-8576-682e759e44a0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share-based compensation expense, weighted-average recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_729bc8f9-67ae-4e5e-9768-278a016da0ad_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GROSS PROFIT</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b8fd70bb-3d70-48a7-b9fd-81e74af24178_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3ebb8dc8-bee3-4b44-909c-b72b9d3d8b4f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3a1317d5-57a8-443e-94a3-51965d29c027_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9d1f8df9-9c8d-42f1-b97b-a17671a6c7f7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_746521d3-3772-40a1-8ad2-06004bc1bcb6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock - public offering, net of underwriting discounts &amp; private placement, net of private placement fees (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_797fb7da-d186-48cc-80e3-b9ad11f3daed_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aaf214c0-867e-421a-95ed-d975d0fa4485_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (%)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19_3f948879-b98d-4fb2-ac5a-9834d4a5d734_verboseLabel_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of COVID-19 PCR testing inventory and equipment</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19_342ce0e1-c2f4-4b3a-bd5d-6d9598ac1250_terseLabel_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCR testing, amount recorded, COVID-19</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19_label_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, Exit Costs, COVID-19</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19_documentation_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, Exit Costs, COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:href="neo-20220930.xsd#neo_PolymeraseChainReactionTestingExitCostsCOVID19"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:to="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_3b81559c-fbd0-445b-8f27-9585ef7cf55a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8346e342-d830-4b39-aa26-eafa5825f49c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount_2623a3ae-23f3-4a63-ac64-a922a0bed9a8_terseLabel_en-US" xlink:label="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, accretion of debt discount</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount_label_en-US" xlink:label="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Accretion Of Debt Discount</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount_documentation_en-US" xlink:label="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Accretion Of Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:href="neo-20220930.xsd#neo_InterestExpenseDebtAccretionOfDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:to="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_15fa63f5-ddde-40cb-b6c1-f1f9f0206f98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_126b80ce-9b1b-4bf3-9a01-a9944cb9b82d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock, net of forfeitures</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6b7b3a93-b302-408e-8233-81ad1b05ed32_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_dace7f3e-f263-4c74-9abd-ea185805f56e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8a7c8455-7d7f-4e38-bd2a-fa21c703a6ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_423bde6c-1bf5-41b1-8f43-f7258ebdbccc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of COVID-19 PCR testing inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8098a78d-bdd1-4a8d-957b-16d32183f8f6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_acbcea79-02b0-42a3-b98e-36416a4f04f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e04fe840-7adc-4a60-b484-15f1ee1ec9dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fd332516-1fb7-48d4-9ceb-0385494b5653_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_553d7e1b-543a-40ab-a2c8-bd4f250015c7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_af2735a6-99bb-4f7b-97a3-1a44afeb2f99_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_96af4657-f55a-4b7f-8ca9-2d1e7501ae43_terseLabel_en-US" xlink:label="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, amortization of debt issuance costs</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_label_en-US" xlink:label="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Amortization Of Debt Issuance Costs</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_documentation_en-US" xlink:label="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Amortization Of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:href="neo-20220930.xsd#neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:to="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_adfcbd63-1a9f-4f69-a586-f286dfe362b0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d678cc62-d4af-4702-b1cb-121d4fd46c48_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_adc0e35c-667a-4435-9280-2386f0a35e4c_terseLabel_en-US" xlink:label="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square feet owned (in sq ft)</link:label>
    <link:label id="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_label_en-US" xlink:label="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Held For Sale, Square Feet Of Facility Owned</link:label>
    <link:label id="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_documentation_en-US" xlink:label="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Held For Sale, Square Feet Of Facility Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:href="neo-20220930.xsd#neo_AssetHeldForSaleSquareFeetOfFacilityOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:to="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_01a47d0a-4866-49aa-be01-ab45dfd6d769_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_e7042389-7d97-4361-98f6-172b4f85fe7a_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_ef96a143-5290-47cb-a874-aae376a66f79_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_05867d30-ba53-47a5-9f15-b2de6efac0eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1d51c1fe-b3d8-4c00-b985-779e7ab36bf6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2d24530e-8c69-486e-9277-04b05fa90ffa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_4bf6002e-42cb-471c-9c1a-1d830842712d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e4e4e568-9168-4115-82bd-561e1ce6e815_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_fd1e4e1a-dd6e-4af4-bc56-27e315acf5d7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_249f2e09-caee-4537-86c6-57ad97ecb9f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_d542db32-7a10-4119-ad7f-31c2c4db3cb2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1bba6875-98a8-4f28-9088-f6ffdd800954_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3dd77298-61b1-4b13-8c43-3d51630d2221_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5005cde6-6977-4584-934d-aaa8a4781b2f_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_1ccbdd3d-6e2f-4786-9c03-92b8352b64a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ce653daa-60c6-496a-adfc-b99402ac5a65_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_b36be3d0-d155-4230-99fc-4965f0678df6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_be9a1e02-5c78-4ed8-b4b4-399ea17fe04e_totalLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pharma capitalized commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ContractualObligationTable_f4381bbd-6b09-4b87-8975-a445f78d3508_terseLabel_en-US" xlink:label="lab_neo_ContractualObligationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation [Table]</link:label>
    <link:label id="lab_neo_ContractualObligationTable_label_en-US" xlink:label="lab_neo_ContractualObligationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation [Table]</link:label>
    <link:label id="lab_neo_ContractualObligationTable_documentation_en-US" xlink:label="lab_neo_ContractualObligationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationTable" xlink:href="neo-20220930.xsd#neo_ContractualObligationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ContractualObligationTable" xlink:to="lab_neo_ContractualObligationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_c39c8ce3-3f67-4911-b0ef-84bdd741a8f2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_c94f2761-d345-4128-b8f8-1e9475aa2d09_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_93a49f87-704b-44ec-9f06-048a63ad2c58_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f342ec5c-e797-4d1a-aa95-4caf04be2235_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7a898a22-bffa-4508-ba9d-31515e3de120_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_21a66c36-9b8a-407d-8e29-f545ae35cce6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_fa339adf-09fc-49c2-9fcd-6e4317959e5b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a62e481-6a2c-432f-9722-8c570a6eb357_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_dd47f9d0-95c1-4fb7-af3d-29871df51f19_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_adf2b66e-6550-4567-9c2e-4cfd8f04c53b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_b41213cb-b5c1-425b-a330-70522f1cbba2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a57a05bc-9254-4541-a042-ab3d44dcd51e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_6ac33a32-5fce-4dbe-a74e-f6235567747c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_662c3b5d-4957-4c6f-a6c8-f4215c11a60f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1ff17d05-4734-45b1-9107-0c3ab86dad7d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_370443d2-2cdb-46f9-8ade-15a919ed6706_terseLabel_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCR testing, write-offs, COVID-19</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_label_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, Write-Offs, COVID-19</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_documentation_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, Write-Offs, COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:href="neo-20220930.xsd#neo_PolymeraseChainReactionTestingWriteOffsCOVID19"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:to="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0aef413b-30d8-4811-8d1a-cb08edad501e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_b3f48090-16b7-4931-8c16-bb4d95719781_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_08a75bca-c5f3-4484-9a9b-1256b4809a35_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, fair value of Purchase Option</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2b33c10c-b4af-4249-adcc-b9ac3edaaa64_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_2c19572b-50a6-4ac5-9765-f3c30a6a042d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c3ed29c5-ee41-4ca7-a59e-a1453f5d66f3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_31402904-88b2-44fa-a202-8dfda5ad4e84_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fcbfc606-4efc-4779-a5c2-570ed8fdda6b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2b010f5a-172c-46a1-9b25-e0e19b00e24b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6294cb30-03ef-4921-ae78-aa31cc94c3be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_9b945c64-129b-4511-9243-ee2da73667f8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, fair value of previously-held equity interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b7fcb2d8-3e93-4d37-92ca-dc5c4d5d3841_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestExpenseDebtContractualCouponInterest_2ba49023-0fb5-48eb-a55e-d16851b3178e_terseLabel_en-US" xlink:label="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, contractual coupon interest</link:label>
    <link:label id="lab_neo_InterestExpenseDebtContractualCouponInterest_label_en-US" xlink:label="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Contractual Coupon Interest</link:label>
    <link:label id="lab_neo_InterestExpenseDebtContractualCouponInterest_documentation_en-US" xlink:label="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Contractual Coupon Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtContractualCouponInterest" xlink:href="neo-20220930.xsd#neo_InterestExpenseDebtContractualCouponInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestExpenseDebtContractualCouponInterest" xlink:to="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b23a09fb-94d0-4ac2-a963-dd50e282059d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c7df1c37-bf41-491e-9619-a84e753c51bb_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f8286887-4091-4508-97f1-3040fa3217e4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b8745af6-1ab5-46fc-b78e-1edebaf87bf3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_194facfa-0654-47b1-953f-631af934c598_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7fa79a6d-3498-4f3e-83ee-ed04a8cb1ffb_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademark - Indefinite lived</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_7307012c-f998-4cb9-8280-fd341ae32ac2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_54138196-ef6b-4a6b-aade-f1387968cc58_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term pharma contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8cd36268-5a9b-4da6-8a8e-3f17fa1b9f74_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_0e879086-7c5b-41ae-b94f-8bbf4c9e2b05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_7e9df3c8-8b65-41c2-b5db-b40a2404e13d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_83b1e503-35b4-4e37-9cd9-8b9a80a7d1e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8f6587a0-a6f4-4b10-87fb-ae7dc9caf5a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2f829b90-d92b-4cb0-9d5b-ce240729a8ad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_bf9b72a9-899f-4bd6-8f4f-a8a2806aa660_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2d92e2e8-8879-47e7-ba3b-503627ac822a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_083d1c57-2511-4078-85da-2eb9b0b574a9_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_ffbe1fc1-e230-423a-9067-5c7167b74cb3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Line of Credit</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f67cd65c-431f-4a46-8e4f-691151691abd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_YankeeBondsMember_4cabd22d-9e5c-4955-9dd6-cf2303213afa_terseLabel_en-US" xlink:label="lab_neo_YankeeBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee bonds</link:label>
    <link:label id="lab_neo_YankeeBondsMember_label_en-US" xlink:label="lab_neo_YankeeBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee Bonds [Member]</link:label>
    <link:label id="lab_neo_YankeeBondsMember_documentation_en-US" xlink:label="lab_neo_YankeeBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember" xlink:href="neo-20220930.xsd#neo_YankeeBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_YankeeBondsMember" xlink:to="lab_neo_YankeeBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_60cffb4d-00c3-447e-9766-5bdc9acb558e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_e1a8b25c-8a6a-4311-9732-ab6fb578537b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_1927fb84-0524-4bca-8b88-101a590d3ad7_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6ef4a646-bae3-4057-80d6-85c087eccbdf_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_42b307d7-a930-4cd8-accc-585bc09e715a_terseLabel_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes</link:label>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Two Five Percent Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Two Five Percent Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:href="neo-20220930.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:to="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_79ee5eff-124e-4b0e-b7cc-1a4b880234c6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a97e0bc2-8f05-4a7f-af92-f6f13031ec0c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_011239b3-fbdf-48db-a31f-eb2b7f01b1a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d2d0f0d9-cf13-45e8-b371-671e8fd2cb84_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_332b9dd7-a3f3-4f5a-ac30-50724a8f760b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a1420f38-2ccb-43a7-8caf-5b29d9cda626_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f89dd9d9-639b-42c7-ada6-5b14bda91c61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f04d5297-41e0-4e77-bb26-82fba031dacf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_6ce73bce-fc1c-4e1d-89c5-baec3d4223d2_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b35c84a1-d1e2-43cc-80a2-c56f79630ec4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_ef28a215-7eb7-4017-8ff4-a6ddbcc54ee5_terseLabel_en-US" xlink:label="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Asset Amortization Expense [Table Text Block]</link:label>
    <link:label id="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_documentation_en-US" xlink:label="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Asset Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:href="neo-20220930.xsd#neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:to="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_ddf1d283-df71-4a4a-95f4-6e514919cd33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d7e87ee7-df8c-49a3-afa3-7f15248374d8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c5d53cfd-10a1-4c17-9367-add05097a0df_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fcb7c1bf-e4a2-4ce5-83f6-f23957c7c2a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_bb882d08-3b0c-454b-92c7-0bfc75382089_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract_f5218c01-bfaf-40e0-a233-1960db7f1a72_terseLabel_en-US" xlink:label="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Reduction in Options Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Reduction in Options Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:href="neo-20220930.xsd#neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:to="lab_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f6683ad3-5307-4f51-a4f9-442c53a4d841_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_de262f65-c691-48c9-8a1f-f3f49115c6a8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities_77343f52-367e-4990-95f2-24d1b9dd160e_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, deferred income tax liabilities</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Deferred Income Tax Liabilities</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_45d4ac6c-47bb-4d08-81e3-a99f8c1c545d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3624fd09-5081-4ff6-8d47-4ea0162ae6c5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6fecc779-24e2-4f20-b55e-3dc26044a8c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ad366943-239d-4908-98c3-7f0140f08b66_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_daf5f376-6299-4103-86fe-aae89f66612a_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_759a1431-0b3e-47bc-88d9-2004067e99fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_f6c4b155-a5bf-41c1-b2b0-6bce41486113_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b2182560-28ac-4a79-9854-ac79b09f3ff4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net (loss) income to net&#160;cash&#160;used in operating&#160;activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_fb2c6f7d-1a40-426b-8217-be33abcc309b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d04149b9-648b-4fe9-a657-418d3e4372c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fdfdf438-a25f-4f95-becd-41c515213541_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_27369bf5-c877-45fb-938e-0d27352f2f06_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6b346f37-9a69-420c-a458-8edcfe4fad48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_88b916c4-a451-4ab1-86bc-1d157c57a02b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_COVID19PCRTestingMember_c9227920-3237-40cf-b67b-9ab98116266f_terseLabel_en-US" xlink:label="lab_neo_COVID19PCRTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PCR Testing</link:label>
    <link:label id="lab_neo_COVID19PCRTestingMember_label_en-US" xlink:label="lab_neo_COVID19PCRTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PCR Testing [Member]</link:label>
    <link:label id="lab_neo_COVID19PCRTestingMember_documentation_en-US" xlink:label="lab_neo_COVID19PCRTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PCR Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_COVID19PCRTestingMember" xlink:href="neo-20220930.xsd#neo_COVID19PCRTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_COVID19PCRTestingMember" xlink:to="lab_neo_COVID19PCRTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f168fa3e-1c70-43b9-b39a-c67663c7994c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CommercialInsuranceMember_280b697f-4e8d-4f91-b805-5b3acbeb9d05_terseLabel_en-US" xlink:label="lab_neo_CommercialInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Insurance</link:label>
    <link:label id="lab_neo_CommercialInsuranceMember_label_en-US" xlink:label="lab_neo_CommercialInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Insurance [Member]</link:label>
    <link:label id="lab_neo_CommercialInsuranceMember_documentation_en-US" xlink:label="lab_neo_CommercialInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommercialInsuranceMember" xlink:href="neo-20220930.xsd#neo_CommercialInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CommercialInsuranceMember" xlink:to="lab_neo_CommercialInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_c5cf270e-b49c-4c24-b6fb-b87137a5f54b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e6c777af-c46d-4d8d-84e7-546beb0d8d17_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COST OF REVENUE</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d63447b1-7762-4762-b096-5073680dcd02_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb99297a-7409-4cd5-8ed9-6d8a838bca7f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c7f816f5-10e1-4156-adfd-fdc5cc5294a7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_44046342-ccad-4802-a47f-2f2558ce255d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_52101317-1fc6-41d0-b1c6-68346f50572b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7ef6ba1d-0c15-4be5-92b5-f99fb33b0b94_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_089fe285-5448-4e27-ab4d-954ca96c1a95_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_6ddc2c9c-fadb-43a1-80de-fcbc80fe9172_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1402adb8-9c5b-4c3d-a83e-993cbb33c2cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_79e49b7b-0801-455a-afd1-026d7df60dc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_c9bc48e2-b331-41fa-aadd-2472db7c9a67_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9a014d09-0b36-40ad-9e44-e9787b43fda8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_81255a04-5402-40b3-b9cc-10e2a9954cc9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_36877afe-a760-4798-a1a9-4d1b17ff1de8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_5e14db91-cc85-48d3-9f06-72ed03277b76_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_662f4465-1112-4e83-aa82-8f366a45663c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investment in and loan receivable from non-consolidated affiliate, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_94176268-86d1-45c4-a83e-9739564684eb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_61658777-8071-452a-846a-8f2605e0b829_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_abcbbbc8-d5ad-422f-a7f0-172cbb59a13d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0850a867-e881-46e2-b441-3928607a11d4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct_ce4f51a8-1f50-465e-ac14-bbba198d33a4_terseLabel_en-US" xlink:label="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, deferred social security payroll tax</link:label>
    <link:label id="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct_label_en-US" xlink:label="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:label id="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct_documentation_en-US" xlink:label="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:href="neo-20220930.xsd#neo_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:to="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2d492156-65bf-424f-911a-5ff5fdc53dca_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments an Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_57715808-2357-4525-b54a-ab0077c3bc97_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c6f724fc-253d-4e21-977f-97e388adc32a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4be77251-13df-4ba9-9b8f-1b8cca2092a2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET (LOSS) INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionOtherMember_8db1ebcf-bab8-40dc-9085-a434b2778d61_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Other</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionOtherMember_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionOtherMember" xlink:to="lab_us-gaap_ErrorCorrectionOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_9d9c2ac5-6816-4b8f-92bd-c651c7577493_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, at fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_d9ee483d-340f-43a2-8eff-516ae3ff5d54_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_73136222-bfbb-4faa-b759-abd6da083a92_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_addc6cf8-bc44-411d-955f-159fd15f53aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ClinicalServicesMember_49fc7b2d-521d-4bde-bf58-f3c4ed2508fe_terseLabel_en-US" xlink:label="lab_neo_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services</link:label>
    <link:label id="lab_neo_ClinicalServicesMember_label_en-US" xlink:label="lab_neo_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:label id="lab_neo_ClinicalServicesMember_documentation_en-US" xlink:label="lab_neo_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ClinicalServicesMember" xlink:to="lab_neo_ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations_c6a5b695-f49e-4dee-bdc4-0c4e0608ccbe_negatedTerseLabel_en-US" xlink:label="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums paid for capped call confirmations</link:label>
    <link:label id="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations_label_en-US" xlink:label="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Premiums For Capped Call Confirmations</link:label>
    <link:label id="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations_documentation_en-US" xlink:label="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Premiums For Capped Call Confirmations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:href="neo-20220930.xsd#neo_PaymentsOfPremiumsForCappedCallConfirmations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:to="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_55a6292b-29eb-434c-a37d-06127cda3f4e_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_b2a79412-ceee-4d6c-884e-db66e716a61b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_198e80e7-522c-4abf-bf3f-5162272e7aba_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9fa5cdf3-7b22-493e-86e2-111e339b2fb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_149e3cb9-ad31-43fc-b464-0b0f0b87ba97_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of equipment financing obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b01ec8b5-7abf-4362-8ddb-e851322eae66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_133c64f2-8c86-4c7f-b6cf-14341811d94d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_35b6197c-2eae-433f-9ee3-17e65c9ed41b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_60287211-d975-43b7-8b79-c1c3b84bfc21_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_84080b5f-a2e9-4e32-a2cd-0e08f1d1140d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_55e61e4f-7477-4309-b620-c838a726fbb0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuance ESPP Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SelfPayServicesMember_fe1f849c-b37f-47d1-8893-1e7b7112c80f_terseLabel_en-US" xlink:label="lab_neo_SelfPayServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay</link:label>
    <link:label id="lab_neo_SelfPayServicesMember_label_en-US" xlink:label="lab_neo_SelfPayServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Pay Services [Member]</link:label>
    <link:label id="lab_neo_SelfPayServicesMember_documentation_en-US" xlink:label="lab_neo_SelfPayServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Pay Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SelfPayServicesMember" xlink:href="neo-20220930.xsd#neo_SelfPayServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SelfPayServicesMember" xlink:to="lab_neo_SelfPayServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_6c71a30c-a333-4a08-a9c0-7db93f4d1005_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of previously-held equity interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5e491f06-f9cc-4891-9812-ebaa03ec578d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPREHENSIVE (LOSS) INCOME</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_affce099-f4eb-4ecb-ae03-3e3fc1f1da99_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_456b7645-4970-4069-bd3f-15dd59839276_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current pharma capitalized commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_4fe1842b-a1d6-4aa1-a947-3d2d980c6212_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_FederalHealthcareProgramRevenueMember_aa7be78c-f383-4016-a934-b3cb2de318dd_terseLabel_en-US" xlink:label="lab_neo_FederalHealthcareProgramRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Healthcare Program Revenue</link:label>
    <link:label id="lab_neo_FederalHealthcareProgramRevenueMember_label_en-US" xlink:label="lab_neo_FederalHealthcareProgramRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Healthcare Program Revenue [Member]</link:label>
    <link:label id="lab_neo_FederalHealthcareProgramRevenueMember_documentation_en-US" xlink:label="lab_neo_FederalHealthcareProgramRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Healthcare Program Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FederalHealthcareProgramRevenueMember" xlink:href="neo-20220930.xsd#neo_FederalHealthcareProgramRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_FederalHealthcareProgramRevenueMember" xlink:to="lab_neo_FederalHealthcareProgramRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_753dbbbf-5e43-4dbe-8688-4d913dc341ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_107cfc39-b0f1-4096-8e61-b030a45423a8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_42e8db6c-f3b5-47b9-98a2-8717d61ca4db_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ContractualObligationLineItems_62b6c560-c99a-4bcd-b91c-accd979bdd53_terseLabel_en-US" xlink:label="lab_neo_ContractualObligationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation [Line Items]</link:label>
    <link:label id="lab_neo_ContractualObligationLineItems_label_en-US" xlink:label="lab_neo_ContractualObligationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation [Line Items]</link:label>
    <link:label id="lab_neo_ContractualObligationLineItems_documentation_en-US" xlink:label="lab_neo_ContractualObligationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationLineItems" xlink:href="neo-20220930.xsd#neo_ContractualObligationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ContractualObligationLineItems" xlink:to="lab_neo_ContractualObligationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_80c7039c-acb5-4494-9a7d-291405309fb3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_5105bdad-eb09-4cb3-b5b4-cc7112c00ba4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in goodwill from deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_706899a7-3b8b-4798-bc14-c8240f4bf812_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5c42368e-f890-42de-aa71-a4cbc6606d27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d90101d0-c196-487b-a440-9c8d1ae926a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_bb2b6528-733f-43e2-9686-9a4db841ac42_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_f9101e78-e84b-4ddb-bec4-f4f3bf7ce70d_terseLabel_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes</link:label>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:href="neo-20220930.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:to="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_1c08c076-a81a-4878-878f-08ba7b656ff2_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_a70a4d78-ff0d-4b65-bb15-870aef706a53_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term pharma capitalized commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0d2a6823-bf04-431a-83ba-c649aa322199_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuance ESPP Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3d522a99-a4cb-4812-ae53-27ed479a128a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e19656ca-d368-430a-b416-5c59ac3a73d0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_422d5ce0-8324-48f9-b542-eabf76d4ff18_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_8a8fed2c-a448-4d10-b3dc-5b16b8c92039_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e2d1d70d-ee0a-4346-9b46-57a9c1765f01_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_843dc9e3-dd2f-4a4c-9139-1b47cc1b4c8d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a0bbd3be-d55d-47bf-a6ba-3287bf61cbb8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment (net of accumulated depreciation of $125,018 and $109,952, respectively)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent_41156a21-c113-454d-bfb4-c9712c1967d1_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, current liabilities</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities, Current</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_35c66462-a737-4a5a-a21e-4fbd75fb2a0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_GainLossOnInvestmentAndLoanReceivable_6cb6923d-c0b7-494d-8d57-893c22d92d51_negatedTerseLabel_en-US" xlink:label="lab_neo_GainLossOnInvestmentAndLoanReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investment in and loan receivable from non-consolidated affiliate, net</link:label>
    <link:label id="lab_neo_GainLossOnInvestmentAndLoanReceivable_label_en-US" xlink:label="lab_neo_GainLossOnInvestmentAndLoanReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Investment and Loan Receivable</link:label>
    <link:label id="lab_neo_GainLossOnInvestmentAndLoanReceivable_documentation_en-US" xlink:label="lab_neo_GainLossOnInvestmentAndLoanReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Investment and Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable" xlink:href="neo-20220930.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_GainLossOnInvestmentAndLoanReceivable" xlink:to="lab_neo_GainLossOnInvestmentAndLoanReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e5cd5b24-d3ab-4473-8640-20d94b69885f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_854dffcb-dced-4bde-b176-59d14b3722ad_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_959fde3f-3384-4a3b-8165-3d3d690e6234_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (%)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_4c18ee75-6d80-4142-9bf0-b5dc92188c8c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_1abc388b-f9ef-4c5c-b76c-526cd0a67083_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of assets held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_26d5f60b-ec9b-41fc-abdb-f1c939264ca4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_abbdfd14-c8a3-4fc2-b80e-83f6553fe49c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5bc6dde1-6668-4ba4-950f-f8f3c7106ddd_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_ec206516-31e6-4cb3-ab81-ca6f0179453a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in minority interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest in Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:to="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8a8e75bb-54a1-4134-a59b-abb284b041d3_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_42f9fac0-3005-4dc4-91a1-aafd01b95b40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_0bf4780e-3f6c-4fc4-aa41-3c5a920b8578_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_bd4d22c3-8a85-445e-a4e1-4c56555ec7a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8bfa160-b235-4720-96f6-ea3050d349e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d65412f8-2ffd-444a-a78a-cdaa9088acdd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9fbd0750-2af2-444d-9c3c-3d37207b0222_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f5e908ad-5f3d-4f00-9d5e-f61225c1f5af_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CappedCallTransactionsMember_d86077bd-9943-4cbb-82c7-0db39ff46783_terseLabel_en-US" xlink:label="lab_neo_CappedCallTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions</link:label>
    <link:label id="lab_neo_CappedCallTransactionsMember_label_en-US" xlink:label="lab_neo_CappedCallTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions [Member]</link:label>
    <link:label id="lab_neo_CappedCallTransactionsMember_documentation_en-US" xlink:label="lab_neo_CappedCallTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember" xlink:href="neo-20220930.xsd#neo_CappedCallTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CappedCallTransactionsMember" xlink:to="lab_neo_CappedCallTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_MedicareAndOtherGovernmentalMember_1c5fdc85-8ae5-4bb4-867f-7bea64390d02_terseLabel_en-US" xlink:label="lab_neo_MedicareAndOtherGovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicaid</link:label>
    <link:label id="lab_neo_MedicareAndOtherGovernmentalMember_label_en-US" xlink:label="lab_neo_MedicareAndOtherGovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare And Other Governmental [Member]</link:label>
    <link:label id="lab_neo_MedicareAndOtherGovernmentalMember_documentation_en-US" xlink:label="lab_neo_MedicareAndOtherGovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare And Other Governmental [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_MedicareAndOtherGovernmentalMember" xlink:href="neo-20220930.xsd#neo_MedicareAndOtherGovernmentalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_MedicareAndOtherGovernmentalMember" xlink:to="lab_neo_MedicareAndOtherGovernmentalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c0f59b35-35ac-4f29-86f2-f9d09c4c9cb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_05c984bf-50c0-4655-b259-338b5d3d406e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8bdeb8b1-8cd1-4292-8584-513c1b9f3d3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3964c00b-305e-49e8-81f0-09bb56de99c6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_e6d6ce0f-7599-476c-baad-bba72ad9c7d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1326e058-fe07-46f9-8523-21dc5ec207fb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma contract liability, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_f3c0dac8-8303-48a1-a57f-2f9b0e8c87e3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_ba86a612-4e8d-4644-8648-beb8361331f8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1c4fe36e-3daf-4da0-935e-d2f6a1a32bbb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_cd36d9b1-5f11-4f9b-8dcb-cef5c3d78c98_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_0ff9137b-85f6-4e81-ae4c-4b9c75d7ca39_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c0dfcb3f-8df9-4894-bdf1-0badf7c003df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_492b56c9-e49c-4319-8127-a67c91fe7b09_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7160d1c3-3126-4024-b79e-1bc5cb32d650_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_02841818-63f2-42b1-b188-bc3b460e8ee5_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_8432eb0a-abc5-4a4c-942b-1be60d9fa577_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_66ed8421-62c6-41f9-8da1-6747b8096a7a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1bdca65c-11a9-43f4-a789-ce674debccb1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0670c097-d20b-42ae-8c7a-760b5b92d739_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days (in days)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_b8eaa8a9-a5c1-458b-a803-cd230a067e4a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of convertible debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_71d94469-fb0c-4fbb-b454-986efeaf5b05_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f2d0d054-69d4-485d-b140-5b3bff9bc263_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7951609b-de78-41c3-ab58-ef98e22139b8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_bdff5092-a009-4f7d-a7f6-1bcb2f830485_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_e98ae544-1b46-4141-b4d0-79fe0554897f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_899ec1f8-5800-42aa-9877-fef407e5251d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock_b21acc86-8009-4413-ab88-3cf988155478_terseLabel_en-US" xlink:label="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held for Sale</link:label>
    <link:label id="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock_label_en-US" xlink:label="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held For Sale, Policy [Policy Text Block]</link:label>
    <link:label id="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held For Sale, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:href="neo-20220930.xsd#neo_AssetsHeldForSalePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:to="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_b305add2-72f7-4f6e-b6b2-f34c52ad21b0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_c3212f1f-b1e1-48cb-94b7-392210037080_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Classes of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_465fdd88-cc61-47bd-9719-0799c7b80142_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c9ed7f41-8360-44ff-b0aa-1d943a6552cb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3164997d-a911-4d95-ae10-35736e9abf33_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_b1761fce-a5a2-4896-ac27-112153f7ae40_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9daff730-03fb-47b8-a307-05e6133ae820_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56614047-6c25-4680-ae73-740bd877c4d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_211ffdfc-59b5-4b20-a146-31d107442bed_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PharmaServicesMember_a318dbb5-97ee-4bac-ae26-dbad2d059515_terseLabel_en-US" xlink:label="lab_neo_PharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services</link:label>
    <link:label id="lab_neo_PharmaServicesMember_label_en-US" xlink:label="lab_neo_PharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services [Member]</link:label>
    <link:label id="lab_neo_PharmaServicesMember_documentation_en-US" xlink:label="lab_neo_PharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PharmaServicesMember" xlink:to="lab_neo_PharmaServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_3835dd3b-9943-4cc7-ad52-eed0c3b1bd12_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_a0e1aab3-dca1-4932-bc0f-435f57c58d6c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_b9c46b51-e9ba-47fa-9f91-ada15b911d7e_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7923ee36-d962-43cc-8afb-eddffb18af9b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_08816d4f-278e-41c0-9521-7f77503c11ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price on applicable trading day (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_777ca29e-819b-4146-9b74-4417f5d7b0df_negatedTerseLabel_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums paid for capped call confirmations</link:label>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_label_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt</link:label>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_documentation_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:href="neo-20220930.xsd#neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:to="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_3e9c2b2a-9574-4b0a-a49f-56d1136cfda3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7bcd1766-5daf-4673-8970-857dc5f4d965_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income (loss) per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_92aad1d3-0189-417e-9195-7b1dd8fa4a8a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_95bcf763-86fd-4e9d-89ba-77c2fff75d2b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3fc0a585-b19b-4974-9abe-5b73d4f5dee3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e3e1fc05-9dce-49cf-8b25-b6ae1368781b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_a3c7ab14-6e4a-4986-8378-22181d0b363e_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of purchase option</link:label>
    <link:label id="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_label_en-US" xlink:label="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Purchase Option, Fair Value</link:label>
    <link:label id="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_documentation_en-US" xlink:label="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Purchase Option, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:href="neo-20220930.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:to="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_3f5c08c2-33c0-4b09-b046-9a1320480b60_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ClientDirectBillingMember_1e1e3b58-f1bd-4b9a-8871-bf4266d8df90_terseLabel_en-US" xlink:label="lab_neo_ClientDirectBillingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client direct billing</link:label>
    <link:label id="lab_neo_ClientDirectBillingMember_label_en-US" xlink:label="lab_neo_ClientDirectBillingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Direct Billing [Member]</link:label>
    <link:label id="lab_neo_ClientDirectBillingMember_documentation_en-US" xlink:label="lab_neo_ClientDirectBillingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Direct Billing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClientDirectBillingMember" xlink:href="neo-20220930.xsd#neo_ClientDirectBillingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ClientDirectBillingMember" xlink:to="lab_neo_ClientDirectBillingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_0cce7574-3fea-423b-bd3e-44508e9d41b4_terseLabel_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCR testing, general and administrative expenses, COVID-19</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_label_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_documentation_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:href="neo-20220930.xsd#neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:to="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d89e9b28-c6d0-4173-94b7-1b089ef5dbcf_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense (gain)</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e69ecc33-47dd-4583-b728-d0d7c6b1303d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_849d3956-06ca-44fc-868d-a90112b8cb94_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a0e0ea2b-5402-4fa2-8a15-ac01cc45f86e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_178a06f8-57e6-4489-8b29-e473b745c57b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_647c012e-9528-4107-8bae-14f7437a09f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_980504aa-eea1-4e88-94b2-ebd5f4358ac1_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period of acquired intangible assets (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_766605c1-0e32-4b7d-9e3b-2694f7eae8d3_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Period (years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_762d2ea8-da41-477d-a567-5edde867e619_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_94add245-7c01-496e-afcd-b89c01b36c7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_92967be0-00a9-4526-aa67-3e3a0edaab3d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles included in general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_IncreaseDecreaseInPrepaidConstruction_4b88cd69-33ad-4326-ac79-c6529bdcc8e1_negatedLabel_en-US" xlink:label="lab_neo_IncreaseDecreaseInPrepaidConstruction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid lease asset</link:label>
    <link:label id="lab_neo_IncreaseDecreaseInPrepaidConstruction_label_en-US" xlink:label="lab_neo_IncreaseDecreaseInPrepaidConstruction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Construction</link:label>
    <link:label id="lab_neo_IncreaseDecreaseInPrepaidConstruction_documentation_en-US" xlink:label="lab_neo_IncreaseDecreaseInPrepaidConstruction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Construction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncreaseDecreaseInPrepaidConstruction" xlink:href="neo-20220930.xsd#neo_IncreaseDecreaseInPrepaidConstruction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_IncreaseDecreaseInPrepaidConstruction" xlink:to="lab_neo_IncreaseDecreaseInPrepaidConstruction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_82012f69-2b74-4c73-a145-1419f0ad906b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f59d9abf-528b-40b7-83ab-b9285f614cb7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock at Trapelo Acquisition Date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_4f1a83bf-42a5-43cc-8505-9835cb1c912a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_51f2f632-9239-4705-a9f8-c91d6f0263fb_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_528323b1-0f47-458a-8d6b-f8acfb0b073e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_810b7ef8-a800-47ea-b55c-5581c525a1ce_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fce2c970-aac4-410f-975b-7ea4fb807925_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_cbdf8ca2-ddc4-4d04-9f41-eb2512da0ef5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_e8f71e5a-16d0-463b-a63b-07a6e774fe56_negatedTerseLabel_en-US" xlink:label="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable on loan receivable from non-consolidated affiliate</link:label>
    <link:label id="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_label_en-US" xlink:label="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable With Imputed Interest, Non-Consolidated Affiliates</link:label>
    <link:label id="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_documentation_en-US" xlink:label="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable With Imputed Interest, Non-Consolidated Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:href="neo-20220930.xsd#neo_ReceivableWithImputedInterestNonConsolidatedAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:to="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a641e146-fcbc-46e5-9751-94a9d4145cc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (%)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f8b14949-a0da-4c92-876c-e6b6fcf197fe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_25e8a213-8359-43fc-9bc8-9d27e771d78c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property Held-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_44909074-10c9-4e70-9340-e14c3a22ba7a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issue costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_60eef79c-3f87-48c7-af6e-10fb91b57799_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_92b27605-7a1a-4e86-bbba-13fa1754f3a7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_51bd7508-b708-4992-885d-bbb6c8d99640_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_67cdc4ee-a222-48d1-b60d-8a8fa03c0a98_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of stock options and restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f34db210-1c18-4d46-910f-ec9ac2d4bffb_negatedNetLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c5abbfb6-501c-49f6-9390-cd63dc083805_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_dbd22e56-f441-43f0-8144-3fd17b85bd06_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus: Cash paid at closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7d680263-cb25-40bb-83eb-d082edae6366_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_55a34a86-ef3c-4d8b-93cb-4d1c140a1111_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b17cedfa-b01f-4b0b-87a0-28e984ad5cea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e702dd66-a8e1-4dac-b5e9-6b88605ac426_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_839277fb-711f-4686-af86-50974628666d_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, total identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0db4cb5a-ba2a-452f-ba4a-cffa92c3b596_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_f6c17fee-b63a-43fd-8933-65ed42b47162_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7f771c19-1730-406b-b774-f1dacd572e1e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_abf85190-44b7-41b2-b61a-6b0ed8a6388f_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_92abf72b-c8d1-4bdb-9ebe-7d9305f65662_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d4942d45-1596-4310-9d00-9f320dd838c3_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of property</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b106c355-00dd-4b4f-b9e4-cfda6f9db99c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense - options and restricted stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAbstract_6c9fa9b3-0de7-47a4-9d07-a096064d2fe7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract" xlink:to="lab_us-gaap_CapitalizedContractCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ca38a3ff-2201-4d0f-a4c1-a959201034b7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_63106dfb-0a34-4295-ba5d-4099269283c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0c1fbaee-ccc5-476c-b348-beec23af3f1c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative-effect adjustment from change in accounting principle</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_09c9a915-09eb-448a-9aed-c11c8fc2cc43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a163de3e-5cc9-4b7d-99ea-3cbf030bfdab_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_4db4a4e6-7fde-4743-8f5f-945e7dae1a84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_f5ab2d96-bbbd-48f0-b2ed-0b2dd5a35e38_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid to other shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d8197bf8-14a2-4f7e-8fc8-d5538cbdc458_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_822dca5d-e4e8-4763-8187-9514cfb1d83d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_57dac9fb-f636-4563-bc92-e4761fa2074b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable from non-consolidated affiliate</link:label>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Fund Long-Term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_87895cc3-2a16-492f-ad4d-3a12af93dc5a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_91f865d5-77b4-4a39-a321-074a585b76d6_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_b831f1c6-040f-4f22-8871-a52ad881c515_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_StrategicAllianceWithInivataLimitedMember_477592f0-a999-4b12-90a6-4281f50cf097_terseLabel_en-US" xlink:label="lab_neo_StrategicAllianceWithInivataLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliance With Inivata Limited</link:label>
    <link:label id="lab_neo_StrategicAllianceWithInivataLimitedMember_label_en-US" xlink:label="lab_neo_StrategicAllianceWithInivataLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliance With Inivata Limited [Member]</link:label>
    <link:label id="lab_neo_StrategicAllianceWithInivataLimitedMember_documentation_en-US" xlink:label="lab_neo_StrategicAllianceWithInivataLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliance With Inivata Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StrategicAllianceWithInivataLimitedMember" xlink:href="neo-20220930.xsd#neo_StrategicAllianceWithInivataLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_StrategicAllianceWithInivataLimitedMember" xlink:to="lab_neo_StrategicAllianceWithInivataLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ProceedsFromEquityOfferingNet_dd5931a0-c6c3-4996-b339-576a7c8344fa_terseLabel_en-US" xlink:label="lab_neo_ProceedsFromEquityOfferingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity offering, net of issuance costs</link:label>
    <link:label id="lab_neo_ProceedsFromEquityOfferingNet_label_en-US" xlink:label="lab_neo_ProceedsFromEquityOfferingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Equity Offering, Net</link:label>
    <link:label id="lab_neo_ProceedsFromEquityOfferingNet_documentation_en-US" xlink:label="lab_neo_ProceedsFromEquityOfferingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Equity Offering, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ProceedsFromEquityOfferingNet" xlink:href="neo-20220930.xsd#neo_ProceedsFromEquityOfferingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ProceedsFromEquityOfferingNet" xlink:to="lab_neo_ProceedsFromEquityOfferingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_68ba6b01-58c9-41e9-880c-3f095639996d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_007964e4-d8a2-4513-968c-051c5502fa60_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5aad8236-2c75-4196-9043-20958ec62878_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_013ea5a7-ce31-4ee9-bd38-1be3858ec068_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f30098ae-1e21-43a2-b399-f74ee784cc2d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5b0aa58b-5c17-4118-af27-d49e1a7fdbd6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e96897e4-db88-4120-98db-8ae5450de8fb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet_f365ca2c-2e78-4afa-9b25-0e564a0a181a_negatedTerseLabel_en-US" xlink:label="lab_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investment in and loan receivable from non-consolidated affiliate, net</link:label>
    <link:label id="lab_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet_label_en-US" xlink:label="lab_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Investment In And Loan Receivable From Non-Consolidated Affiliate, Net</link:label>
    <link:label id="lab_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet_documentation_en-US" xlink:label="lab_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Investment In And Loan Receivable From Non-Consolidated Affiliate, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" xlink:href="neo-20220930.xsd#neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" xlink:to="lab_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_TrapeloHealthMember_1e7a3dba-65f2-4613-af35-1f0a7a7b66ff_terseLabel_en-US" xlink:label="lab_neo_TrapeloHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trapelo Health</link:label>
    <link:label id="lab_neo_TrapeloHealthMember_label_en-US" xlink:label="lab_neo_TrapeloHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trapelo Health [Member]</link:label>
    <link:label id="lab_neo_TrapeloHealthMember_documentation_en-US" xlink:label="lab_neo_TrapeloHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trapelo Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember" xlink:href="neo-20220930.xsd#neo_TrapeloHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_TrapeloHealthMember" xlink:to="lab_neo_TrapeloHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6b6bef8f-7b63-474d-8b64-4df0e7dddb39_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_323d400f-3bea-4492-a1c4-97ac02c887be_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current pharma contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d41e6856-3bd3-49eb-b65d-ad05fb3f911a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_e818e8c0-8b4b-4b38-9b4e-d671784fa325_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_3620a4c5-7f0a-4f96-8536-b4eceb0ab688_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate on Convertible Notes (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2245b71d-4649-4d88-9b03-dc34a6b85a20_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_dc44a2fa-655e-4cba-b52a-2626fb8e612d_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f78702d9-546b-4e73-a87b-a5b900c98160_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c84cc413-66c6-4200-bd4b-f4108d314180_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_81815b61-7a23-463c-b101-17884dfecbef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_272ccb9a-9041-4f6f-b86a-63ee5c98b94c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5540efea-65ef-43cd-b087-fdbe4fbf70db_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f38cef46-1ed4-4b8f-a370-4af0a0c12f87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_66bba2d4-0f20-4c05-ab9f-1e36cedb2e33_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_46be9560-0858-46a0-9fd6-56415170be80_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5332c9eb-830d-45ed-90b4-896667d8378e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_615d7b3b-b6f0-4736-8217-bae1825371fa_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_2b79bc37-b61e-4cdd-a6c9-3ea5fcb921ef_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e9ddd592-6eaa-4853-9c10-b1958bbd60bb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InivataMember_c9119787-5c58-480c-b01e-42515ec06a50_terseLabel_en-US" xlink:label="lab_neo_InivataMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inivata</link:label>
    <link:label id="lab_neo_InivataMember_label_en-US" xlink:label="lab_neo_InivataMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inivata [Member]</link:label>
    <link:label id="lab_neo_InivataMember_documentation_en-US" xlink:label="lab_neo_InivataMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inivata</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember" xlink:href="neo-20220930.xsd#neo_InivataMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InivataMember" xlink:to="lab_neo_InivataMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3fb55b89-2805-4f9e-87b7-c19e64abbe62_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_4749f067-e8b2-4f52-8f0b-5acbe1ee93f8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses and Sales and Marketing Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_bdd70265-b779-40e0-8c5a-e3e26a5df96c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_2f5c8aaa-93e7-4cae-9f93-e3f16f654d44_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_32746a7e-c726-4178-9c8a-0d0eb2c80715_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of business combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e0ada9bb-11a7-4b39-a3c1-05d5594b464b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing information:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e2dff857-db55-4d6b-8aa9-81834e944517_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_c3185a43-f098-420c-8762-5e1d8720d54e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_588d3ad6-ea6a-4676-823d-e986ab24b809_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9ef361eb-3875-4ffb-983a-3bdd0e6a6661_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7044b942-c49a-4fc5-a7ca-36f9d0b6970e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bdd43af1-a7de-41ef-8eee-e0b09659db3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_2b2e28e4-d1db-43b1-bed2-b87ff1c80a1d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles included in cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>neo-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2d7a6b14-636e-498a-9bb1-3c76242be649,g:a2221670-aa14-4f97-b400-5f284572b74c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://neogenomics.com/role/Cover" xlink:type="simple" xlink:href="neo-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8f5699aa-a999-4847-9656-5a19715c15e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_DocumentType_8f5699aa-a999-4847-9656-5a19715c15e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a8957494-523a-453a-b015-19c17e67c10d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_DocumentQuarterlyReport_a8957494-523a-453a-b015-19c17e67c10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_72856047-19b9-4323-a9d5-4f1caa1212b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_DocumentPeriodEndDate_72856047-19b9-4323-a9d5-4f1caa1212b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_56822db5-7c69-4cd7-9e60-6adb94ce1ee6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_DocumentTransitionReport_56822db5-7c69-4cd7-9e60-6adb94ce1ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9c746983-3621-45d5-89bd-f51ef576522f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityFileNumber_9c746983-3621-45d5-89bd-f51ef576522f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_09d4ace5-8d93-4df1-bd6f-1e5506bd334b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityRegistrantName_09d4ace5-8d93-4df1-bd6f-1e5506bd334b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e095abc7-6786-4ee2-b756-02519946ee0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e095abc7-6786-4ee2-b756-02519946ee0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_35b3af98-c9c7-4f8f-ac04-2364151ad677" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityTaxIdentificationNumber_35b3af98-c9c7-4f8f-ac04-2364151ad677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1b9e1295-d22f-4831-8236-28aa0c334188" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityAddressAddressLine1_1b9e1295-d22f-4831-8236-28aa0c334188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_744a0ee1-299d-430e-b208-0c9cb2ac5dce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityAddressCityOrTown_744a0ee1-299d-430e-b208-0c9cb2ac5dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_52d0e826-dcf0-49cb-96af-41d2e60e1d8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityAddressStateOrProvince_52d0e826-dcf0-49cb-96af-41d2e60e1d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_67a6f845-41c2-488f-9c1b-0e799170f611" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityAddressPostalZipCode_67a6f845-41c2-488f-9c1b-0e799170f611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a317d69d-0e70-40a8-9316-c4363d473216" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_CityAreaCode_a317d69d-0e70-40a8-9316-c4363d473216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7b570d28-859a-430c-b3b4-c43c4b544b6b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_LocalPhoneNumber_7b570d28-859a-430c-b3b4-c43c4b544b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9e1f6106-752a-4e3c-aa5d-8d9b42eeb694" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_Security12bTitle_9e1f6106-752a-4e3c-aa5d-8d9b42eeb694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9c7dc5ed-dbf4-4f4d-aae2-8815b698153f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_TradingSymbol_9c7dc5ed-dbf4-4f4d-aae2-8815b698153f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_42ce6d98-b306-4dec-8613-7716d3ea795b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_SecurityExchangeName_42ce6d98-b306-4dec-8613-7716d3ea795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_73bce915-1021-4d9e-8d7d-81a6dbbd9724" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityCurrentReportingStatus_73bce915-1021-4d9e-8d7d-81a6dbbd9724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ccde8f4c-00fb-4958-aed2-ef6c4a8b01bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityInteractiveDataCurrent_ccde8f4c-00fb-4958-aed2-ef6c4a8b01bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_eaef6f89-86fc-47a7-968e-a1e8f092968c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityFilerCategory_eaef6f89-86fc-47a7-968e-a1e8f092968c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_710d54df-9906-4dd5-ab9e-c61a4a664e24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntitySmallBusiness_710d54df-9906-4dd5-ab9e-c61a4a664e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7a3b843c-6340-4436-93f7-121b2490972d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityEmergingGrowthCompany_7a3b843c-6340-4436-93f7-121b2490972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_927b3af1-1c08-4893-8f78-c82177e1c94a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityShellCompany_927b3af1-1c08-4893-8f78-c82177e1c94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_44d09b4b-266c-49c4-9f6c-7857390817b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_44d09b4b-266c-49c4-9f6c-7857390817b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b5f8517d-f7fc-4a71-b5ba-f83ce7406d09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_EntityCentralIndexKey_b5f8517d-f7fc-4a71-b5ba-f83ce7406d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8aecee60-0976-4cf1-a77f-b9f25e38ff21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_CurrentFiscalYearEndDate_8aecee60-0976-4cf1-a77f-b9f25e38ff21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2ed12625-8243-46a9-930f-78ba9b5133bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_DocumentFiscalYearFocus_2ed12625-8243-46a9-930f-78ba9b5133bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b2aebbf3-afab-4838-9308-cac9a55b8b24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b2aebbf3-afab-4838-9308-cac9a55b8b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cd0966c0-1e23-45d9-95f1-b3f3d0b65bc8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f97b63b7-9df3-443e-80af-d282ba1ecca1" xlink:to="loc_dei_AmendmentFlag_cd0966c0-1e23-45d9-95f1-b3f3d0b65bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c1474abc-9348-40ac-86fd-05f5a0b5a024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1474abc-9348-40ac-86fd-05f5a0b5a024" xlink:to="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d00800a-b034-4445-8156-0302995a8aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d00800a-b034-4445-8156-0302995a8aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_6a52c9f2-fcac-4784-8df2-69412f533361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_6a52c9f2-fcac-4784-8df2-69412f533361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_65112683-5a58-4689-9e94-7b2bc79b4529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_65112683-5a58-4689-9e94-7b2bc79b4529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0e9eb5b5-7d80-46c9-922d-1e52d06a67cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:to="loc_us-gaap_InventoryNet_0e9eb5b5-7d80-46c9-922d-1e52d06a67cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3db13fd4-17f4-497f-adca-4cb86ca2e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3db13fd4-17f4-497f-adca-4cb86ca2e66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_c17b96ee-6a1b-4816-9bff-5d8261931612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_c17b96ee-6a1b-4816-9bff-5d8261931612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_290983b9-62c8-4e45-8db1-2478d28e4185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:to="loc_us-gaap_OtherAssetsCurrent_290983b9-62c8-4e45-8db1-2478d28e4185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3ccc38b6-231c-47e1-8e18-97046c76976f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ad96335-1e7c-48dd-9c08-36bd5873e5ff" xlink:to="loc_us-gaap_AssetsCurrent_3ccc38b6-231c-47e1-8e18-97046c76976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c0149d34-3676-42ac-aec5-b65f5fab7533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c0149d34-3676-42ac-aec5-b65f5fab7533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca565d00-6044-4d08-bfce-90e0575a4758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca565d00-6044-4d08-bfce-90e0575a4758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_700a9c8b-76df-40c0-8b60-a7ec7a3d7a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_700a9c8b-76df-40c0-8b60-a7ec7a3d7a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_be41f336-2894-4b22-b07e-dffba759b382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:to="loc_us-gaap_Goodwill_be41f336-2894-4b22-b07e-dffba759b382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_35c9649e-bad4-4d75-a962-6bbf6908e53d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_35c9649e-bad4-4d75-a962-6bbf6908e53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_a0b550f0-aa7a-4571-b01d-80e1720c0371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:to="loc_us-gaap_AssetsNoncurrent_a0b550f0-aa7a-4571-b01d-80e1720c0371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_40c99a58-4311-4815-a44a-18086e0e5ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8c0de95b-42e2-4fe0-af1b-a4fdbca9c4fa" xlink:to="loc_us-gaap_Assets_40c99a58-4311-4815-a44a-18086e0e5ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b80b77e1-07f8-4456-b44e-3fb3eb8b9ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1474abc-9348-40ac-86fd-05f5a0b5a024" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b80b77e1-07f8-4456-b44e-3fb3eb8b9ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2f06b652-a8b9-40c8-b010-e70280cb0363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b80b77e1-07f8-4456-b44e-3fb3eb8b9ce3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2f06b652-a8b9-40c8-b010-e70280cb0363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b0e97b4d-4ed5-4d77-9813-30d6ee1640e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2f06b652-a8b9-40c8-b010-e70280cb0363" xlink:to="loc_us-gaap_AccountsPayableCurrent_b0e97b4d-4ed5-4d77-9813-30d6ee1640e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e3302bdf-c0d1-4fe6-b4de-261e0ad9f02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2f06b652-a8b9-40c8-b010-e70280cb0363" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e3302bdf-c0d1-4fe6-b4de-261e0ad9f02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_9bf60f89-126c-4065-92dd-95bca94d1a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2f06b652-a8b9-40c8-b010-e70280cb0363" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_9bf60f89-126c-4065-92dd-95bca94d1a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_15eecdd9-b261-4597-864d-4d0d5c19b565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2f06b652-a8b9-40c8-b010-e70280cb0363" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_15eecdd9-b261-4597-864d-4d0d5c19b565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e820981d-7039-4375-9f55-cb2f9e280113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2f06b652-a8b9-40c8-b010-e70280cb0363" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e820981d-7039-4375-9f55-cb2f9e280113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6e8ab641-8259-4836-a82c-9874460712ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2f06b652-a8b9-40c8-b010-e70280cb0363" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6e8ab641-8259-4836-a82c-9874460712ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f92abebb-1b1e-4d11-8b01-c9baec1815cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2f06b652-a8b9-40c8-b010-e70280cb0363" xlink:to="loc_us-gaap_LiabilitiesCurrent_f92abebb-1b1e-4d11-8b01-c9baec1815cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_e3f53abe-e7df-42c9-9ef1-fdd97a2d24ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b80b77e1-07f8-4456-b44e-3fb3eb8b9ce3" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_e3f53abe-e7df-42c9-9ef1-fdd97a2d24ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_2a2a7a8f-aa01-4c34-b882-b54156192226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e3f53abe-e7df-42c9-9ef1-fdd97a2d24ae" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_2a2a7a8f-aa01-4c34-b882-b54156192226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_40cc3a3c-9b5c-4007-8c51-2f4bdd96933d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e3f53abe-e7df-42c9-9ef1-fdd97a2d24ae" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_40cc3a3c-9b5c-4007-8c51-2f4bdd96933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7290bf08-6d3f-4bdb-bf4c-ba5670c3a48a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e3f53abe-e7df-42c9-9ef1-fdd97a2d24ae" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7290bf08-6d3f-4bdb-bf4c-ba5670c3a48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3d4ee29d-396b-4104-9036-70fdf06c17a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e3f53abe-e7df-42c9-9ef1-fdd97a2d24ae" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3d4ee29d-396b-4104-9036-70fdf06c17a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_22c32620-bb6b-4b6e-b604-991ab87eeb77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e3f53abe-e7df-42c9-9ef1-fdd97a2d24ae" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_22c32620-bb6b-4b6e-b604-991ab87eeb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4c9c54b3-e26c-427d-bfe7-22d0546229f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b80b77e1-07f8-4456-b44e-3fb3eb8b9ce3" xlink:to="loc_us-gaap_Liabilities_4c9c54b3-e26c-427d-bfe7-22d0546229f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5f21b45d-1ec0-4778-a876-c5742785ce7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b80b77e1-07f8-4456-b44e-3fb3eb8b9ce3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5f21b45d-1ec0-4778-a876-c5742785ce7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6505cfa4-176b-43b0-9257-8f4968d7fe3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b80b77e1-07f8-4456-b44e-3fb3eb8b9ce3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6505cfa4-176b-43b0-9257-8f4968d7fe3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_4658ea49-9a68-4ffa-a4dc-1e322de25b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6505cfa4-176b-43b0-9257-8f4968d7fe3f" xlink:to="loc_us-gaap_CommonStockValueOutstanding_4658ea49-9a68-4ffa-a4dc-1e322de25b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_29ccbbe4-68b5-47ae-a7e2-8c093a3a69b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6505cfa4-176b-43b0-9257-8f4968d7fe3f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_29ccbbe4-68b5-47ae-a7e2-8c093a3a69b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_da6397b5-daac-45bc-8957-a117077da7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6505cfa4-176b-43b0-9257-8f4968d7fe3f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_da6397b5-daac-45bc-8957-a117077da7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d36a1319-316d-4cc3-a085-b0cd6606ed8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6505cfa4-176b-43b0-9257-8f4968d7fe3f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d36a1319-316d-4cc3-a085-b0cd6606ed8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db814a07-bcac-4054-b865-992d8852cb43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6505cfa4-176b-43b0-9257-8f4968d7fe3f" xlink:to="loc_us-gaap_StockholdersEquity_db814a07-bcac-4054-b865-992d8852cb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4600b746-93aa-4730-8753-bdda570fdf69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b80b77e1-07f8-4456-b44e-3fb3eb8b9ce3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4600b746-93aa-4730-8753-bdda570fdf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4898c60b-2155-4866-9eb3-8e80886fd91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_28f8a4a4-43ab-4a06-8891-7301f1824dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4898c60b-2155-4866-9eb3-8e80886fd91c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_28f8a4a4-43ab-4a06-8891-7301f1824dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e8e2488-1cac-4bd7-85f9-f5330a2eeda0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4898c60b-2155-4866-9eb3-8e80886fd91c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e8e2488-1cac-4bd7-85f9-f5330a2eeda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b703eec4-0349-46ea-a40a-d8d39e6707b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4898c60b-2155-4866-9eb3-8e80886fd91c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b703eec4-0349-46ea-a40a-d8d39e6707b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8760d386-aa64-4b78-91da-cb23b7222ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4898c60b-2155-4866-9eb3-8e80886fd91c" xlink:to="loc_us-gaap_CommonStockSharesIssued_8760d386-aa64-4b78-91da-cb23b7222ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_37786caf-575b-4476-bd70-c350fed23fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4898c60b-2155-4866-9eb3-8e80886fd91c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_37786caf-575b-4476-bd70-c350fed23fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_53cdef4e-eb28-4ab1-9f01-bd13595caf12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1c9c03b4-761e-4b8b-93e5-aaf93c2f0411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53cdef4e-eb28-4ab1-9f01-bd13595caf12" xlink:to="loc_us-gaap_StatementTable_1c9c03b4-761e-4b8b-93e5-aaf93c2f0411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e44e8ee5-519c-461c-b43c-c22b9b546cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1c9c03b4-761e-4b8b-93e5-aaf93c2f0411" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e44e8ee5-519c-461c-b43c-c22b9b546cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae7c98a1-8af5-4633-99dd-e8450e945177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e44e8ee5-519c-461c-b43c-c22b9b546cce" xlink:to="loc_us-gaap_SegmentDomain_ae7c98a1-8af5-4633-99dd-e8450e945177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_85804291-d884-4f83-86e9-dd11b72d7186" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ae7c98a1-8af5-4633-99dd-e8450e945177" xlink:to="loc_neo_ClinicalServicesMember_85804291-d884-4f83-86e9-dd11b72d7186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_fe7a4e3c-781a-45ac-8992-4fba07eeea04" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ae7c98a1-8af5-4633-99dd-e8450e945177" xlink:to="loc_neo_PharmaServicesMember_fe7a4e3c-781a-45ac-8992-4fba07eeea04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1c9c03b4-761e-4b8b-93e5-aaf93c2f0411" xlink:to="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_271a5b1a-4298-42f0-9981-f6472a5dc4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_271a5b1a-4298-42f0-9981-f6472a5dc4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9ea35ad1-d2ef-4525-99b4-cc78698e1030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9ea35ad1-d2ef-4525-99b4-cc78698e1030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_aae184c7-9276-40e8-afa9-6f455dcc39ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_GrossProfit_aae184c7-9276-40e8-afa9-6f455dcc39ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a0206d56-3a9c-4411-ba05-fe9615cafe32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a0206d56-3a9c-4411-ba05-fe9615cafe32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_33e02397-5a75-4ecd-ae00-55cdce522011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_33e02397-5a75-4ecd-ae00-55cdce522011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_75a38153-ac36-45fe-b98e-64a276455e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:to="loc_us-gaap_SellingAndMarketingExpense_75a38153-ac36-45fe-b98e-64a276455e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3247b6e9-947c-4812-8d3b-e63fcebb5b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f430f74-53d3-48ca-82b0-db5a9e4995b1" xlink:to="loc_us-gaap_OperatingExpenses_3247b6e9-947c-4812-8d3b-e63fcebb5b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7f96bb13-389f-49c7-8243-537d9e18d10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_OperatingIncomeLoss_7f96bb13-389f-49c7-8243-537d9e18d10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bb3bb6bd-78ef-42a7-ad54-c4e2ade90342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_InterestExpense_bb3bb6bd-78ef-42a7-ad54-c4e2ade90342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_049ac324-d707-42cc-97de-d21f7af978c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_049ac324-d707-42cc-97de-d21f7af978c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable_42784afb-8a6a-48ea-b85c-a39633d292ca" xlink:href="neo-20220930.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_neo_GainLossOnInvestmentAndLoanReceivable_42784afb-8a6a-48ea-b85c-a39633d292ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2084d3f5-528e-4eca-b001-fda538d2796f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2084d3f5-528e-4eca-b001-fda538d2796f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1ea43b87-b6ef-451e-abfe-069c07c24b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1ea43b87-b6ef-451e-abfe-069c07c24b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de3ae97b-520c-48f0-beb0-88cdf439af77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_NetIncomeLoss_de3ae97b-520c-48f0-beb0-88cdf439af77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_addb7a32-ceee-43da-a461-8f7fcb6a3b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_addb7a32-ceee-43da-a461-8f7fcb6a3b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_aa6ed8b6-0c6d-45d0-a691-8e9949f8a0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_addb7a32-ceee-43da-a461-8f7fcb6a3b34" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_aa6ed8b6-0c6d-45d0-a691-8e9949f8a0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_30f6e6dd-c7f6-4ddd-ba4f-be742d95a39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_addb7a32-ceee-43da-a461-8f7fcb6a3b34" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_30f6e6dd-c7f6-4ddd-ba4f-be742d95a39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1b6fb153-f505-4b4d-a3eb-f12d4e17a794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55858a9b-e434-46ae-9265-4e58a90bac4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1b6fb153-f505-4b4d-a3eb-f12d4e17a794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfe31ef8-8b36-4b16-819f-f537987fcd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1b6fb153-f505-4b4d-a3eb-f12d4e17a794" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfe31ef8-8b36-4b16-819f-f537987fcd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_085626cf-240e-4f97-9437-bfa4a0b82333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1b6fb153-f505-4b4d-a3eb-f12d4e17a794" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_085626cf-240e-4f97-9437-bfa4a0b82333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bbb932e0-b7ee-4986-8b4b-c28a25201399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_781463f9-472f-4168-bfd4-2e2728cd3b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bbb932e0-b7ee-4986-8b4b-c28a25201399" xlink:to="loc_us-gaap_NetIncomeLoss_781463f9-472f-4168-bfd4-2e2728cd3b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d81414d4-cf29-4c7c-96d8-21090a8b5553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bbb932e0-b7ee-4986-8b4b-c28a25201399" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d81414d4-cf29-4c7c-96d8-21090a8b5553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0e9e6e7a-eb90-4b18-b5fe-1ae847f649c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d81414d4-cf29-4c7c-96d8-21090a8b5553" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0e9e6e7a-eb90-4b18-b5fe-1ae847f649c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_de31feaf-fdb1-402f-8bba-ff6048c4684a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d81414d4-cf29-4c7c-96d8-21090a8b5553" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_de31feaf-fdb1-402f-8bba-ff6048c4684a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3cc83070-0464-412b-b7f9-db17644c0bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bbb932e0-b7ee-4986-8b4b-c28a25201399" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3cc83070-0464-412b-b7f9-db17644c0bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_14df4420-c83b-4ff7-8adf-87d4da198236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c76a89bb-85b3-43c1-801c-fcfa06669d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_14df4420-c83b-4ff7-8adf-87d4da198236" xlink:to="loc_us-gaap_StatementTable_c76a89bb-85b3-43c1-801c-fcfa06669d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ed051d2e-a750-445d-bdbe-d18bee12ba8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c76a89bb-85b3-43c1-801c-fcfa06669d04" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ed051d2e-a750-445d-bdbe-d18bee12ba8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ed051d2e-a750-445d-bdbe-d18bee12ba8d" xlink:to="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c433c874-cb3c-4a2e-bfef-bcddb597801f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:to="loc_us-gaap_CommonStockMember_c433c874-cb3c-4a2e-bfef-bcddb597801f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_26393fbd-8914-43ec-98f6-18922dde45dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_26393fbd-8914-43ec-98f6-18922dde45dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bbdbfcb3-206e-422c-ba10-159ab80259ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bbdbfcb3-206e-422c-ba10-159ab80259ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9100948a-8f9c-4fd2-8731-9be310888a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1189785e-6748-4f4c-b911-33da052162c9" xlink:to="loc_us-gaap_RetainedEarningsMember_9100948a-8f9c-4fd2-8731-9be310888a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_179a1cf8-2469-4034-b3f6-8e0e6fb1f5a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c76a89bb-85b3-43c1-801c-fcfa06669d04" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_179a1cf8-2469-4034-b3f6-8e0e6fb1f5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a99c8e5c-5972-4cde-b8b7-8b832d5ac2ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_179a1cf8-2469-4034-b3f6-8e0e6fb1f5a0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a99c8e5c-5972-4cde-b8b7-8b832d5ac2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3c0bb4e4-b7b9-4f29-a86c-981f1f277e3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a99c8e5c-5972-4cde-b8b7-8b832d5ac2ac" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3c0bb4e4-b7b9-4f29-a86c-981f1f277e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b30db1a2-14eb-4905-a661-aa90483ae58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c76a89bb-85b3-43c1-801c-fcfa06669d04" xlink:to="loc_us-gaap_StatementLineItems_b30db1a2-14eb-4905-a661-aa90483ae58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b30db1a2-14eb-4905-a661-aa90483ae58c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_57bee929-8c7d-4607-af0d-0558650c6898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_SharesOutstanding_57bee929-8c7d-4607-af0d-0558650c6898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1e264ed-4c13-4f1c-957b-cf4adb268f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockholdersEquity_b1e264ed-4c13-4f1c-957b-cf4adb268f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_99b74f4d-0e23-4194-a095-b05d025aae86" xlink:href="neo-20220930.xsd#neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_99b74f4d-0e23-4194-a095-b05d025aae86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b91ac11a-a765-4dd8-9a3f-1c592a3be0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b91ac11a-a765-4dd8-9a3f-1c592a3be0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9555c59b-baa2-418e-9401-90bf48d49f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9555c59b-baa2-418e-9401-90bf48d49f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5f3c9591-96ca-49ff-8037-bb3c178b39e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5f3c9591-96ca-49ff-8037-bb3c178b39e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a4de90e9-ef27-4941-8a97-acba8caeda38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a4de90e9-ef27-4941-8a97-acba8caeda38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12ec8768-6374-412a-9338-f1c5a2732cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12ec8768-6374-412a-9338-f1c5a2732cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d805af49-65d7-4e66-be79-ffd33d416d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d805af49-65d7-4e66-be79-ffd33d416d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_99ddf721-ee9a-4950-90ca-7d5ae5d36d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_99ddf721-ee9a-4950-90ca-7d5ae5d36d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c51e903b-d8ac-41b6-a8d5-de09696bf0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c51e903b-d8ac-41b6-a8d5-de09696bf0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_535b5585-2639-4f5c-86cc-b0e493e58a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_535b5585-2639-4f5c-86cc-b0e493e58a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_9067e3b9-9b5b-46d9-997c-e252537a372f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_9067e3b9-9b5b-46d9-997c-e252537a372f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_8934d9b2-17a3-467b-b49c-d261a3cd48c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_8934d9b2-17a3-467b-b49c-d261a3cd48c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_59d57086-eefe-40f1-9883-b42348482e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_59d57086-eefe-40f1-9883-b42348482e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_46482d45-d69d-4bee-bb52-f7ee836ed478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_46482d45-d69d-4bee-bb52-f7ee836ed478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a50fbbd7-76da-4d2b-abce-ec93efe80a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a50fbbd7-76da-4d2b-abce-ec93efe80a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8c5202d-f7dc-4885-a238-e04c1f766e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_NetIncomeLoss_c8c5202d-f7dc-4885-a238-e04c1f766e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_96a4aa0b-643e-4de9-a0ec-2ef51f401cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_SharesOutstanding_96a4aa0b-643e-4de9-a0ec-2ef51f401cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f9eb6d2b-c578-4df8-adac-36a507cf2b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86c1a068-1d31-45a9-a88a-4ac593e7ff46" xlink:to="loc_us-gaap_StockholdersEquity_f9eb6d2b-c578-4df8-adac-36a507cf2b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="neo-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9240fa1-c0d2-48b7-913b-3fcf09108747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9240fa1-c0d2-48b7-913b-3fcf09108747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c19ef194-581f-4adf-8a5b-6c1e808f7478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9240fa1-c0d2-48b7-913b-3fcf09108747" xlink:to="loc_us-gaap_NetIncomeLoss_c19ef194-581f-4adf-8a5b-6c1e808f7478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9240fa1-c0d2-48b7-913b-3fcf09108747" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2b842621-5ab6-47da-a861-ed95a61b6b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_Depreciation_2b842621-5ab6-47da-a861-ed95a61b6b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_17548675-594d-43c0-876b-5b6150b20c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_17548675-594d-43c0-876b-5b6150b20c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a7723c5d-c80e-41bd-a8e4-3e6366af182d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_ShareBasedCompensation_a7723c5d-c80e-41bd-a8e4-3e6366af182d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_22eadadd-e303-42b6-8c3b-0d6f4ec67f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_OperatingLeaseExpense_22eadadd-e303-42b6-8c3b-0d6f4ec67f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_c9390e86-9142-43a8-b291-fea2c3d94204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_c9390e86-9142-43a8-b291-fea2c3d94204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6d63003e-fbae-4a29-92f4-b98349a50c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6d63003e-fbae-4a29-92f4-b98349a50c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet_762001b9-2369-4c5c-8001-3f27c4e6d993" xlink:href="neo-20220930.xsd#neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet_762001b9-2369-4c5c-8001-3f27c4e6d993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_8c915677-b418-4459-80ac-1aeffa7b3cc0" xlink:href="neo-20220930.xsd#neo_ReceivableWithImputedInterestNonConsolidatedAffiliates"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_8c915677-b418-4459-80ac-1aeffa7b3cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_86ee9312-998a-4c62-96d4-35cb1d133fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_86ee9312-998a-4c62-96d4-35cb1d133fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_6e806949-09bb-4732-a283-58df2814c8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_6e806949-09bb-4732-a283-58df2814c8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_227e8675-eba1-4b22-9fc5-aeeba30f707f" xlink:href="neo-20220930.xsd#neo_PolymeraseChainReactionTestingExitCostsCOVID19"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_227e8675-eba1-4b22-9fc5-aeeba30f707f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a5355478-1964-4b09-a809-beb67d355017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a5355478-1964-4b09-a809-beb67d355017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46dc7045-e380-46c6-8566-bdde15699397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4e339c-f0ce-491c-a332-394fd2223d21" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46dc7045-e380-46c6-8566-bdde15699397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_471dd43a-4eb5-4a98-8fb4-66a9a747e313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46dc7045-e380-46c6-8566-bdde15699397" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_471dd43a-4eb5-4a98-8fb4-66a9a747e313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7189a00b-6f79-4cbc-b6fd-0a02dad29d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46dc7045-e380-46c6-8566-bdde15699397" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7189a00b-6f79-4cbc-b6fd-0a02dad29d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncreaseDecreaseInPrepaidConstruction_e7706922-092b-42cf-befc-0871279ba8f1" xlink:href="neo-20220930.xsd#neo_IncreaseDecreaseInPrepaidConstruction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46dc7045-e380-46c6-8566-bdde15699397" xlink:to="loc_neo_IncreaseDecreaseInPrepaidConstruction_e7706922-092b-42cf-befc-0871279ba8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c64e4e4c-7c03-4e67-a3cc-3ea33f6c8879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46dc7045-e380-46c6-8566-bdde15699397" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c64e4e4c-7c03-4e67-a3cc-3ea33f6c8879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_cf442287-9df6-4501-b642-e48528713edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46dc7045-e380-46c6-8566-bdde15699397" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_cf442287-9df6-4501-b642-e48528713edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44d62384-0b20-45e2-b634-ce51a76eaf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9240fa1-c0d2-48b7-913b-3fcf09108747" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44d62384-0b20-45e2-b634-ce51a76eaf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6fdf7d1c-882f-4d65-aa1d-58e5ef98b256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6fdf7d1c-882f-4d65-aa1d-58e5ef98b256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_52c23087-191b-4dc1-8a3d-8edc663c79f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6fdf7d1c-882f-4d65-aa1d-58e5ef98b256" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_52c23087-191b-4dc1-8a3d-8edc663c79f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d12dfa7f-1c4a-4130-8c32-d17a3a6deac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6fdf7d1c-882f-4d65-aa1d-58e5ef98b256" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d12dfa7f-1c4a-4130-8c32-d17a3a6deac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e908a7e-3e5c-4cb6-a028-af9024f0ef1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6fdf7d1c-882f-4d65-aa1d-58e5ef98b256" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e908a7e-3e5c-4cb6-a028-af9024f0ef1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5512c38b-9726-489e-944b-89450f2706f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6fdf7d1c-882f-4d65-aa1d-58e5ef98b256" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5512c38b-9726-489e-944b-89450f2706f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4b4331c7-9486-488c-bd29-6471249958f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6fdf7d1c-882f-4d65-aa1d-58e5ef98b256" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4b4331c7-9486-488c-bd29-6471249958f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_a2ea92b5-4238-4255-9943-24cd4e6e4b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6fdf7d1c-882f-4d65-aa1d-58e5ef98b256" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_a2ea92b5-4238-4255-9943-24cd4e6e4b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d145e644-184a-4deb-907b-287d1998d64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6fdf7d1c-882f-4d65-aa1d-58e5ef98b256" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d145e644-184a-4deb-907b-287d1998d64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1ec0242d-9771-41b9-8fce-c993faa98c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1ec0242d-9771-41b9-8fce-c993faa98c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_b3146546-68a1-4c27-92b1-c3bba6eb1953" xlink:href="neo-20220930.xsd#neo_RepaymentsOfEquipmentAndOtherFinanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1ec0242d-9771-41b9-8fce-c993faa98c80" xlink:to="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_b3146546-68a1-4c27-92b1-c3bba6eb1953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8ba634a3-3dbe-48f7-afa8-955c5adf3f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1ec0242d-9771-41b9-8fce-c993faa98c80" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8ba634a3-3dbe-48f7-afa8-955c5adf3f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_f710f3b5-a042-4b36-85d6-ed466742a7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1ec0242d-9771-41b9-8fce-c993faa98c80" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_f710f3b5-a042-4b36-85d6-ed466742a7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations_28d2386f-ee49-42c9-b712-3c179cb0883e" xlink:href="neo-20220930.xsd#neo_PaymentsOfPremiumsForCappedCallConfirmations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1ec0242d-9771-41b9-8fce-c993faa98c80" xlink:to="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations_28d2386f-ee49-42c9-b712-3c179cb0883e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ProceedsFromEquityOfferingNet_40a913a1-2b67-4c87-839c-e5b66398bd99" xlink:href="neo-20220930.xsd#neo_ProceedsFromEquityOfferingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1ec0242d-9771-41b9-8fce-c993faa98c80" xlink:to="loc_neo_ProceedsFromEquityOfferingNet_40a913a1-2b67-4c87-839c-e5b66398bd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5d85514-a5af-4e1e-9982-c8022df77e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1ec0242d-9771-41b9-8fce-c993faa98c80" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5d85514-a5af-4e1e-9982-c8022df77e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0bff90ea-bd46-42ef-b3bc-552ebee810ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0bff90ea-bd46-42ef-b3bc-552ebee810ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a4465fe-495d-46b3-b3b1-86318ae3538a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a4465fe-495d-46b3-b3b1-86318ae3538a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c7d2bc6-8aca-4f06-bb88-f92b05bccba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c7d2bc6-8aca-4f06-bb88-f92b05bccba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_6c391f23-4a20-4947-b822-1b59db477a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_6c391f23-4a20-4947-b822-1b59db477a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b8663f36-e63c-4ac0-9636-e0f041376562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_6c391f23-4a20-4947-b822-1b59db477a92" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b8663f36-e63c-4ac0-9636-e0f041376562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8b6ffd77-873d-4ecf-be65-ef94e53882e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_6c391f23-4a20-4947-b822-1b59db477a92" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8b6ffd77-873d-4ecf-be65-ef94e53882e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a65d655e-8694-4715-9147-f53529c8a035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_6c391f23-4a20-4947-b822-1b59db477a92" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a65d655e-8694-4715-9147-f53529c8a035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_dcb5de7b-73c6-452f-a0b0-5dd4e15e0a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_dcb5de7b-73c6-452f-a0b0-5dd4e15e0a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_07b2fcb7-190b-49e8-9de2-f09f3a7c9932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dcb5de7b-73c6-452f-a0b0-5dd4e15e0a2c" xlink:to="loc_us-gaap_InterestPaidNet_07b2fcb7-190b-49e8-9de2-f09f3a7c9932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_54f3ce2b-0c0d-4bc9-b272-1f5df998e966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dcb5de7b-73c6-452f-a0b0-5dd4e15e0a2c" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_54f3ce2b-0c0d-4bc9-b272-1f5df998e966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_318590f6-2504-4d76-8382-3fc2aa183ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03ac6a57-54b0-43c5-9bc8-60ac7a16a07a" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_318590f6-2504-4d76-8382-3fc2aa183ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FairValueOfCommonStockIssuedToFundAcquisition_2c5b6496-1a6d-4b11-90a5-2166de30624d" xlink:href="neo-20220930.xsd#neo_FairValueOfCommonStockIssuedToFundAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_318590f6-2504-4d76-8382-3fc2aa183ec2" xlink:to="loc_neo_FairValueOfCommonStockIssuedToFundAcquisition_2c5b6496-1a6d-4b11-90a5-2166de30624d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5039061f-cd85-490f-b691-d9b540d8f7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_318590f6-2504-4d76-8382-3fc2aa183ec2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5039061f-cd85-490f-b691-d9b540d8f7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NatureoftheBusiness" xlink:type="simple" xlink:href="neo-20220930.xsd#NatureoftheBusiness"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NatureoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee4a4563-9da6-49eb-b64a-87e0ae59ee24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a05e6b5c-2972-4d81-9d3d-08c1738ca60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee4a4563-9da6-49eb-b64a-87e0ae59ee24" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a05e6b5c-2972-4d81-9d3d-08c1738ca60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="neo-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_59106885-9f69-4dfc-90b8-fcaf3a7c4104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_2248f58c-a6bf-49a4-a6c7-461d8230b115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_59106885-9f69-4dfc-90b8-fcaf3a7c4104" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_2248f58c-a6bf-49a4-a6c7-461d8230b115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/Acquisitions" xlink:type="simple" xlink:href="neo-20220930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f88d3128-2843-4cec-8c14-b66511c5767e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3029d2bc-9336-42c8-b5ac-04ad60eee330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f88d3128-2843-4cec-8c14-b66511c5767e" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3029d2bc-9336-42c8-b5ac-04ad60eee330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5ccb61e9-5025-4875-824a-76d957c1b221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c1409419-62e6-4657-9022-f70a6ed64d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ccb61e9-5025-4875-824a-76d957c1b221" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c1409419-62e6-4657-9022-f70a6ed64d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c9c661dc-3af0-4ff7-845c-9788d874b331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_70615949-8760-46b0-a2bc-b826b4cc5767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c9c661dc-3af0-4ff7-845c-9788d874b331" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_70615949-8760-46b0-a2bc-b826b4cc5767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/Debt" xlink:type="simple" xlink:href="neo-20220930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e6433761-39a1-4721-b012-79a445567a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_26923757-46b8-49bd-9747-927d8611f175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e6433761-39a1-4721-b012-79a445567a59" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_26923757-46b8-49bd-9747-927d8611f175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="neo-20220930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2e01c551-d30c-486a-8fe5-412360d6c40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60ee872c-081c-422e-8c28-c4cb5d192167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2e01c551-d30c-486a-8fe5-412360d6c40f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60ee872c-081c-422e-8c28-c4cb5d192167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="neo-20220930.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1b2a81f6-95c9-44b6-94c0-0c65ea08393a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5ab12482-7bd1-4919-8f5a-ddc76ca0f8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1b2a81f6-95c9-44b6-94c0-0c65ea08393a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5ab12482-7bd1-4919-8f5a-ddc76ca0f8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="neo-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e042a77b-c6e3-4cea-97e5-ae4b13d79e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_009fa7e8-cbe9-4535-917d-14c1704ce202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e042a77b-c6e3-4cea-97e5-ae4b13d79e4c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_009fa7e8-cbe9-4535-917d-14c1704ce202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomePerShare" xlink:type="simple" xlink:href="neo-20220930.xsd#NetLossIncomePerShare"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_18626312-edd1-44ad-aae2-3bad1aca97b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8030385d-b7d0-42f4-8c4e-c2290e90481f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_18626312-edd1-44ad-aae2-3bad1aca97b0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8030385d-b7d0-42f4-8c4e-c2290e90481f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="neo-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a142b9a-1bb5-4319-ac97-1755f0cfacef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8bb69324-9469-446a-bcb6-39712093ac7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a142b9a-1bb5-4319-ac97-1755f0cfacef" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8bb69324-9469-446a-bcb6-39712093ac7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="neo-20220930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_659c2ede-fe14-4523-aff3-cd0f571f2ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_62e5ad6d-1b08-4039-93ce-c75d0900360c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_659c2ede-fe14-4523-aff3-cd0f571f2ebb" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_62e5ad6d-1b08-4039-93ce-c75d0900360c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformation" xlink:type="simple" xlink:href="neo-20220930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ef9f4b49-71de-4809-9925-2c3b1ce2ecac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_77d2ac73-101e-4dde-9ee5-3fe4cdaa97d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ef9f4b49-71de-4809-9925-2c3b1ce2ecac" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_77d2ac73-101e-4dde-9ee5-3fe4cdaa97d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="neo-20220930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_9d011c46-0073-4035-90f5-778d64687e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a451014f-2d76-4803-8ba6-2be226f76dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_9d011c46-0073-4035-90f5-778d64687e1f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a451014f-2d76-4803-8ba6-2be226f76dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_bd7cfbcb-a25e-4fa9-861a-2842b9bd263f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_9d011c46-0073-4035-90f5-778d64687e1f" xlink:to="loc_us-gaap_UseOfEstimates_bd7cfbcb-a25e-4fa9-861a-2842b9bd263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetsHeldForSalePolicyPolicyTextBlock_1e7b656e-2817-4072-ada9-f2d02a33231a" xlink:href="neo-20220930.xsd#neo_AssetsHeldForSalePolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_9d011c46-0073-4035-90f5-778d64687e1f" xlink:to="loc_neo_AssetsHeldForSalePolicyPolicyTextBlock_1e7b656e-2817-4072-ada9-f2d02a33231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_93122f5c-9946-4878-a45e-abe6f7ccd3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_9d011c46-0073-4035-90f5-778d64687e1f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_93122f5c-9946-4878-a45e-abe6f7ccd3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0cd1be3f-fc90-4a17-bf78-9bf177e2be3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_9d011c46-0073-4035-90f5-778d64687e1f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0cd1be3f-fc90-4a17-bf78-9bf177e2be3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7b9691f6-de90-4cf3-bd45-727f9d3003cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_9d011c46-0073-4035-90f5-778d64687e1f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7b9691f6-de90-4cf3-bd45-727f9d3003cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="neo-20220930.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1d041eb5-33c8-4c48-a2a7-835d16d64a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_206fd68b-9671-4c8e-9ea7-a2a2c82cf1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1d041eb5-33c8-4c48-a2a7-835d16d64a44" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_206fd68b-9671-4c8e-9ea7-a2a2c82cf1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_adc70c74-bce7-448a-a8a9-08b049c6c25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1d041eb5-33c8-4c48-a2a7-835d16d64a44" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_adc70c74-bce7-448a-a8a9-08b049c6c25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5e26e3bf-933b-4890-ba17-6239abf29a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d080b336-079b-46b4-8599-7f0588f24dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e26e3bf-933b-4890-ba17-6239abf29a02" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d080b336-079b-46b4-8599-7f0588f24dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_efb56719-d061-48dc-9df0-4333ea6666ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e26e3bf-933b-4890-ba17-6239abf29a02" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_efb56719-d061-48dc-9df0-4333ea6666ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4d6c3c8d-6571-4c7f-a3ca-ecf9b38a8ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e26e3bf-933b-4890-ba17-6239abf29a02" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4d6c3c8d-6571-4c7f-a3ca-ecf9b38a8ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_63a53cdc-0e3b-437d-98c4-84d6bd0e03b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_675e1df6-87e8-44e8-b56d-3ab82c93ce8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_63a53cdc-0e3b-437d-98c4-84d6bd0e03b4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_675e1df6-87e8-44e8-b56d-3ab82c93ce8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e9329939-d27b-42b3-81f6-f41e66954369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_63a53cdc-0e3b-437d-98c4-84d6bd0e03b4" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e9329939-d27b-42b3-81f6-f41e66954369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_d5a5e6bf-1437-434b-aeca-d03910cbe37b" xlink:href="neo-20220930.xsd#neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_63a53cdc-0e3b-437d-98c4-84d6bd0e03b4" xlink:to="loc_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_d5a5e6bf-1437-434b-aeca-d03910cbe37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3f10071b-1904-43dd-b783-c590d3b6d89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_63a53cdc-0e3b-437d-98c4-84d6bd0e03b4" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3f10071b-1904-43dd-b783-c590d3b6d89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="neo-20220930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_058fb959-0e9a-4fb1-8c4e-a7b85fd2e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_da5edaf8-4b54-4dd5-8651-e929ab9d752b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_058fb959-0e9a-4fb1-8c4e-a7b85fd2e0f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_da5edaf8-4b54-4dd5-8651-e929ab9d752b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_990b6bff-b06f-4c7f-b3df-25b013b52d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_058fb959-0e9a-4fb1-8c4e-a7b85fd2e0f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_990b6bff-b06f-4c7f-b3df-25b013b52d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_77d88f00-eaa8-4f0f-8caf-0db31250dbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_058fb959-0e9a-4fb1-8c4e-a7b85fd2e0f7" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_77d88f00-eaa8-4f0f-8caf-0db31250dbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="neo-20220930.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5a4b378-631c-4fce-b04d-b85e98351d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_476e6410-34d2-41e4-b640-7633dbcb2abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5a4b378-631c-4fce-b04d-b85e98351d06" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_476e6410-34d2-41e4-b640-7633dbcb2abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_76e37629-f10b-4f40-a58c-ce8b8c35ffd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5a4b378-631c-4fce-b04d-b85e98351d06" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_76e37629-f10b-4f40-a58c-ce8b8c35ffd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomePerShareTables" xlink:type="simple" xlink:href="neo-20220930.xsd#NetLossIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_63f4be7a-3c80-4a70-9f18-aa6444c94de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4afb52b6-45e7-4a37-8532-978b8aaed883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_63f4be7a-3c80-4a70-9f18-aa6444c94de8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4afb52b6-45e7-4a37-8532-978b8aaed883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_68a50034-f8eb-4549-9079-ac9b90eb75b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_63f4be7a-3c80-4a70-9f18-aa6444c94de8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_68a50034-f8eb-4549-9079-ac9b90eb75b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="neo-20220930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7e1603af-ad7c-4216-a3bb-d0b6f6c01d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_da9af062-9bf6-4e60-9d80-deb1644a6562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e1603af-ad7c-4216-a3bb-d0b6f6c01d4e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_da9af062-9bf6-4e60-9d80-deb1644a6562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NatureoftheBusinessNarrativeDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#NatureoftheBusinessNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NatureoftheBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4317827-44f3-4ff6-871b-cf3f6e91ac10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_2d103a69-cc26-4b24-8b51-3342ccd08c09" xlink:href="neo-20220930.xsd#neo_PolymeraseChainReactionTestingExitCostsCOVID19"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4317827-44f3-4ff6-871b-cf3f6e91ac10" xlink:to="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_2d103a69-cc26-4b24-8b51-3342ccd08c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_5c5d8c9e-9875-4a44-b6d7-18d694371bbf" xlink:href="neo-20220930.xsd#neo_PolymeraseChainReactionTestingWriteOffsCOVID19"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4317827-44f3-4ff6-871b-cf3f6e91ac10" xlink:to="loc_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_5c5d8c9e-9875-4a44-b6d7-18d694371bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_54be917c-7d39-46aa-818a-d74ac78046fd" xlink:href="neo-20220930.xsd#neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4317827-44f3-4ff6-871b-cf3f6e91ac10" xlink:to="loc_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_54be917c-7d39-46aa-818a-d74ac78046fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SocialSecurityTaxEmployerDeferralCARESAct_4db6483b-0ee5-4801-8ab6-b81f504a86f5" xlink:href="neo-20220930.xsd#neo_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4317827-44f3-4ff6-871b-cf3f6e91ac10" xlink:to="loc_neo_SocialSecurityTaxEmployerDeferralCARESAct_4db6483b-0ee5-4801-8ab6-b81f504a86f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f75a92a1-fcc1-4f79-a1a1-b4c6264d7709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_4da1954b-52dd-4ed4-b86d-0871ebc8199c" xlink:href="neo-20220930.xsd#neo_AssetHeldForSaleSquareFeetOfFacilityOwned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f75a92a1-fcc1-4f79-a1a1-b4c6264d7709" xlink:to="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_4da1954b-52dd-4ed4-b86d-0871ebc8199c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_4184dd9f-03ce-458e-8783-e82070e07e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f75a92a1-fcc1-4f79-a1a1-b4c6264d7709" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_4184dd9f-03ce-458e-8783-e82070e07e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_78a4ea47-0a55-45fe-9bbe-9b9006c18d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f75a92a1-fcc1-4f79-a1a1-b4c6264d7709" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_78a4ea47-0a55-45fe-9bbe-9b9006c18d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_981a27c0-4415-4624-bffc-e135b44d132e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f75a92a1-fcc1-4f79-a1a1-b4c6264d7709" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_981a27c0-4415-4624-bffc-e135b44d132e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_64577684-788b-4d2d-a4fe-7aa82fdb85b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f75a92a1-fcc1-4f79-a1a1-b4c6264d7709" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_64577684-788b-4d2d-a4fe-7aa82fdb85b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ee8c48c6-12b3-4d25-9e9f-e5de3ab79921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ee8c48c6-12b3-4d25-9e9f-e5de3ab79921" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a59f6e30-8763-4f0f-a9fd-dbc008d85658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a59f6e30-8763-4f0f-a9fd-dbc008d85658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e60e3864-0c10-45df-bc9b-4cbacbcd1d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a59f6e30-8763-4f0f-a9fd-dbc008d85658" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e60e3864-0c10-45df-bc9b-4cbacbcd1d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_9e4ac7ab-31ef-45a5-8ca7-f08ffb628b7b" xlink:href="neo-20220930.xsd#neo_TrapeloHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e60e3864-0c10-45df-bc9b-4cbacbcd1d77" xlink:to="loc_neo_TrapeloHealthMember_9e4ac7ab-31ef-45a5-8ca7-f08ffb628b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_70fc79f4-0e7c-41c4-a061-5a5607abdb42" xlink:href="neo-20220930.xsd#neo_InivataMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e60e3864-0c10-45df-bc9b-4cbacbcd1d77" xlink:to="loc_neo_InivataMember_70fc79f4-0e7c-41c4-a061-5a5607abdb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_38f6ad2e-5088-4a5d-bfb9-8652e0cfa235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_38f6ad2e-5088-4a5d-bfb9-8652e0cfa235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_38f6ad2e-5088-4a5d-bfb9-8652e0cfa235" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_03972c14-4a9d-4d32-8374-39c30ace3d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_03972c14-4a9d-4d32-8374-39c30ace3d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_d49285c0-5506-40e6-9785-1b7315196108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_d49285c0-5506-40e6-9785-1b7315196108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_0ab9f55c-6862-4bc8-b940-d5482839d22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:to="loc_us-gaap_TrademarksMember_0ab9f55c-6862-4bc8-b940-d5482839d22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_456a07f8-ba30-4081-a031-0d86f35d6333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39a01659-fb21-4611-ab96-621e1f72cc6d" xlink:to="loc_us-gaap_TradeNamesMember_456a07f8-ba30-4081-a031-0d86f35d6333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_eb385ee2-bcab-47b7-af90-3192509d6ff9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_eb385ee2-bcab-47b7-af90-3192509d6ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ac33174a-ad45-4202-bab2-d1123c08b71a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_eb385ee2-bcab-47b7-af90-3192509d6ff9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ac33174a-ad45-4202-bab2-d1123c08b71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b53c8f4f-cc6c-4f18-963d-25649c642fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ac33174a-ad45-4202-bab2-d1123c08b71a" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b53c8f4f-cc6c-4f18-963d-25649c642fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e444a24d-362f-44ef-8c02-3c0b9a319b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e444a24d-362f-44ef-8c02-3c0b9a319b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_373ef24b-29db-4e35-8e92-413690db7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e444a24d-362f-44ef-8c02-3c0b9a319b79" xlink:to="loc_us-gaap_RelatedPartyDomain_373ef24b-29db-4e35-8e92-413690db7ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_61747ab3-5c17-45db-a04d-090542d4a157" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_373ef24b-29db-4e35-8e92-413690db7ee0" xlink:to="loc_srt_AffiliatedEntityMember_61747ab3-5c17-45db-a04d-090542d4a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fa24f6c7-4cc2-4d7e-bcea-078e5ca58745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fa24f6c7-4cc2-4d7e-bcea-078e5ca58745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_babd7ce5-2526-4713-aa4d-1d8c934b9216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fa24f6c7-4cc2-4d7e-bcea-078e5ca58745" xlink:to="loc_us-gaap_SegmentDomain_babd7ce5-2526-4713-aa4d-1d8c934b9216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_de775144-9b81-4fd2-9e04-147844052d34" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_babd7ce5-2526-4713-aa4d-1d8c934b9216" xlink:to="loc_neo_ClinicalServicesMember_de775144-9b81-4fd2-9e04-147844052d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_9a11b076-3745-45d7-a9ea-c38b5d47e8ce" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_babd7ce5-2526-4713-aa4d-1d8c934b9216" xlink:to="loc_neo_PharmaServicesMember_9a11b076-3745-45d7-a9ea-c38b5d47e8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d096d4d-efd8-44e5-9897-a247f6a96a1d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2c63cc7e-d7c4-41a6-b36f-1f5431e08983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2c63cc7e-d7c4-41a6-b36f-1f5431e08983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_76840247-ef9b-4de8-8fa2-808e074b1a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_76840247-ef9b-4de8-8fa2-808e074b1a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_e5ffd6ed-956c-46f1-8efa-5623b09d9bf0" xlink:href="neo-20220930.xsd#neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_e5ffd6ed-956c-46f1-8efa-5623b09d9bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8ec130a3-b109-4a3f-8855-1d671f781fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8ec130a3-b109-4a3f-8855-1d671f781fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_027bfab2-70de-460c-b918-944a73f2415a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_027bfab2-70de-460c-b918-944a73f2415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_885d42b6-d7c6-4a89-8c83-00bac053cef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_885d42b6-d7c6-4a89-8c83-00bac053cef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_91e4d155-fecb-4e41-84f0-ed61a409b282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_91e4d155-fecb-4e41-84f0-ed61a409b282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_57ca7941-5bcf-4c3c-9ebd-514b6652bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_57ca7941-5bcf-4c3c-9ebd-514b6652bc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8657ccd7-b2d7-4185-81c8-673ba144ffbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8657ccd7-b2d7-4185-81c8-673ba144ffbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_432589d7-acaf-4558-a693-20d6c9ba8d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_432589d7-acaf-4558-a693-20d6c9ba8d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_d92b87f7-fc65-4536-8b9a-56659a4911f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_d92b87f7-fc65-4536-8b9a-56659a4911f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_561242b9-ce41-4c63-b580-58488317e5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_561242b9-ce41-4c63-b580-58488317e5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_d156a65c-11e9-4e52-8e4c-7807c8087eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_d156a65c-11e9-4e52-8e4c-7807c8087eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_f5e51ced-fe75-493e-b70d-52c506f78fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_f5e51ced-fe75-493e-b70d-52c506f78fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_035ab4ab-45e6-4d47-b510-0782b5f3b455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_035ab4ab-45e6-4d47-b510-0782b5f3b455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_6391e6df-de0d-4306-b1ed-a839eea7500e" xlink:href="neo-20220930.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_6391e6df-de0d-4306-b1ed-a839eea7500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1c0374eb-2bfd-4f6a-81d1-caa529d18fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_LineOfCredit_1c0374eb-2bfd-4f6a-81d1-caa529d18fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_bb70b985-9f44-48f8-852f-095db9bfda94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_bb70b985-9f44-48f8-852f-095db9bfda94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_304e35af-e914-4d74-8f75-5f06f7b30ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_304e35af-e914-4d74-8f75-5f06f7b30ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d154b16d-0194-4ced-8da9-bd433084b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d154b16d-0194-4ced-8da9-bd433084b2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_8f86b946-f7a6-4d2b-b0ae-b50cd6f2b90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_8f86b946-f7a6-4d2b-b0ae-b50cd6f2b90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate_01b26fa1-cc06-4229-a518-01153a8d8eb8" xlink:href="neo-20220930.xsd#neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3beecc59-8833-4f19-8332-9328dc051a11" xlink:to="loc_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate_01b26fa1-cc06-4229-a518-01153a8d8eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#AcquisitionsScheduleofProvisionalInformationDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5acc7805-f4e5-4b31-8326-ca35b198f8af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5acc7805-f4e5-4b31-8326-ca35b198f8af" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7adf0cd5-f0dd-4971-8907-a2b106d7b82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7adf0cd5-f0dd-4971-8907-a2b106d7b82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b82345-55c8-46aa-a746-e38e99eeb7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7adf0cd5-f0dd-4971-8907-a2b106d7b82c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b82345-55c8-46aa-a746-e38e99eeb7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_ff2fe900-9a2c-455a-ab57-1842012f9942" xlink:href="neo-20220930.xsd#neo_TrapeloHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b82345-55c8-46aa-a746-e38e99eeb7fb" xlink:to="loc_neo_TrapeloHealthMember_ff2fe900-9a2c-455a-ab57-1842012f9942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_493bff56-5425-48f3-b5d3-18b461cc5517" xlink:href="neo-20220930.xsd#neo_InivataMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b82345-55c8-46aa-a746-e38e99eeb7fb" xlink:to="loc_neo_InivataMember_493bff56-5425-48f3-b5d3-18b461cc5517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80181af4-cca9-431a-b14e-0d781b033bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80181af4-cca9-431a-b14e-0d781b033bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80181af4-cca9-431a-b14e-0d781b033bbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_0c03cf4e-868c-49f0-be9b-0fd1ce57d268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_0c03cf4e-868c-49f0-be9b-0fd1ce57d268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e3e03d98-3944-45df-a38c-c8372de9b152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e3e03d98-3944-45df-a38c-c8372de9b152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_9aa1845d-d2e2-474d-aaa6-30a1948428e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:to="loc_us-gaap_TrademarksMember_9aa1845d-d2e2-474d-aaa6-30a1948428e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9caabda0-22a2-4dff-b40e-cd63456539fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2338d5e-81b3-49c8-adbd-3333897e1ee9" xlink:to="loc_us-gaap_TradeNamesMember_9caabda0-22a2-4dff-b40e-cd63456539fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_17397809-b25a-4b70-ae40-8fa6316416df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:to="loc_srt_RestatementAxis_17397809-b25a-4b70-ae40-8fa6316416df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_3197ef12-b24b-405b-93bf-35d709b53d87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_17397809-b25a-4b70-ae40-8fa6316416df" xlink:to="loc_srt_RestatementDomain_3197ef12-b24b-405b-93bf-35d709b53d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_348cdc36-81fc-452c-bd61-30bb5bd5f051" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3197ef12-b24b-405b-93bf-35d709b53d87" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_348cdc36-81fc-452c-bd61-30bb5bd5f051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_d7d69ec2-6b3b-4a43-861c-8467a75d0a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_d7d69ec2-6b3b-4a43-861c-8467a75d0a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_a8970b6a-40f1-453f-8568-0c611a5b9e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_d7d69ec2-6b3b-4a43-861c-8467a75d0a06" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_a8970b6a-40f1-453f-8568-0c611a5b9e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionOtherMember_c9eac279-27b2-4154-ad4f-1a70246df170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_a8970b6a-40f1-453f-8568-0c611a5b9e18" xlink:to="loc_us-gaap_ErrorCorrectionOtherMember_c9eac279-27b2-4154-ad4f-1a70246df170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0792f2fe-b7b5-4dbb-90ed-6f708e1b0888" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_837bae1b-0c36-4d9c-9c2e-aa89086fc0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_837bae1b-0c36-4d9c-9c2e-aa89086fc0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1d8f1296-3b6c-47fb-9aa5-d4fb420111df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1d8f1296-3b6c-47fb-9aa5-d4fb420111df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e93cf150-9663-47eb-bc32-580d1c333f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e93cf150-9663-47eb-bc32-580d1c333f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_562e0005-a169-4f11-a457-24e860cb7ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_562e0005-a169-4f11-a457-24e860cb7ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_d4a08b6c-cfa2-4b4c-bb5c-bb3de90b6a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_d4a08b6c-cfa2-4b4c-bb5c-bb3de90b6a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7f71a480-2ad5-4f46-bdb1-451472821bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7f71a480-2ad5-4f46-bdb1-451472821bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_a96e7dd5-0c63-4572-8025-7c76289f77b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_a96e7dd5-0c63-4572-8025-7c76289f77b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a8d9f795-ef13-48d1-bf4c-e7f95a63e05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a8d9f795-ef13-48d1-bf4c-e7f95a63e05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_69c09670-fe86-4916-9d4c-d4b996bd0049" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_69c09670-fe86-4916-9d4c-d4b996bd0049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_667df282-d347-4ed1-a25f-a0d167c9e3a4" xlink:href="neo-20220930.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_667df282-d347-4ed1-a25f-a0d167c9e3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_843c5b97-45b8-43e5-a8c8-14094edff8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_843c5b97-45b8-43e5-a8c8-14094edff8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_1a5d785e-a9aa-465b-96e3-5c05a2d8cd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_1a5d785e-a9aa-465b-96e3-5c05a2d8cd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1fc56941-25ab-4221-92db-b9f430e4873b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1fc56941-25ab-4221-92db-b9f430e4873b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_89bd6563-4332-4a5a-af5a-1d2f908d8c9e" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_89bd6563-4332-4a5a-af5a-1d2f908d8c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_14803819-e556-40b6-a750-4a882a25475d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_14803819-e556-40b6-a750-4a882a25475d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3c05cf92-aa8f-452f-92f4-0e581f3f50d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3c05cf92-aa8f-452f-92f4-0e581f3f50d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_2e4a6633-5d2e-49e9-95a4-9e80c30263d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_2e4a6633-5d2e-49e9-95a4-9e80c30263d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8dea726a-568f-4afc-9fd7-c971da567cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8dea726a-568f-4afc-9fd7-c971da567cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_ceb7afd6-ec04-43fa-ab5c-987532a7e28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_ceb7afd6-ec04-43fa-ab5c-987532a7e28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_c5f26a6c-f252-4c59-ae8f-acab5c7812ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_c5f26a6c-f252-4c59-ae8f-acab5c7812ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_12721ebe-90e3-4d25-8ff9-5642913ad273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_12721ebe-90e3-4d25-8ff9-5642913ad273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent_3a7cfdd6-1669-41e6-b42e-387d63f1f7b3" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent_3a7cfdd6-1669-41e6-b42e-387d63f1f7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_be77cb37-d4e7-4252-86b4-8987af27c639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_be77cb37-d4e7-4252-86b4-8987af27c639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities_82d80409-7604-45bf-b5b9-598ead524391" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities_82d80409-7604-45bf-b5b9-598ead524391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ba4cd153-c6b8-4347-a5a7-3bbe6f6e5700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ba4cd153-c6b8-4347-a5a7-3bbe6f6e5700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_bd3dccfe-8097-4c58-afc5-eb749959bdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_bd3dccfe-8097-4c58-afc5-eb749959bdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_b79d879d-9bf1-44b0-8ddb-72eb31a3420c" xlink:href="neo-20220930.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_b79d879d-9bf1-44b0-8ddb-72eb31a3420c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b4c19920-56cb-472b-a165-0fe519ad6916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b4c19920-56cb-472b-a165-0fe519ad6916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_04cd85da-f7a2-4da5-93bb-e538617b98f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_04cd85da-f7a2-4da5-93bb-e538617b98f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f1b33825-8938-4b2b-8197-cf430a17468e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_Goodwill_f1b33825-8938-4b2b-8197-cf430a17468e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0f375296-9f41-4a8d-87d2-f40c2313ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bcb6da53-f7d7-44ea-9fe9-94d954908da2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0f375296-9f41-4a8d-87d2-f40c2313ddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#AcquisitionsProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7fccafd0-fbf3-48dd-a206-be3e332db48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b802d92-4b94-49ad-9427-d30ce238534b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7fccafd0-fbf3-48dd-a206-be3e332db48e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b802d92-4b94-49ad-9427-d30ce238534b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_697c9dbb-fb35-42de-841f-4d5e897c785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b802d92-4b94-49ad-9427-d30ce238534b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_697c9dbb-fb35-42de-841f-4d5e897c785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7b2f122-e8c4-4a42-a4ab-79ff89c8be71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_697c9dbb-fb35-42de-841f-4d5e897c785f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7b2f122-e8c4-4a42-a4ab-79ff89c8be71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_9c4a5d43-08d5-4135-b9e5-91489394d428" xlink:href="neo-20220930.xsd#neo_InivataMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7b2f122-e8c4-4a42-a4ab-79ff89c8be71" xlink:to="loc_neo_InivataMember_9c4a5d43-08d5-4135-b9e5-91489394d428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_261422c8-7fc6-4a0a-bc2a-1685c99f847f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b802d92-4b94-49ad-9427-d30ce238534b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_261422c8-7fc6-4a0a-bc2a-1685c99f847f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4d410af2-f312-4783-b377-e6876edfee46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_261422c8-7fc6-4a0a-bc2a-1685c99f847f" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4d410af2-f312-4783-b377-e6876edfee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_50c15e35-f4d9-48d4-971c-b81ea91163da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_261422c8-7fc6-4a0a-bc2a-1685c99f847f" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_50c15e35-f4d9-48d4-971c-b81ea91163da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsScheduleofAmortizedCostDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1a4ab04f-d233-49a9-9b2d-b1d1c22443ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26e0b401-5da1-4387-a425-c4f953016ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1a4ab04f-d233-49a9-9b2d-b1d1c22443ae" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26e0b401-5da1-4387-a425-c4f953016ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d1ba08b1-a342-4363-8132-dd41d8769320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26e0b401-5da1-4387-a425-c4f953016ec0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d1ba08b1-a342-4363-8132-dd41d8769320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d1ba08b1-a342-4363-8132-dd41d8769320" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_36b81d27-c58a-4083-bc15-438cc9122655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_36b81d27-c58a-4083-bc15-438cc9122655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_0baf7400-7e98-4662-9c24-500feb96ed1b" xlink:href="neo-20220930.xsd#neo_YankeeBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_neo_YankeeBondsMember_0baf7400-7e98-4662-9c24-500feb96ed1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_c759319c-db34-4c09-b6eb-3a5177186659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_AgencySecuritiesMember_c759319c-db34-4c09-b6eb-3a5177186659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_1d8283a9-469f-4ea8-9055-369bc3e078d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_MunicipalBondsMember_1d8283a9-469f-4ea8-9055-369bc3e078d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d488638a-e6ec-4e2e-a37b-649d380d7a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_CommercialPaperMember_d488638a-e6ec-4e2e-a37b-649d380d7a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e3436e60-1799-40a7-88f6-972d67c06bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e3436e60-1799-40a7-88f6-972d67c06bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_b6c54715-1731-48ea-8bce-40a541c0d057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98366334-2800-4746-893e-4329b91c987f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_b6c54715-1731-48ea-8bce-40a541c0d057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26e0b401-5da1-4387-a425-c4f953016ec0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_21bb05f8-69eb-4e88-a492-33c299e09d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_21bb05f8-69eb-4e88-a492-33c299e09d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bf7d0de2-7593-4d83-bc1b-d5bc36bb59db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bf7d0de2-7593-4d83-bc1b-d5bc36bb59db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b2e3e847-c79d-4e5b-b973-00868343d76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b2e3e847-c79d-4e5b-b973-00868343d76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_aae9eef8-ea05-4e02-acf6-6fcc52734a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_aae9eef8-ea05-4e02-acf6-6fcc52734a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_0fe666e1-cbcc-4a8b-892a-945ca699af53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da3ac651-c41b-46e5-80bb-ebef062822f9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_0fe666e1-cbcc-4a8b-892a-945ca699af53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsFairValuebyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d00d2024-808c-4d0a-956a-cd80cdf80b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b18a00e-d7d3-4437-aa64-65739bfc2e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d00d2024-808c-4d0a-956a-cd80cdf80b5f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b18a00e-d7d3-4437-aa64-65739bfc2e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0bc668da-bd44-40c5-8ddc-41c5146e39db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b18a00e-d7d3-4437-aa64-65739bfc2e7a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0bc668da-bd44-40c5-8ddc-41c5146e39db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0bc668da-bd44-40c5-8ddc-41c5146e39db" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_9926d970-843b-4112-a2e0-506a7667e34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_9926d970-843b-4112-a2e0-506a7667e34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_d21cef6b-1f12-4856-8f4e-a8a3dde9b59e" xlink:href="neo-20220930.xsd#neo_YankeeBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_neo_YankeeBondsMember_d21cef6b-1f12-4856-8f4e-a8a3dde9b59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_60205c01-75e5-451b-93ed-f5d8575e39a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_AgencySecuritiesMember_60205c01-75e5-451b-93ed-f5d8575e39a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_f1aac5c1-b29b-4d4f-a7ec-28087bb4e1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_MunicipalBondsMember_f1aac5c1-b29b-4d4f-a7ec-28087bb4e1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_98331023-c685-4e99-a34a-e1f7e390105c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_CommercialPaperMember_98331023-c685-4e99-a34a-e1f7e390105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9d6f978e-65c3-4746-a3a2-d1825aab52aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9d6f978e-65c3-4746-a3a2-d1825aab52aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_521f82a0-69d2-4202-a0a8-8fccc1a8ae81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1f9c1d4-38ff-40c1-9271-9dfd95c18989" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_521f82a0-69d2-4202-a0a8-8fccc1a8ae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b18a00e-d7d3-4437-aa64-65739bfc2e7a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a8a01b70-b1fd-4682-978c-8707105cddcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a8a01b70-b1fd-4682-978c-8707105cddcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_21df1c79-774d-43a6-bb3c-1ce04d700d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_21df1c79-774d-43a6-bb3c-1ce04d700d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_04281038-6615-4b03-a58c-26887d091fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_04281038-6615-4b03-a58c-26887d091fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e18ad181-e5b0-494b-b181-9a81c050f2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8be74bfe-b632-4be0-ae67-559b1cd8a1d7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e18ad181-e5b0-494b-b181-9a81c050f2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_017f71a1-2a9c-4522-86b4-703c101f27e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_017f71a1-2a9c-4522-86b4-703c101f27e9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_be1ba742-dc94-4cf7-bd40-1fb0016ee60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_be1ba742-dc94-4cf7-bd40-1fb0016ee60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7577f4a4-2dfe-4316-844e-007b5cf748b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_be1ba742-dc94-4cf7-bd40-1fb0016ee60d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7577f4a4-2dfe-4316-844e-007b5cf748b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9181e46b-756a-4460-8e72-aa6d6c02a7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7577f4a4-2dfe-4316-844e-007b5cf748b8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9181e46b-756a-4460-8e72-aa6d6c02a7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1cf68d83-631d-4a79-851a-6cfc8d903c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1cf68d83-631d-4a79-851a-6cfc8d903c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1cf68d83-631d-4a79-851a-6cfc8d903c90" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9b654243-9b44-437b-b0fb-e28ae7491d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9b654243-9b44-437b-b0fb-e28ae7491d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2d83c1af-36e2-4329-9b03-83c9531165d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2d83c1af-36e2-4329-9b03-83c9531165d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_15383b60-477c-468c-947a-89affa7751b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bf2815-6c6c-4744-a9c6-742ce74f24ab" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_15383b60-477c-468c-947a-89affa7751b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_36ef4f54-2a70-4347-be12-84e3c26cb6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_36ef4f54-2a70-4347-be12-84e3c26cb6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_36ef4f54-2a70-4347-be12-84e3c26cb6b0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f5b7265c-bf3b-4132-aa8d-b9a8db0dfed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f5b7265c-bf3b-4132-aa8d-b9a8db0dfed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_9b80cb50-72b4-4642-bc0a-5a7b67dfc58d" xlink:href="neo-20220930.xsd#neo_YankeeBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_neo_YankeeBondsMember_9b80cb50-72b4-4642-bc0a-5a7b67dfc58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_ff12604a-8209-41d0-806f-f1db27d41f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_AgencySecuritiesMember_ff12604a-8209-41d0-806f-f1db27d41f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_104c92d1-eab2-4ce8-9d7a-b692e6903ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_MunicipalBondsMember_104c92d1-eab2-4ce8-9d7a-b692e6903ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1c785258-57ff-480b-aa54-6c81bbe08c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_CommercialPaperMember_1c785258-57ff-480b-aa54-6c81bbe08c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_76a52333-52e7-476a-a56f-0362e95d8ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_76a52333-52e7-476a-a56f-0362e95d8ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_931938d3-c207-4624-a6d2-bf440cc3478c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b205ac4-9e76-4b3a-8062-273feb135fe0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_931938d3-c207-4624-a6d2-bf440cc3478c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e45148fd-1840-4377-bd2a-cfefb072b80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e45148fd-1840-4377-bd2a-cfefb072b80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77504af0-b540-4940-b1ae-dc4b38071b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e45148fd-1840-4377-bd2a-cfefb072b80e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77504af0-b540-4940-b1ae-dc4b38071b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_464f3cac-1b5c-4be6-b40a-46b4b5bdce64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77504af0-b540-4940-b1ae-dc4b38071b11" xlink:to="loc_us-gaap_MoneyMarketFundsMember_464f3cac-1b5c-4be6-b40a-46b4b5bdce64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4815f7f7-2e22-4014-9f4f-a95db9df253f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77504af0-b540-4940-b1ae-dc4b38071b11" xlink:to="loc_us-gaap_CommercialPaperMember_4815f7f7-2e22-4014-9f4f-a95db9df253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60265bc8-42c8-4334-a7f0-b5b6a5dab02a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0eea4bca-24ab-4dc8-ad26-dccb03a7a7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0eea4bca-24ab-4dc8-ad26-dccb03a7a7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e5506de1-4e2d-4556-9201-74c9b4849fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e5506de1-4e2d-4556-9201-74c9b4849fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a3bfadd3-348e-4f5d-80fa-15e853725823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_918accad-5acd-4e47-b463-24c1ccf53b88" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a3bfadd3-348e-4f5d-80fa-15e853725823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a9d359ba-9050-4901-9d4c-1b6f752f1234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a9d359ba-9050-4901-9d4c-1b6f752f1234" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c7710433-67e2-443c-93b9-16bede76a8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c7710433-67e2-443c-93b9-16bede76a8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_44a1b9cd-fc4e-4660-aa5b-e7c841dc2f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c7710433-67e2-443c-93b9-16bede76a8d9" xlink:to="loc_us-gaap_SegmentDomain_44a1b9cd-fc4e-4660-aa5b-e7c841dc2f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_4c3b5bd7-4989-4613-a278-6fb0bb9883d0" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_44a1b9cd-fc4e-4660-aa5b-e7c841dc2f9d" xlink:to="loc_neo_ClinicalServicesMember_4c3b5bd7-4989-4613-a278-6fb0bb9883d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_5f5206fb-3147-482a-9ae4-90073d1d2fa8" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_44a1b9cd-fc4e-4660-aa5b-e7c841dc2f9d" xlink:to="loc_neo_PharmaServicesMember_5f5206fb-3147-482a-9ae4-90073d1d2fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a42bd6f4-a066-4eef-8618-77e87a7deb66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a42bd6f4-a066-4eef-8618-77e87a7deb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53230274-dfb2-4a15-91e6-65ce0a925bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a42bd6f4-a066-4eef-8618-77e87a7deb66" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53230274-dfb2-4a15-91e6-65ce0a925bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_e4fd618c-3d6c-41ec-b783-14b3762343f8" xlink:href="neo-20220930.xsd#neo_InivataMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53230274-dfb2-4a15-91e6-65ce0a925bf2" xlink:to="loc_neo_InivataMember_e4fd618c-3d6c-41ec-b783-14b3762343f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_e05108b4-3fc3-4b37-8e8e-b9b635d307bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_e05108b4-3fc3-4b37-8e8e-b9b635d307bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_82ebd39f-a920-4404-8fbd-c6c4a2851c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_e05108b4-3fc3-4b37-8e8e-b9b635d307bb" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_82ebd39f-a920-4404-8fbd-c6c4a2851c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionOtherMember_62d35d87-5b37-45df-90ac-4798f04aaf47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_82ebd39f-a920-4404-8fbd-c6c4a2851c15" xlink:to="loc_us-gaap_ErrorCorrectionOtherMember_62d35d87-5b37-45df-90ac-4798f04aaf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2dc23482-6f2b-4ab6-8d37-207edb689196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_51d7dc69-d101-4b30-bc86-3d46518a964d" xlink:to="loc_us-gaap_GoodwillLineItems_2dc23482-6f2b-4ab6-8d37-207edb689196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_474a66b3-422b-4ede-be13-e034facc9f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2dc23482-6f2b-4ab6-8d37-207edb689196" xlink:to="loc_us-gaap_GoodwillRollForward_474a66b3-422b-4ede-be13-e034facc9f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5c89c676-0e9b-40ce-9d14-c328a4d7023e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_474a66b3-422b-4ede-be13-e034facc9f4f" xlink:to="loc_us-gaap_Goodwill_5c89c676-0e9b-40ce-9d14-c328a4d7023e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_23643f6d-ec94-4eef-a5eb-06b057862fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_474a66b3-422b-4ede-be13-e034facc9f4f" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_23643f6d-ec94-4eef-a5eb-06b057862fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0df4f277-75a0-45d6-966b-d256b02a516e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_474a66b3-422b-4ede-be13-e034facc9f4f" xlink:to="loc_us-gaap_Goodwill_0df4f277-75a0-45d6-966b-d256b02a516e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_d85381c8-0eb1-43d8-a197-040b678ccd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2dc23482-6f2b-4ab6-8d37-207edb689196" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_d85381c8-0eb1-43d8-a197-040b678ccd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f82b2f4a-7ce8-4a2b-94c5-4f32564daf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f82b2f4a-7ce8-4a2b-94c5-4f32564daf4b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2578e62c-b40c-415e-98f6-4eed195f7bf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:to="loc_srt_RangeAxis_2578e62c-b40c-415e-98f6-4eed195f7bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bfe971e8-82da-487f-b2eb-bf285262140e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2578e62c-b40c-415e-98f6-4eed195f7bf0" xlink:to="loc_srt_RangeMember_bfe971e8-82da-487f-b2eb-bf285262140e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e146fc4-a412-4c90-a7cc-ed3f346083fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bfe971e8-82da-487f-b2eb-bf285262140e" xlink:to="loc_srt_MinimumMember_1e146fc4-a412-4c90-a7cc-ed3f346083fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b6efd4f9-831e-4669-bf0a-765428ee3b07" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bfe971e8-82da-487f-b2eb-bf285262140e" xlink:to="loc_srt_MaximumMember_b6efd4f9-831e-4669-bf0a-765428ee3b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3b15e8e0-798c-48a4-9862-924aad22a0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3b15e8e0-798c-48a4-9862-924aad22a0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3b15e8e0-798c-48a4-9862-924aad22a0d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6047db93-1a8e-46ef-92c9-0ea318818729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6047db93-1a8e-46ef-92c9-0ea318818729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6cf433a2-64ff-4dd2-84c3-b430632f72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6cf433a2-64ff-4dd2-84c3-b430632f72f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_c539b303-227c-46af-9183-53ec8374c8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_c539b303-227c-46af-9183-53ec8374c8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_6ba4ae09-70f3-4394-8ef5-e5a788f33d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_TrademarksMember_6ba4ae09-70f3-4394-8ef5-e5a788f33d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_125297df-b3b7-4c3a-aa5f-8731da3ab706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce889ba6-862d-479e-ba22-9b4fa5f1640d" xlink:to="loc_us-gaap_TradeNamesMember_125297df-b3b7-4c3a-aa5f-8731da3ab706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4addd612-52a4-41a2-90af-a9dc74b03119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4addd612-52a4-41a2-90af-a9dc74b03119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1886f355-8e69-4526-9852-938b135c8ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4addd612-52a4-41a2-90af-a9dc74b03119" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1886f355-8e69-4526-9852-938b135c8ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_e9280d12-9521-4b69-8b81-3a39094aab41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1886f355-8e69-4526-9852-938b135c8ce1" xlink:to="loc_us-gaap_TrademarksMember_e9280d12-9521-4b69-8b81-3a39094aab41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0c1148f3-a880-40b2-a391-ac9ac8c3a232" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_12164fe9-de38-436c-a80a-015ac65ff318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_12164fe9-de38-436c-a80a-015ac65ff318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_19f47b73-ae8b-48b4-b5fb-64cd027fa434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_19f47b73-ae8b-48b4-b5fb-64cd027fa434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_46771c60-19e6-404d-86cb-2a92a1d7740c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_46771c60-19e6-404d-86cb-2a92a1d7740c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_20631fa7-1a25-4a9b-98d7-58dfdd2b9c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_20631fa7-1a25-4a9b-98d7-58dfdd2b9c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_56a5d446-1d47-4d8d-bd6d-4eebfbccef0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_56a5d446-1d47-4d8d-bd6d-4eebfbccef0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_15acee90-9851-4366-8186-9acf015e4aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_15acee90-9851-4366-8186-9acf015e4aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_aaa69cb5-50be-4104-8ff0-4ad6448b7d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a6d0ba7-55fc-4cc8-ad4d-5cba9d1e32da" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_aaa69cb5-50be-4104-8ff0-4ad6448b7d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b20dc8ef-c656-4974-b97c-16c62536be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_74c36f8f-2e72-4726-930a-2024ec646fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b20dc8ef-c656-4974-b97c-16c62536be3c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_74c36f8f-2e72-4726-930a-2024ec646fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_542652e0-1ef6-4302-bf25-ebd4ae992bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_74c36f8f-2e72-4726-930a-2024ec646fad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_542652e0-1ef6-4302-bf25-ebd4ae992bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_add506a3-f396-4a89-8793-b2512d7c28af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_542652e0-1ef6-4302-bf25-ebd4ae992bda" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_add506a3-f396-4a89-8793-b2512d7c28af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b1d27142-66d9-4316-aa5a-c782d3100474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_add506a3-f396-4a89-8793-b2512d7c28af" xlink:to="loc_us-gaap_CostOfSalesMember_b1d27142-66d9-4316-aa5a-c782d3100474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8ade55b6-7686-4fbb-a12c-4193bdcdaa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_add506a3-f396-4a89-8793-b2512d7c28af" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8ade55b6-7686-4fbb-a12c-4193bdcdaa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b75f32a-ddda-462b-a197-0a9abbf7dc25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_74c36f8f-2e72-4726-930a-2024ec646fad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b75f32a-ddda-462b-a197-0a9abbf7dc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_52530f62-8d54-4ea7-8dc1-40d4b5a0ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b75f32a-ddda-462b-a197-0a9abbf7dc25" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_52530f62-8d54-4ea7-8dc1-40d4b5a0ff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_feeb73ac-3bf9-4552-8f8c-744c1dde392b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7d3aa61c-c83d-4d1c-85f1-0b2a062478f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_feeb73ac-3bf9-4552-8f8c-744c1dde392b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7d3aa61c-c83d-4d1c-85f1-0b2a062478f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_eef01fa7-d6b4-42d5-9090-5ba69bb9597b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_feeb73ac-3bf9-4552-8f8c-744c1dde392b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_eef01fa7-d6b4-42d5-9090-5ba69bb9597b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ab9565b3-1d27-4fb8-bbae-1b16d7653bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_feeb73ac-3bf9-4552-8f8c-744c1dde392b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ab9565b3-1d27-4fb8-bbae-1b16d7653bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_93507207-39d1-4ae0-845d-f82ef3982ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_feeb73ac-3bf9-4552-8f8c-744c1dde392b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_93507207-39d1-4ae0-845d-f82ef3982ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_65cbf215-d63e-46aa-90a3-571bc57987ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_feeb73ac-3bf9-4552-8f8c-744c1dde392b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_65cbf215-d63e-46aa-90a3-571bc57987ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_eb8404a5-b6fb-4b5c-8fa2-bdac7a5d026b" xlink:href="neo-20220930.xsd#neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_feeb73ac-3bf9-4552-8f8c-744c1dde392b" xlink:to="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_eb8404a5-b6fb-4b5c-8fa2-bdac7a5d026b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_25580255-a6ea-45cd-aa71-1b8fac5793eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_feeb73ac-3bf9-4552-8f8c-744c1dde392b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_25580255-a6ea-45cd-aa71-1b8fac5793eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2d89bbce-0fa3-49b3-8293-09c5e50d4489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2d89bbce-0fa3-49b3-8293-09c5e50d4489" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7a95e1a8-43a2-41df-af3d-b5d7b712f288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:to="loc_us-gaap_DebtInstrumentAxis_7a95e1a8-43a2-41df-af3d-b5d7b712f288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ee5933fa-b664-4d85-b606-71f6c24a95e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a95e1a8-43a2-41df-af3d-b5d7b712f288" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ee5933fa-b664-4d85-b606-71f6c24a95e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_aef9bac4-34c3-4f33-a4df-a46b57c17579" xlink:href="neo-20220930.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee5933fa-b664-4d85-b606-71f6c24a95e2" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_aef9bac4-34c3-4f33-a4df-a46b57c17579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_d3849bb1-c122-4518-a337-747fbf7d9495" xlink:href="neo-20220930.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee5933fa-b664-4d85-b606-71f6c24a95e2" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_d3849bb1-c122-4518-a337-747fbf7d9495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b1a59ab9-d6a2-4aa3-825a-ff1cd276784a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b1a59ab9-d6a2-4aa3-825a-ff1cd276784a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ce4390cf-ad01-4292-8274-f0babb24bc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b1a59ab9-d6a2-4aa3-825a-ff1cd276784a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ce4390cf-ad01-4292-8274-f0babb24bc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_f8de5183-e08e-40fd-9b82-bb5c0bf5874e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ce4390cf-ad01-4292-8274-f0babb24bc9a" xlink:to="loc_us-gaap_ConvertibleDebtMember_f8de5183-e08e-40fd-9b82-bb5c0bf5874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b13f6415-a294-4cf6-8969-21f24803b298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b13f6415-a294-4cf6-8969-21f24803b298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1871f247-6e7f-4bdd-bf3e-266bbd692ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b13f6415-a294-4cf6-8969-21f24803b298" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1871f247-6e7f-4bdd-bf3e-266bbd692ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_bcda3b0f-ab97-43b5-a80e-9036e63e2d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1871f247-6e7f-4bdd-bf3e-266bbd692ac1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_bcda3b0f-ab97-43b5-a80e-9036e63e2d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cce697b-8920-45d2-84e9-c056264d758b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cce697b-8920-45d2-84e9-c056264d758b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d86d9ab-fdf8-45b6-a879-9eaabdb933d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cce697b-8920-45d2-84e9-c056264d758b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d86d9ab-fdf8-45b6-a879-9eaabdb933d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_01851902-98ad-48c4-be35-c792b7b1c24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d86d9ab-fdf8-45b6-a879-9eaabdb933d6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_01851902-98ad-48c4-be35-c792b7b1c24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c2873725-af20-4a1c-979b-3d2367dc85e4" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d3d999c6-317a-441b-a590-2a11954abbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d3d999c6-317a-441b-a590-2a11954abbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c1956f81-154d-4e85-b146-002cca3a431e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c1956f81-154d-4e85-b146-002cca3a431e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f7931dad-28bc-48ec-b778-898f739b5481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f7931dad-28bc-48ec-b778-898f739b5481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0aea8b49-ef8e-4615-a54f-a76fad6bcee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0aea8b49-ef8e-4615-a54f-a76fad6bcee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_d6b119bd-0cc7-4b2c-9a27-fc23b9723d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_d6b119bd-0cc7-4b2c-9a27-fc23b9723d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_dd1cb973-827a-41cb-b517-d8b27b879c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_dd1cb973-827a-41cb-b517-d8b27b879c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtContractualCouponInterest_047b860d-7f7f-47e7-9fa7-5f9b2940c993" xlink:href="neo-20220930.xsd#neo_InterestExpenseDebtContractualCouponInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_neo_InterestExpenseDebtContractualCouponInterest_047b860d-7f7f-47e7-9fa7-5f9b2940c993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_70c83543-db9a-403b-8ba5-c91584169c28" xlink:href="neo-20220930.xsd#neo_InterestExpenseDebtAccretionOfDebtDiscount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_70c83543-db9a-403b-8ba5-c91584169c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_52167381-850f-4c05-8c4f-54e9113bec10" xlink:href="neo-20220930.xsd#neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_52167381-850f-4c05-8c4f-54e9113bec10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_9521a6bc-23b8-4c9d-af02-3c5a7ce3a335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_9521a6bc-23b8-4c9d-af02-3c5a7ce3a335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_eb595733-e3a2-4a8c-a6cf-ab4f705bcae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_528c6a98-7ca1-4e50-8e12-ddaa14186b34" xlink:to="loc_us-gaap_DebtInstrumentFairValue_eb595733-e3a2-4a8c-a6cf-ab4f705bcae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_afce8492-3ec1-471e-8f04-24ef0c9bfe08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23f7917d-4068-45ce-aecf-f38c60f28d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_afce8492-3ec1-471e-8f04-24ef0c9bfe08" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23f7917d-4068-45ce-aecf-f38c60f28d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a624b806-ed33-4967-acea-7b0a4224b0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23f7917d-4068-45ce-aecf-f38c60f28d60" xlink:to="loc_us-gaap_AwardTypeAxis_a624b806-ed33-4967-acea-7b0a4224b0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8440418-f0fe-467d-b1c9-e647587c7590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a624b806-ed33-4967-acea-7b0a4224b0bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8440418-f0fe-467d-b1c9-e647587c7590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_af5c6d01-d3f0-4ff4-935b-e7bcc05ea571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8440418-f0fe-467d-b1c9-e647587c7590" xlink:to="loc_us-gaap_RestrictedStockMember_af5c6d01-d3f0-4ff4-935b-e7bcc05ea571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f767f6fa-cf1c-433e-a151-d5fc19d1954e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8440418-f0fe-467d-b1c9-e647587c7590" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f767f6fa-cf1c-433e-a151-d5fc19d1954e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8352ec38-fc98-49ae-b010-351a04006d8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23f7917d-4068-45ce-aecf-f38c60f28d60" xlink:to="loc_srt_TitleOfIndividualAxis_8352ec38-fc98-49ae-b010-351a04006d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b801dc41-e445-451d-b4e9-9ceb1c94ad19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_8352ec38-fc98-49ae-b010-351a04006d8d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b801dc41-e445-451d-b4e9-9ceb1c94ad19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ChiefLegalOfficerMember_33d09320-20d7-4c3c-b85f-9485c80a45a5" xlink:href="neo-20220930.xsd#neo_ChiefLegalOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b801dc41-e445-451d-b4e9-9ceb1c94ad19" xlink:to="loc_neo_ChiefLegalOfficerMember_33d09320-20d7-4c3c-b85f-9485c80a45a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_0bcf6b01-8ade-4d05-b2e3-9290626c53d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b801dc41-e445-451d-b4e9-9ceb1c94ad19" xlink:to="loc_srt_ChiefExecutiveOfficerMember_0bcf6b01-8ade-4d05-b2e3-9290626c53d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23f7917d-4068-45ce-aecf-f38c60f28d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_895fe541-04ec-48e7-abe8-5a635ed8276f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_895fe541-04ec-48e7-abe8-5a635ed8276f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a741684d-d505-4650-a91f-a3d3b61d9cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a741684d-d505-4650-a91f-a3d3b61d9cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6c42b245-481d-42c6-9878-290afd020022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6c42b245-481d-42c6-9878-290afd020022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_d76aee84-1ba3-437c-b14c-e73c98fd0af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_d76aee84-1ba3-437c-b14c-e73c98fd0af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_68ae9196-fdb0-497c-b7c4-d68e39427758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchaseProgramAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a6319b8-de90-4d76-ba23-bd2376d50eca" xlink:to="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_68ae9196-fdb0-497c-b7c4-d68e39427758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7fac090e-8c86-444b-b663-285bbba25f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_71ea2500-8c17-4ef8-bdd3-0e97ed7ddb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7fac090e-8c86-444b-b663-285bbba25f7d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_71ea2500-8c17-4ef8-bdd3-0e97ed7ddb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03b5db92-3bc6-4784-9730-0b54a924a372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_71ea2500-8c17-4ef8-bdd3-0e97ed7ddb58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03b5db92-3bc6-4784-9730-0b54a924a372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c3466244-887f-40dc-a19e-0d44fb905670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_71ea2500-8c17-4ef8-bdd3-0e97ed7ddb58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c3466244-887f-40dc-a19e-0d44fb905670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract_d471d206-0057-4ad6-b9f5-ea06422b3d74" xlink:href="neo-20220930.xsd#neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_71ea2500-8c17-4ef8-bdd3-0e97ed7ddb58" xlink:to="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract_d471d206-0057-4ad6-b9f5-ea06422b3d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a70098fc-91b6-450d-9463-9bc319d2d8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract_d471d206-0057-4ad6-b9f5-ea06422b3d74" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a70098fc-91b6-450d-9463-9bc319d2d8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_acd35627-3ad0-4d30-aa03-6de5a3f3d116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract_d471d206-0057-4ad6-b9f5-ea06422b3d74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_acd35627-3ad0-4d30-aa03-6de5a3f3d116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d8e283c-b12b-49eb-b3f5-a4d68c1ad0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_71ea2500-8c17-4ef8-bdd3-0e97ed7ddb58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d8e283c-b12b-49eb-b3f5-a4d68c1ad0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ac8a66e6-41e8-4d03-a245-a0462609dd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7fac090e-8c86-444b-b663-285bbba25f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ac8a66e6-41e8-4d03-a245-a0462609dd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2f8167a-1613-46e4-a703-2255c2d105d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7fac090e-8c86-444b-b663-285bbba25f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2f8167a-1613-46e4-a703-2255c2d105d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dd69b93b-1104-4d4b-9bfd-21cfc4ccd824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2f8167a-1613-46e4-a703-2255c2d105d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dd69b93b-1104-4d4b-9bfd-21cfc4ccd824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5c10115-2e4d-45e7-819a-84abe0ab5428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2f8167a-1613-46e4-a703-2255c2d105d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5c10115-2e4d-45e7-819a-84abe0ab5428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract_58a7ff60-5ad4-4871-94c2-f8e4b0cb0e3a" xlink:href="neo-20220930.xsd#neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2f8167a-1613-46e4-a703-2255c2d105d7" xlink:to="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract_58a7ff60-5ad4-4871-94c2-f8e4b0cb0e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e036e897-d827-44fe-8bf7-2f9fa12102b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract_58a7ff60-5ad4-4871-94c2-f8e4b0cb0e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e036e897-d827-44fe-8bf7-2f9fa12102b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_da731ee0-ff8b-4676-9e87-b2339ddc1719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract_58a7ff60-5ad4-4871-94c2-f8e4b0cb0e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_da731ee0-ff8b-4676-9e87-b2339ddc1719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2fb1f87c-7d35-403e-bdcd-10e7d7f9655c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2f8167a-1613-46e4-a703-2255c2d105d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2fb1f87c-7d35-403e-bdcd-10e7d7f9655c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2c9808ef-7b75-4288-8d2d-79c850bb601e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7fac090e-8c86-444b-b663-285bbba25f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2c9808ef-7b75-4288-8d2d-79c850bb601e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0cb4b131-070a-41c7-ab12-4d51b399e6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b1488b-189e-4136-9a6c-c0b5ed754113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cb4b131-070a-41c7-ab12-4d51b399e6c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b1488b-189e-4136-9a6c-c0b5ed754113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb9d5440-c2b2-48ef-8e33-4e2a690a7cdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b1488b-189e-4136-9a6c-c0b5ed754113" xlink:to="loc_srt_RangeAxis_eb9d5440-c2b2-48ef-8e33-4e2a690a7cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ad675e9-0179-4da7-a8f5-15cf794914c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eb9d5440-c2b2-48ef-8e33-4e2a690a7cdd" xlink:to="loc_srt_RangeMember_8ad675e9-0179-4da7-a8f5-15cf794914c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fabff48-653e-4102-b953-a6ea28efc9b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8ad675e9-0179-4da7-a8f5-15cf794914c9" xlink:to="loc_srt_MinimumMember_8fabff48-653e-4102-b953-a6ea28efc9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ee1da91-2f76-431f-8806-442b4e94fb42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8ad675e9-0179-4da7-a8f5-15cf794914c9" xlink:to="loc_srt_MaximumMember_1ee1da91-2f76-431f-8806-442b4e94fb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b1488b-189e-4136-9a6c-c0b5ed754113" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cf45bd11-f43d-4db5-baf8-51fd14ae1429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cf45bd11-f43d-4db5-baf8-51fd14ae1429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b4780397-f5ae-4850-91c0-456874ccec86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b4780397-f5ae-4850-91c0-456874ccec86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_56a787ce-192c-4dd2-a639-5d6ae05d8d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_56a787ce-192c-4dd2-a639-5d6ae05d8d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c4e84622-54d5-470c-bc30-0c814c42a983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c4e84622-54d5-470c-bc30-0c814c42a983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3d7c98de-a4e0-432a-9193-00920207f951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d532290-54b0-41cc-950e-df42371be362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3d7c98de-a4e0-432a-9193-00920207f951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_780e9ea5-2e3a-4e8c-9dc2-442fdbffeee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b426dd7-ca0b-473b-a5e8-716ca9399031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_780e9ea5-2e3a-4e8c-9dc2-442fdbffeee0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b426dd7-ca0b-473b-a5e8-716ca9399031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5f7a6f5a-08f6-4cb9-a6f6-25e0866f6442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b426dd7-ca0b-473b-a5e8-716ca9399031" xlink:to="loc_us-gaap_AwardTypeAxis_5f7a6f5a-08f6-4cb9-a6f6-25e0866f6442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b4185a7-4254-44ce-9cb3-dcee08b634ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5f7a6f5a-08f6-4cb9-a6f6-25e0866f6442" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b4185a7-4254-44ce-9cb3-dcee08b634ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c8a55461-a125-4884-86d0-948e8ca39230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b4185a7-4254-44ce-9cb3-dcee08b634ff" xlink:to="loc_us-gaap_RestrictedStockMember_c8a55461-a125-4884-86d0-948e8ca39230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2621252-e0c8-4da0-ab1a-a468e1101d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b426dd7-ca0b-473b-a5e8-716ca9399031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2621252-e0c8-4da0-ab1a-a468e1101d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2621252-e0c8-4da0-ab1a-a468e1101d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6c9eaae8-0acf-46a2-8a62-5bc355a95ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6c9eaae8-0acf-46a2-8a62-5bc355a95ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6e7ffde-4a95-4cb4-8681-8e838cb91742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6e7ffde-4a95-4cb4-8681-8e838cb91742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_14a8d1bc-f1de-44bf-bd76-42a2fa885b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_14a8d1bc-f1de-44bf-bd76-42a2fa885b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4fdc21e3-0def-470c-83fa-de3b1866dd62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4fdc21e3-0def-470c-83fa-de3b1866dd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_13358a69-1c5a-43c2-a64a-1fbf164d3c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cda89770-2644-4dda-a71a-47a1a7ded0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_13358a69-1c5a-43c2-a64a-1fbf164d3c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2621252-e0c8-4da0-ab1a-a468e1101d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7efd6b9c-e894-4e8f-b469-a7e5663a091d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7efd6b9c-e894-4e8f-b469-a7e5663a091d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0306bba9-50e7-4968-bbe3-9a01aa750c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0306bba9-50e7-4968-bbe3-9a01aa750c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_caf3efc1-a98c-4ea9-aa74-1a7b171b5521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_caf3efc1-a98c-4ea9-aa74-1a7b171b5521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a55da3e-a0d8-4d12-92ef-aa6f57285df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a55da3e-a0d8-4d12-92ef-aa6f57285df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a4d7d83-4465-4eb3-ab74-6af4345b93f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_421e8a38-c212-4703-ac7f-e84af3249da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a4d7d83-4465-4eb3-ab74-6af4345b93f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fefb66fe-70d9-4a0a-a572-778e97574cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_82da1c30-4d21-4713-ae86-5a6ea19510e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fefb66fe-70d9-4a0a-a572-778e97574cb8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_82da1c30-4d21-4713-ae86-5a6ea19510e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_09cfa9a2-7ac4-49e3-8200-435a1a1aee21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fefb66fe-70d9-4a0a-a572-778e97574cb8" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_09cfa9a2-7ac4-49e3-8200-435a1a1aee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_feea910a-76d2-4be5-b1e9-b5cca2b61970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fefb66fe-70d9-4a0a-a572-778e97574cb8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_feea910a-76d2-4be5-b1e9-b5cca2b61970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_c6d61a50-5a74-47d1-8103-7a8186fbb30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fefb66fe-70d9-4a0a-a572-778e97574cb8" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_c6d61a50-5a74-47d1-8103-7a8186fbb30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#RevenueRecognitionContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b3616e03-2308-4c1d-aaca-9899c54ddd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_590a2c5c-851f-482b-b18f-a6d56dce4902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b3616e03-2308-4c1d-aaca-9899c54ddd5c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_590a2c5c-851f-482b-b18f-a6d56dce4902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6acf4150-2d0b-4f8b-818d-5ff02f8fd413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_590a2c5c-851f-482b-b18f-a6d56dce4902" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6acf4150-2d0b-4f8b-818d-5ff02f8fd413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_3133e3a3-6c76-4711-9102-7f591234d9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_590a2c5c-851f-482b-b18f-a6d56dce4902" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_3133e3a3-6c76-4711-9102-7f591234d9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_50b502b7-d4ce-45d4-882e-cab7618c0b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_590a2c5c-851f-482b-b18f-a6d56dce4902" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_50b502b7-d4ce-45d4-882e-cab7618c0b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAbstract_19b48e3b-d58e-47c4-bb1c-1b03c3369b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b3616e03-2308-4c1d-aaca-9899c54ddd5c" xlink:to="loc_us-gaap_CapitalizedContractCostAbstract_19b48e3b-d58e-47c4-bb1c-1b03c3369b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_98a0b122-afca-4479-8511-2266a3a9d676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract_19b48e3b-d58e-47c4-bb1c-1b03c3369b56" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_98a0b122-afca-4479-8511-2266a3a9d676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_218a00c8-5e30-43af-90a9-856600391bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract_19b48e3b-d58e-47c4-bb1c-1b03c3369b56" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_218a00c8-5e30-43af-90a9-856600391bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_93ee1c1e-8e29-4302-aaec-0bfa5d245e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract_19b48e3b-d58e-47c4-bb1c-1b03c3369b56" xlink:to="loc_us-gaap_CapitalizedContractCostGross_93ee1c1e-8e29-4302-aaec-0bfa5d245e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_7e7ccc13-24a2-49a1-bc3a-7e10d559fc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b3616e03-2308-4c1d-aaca-9899c54ddd5c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_7e7ccc13-24a2-49a1-bc3a-7e10d559fc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_14418626-6a5b-4e82-abe8-6e5af8e20f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_7e7ccc13-24a2-49a1-bc3a-7e10d559fc01" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_14418626-6a5b-4e82-abe8-6e5af8e20f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d50160be-f0d7-4db2-a666-f143fa239f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_7e7ccc13-24a2-49a1-bc3a-7e10d559fc01" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d50160be-f0d7-4db2-a666-f143fa239f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_62685cc6-5aff-4352-a721-ea8fca699983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_7e7ccc13-24a2-49a1-bc3a-7e10d559fc01" xlink:to="loc_us-gaap_ContractWithCustomerLiability_62685cc6-5aff-4352-a721-ea8fca699983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a36dfdb6-97ea-4f18-b513-8c3a467e89d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_252c5da8-07ec-492d-948a-2b9d735d3f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a36dfdb6-97ea-4f18-b513-8c3a467e89d2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_252c5da8-07ec-492d-948a-2b9d735d3f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_baa2351f-e4c5-47c7-b3ae-f3b6e8e01ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_252c5da8-07ec-492d-948a-2b9d735d3f65" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_baa2351f-e4c5-47c7-b3ae-f3b6e8e01ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3a5b80d9-41ee-4fe6-b1e8-216f228f6cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_baa2351f-e4c5-47c7-b3ae-f3b6e8e01ca9" xlink:to="loc_us-gaap_SegmentDomain_3a5b80d9-41ee-4fe6-b1e8-216f228f6cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_e11b481e-eeb1-4116-9fe9-a1b507de3e78" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3a5b80d9-41ee-4fe6-b1e8-216f228f6cd5" xlink:to="loc_neo_ClinicalServicesMember_e11b481e-eeb1-4116-9fe9-a1b507de3e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_07022680-9934-4e1b-aef0-687f19c27281" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3a5b80d9-41ee-4fe6-b1e8-216f228f6cd5" xlink:to="loc_neo_PharmaServicesMember_07022680-9934-4e1b-aef0-687f19c27281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_585dc2f3-93aa-4612-9680-67879f21ac8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_252c5da8-07ec-492d-948a-2b9d735d3f65" xlink:to="loc_srt_ProductOrServiceAxis_585dc2f3-93aa-4612-9680-67879f21ac8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_585dc2f3-93aa-4612-9680-67879f21ac8e" xlink:to="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClientDirectBillingMember_99fe6fef-9623-4b68-beab-f90a4fa98e60" xlink:href="neo-20220930.xsd#neo_ClientDirectBillingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:to="loc_neo_ClientDirectBillingMember_99fe6fef-9623-4b68-beab-f90a4fa98e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommercialInsuranceMember_0e3e304a-add0-406a-90df-cd7ca585a658" xlink:href="neo-20220930.xsd#neo_CommercialInsuranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:to="loc_neo_CommercialInsuranceMember_0e3e304a-add0-406a-90df-cd7ca585a658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_MedicareAndOtherGovernmentalMember_14857c1f-c33f-41f1-8668-b4da64b70f22" xlink:href="neo-20220930.xsd#neo_MedicareAndOtherGovernmentalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:to="loc_neo_MedicareAndOtherGovernmentalMember_14857c1f-c33f-41f1-8668-b4da64b70f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SelfPayServicesMember_5073e24a-8575-4a8a-90cd-80df3c0a6812" xlink:href="neo-20220930.xsd#neo_SelfPayServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80d6ea68-c709-401b-b418-b50c5f975aa9" xlink:to="loc_neo_SelfPayServicesMember_5073e24a-8575-4a8a-90cd-80df3c0a6812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_777119c2-4caf-4852-9220-50eac95b3df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_252c5da8-07ec-492d-948a-2b9d735d3f65" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_777119c2-4caf-4852-9220-50eac95b3df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0d7978ec-a722-4fcd-a4c1-c33f8698ca37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_777119c2-4caf-4852-9220-50eac95b3df3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0d7978ec-a722-4fcd-a4c1-c33f8698ca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4201a3a9-e4b1-41a6-b243-47e1127b359c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_ea3d0684-65b3-4055-abfb-c4d3f08a83c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4201a3a9-e4b1-41a6-b243-47e1127b359c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_ea3d0684-65b3-4055-abfb-c4d3f08a83c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a9b1b74-07be-444f-acf8-5a88f8450ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_ea3d0684-65b3-4055-abfb-c4d3f08a83c4" xlink:to="loc_us-gaap_AwardTypeAxis_6a9b1b74-07be-444f-acf8-5a88f8450ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a543e09-d38c-4af6-afa7-12dff76ac743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6a9b1b74-07be-444f-acf8-5a88f8450ee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a543e09-d38c-4af6-afa7-12dff76ac743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cd167bae-f1f8-42b4-8dc3-ed71e34746dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a543e09-d38c-4af6-afa7-12dff76ac743" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cd167bae-f1f8-42b4-8dc3-ed71e34746dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b5059d6f-3fc5-4789-99c2-58c25ed584ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a543e09-d38c-4af6-afa7-12dff76ac743" xlink:to="loc_us-gaap_RestrictedStockMember_b5059d6f-3fc5-4789-99c2-58c25ed584ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a8715c2f-3310-4e60-891b-6f1f768407a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_ea3d0684-65b3-4055-abfb-c4d3f08a83c4" xlink:to="loc_us-gaap_DebtInstrumentAxis_a8715c2f-3310-4e60-891b-6f1f768407a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_969fe21a-764f-40b4-9c9e-705cac64a041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a8715c2f-3310-4e60-891b-6f1f768407a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_969fe21a-764f-40b4-9c9e-705cac64a041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_f2ddc774-4b7a-4907-a3e7-da2899d50d79" xlink:href="neo-20220930.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_969fe21a-764f-40b4-9c9e-705cac64a041" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_f2ddc774-4b7a-4907-a3e7-da2899d50d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_08e65145-fd75-4bc8-ac38-79b8e0c0f7b7" xlink:href="neo-20220930.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_969fe21a-764f-40b4-9c9e-705cac64a041" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_08e65145-fd75-4bc8-ac38-79b8e0c0f7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_ea3d0684-65b3-4055-abfb-c4d3f08a83c4" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_93ea6e36-4edb-4869-bf42-5863a03556cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_93ea6e36-4edb-4869-bf42-5863a03556cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_2a05549c-8c36-49e4-a90b-b300089e44b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_2a05549c-8c36-49e4-a90b-b300089e44b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_077f7cdc-b4c2-439a-bcdc-3c488811589a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_077f7cdc-b4c2-439a-bcdc-3c488811589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_e25203f5-40d1-486a-9280-4fbf92736b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_e25203f5-40d1-486a-9280-4fbf92736b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4edd45ac-760e-496e-b3a0-5678148a122b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4edd45ac-760e-496e-b3a0-5678148a122b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_30329e0f-7e18-469a-bccd-efc31320d639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_30329e0f-7e18-469a-bccd-efc31320d639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_306db56d-85d0-4642-b008-3bb9a4ae6b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_59fdd506-664d-49f8-ae76-29efef1ba080" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_306db56d-85d0-4642-b008-3bb9a4ae6b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_28e5e484-f535-4810-80cd-b279bf7075b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_28e5e484-f535-4810-80cd-b279bf7075b5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_89c67956-e2f7-4c60-8639-fc6a2c016848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_89c67956-e2f7-4c60-8639-fc6a2c016848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_89c67956-e2f7-4c60-8639-fc6a2c016848" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a4c699a-a622-4a3e-b5a4-4f83b15eed32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a4c699a-a622-4a3e-b5a4-4f83b15eed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_881a78ec-eadd-44cc-bfdb-fe988a704c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:to="loc_us-gaap_RestrictedStockMember_881a78ec-eadd-44cc-bfdb-fe988a704c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_6c01f208-a307-4354-88bf-b2a2b845bc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac97bfa2-68e8-40cd-99d3-b5d787094298" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_6c01f208-a307-4354-88bf-b2a2b845bc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_712ecde4-2acf-4a1b-b929-3862bd16e952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_712ecde4-2acf-4a1b-b929-3862bd16e952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fcd72def-ec79-40cc-9ba1-943ddd2780aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_712ecde4-2acf-4a1b-b929-3862bd16e952" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fcd72def-ec79-40cc-9ba1-943ddd2780aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_284dcfe8-bb05-4c9f-8876-c7c0a52d64b2" xlink:href="neo-20220930.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fcd72def-ec79-40cc-9ba1-943ddd2780aa" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_284dcfe8-bb05-4c9f-8876-c7c0a52d64b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_97fa4dcf-39e2-45f6-9eb6-49663a135991" xlink:href="neo-20220930.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fcd72def-ec79-40cc-9ba1-943ddd2780aa" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_97fa4dcf-39e2-45f6-9eb6-49663a135991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d48a55be-74f7-414c-a9f0-5c21a74d1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d48a55be-74f7-414c-a9f0-5c21a74d1e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_431b60bc-2f9a-497a-93e6-38e4de1ffe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d48a55be-74f7-414c-a9f0-5c21a74d1e58" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_431b60bc-2f9a-497a-93e6-38e4de1ffe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember_57af0161-6c10-4918-9de3-17d41c218388" xlink:href="neo-20220930.xsd#neo_CappedCallTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_431b60bc-2f9a-497a-93e6-38e4de1ffe79" xlink:to="loc_neo_CappedCallTransactionsMember_57af0161-6c10-4918-9de3-17d41c218388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_391c283d-3fbc-4121-8d38-c52d6e52c2c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3cfe9f0c-39ba-4645-bb0f-8e4cda4d4223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3cfe9f0c-39ba-4645-bb0f-8e4cda4d4223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_8e9cf793-36ea-4037-a6c3-6231883d76c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_8e9cf793-36ea-4037-a6c3-6231883d76c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c812cc98-794d-479f-83f6-5ef2f2389f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_876699b8-a632-4829-bfad-ff33957eac59" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c812cc98-794d-479f-83f6-5ef2f2389f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18ba60fe-38b9-40ad-8310-a5739e3f2973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationTable_74aab52f-cc30-4b4a-8945-38b9973eeac2" xlink:href="neo-20220930.xsd#neo_ContractualObligationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18ba60fe-38b9-40ad-8310-a5739e3f2973" xlink:to="loc_neo_ContractualObligationTable_74aab52f-cc30-4b4a-8945-38b9973eeac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1f5f8144-eb7c-4c25-a825-3d7741857356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ContractualObligationTable_74aab52f-cc30-4b4a-8945-38b9973eeac2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1f5f8144-eb7c-4c25-a825-3d7741857356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b127abc7-70cb-4f32-88a8-16a9b711003a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1f5f8144-eb7c-4c25-a825-3d7741857356" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b127abc7-70cb-4f32-88a8-16a9b711003a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PatentInfringementComplaintMember_2554a8e5-8dcf-4ec3-830a-cabb1ab40fde" xlink:href="neo-20220930.xsd#neo_PatentInfringementComplaintMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b127abc7-70cb-4f32-88a8-16a9b711003a" xlink:to="loc_neo_PatentInfringementComplaintMember_2554a8e5-8dcf-4ec3-830a-cabb1ab40fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FederalHealthcareProgramRevenueMember_fd8fe2e0-7953-4ae0-8542-7fadc2addff3" xlink:href="neo-20220930.xsd#neo_FederalHealthcareProgramRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b127abc7-70cb-4f32-88a8-16a9b711003a" xlink:to="loc_neo_FederalHealthcareProgramRevenueMember_fd8fe2e0-7953-4ae0-8542-7fadc2addff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationLineItems_6842d6db-96fc-4ac0-bc5a-c8a8a6d09049" xlink:href="neo-20220930.xsd#neo_ContractualObligationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ContractualObligationTable_74aab52f-cc30-4b4a-8945-38b9973eeac2" xlink:to="loc_neo_ContractualObligationLineItems_6842d6db-96fc-4ac0-bc5a-c8a8a6d09049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_362aa612-c7ae-418e-b1c7-0a4d7d556adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ContractualObligationLineItems_6842d6db-96fc-4ac0-bc5a-c8a8a6d09049" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_362aa612-c7ae-418e-b1c7-0a4d7d556adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_320d95fc-fd8a-4d63-be3b-d7b91cbf7908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ContractualObligationLineItems_6842d6db-96fc-4ac0-bc5a-c8a8a6d09049" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_320d95fc-fd8a-4d63-be3b-d7b91cbf7908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_919c4096-7483-4b84-a29a-ec8f917fcff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d90743c-afe3-437d-8271-77ca1922665b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_919c4096-7483-4b84-a29a-ec8f917fcff4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d90743c-afe3-437d-8271-77ca1922665b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef71507e-e493-4835-b178-0ac2aca0217e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d90743c-afe3-437d-8271-77ca1922665b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef71507e-e493-4835-b178-0ac2aca0217e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0311bba9-fdfe-4c2c-8285-f5a3771825f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef71507e-e493-4835-b178-0ac2aca0217e" xlink:to="loc_us-gaap_RelatedPartyDomain_0311bba9-fdfe-4c2c-8285-f5a3771825f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_18374068-faa8-4de7-b3b7-6653404c86fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0311bba9-fdfe-4c2c-8285-f5a3771825f5" xlink:to="loc_srt_AffiliatedEntityMember_18374068-faa8-4de7-b3b7-6653404c86fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_182bff63-953f-4f6a-9948-a51398cb7378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d90743c-afe3-437d-8271-77ca1922665b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_182bff63-953f-4f6a-9948-a51398cb7378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_182bff63-953f-4f6a-9948-a51398cb7378" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StrategicAllianceWithInivataLimitedMember_739c8441-943d-4f85-924f-a57f6a2c8e5e" xlink:href="neo-20220930.xsd#neo_StrategicAllianceWithInivataLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:to="loc_neo_StrategicAllianceWithInivataLimitedMember_739c8441-943d-4f85-924f-a57f6a2c8e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember_513601bb-b9db-4f6e-8a98-448102900f77" xlink:href="neo-20220930.xsd#neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:to="loc_neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember_513601bb-b9db-4f6e-8a98-448102900f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_75807202-c1a0-417b-ab7e-c2336b5a9249" xlink:href="neo-20220930.xsd#neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f05ad3b0-1a45-4cb0-b962-dc28d6e94372" xlink:to="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_75807202-c1a0-417b-ab7e-c2336b5a9249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3a59d0e0-e9e6-4ac3-bae1-2da03c93d591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d90743c-afe3-437d-8271-77ca1922665b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_3a59d0e0-e9e6-4ac3-bae1-2da03c93d591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_fa9647c1-f80b-44ef-a743-00b2b8b3f7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3a59d0e0-e9e6-4ac3-bae1-2da03c93d591" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_fa9647c1-f80b-44ef-a743-00b2b8b3f7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_6afe108a-3722-4930-bfcb-150d33a3ac7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3a59d0e0-e9e6-4ac3-bae1-2da03c93d591" xlink:to="loc_us-gaap_RevenueFromRelatedParties_6afe108a-3722-4930-bfcb-150d33a3ac7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="neo-20220930.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_195cab45-3ff6-4132-b3dd-f92c9bc4c22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f3f1087a-b33e-4e54-b3f7-efb034c7eec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_195cab45-3ff6-4132-b3dd-f92c9bc4c22e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f3f1087a-b33e-4e54-b3f7-efb034c7eec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c73fd5c-9628-4744-a554-4fb3db3de79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_195cab45-3ff6-4132-b3dd-f92c9bc4c22e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c73fd5c-9628-4744-a554-4fb3db3de79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0d4ad3f3-0c7b-4719-b016-13c20f4a4d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c73fd5c-9628-4744-a554-4fb3db3de79b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0d4ad3f3-0c7b-4719-b016-13c20f4a4d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f77e3e53-53da-4931-a7df-fa043195ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0d4ad3f3-0c7b-4719-b016-13c20f4a4d9b" xlink:to="loc_us-gaap_SegmentDomain_f77e3e53-53da-4931-a7df-fa043195ce29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_5f4070d5-b0e1-4fd9-9d90-858e305f3ab4" xlink:href="neo-20220930.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f77e3e53-53da-4931-a7df-fa043195ce29" xlink:to="loc_neo_ClinicalServicesMember_5f4070d5-b0e1-4fd9-9d90-858e305f3ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_bc255b3c-d732-4c6e-a623-ebe9c28744e5" xlink:href="neo-20220930.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f77e3e53-53da-4931-a7df-fa043195ce29" xlink:to="loc_neo_PharmaServicesMember_bc255b3c-d732-4c6e-a623-ebe9c28744e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_36a92e45-8a28-440a-b93b-2c608d4cfb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c73fd5c-9628-4744-a554-4fb3db3de79b" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_36a92e45-8a28-440a-b93b-2c608d4cfb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_14c42ecc-7472-42e2-b760-75c8091acf81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_36a92e45-8a28-440a-b93b-2c608d4cfb8e" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_14c42ecc-7472-42e2-b760-75c8091acf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_COVID19PCRTestingMember_08aac5c1-bb23-449b-beae-a8ac1486d165" xlink:href="neo-20220930.xsd#neo_COVID19PCRTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_14c42ecc-7472-42e2-b760-75c8091acf81" xlink:to="loc_neo_COVID19PCRTestingMember_08aac5c1-bb23-449b-beae-a8ac1486d165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c73fd5c-9628-4744-a554-4fb3db3de79b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6ae85353-7507-4732-8bb7-94364b4f6dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6ae85353-7507-4732-8bb7-94364b4f6dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_529f3444-d8d1-49ba-bbff-501133c784dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_529f3444-d8d1-49ba-bbff-501133c784dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_dc42976b-5398-4788-99f0-9a3e21e85f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_GrossProfit_dc42976b-5398-4788-99f0-9a3e21e85f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7d779e14-93e5-4b84-881b-441459377f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7d779e14-93e5-4b84-881b-441459377f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8baf65b6-05d3-46dc-9d38-8a5f6d95c977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8baf65b6-05d3-46dc-9d38-8a5f6d95c977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_0170c5c0-8e18-4f1e-8381-db3cf2c595da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_SellingAndMarketingExpense_0170c5c0-8e18-4f1e-8381-db3cf2c595da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_56e3426f-ce4c-486f-8b17-b77d55a70aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_OperatingExpenses_56e3426f-ce4c-486f-8b17-b77d55a70aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6fa3c83c-f963-4018-a459-73a877321640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_OperatingIncomeLoss_6fa3c83c-f963-4018-a459-73a877321640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3ed5fee7-bc55-4c26-927a-44a6c7083b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_InterestExpense_3ed5fee7-bc55-4c26-927a-44a6c7083b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_556b29eb-da81-412a-9179-0c75a5014198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_556b29eb-da81-412a-9179-0c75a5014198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_f2e50eb1-bf31-4831-947c-64a449120589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_GainLossOnInvestments_f2e50eb1-bf31-4831-947c-64a449120589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d8ed012-59f9-4b21-8f8d-ce2002256419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d8ed012-59f9-4b21-8f8d-ce2002256419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a7bb9a62-d84f-4f26-b3c7-1f32d1d0f1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a7bb9a62-d84f-4f26-b3c7-1f32d1d0f1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_251fde62-acc6-4b28-9af0-ba0fc98b027e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_NetIncomeLoss_251fde62-acc6-4b28-9af0-ba0fc98b027e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IntangibleAssetsAcquiredAmortizationExpense_777ba963-2ad8-4d6b-bcbc-f7a50a85c4f3" xlink:href="neo-20220930.xsd#neo_IntangibleAssetsAcquiredAmortizationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_neo_IntangibleAssetsAcquiredAmortizationExpense_777ba963-2ad8-4d6b-bcbc-f7a50a85c4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_09ceef32-52be-4641-b95f-eb19f99e825e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_da45f602-9ae2-494b-8ab9-1a38b639b02e" xlink:to="loc_us-gaap_InventoryWriteDown_09ceef32-52be-4641-b95f-eb19f99e825e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (@ Q8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'YI?$3_ )'_ ,3?]A2Z_P#1K5SU=#\1/^1_\3?]A2Z_]&M7/5^_T/X4/1?D
M?PGC?]ZJ_P")_FSZ*_8I_P"1ZU[_ +!W_M5**/V*?^1ZU[_L'?\ M5**_)^(
M_P#D8R]%^1_4GA[_ ,B"E_BE_P"E,^Q****^8/T@**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"+<6SD)'X@M8@KQG_IO&O##_ &D (_NG.1XF.X8Q&'BZF'ESKML_^#_6A[>
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M !2&EI#TH \0_:Y\:^&/A_\ "JXU?7K;[7J'F"#2X8G"323MS@-@X0 $MQC
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M7EM*4=&!1XW4X((Z@@BOU=_8X_: 7XX?#6.'4K@/XKT4):ZBK'YIUQ^[N/\
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M8'J"*?17RY]0?-'QX_8:\%?%*RN;[P[:V_A#Q, 6CFLXPEI.W7$T2C SS\Z
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M#^9I?K^AY/AYA/K&>1JM:4XRE]_N_P#MQZ[1117X^?U0%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (:\Z_:%^(A^%?P9\5^)(I!'>6UFT
M=H2?^7B0B.(^^'<'CL#7HM?''_!3'Q6VG?#+POX?1]C:IJ;7+@'EXX(\$8]-
MTR'Z@5Z>68=8K&4J+V;U]%J_P/,S/$/"X.K66Z6GJ]%^)XY_P3M^$P\9?$^_
M\9:C%YUEX=C!@+\A[R7(4^^U Y]BR&OTI%> ?L+^!D\%_LZZ#,T>R[UIY-5G
M..3O.V/_ ,A)&?Q-?0!KKSS%/%XZ;OI'W5\O^#=G'D>$6$P--=9>\_5_\"R/
MEGXW>')/!WQ!&HV68(KPB]A9>-DH/SX]]V&_X$*^D_#&M)XB\/:=J<>-MU D
MI _A)'*_@<C\*\\_:-T-=0\#QZ@%'FZ?<*V[_8?Y"/S*?E4W[.NJF_\ A\+9
MB2UE=20@'^Z<./U<_E7Y5@8_4,ZK89?#47,O7^KG;27LL1*"V>IZC1117VYZ
M1^%WB7_D8]5_Z^Y?_0S7ZE?L$?\ )L7AO_KXO/\ TIDK\M?$O_(QZK_U]R_^
MAFOU+_8'_P"38_#?_7Q>?^E,E?JO$_\ R+X?XE^3/RGA?_D8U/\ "_S1\Z?\
M%"_V?3X>UY/B5HEKC3=3=8=7CC7B&YZ+-QT$@&"?[XR>7KYS^ 7QCO\ X'?$
MS3/$MIOEM%;R-0M%./M%LQ&]/J,!@>S**_83QAX3TSQWX7U/P_K-N+K3-1@:
MWGB/7:>X/9@<$'L0#VK\;/C-\*]3^#/Q%U;PKJ@+M:ONM[G:0MS W,<B_4=?
M1@P[&L\@QT,PPLL#B-6E;UC_ ,#_ "-.(,#/+\5''X?1-W])?\'_ #/V:\/>
M(+#Q5H>GZQI5REYIM_ EQ;SQGAT89!_7IVK2KX!_X)X?M!_8;M_AAKESBWG+
MW&BRRMPDGWI+?GLW+J/7>.K 5]^BO@<QP,\OQ,J$MNC[KI_P?,^^RW'0S##1
MKQWZKL^O]=C\B/VT/^3G/'7_ %\0?^DT5?0W_!+?_FIO_<,_]NZ^>?VT/^3G
M/'7_ %\0?^DT5?0W_!+?_FIO_<,_]NZ_1LQ_Y$"_PP_.)^<Y=_R4#_Q3_*1Z
M=_P4:_Y-ZB_[#5M_Z!+7YM>";Z#3/&>@WEU((;:WO[>:60C(5%D4D\>@!K])
M?^"C7_)O47_8:MO_ $"6OS#@@DN9HX88VEED8(D:*69B3@  =2?2GPRE++FG
MW?Z"XGDXYDI+HE^;/UX_X;(^#.?^1[LO^_$__P ;H_X;)^#/_0]V7_?B?_XW
M7Y9_\*=\>_\ 0D>(_P#P4W'_ ,11_P *=\>_]"1XC_\ !3<?_$5Q?ZM9=_S^
M?WQ_R.[_ %ES'_GPONE_F?J9_P -D_!G_H>[+_OQ/_\ &Z]3\,^)=-\8:#8Z
MUHUVM]I=[&);>Y0$"1#T(! /YBOQ@_X4[X]_Z$CQ'_X*;C_XBOUK_9PT^72O
M@/X$L[BUFL;F#28$FM[B)HY$D"_.&5@"#NS7S^<Y5A<OI1G0J.3;MNNWDCZ#
M)LVQ68590KTU%)7V??S/S^_X*&>)&UK]HNZL2Y9-(TZUM O92RF<_C^^'Z51
M_8&\&Q>+?VB]+GG4/%HMI/JFPC@LH6-#^#RJWU45B?ML"4?M0>.?.SO\VVQN
M_N_98=OZ8KU7_@F45_X6OXJ!(WG1,@=\>?'G^E?957[#(KP_Y]K\4K_F?&4E
M]8SYJ?\ S\?X-V_(_1VEHHK\@/V **** "F3PI<0R12HLD;J59&&0P/!!%/H
MH _$;XJ>$AX#^)?BGPZ@(ATO4[BUBR<YC60A#^*[3^-?:W_!,#Q))-H?CO0'
M)\FWN;6^B&>-TBNC_3B&/Z_A7S!^U]Y?_#2?CSRM^W[<,[\9W>4F[IVSG'MB
MO=O^"80/_":^-SCC^SX.?^VC5^OYL_;Y*ZD]W&+^=T?D&4KV&=JG#92DOE9G
MZ&4445^0'Z^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A
MI:0T ?)?[;/B,2ZOX<T%'_U$,EY*H]7;8F?IL?\ .OF2O1?V@_$W_"5?%[Q%
M<JY>"WG^Q1>@6(!#CV+*Q_&O.J_<\HP_U; TJ;WM=^KU_4_C/BG'?VAG.)KI
MW7-9>D?=7WVN/M[>2[GC@B0O+(P1%'4DG %?IQX6T1/#7AK2=)CQY=C:Q6PQ
MWV(%S^E? _[/_AO_ (2CXO>&[9DW0PW'VR3T"Q R#/L651^-?H8.M?&<6U[U
M*5!=$W]^B_)GZWX7X+EH8C&M?$U%?)7?YK[A:***_/S]Q"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OSP_X*=ZDTWCGP5IYSL@TV:<?6
M24*?_10K]#C7YO?\%,XI!\7?##F4F)M"55BQ]UA<39.??('_  'WKZCAM)YE
M!^3_ "/E^)6UEL_5?F?H!\.=%3PW\/\ PQI,2[8[#2[:U49S@)$J_P!*Z*J>
MDLCZ79,B>6AA0JF<[1M&!GO5ROFIMRDY/J?2P2C%170YCXFVBWWP]\11MT6R
MEEY]44L/U6O,?V7;HM;^(K<GA'@D SZAP?\ T$5ZYXSD6'P?KLCG"+83L3Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L/QOXCC\(^#]9UJ3I8VDDX']Y@IVK^)P/QK;/2O _VQ_%@T?X=VFBQ
MOB?5[D!E]8HL.W_CWEUZ&7X;ZWBJ=#N]?3K^!XF=X]99EM?&7UC%V]=H_BT?
M%\\[W,TDLK%Y)&+LS=6).2:9117[Y8_B5MMW9]-?L3^%_.UCQ!X@D3BWA2RA
M8]V<[GQ[@(G_ 'U7UM7D_P"S%X5_X1?X0Z2SIMN-2+:A)QUW_<_\AJE>L5^'
MYUB/K./JS6R=E\M/^"?V+PC@/[.R3#TFO>:YGZRU_!-+Y!1117AGV 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ5^?W_!3[1C%K_@+5
M@GRSVMU:E@O0H\; $_\ ;0X_&OT!KY6_X*,^#GU_X%VVLQ+F30]3BGD;&<12
M Q-_X^\7Y5[V1551S&DWU=OO5OS/ SVDZV758KHK_<T_R/=?@IXA7Q9\(?!>
MKJ<F[TBUD<>C^4H<?@P(_"NUKY9_X)V^/T\4? ]] DEW7OAR\D@V$Y802DRQ
MM]-QE4?[E?4U<&/H/#8NI2?1O[NGX'H9?76)PE.LNJ7W]?Q./^+NHC3/AOKT
MI.-]N8![^80G_LU<#^R_8F/2-=O,<2SQQ9_W%)_]GJ7]ICQ MMH6FZ,C?O;J
M8SR =D08&?J6_P#':Z?X$:-_9'PXL&9=LEX[W3#_ 'CA3_WRJU^>RE]9X@BH
M[4H:^K_X#0K\^*5OLK^OS/0J***^S/0/PN\2_P#(QZK_ -?<O_H9K]2_V!_^
M38_#?_7Q>?\ I3)7Y:>)?^1CU7_K[E_]#-?J7^P/_P FQ^&_^OB\_P#2F2OU
M7B?_ )%\/\2_)GY3PO\ \C&I_A?YH^AJ0TM%?E1^K'%?%_X7:5\9/A]JWA75
ME"Q7<>8;@+EK>8<QRK[J?S!(Z$U^-GC3P?JGP_\ %>J>'=:MS;:GIL[6\\?;
M(Z,I[J1@@]P0>]?N.:^,_P#@H1^S\/%'AQ/B/HMMG5=(B$>J)&.9K4=)3[QD
M\_[).>$%?9\-YG]5K?5JC]R>WD_^#M]Q\9Q)EGUJC]9IKWX;^:_X&_WGYW3W
M$MTX>:5YG"*@:1BQ"JH51SV   '8 "ONS_@EO_S4W_N&?^W=?!U?>/\ P2W_
M .:F_P#<,_\ ;NOM>(?^195_[=_]*1\1P]_R-*7_ &]_Z2ST[_@HU_R;U%_V
M&K;_ - EK\W? =S%9^.?#L\\J001:C;O)+(P5442J223P !WK](O^"C7_)O4
M7_8:MO\ T"6OS KAX9CS9<X]V_T._B>7)F2EV2_-G[3#X^_##_HH_A+_ ,'E
MK_\ '*7_ (7[\,?^BC^$O_!Y:_\ QROQ8HKC_P!4J'_/U_<CK_UNK_\ /I?>
MS]I_^%^_#'_HH_A+_P 'EK_\<I#\??AA_P!%'\)?^#RU_P#CE?BS0.M'^J5#
M_GZ_N0_];J__ #Z7WL_=.YM]-\5:')!*MOJFDZC;E&&1)#<0R+SR.&5E/T(-
M?DG^U!^SMJ7P!\=S6ZQRW'A>_=I=*OR"04SGR7/_ #T3H?48;O@?1'[!G[4T
M%K;VOPS\67JP@-MT.^G; .3_ ,>K'MSRA/KM_NBOM+QYX!T'XF>&+OP_XDTZ
M+4M+N1\T4G!5AT=&'*L.S#D5X-"O7X;QLJ557@_Q71KS_P"&/?Q%"AQ)@HU:
M;M-?@^J?E_PY^1'P)^/?B3X!>+#JVANL]I<!4O\ 3)C^ZNXP3@'NK#)PPY!]
M02#^F7P=_:S^'GQDMH8[+6(]'UI@/,TC5'$,P;T0D[9!_NDGU KXL^.W[ WC
M#X?7%SJ7@Y)?%_AX$N(H5'VZW7T:,?ZS'3*<GKM%?+EW:3V%S+;W,,EO<1L4
MDBE4JZ,.H(/(/UKZW$8#+\_A[:E.TNZW_P"WE_PS\SY'#X_,,@E["M"\>SV_
M[=?_  _I<_=P5'<W,5G \T\J00H,M)(P55'J2>E?B)I7Q'\6Z%:+:Z9XHUK3
MK9  L-IJ$T2*!T 56 JIKGC#7O$^!K&N:EJVTY'VZ[DFP?;<37AKA&?-K65O
M3_@GN/B^'+I1=_7_ (!^EGQT_;P\$_#>SN;'PM<0^,/$>"J"T?=9P-CAI)1P
M^/[J$YZ$KUK\V_'GCS6_B7XJO_$7B&]>_P!4O'W22-PJCLBCHJJ. !T JIX;
M\*:UXRU6/3="TJ\UB_D^[;6,#2N1ZX4' ]^@K[6_9X_X)Z7(N[77OB@4CBC(
MDC\.V\@<N>WVB1> /]A"<]V'(KW:=++N':;E*7OO_P "?DET7]-GA5*N8\15
M%&,;07RBO-OJ_P"DCF_V#OV8Y_%NOVOQ&\26A30-.DWZ7;S)_P ?EPIXEP>J
M(>A[N!_=-?HV*@L+&WTRS@M+.".UM((UBB@A0(D:*,*J@<  #  JQ7YMF685
M,RKNM/1;)=E_6Y^E9;E]/+:"HPU>[?=_UL%%%%>4>J%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 AZ5\,?M9>+_ /A)/BI-81N6M='A6T4#
MH9#\\A^N6"_\ K[4\4:_;^%?#FIZQ=?\>]C;R7#@=6"J3@>YQ@?6OS-U;4Y]
M:U2\U"Z;?<W<SSRMZNS%F/YDU]YPGA>>O/$M:15EZO\ X'YGXMXF9E[+!T<O
M@]:CYGZ1V^]O\"K6MX3\/3>+/$^E:-;Y\V^N8X 1_"&8 GZ 9/X5DU[U^QWX
M0.M?$6YUJ1,P:/;%E8C_ ):R HO_ ([YA_ 5^A8_$K!X6I7_ )5IZ]/Q/P[)
M,O>:9E0P:VG)7]-Y?A<^SK&SAT^T@M;=!'!!&L4:#HJJ, ?D*L4@XI:_ FV]
M6?VRDHJR"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *YSXC>#+;XB> ]?\,W>%@U6REM2Y&?+9E(5_JK88?2NCI#50DX24H[HF45
M.+C+9GY2_LE?$RX_9]^/[:3X@)L;"]F?1=6CD( @E#[4<_[D@P3V5F-?JO)(
ML,;22,$11N9F.  .IK\Z/^"B7P/?PUXQM_B'ID#?V;K96#4-H^6*[5<*WL'1
M?^^D;^]71_!S]JG4?'?P9B\&7TI;Q!8*+>>\9_GN+( !#ZEOX&/H 3R]?4<3
MU*<LM6>TU>R]Y+OLOQT;[69\)E6)>5UZF6U^C;CYKM\]_O/0/%FJS_%GXFA+
M0DQW$RVEKD?=B!QN/M]YS]37UA8646FV5O:0+L@@C6*-?15  'Y"O#/V;_ [
M>9/XGNX\+@P688=>SN/_ $$?5J][K\DX;PU3V4\=7^.J[_+I]_Y6/K<)!\KJ
M2WD%(>E+4-Y=1V-I/<S-MAA1I';T4#)/Y5]@VDKL] P?$>H>&/"EK]JU<6%G
M&Q.W?$I9SWVJ!EC]!7(6_P"T!X,MG%O%]JA@!X9+7"#WP#G]*XKP%X?E^-?B
MW4?$'B!GDTVV<)%:!B%.>5C!'15')QR21ZFO;6\%Z ;+[(=$T_[-T\K[,FWZ
M].OO7S-'%YCF477PSC"G]GF3;E;J]59?B<,)5*OO4[)?F2>'?%.D^*[/[5I-
M]%>P@X;8<,I]&4\C\16)JWQ>\):%J5Q87VK>1=P-LDC^S3-M/U"$'\*M>$?A
MSH?@BZOKC2[=HI+MLL7<ML7^XN>BYY[GWX&/*= T6PU[X_\ B2VU&SAO;<)(
MXBG0.NX%,'!^IJL5B\=AZ5"-H*I.7*]W'KJMGT*G4JQ45I=NWD>@GXZ>!\?\
MAO\ \E)__B*Z/4/%.D67AD:Y=7(71WBCE\XQ,P*28"G:!NYW#C'?FJ?_  K3
MPI_T+NF_^ R_X5A?&JVBLOA%JUO!$L,$*6\<<:#"JHFC  'H!71.KC\-AZU;
M$.#Y8MKE4MTKZW>WH4Y581E*=M%TN;?AC5/"WC*UEN='2TO(8G\MR+;85;&>
M0R@].];,YT_P]87=ZT45G;0QM-,\4>,(H))(49.!FOFWP;>WGPDU+0-;D9Y=
M!UNW47&!G:<\CZJ?F'J"1ZU[_P".9DN/A_X@EB=9(GTNX974Y# Q-@@UEE^:
MU,9A9RJJU2"NUTVNFO)KS)HU>>#;5I(LZ-K6D>-=*6\L7CU"Q+E0TD1 W#@\
M. ?TK-\3ZYX3\&PK)JWV&U+C*1>2&D?Z*!G'OTKCO@WK,?A[X,W.IRC<EHUQ
M,5SC<1R%_$\?C7-?"CP3_P +-U&^\6^)R;Y#.4BMWR$=@ 22/[BY "].N>G.
M*S;$5*6'IT(IU:L>;KRQ75OKZ(GVTI1@HI<TE\D=-!\:_A]+/Y;VK0IG_6O8
M K^F3^E>@:0N@:]9)=Z=%87EL_22*-&&?0\<'V--O/!'AZ^LOLD^B6#6^"H0
M6ZKM'^R0 1]17BT=O/\  _XJ6EM;S2/X?U4J"CMG"EMO/^TAYSZ'W-74QN/R
MZ4)XQQG3;2;BFG%O:Z;=U^(.4Z33J6:\NAZOXH\1>$?!;VZ:R+6S:X#-$/L;
M/N"XS]U3CJ.M:NCQ:%KVFV^H6%M:7%G.N^.00 ;A]" 1]#7DG[0]@-5\3>#[
M)F*"Y=X2P[;GC&?UK3_9ZUB:VM-8\+7IVW>EW#,J$]%+$.![!QG_ ('2IYO6
M_M6>"J)<FR>M[\JE9ZVVOT!5?W[IM*QZ9J-OHVBV%Q?W5K:V]M;(99)?('R@
M<D\#/Y<U0\,?$7P]XRNY;;1]0^V3Q)YCIY,B87(&<LH[D5Q?[0FN2Q>'[#P_
M:9>\U>X5/+7JR*1Q^+%/R-<O\ ]+_L3XD^)].W^9]DCEM]_][9,%S^E3B,WK
M1S.G@J:3AHI-WO=INRU[6Z!*LXUE3BM.I['IGC;1=8\07FB6E[YNIV89IX/*
M==@5@I^8@ \L.A[UG^.OASX*\9VDDWBWP_H^J11)DW.HVT;-$H[B1AE?P(KS
MOX:?\E]\8?\ 7*X_]'Q57^*NH7_Q!^(]CX(L9F@LXF4W# <,VW>S'U"KT'KG
MVIT\[JTL*\1;]YSN$5&ZN[V77[R955.D^>*>MK=SSGQ#\&OV96O)%'AB=Y"P
MW2Z==7:H/H#*%Q]!77?#O]G3]GC6)]VB>%[.[NT 9H-0N+F5^,\^7+(01ZX&
M.GM7M?A_X<^'?#EBEM:Z5;/A=KS3Q+)))ZEF(YSZ=/050C^$?ARV\5VVOVMJ
MUG<09806[>7$7[-M'3OP, YY%>S#,.(DXNI74HO>*<U9>3N[V\T<L<NHQDIN
MC#_P%?F7%@\(_"702;>STWPUI8( BLK9859L' "(!N.,]!GK7/VW[07@^XNQ
M"US<P*>/.EMSL_3)_2N,^+[6MQ\8?#MOKLI30Q%&S"0XC&7;=GT!(4$^GTKU
M;5/ ?AKQ+HHLWTVT-HZ@Q26J*A3T9&7I_(^XKQY8S'XW$5HX:45[-V]Z[<G;
MK9Z+L]3LC*<FXTK)1_KY'065Y!J%M%<VTR7%O*H:.6-@RL#T((ZU/5/2M+M-
M$T^"QL8%MK2!=D<2= /\]^]7*^CAS<JY]^MCM5[:A1115C"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ I#TI:0]* /GW]L?QK_8W@:R\/0OBXU>;
M=(!_SQC(8_3+E/K@U\95Z=^T;XX_X3CXJ:I+%)YEC8'[!;8.050G<1ZY<N<^
MF*\QK]OR/"?4\#"#6KU?J_\ )61_'W&&:?VKG%:I%WA#W(^D?\W=_,*^[OV5
MO!I\*_"FSN94VW>KR&^?UV$ 1CZ;0&_X$:^+_ ?A6;QOXQTC0H,AKZX6)F7J
MB=7;\%#'\*_2NRM(K"U@M;=!%!"BQQH.BJ!@ ?0"OGN+,7RTH86+UEJ_1;?>
M_P C[GPRRSVF(K9C-:07+'U>K^Y6_P# B>BBBOS$_H@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***0T +16=K.L+HUKYS6EY>,?NPV=
MNTKM^7 _$BO%_'7C'XB>)8Y;32O#>I:/8/P62)C.X]VQ\H]E_,UY6.S&G@8W
M<7*7:*;_ . OF85*RIK:[\B3]H_QKX?UGPAJ_@F6"+5I=0C\FY!Y2VYR&R/^
M6BD CT(!/3!_,#7M%USX1^,%,<SP3PL7M;M!A9D_D<CAE^HYK] /"WP5\3>(
M=52"ZL)]*M<AI;JZ0J%7_9!Y8^WYD5ZO\0OV8O!7Q%^'*>$[VS,/V?=+:ZG&
M!]I@G(P9-W?.!N4\$ #C (TX0SW,7BJKS"G_ +)45G!K\4GOII*^C^6GR699
M96S5>VC[LX[?Y?\ ![G#_LF?M7^'/BUH&G^&KX6V@>+K.%8A8;ML5X%'WX"3
MR<#)0_,.3R 37TH.M?DAXT_8^^+/@#Q9-9V/AO4=:2W<26NK:-$SQR '*N".
M4;CH>0?7@GZ:^!_QR^/7@V"WTGQY\,O$OBO3(P%748;1EOXU_P!K=A9O^!%6
M[EC7Z'F&38:WMLNJ1<7]FZ5O3R\GL&69OB(_[/CZ4E):<W*[?.R_%:'VM61X
MOLY-1\)ZU:P@F:>RGB0#^\T; ?SH\,^(XO$^FI>0V>H6&>&M]2LY+:9#C."K
M@9Z]1D>]:QKXNK3YHRIRZZ'V.DXZ;,\:_9EU"%_"VJV(8?:8KSSF7OM9% /Y
MH:[?X@^$=7\60V2:5X@N-!:!F,C6[.#*"!@':R],'\Z\_P#%'PX\1>"/%<OB
M;P2!/',2T]A@$C)RR[3]Y"><#D=NF:L+\;O%"Q>6_@"_-T/E+ 2A=W^[Y>?P
MS7Q.'KTL)A/[.S&,H\NETI6DKW33C^)P0G&G#V59-6]=?N*WPEN=:L?BMKFA
MZGKE[J\=G9R &XG=D+"2+Y@K,<'#$?C7.2^#D\<_&_Q%ITEY-8J-\OFP?>.-
M@Q].:ZWX1>'?$LOCS5_%.N:9_9J7ULZ;&^0[R\9P$)+ 84]:Q+VW\5>$_BSK
MFNZ9X;NM3BF+QH?*;8RG:<@C_=KS)4KX.A[:$G#VK=FI-\NMO,P<?W<>9.W-
MY[&__P ,XVH_YF34OR'^-;WQHMA9_"#5( Q<1);)N/4XFC&:P3\4?'^/^1#F
M_P"^9/\ "MSQ]'JWBSX.70.ERQZM=1PLUA&A+J1,A(QUX )KV$L"\)B88&G)
M2<);J2OH[;^O0Z%[/DFJ:>S[E?0?"%MXW^"FE:7<85WM \,I'^JD&=K?T/L3
M7&^"O&%Q;^!_%O@S6<Q:EIVG78@#GDH(VW)GOMZC_9/H*]9^&MC<:9X#T2UN
MH7M[F*W"O%(,,IR>"*\_^.GPTO-7EAU_0K>274-OV>ZAMQ\\J$$!@!UX)4^H
M(]*G&8:K2PM+&X>-YQ@HR7>+7YQ>J"I"481J06J5GZ&=X0LI+_\ 9QUB*+.\
M>?)@=2%8,?T4UU7[/&H07?P\BMXV'FVL\B2KW!)W _DWZ&KGP2T2\T?P!'9:
MG9R6LWG2EH9TP2I/<'L:XJ_\">*OA3XBN=6\'Q?VGI-P<R6."[*N<A2O5L9.
M&7GU]\:-.K@HX7'<CDE34))+5+1IV\GN3%2IJ%2U]+,]VKPC]H.9=4\7^$M)
MMP'O0Q)4?]-'14'YH:OR_&GQ==P>19^ [R*]88$DBRN@/KMV+Q_P*K?PU^%^
MJ#Q#)XL\6R^;K#DM#;E@WEDC&YL<9 X"C@?7IU8[%1SB"P>$BVI-<TFFE%)I
M]4M=-$74FL0O9TUONRG\<?\ D>_ 7_7U_P"U8JA\9#_A7?QLTK7E_=:=JX\J
MY(X7/"/GV'[M_KFM?XO^'M3UCQEX,N+&QGNX+6XW3R1(66,>9&<D]N ?RK;^
M-/@^3Q?X*FCM83/J%HZW$"(,LQ'#*/JI/'J!7/B<+5J5,75IQ]Z$H3CYN,5>
MW>ZNB)PDW4DEJFFODCDM(7_A87QVO;\_O--T!/*C/4&0$@?^/EV!_P!D5!\(
MO^2S^.?^NMS_ .E%=?\ !'P?/X2\&@WL+0:C>RM/.D@PRCHJG\!G_@1K"^&/
MAO5-,^*_B^^N]/N+:RN9+@PSR1D)(#/N&#WR.:FEAJJEA*]2+YISE.7E=:)]
MK*R",)7A)K5N[,WX:?\ )??&'_7*X_\ 1\55](D71/VDK]+O$?VO>L3-T)>-
M67\\8^O%;/@'PWJNG_&GQ1J5S87$%A<1SB*YD0A')FC(P>^0"?PK8^+7PMD\
M9K;ZII,HM=>LP/+<MM$J@Y W=F!Y!]^?413PN(>#56G"\J=5SMM=7>WJMA*G
M)T^9+52N>D"@UXI8?%KQMH$(LM:\%W>HW40V_:(0\8?'<[493]5P*L^&KOXA
M>.?%EEJES')X9T2V/S6SJ1YRYY&QN6)_O$  <CGK[T,ZH57&%*$G)O;E:MWN
MW9:>ITK$1E913OZ'H/C+P+I'CNP2UU6!F,9)BGB.V2(GKM/OQP<C@<5X[XB\
M ^)O@[:2:SX=UV6XTR%@TULXQM!.,LG*N.0,X!&>G>NP^(>J^/?#GB>#4])M
M5U7043:;.WC+-SC=O ^;.1PPX Z]\\UXH\9>,?B=IS:!IWA*ZTJ*XV_:)KDM
MC:"#C<RJ%&1[D@5XV:3P=6=3]W..(CI%I--OHTUHUZ]#GK.G)O1J73?4]9\!
M^*5\9^%-/U<1B%YU(DC'174E6Q[9!(]B*Z"L'P/X83P;X6T_2$D\XVZ'?)C&
M]V8LQ^F2<>V*WJ^PPOM?80]O\=E?UMK^)Z$.;E7-N%%%%=)84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 )7"?&WQT/AW\-M7U6-]EZT?V:TP<'SG
MX4C_ '>6^BFN[-?&G[8OQ _MKQA9^%[:3=:Z2GF7&T\-<. <?\!3'XNPKW,F
MP7U[&PIM>ZM7Z+_/;YGR'%>;?V-E-6O%VF_=C_B?7Y*[^1\]DY))Y)[T44Z*
M)YI4CC1GD<A551DL3T %?N3T/XYW9]+_ +%W@?[5J^K>*[B/,=JGV*U)_P">
MC8:0CW"[1_P,U];UQOPB\$)\//A]H^B[0+F*(273#^*9OF?GO@G ]@*[*OPG
M-\9]>QDZJVV7HO\ /?YG]E\,95_8^54<+)6E:\O\3U?W;?(****\<^J"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD-
M &#X[\76O@3PCJFNWA'DV4)D"DXWOT1![LQ _&OS4UC5KK7M6O=2O9/-O+R9
M[B9_5V))/YFOI7]L[XE>?>6/@NRE_=P;;N_VGJY'[M#] 2Q'^TOI7R]UK];X
M8P'U?"_6)KWJGY=/OW^X_F7Q"SCZ]F"P5-^Y1T?G)[_=HO6Y(K9X->Q_LN>
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MG)O[)RN,JBM4J^]+R7V5\E^+84445\R?H 4444 %%%% !1110 4444 %%%%
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M:/@;+8^(/C=\/O#.F?#N\O(;*YUGPMJTD\VBF9PL<ERD@ >,,0K,F,$YYX!
M/KBBOGGXV_M#^,_!7QI\+_#?P/X0L/%6K^)-#NM1M);V^-K#!+%(@W2N ?W0
M1F8[06)"J/O9%?X(_M ?$#Q3XX\:?##X@^%]'\/_ !,T/3$UBS?2+IY],OK:
M7*1L"Q\Q2L@"L._;% 'T=17R8G[<83]C#Q#\7M0T1--\6://<:+<^'-Y;R=7
M6?R$M\C)8;GC<_[)/2NO^)W[5*Z3X;^#MQX%L+;Q'J_Q.U*UM]*MYY"(X[1X
MQ+<7+E3G$*%20.<G% 'T)17S%K_[1'Q-^(WQ"\7>&/@EX7\,ZA8^$+S^S-7\
M1>,=0FM[62_"AI+6WCA5G9H\@,[8&3CI@GL?@1^T'J7Q;T#QI8:EX6_L/XC>
M#+I]/U?PZMX)(7G\LO \-QMP8IEP58KD<Y!P"0#VNO*_'GQCO/"/Q^^%?P]A
MTZ">T\86VL3W%Z[D26_V.&)U"*.#N,I!STQ7A_CW]IWXZ_ WP[-\0/B1X#\#
MP?#^RN+:+5=.T'79[G6=,2>5(E=B8Q#(5:095<;NQ'6NL^,[!_VW_P!FE@<@
MZ=XI(_\  6UH ^C8]6L9M2FT^.]MWOX4$DEJLJF5%/1F3.0#ZXKS;]GWXQWG
MQEL?'=Q>:=!IW_".^,-4\-0K Y;SH[24(LK9Z,V<D#@5\X?"O5?B;)_P4?\
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M\%V%WH_ANZ\7^*M<U&'1M#T6V)47%W+G:97P?+B4*2S'CH,C.1YM_P %%?\
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M?KVJ_P#!K_AIK_A-$_X6K_PJS_A$_L\F[_A$O[1^V^=QLQY_R;>N>_I7O5%
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M#]SGP]:/_I-Q&>+V4'L>\:GIZGGD!37;_M7?M#BQ2[\#^&KG_2'!BU6]B/\
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M_!WPLMA;[;G5+C$E_?;<&9\=!W"+R /J>I->B5^.9[G#S&I[*D_W<=O-]_\
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MF@7.A^)=&T_Q!HMUM\_3M4MDN+>7:P==T;@J<,JL,C@@'M6L %&   .PIU%
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M9&+O(Y+,S$Y))/4FFJU-K2\.^'M1\5ZU9Z3I-I)?:A=.(X8(QDL?Y  9))X
M!)XK]&;5--R=DC\2C"562C%7;^;;&:7I-YKNI6UAI]M)>7MRXBA@B7<SL>@
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M8K>R6WFL4M;D:3/>*N#-]N%QY8@8_/N'0''7FOHKXO?!3Q/\/[#]GSXB^!?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !112&@!:BNKJ&RMI;BXEC@@B4O)+*P5$4#)))X
M'K7"?%7XW^%OA!IYEUJ]$E^Z[H-,MB&N)??;GY5_VFP..YXKX2^,O[1OBCXP
MW#V]Q*=*T -F/2K5SL/.09&X,C?7 &. *^CRO(L3F34DN6'\S_1=?R\SX[.^
M*,%DR<&^>K_*OU?3\_(]U^.7[:$-G]HT3X?NMQ-@I+KCK\B'N(5(^8_[9X]
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MBKS>\GN_\EY??=A1117B'TX4444 %%%% !1110 4444 %%%% !1110 4444
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M1U:TN:3ZG[KA<)0P-%4,-!1BNB_K?SW"BBBN<ZPHHHH **** "BBB@ HHHH
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0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@  !60    $" (   "&(Z$;    -4E$051X7NW8
M,1$   @#,?R;AK5@@63KU<%7 0   .]UN!\   #PT(H%.0    #$ @   & 9
4J:I1<04&2T(     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176880473824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEOGENOMICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2897368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9490 NeoGenomics Way,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort Myers,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">768-0600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock ($0.001 par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NEO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,303,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001077183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881125168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 266,126<span></span>
</td>
<td class="nump">$ 316,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">177,414<span></span>
</td>
<td class="nump">198,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">111,994<span></span>
</td>
<td class="nump">112,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">23,799<span></span>
</td>
<td class="nump">23,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">16,511<span></span>
</td>
<td class="nump">12,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,516<span></span>
</td>
<td class="nump">8,189<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">603,360<span></span>
</td>
<td class="nump">681,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment (net of accumulated depreciation of $125,018 and $109,952, respectively)</a></td>
<td class="nump">106,818<span></span>
</td>
<td class="nump">109,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">98,945<span></span>
</td>
<td class="nump">102,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">416,848<span></span>
</td>
<td class="nump">442,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">522,766<span></span>
</td>
<td class="nump">527,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,845<span></span>
</td>
<td class="nump">7,168<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,152,222<span></span>
</td>
<td class="nump">1,188,270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,755,582<span></span>
</td>
<td class="nump">1,869,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">13,708<span></span>
</td>
<td class="nump">17,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">37,992<span></span>
</td>
<td class="nump">38,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">20,420<span></span>
</td>
<td class="nump">17,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of equipment financing obligations</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">6,379<span></span>
</td>
<td class="nump">6,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Pharma contract liabilities</a></td>
<td class="nump">6,386<span></span>
</td>
<td class="nump">5,192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">85,003<span></span>
</td>
<td class="nump">87,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">534,609<span></span>
</td>
<td class="nump">532,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">70,471<span></span>
</td>
<td class="nump">72,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities, net</a></td>
<td class="nump">38,345<span></span>
</td>
<td class="nump">55,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">14,166<span></span>
</td>
<td class="nump">14,022<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">657,591<span></span>
</td>
<td class="nump">674,269<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">742,594<span></span>
</td>
<td class="nump">761,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, (250,000,000 shares authorized; 126,562,037 and 124,107,500 shares issued and outstanding, respectively)</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,154,365<span></span>
</td>
<td class="nump">1,123,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5,104)<span></span>
</td>
<td class="num">(638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(136,400)<span></span>
</td>
<td class="num">(14,837)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,012,988<span></span>
</td>
<td class="nump">1,108,277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,755,582<span></span>
</td>
<td class="nump">$ 1,869,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982154&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881320784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 125,018<span></span>
</td>
<td class="nump">$ 109,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">126,562,037<span></span>
</td>
<td class="nump">124,107,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">126,562,037<span></span>
</td>
<td class="nump">124,107,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176882309984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 128,782<span></span>
</td>
<td class="nump">$ 121,340<span></span>
</td>
<td class="nump">$ 371,023<span></span>
</td>
<td class="nump">$ 358,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF REVENUE</a></td>
<td class="nump">79,889<span></span>
</td>
<td class="nump">74,101<span></span>
</td>
<td class="nump">239,952<span></span>
</td>
<td class="nump">216,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">48,893<span></span>
</td>
<td class="nump">47,239<span></span>
</td>
<td class="nump">131,071<span></span>
</td>
<td class="nump">141,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">64,282<span></span>
</td>
<td class="nump">63,839<span></span>
</td>
<td class="nump">188,481<span></span>
</td>
<td class="nump">158,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,312<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
<td class="nump">23,651<span></span>
</td>
<td class="nump">13,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">16,809<span></span>
</td>
<td class="nump">15,704<span></span>
</td>
<td class="nump">50,179<span></span>
</td>
<td class="nump">46,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">88,403<span></span>
</td>
<td class="nump">86,952<span></span>
</td>
<td class="nump">262,311<span></span>
</td>
<td class="nump">218,990<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(39,510)<span></span>
</td>
<td class="num">(39,713)<span></span>
</td>
<td class="num">(131,240)<span></span>
</td>
<td class="num">(77,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">3,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_GainLossOnInvestmentAndLoanReceivable', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,750)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(109,260)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before taxes</a></td>
<td class="num">(39,624)<span></span>
</td>
<td class="num">(23,170)<span></span>
</td>
<td class="num">(133,818)<span></span>
</td>
<td class="nump">29,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(2,772)<span></span>
</td>
<td class="num">(2,822)<span></span>
</td>
<td class="num">(12,255)<span></span>
</td>
<td class="num">(4,283)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS) INCOME</a></td>
<td class="num">$ (36,852)<span></span>
</td>
<td class="num">$ (20,348)<span></span>
</td>
<td class="num">$ (121,563)<span></span>
</td>
<td class="nump">$ 33,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET (LOSS) INCOME PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">124,425<span></span>
</td>
<td class="nump">122,559<span></span>
</td>
<td class="nump">124,055<span></span>
</td>
<td class="nump">119,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">124,425<span></span>
</td>
<td class="nump">122,559<span></span>
</td>
<td class="nump">124,055<span></span>
</td>
<td class="nump">121,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 106,162<span></span>
</td>
<td class="nump">$ 102,227<span></span>
</td>
<td class="nump">$ 310,588<span></span>
</td>
<td class="nump">$ 300,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF REVENUE</a></td>
<td class="nump">65,261<span></span>
</td>
<td class="nump">59,560<span></span>
</td>
<td class="nump">197,563<span></span>
</td>
<td class="nump">178,358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">40,901<span></span>
</td>
<td class="nump">42,667<span></span>
</td>
<td class="nump">113,025<span></span>
</td>
<td class="nump">121,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">22,620<span></span>
</td>
<td class="nump">19,113<span></span>
</td>
<td class="nump">60,435<span></span>
</td>
<td class="nump">58,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF REVENUE</a></td>
<td class="nump">14,628<span></span>
</td>
<td class="nump">14,541<span></span>
</td>
<td class="nump">42,389<span></span>
</td>
<td class="nump">38,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">$ 7,992<span></span>
</td>
<td class="nump">$ 4,572<span></span>
</td>
<td class="nump">$ 18,046<span></span>
</td>
<td class="nump">$ 20,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_GainLossOnInvestmentAndLoanReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Investment and Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_GainLossOnInvestmentAndLoanReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881050368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS) INCOME</a></td>
<td class="num">$ (36,852)<span></span>
</td>
<td class="num">$ (20,348)<span></span>
</td>
<td class="num">$ (121,563)<span></span>
</td>
<td class="nump">$ 33,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>OTHER COMPREHENSIVE LOSS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(4,466)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss, net of tax</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(4,466)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE (LOSS) INCOME</a></td>
<td class="num">$ (37,900)<span></span>
</td>
<td class="num">$ (20,405)<span></span>
</td>
<td class="num">$ (126,029)<span></span>
</td>
<td class="nump">$ 33,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176873738240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative-effect adjustment from change in accounting principle</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative-effect adjustment from change in accounting principle</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative-effect adjustment from change in accounting principle</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,075,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 694,294<span></span>
</td>
<td class="num">$ (22,575)<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 701,357<span></span>
</td>
<td class="num">$ (23,271)<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (7,185)<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt', window );">Premiums paid for capped call confirmations</a></td>
<td class="num">(29,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issuance ESPP Plan</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">2,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts &amp; private placement, net of private placement fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,693,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts &amp; private placement, net of private placement fees</a></td>
<td class="nump">218,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">218,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance fees and expenses</a></td>
<td class="num">(242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">ESPP expense</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">2,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(22,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,136,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">843,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">872,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(28,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,075,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">694,294<span></span>
</td>
<td class="num">$ (22,575)<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">701,357<span></span>
</td>
<td class="num">$ (23,271)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(7,185)<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">33,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,217,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">1,137,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">1,110,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="nump">26,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,136,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">843,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">872,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(28,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issuance ESPP Plan</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">4,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts &amp; private placement, net of private placement fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,444,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts &amp; private placement, net of private placement fees</a></td>
<td class="nump">189,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">189,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for acquisition</a></td>
<td class="nump">29,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">29,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance fees and expenses</a></td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">ESPP expense</a></td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">4,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">75,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,711,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">1,148,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">1,101,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(333)<span></span>
</td>
<td class="nump">47,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issuance ESPP Plan</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">3,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance fees and expenses</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">ESPP expense</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">5,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(20,348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,217,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">1,137,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">1,110,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="nump">26,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">1,108,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">1,123,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(638)<span></span>
</td>
<td class="num">(14,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issuance ESPP Plan</a></td>
<td class="nump">971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(1,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">6,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">ESPP expense</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">11,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(2,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(49,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,722,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">1,075,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">1,142,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,009)<span></span>
</td>
<td class="num">(64,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,108,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">1,123,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(638)<span></span>
</td>
<td class="num">(14,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="nump">804,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">$ (4,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(121,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,562,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">1,012,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">1,154,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,104)<span></span>
</td>
<td class="num">(136,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,722,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">1,075,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">1,142,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,009)<span></span>
</td>
<td class="num">(64,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issuance ESPP Plan</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">ESPP expense</a></td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">3,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(1,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(35,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,679,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">1,043,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">1,146,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,056)<span></span>
</td>
<td class="num">(99,548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issuance ESPP Plan</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">ESPP expense</a></td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">4,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(36,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,562,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 1,012,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 1,154,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,104)<span></span>
</td>
<td class="num">$ (136,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176880617264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (121,563)<span></span>
</td>
<td class="nump">$ 33,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net&#160;cash&#160;used in operating&#160;activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">25,894<span></span>
</td>
<td class="nump">21,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">25,470<span></span>
</td>
<td class="nump">14,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">20,009<span></span>
</td>
<td class="nump">12,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">7,375<span></span>
</td>
<td class="nump">6,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible debt discount</a></td>
<td class="nump">1,989<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issue costs</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(109,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates', window );">Interest receivable on loan receivable from non-consolidated affiliate</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets, net</a></td>
<td class="nump">3,066<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of assets held for sale</a></td>
<td class="num">(2,048)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_PolymeraseChainReactionTestingExitCostsCOVID19', window );">Write-off of COVID-19 PCR testing inventory and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other adjustments</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">2,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(403)<span></span>
</td>
<td class="nump">3,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_IncreaseDecreaseInPrepaidConstruction', window );">Prepaid lease asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="num">(3,605)<span></span>
</td>
<td class="num">(11,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable, operating lease liabilities, deferred taxes, accrued and other liabilities</a></td>
<td class="num">(20,192)<span></span>
</td>
<td class="nump">15,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(62,308)<span></span>
</td>
<td class="num">(6,947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(73,973)<span></span>
</td>
<td class="num">(180,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">89,812<span></span>
</td>
<td class="nump">44,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(26,357)<span></span>
</td>
<td class="num">(52,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from assets held for sale</a></td>
<td class="nump">12,098<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(419,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Loan receivable from non-consolidated affiliate</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">1,580<span></span>
</td>
<td class="num">(622,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_RepaymentsOfEquipmentAndOtherFinanceObligation', window );">Repayment of equipment financing obligations</a></td>
<td class="num">(706)<span></span>
</td>
<td class="num">(2,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="nump">10,733<span></span>
</td>
<td class="nump">12,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible debt, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">334,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_PaymentsOfPremiumsForCappedCallConfirmations', window );">Premiums paid for capped call confirmations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29,291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_ProceedsFromEquityOfferingNet', window );">Proceeds from equity offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">408,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,027<span></span>
</td>
<td class="nump">722,825<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(50,701)<span></span>
</td>
<td class="nump">93,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">316,827<span></span>
</td>
<td class="nump">250,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">266,126<span></span>
</td>
<td class="nump">343,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">266,126<span></span>
</td>
<td class="nump">340,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,161<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">266,126<span></span>
</td>
<td class="nump">343,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">2,145<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid, net</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_FairValueOfCommonStockIssuedToFundAcquisition', window );">Fair value of common stock issued to fund business acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable</a></td>
<td class="nump">$ 1,144<span></span>
</td>
<td class="nump">$ 2,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_FairValueOfCommonStockIssuedToFundAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Common Stock Issued To Fund Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_FairValueOfCommonStockIssuedToFundAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Investment In And Loan Receivable From Non-Consolidated Affiliate, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_IncreaseDecreaseInPrepaidConstruction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Construction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_IncreaseDecreaseInPrepaidConstruction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PaymentsOfPremiumsForCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Premiums For Capped Call Confirmations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PaymentsOfPremiumsForCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PolymeraseChainReactionTestingExitCostsCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Polymerase Chain Reaction Testing, Exit Costs, COVID-19</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PolymeraseChainReactionTestingExitCostsCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ProceedsFromEquityOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Equity Offering, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ProceedsFromEquityOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable With Imputed Interest, Non-Consolidated Affiliates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ReceivableWithImputedInterestNonConsolidatedAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_RepaymentsOfEquipmentAndOtherFinanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of Equipment and Other Finance Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_RepaymentsOfEquipmentAndOtherFinanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176963889200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business</a></td>
<td class="text">Nature of the Business<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Nature of the Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeoGenomics, Inc., a Nevada corporation (the &#8220;Company,&#8221; or &#8220;NeoGenomics&#8221;), and its subsidiaries, operate as a certified, high complexity clinical laboratory in accordance with the federal government&#8217;s CLIA, as amended, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">COVID-19 Pandemic Update</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact from the COVID-19 pandemic, including recent COVID-19 variants, and the related disruptions had a significant adverse impact on the Company&#8217;s results of operations, volume growth rates and test volumes in 2020, 2021, and in the first three quarters of 2022. The full extent to which the COVID-19 outbreak will impact the Company&#8217;s business, results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#8217;s results of operations, financial condition, and cash flows may continue to be materially adversely affected, particularly if the pandemic continues to persist for a significant amount of time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the cash on hand, marketable securities, and expected cash collections are sufficient to fund near-term capital and operating needs for at least the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the first quarter 2021, due to the broad roll-out of the COVID-19 vaccine and a sharp decline in COVID-19 polymerase chain reaction (&#8220;PCR&#8221;) testing demand, the Company made the decision to exit COVID-19 PCR testing and the Company recorded a $6.1&#160;million expense related to the exit from COVID-19 PCR testing. This amount consisted of write-offs of $5.3&#160;million for all remaining COVID-19 PCR testing inventory recorded to cost of revenue and $0.8&#160;million for all remaining COVID-19 PCR testing laboratory equipment recorded to general and administrative expenses </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Consolidated Statements of Operations for the nine months ended September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There were no COVID-19 PCR testing laboratory equipment or COVID-19 PCR testing inventory write-offs recorded for the three months ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the three and nine months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal government passed legislation that the President of the United States signed into law on March 27, 2020, known as the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). The CARES Act permits the deferral of payment of the employer portion of social security taxes between March 27, 2020 and December 31, 2020. Fifty percent of the deferred amount was due on December 31, 2021 and the remaining 50% is due on December 31, 2022. As of September 30, 2022 and December 31, 2021, the total accrued deferred social security taxes related to the CARES Act was $3.0&#160;million. This amount was recorded in accrued expenses and other liabilities on the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176964106016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with GAAP for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, except for new accounting standards discussed under Recent Accounting Pronouncements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in the Company&#8217;s annual audited Consolidated Financial Statements and accompanying notes have been condensed or omitted in these accompanying interim Consolidated Financial Statements and footnotes. Accordingly, the accompanying interim unaudited Consolidated Financial Statements included herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations presented in this Quarterly Report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited Consolidated Financial Statements include all adjustments and accruals, consisting only of normal, recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#8217;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Assets Held for Sale</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned 43,560 square feet of its Carlsbad, California facility. During the third quarter of 2021, the Company committed to selling this property and the associated land and concluded that these assets met the held for sale criteria. As of December 31, 2021, $10.1&#160;million was recorded as assets held for sale within current assets on the Consolidated Balance Sheets for this property and associated land and reflected its carrying value which was lower than its fair value less costs to sell. The Company sold this property and associated land for proceeds of $12.1&#160;million, net of closing costs, in the first quarter of 2022. For the nine months ended September 30, 2022, a net gain on the sale of this property and associated land of $2.0&#160;million is included in general and administrative expenses on the Consolidated Statements of Operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#8217;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#8217; data. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2022, the Company performed a qualitative assessment to determine whether it was more likely than not that the fair values of its reporting units were less than their carrying values. Such qualitative factors included macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. As a result of the qualitative assessment, the Company determined that there were indicators that it was more likely than not that the fair values of its reporting units were less than their carrying values. Accordingly, the Company performed a quantitative analysis and determined the reporting units&#8217; fair values exceeded the reporting units&#8217; carrying values and there was no impairment of the recorded goodwill as of June 30, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of payroll and payroll related costs for the Company&#8217;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, gains or losses on disposals of assets, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three and nine months ended September 30, 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-10&#8221;). This update requires business entities to disclose information annually about certain government assistance they receive. Such annual disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this new accounting standard in its Annual Report on Form 10-K for the year ended December 31, 2022 and does not expect the adoption of this standard to have a material impact on its Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-08</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating its adoption date of this standard and the impact of the standard on its Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIBOR</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of September 30, 2022, there was no impact to the Company&#8217;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176886104288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Trapelo Health</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2021 (the &#8220;Trapelo Acquisition Date&#8221;), the Company completed the acquisition of a 100% ownership interest in Intervention Insights, Inc. d/b/a Trapelo Health (&#8220;Trapelo&#8221;), an information technology company focused on precision oncology. The purchase price consisted of (i) cash consideration of $35.6&#160;million, which included a net adjustment of $0.6&#160;million for estimated cash on hand of Trapelo and estimated working capital adjustments on the Trapelo Acquisition Date, and (ii) equity consideration of $29.2&#160;million, consisting of 597,712 shares of the Company&#8217;s common stock, par value $0.001 per share, valued at $48.81 per share. The Company acquired control of Trapelo on the Trapelo Acquisition Date; therefore, the fair value of the common stock issued as part of consideration was determined on the basis of the closing market price of the Company&#8217;s common stock immediately prior to the Trapelo Acquisition Date. The Trapelo acquisition enhances the Company&#8217;s ability to provide customers clinical decision support to help answer complex questions related to precision oncology biomarker testing and treatment options as part of the Company&#8217;s comprehensive oncology offerings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Trapelo was determined to be a business combination and has been accounted for using the acquisition method. The purchase price and purchase price allocation were based upon management&#8217;s best estimates and assumptions and were considered final as of March 31, 2022. The following table summarizes the purchase consideration recorded for the acquisition of Trapelo, the fair value of the net assets acquired and liabilities assumed, and the calculation of goodwill based on </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the excess of the consideration transferred over the fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"/><td style="width:74.247%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued as consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share value of common stock issued as consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of common stock at Trapelo Acquisition Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Cash paid at closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of the purchase consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - marketing assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identified developed technology and marketing intangible assets are being amortized over ten years and four years, respectively, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Trapelo acquisition is 9.8 years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The marketing intangible assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the marketing intangible assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the marketing intangible assets had the intangible assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#8217;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized, all of which was assigned to the Clinical Services segment, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. None of the goodwill resulting from the acquisition of Trapelo is expected to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of Trapelo are included in the Company&#8217;s unaudited Consolidated Financial Statements beginning on the Trapelo Acquisition Date. No pro forma information has been included relating to the Trapelo acquisition, as this acquisition was not deemed to be material to the Company&#8217;s revenue or net loss on a pro forma basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Inivata Limited</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021 (the &#8220;Inivata Acquisition Date&#8221;), the Company completed the acquisition of the remaining equity interests in Inivata Limited, a private limited company incorporated in England and Wales (&#8220;Inivata&#8221;). Inivata is a global, commercial stage, liquid biopsy platform company. The acquisition follows a $25.0&#160;million minority equity investment by the Company in Series C1 Preference Shares (the &#8220;Preference Shares&#8221; or &#8220;previously-held equity interest&#8221;) in Inivata in May 2020, at which time the Company also acquired a fixed price option to purchase the remainder of equity interests in Inivata for $390.0&#160;million (the &#8220;Purchase Option&#8221;). The Company and Inivata also entered into a line of credit agreement in the amount of $15.0&#160;million (the &#8220;Line of Credit&#8221;) in May 2020. In the first quarter of 2021, prior to the Inivata Acquisition Date, an observable transaction of an identical investment in Inivata Preference Shares occurred which resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Company recorded a net unrealized loss of $5.0&#160;million on investment in non-consolidated affiliate for this remeasurement for the three months ended March 31, 2021 in other expense (income), net on the Consolidated Statements of Operations.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inivata acquisition adds liquid biopsy platform technology, including minimal residual disease testing capabilities, to the Company&#8217;s comprehensive portfolio of oncology testing solutions. The purchase price consisted of cash consideration of $398.6&#160;million, which included a net adjustment of $8.6&#160;million for estimated cash on hand of Inivata and other adjustments on the Inivata Acquisition Date, and was funded through cash on hand and a private placement of equity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the acquisition of the remaining equity interests in Inivata, the Company accounted for its previously-held equity interest and the Purchase Option in Inivata as equity securities without a readily determinable fair value. The equity interests were recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Therefore, the Company&#8217;s acquisition of control of Inivata on the Inivata Acquisition Date was accounted for as a business combination achieved in stages under the acquisition method. Accordingly, the Company used a discounted cash flow to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#8217;s previously-held equity interest and Purchase Option in Inivata. To determine the fair value of the previously-held equity interest, the fair value of Inivata&#8217;s total equity was allocated to its various classes of equity based on the respective rights and privileges of each class of stock in liquidation. The business enterprise value and a Black-Scholes model were then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at the fair value at the Inivata Acquisition Date based on its settlement value. This resulted in fair values of $64.9 million in Preference Shares and a $74.3 million Purchase Option, immediately prior to the acquisition. On the Inivata Acquisition Date, the $10.3&#160;million outstanding under the Line of Credit extended by the Company to Inivata was effectively settled as part of the acquisition of Inivata at the $15.0&#160;million principal amount and was recorded as part of the consideration transferred in the acquisition. The Company recorded a gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#8217;s Consolidated Statements of Operations of $109.3&#160;million for the year ended December 31, 2021 for the excess of the acquisition-date fair value of the Company&#8217;s previously-held equity interest, Purchase Option, and Line of Credit over their carrying values.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price and purchase price allocation were based upon management&#8217;s best estimates and assumptions and were considered final as of June 30, 2022. The following table summarizes the calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit, and the estimated fair value of the previously-held equity interest and Purchase Option, over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:33.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.709%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 18, 2021<br/>(as initially reported)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Measurement Period Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 18, 2021 <br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of Line of Credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of previously-held equity interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of Purchase Option</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allocation of the fair value business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets - developed technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets - trademarks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible asset - trade name</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net identifiable assets acquired </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,388)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangibles assets and related future amortization.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2022, we recorded a $4.3&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identified developed technology intangible assets and the trademark intangible assets are both being amortized over fifteen years, and the trade name intangible asset is being amortized over five years, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Inivata acquisition is 14.9 years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The trademarks and trade name assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the trademarks and trade name assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the trademarks and trade name assets had the assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#8217;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized, of which $234.6&#160;million and $32.4&#160;million was assigned to the Clinical Services and Pharma Services segments, respectively, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of liquid biopsy technology for oncology testing. The recording of amortizable intangibles has given rise to a deferred tax liability upon the acquisition of Inivata which increased goodwill by $56.6 million. None of the goodwill resulting from the acquisition of Inivata is expected to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:40.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.499%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30, 2021 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These unaudited pro forma results represent the combined results of operations of the Company and Inivata, on an unaudited pro forma basis, for the period in which the acquisition of Inivata occurred and the prior reporting period as though the companies had been combined as of the beginning of the earliest period presented. Therefore, the unaudited pro forma consolidated results have been prepared by adjusting the Company&#8217;s historical results to include the acquisition of Inivata as if it occurred on January 1, 2020. These unaudited pro forma consolidated historical results exclude, $17.8&#160;million of measurement period adjustments recorded in the three months ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and $109.3&#160;million of gain on investment in and loan receivable from non-consolidated affiliate, net, recorded in the nine months ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176964163104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.&#160;These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly.&#160;These are typically obtained from readily-available pricing sources for comparable instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs, where there is little or no market activity for the asset or liability.&#160;These inputs reflect the reporting entity&#8217;s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#8217;s marketable securities accounted for as available-for-sale securities as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,782&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,368)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $0.7&#160;million and $0.6&#160;million of accrued interest receivable at September 30, 2022 and December 31, 2021, respectively, included in other current assets on its Consolidated Balance Sheets related to its marketable securities. Realized gains or losses on marketable securities for the three and nine months ended September 30, 2022 and September 30, 2021 were immaterial. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at September 30, 2022 and December 31, 2021. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of September 30, 2022 and December 31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the three and nine months ended September 30, 2022 and September 30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other liabilities, and other current assets and liabilities, are considered reasonable estimates of their respective fair values at September 30, 2022 and December 31, 2021 due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, and long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and, as such, these are considered Level 3 fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176886104288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amounts of goodwill by segment at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pharma Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2022, we recorded a $4.3&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amortization expense within cost of revenue and general and administrative expense on the Consolidated Statement of Operations. The following table summarizes the amortization expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense related to amortizable intangible assets for each of the following periods as of September 30, 2022 is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176885398992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2028 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, the Company completed the sale of $345.0&#160;million of Convertible Senior Notes with a stated interest rate of 0.25% and a maturity date of January 15, 2028 (the &#8220;2028 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended June 30, 2022. Based on the terms of the 2028 Convertible Notes, the holders could not have converted all or a portion of their 2028 Convertible Notes in the third quarter of 2022. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended September 30, 2022. Based on the terms of the 2028 Convertible Notes, the holders cannot convert all or a portion of their 2028 Convertible Notes in the fourth quarter of 2022. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $8.61 on September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2028 Convertible Notes includes $0.2&#160;million, $0.4&#160;million and $8,500 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2022. The interest expense recognized on the 2028 Convertible Notes includes $0.7&#160;million, $1.1&#160;million and $25,300 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2022. The interest expense </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized on the 2028 Convertible Notes includes $0.2&#160;million, $0.4&#160;million and $8,400 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2021. The interest expense recognized on the 2028 Convertible Notes includes $0.6&#160;million, $1.0&#160;million and $23,700 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2021. The effective interest rate on the 2028 Convertible Notes is 0.70%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of 0.25% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the estimated fair values (Level 2) of the 0.25% Convertible Senior Notes due 2028 was $217.4&#160;million. At December 31, 2021, the estimated fair value (Level 2) of the 0.25% Convertible Senior Notes due 2028 was $297.6&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2025 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2020, the Company completed the sale of $201.3&#160;million of Convertible Senior Notes with a stated interest rate of 1.25% and a maturity date of May 1, 2025 (the &#8220;2025 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended June 30, 2022. Based on the terms of the 2025 Convertible Notes, the holders could not have converted all or a portion of their 2025 Convertible Notes in the third quarter of 2022. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended September 30, 2022. Based on the terms of the 2025 Convertible Notes, the holders cannot convert all or a portion of their 2025 Convertible Notes in the fourth quarter of 2022. The value of the 2025 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $8.61 on September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2025 Convertible Notes includes $0.6&#160;million, $0.3&#160;million and $37,200 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2022. The interest expense recognized on the 2025 Convertible Notes includes $1.9&#160;million, $0.9&#160;million and $0.1&#160;million for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2022. The interest expense recognized on the 2025 Convertible Notes includes $0.6&#160;million, $0.3&#160;million and $36,500 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2021. The interest expense recognized on the 2025 Convertible Notes includes $1.9&#160;million, $0.9&#160;million and $0.1&#160;million for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2021. The effective interest rate on the 2025 Convertible Notes is 1.96%, which includes the interest on the 2025 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2025 Convertible Notes bear interest at a rate of 1.25% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, which began on November 1, 2020.</span></div>At September 30, 2022, the estimated fair values (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $171.1&#160;million. At December 31, 2021, the estimated fair value (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $238.9&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176884270992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $4.3 million and $5.2 million for stock-based compensation in general and administrative expenses </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended September 30, 2022 and 2021, respectively, and approximately $20.0 million and $12.4 million for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s plans for the nine months ended September 30, 2022 is as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,075&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award granted during the nine months ended September 30, 2022 was estimated as of the grant date using a Black-Scholes model with the following assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 - 5.5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 3.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (%)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42% - 60%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.51</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there was approximately $14.8 million of unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of approximately 2.2 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Awards</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted stock activity under the Company&#8217;s plans for the nine months ended September 30, 2022 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,022,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994,862&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there was approximately $19.8&#160;million of unrecognized stock-based compensation expense related to restricted stock that will be recognized over a weighted-average period of approximately 2.2 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Modification of Stock Option and Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, upon the Chief Legal Officer&#8217;s departure from the Company and in accordance with the terms of the Chief Legal Officer&#8217;s employment agreement, 41,487 previously granted time-based vesting stock option awards and 76,138 previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $2.2 million of incremental stock-based compensation which consisted of $0.3 million and $1.9 million for the acceleration of stock option awards and restricted stock </span></div>awards, respectively, within general and administrative expenses on the Consolidated Statements of Operations for the nine months ended September 30, 2022. There were no such amounts for the three months ended September 30, 2022. In the first quarter of 2022, upon the Chief Executive Officer&#8217;s departure from the Company and in accordance with the terms of the Chief Executive Officer&#8217;s separation agreement, 237,960 previously granted time-based vesting stock option awards and 142,302 previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $5.9 million of incremental stock-based compensation which consisted of $2.3 million and $3.6 million for the acceleration of stock option awards and restricted stock awards, respectively, within general and administrative expenses on the Consolidated Statements of Operations for the nine months ended September 30, 2022. There were no such amounts for the three months ended September 30, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176886104288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s two reportable segments for which it recognizes revenue are (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience and other anticipated adjustments, including anticipated payer denials. Collection of consideration the Company expects to receive typically occurs within 90 to 120 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharma Services segment generally enters into contracts with pharmaceutical customers as well as other CROs to provide research and clinical trial services ranging in duration from one month to several years.&#160;The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, and/or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is usually recognized over time based on the number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to the sponsor(s) at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics is the sale of de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected in advance of services being provided are deferred as contract liabilities on the Consolidated Balance Sheets. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. Contract assets are established for revenue recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets. All others are classified as non-current assets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customers, either immediately or according to advance notice terms specified within the contracts.&#160;All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma capitalized commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized for the three and nine months ended September 30, 2022 related to Pharma contract liability balances outstanding at the beginning of the period was $0.7&#160;million and $4.8&#160;million, respectively. Revenue recognized for the three and nine months ended September 30, 2021 related to Pharma contract liability balances outstanding at the beginning of the period was $0.4 million and $4.2 million, respectively. Amortization of capitalized commissions for the three and nine months ended September 30, 2022 was $0.3&#160;million and $0.6&#160;million, respectively. Amortization of capitalized commissions for the three and nine months ended September 30, 2021 was $0.2 million and $0.9 million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered various factors for both its Clinical Services and Pharma Services segments in determining appropriate levels of homogeneous data for its disaggregation of revenue; including the nature, amount, timing, and uncertainty of revenue and cash flows. Clinical Services categories align with the types of customers due to similarities of billing method, level of reimbursement, and timing of cash receipts. Unbilled amounts are accrued and allocated to payer categories based on historical experience. In future periods actual billings by payer category may differ from accrued amounts. Pharma Services relate to contracts with large pharmaceutical and biotech customers as well as other CROs. Because the nature, timing, and uncertainty of revenue and cash flows are similar and primarily driven by individual contract terms Pharma Services revenue is not further disaggregated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Client direct billing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial Insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Medicare and Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Self-Pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Clinical Services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,588&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,782&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176964187040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of each interim period, management estimates the annual effective tax rate based on forecasted pre-tax results of the Company&#8217;s global operations and applies such rate to its ordinary quarterly earnings to calculate income tax expense related to ordinary income. The tax effects of items significant, unusual and infrequent in nature are discretely calculated and recognized in the period during which they occur. These discrete items often relate to changes in tax laws, excess tax benefits/deficiencies related to share-based compensation or adjustments to previously reported tax expense/benefits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing available positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred income tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome. Cumulative loss in recent years is commonly defined as a three-year cumulative loss position. As of September 30, 2022, the Company&#8217;s U.S. ongoing operations were in a three-year cumulative loss position. Management determined that sufficient objectively verifiable positive evidence did not exist to overcome the negative evidence of the Company&#8217;s U.S. cumulative loss position. Accordingly, the Company&#8217;s estimated annual effective tax rate applied to the Company&#8217;s pre-tax loss for the three and nine months ended September 30, 2022, includes the unfavorable impact of a valuation allowance against the Company&#8217;s deferred income tax assets expected to be created in 2022 for additional U.S. net operating loss and tax credit carryforwards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176964106016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text">Net (Loss) Income Per Share<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents both basic earnings per share (&#8220;EPS&#8221;) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised and if the 2028 Convertible Notes and 2025 Convertible Notes were converted. The potential dilution from stock awards is accounted for using the treasury stock method based on the average market value of the Company&#8217;s common stock. The potential dilution from conversion of the 2028 Convertible Notes and 2025 Convertible Notes is accounted for using the if-converted method, which requires that all of the shares of the Company&#8217;s common stock issuable upon conversion of the 2028 Convertible Notes and the 2025 Convertible Notes will be included in the calculation of diluted EPS assuming conversion of the 2028 Convertible Notes and the 2025 Convertible Notes at the beginning of the reporting period (or at time of issuance, if later).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculations (in thousands, except net loss per share amounts):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,852)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,348)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,563)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of Convertible Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of Convertible Notes due 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,425&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:37.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.725%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the &#8220;Capped Call Transactions&#8221;) with option counterparties pursuant to capped call confirmations at a cost of approximately $29.3&#160;million. The potential effect of the Capped Call Transactions were excluded from the calculation of diluted net loss per share in the three and nine months ended September 30, 2022 as the Company&#8217;s closing price on September 30, 2022 did not exceed the conversion price of $85.75 per share. The Capped Call Transactions are not reflected in diluted net loss per share as they are anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881040800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments an Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceeding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2021, Natera, Inc. filed a patent infringement complaint against the Company&#8217;s newly-acquired subsidiary Inivata Limited and its subsidiary Inivata, Inc. in United States District Court for the district of Delaware, alleging Inivata&#8217;s InVisionFirst-Lung&#8482; cancer diagnostic test of infringing two patents. The litigation is presently in the pleadings stage. The Company believes that it has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. At the time of filing, the outcome of this matter is not estimable or probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, the Company is voluntarily conducting an internal investigation that focuses on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;) of the Company&#8217;s internal investigation in November 2021. The Company&#8217;s review of this matter is ongoing. The Company has a reserve of $11.2 million in other long-term liabilities as of September 30, 2022 and December 31, 2021 on the Consolidated Balance Sheets for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#8217;s best estimate of the minimum probable loss associated with this matter. As a result of the ongoing investigation and interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. The Company was notified on June 30, 2022 that the Department of Justice (&#8220;DOJ&#8221;) will be participating in the investigation of this matter. At this time, the Company is unable to predict the duration, scope, result or related costs associated with any further investigation, including by the OIG, DOJ, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Any determination that the Company&#8217;s operations or activities are not in compliance with existing laws or regulations, however, could result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, or other losses or conduct restrictions, which could be material to the Company&#8217;s financial results or business operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176885370976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company formed a strategic alliance with Inivata and entered into a Strategic Alliance Agreement and Laboratory Services Agreement whereas Inivata, prior to the Inivata Acquisition Date, would render and perform certain laboratory testing which the Company made available to customers. In connection with this agreement, Inivata provided $0.8 million of testing services to the Company recorded in cost of revenue in the Consolidated Statements of Operations for the nine months ended September 30, 2021 through the Inivata Acquisition Date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company completed its acquisition of all remaining equity interest in Inivata by exercising its Purchase Option. Beginning June 18, 2021, Inivata is a wholly-owned consolidated subsidiary of the Company. As of the Inivata Acquisition Date, Inivata&#8217;s financial statement activity is being consolidated within the Company&#8217;s unaudited Consolidated Financial Statements. For further details on the acquisition of Inivata, please refer to Note 3. Acquisitions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has Pharma Services contracts with CytomX Therapeutics, Inc., an entity with whom a director of the Company, Dr. Alison L. Hannah, was an officer at until September 2022, and the Company&#8217;s former Chief Legal Officer, Halley E. </span></div>Gilbert, is a director. In connection with these contracts, the Company recognized $0.1&#160;million and $0.5&#160;million of revenue in the Consolidated Statements of Operations for the three and nine months ended September 30, 2022, respectively. For the three and nine months ended September 30, 2021, the Company recognized revenue in the Consolidated Statements Operations of $0.2&#160;million and $0.4&#160;million, respectively.The Company has Pharma Services contracts with HOOKIPA Pharma, Inc., an entity with whom a director of the Company, Michael A. Kelly, is a director. In connection with these contracts, the Company recognized $0.3&#160;million of revenue in the Consolidated Statements of Operations for both the three and nine months ended September 30, 2022. For the three and nine months ended September 30, 2021, the Company recognized revenue in the Consolidated Statements of Operations of $0.2&#160;million and $0.4&#160;million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176884341184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under two reportable segments, (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology and oncology practices, hospital pathology labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and self-pay patients. The Pharma Services segment supports pharmaceutical firms&#8217; drug development programs by assisting with various clinical trials and research as well as providing informatics related services often supporting pharmaceutical commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) includes revenues, cost of revenue, and gross profit for both reportable segments.&#160;Assets are not presented at the segment level as that information&#160;is not used by the CODM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the segment information (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,597&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,803&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,952&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,311&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,990&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,510)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,713)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,240)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,187)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,624)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,170)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,818)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,852)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,348)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,563)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 includes $4.3&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2022 include $12.8&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2021 include write-offs of $5.3&#160;million for COVID-19 PCR testing inventory and $5.0&#160;million of amortization of acquired Inivata developed technology intangible assets.</span></div>(2) Pharma Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 include $0.6&#160;million of amortization of acquired Inivata developed technology intangible assets. Pharma Services cost of revenue for the nine months ended September 30, 2022 and September 30, 2021 includes $1.8&#160;million and $0.6&#160;million of amortization, respectively, of acquired Inivata developed technology intangible assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176885578944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with GAAP for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, except for new accounting standards discussed under Recent Accounting Pronouncements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#8217;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_AssetsHeldForSalePolicyPolicyTextBlock', window );">Assets Held for Sale</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Assets Held for Sale</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">GoodwillThe Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#8217;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#8217; data.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses and Sales and Marketing Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of payroll and payroll related costs for the Company&#8217;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, gains or losses on disposals of assets, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services </span></div>segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three and nine months ended September 30, 2022 and 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-10&#8221;). This update requires business entities to disclose information annually about certain government assistance they receive. Such annual disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this new accounting standard in its Annual Report on Form 10-K for the year ended December 31, 2022 and does not expect the adoption of this standard to have a material impact on its Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-08</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating its adoption date of this standard and the impact of the standard on its Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIBOR</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of September 30, 2022, there was no impact to the Company&#8217;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AssetsHeldForSalePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Held For Sale, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AssetsHeldForSalePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176885438064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table summarizes the purchase consideration recorded for the acquisition of Trapelo, the fair value of the net assets acquired and liabilities assumed, and the calculation of goodwill based on <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the excess of the consideration transferred over the fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"/><td style="width:74.247%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued as consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share value of common stock issued as consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of common stock at Trapelo Acquisition Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Cash paid at closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of the purchase consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - marketing assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The purchase price and purchase price allocation were based upon management&#8217;s best estimates and assumptions and were considered final as of June 30, 2022. The following table summarizes the calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit, and the estimated fair value of the previously-held equity interest and Purchase Option, over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):<div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:33.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.709%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 18, 2021<br/>(as initially reported)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Measurement Period Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 18, 2021 <br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of Line of Credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of previously-held equity interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of Purchase Option</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allocation of the fair value business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets - developed technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets - trademarks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible asset - trade name</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net identifiable assets acquired </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,388)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangibles assets and related future amortization.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2022, we recorded a $4.3&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Business Acquisition, Pro Forma Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:40.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.499%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30, 2021 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176885447024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets Measured on Recurring and Nonrecurring Basis</a></td>
<td class="text">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#8217;s marketable securities accounted for as available-for-sale securities as of September 30, 2022 and December 31, 2021.<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,782&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,368)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at September 30, 2022 and December 31, 2021. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of September 30, 2022 and December 31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176880472736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amounts of goodwill by segment at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pharma Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2022, we recorded a $4.3&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Classes of Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Asset Amortization Expense</a></td>
<td class="text">The following table summarizes the amortization expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense related to amortizable intangible assets for each of the following periods as of September 30, 2022 is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Intangible Asset Amortization Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176885419312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s plans for the nine months ended September 30, 2022 is as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,075&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Each Stock Option Award Granted</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award granted during the nine months ended September 30, 2022 was estimated as of the grant date using a Black-Scholes model with the following assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 - 5.5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 3.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (%)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42% - 60%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.51</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted stock activity under the Company&#8217;s plans for the nine months ended September 30, 2022 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,022,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994,862&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176884254096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma capitalized commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets. </span></div>(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Client direct billing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial Insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Medicare and Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Self-Pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Clinical Services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,588&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,782&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176885357808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculations (in thousands, except net loss per share amounts):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,852)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,348)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,563)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of Convertible Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of Convertible Notes due 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,425&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:37.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.725%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176884262032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text">The following table summarizes the segment information (in thousands):<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,597&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,803&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,952&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,311&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,990&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,510)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,713)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,240)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,187)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,624)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,170)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,818)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,852)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,348)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,563)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 includes $4.3&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2022 include $12.8&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2021 include write-offs of $5.3&#160;million for COVID-19 PCR testing inventory and $5.0&#160;million of amortization of acquired Inivata developed technology intangible assets.</span></div>(2) Pharma Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 include $0.6&#160;million of amortization of acquired Inivata developed technology intangible assets. Pharma Services cost of revenue for the nine months ended September 30, 2022 and September 30, 2021 includes $1.8&#160;million and $0.6&#160;million of amortization, respectively, of acquired Inivata developed technology intangible assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881188896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_PolymeraseChainReactionTestingExitCostsCOVID19', window );">PCR testing, amount recorded, COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,061,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_PolymeraseChainReactionTestingWriteOffsCOVID19', window );">PCR testing, write-offs, COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19', window );">PCR testing, general and administrative expenses, COVID-19</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_SocialSecurityTaxEmployerDeferralCARESAct', window );">COVID-19, deferred social security payroll tax</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PolymeraseChainReactionTestingExitCostsCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Polymerase Chain Reaction Testing, Exit Costs, COVID-19</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PolymeraseChainReactionTestingExitCostsCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PolymeraseChainReactionTestingWriteOffsCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Polymerase Chain Reaction Testing, Write-Offs, COVID-19</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PolymeraseChainReactionTestingWriteOffsCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_SocialSecurityTaxEmployerDeferralCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Social Security Tax, Employer, Deferral, CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_SocialSecurityTaxEmployerDeferralCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176880478592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_AssetHeldForSaleSquareFeetOfFacilityOwned', window );">Square feet owned (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale', window );">Proceeds from sale of property</a></td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AssetHeldForSaleSquareFeetOfFacilityOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Held For Sale, Square Feet Of Facility Owned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AssetHeldForSaleSquareFeetOfFacilityOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982154&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176878917440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 18, 2021</div></th>
<th class="th"><div>Apr. 07, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 419,404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Inivata Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Inivata Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Investment in minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Consideration paid to other shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period of acquired intangible assets (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period of acquired intangible assets (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period of acquired intangible assets (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments', window );">Payments to acquire business, adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of common stock at Trapelo Acquisition Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares of common stock issued as consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Stock price per share on closing date (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period of acquired intangible assets (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, tax deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Marketing Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments', window );">Payments to acquire business, adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period of acquired intangible assets (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, tax deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of previously-held equity interest</a></td>
<td class="nump">$ 64,900,000<span></span>
</td>
<td class="nump">64,906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue', window );">Fair value of purchase option</a></td>
<td class="nump">$ 74,300,000<span></span>
</td>
<td class="nump">74,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Increase in goodwill from deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Measurement period adjustments, net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Step Acquisition, Purchase Option, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Acquired From Acquisition And Working Capital Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Investments And Loan Receivable From Non-Consolidated Affiliate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176874355248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Schedule of Provisional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 18, 2021</div></th>
<th class="th"><div>Apr. 07, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Plus: Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 419,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares of common stock issued as consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Per share value of common stock issued as consideration (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of common stock at Trapelo Acquisition Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Plus: Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Marketing Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Plus: Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Fair value of Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests', window );">Measurement period adjustments, fair value of previously-held equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of previously-held equity interest</a></td>
<td class="nump">$ 64,900<span></span>
</td>
<td class="nump">64,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue', window );">Measurement period adjustments, fair value of Purchase Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue', window );">Fair value of purchase option</a></td>
<td class="nump">$ 74,300<span></span>
</td>
<td class="nump">74,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Measurement period adjustments, net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Total fair value of business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther', window );">Measurement period adjustments, other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets', window );">Measurement period adjustments, total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent', window );">Measurement period adjustments, current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities', window );">Measurement period adjustments, deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet', window );">Measurement period adjustments, net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Error Correction, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities', window );">Measurement period adjustments, deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet', window );">Measurement period adjustments, net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Plus: Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Fair value of Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of previously-held equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue', window );">Fair value of purchase option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Total fair value of business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Measurement period adjustments, identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Developed technology | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Measurement period adjustments, identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Trademarks | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Measurement period adjustments, identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Trade Name | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Assets Acquired and Liabilities Assumed, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Deferred Income Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Step Acquisition, Purchase Option, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to equity interests acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to financial assets acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881184928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Pro Forma Information (Details) - Inivata - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenue</a></td>
<td class="nump">$ 121,340<span></span>
</td>
<td class="nump">$ 358,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,017)<span></span>
</td>
<td class="num">$ (88,134)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176882337216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Amortized Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 182,782<span></span>
</td>
<td class="nump">$ 199,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5,368)<span></span>
</td>
<td class="num">(923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">177,414<span></span>
</td>
<td class="nump">198,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest receivable</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">52,826<span></span>
</td>
<td class="nump">52,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(889)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">51,937<span></span>
</td>
<td class="nump">52,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember', window );">Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">8,373<span></span>
</td>
<td class="nump">6,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">8,232<span></span>
</td>
<td class="nump">6,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">8,890<span></span>
</td>
<td class="nump">17,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">8,743<span></span>
</td>
<td class="nump">17,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">12,877<span></span>
</td>
<td class="nump">12,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,119)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">11,758<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">6,974<span></span>
</td>
<td class="nump">17,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">6,945<span></span>
</td>
<td class="nump">17,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">30,117<span></span>
</td>
<td class="nump">27,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(510)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">29,607<span></span>
</td>
<td class="nump">27,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">62,725<span></span>
</td>
<td class="nump">65,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,533)<span></span>
</td>
<td class="num">(452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">$ 60,192<span></span>
</td>
<td class="nump">$ 64,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL121698322-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267856-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176874173696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">$ 112,167<span></span>
</td>
<td class="nump">$ 104,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">65,247<span></span>
</td>
<td class="nump">93,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">177,414<span></span>
</td>
<td class="nump">198,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">36,102<span></span>
</td>
<td class="nump">22,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">15,835<span></span>
</td>
<td class="nump">30,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">51,937<span></span>
</td>
<td class="nump">52,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember', window );">Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">5,704<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">2,528<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">8,232<span></span>
</td>
<td class="nump">6,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">6,419<span></span>
</td>
<td class="nump">14,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">2,324<span></span>
</td>
<td class="nump">3,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">8,743<span></span>
</td>
<td class="nump">17,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">11,758<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">11,758<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">6,945<span></span>
</td>
<td class="nump">17,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">6,945<span></span>
</td>
<td class="nump">17,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">25,052<span></span>
</td>
<td class="nump">20,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">4,555<span></span>
</td>
<td class="nump">6,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">29,607<span></span>
</td>
<td class="nump">27,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">31,945<span></span>
</td>
<td class="nump">25,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">28,247<span></span>
</td>
<td class="nump">39,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">$ 60,192<span></span>
</td>
<td class="nump">$ 64,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176872912304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">$ 177,414<span></span>
</td>
<td class="nump">$ 198,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">51,937<span></span>
</td>
<td class="nump">52,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember', window );">Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">8,232<span></span>
</td>
<td class="nump">6,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">8,743<span></span>
</td>
<td class="nump">17,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">11,758<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">6,945<span></span>
</td>
<td class="nump">17,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">29,607<span></span>
</td>
<td class="nump">27,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">60,192<span></span>
</td>
<td class="nump">64,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">411,214<span></span>
</td>
<td class="nump">475,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">197,901<span></span>
</td>
<td class="nump">254,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">35,899<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">51,937<span></span>
</td>
<td class="nump">52,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">8,232<span></span>
</td>
<td class="nump">6,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">8,743<span></span>
</td>
<td class="nump">17,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">11,758<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">6,945<span></span>
</td>
<td class="nump">17,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">29,607<span></span>
</td>
<td class="nump">27,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">60,192<span></span>
</td>
<td class="nump">64,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">278,571<span></span>
</td>
<td class="nump">342,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">197,901<span></span>
</td>
<td class="nump">254,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">51,937<span></span>
</td>
<td class="nump">52,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">8,232<span></span>
</td>
<td class="nump">6,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">8,743<span></span>
</td>
<td class="nump">17,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">11,758<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">132,643<span></span>
</td>
<td class="nump">132,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">35,899<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">6,945<span></span>
</td>
<td class="nump">17,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">29,607<span></span>
</td>
<td class="nump">27,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">60,192<span></span>
</td>
<td class="nump">64,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176875432144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 18, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 267,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments, goodwill</a></td>
<td class="num">(27,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Error Correction, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments, goodwill</a></td>
<td class="nump">$ 4,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176874296448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Classes of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total cost of intangibles</a></td>
<td class="nump">$ 501,380<span></span>
</td>
<td class="nump">$ 501,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">84,532<span></span>
</td>
<td class="nump">59,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">403,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">416,848<span></span>
</td>
<td class="nump">442,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Trademark - Indefinite lived</a></td>
<td class="nump">13,447<span></span>
</td>
<td class="nump">13,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">143,101<span></span>
</td>
<td class="nump">143,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">53,172<span></span>
</td>
<td class="nump">45,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">89,929<span></span>
</td>
<td class="nump">97,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">310,226<span></span>
</td>
<td class="nump">310,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">27,787<span></span>
</td>
<td class="nump">11,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">$ 282,439<span></span>
</td>
<td class="nump">$ 298,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 31,473<span></span>
</td>
<td class="nump">$ 31,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,699<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">$ 28,774<span></span>
</td>
<td class="nump">$ 30,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 2,584<span></span>
</td>
<td class="nump">$ 2,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="nump">$ 2,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176874148576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total amortization of intangibles</a></td>
<td class="nump">$ 8,490<span></span>
</td>
<td class="nump">$ 8,474<span></span>
</td>
<td class="nump">$ 25,470<span></span>
</td>
<td class="nump">$ 14,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Amortization of intangibles included in cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total amortization of intangibles</a></td>
<td class="nump">4,853<span></span>
</td>
<td class="nump">4,825<span></span>
</td>
<td class="nump">14,559<span></span>
</td>
<td class="nump">5,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Amortization of intangibles included in general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total amortization of intangibles</a></td>
<td class="nump">$ 3,637<span></span>
</td>
<td class="nump">$ 3,649<span></span>
</td>
<td class="nump">$ 10,911<span></span>
</td>
<td class="nump">$ 9,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176885903904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 8,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">33,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">33,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">33,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">33,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">259,583<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 403,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176875543104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - Convertible Debt<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>day</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>Rate</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Rate</div>
</th>
<th class="th">
<div>Jan. 11, 2021 </div>
<div>USD ($) </div>
<div>Rate</div>
</th>
<th class="th">
<div>May 04, 2020 </div>
<div>USD ($) </div>
<div>Rate</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent) | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible Notes, conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtContractualCouponInterest', window );">Interest expense, contractual coupon interest</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtAccretionOfDebtDiscount', window );">Interest expense, accretion of debt discount</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts', window );">Interest expense, amortization of debt issuance costs</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">$ 25,300<span></span>
</td>
<td class="nump">23,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate on Convertible Notes (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value of debt</a></td>
<td class="nump">217,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible Notes, conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtContractualCouponInterest', window );">Interest expense, contractual coupon interest</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtAccretionOfDebtDiscount', window );">Interest expense, accretion of debt discount</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts', window );">Interest expense, amortization of debt issuance costs</a></td>
<td class="nump">37,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,500<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate on Convertible Notes (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value of debt</a></td>
<td class="nump">$ 171,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Conversion price on applicable trading day (as a percent)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days (in days) | day</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days (in days) | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_InterestExpenseDebtAccretionOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Accretion Of Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_InterestExpenseDebtAccretionOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Amortization Of Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_InterestExpenseDebtContractualCouponInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Contractual Coupon Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_InterestExpenseDebtContractualCouponInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881140192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense (gain)</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, weighted-average recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=neo_ChiefLegalOfficerMember', window );">Chief Legal Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="nump">19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, weighted-average recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Chief Legal Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Chief Legal Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to adjust previously recorded stockholders' equity balances to the actual aggregate amounts paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchaseProgramAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=neo_ChiefLegalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=neo_ChiefLegalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176880661904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,961,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">3,849,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">804,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="nump">1,758,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">4,247,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">1,019,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 25.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">14.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">11.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">28.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">17.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, ending balance (in dollars per share)</a></td>
<td class="nump">$ 24.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Reduction in Options Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Reductions in Options Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176873718128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average fair value/share at grant date (in dollars per share)</a></td>
<td class="nump">$ 6.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">60.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176875773872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">851,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,477,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(311,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(1,022,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1,994,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160;Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">14.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">36.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">27.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176874150848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Revenue payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Collection of consideration the Company expects to receive typically occurs within 90 to 120 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Pharma contract liability, revenue recognized</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract commissions</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881205904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract with Customer, Asset, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Current pharma contract assets</a></td>
<td class="nump">$ 2,679<span></span>
</td>
<td class="nump">$ 1,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Long-term pharma contract assets</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Total pharma contract assets</a></td>
<td class="nump">2,936<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAbstract', window );"><strong>Capitalized Contract Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetCurrent', window );">Current pharma capitalized commissions</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Long-term pharma capitalized commissions</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Total pharma capitalized commissions</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current pharma contract liabilities</a></td>
<td class="nump">6,386<span></span>
</td>
<td class="nump">5,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term pharma contract liabilities</a></td>
<td class="nump">1,128<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total pharma contract liabilities</a></td>
<td class="nump">$ 7,514<span></span>
</td>
<td class="nump">$ 6,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176882350160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 128,782<span></span>
</td>
<td class="nump">$ 121,340<span></span>
</td>
<td class="nump">$ 371,023<span></span>
</td>
<td class="nump">$ 358,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">106,162<span></span>
</td>
<td class="nump">102,227<span></span>
</td>
<td class="nump">310,588<span></span>
</td>
<td class="nump">300,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Client direct billing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">73,234<span></span>
</td>
<td class="nump">64,195<span></span>
</td>
<td class="nump">208,123<span></span>
</td>
<td class="nump">188,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Commercial Insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">17,105<span></span>
</td>
<td class="nump">19,539<span></span>
</td>
<td class="nump">53,904<span></span>
</td>
<td class="nump">58,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Medicare and Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">15,795<span></span>
</td>
<td class="nump">18,295<span></span>
</td>
<td class="nump">48,427<span></span>
</td>
<td class="nump">52,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Self-Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 22,620<span></span>
</td>
<td class="nump">$ 19,113<span></span>
</td>
<td class="nump">$ 60,435<span></span>
</td>
<td class="nump">$ 58,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_ClientDirectBillingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_ClientDirectBillingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_CommercialInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_CommercialInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_MedicareAndOtherGovernmentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_MedicareAndOtherGovernmentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_SelfPayServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_SelfPayServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881240880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET (LOSS) INCOME</a></td>
<td class="num">$ (36,852)<span></span>
</td>
<td class="num">$ (20,348)<span></span>
</td>
<td class="num">$ (121,563)<span></span>
</td>
<td class="nump">$ 33,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Basic weighted average shares outstanding (in shares)</a></td>
<td class="nump">124,425<span></span>
</td>
<td class="nump">122,559<span></span>
</td>
<td class="nump">124,055<span></span>
</td>
<td class="nump">119,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">124,425<span></span>
</td>
<td class="nump">122,559<span></span>
</td>
<td class="nump">124,055<span></span>
</td>
<td class="nump">121,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income (loss) per share (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income (loss) per share (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect of Convertible Notes (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect of Convertible Notes (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and restricted stock awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and restricted stock awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176880951888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Schedule of Antidilutive Shares (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 334,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember', window );">Capped Call Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible debt, net of issuance costs</a></td>
<td class="nump">$ 29,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">1,811,000<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,000<span></span>
</td>
<td class="nump">201,000<span></span>
</td>
<td class="nump">266,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | 1.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,538,000<span></span>
</td>
<td class="nump">5,538,000<span></span>
</td>
<td class="nump">5,538,000<span></span>
</td>
<td class="nump">5,538,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | 0.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,215,000<span></span>
</td>
<td class="nump">5,215,000<span></span>
</td>
<td class="nump">5,215,000<span></span>
</td>
<td class="nump">5,101,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176880935776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 20, 2021 </div>
<div>patent</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_PatentInfringementComplaintMember', window );">Patent Infringement Complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_ContractualObligationLineItems', window );"><strong>Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents allegedly infringed upon | patent</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_FederalHealthcareProgramRevenueMember', window );">Federal Healthcare Program Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_ContractualObligationLineItems', window );"><strong>Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ContractualObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ContractualObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_PatentInfringementComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_PatentInfringementComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_FederalHealthcareProgramRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_FederalHealthcareProgramRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176881229616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Affiliated Entity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Strategic Alliance With Inivata Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Payments to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Pharma Service Contracts with CytomX Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related party</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Pharma Services contracts with HOOKIPA Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related party</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=neo_StrategicAllianceWithInivataLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=neo_StrategicAllianceWithInivataLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140176871553408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 128,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,023<span></span>
</td>
<td class="nump">$ 358,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">79,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,952<span></span>
</td>
<td class="nump">216,794<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">48,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,071<span></span>
</td>
<td class="nump">141,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">64,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,481<span></span>
</td>
<td class="nump">158,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,651<span></span>
</td>
<td class="nump">13,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">16,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,179<span></span>
</td>
<td class="nump">46,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">88,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,311<span></span>
</td>
<td class="nump">218,990<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(39,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131,240)<span></span>
</td>
<td class="num">(77,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">3,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(109,260)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before taxes</a></td>
<td class="num">(39,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133,818)<span></span>
</td>
<td class="nump">29,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(2,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,255)<span></span>
</td>
<td class="num">(4,283)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS) INCOME</a></td>
<td class="num">(36,852)<span></span>
</td>
<td class="num">$ (35,303)<span></span>
</td>
<td class="num">$ (49,408)<span></span>
</td>
<td class="num">(20,348)<span></span>
</td>
<td class="nump">$ 75,873<span></span>
</td>
<td class="num">$ (22,114)<span></span>
</td>
<td class="num">(121,563)<span></span>
</td>
<td class="nump">33,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">106,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,588<span></span>
</td>
<td class="nump">300,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">65,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,563<span></span>
</td>
<td class="nump">178,358<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">40,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,025<span></span>
</td>
<td class="nump">121,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_IntangibleAssetsAcquiredAmortizationExpense', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | COVID-19 PCR Testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write off of COVID-19 PCR testing inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">22,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,435<span></span>
</td>
<td class="nump">58,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">14,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,389<span></span>
</td>
<td class="nump">38,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">7,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,046<span></span>
</td>
<td class="nump">20,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_IntangibleAssetsAcquiredAmortizationExpense', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_IntangibleAssetsAcquiredAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Acquired, Amortization Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_IntangibleAssetsAcquiredAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=neo_COVID19PCRTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=neo_COVID19PCRTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>neo-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:neo="http://neogenomics.com/20220930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="neo-20220930.xsd" xlink:type="simple"/>
    <context id="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if9648e920d3546c49f4130aefa7f79ff_I20221104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="i83580aae10c642e8968c0f73731cc216_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic8321097bff14046a282e8abcc199611_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibd7160abe114438ea10e14d931ab82b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabd4ac9e3d6c4f07b201d7d092bbaa5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedad137938d1409a9e8fbc5c4f397c9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6690cf98ad3d4222abbea100fb427703_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if597821897f345c99cbbeebab1378c50_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i529f30ec7dff4e9b85a9c64c0c6dc63f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if9c30d1bc7c04d6ebec2ff027f47d17c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id5831a61214043b5a99770b3ea06868d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if71720d4e7b844b096debe1ed180ea82_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5f993779fd3b4952a907b9dd4f4b3d4d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3dea28d0e93949f5aefc5a14f49c8485_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i20c1c0ca88b04fc9862f5dd8242e69fd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i894e20df066b4a5988b63308c44592af_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icac541c50198437baeb6432443c98ca9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i21d90e116c7a466cba2f377d4f8ca18a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i44fa76d75a604e91bc3f64022a394556_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6b81d3b93d874a9db542449b4531b9ab_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i17cd1a8aeece46c2965383c6ff51f141_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i818d019ce1c04ff989dc836cb55d44ec_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if54a2cabacf746aaa21fa48bec9ae3b1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iad9898a18252459abeaaa2287043243d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idf24d4d87dae432094313f13b0433e46_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i29cb3ad0f407462c9898cd940c1d37f7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id315e694cb304a8dbb920f3d1bca41dc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifd47353cc04d40d487c363e58d6cd0d8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if1530977a71d4f31a22fb39f5d0e7492_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i08d8c97e16ec459e907fcfda4a1c55d2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i27adbda67be34d02b60f48394e1038b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48785c4f7e124415b6108ca28afcff05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2eb88896ee74655baa3b18785a707ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i245eb6ec3baa4df3b5146a6e6b182283_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia78d78a3c9db493697ca176e09b7aa91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i595026d5245f4feeafe415ec5546194b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1264117696a4469a67e0ec136421d1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbbb19f83f1e4ad79e3dc7bea4c0e730_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic1bf40a8250f436ba33bacfac6825360_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i405da8647b38440ebba559d212b5dd7c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icc37ab8dceb2404d8981b679d85008ed_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib52b9deb5b5e412c986b3a960ef6ec52_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3cb2d646d0b14c8c9d1612c5c39524e8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iee2a6c9923d645828b82bac68cf565f0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib8d80520822e4942b1b02b3aede5033c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c8a738d631c488c8a6d2ef8b1207ad6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e83cb2ada244e87863fccb0435f1caa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3b87d5129c424480b7bca5c7de9631c3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8d53da225c7543cc8626b67085ff1039_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i292a317c53d4440db036498f37a42c80_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i63a18efae1e24ac0a0f14cc9cb60d3d6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1d66426c727144e6a0ed073ec7de01aa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab400f484a364301b9f34d240511f761_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic547475396b745199691ec6a3e16bdbc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6b5778ebf6a4a509905cb89051df5f5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i46b48692e0ad44bfa45dab1bc766eee5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9b574e55d4754f55a7a02ba000cdea51_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic5524fa47c894252b50792cf5bfb8a1e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i634952822d8f47419d1fb60b6c946c77_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i23d019f81e5749f4a1f01a51d0b349d0_I20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-07</instant>
        </period>
    </context>
    <context id="i0254e4cf16114941859a750438514071_D20210407-20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-07</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="iff7308f890e64260ae7552498699b417_I20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2021-04-07</instant>
        </period>
    </context>
    <context id="ib2c2a0a7992f4f9c87c6ec0df05f6881_I20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-07</instant>
        </period>
    </context>
    <context id="i47dac90fa672439484bfb0a011afa79b_I20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-07</instant>
        </period>
    </context>
    <context id="i2fb74da8b2fb46a5bb928c2ae920bddb_D20210407-20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-07</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="i752263ab04214611a5770e4027948a06_D20210407-20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-07</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="id9000f1ccba54fd19804e3f40e0611cb_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i6a29368d78684750a6b47e75d93b5fe5_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i39681a3fb607451684256d16e371d9c7_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ie866a05c754c4aea88ba72656f3dfaf1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i447890f585a7488ca3884eedd5e3f87b_D20210930-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i42f304bd718a4345825da30d39801aa4_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i19602c53e9f24c5e9c34e6540ce4ce9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia684065582284ea892447e0db574adc0_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i972519f375d24149b066529619e13c9d_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="if0bbfe44413e450596641e770fb62e42_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="iddea112c263e4efd98f07f82c1942c43_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="icc7e8245487f4f58b121fa84f4613dc4_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ifc78548fd43f4d83ac64d4a4b191d44e_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="iec4e93a323ef4cc3a8b43b840cbbf66c_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="ieb7a81052f8342aaaa4c62d41e183a9e_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i8b166ff4628f47a6a659a300bfe3a6bd_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i57af656e837042e79c7838e6547334dc_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="id7214014d96a45c489ea60bba444a28e_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i865870f7a6e3486b94e11d31cbf92518_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ie1bbf95ea8de4373bbdc6c8c9dfb2a77_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i5190e0e6e6094a9aba5a2f9550f41b08_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i42a24c5b482d4c868eb1ce13b760dbe9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibbdaab51178b41529b740316e578e1d9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i18fb7d36fca64200a81888dd0251b185_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie54101ba639b4d8da6ecd576e651fccd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i766ee8715c984f5a91d4e9e5957aa027_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8e89a70008f0452185c38f35f5c3160f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i449f2af14b0146a5a78576a510536145_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i45be316a68fd49828e355ae260885a25_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifdae249624a24acd9b708eff8cd37977_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06d8161afc2042ec9e387fdb20260efb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i270d8802e355431a87805141beb22e21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0387bd97bb24097a69a3236c020cbf9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67a59efcaaa54315abd137625d2903be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6004076cc7944a468953c8b1ff560f34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i836abb9e08624532bd3983b006965c8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i836132e570fa408799f2204a799b968a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i75847b6fd90245879f447b248c88a3c6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib63051c22ad4419daca3d275e18517da_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i743caf65823d4bd1958a8cbb299c0895_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i51799610f4064775a69dfb0cac87a703_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if6bf0ff21f364dc0a684dbf075b53b37_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iae95464f5ee74284b6ae32d61d93ce73_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1af9878ff27e4d028b3550392083c7b2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i79ea5826458e41d99aa352a497ffafd4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i118589658cf34ed5b9ddf840fb4e46c8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i604eda05df5c4b31b29a38fc217c0cbb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6936f18c703b4b55a0cdedf5a286c9e3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1bbc37daa8d04bef9ffd619049eca18d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibf405aba888440c491e4e49e02bde83d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie2698d44ba514d578ea6e059ae78c719_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibac99a06e90442119500a802935b5fc5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id067a8d27c5e4dde917550297727f471_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib8dbf4d41b6a462f9551daf656d6df24_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i200b62a58197422faf0e93c36a17fcf2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id0f5e669517d4caf99147dede75e60cd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia425bc11b6e14936bb3bb334c3fcd38d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib5eb1da66af64627bcc27ca09542053d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib59406768d67448cb2b65eb67fed6dd0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9dc03daff727488d8a6291b702771aaa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3aa480d457354319b83badeb66ffb82a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9d0f765f52554a9c8dd28422846ea647_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9e9885cc6a7e41a58d60dbb43b197069_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icf8cb448cee344b8bf8f9dd3f02aecf6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie81bbebaf499410a8b2e96ff47a6f837_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia10649a3764d48f99a112b7824cbe5ee_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iea910074ae8048cb9c2564fc116234c3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia2be2fd21f9148e0b393eeafdff75ecf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibf8ac5a2c2b446f397a0b928f822a84c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3d7ac3af4f1f4aba835faf1dec1ae2d7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7758f3fc5d2843889d3dccc581512940_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i18f5b2b00f414b6cb866b819f1811ee6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iecbb10c34a5e40a192afaea2596f4d4b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iea762de04e3247bd84d1cc134af37b04_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3b3c9ac9f23540ddbfd3c2431b55c0cb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iacdf3ffa20844c33b3b4b233621d3bda_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i12a6b55ac524499facd15cc496171051_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75652f68da664faa9631192fcc0b0756_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i542bc1cf4cff4dbf8c06c801299e4c0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i195050c8c9bc4002b86ccce162741c31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if242353c50be44199306bd42b828c140_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8e94869d91d484ba640ce057070111e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic977ba257bc74ed0ac2c4dcf4afc8570_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e8311a90b3b424cac6df4bef4c4fbdf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3004fdeeb1e74b4ca1d1b3699743ba6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28d3e0ab7458409591d23b08216cb230_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a655c1539e343408dda30ab3e70fe06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b4e60329fa940689159d4dd319eb066_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc756c44664b43f4b23fb38f1e93addd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99e9f544c88447d2a59495913c96164d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idcc93136cd934c7ebd896d313b7290a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99c789341c8e4a58bd9ab39f1bf6644b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5e98456b3d846289512b6de773624bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabe8bbfc732445e9aceeb47b5e0c3c5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idcc990a87d7a472183c3ef562e4fdfc4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f5ddba725f1440e874eacac1370e4dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibedaa1c912184478b0503bfd2e5d722b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2e72e0725a14c9ca1b8b6e1a39fc880_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4319725e3601450bad41434e87073ac6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fbddcccd95b4981920388808f6beba8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62f94087a2cb4149929f3d7ce3682734_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i105dd178cd01422fa6a4e525c0693dae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62854311ca47485eae6a22edb90202c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6e5dd926f964588ba31f770c52749a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia89899f69b9044c0a9086495bace3ae2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f7167428b0340b584497251fb87718a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i321e7755d58a4125b1abe353704933f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4822392b9ab44df6b413f0f3ac8e55be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0b09d8a7a9546a1bddda55ed781ae42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb1d46b14a944988aae7942c987d7d5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e4ee5f830e74fdc9b4bbb24f9d53418_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i472970cdec304f53a5e8cd5cd075b4bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia93e0b2a1e3d464f8e6df2d0e9f52148_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib40d6f4a0a5143328f21dd179932836c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d9995d5167f4c7bb2a4f642fe88981d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59e0361f10ac4f76b5eba47b82775cbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75670d9ce45547bc99a81d6754f3d28c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ae39a4495a641b8aa5ccb48e1ae2a5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb880a76146242968e6bfd45a3fcc254_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i98b823d3747b4ba79fe123db7bc136cb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i549421f861aa49dc823adf1f4747dd6d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i79e1457052954b8b8b8d8d0bbe2ac708_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d4e012e5ff04c92ba9762ee777b5ee0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i797aec3fed494b6da15b5b1d78e7afaf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie84a64cf52bf488aa8c4b5c32b37ab49_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idfd5d3b7d14541ccb4c98224679c859c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1ac8a4996bb34043b19229ddcdd8fcf5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibfbdc2914bf44ebf9369d82276e58d62_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i106e8545ca314dd797829120c72a1131_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idede4c70818e4ec8b5e2e8f0405ddf00_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i361720e05c8e458d9eda92fc5388b6e8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6ef158959bfb4e7f9623bff4b4a573cb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib216f20bf24c458d809516016332ecd5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifd6c3992b5294ed89c00bb7e4387a2ff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib759ebff98dd441ca6275338c855db76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1e053abf65147d29a5dd6a6ac867b9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd8360c0431e46e48e0c165b0287f029_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i19cd4a991b204018b122a75e5768a87f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c8ecbf116e841a9b4dfffda832ac632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0b5bb4b553741e0bed88b54c12490b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i240234cbd1b048a88a80ecfb7db9b243_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9cf7af964324575b1e90a208499969a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2acb703fa2e4b3d8f2adf8f1ccf8251_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7474ff176c7846c0acef3250e51c454e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1287835862df47c8bc96b7ec0def19bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad4649c38cd34257bb5c56cd8d83cd45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56e071a65fde4540a8f2f69263d43769_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic77b4f7ab7454a149dc9bb68b7337a50_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifac78e36d8f94115b39886bb71273081_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4ac44e2ebca3469bb5add1f5bc673f54_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8950ddf7dc73426abd2e59bb9e3428cd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2b5b9002c6c54807843802a2269d680c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i985788d5c071467d85f2f33e2f2e2fe3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i613c8ef800af4acbb247578aff04da3d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2e078001d1454b3cbc7f7d7b83568f2e_I20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7e9577a5d34442988876254f1f4de500_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i09ab64c3de5a4744a9608181e3687f96_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie2b7a7f93dbb4b1ca8195ad0d4023f57_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6cf3c51ab90a4a2898937c535e682135_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf48e559e728411498f7b81a86313e8e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie5639e39468f41488a1252639d4ef0c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i766de052b6724a39ac4cff4bcdcc1a5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8696c4831ac447f91dae99b16f092c2_I20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="ied71922b6fb843699775ee25dc037112_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia865031156044a7dbb6c87daac4c70d7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5ca9c808340f4bfcb031c666d2d97909_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1edd2c29bc214bb28b0e32e7fd84ca23_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5cc7c64aab7049d8bf4e97fd24d8055d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8dfff7d2e5c04e57a4f8de1a51fac23f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2582f1fdaa5d4fd58b8edb349ee79064_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23b5d383d9e84db6b635cdcd0c0f9d95_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i62713aa84dd049d68dc66b6a1fe200e6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id36af2f403f24cf7b4525fc88fa61cb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9abed8a09c214319a4423cf3fb5ecb73_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idda8fd6e0a664803b84d581d6ad6b27a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7ae752c4884e4e67ad202713d68fe1b2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i79b69f5ad10b449dac5c4fc387dfccf0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0739f9f5cb43425cb2d6fc5c3d1947da_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i90a3daea84f54e7bbfd7da40f557227c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">neo:ChiefLegalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i403368f4b4754ed4b335bff0b80a92da_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if65fbf7f2c924f07a648c17a334c7c42_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i402c8314c37b4397a60a9dc5100ead32_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i915d2ee33bfe41828d288f2c9e850276_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2983b693db614e67a0385420d6fe04db_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8422c990601641b9923d741a1879f6f6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie06ce2ae770d4cf98f1c70856a4ca493_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i12404422705e4e5db442f2c6fa044950_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0c4daaae4c144b64bf090d8b0ec28bde_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic2ce6ba5e4be4b41adb542d8cc8b71c4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2c9f8f865eca4dee9704f9ae41b2c4a2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2e4e564189e94f8da0931134c08f04e2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9077f666a17a48f3b7bc80bc791c4661_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i11e2ed3be0744fb0a5fa17de9fd64cb8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i518f32fbbb6149f08c71ce0cf09bfa3e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia6531ec4b2bd491d919cb52b975afca2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idadb4a2ecea94787888cba5a2ec1fdf4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e676b3f14974a14b21ed4e1353a4970_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0430c68b11e441a1932ef5b6bf20883e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f4d4146b09f46f8bae21fa55af4e603_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i00c17f0a685d4b4bb4ac9262b0409185_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4359f136a8724314ae74fdfcb5cf1ddb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i31361b8430c34cb1a61a5212cab1d7e4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4429118382147fe986ee5dbfc122521_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c42bc6f38d647e19f5951ebd7219933_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36c5815174fc465484a397d6b8310ed5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2ee7ce21290e41ef94470a95e2d94830_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if05bf8eb6bc645cd9e362b07a66b1d8c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3db9446bf9344b45b0f702886c5f0051_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69da659e90044db1a544a5bde21c110c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a46098d95ff4c398528d14d94cf1462_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0f31d48f948140049d3ec9c0b3ce5eb3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i277bb1a3397c493eab6081211ecad60e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d2147cc98bb480fb457363bd7cdaef9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ce2989799cb43159de5d33b523a462c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i75ab618a9f5c4dd0a3656bbe96c190ad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i242b0a5a38704451a6823784364be43c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i86ad372323184dde948139f6d77bc2bd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3cf08791a42c4b12b704b3c8c21f8f15_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i05e8201ba8544204b7f58c994e8ac179_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i50746063c011499591f6bd542aedaab2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i72f0500c13d24ac7bcf932ec6cb56213_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94151c90de104b8dbe11dec588578819_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i96522c45dcd84160880608c828bd86b3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic226270fce13411aaa7fde2cdeb1e234_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i953f791557df441a893456e3ce3c860a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62cba84218e84f778d2010e7be8c7e0d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6e5b26bbdce64c3ca2829078807c061f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia40344f3d7174e60be2e0dbaf9533460_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9dd0bf6f3fb647c1a101a318ce23fbad_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i98e63a0f57c2427c9d3b54f1c162de3c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4bbde1a0788e4d5e98970b3bd2cb180a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i346de9f05ee645788bff3412f862de33_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i879e090b3f4e4e71bc92de7e2ad882b2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib4d31e5c09604f229766351b8ba0d0fc_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="i68c2a2f8b6bc4a8f9ea7991d94b969f2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie54a7a7e84624ef48b6fa7119e60f286_D20210120-20210120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:PatentInfringementComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-20</startDate>
            <endDate>2021-01-20</endDate>
        </period>
    </context>
    <context id="idbe5ba6b460e48cea499cfd288684c3c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i72c663a25f6742dea0c2944423d3ba66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79ee0320473e4c25be7915c5434f0efe_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:StrategicAllianceWithInivataLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6eb774483c5d44a88b442c3a493331f4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServiceContractsWithCytomXTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d2b85ad77a2443083ab566f9d503e37_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServiceContractsWithCytomXTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3640c3db5b114ab3997daf6009f1e121_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServiceContractsWithCytomXTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ce9041f492249c4a99391bfbb0cddc4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServiceContractsWithCytomXTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6637559ec6a04ab5b9435cf6158fd0c4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6f4bd7a8247d417ea28e862e1cf803db_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i250039242aab493dabb7b5413e5f5a41_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb967b231404449cb3a51eadf05ece29_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19908e283dc94d0d945d062e4df46a9a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">neo:COVID19PCRTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="day">
        <measure>neo:day</measure>
    </unit>
    <unit id="segment">
        <measure>neo:segment</measure>
    </unit>
    <unit id="patent">
        <measure>neo:patent</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV8zLTEtMS0xLTEyNjYyOA_31f5b906-49c3-41ff-8bd2-81925b108c48">0001077183</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV80LTEtMS0xLTEyNjYyOA_f5da2ad5-d462-4391-8127-93118be1f632">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV81LTEtMS0xLTEyNjYyOA_30d8d38f-f6a3-4103-b0aa-eb164e1acd5e">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV82LTEtMS0xLTEyNjYyOA_b63d9db4-9052-4793-9e2f-8476e4bb496d">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80L2ZyYWc6YzcwNTJiZDU2NmUyNDhhNmFjNWI4MjZhNDI0NTA0NmUvdGFibGU6MjhlYzlmZTE5ZmUyNDQxYjk0ODhhZWRhZTQ0YThmZDkvdGFibGVyYW5nZToyOGVjOWZlMTlmZTI0NDFiOTQ4OGFlZGFlNDRhOGZkOV83LTEtMS0xLTEyNjYyOA_9080c953-5fbf-4de9-b7d7-65fecaa43ed0">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl84NA_1f066c47-e003-40dd-b863-5a23b457b07b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6N2M2Y2VmMGM2MmYyNDc4YzlmMDAzNGEwMDM0MTkwODIvdGFibGVyYW5nZTo3YzZjZWYwYzYyZjI0NzhjOWYwMDM0YTAwMzQxOTA4Ml8wLTAtMS0xLTEyNjYyOA_f36c487a-92aa-4f79-bc35-c8040623bb2f">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8xMjA_2b629b26-b996-4932-989d-b4a11acd9e77">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6YjQ1YjgyNDJmMGE5NDE4Yzk2ZWQ5MDU5NGM5YmE3YTAvdGFibGVyYW5nZTpiNDViODI0MmYwYTk0MThjOTZlZDkwNTk0YzliYTdhMF8wLTAtMS0xLTEyNjYyOA_8d51c65a-6d93-45b9-b4a1-c063fe67aa8a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8yMTQ_333f6a57-0447-415c-8462-a44c3a9585a6">001-35756</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8yMTc_606a9227-cedd-4957-b3c4-57b4b44c848d">NEOGENOMICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl8wLTAtMS0xLTEyNjYyOA_63eafb76-3833-4aea-a9bb-8e99003c449d">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl8wLTMtMS0xLTEyNjYyOA_2d341abb-0e53-4cd3-9b06-09c79f053b80">74-2897368</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl8zLTAtMS0xLTEyNjYyOA_8513d8db-260e-4124-b7aa-b0f6cf36cb52">9490 NeoGenomics Way,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl8zLTEtMS0xLTEyNjYyOA_6e80ab77-f04c-4f44-b7cc-f0941970389d">Fort Myers,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl80LTAtMS0xLTEyNjYyOA_93cc1b1d-b5ad-4199-8909-207ebab4709d">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6ZGIzZjJmNmI4OTMxNDdkYWE1ZDIyMjA5NDI1MWRiNGYvdGFibGVyYW5nZTpkYjNmMmY2Yjg5MzE0N2RhYTVkMjIyMDk0MjUxZGI0Zl80LTMtMS0xLTEyNjYyOA_05e6008c-4b94-4bbd-8263-54cbc4b9a19a">33912</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8yODA_c52f5e71-87af-4ee4-81ed-6a546cb3e65e">(239)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8yODM_82135441-d69b-469b-9e43-90c0463016fe">768-0600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MDBjNjBkMzY5ZDhmNDQ2NGFlZjgxNGU2NTA2MDE3N2MvdGFibGVyYW5nZTowMGM2MGQzNjlkOGY0NDY0YWVmODE0ZTY1MDYwMTc3Y18xLTAtMS0xLTEyNjYyOA_0429a6ac-5206-473f-9166-9450ff0dc0e4">Common stock ($0.001 par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MDBjNjBkMzY5ZDhmNDQ2NGFlZjgxNGU2NTA2MDE3N2MvdGFibGVyYW5nZTowMGM2MGQzNjlkOGY0NDY0YWVmODE0ZTY1MDYwMTc3Y18xLTItMS0xLTEyNjYyOA_aa874f76-5b65-42bf-ab8b-cccc191a52b2">NEO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MDBjNjBkMzY5ZDhmNDQ2NGFlZjgxNGU2NTA2MDE3N2MvdGFibGVyYW5nZTowMGM2MGQzNjlkOGY0NDY0YWVmODE0ZTY1MDYwMTc3Y18xLTQtMS0xLTEyNjYyOA_16e3bab1-92c0-4255-8b64-937d749cfa36">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl83NTA_ed4c803d-e4be-4a78-bd2c-8092b3f3178a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8xMDc0_afa21a17-348d-4cb9-8c2e-20be0f40e013">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MjI4YTU5YjE4MTFkNDM4ZGE1OGY5ZDhhNzczYTZjOGEvdGFibGVyYW5nZToyMjhhNTliMTgxMWQ0MzhkYTU4ZjlkOGE3NzNhNmM4YV8wLTAtMS0xLTEyNjYyOA_fbf1b7c8-f176-40fc-bf01-fc5b3e15d6d8">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MjI4YTU5YjE4MTFkNDM4ZGE1OGY5ZDhhNzczYTZjOGEvdGFibGVyYW5nZToyMjhhNTliMTgxMWQ0MzhkYTU4ZjlkOGE3NzNhNmM4YV8xLTQtMS0xLTEyNjYyOA_46a98cd7-c5c7-48d2-9243-9bc01461d4ef">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGFibGU6MjI4YTU5YjE4MTFkNDM4ZGE1OGY5ZDhhNzczYTZjOGEvdGFibGVyYW5nZToyMjhhNTliMTgxMWQ0MzhkYTU4ZjlkOGE3NzNhNmM4YV8yLTQtMS0xLTEyNjYyOA_d9a5abee-27a1-43e9-99b7-6fbb63051b1a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8xOTE3_c5411440-df28-417a-98a6-2b8ba93889d1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if9648e920d3546c49f4130aefa7f79ff_I20221104"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xL2ZyYWc6ZTM4ZjNhZjkxNzAzNGM2ZTllODJmMzRjMmRlMWQ0MWYvdGV4dHJlZ2lvbjplMzhmM2FmOTE3MDM0YzZlOWU4MmYzNGMyZGUxZDQxZl8xODQ5_510748ed-d6cc-4ec3-8123-5650c203fa84"
      unitRef="shares">126303261</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMy0yLTEtMS0xMjY2Mjg_1eb98a78-1049-4648-aaf2-25c8d082ce54"
      unitRef="usd">266126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMy00LTEtMS0xMjY2Mjg_1ae62197-76f0-4879-acfa-834fffc777b3"
      unitRef="usd">316827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNS0yLTEtMS0xMjY2Mjg_89f9f3a7-31c3-4901-b0ef-12bccfcffa90"
      unitRef="usd">177414000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNS00LTEtMS0xMjY2Mjg_5a020ddc-ac68-4d2d-b1cf-716babeed906"
      unitRef="usd">198563000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNi0yLTEtMS0xMjY2Mjg_869ee3d9-5f7a-4038-9ceb-75b86ece5e3f"
      unitRef="usd">111994000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNi00LTEtMS0xMjY2Mjg_296e42ae-9514-45f9-9d97-7a37a7ec507c"
      unitRef="usd">112130000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNy0yLTEtMS0xMjY2Mjg_29987d86-b7da-4c60-b436-ae9ca8a52a34"
      unitRef="usd">23799000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNy00LTEtMS0xMjY2Mjg_b7841bf8-aae4-4a13-b8ff-e646909fddc5"
      unitRef="usd">23395000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfOC0yLTEtMS0xMjY2Mjg_f9dd14f7-5dc1-4f6f-83d1-5c7ba15ef0f8"
      unitRef="usd">16511000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfOC00LTEtMS0xMjY2Mjg_aad4f64e-83ad-4129-aa8a-d22bd1816e2e"
      unitRef="usd">12354000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfOS0yLTEtMS0xMjY2Mjg_602ed40d-feac-44b3-8b57-53d6d82801f0"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfOS00LTEtMS0xMjY2Mjg_ca50e6c0-8cf6-4a1c-889c-14e5a4f67a87"
      unitRef="usd">10050000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTAtMi0xLTEtMTI2NjI4_dd61b276-6d23-46d6-a70d-354775504f91"
      unitRef="usd">7516000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTAtNC0xLTEtMTI2NjI4_8491878b-e154-4210-8ea1-8ee4a9d26c6f"
      unitRef="usd">8189000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTEtMi0xLTEtMTI2NjI4_d9a45aaa-f425-4dc6-9727-f0e5c84f83c0"
      unitRef="usd">603360000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTEtNC0xLTEtMTI2NjI4_81f4109b-49f0-473e-b8b4-8dd7682591a3"
      unitRef="usd">681508000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTItMC0xLTEtMTI2NjI4L3RleHRyZWdpb246NTcxMDFkMzQxOGY0NGU5MDliYThjNDA4NjU3YWE2M2JfNjM_f4b78064-200f-4d72-99c1-21b9e9e8da70"
      unitRef="usd">125018000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTItMC0xLTEtMTI2NjI4L3RleHRyZWdpb246NTcxMDFkMzQxOGY0NGU5MDliYThjNDA4NjU3YWE2M2JfNzA_3d064a2a-22c5-45b4-8375-15e2227f446a"
      unitRef="usd">109952000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTItMi0xLTEtMTI2NjI4_1e57dfc0-63f4-4722-a19f-cc3279f783f9"
      unitRef="usd">106818000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTItNC0xLTEtMTI2NjI4_26502944-faa9-4c9b-91a2-e5f8dce5f7a9"
      unitRef="usd">109465000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTMtMi0xLTEtMTI2NjI4_fd8d6e03-20ae-43a9-8d7c-f8709ee5387b"
      unitRef="usd">98945000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTMtNC0xLTEtMTI2NjI4_db6b1305-f001-427a-bf5a-b53221d851f0"
      unitRef="usd">102197000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTUtMi0xLTEtMTI2NjI4_3dabe311-08fd-4127-a448-a17ba25f8ace"
      unitRef="usd">416848000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTUtNC0xLTEtMTI2NjI4_c882c2ec-1fb8-4f10-af5c-6c59bb2de4a9"
      unitRef="usd">442325000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTYtMi0xLTEtMTI2NjI4_a0981086-da7b-422d-b1e8-20db375e8aa5"
      unitRef="usd">522766000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMTYtNC0xLTEtMTI2NjI4_8ad9498f-f3c5-4af1-92a6-e8108b5aef90"
      unitRef="usd">527115000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjEtMi0xLTEtMTI2NjI4_02ba34e6-433b-483c-a33c-ce0d4ff0b16a"
      unitRef="usd">6845000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjEtNC0xLTEtMTI2NjI4_f51e13d8-2c92-43bc-9026-1fae381af0ab"
      unitRef="usd">7168000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjItMi0xLTEtMTI2NjI4_c2c1f80a-b000-4741-836a-958d1823cbd4"
      unitRef="usd">1152222000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjItNC0xLTEtMTI2NjI4_11e99869-3311-4d0c-8291-022bc9e58396"
      unitRef="usd">1188270000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjMtMi0xLTEtMTI2NjI4_ae0532da-f047-4abd-b83b-0cd8eb2cbd09"
      unitRef="usd">1755582000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjMtNC0xLTEtMTI2NjI4_2793bca3-6e6f-4faa-bfcd-865e06d0e996"
      unitRef="usd">1869778000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjYtMi0xLTEtMTI2NjI4_a3d360fe-3d38-4ed6-915c-0f93aca80789"
      unitRef="usd">13708000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjYtNC0xLTEtMTI2NjI4_36f0c0b7-2387-45b2-ae10-fab458c858d0"
      unitRef="usd">17921000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjctMi0xLTEtMTI2NjI4_791e0ac6-f82d-4115-abeb-d56e02dfe9f4"
      unitRef="usd">37992000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjctNC0xLTEtMTI2NjI4_b02bf8a6-d415-4bf2-b335-616f62fd0545"
      unitRef="usd">38304000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjgtMi0xLTEtMTI2NjI4_662b1548-3312-4caa-900b-78ba2a7c9441"
      unitRef="usd">20420000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjgtNC0xLTEtMTI2NjI4_c63bca46-0f95-4938-b6f4-20f62e77d4ec"
      unitRef="usd">17796000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjktMi0xLTEtMTI2NjI4_12ac546c-a4ee-4d06-834c-2e09fcee5515"
      unitRef="usd">118000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMjktNC0xLTEtMTI2NjI4_9bb89f2c-f7f2-4580-b1fd-f272d7f4aff5"
      unitRef="usd">1135000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzAtMi0xLTEtMTI2NjI4_f9c2e54b-6c79-44e2-8fd8-83b05f1f7214"
      unitRef="usd">6379000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzAtNC0xLTEtMTI2NjI4_c0fcf666-e129-44b0-8dae-bcc5cadb43ca"
      unitRef="usd">6884000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzMtMi0xLTEtMTI2NjI4_f280e7f2-1247-4750-a88d-d24af6159940"
      unitRef="usd">6386000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzMtNC0xLTEtMTI2NjI4_7c3fa6ea-666e-40bd-a553-945d111e613e"
      unitRef="usd">5192000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzQtMi0xLTEtMTI2NjI4_c3aa069f-6fb5-436e-8b36-5143c74a4eeb"
      unitRef="usd">85003000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzQtNC0xLTEtMTI2NjI4_62eb747d-725a-4aba-862c-df132980e435"
      unitRef="usd">87232000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzYtMi0xLTEtMTI2NjI4_b38cf00e-a73c-4a7c-9563-27f389254680"
      unitRef="usd">534609000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzYtNC0xLTEtMTI2NjI4_85f5a05b-61d8-4ad4-8e4a-52265c02c394"
      unitRef="usd">532483000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzgtMi0xLTEtMTI2NjI4_9149ad8c-d63f-4f60-8e07-bf8b306050a6"
      unitRef="usd">70471000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfMzgtNC0xLTEtMTI2NjI4_2a35355c-4ce3-47ea-8d81-18f53d406f99"
      unitRef="usd">72289000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDEtMi0xLTEtMTI2NjI4_612cc89a-b7fa-4201-adaf-3a8bf544ab87"
      unitRef="usd">38345000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDEtNC0xLTEtMTI2NjI4_3277d20b-7d6f-4090-b6a4-aa4ea6f0bb94"
      unitRef="usd">55475000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDItMi0xLTEtMTI2NjI4_20394cef-2682-44f4-99d8-5788b55bb8e4"
      unitRef="usd">14166000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDItNC0xLTEtMTI2NjI4_b5e1f766-dd0b-4923-90eb-d9b228816d08"
      unitRef="usd">14022000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDMtMi0xLTEtMTI2NjI4_4fc3e00a-e1ef-44ac-8334-3f2e7ac3e625"
      unitRef="usd">657591000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDMtNC0xLTEtMTI2NjI4_b9d425e2-d70a-43da-99e2-9d9fc1fe9b60"
      unitRef="usd">674269000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDQtMi0xLTEtMTI2NjI4_73ddc341-a573-4af3-bac8-f00c890f4ca3"
      unitRef="usd">742594000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDQtNC0xLTEtMTI2NjI4_fa3b0e12-d8ad-4a5f-b7ac-cd733bb97409"
      unitRef="usd">761501000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDUtMi0xLTEtMTI2NjI4_22a96c79-e846-4d6b-81d4-d69da3409d10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDUtNC0xLTEtMTI2NjI4_faaadb24-d901-4612-8a0f-3e101e671cae"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfMTg_14d98f18-bf64-4d1f-93e8-acd9f14e5f88"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfMTg_b423a05e-4a54-472d-af6b-42c1831204e9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfMzM_046a56d7-707d-41a3-aaef-c20b7da75be5"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfMzM_70c229f9-4960-436e-8b85-380dcabc19ce"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfNTU_004b4ef1-02ce-4ac2-8ce6-99034807207b"
      unitRef="shares">126562037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfNTU_24b27d84-a760-4014-a399-60bfcc2eec07"
      unitRef="shares">126562037</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfNjI_deeab515-be88-4679-8583-afd9bceccb8a"
      unitRef="shares">124107500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMC0xLTEtMTI2NjI4L3RleHRyZWdpb246ZTc5MTk0OGMxMzZhNDRmZTlmYjI5NDIyZTQ5NDYxNTlfNjI_fdaf90b2-d4ce-421b-a08f-ca128bc8191e"
      unitRef="shares">124107500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctMi0xLTEtMTI2NjI4_07bedd65-e127-4029-832d-4952ce6c2e6b"
      unitRef="usd">127000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDctNC0xLTEtMTI2NjI4_13fdf742-b61b-46bf-837e-a486ff13e38a"
      unitRef="usd">124000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDgtMi0xLTEtMTI2NjI4_5b8265d6-d427-4096-8c1d-6e7a27a25aaa"
      unitRef="usd">1154365000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDgtNC0xLTEtMTI2NjI4_3808e484-942b-4620-a77c-b4fdda600886"
      unitRef="usd">1123628000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDktMi0xLTEtMTI2NjI4_d982dc43-bd49-487a-926a-c442cb5b6b02"
      unitRef="usd">-5104000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNDktNC0xLTEtMTI2NjI4_b212cb2b-0eeb-4575-bf30-455faca32d18"
      unitRef="usd">-638000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTAtMi0xLTEtMTI2NjI4_6d878d6a-aaf2-4114-a1ca-4e2e9aa0dc69"
      unitRef="usd">-136400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTAtNC0xLTEtMTI2NjI4_20226bf3-5808-447a-9a13-0306b734ccd8"
      unitRef="usd">-14837000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTEtMi0xLTEtMTI2NjI4_b85f9da8-2117-4f84-9bd4-40f14a89c4f1"
      unitRef="usd">1012988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTEtNC0xLTEtMTI2NjI4_b25c9890-7bcc-4236-80d4-3d6f1b472a77"
      unitRef="usd">1108277000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTItMi0xLTEtMTI2NjI4_8d4df16e-aab7-4a76-9885-67bc22b10d33"
      unitRef="usd">1755582000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8xOS9mcmFnOjY4M2RiNDE0NmE4OTQ3NTFiNDcxN2UwZDVmNjIzZjU5L3RhYmxlOjdmYzZmZDE5MTE0ZTRkOWNiY2Q1ZGEyN2MxZGE4ZjM3L3RhYmxlcmFuZ2U6N2ZjNmZkMTkxMTRlNGQ5Y2JjZDVkYTI3YzFkYThmMzdfNTItNC0xLTEtMTI2NjI4_e5a0a51d-7b4b-4448-82e4-c2a069a1d945"
      unitRef="usd">1869778000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMy0xLTEtMS0xMjY2Mjg_9a2cc4fa-9e32-424a-a450-691c06abf9ac"
      unitRef="usd">106162000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMy0zLTEtMS0xMjY2Mjg_9ab0de20-2fd6-477b-92d0-7573d0d23cdd"
      unitRef="usd">102227000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMy01LTEtMS0xMjY2Mjg_43f7c95c-a4b4-40b4-92c1-8c74aede0936"
      unitRef="usd">310588000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMy03LTEtMS0xMjY2Mjg_8803075b-1692-4a2c-ab2c-8e34f07fc106"
      unitRef="usd">300119000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNC0xLTEtMS0xMjY2Mjg_81bd774e-960c-4efb-bd24-510e2e81d0a5"
      unitRef="usd">22620000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNC0zLTEtMS0xMjY2Mjg_5bf12147-4d3c-4bdf-ba00-9c54aeca807f"
      unitRef="usd">19113000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNC01LTEtMS0xMjY2Mjg_d46df4bf-935b-4c8f-8e6b-61503179b08e"
      unitRef="usd">60435000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNC03LTEtMS0xMjY2Mjg_527f22d9-9280-4c33-acf6-f8a1129050c4"
      unitRef="usd">58478000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNS0xLTEtMS0xMjY2Mjg_cd1b9f4f-07c1-4add-b468-ecaab3b7f2e0"
      unitRef="usd">128782000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNS0zLTEtMS0xMjY2Mjg_7df3e5bf-3e4e-4d69-a382-5885e9d8baf3"
      unitRef="usd">121340000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNS01LTEtMS0xMjY2Mjg_9df75f0f-b565-4545-94a0-baf36ea9fc54"
      unitRef="usd">371023000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNS03LTEtMS0xMjY2Mjg_037ef3ea-3020-43a6-9427-8dc39429fde3"
      unitRef="usd">358597000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNy0xLTEtMS0xMjY2Mjg_ed4ba55c-952a-4cb7-958a-03b548771652"
      unitRef="usd">79889000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNy0zLTEtMS0xMjY2Mjg_3355f19f-537a-46d1-bde7-ed9b729d6e68"
      unitRef="usd">74101000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNy01LTEtMS0xMjY2Mjg_9b04607c-c51a-4905-ba85-ddb0d5f821dd"
      unitRef="usd">239952000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfNy03LTEtMS0xMjY2Mjg_3dca421f-5fd2-491b-9158-3d701a285d93"
      unitRef="usd">216794000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfOS0xLTEtMS0xMjY2Mjg_f37ecd72-46cb-4da3-9ddb-4fe3d933d58f"
      unitRef="usd">48893000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfOS0zLTEtMS0xMjY2Mjg_30e22ab3-643a-489c-b425-ea37f9b04440"
      unitRef="usd">47239000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfOS01LTEtMS0xMjY2Mjg_8afcad4a-f6a1-402a-bea5-0c4cc6084dd0"
      unitRef="usd">131071000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfOS03LTEtMS0xMjY2Mjg_5be7a455-0f57-405d-8548-b0feec695fcf"
      unitRef="usd">141803000</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTEtMS0xLTEtMTI2NjI4_c4082697-a0b7-4b52-afc0-2192acf2c2cd"
      unitRef="usd">64282000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTEtMy0xLTEtMTI2NjI4_1c325530-3c79-4cc0-8607-c75fe2f68d3f"
      unitRef="usd">63839000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTEtNS0xLTEtMTI2NjI4_79fffba6-477c-4b1f-ae15-65c5967a37ff"
      unitRef="usd">188481000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTEtNy0xLTEtMTI2NjI4_9164d045-f1ad-4b10-8b47-8289550f3c4e"
      unitRef="usd">158953000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTItMS0xLTEtMTI2NjI4_551104e5-6f57-4805-ad7a-777c6f94d833"
      unitRef="usd">7312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTItMy0xLTEtMTI2NjI4_d4f8aeac-9cee-4ad5-befc-3f9c54693f61"
      unitRef="usd">7409000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTItNS0xLTEtMTI2NjI4_a9e786b0-6aaa-4b8d-91a3-3e18cba07c32"
      unitRef="usd">23651000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTItNy0xLTEtMTI2NjI4_c923e8c9-389c-4cd7-bffe-5cbf32ebb314"
      unitRef="usd">13360000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTMtMS0xLTEtMTI2NjI4_78a780f8-a163-4d3a-b2ba-b776bd22a4d3"
      unitRef="usd">16809000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTMtMy0xLTEtMTI2NjI4_52d294c6-789c-4ca2-b740-19d44dcc0e1e"
      unitRef="usd">15704000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTMtNS0xLTEtMTI2NjI4_9af2bf22-06b0-4dae-be48-177ac62ddb8f"
      unitRef="usd">50179000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTMtNy0xLTEtMTI2NjI4_c83c2fe9-05ed-4bb8-ad4c-1f5a7b592c84"
      unitRef="usd">46677000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OperatingExpenses
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTQtMS0xLTEtMTI2NjI4_5ba20da2-c3f2-4dc3-aff4-5e5c991c2405"
      unitRef="usd">88403000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTQtMy0xLTEtMTI2NjI4_b4aded1e-f679-46fa-81a4-cb86f4b04b02"
      unitRef="usd">86952000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTQtNS0xLTEtMTI2NjI4_4c63d2e9-f620-4d3e-a754-8fe2159f813a"
      unitRef="usd">262311000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTQtNy0xLTEtMTI2NjI4_e04ab56f-cf42-47a4-8b60-e5afc61fea7f"
      unitRef="usd">218990000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTUtMS0xLTEtMTI2NjI4_45bb2265-86b9-4ca0-a66f-09be4e6d0a5d"
      unitRef="usd">-39510000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTUtMy0xLTEtMTI2NjI4_af6bde4d-aa1d-415e-b26b-5b9fedd48259"
      unitRef="usd">-39713000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTUtNS0xLTEtMTI2NjI4_0208bb73-6303-43a2-a45b-0b1203a3f233"
      unitRef="usd">-131240000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTUtNy0xLTEtMTI2NjI4_3440e5df-6e1d-413a-9c1b-b640b2e19a0e"
      unitRef="usd">-77187000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTYtMS0xLTEtMTI2NjI4_1edf6ce3-87a4-43e7-b3d8-5d90e46565fd"
      unitRef="usd">139000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTYtMy0xLTEtMTI2NjI4_5eac69e9-32fd-46f1-8f00-11973560ca52"
      unitRef="usd">1296000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTYtNS0xLTEtMTI2NjI4_f955101e-5cea-48fd-9508-39b59846a05c"
      unitRef="usd">2366000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTYtNy0xLTEtMTI2NjI4_54de532a-20d7-4911-bb2e-7efa64c352da"
      unitRef="usd">3375000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTctMS0xLTEtMTI2NjI4_59494f84-dd39-4eca-a934-9c7b6311c695"
      unitRef="usd">25000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTctMy0xLTEtMTI2NjI4_0dfe6f22-3fd4-4d23-9c46-af0034d0ec99"
      unitRef="usd">89000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTctNS0xLTEtMTI2NjI4_c58ae205-a078-4c05-bb92-5bcd0ee42167"
      unitRef="usd">-212000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTctNy0xLTEtMTI2NjI4_1632bca7-1dc1-4346-b6af-1c8636025866"
      unitRef="usd">431000</us-gaap:OtherNonoperatingIncomeExpense>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTgtMS0xLTEtMTI2NjI4_5fbfc9fe-f555-4bbd-a12b-aa8d9ec844be"
      unitRef="usd">0</neo:GainLossOnInvestmentAndLoanReceivable>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTgtMy0xLTEtMTI2NjI4_f804ae8c-d4a0-4883-823e-d58313a7c93e"
      unitRef="usd">17750000</neo:GainLossOnInvestmentAndLoanReceivable>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTgtNS0xLTEtMTI2NjI4_39c57ffa-d93c-49bf-83ca-9a502b64b870"
      unitRef="usd">0</neo:GainLossOnInvestmentAndLoanReceivable>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMTgtNy0xLTEtMTI2NjI4_8064233c-4c95-486f-96c1-899662da96f4"
      unitRef="usd">109260000</neo:GainLossOnInvestmentAndLoanReceivable>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjEtMS0xLTEtMTI2NjI4_5b9f5329-19ed-4b72-a235-627ce993a3d4"
      unitRef="usd">-39624000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjEtMy0xLTEtMTI2NjI4_e93e42fa-f381-4223-89d0-e4ff36216a0d"
      unitRef="usd">-23170000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjEtNS0xLTEtMTI2NjI4_1d8306f1-55a4-4053-af13-fcea23e8c492"
      unitRef="usd">-133818000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjEtNy0xLTEtMTI2NjI4_8a1ed9ed-fb6b-4d4c-9f25-96da7eea4cb6"
      unitRef="usd">29129000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjItMS0xLTEtMTI2NjI4_395cbcfe-5d08-40bb-bbd8-345e825375dc"
      unitRef="usd">-2772000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjItMy0xLTEtMTI2NjI4_56148a96-7735-4a8d-9988-a912efe74584"
      unitRef="usd">-2822000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjItNS0xLTEtMTI2NjI4_ede2cd7a-5b9c-4367-a7a2-1191dd0cf260"
      unitRef="usd">-12255000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjItNy0xLTEtMTI2NjI4_0ee21359-c7aa-4ad9-a9fc-1fa6956a77e7"
      unitRef="usd">-4283000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjMtMS0xLTEtMTI2NjI4_c67aa505-967f-4847-9be5-cce9be584bb8"
      unitRef="usd">-36852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjMtMy0xLTEtMTI2NjI4_fbda78ce-c9b8-40ec-b0b9-f62670b5e34a"
      unitRef="usd">-20348000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjMtNS0xLTEtMTI2NjI4_7b4a013d-f17f-467a-b937-e6a602833f2b"
      unitRef="usd">-121563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMjMtNy0xLTEtMTI2NjI4_fb274829-f6a7-41d5-9eaa-8fb53045746e"
      unitRef="usd">33412000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzEtMS0xLTEtMTI2NjI4_856697ab-326b-44f1-9409-19bf01f4a7f7"
      unitRef="usdPerShare">-0.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzEtMy0xLTEtMTI2NjI4_4f3a887d-ead4-4fd5-bb79-af9307b6c46f"
      unitRef="usdPerShare">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzEtNS0xLTEtMTI2NjI4_4b9826d6-d9b7-4b43-b2f1-84563e717ef8"
      unitRef="usdPerShare">-0.98</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzEtNy0xLTEtMTI2NjI4_4abb32fa-fcdd-411a-8dc1-de46d237297c"
      unitRef="usdPerShare">0.28</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzItMS0xLTEtMTI2NjI4_a6f9a2e3-2f70-4ff9-bb97-86f26520b865"
      unitRef="usdPerShare">-0.30</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzItMy0xLTEtMTI2NjI4_5e65e33f-50b1-4e54-a942-28b69750c3e0"
      unitRef="usdPerShare">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzItNS0xLTEtMTI2NjI4_bbb2304b-e04d-4d1b-bd99-20ac14037a8f"
      unitRef="usdPerShare">-0.98</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzItNy0xLTEtMTI2NjI4_0a5ceb70-d73d-4dcd-8b3e-0e5b1378415d"
      unitRef="usdPerShare">0.28</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzUtMS0xLTEtMTI2NjI4_b63b3d8c-d5b3-4da4-a6f7-580ad08acd65"
      unitRef="shares">124425000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzUtMy0xLTEtMTI2NjI4_16610e0f-6641-41b3-922c-7a0e46078323"
      unitRef="shares">122559000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzUtNS0xLTEtMTI2NjI4_07928ebd-171d-41b5-b5df-8e1e17adaf3f"
      unitRef="shares">124055000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzUtNy0xLTEtMTI2NjI4_0c461b4c-fb63-4795-830b-1d5fb8350e87"
      unitRef="shares">119087000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzYtMS0xLTEtMTI2NjI4_0ba81adc-e937-47c6-9095-664160d3c526"
      unitRef="shares">124425000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzYtMy0xLTEtMTI2NjI4_7387ff57-beba-4320-bb9a-38fc5e3ac98c"
      unitRef="shares">122559000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzYtNS0xLTEtMTI2NjI4_ac233831-a47b-4fe2-a3c4-06264d5a9fb2"
      unitRef="shares">124055000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yMi9mcmFnOjJmYTAxYjJjOTk1YzQxY2NhZGNmYzUzNjgyODVkNjIyL3RhYmxlOmEyMzIzMjMyNTc2ZjQ5Yzc4OGMzZDk2OGYzNzAxYTUyL3RhYmxlcmFuZ2U6YTIzMjMyMzI1NzZmNDljNzg4YzNkOTY4ZjM3MDFhNTJfMzYtNy0xLTEtMTI2NjI4_414dbf98-ae1e-4967-b711-ed56d872f911"
      unitRef="shares">121356000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMi0yLTEtMS0xMjY2Mjg_b7185dda-ef27-42f9-aae1-d0aba5df6155"
      unitRef="usd">-36852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMi00LTEtMS0xMjY2Mjg_772094ab-d114-419e-909f-81b7214f27b8"
      unitRef="usd">-20348000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMi02LTEtMS0xMjY2Mjg_b1f99eb4-a88d-4a9b-b185-64f51e7b97ad"
      unitRef="usd">-121563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMi04LTEtMS0xMjY2Mjg_d2bd0094-4d59-4040-bf21-22dfa8d81e4d"
      unitRef="usd">33412000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfNi0yLTEtMS0xMjY2Mjg_b6dd4c85-50b1-4931-88e2-d41cb6ecc1f9"
      unitRef="usd">-1048000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfNi00LTEtMS0xMjY2Mjg_81f41edd-48ce-4fc1-9c07-981b59653bfc"
      unitRef="usd">-57000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfNi02LTEtMS0xMjY2Mjg_2a5ecc77-abaf-43ed-91fd-62147b0b7948"
      unitRef="usd">-4466000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfNi04LTEtMS0xMjY2Mjg_87728f24-e9d4-4faa-9890-7466607652e8"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfOS0yLTEtMS0xMjY2Mjg_b6dd1dd7-4ef6-41d9-a948-b6f66f65eb5e"
      unitRef="usd">-1048000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfOS00LTEtMS0xMjY2Mjg_1c5ca160-fc05-4546-b0c5-9f6a79fbdfff"
      unitRef="usd">-57000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfOS02LTEtMS0xMjY2Mjg_641ede91-4e60-4180-9ab5-613e0399c295"
      unitRef="usd">-4466000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfOS04LTEtMS0xMjY2Mjg_e12c713f-ae34-4de6-8299-a77316db2f86"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMTAtMi0xLTEtMTI2NjI4_cb36fbd5-ad3a-4f1a-a220-96ca070a78f7"
      unitRef="usd">-37900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMTAtNC0xLTEtMTI2NjI4_b67606d6-38e9-400c-b24e-b1d5d13b6311"
      unitRef="usd">-20405000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMTAtNi0xLTEtMTI2NjI4_6c260a39-7e16-4c7b-8c50-a59167c0646d"
      unitRef="usd">-126029000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yNS9mcmFnOmY0MTQwZTI5ODQzZDRiN2VhNWMzMDJhOGNjYzFjZTZkL3RhYmxlOjA5NGMxZDNkNjYwZjQ3ZTNhMzYyZTE5ZGI2Y2Y5NDVlL3RhYmxlcmFuZ2U6MDk0YzFkM2Q2NjBmNDdlM2EzNjJlMTlkYjZjZjk0NWVfMTAtOC0xLTEtMTI2NjI4_06c8901e-7f63-48a3-96f4-89d316c49012"
      unitRef="usd">33012000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ibd7160abe114438ea10e14d931ab82b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi02LTEtMS0xMjY2Mjg_0d781019-a744-45fd-8fd6-abc1c20d0d0d"
      unitRef="shares">124107500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibd7160abe114438ea10e14d931ab82b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi04LTEtMS0xMjY2Mjg_baeb671c-8eb9-489e-bd75-635d7020ca13"
      unitRef="usd">124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iabd4ac9e3d6c4f07b201d7d092bbaa5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi0xMC0xLTEtMTI2NjI4_5a2bfc56-f21d-47b4-92a5-f5d87806e22c"
      unitRef="usd">1123628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedad137938d1409a9e8fbc5c4f397c9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi0xMi0xLTEtMTI2NjI4_58242688-df27-4555-b335-f42b7c25b109"
      unitRef="usd">-638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6690cf98ad3d4222abbea100fb427703_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi0xNC0xLTEtMTI2NjI4_37f66b27-14e7-4f3f-9b03-02acd6a98c8b"
      unitRef="usd">-14837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMi0xNi0xLTEtMTI2NjI4_17077d5c-a56b-47a3-b333-096be3aff1d4"
      unitRef="usd">1108277000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if597821897f345c99cbbeebab1378c50_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMy02LTEtMS0xMjY2Mjg_4887ede7-a5d1-4dba-9b0d-d7ff79f9e53c"
      unitRef="shares">47853</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMy0xMC0xLTEtMTI2NjI4_a072a80e-35eb-46dd-b885-b3a20617cba2"
      unitRef="usd">971000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMy0xNi0xLTEtMTI2NjI4_efd857fa-fb80-4f1f-93b5-56375d67269f"
      unitRef="usd">971000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if597821897f345c99cbbeebab1378c50_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNC02LTEtMS0xMjY2Mjg_31a2eb02-bf52-4a76-b71c-aba0abed0f50"
      unitRef="shares">100253</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNC0xMC0xLTEtMTI2NjI4_853fcf7f-d8b1-47e6-bcd7-f47f9b320222"
      unitRef="usd">-1049000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNC0xNi0xLTEtMTI2NjI4_51b3eabc-5dfd-4825-abff-bc731779bba2"
      unitRef="usd">-1049000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if597821897f345c99cbbeebab1378c50_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNS02LTEtMS0xMjY2Mjg_ea80db57-bd4b-4aef-b876-4535f17ebc63"
      unitRef="shares">466609</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if597821897f345c99cbbeebab1378c50_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNS04LTEtMS0xMjY2Mjg_c61cf23e-509f-4895-81da-344f1e1e1d8a"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNS0xMC0xLTEtMTI2NjI4_622ba250-04b3-419c-86a5-22a64a388283"
      unitRef="usd">6479000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNS0xNi0xLTEtMTI2NjI4_cce720be-96a0-4d31-8708-4c70ffb7ca5f"
      unitRef="usd">6480000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNy0xMC0xLTEtMTI2NjI4_5fa3dcd1-3940-431b-8be8-653f96792be7"
      unitRef="usd">249000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfNy0xNi0xLTEtMTI2NjI4_ffa2c1e1-cc14-4915-a8d6-f5bc42d96311"
      unitRef="usd">249000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i30fb6e0e172544838573a8bfe166a874_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfOC0xMC0xLTEtMTI2NjI4_b470a3bc-4731-4bb7-a6d1-f33488b3906c"
      unitRef="usd">11855000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfOC0xNi0xLTEtMTI2NjI4_10f92068-f833-4e71-b55a-6f1c756af714"
      unitRef="usd">11855000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i529f30ec7dff4e9b85a9c64c0c6dc63f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfOS0xMi0xLTEtMTI2NjI4_d43e8dfb-12ca-4726-a7dd-a2265f70d047"
      unitRef="usd">-2371000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfOS0xNi0xLTEtMTI2NjI4_ca7be6e0-c44c-4673-83eb-a2e600b60d13"
      unitRef="usd">-2371000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="if9c30d1bc7c04d6ebec2ff027f47d17c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTAtMTQtMS0xLTEyNjYyOA_b13c19c1-1103-442d-8153-0fe537644085"
      unitRef="usd">-49408000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTAtMTYtMS0xLTEyNjYyOA_d8cf4266-fd74-4a5f-a05e-c481a4e8ba86"
      unitRef="usd">-49408000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id5831a61214043b5a99770b3ea06868d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtNi0xLTEtMTI2NjI4_3aad99b0-f190-4417-923b-6136ba632cbf"
      unitRef="shares">124722215</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id5831a61214043b5a99770b3ea06868d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtOC0xLTEtMTI2NjI4_48017c01-e448-43a7-81b9-f0543d7097cf"
      unitRef="usd">125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if71720d4e7b844b096debe1ed180ea82_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtMTAtMS0xLTEyNjYyOA_087cd864-ea7c-4710-abcf-b7af3a2b218c"
      unitRef="usd">1142133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f993779fd3b4952a907b9dd4f4b3d4d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtMTItMS0xLTEyNjYyOA_efd8adde-c4a9-49bd-953b-c340b658307c"
      unitRef="usd">-3009000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3dea28d0e93949f5aefc5a14f49c8485_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtMTQtMS0xLTEyNjYyOA_d861ddfe-2983-4331-94b5-17ab31604028"
      unitRef="usd">-64245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20c1c0ca88b04fc9862f5dd8242e69fd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTEtMTYtMS0xLTEyNjYyOA_774bd9a7-55c4-4c1e-81aa-0972c6da7c2e"
      unitRef="usd">1075004000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i894e20df066b4a5988b63308c44592af_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTItNi0xLTEtMTI2NjI4_7ab27c27-3b15-4750-90d7-313afdd57f09"
      unitRef="shares">89374</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTItMTAtMS0xLTEyNjYyOA_ba6b766a-1465-43f5-a9de-c0c38c58a3cc"
      unitRef="usd">807000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTItMTYtMS0xLTEyNjYyOA_6079f849-4a88-4a69-adde-992f7a98aa3d"
      unitRef="usd">807000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i894e20df066b4a5988b63308c44592af_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTMtNi0xLTEtMTI2NjI4_215fe1bf-b974-44cb-bd95-ba10b8665435"
      unitRef="shares">773010</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i894e20df066b4a5988b63308c44592af_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTMtOC0xLTEtMTI2NjI4_b925f8d1-7042-437e-be5c-07514c429914"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTMtMTAtMS0xLTEyNjYyOA_fd9457d3-9236-47a6-8ebc-d8c3df2f1fa1"
      unitRef="usd">-311000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTMtMTYtMS0xLTEyNjYyOA_f02cdb16-d9fa-47dc-88df-e3db565d10cf"
      unitRef="usd">-310000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i894e20df066b4a5988b63308c44592af_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTQtNi0xLTEtMTI2NjI4_b8ec7b54-8171-4d0b-bd0f-cf0288a6275f"
      unitRef="shares">94974</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTQtMTAtMS0xLTEyNjYyOA_61db2c1f-bb1a-4fe7-9cba-aaeeb219d948"
      unitRef="usd">743000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTQtMTYtMS0xLTEyNjYyOA_a7789582-b7e7-4732-b2d9-8091b048f7a2"
      unitRef="usd">743000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTgtMTAtMS0xLTEyNjYyOA_c387b3c5-9d43-4c67-b866-4aeec438db76"
      unitRef="usd">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTgtMTYtMS0xLTEyNjYyOA_845f070b-635e-4fe8-b027-06caa0fb032f"
      unitRef="usd">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icac541c50198437baeb6432443c98ca9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTktMTAtMS0xLTEyNjYyOA_1a10ed7f-973b-4e46-a318-585db33afebd"
      unitRef="usd">3332000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMTktMTYtMS0xLTEyNjYyOA_8449a90f-35ff-485c-a4d8-22c50f3fad07"
      unitRef="usd">3332000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i21d90e116c7a466cba2f377d4f8ca18a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjAtMTItMS0xLTEyNjYyOA_dba69f9c-76e3-4aa2-9a79-49e885afda91"
      unitRef="usd">-1047000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjAtMTYtMS0xLTEyNjYyOA_6712d004-a4e3-4870-9a58-ba72ee53c37e"
      unitRef="usd">-1047000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i44fa76d75a604e91bc3f64022a394556_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjEtMTQtMS0xLTEyNjYyOA_e6697497-3012-4051-8bd2-4b191e221e18"
      unitRef="usd">-35303000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if03bd4c73e4a46299d90cb7977595915_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjEtMTYtMS0xLTEyNjYyOA_be534fc4-a844-49ed-972c-001a492518b2"
      unitRef="usd">-35303000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6b81d3b93d874a9db542449b4531b9ab_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItNi0xLTEtMTI2NjI4_f6e82416-7cd6-4ebd-aceb-a64694ea2acc"
      unitRef="shares">125679573</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6b81d3b93d874a9db542449b4531b9ab_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItOC0xLTEtMTI2NjI4_cd8e8d5f-e4a9-4d2b-8739-ec34b6dadade"
      unitRef="usd">126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17cd1a8aeece46c2965383c6ff51f141_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItMTAtMS0xLTEyNjYyOA_5fad572e-b559-4cb9-901d-3ba12ea4854e"
      unitRef="usd">1146997000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i818d019ce1c04ff989dc836cb55d44ec_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItMTItMS0xLTEyNjYyOA_62f428c8-df9a-4c20-bd54-8a4863b34b9b"
      unitRef="usd">-4056000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if54a2cabacf746aaa21fa48bec9ae3b1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItMTQtMS0xLTEyNjYyOA_0727ba17-67f7-44ac-a3b1-c0d16f4949d8"
      unitRef="usd">-99548000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad9898a18252459abeaaa2287043243d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjItMTYtMS0xLTEyNjYyOA_1857bf70-1642-4eea-b2f7-d3cb465ffd60"
      unitRef="usd">1043519000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjMtNi0xLTEtMTI2NjI4_e69cc0ee-72e9-4360-b69c-44f794d85576"
      unitRef="shares">150585</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjMtMTAtMS0xLTEyNjYyOA_a3281aeb-58e3-47f7-a397-41d5107d74e5"
      unitRef="usd">1133000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjMtMTYtMS0xLTEyNjYyOA_32f350ee-cd39-4e6f-b9c2-8707d0589c07"
      unitRef="usd">1133000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjQtNi0xLTEtMTI2NjI4_c0b1bc60-ad5b-4fda-9ddc-058d4fd6d83d"
      unitRef="shares">493907</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjQtOC0xLTEtMTI2NjI4_b48a4c4a-f55c-41c1-9314-df0b0b58f9a1"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjQtMTAtMS0xLTEyNjYyOA_69e14ee6-a80b-4c72-9175-f4e2d783d656"
      unitRef="usd">-6000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjQtMTYtMS0xLTEyNjYyOA_ff7ee7f0-1328-4e69-a9c5-bf9d4ebe9771"
      unitRef="usd">-5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if6c4596282514c47a0d7d84eac65b127_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjUtNi0xLTEtMTI2NjI4_4897b7fd-ddaf-406b-ad4c-664485816af5"
      unitRef="shares">237972</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjUtMTAtMS0xLTEyNjYyOA_3ce09657-c5b6-49ba-86b3-03182ddcc905"
      unitRef="usd">1961000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjUtMTYtMS0xLTEyNjYyOA_fee07ce9-e128-4b4f-b9f5-3a3be0a753ac"
      unitRef="usd">1961000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjctMTAtMS0xLTEyNjYyOA_24edbc42-72bf-4a1c-8c7d-ce47e3c609bc"
      unitRef="usd">257000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjctMTYtMS0xLTEyNjYyOA_37779f67-d437-4199-8bba-66bced9ca30b"
      unitRef="usd">257000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib24b0258f6bd41e7a887dfd53ed65046_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjgtMTAtMS0xLTEyNjYyOA_28004288-7a20-4c31-8df7-1c50876d6f07"
      unitRef="usd">4023000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjgtMTYtMS0xLTEyNjYyOA_c182561c-6ca0-4ec3-a42d-80dd519e8974"
      unitRef="usd">4023000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idf24d4d87dae432094313f13b0433e46_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjktMTItMS0xLTEyNjYyOA_e627b7ac-5bef-4d57-b816-00b5112fb923"
      unitRef="usd">-1048000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMjktMTYtMS0xLTEyNjYyOA_d5f7f607-ad6f-4d39-9237-f49aeb703c3c"
      unitRef="usd">-1048000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i29cb3ad0f407462c9898cd940c1d37f7_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzAtMTQtMS0xLTEyNjYyOA_7116ea8a-49cd-4ff0-a8ce-3c2e0eef8aeb"
      unitRef="usd">-36852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzAtMTYtMS0xLTEyNjYyOA_90b6c609-07d1-47a7-b07c-4d5e8ecd84bd"
      unitRef="usd">-36852000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id315e694cb304a8dbb920f3d1bca41dc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtNi0xLTEtMTI2NjI4_7bd999a2-8890-44b1-877a-3bde0589fa9c"
      unitRef="shares">126562037</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id315e694cb304a8dbb920f3d1bca41dc_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtOC0xLTEtMTI2NjI4_eaefea55-9fb3-43fa-84cc-f271f02573e4"
      unitRef="usd">127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd47353cc04d40d487c363e58d6cd0d8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtMTAtMS0xLTEyNjYyOA_a86f9807-2e63-49d7-bd1e-51d996815790"
      unitRef="usd">1154365000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1530977a71d4f31a22fb39f5d0e7492_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtMTItMS0xLTEyNjYyOA_25641720-e698-4d84-a105-b53012be41c7"
      unitRef="usd">-5104000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08d8c97e16ec459e907fcfda4a1c55d2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtMTQtMS0xLTEyNjYyOA_24b4c946-8700-4aff-a154-ea20adafa16e"
      unitRef="usd">-136400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmJmY2FiNGQ0YmY2MDQ0YjNiY2JmZjk2NjI4N2NmZDYzL3RhYmxlcmFuZ2U6YmZjYWI0ZDRiZjYwNDRiM2JjYmZmOTY2Mjg3Y2ZkNjNfMzEtMTYtMS0xLTEyNjYyOA_7cc41c6e-aa2c-4bad-9a3a-a244a2ae5501"
      unitRef="usd">1012988000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i27adbda67be34d02b60f48394e1038b2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi02LTEtMS0xMjY3NTQ_96a82123-35d3-4601-b59a-d4c77bb5304b"
      unitRef="shares">112075474</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i27adbda67be34d02b60f48394e1038b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi04LTEtMS0xMjY3NTQ_84570591-314e-44dd-a9ec-6f7bee78edeb"
      unitRef="usd">112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48785c4f7e124415b6108ca28afcff05_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi0xMC0xLTEtMTI2NzU0_f672ddc2-393f-4339-bfa8-736a776b51c7"
      unitRef="usd">701357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib2eb88896ee74655baa3b18785a707ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi0xMi0xLTEtMTI2NzU0_935dfb11-69b0-429f-aa38-777d1e55d801"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i245eb6ec3baa4df3b5146a6e6b182283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi0xNC0xLTEtMTI2NzU0_cb2c73a0-6396-4110-a34f-c72246524eaa"
      unitRef="usd">-7185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia78d78a3c9db493697ca176e09b7aa91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMi0xNi0xLTEtMTI2NzU0_19812104-590d-4ba8-b06b-86cd23118632"
      unitRef="usd">694294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i595026d5245f4feeafe415ec5546194b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMy0xMC0xLTEtMTI2NzU0_6cf3d127-75cf-4509-a278-ea028cf10038"
      unitRef="usd">-23271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1264117696a4469a67e0ec136421d1c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMy0xNC0xLTEtMTI2NzU0_6bee881d-e750-44e7-acf1-472c0dee6600"
      unitRef="usd">696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifbbb19f83f1e4ad79e3dc7bea4c0e730_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMy0xNi0xLTEtMTI2NzU0_c2ef9308-de17-4672-8ea5-104b626d6e03"
      unitRef="usd">-22575000</us-gaap:StockholdersEquity>
    <neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt
      contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNC0xMC0xLTEtMTI2NzU0_974cccb4-f88d-49dc-9383-f0bcd9de947c"
      unitRef="usd">29291000</neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt>
    <neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNC0xNi0xLTEtMTI2NzU0_19f48263-56af-4fbb-946c-17a7b4b13e4e"
      unitRef="usd">29291000</neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNS02LTEtMS0xMjY3NTQ_80c675c2-596f-4906-9c35-39b119508b62"
      unitRef="shares">23917</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNS0xMC0xLTEtMTI2NzU0_46f1ce03-9989-48b3-a271-aef771114693"
      unitRef="usd">1024000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNS0xNi0xLTEtMTI2NzU0_8e5b0299-3c17-4987-84f1-632f4299a114"
      unitRef="usd">1024000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNi02LTEtMS0xMjY3NTQ_42dfcb08-2177-4c7b-80d5-10c139c98fdc"
      unitRef="shares">83220</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNi0xMC0xLTEtMTI2NzU0_0e5f5acb-dbe3-4110-9b5e-90fcf6322dad"
      unitRef="usd">-614000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNi0xNi0xLTEtMTI2NzU0_34cf15e9-7dac-453b-b66f-7f59bf64cfcf"
      unitRef="usd">-614000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNy02LTEtMS0xMjY3NTQ_71392f29-b914-4e20-807e-2dc03aabadac"
      unitRef="shares">260167</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNy0xMC0xLTEtMTI2NzU0_9a02ae34-4851-4fb6-9a18-79c674448d24"
      unitRef="usd">2239000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNy0xNi0xLTEtMTI2NzU0_4ddf9f9b-2edd-4d94-811a-f1d0ccb124d6"
      unitRef="usd">2239000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOC02LTEtMS0xMjY3NTQ_60c62bc7-1e8f-46e2-8759-4b6317190e6a"
      unitRef="shares">4693876</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if209bd2b513745ce8af66204d9a10e91_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOC04LTEtMS0xMjY3NTQ_36e111aa-40d3-4306-950e-9c2c2683bf40"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOC0xMC0xLTEtMTI2NzU0_276070dd-02ba-4186-81fa-3720c2dbbe99"
      unitRef="usd">218495000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOC0xNi0xLTEtMTI2NzU0_e6d3bd37-5232-4418-ad78-0b8c8e978d93"
      unitRef="usd">218500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOS0xMC0xLTEtMTI2NzU0_d7461d80-2219-4dc0-9dcb-0efb3a5ecbe0"
      unitRef="usd">242000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfOS0xNi0xLTEtMTI2NzU0_a856fc2f-7afa-4477-8b28-550aba8503e3"
      unitRef="usd">242000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTAtMTAtMS0xLTEyNjc1NA_06ba91e5-3da1-4ee5-b638-f4ebe71aa3d4"
      unitRef="usd">241000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTAtMTYtMS0xLTEyNjc1NA_a1978341-893e-490f-968c-6fdbbbe0b8a2"
      unitRef="usd">241000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3b1051dda32b424abe99fe964b2f1e6f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTEtMTAtMS0xLTEyNjc1NA_edce5704-c6a0-40d6-97f9-24f85205eead"
      unitRef="usd">2412000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTEtMTYtMS0xLTEyNjc1NA_03366364-4a0a-4dc7-a500-b04f1ac8d933"
      unitRef="usd">2412000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic1bf40a8250f436ba33bacfac6825360_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTItMTItMS0xLTEyNjc1NA_10102210-9cad-4427-a48b-b14af7c467c0"
      unitRef="usd">-160000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTItMTYtMS0xLTEyNjc1NA_7fff1d1e-b5af-4445-812e-184ce1ede0e4"
      unitRef="usd">-160000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i405da8647b38440ebba559d212b5dd7c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTMtMTQtMS0xLTEyNjc1NA_359f9fb6-9bd5-4ca1-bcca-ed82ec3dc7f3"
      unitRef="usd">-22114000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTMtMTYtMS0xLTEyNjc1NA_5a6a0bd4-b1e0-4919-98d9-8e5a31554d8b"
      unitRef="usd">-22114000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="icc37ab8dceb2404d8981b679d85008ed_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtNi0xLTEtMTI2NzU0_1dc8db8b-6c19-43d0-b48e-13a827c9fbf5"
      unitRef="shares">117136654</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icc37ab8dceb2404d8981b679d85008ed_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtOC0xLTEtMTI2NzU0_33930528-c3d3-4f4b-a1fb-b093102e138f"
      unitRef="usd">117000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib52b9deb5b5e412c986b3a960ef6ec52_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtMTAtMS0xLTEyNjc1NA_fd9c448c-1a19-4e2b-8eee-24634d4a2b67"
      unitRef="usd">872350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3cb2d646d0b14c8c9d1612c5c39524e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtMTItMS0xLTEyNjc1NA_a39d15ef-1197-40cc-8368-fa44d4fe071c"
      unitRef="usd">-150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee2a6c9923d645828b82bac68cf565f0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtMTQtMS0xLTEyNjc1NA_c6c12911-8f24-4ba9-aaf3-5927f0973747"
      unitRef="usd">-28603000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8d80520822e4942b1b02b3aede5033c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTQtMTYtMS0xLTEyNjc1NA_8368ae8f-8bfe-492c-83f2-89469ef7a7d5"
      unitRef="usd">843714000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTUtNi0xLTEtMTI2NjI4_de8dcd3e-d6cc-436e-80b7-24b0d39c9232"
      unitRef="shares">31839</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTUtMTAtMS0xLTEyNjYyOA_500d1358-dacd-4a67-93f7-971ac9cb8ef1"
      unitRef="usd">1245000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTUtMTYtMS0xLTEyNjYyOA_a7beafb2-d8b2-42c7-9b48-5d26fe5ff836"
      unitRef="usd">1245000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTYtNi0xLTEtMTI2NjI4_73d2c755-ad86-4134-b195-54ac5b6ac860"
      unitRef="shares">146392</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTYtMTAtMS0xLTEyNjYyOA_47eeff40-c3e8-4fab-ace2-ec2d6b6facdc"
      unitRef="usd">-163000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTYtMTYtMS0xLTEyNjYyOA_76dff0ea-ae5d-43e5-aeca-0f5a764cbb1a"
      unitRef="usd">-163000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTctNi0xLTEtMTI2NjI4_e4ce2d34-1428-4776-bee4-832ea243153a"
      unitRef="shares">354310</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTctOC0xLTEtMTI2NjI4_31a85044-02d9-4fa4-bbb7-9a7945b24c31"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTctMTAtMS0xLTEyNjYyOA_01acbf10-1657-4cc2-af70-cc8886201787"
      unitRef="usd">4429000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTctMTYtMS0xLTEyNjYyOA_4e6149c7-80d1-41a6-b124-51f646aa2d2d"
      unitRef="usd">4430000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTgtNi0xLTEtMTI2NjI4_6d81556a-e7e6-47a1-8bb6-e8ca2ea8e9e7"
      unitRef="shares">4444445</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTgtOC0xLTEtMTI2NjI4_aadda407-4c00-451a-8fd1-b68c1e569b13"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTgtMTAtMS0xLTEyNjYyOA_fb9886b9-9316-4a3c-be23-b361d5828386"
      unitRef="usd">189859000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTgtMTYtMS0xLTEyNjYyOA_499d862c-0b73-4f04-a2ee-57eec662b1e5"
      unitRef="usd">189863000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTktNi0xLTEtMTI2NjI4_f96eb9ce-1121-4265-80d9-29fc19089781"
      unitRef="shares">597712</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i2bd468911ccb4d15b79603d06ac0328c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTktOC0xLTEtMTI2NjI4_c1c26b17-43eb-4e34-b948-a179a83b11b4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTktMTAtMS0xLTEyNjYyOA_fe994823-c00a-4481-828e-b5a1fbc92545"
      unitRef="usd">29174000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMTktMTYtMS0xLTEyNjYyOA_6b7d8227-2aec-43da-91b3-4b87869a9f8a"
      unitRef="usd">29175000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjAtMTAtMS0xLTEyNjYyOA_b7061d55-0dfc-49a0-ae0b-779ccd5c7120"
      unitRef="usd">102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjAtMTYtMS0xLTEyNjYyOA_281d4fef-b049-47fa-87f4-4e4770d67a5a"
      unitRef="usd">102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjEtMTAtMS0xLTEyNjYyOA_c1c18117-3a04-4847-821f-c6421f4ae595"
      unitRef="usd">298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjEtMTYtMS0xLTEyNjYyOA_bc4cc8ed-193e-4b93-9887-7a714e17a5d6"
      unitRef="usd">298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0fa6843c279f4aa1ba246ad1cd75754f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjItMTAtMS0xLTEyNjYyOA_3edcfd9d-eba0-4259-b1ae-b2a94ca7b9ee"
      unitRef="usd">4208000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjItMTYtMS0xLTEyNjYyOA_16cd6c69-0ecc-4f31-9c21-c2cd57a0d95c"
      unitRef="usd">4208000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8c8a738d631c488c8a6d2ef8b1207ad6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjMtMTItMS0xLTEyNjYyOA_ec1dd5e9-9ec9-458f-a585-fb1c83d8da12"
      unitRef="usd">-183000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjMtMTYtMS0xLTEyNjYyOA_02c98190-a4bc-4817-890e-0317af8159b8"
      unitRef="usd">-183000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i9e83cb2ada244e87863fccb0435f1caa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjUtMTQtMS0xLTEyNjYyOA_c7d7556f-ed09-4e71-a939-f8bac830ac88"
      unitRef="usd">75873000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i293fb8d39aa347498fbc34bf6d6c43b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMjUtMTYtMS0xLTEyNjYyOA_163e7191-8359-4783-8058-7354957ff0e1"
      unitRef="usd">75873000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3b87d5129c424480b7bca5c7de9631c3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtNi0xLTEtMTI2NjI4_96f28377-93b5-4d69-a017-1ba073094a3c"
      unitRef="shares">122711352</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3b87d5129c424480b7bca5c7de9631c3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtOC0xLTEtMTI2NjI4_c678c7e6-10a6-4c71-aebf-f23546aab6b9"
      unitRef="usd">123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d53da225c7543cc8626b67085ff1039_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtMTAtMS0xLTEyNjYyOA_c239039b-5a29-4fb4-96b6-f13c655ddbe9"
      unitRef="usd">1101298000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i292a317c53d4440db036498f37a42c80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtMTItMS0xLTEyNjYyOA_40b4b77f-6ba7-4988-86bc-c4f33296561b"
      unitRef="usd">-333000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63a18efae1e24ac0a0f14cc9cb60d3d6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtMTQtMS0xLTEyNjYyOA_c11f98c3-a270-46b5-a3a1-e2326c67e170"
      unitRef="usd">47270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d66426c727144e6a0ed073ec7de01aa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzAtMTYtMS0xLTEyNjYyOA_970584a3-997f-49a3-807a-5ef6c0eeb57a"
      unitRef="usd">1148358000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzEtNi0xLTEtMTI2NjI4_53992fa1-3638-4858-8f48-205fd13f2226"
      unitRef="shares">27210</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzEtMTAtMS0xLTEyNjYyOA_5bc02182-f81c-44fd-863a-565d2b51f422"
      unitRef="usd">1020000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzEtMTYtMS0xLTEyNjYyOA_bc4d6af6-ff57-4305-a394-45afa33e01f5"
      unitRef="usd">1020000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzItNi0xLTEtMTI2NjI4_0bea63ae-0922-4a6d-865f-73db647b9085"
      unitRef="shares">160971</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzItMTAtMS0xLTEyNjYyOA_dd0a9df8-1873-42b0-a41c-dcda8cef1414"
      unitRef="usd">-304000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzItMTYtMS0xLTEyNjYyOA_e264d1d1-d2b7-4554-a967-d45ebd69f882"
      unitRef="usd">-304000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzMtNi0xLTEtMTI2NjI4_3ae19eba-5574-4d5e-8df3-a244b6b10d52"
      unitRef="shares">317477</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i92c9a399fd4d4faba828a07821f732fd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzMtOC0xLTEtMTI2NjI4_c0c83c92-07bc-4265-a14c-9e3b09df2595"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzMtMTAtMS0xLTEyNjYyOA_71fad3a6-27fe-48de-a311-0f6fe9cd1b82"
      unitRef="usd">3374000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzMtMTYtMS0xLTEyNjYyOA_daccac5f-cbe3-4cf0-a73a-1a8f37ceb799"
      unitRef="usd">3374000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzQtMTAtMS0xLTEyNjYyOA_6a7a1fab-1afb-41f7-93c6-2a4f3c54e17c"
      unitRef="usd">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzQtMTYtMS0xLTEyNjYyOA_4ddb0fa7-b133-42a0-b7c6-b0fe584494e3"
      unitRef="usd">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzUtMTAtMS0xLTEyNjYyOA_a1123e90-711e-4383-9a60-8e19d76906ba"
      unitRef="usd">236000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzUtMTYtMS0xLTEyNjYyOA_b6093c5d-aa7f-46f2-894f-3a0a7d84cb9e"
      unitRef="usd">236000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icf7f278e9f5a4fcc8d3a44a77feff198_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzYtMTAtMS0xLTEyNjYyOA_d5aef946-c0c8-4004-ad66-07867b42da34"
      unitRef="usd">5001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzYtMTYtMS0xLTEyNjYyOA_851e4eec-59bc-420a-9a36-73ba0ff65bfa"
      unitRef="usd">5001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iab400f484a364301b9f34d240511f761_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzktMTItMS0xLTEyNjYyOA_e5f0427a-2a7a-4f9d-9889-bec0bd034f59"
      unitRef="usd">-57000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfMzktMTYtMS0xLTEyNjYyOA_07cf4d5e-12a2-4716-ade1-fabf4f264567"
      unitRef="usd">-57000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic547475396b745199691ec6a3e16bdbc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDAtMTQtMS0xLTEyNjYyOA_7a070df3-ea0b-46bd-989d-8d2f64a5a260"
      unitRef="usd">-20348000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDAtMTYtMS0xLTEyNjYyOA_ecb8442d-bf82-4dc1-b273-fa6abbca250f"
      unitRef="usd">-20348000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id6b5778ebf6a4a509905cb89051df5f5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtNi0xLTEtMTI2NjI4_779f8709-1c0b-43f3-a1e3-f775d5242a55"
      unitRef="shares">123217010</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id6b5778ebf6a4a509905cb89051df5f5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtOC0xLTEtMTI2NjI4_07f7dc7e-1109-486b-b7cf-9e1b747c1602"
      unitRef="usd">123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46b48692e0ad44bfa45dab1bc766eee5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtMTAtMS0xLTEyNjYyOA_908446c0-3e0d-4c7b-b891-124dd5737624"
      unitRef="usd">1110590000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b574e55d4754f55a7a02ba000cdea51_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtMTItMS0xLTEyNjYyOA_408f3cec-cced-4e34-b732-845f871d62a4"
      unitRef="usd">-390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5524fa47c894252b50792cf5bfb8a1e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtMTQtMS0xLTEyNjYyOA_ba1367a1-5b77-47dc-a8c5-2815d7233428"
      unitRef="usd">26922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8yOC9mcmFnOjVlNzBiNmIzMTAwNTRhZWY4Zjk1OWM5NzNhMWY2N2FiL3RhYmxlOmNjY2FjOThiMjllODQzOGRhODJiNWUyODJlMDZhYzNmL3RhYmxlcmFuZ2U6Y2NjYWM5OGIyOWU4NDM4ZGE4MmI1ZTI4MmUwNmFjM2ZfNDEtMTYtMS0xLTEyNjYyOA_294ae5a2-e861-4e02-a684-9637c4a0d999"
      unitRef="usd">1137245000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMy0yLTEtMS0xMjY2Mjg_e1e2f3df-8e60-4ff0-9be5-c811e859195c"
      unitRef="usd">-121563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMy00LTEtMS0xMjY2Mjg_115f6a1a-6e34-4752-88d6-0b5f5b95fcba"
      unitRef="usd">33412000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNS0yLTEtMS0xMjY2Mjg_8b53bbbd-3ad9-43a0-a1ef-21c34f8449bb"
      unitRef="usd">25894000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNS00LTEtMS0xMjY2Mjg_bb74b4b9-721f-450d-8781-e1ee7e8003b7"
      unitRef="usd">21807000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNi0yLTEtMS0xMjY2Mjg_f7bc6995-c9d8-4f06-9431-ee5fcdba0b2a"
      unitRef="usd">25470000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNi00LTEtMS0xMjY2Mjg_2c15956d-babd-45a8-82bb-9bb7d7dbb6ce"
      unitRef="usd">14683000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNy0yLTEtMS0xMjY2Mjg_22401d1a-909e-49c9-b969-8b667299ce44"
      unitRef="usd">20009000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNy00LTEtMS0xMjY2Mjg_425ac436-89a1-4afe-90d7-7df2e0ff844c"
      unitRef="usd">12396000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfOC0yLTEtMS0xMjY2Mjg_27746265-0961-490f-a923-680b38115bed"
      unitRef="usd">7375000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfOC00LTEtMS0xMjY2Mjg_ffc6e88e-448a-44be-9668-745354e68861"
      unitRef="usd">6167000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfOS0yLTEtMS0xMjY2Mjg_af17ae6e-7499-44fd-964b-7b3b4be15079"
      unitRef="usd">1989000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfOS00LTEtMS0xMjY2Mjg_abb9406b-1181-4090-9eb2-e3eca10124e9"
      unitRef="usd">1904000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTAtMi0xLTEtMTI2NjI4_ce868b5b-99ab-49ed-8656-8adc0c8dd136"
      unitRef="usd">136000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTAtNC0xLTEtMTI2NjI4_5fe952c2-7903-4d55-bf56-048ad5230862"
      unitRef="usd">133000</us-gaap:AmortizationOfFinancingCosts>
    <neo:GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTItMi0xLTEtMTI2NjI4_4743eafe-3872-4c1d-acf9-dbe5639ea2ba"
      unitRef="usd">0</neo:GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet>
    <neo:GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTItNC0xLTEtMTI2NjI4_32415722-8877-4a29-8c5b-ae2b7569da3f"
      unitRef="usd">109260000</neo:GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet>
    <neo:ReceivableWithImputedInterestNonConsolidatedAffiliates
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTMtMi0xLTEtMTI2NjI4_c646b500-9a2c-4034-a8fe-536a32d924d2"
      unitRef="usd">0</neo:ReceivableWithImputedInterestNonConsolidatedAffiliates>
    <neo:ReceivableWithImputedInterestNonConsolidatedAffiliates
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTMtNC0xLTEtMTI2NjI4_b240b638-42c0-4b15-b862-719f02104490"
      unitRef="usd">391000</neo:ReceivableWithImputedInterestNonConsolidatedAffiliates>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTQtMi0xLTEtMTI2NjI4_6a3e4d67-a18d-4928-bcf4-08c51c89b1df"
      unitRef="usd">-3066000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTQtNC0xLTEtMTI2NjI4_01bcf2c9-f7a1-45bb-bf0e-a22cbab865ef"
      unitRef="usd">-166000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTUtMi0xLTEtMTI2NjI4_2386dc1c-f16c-4873-8a91-9afb0e91023a"
      unitRef="usd">2048000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTUtNC0xLTEtMTI2NjI4_d5c174ba-dda4-495e-b606-6c68b1775bbf"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <neo:PolymeraseChainReactionTestingExitCostsCOVID19
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTYtMi0xLTEtMTI2NjI4_c1a39d64-f7b6-4582-9630-f431d797327d"
      unitRef="usd">0</neo:PolymeraseChainReactionTestingExitCostsCOVID19>
    <neo:PolymeraseChainReactionTestingExitCostsCOVID19
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTYtNC0xLTEtMTI2NjI4_6dc9473e-b4ed-45f0-8596-e2f96582eda3"
      unitRef="usd">6061000</neo:PolymeraseChainReactionTestingExitCostsCOVID19>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTctMi0xLTEtMTI2NjI4_e76e520b-5870-4dc3-a446-926673b6d671"
      unitRef="usd">1428000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTctNC0xLTEtMTI2NjI4_39dfa289-b1ed-4c04-a0ad-a26e316390a9"
      unitRef="usd">1222000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTktMi0xLTEtMTI2NjI4_b37e51ce-8ce6-4d10-a6e9-38b5ef89720d"
      unitRef="usd">-136000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMTktNC0xLTEtMTI2NjI4_16797310-4895-4f3a-ba2d-d98f7b22b177"
      unitRef="usd">-2475000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjAtMi0xLTEtMTI2NjI4_c7dd3e62-b9a1-42f9-92f7-2126bfb89634"
      unitRef="usd">403000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjAtNC0xLTEtMTI2NjI4_20e69472-ac2b-41d4-be2f-3af4c99994db"
      unitRef="usd">-3196000</us-gaap:IncreaseDecreaseInInventories>
    <neo:IncreaseDecreaseInPrepaidConstruction
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjEtMi0xLTEtMTI2NjI4_9e3f1ced-02a8-4088-8fd2-87cfbba03ea7"
      unitRef="usd">0</neo:IncreaseDecreaseInPrepaidConstruction>
    <neo:IncreaseDecreaseInPrepaidConstruction
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjEtNC0xLTEtMTI2NjI4_bc7eacd2-6355-4315-a7dc-2a3555c15e18"
      unitRef="usd">4435000</neo:IncreaseDecreaseInPrepaidConstruction>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjItMi0xLTEtMTI2NjI4_2d9ebcf1-3e29-4493-a167-8a234137f7a8"
      unitRef="usd">3605000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjItNC0xLTEtMTI2NjI4_ced1dfee-41bd-4248-9309-1d1464552caa"
      unitRef="usd">11796000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjQtMi0xLTEtMTI2NjI4_28972b05-7702-497f-92fb-da9c8620edbc"
      unitRef="usd">-20192000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjQtNC0xLTEtMTI2NjI4_01d6cb45-df42-40ba-8083-79cdce0d8133"
      unitRef="usd">15313000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjUtMi0xLTEtMTI2NjI4_39b557ec-6c36-4426-b960-99d97d58c91d"
      unitRef="usd">-62308000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjUtNC0xLTEtMTI2NjI4_24070676-c804-450d-890a-553a8be41b42"
      unitRef="usd">-6947000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjctMi0xLTEtMTI2NjI4_622193f2-d35e-4a97-a1ff-68a9623ef3ff"
      unitRef="usd">73973000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjctNC0xLTEtMTI2NjI4_c955a585-694d-4cfe-acb9-62f1ec2e875c"
      unitRef="usd">180961000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjgtMi0xLTEtMTI2NjI4_92dd89b8-04db-4dab-bd1e-a3ec533f6dda"
      unitRef="usd">89812000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjgtNC0xLTEtMTI2NjI4_114e6ec5-129a-4983-afc4-0d21289b5cca"
      unitRef="usd">44736000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjktMi0xLTEtMTI2NjI4_36119863-794e-42aa-8c7f-d5dce8cfdb38"
      unitRef="usd">26357000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMjktNC0xLTEtMTI2NjI4_4aade9bd-c133-416f-a382-9b16dce2eeef"
      unitRef="usd">52155000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzAtMi0xLTEtMTI2NjI4_f0fdd85b-555a-4c35-adcd-49f39a0c0b1d"
      unitRef="usd">12098000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzAtNC0xLTEtMTI2NjI4_8fa750d7-69f7-4856-b21a-4fef097fa8ab"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzEtMi0xLTEtMTI2NjI4_63cd9655-129b-4f7f-93d4-bfafcc8a458e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzEtNC0xLTEtMTI2NjI4_6004d738-a971-4c6a-b263-6ec2c68f7064"
      unitRef="usd">419404000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzItMi0xLTEtMTI2NjI4_88a2b237-9abf-45fa-869f-ea63bf9a5389"
      unitRef="usd">0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzItNC0xLTEtMTI2NjI4_ce8b4bda-0d9d-4b91-9317-f10707dd7983"
      unitRef="usd">15000000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzMtMi0xLTEtMTI2NjI4_c788272a-0200-4e7f-a0e3-2e3ad8c7d7a7"
      unitRef="usd">1580000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzMtNC0xLTEtMTI2NjI4_3f911a74-085e-4d6d-aacf-8f07c9a32618"
      unitRef="usd">-622784000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <neo:RepaymentsOfEquipmentAndOtherFinanceObligation
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzUtMi0xLTEtMTI2NjI4_01559249-a8a5-4421-8b5e-2d87c87fc35b"
      unitRef="usd">706000</neo:RepaymentsOfEquipmentAndOtherFinanceObligation>
    <neo:RepaymentsOfEquipmentAndOtherFinanceObligation
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzUtNC0xLTEtMTI2NjI4_f2b2b326-a14c-425f-9183-87fe1b25a57e"
      unitRef="usd">2537000</neo:RepaymentsOfEquipmentAndOtherFinanceObligation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzYtMi0xLTEtMTI2NjI4_7c58247e-1255-489f-a337-e2c1bf89f7ee"
      unitRef="usd">10733000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzYtNC0xLTEtMTI2NjI4_cd6639fb-f73d-45a5-94f9-ab01bd912443"
      unitRef="usd">12110000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzgtMi0xLTEtMTI2NjI4_39aea022-fb4b-4c3e-b619-3a1337ced828"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzgtNC0xLTEtMTI2NjI4_89f18a6c-4f7d-410d-992d-d60d623f3004"
      unitRef="usd">334410000</us-gaap:ProceedsFromConvertibleDebt>
    <neo:PaymentsOfPremiumsForCappedCallConfirmations
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzktMi0xLTEtMTI2NjI4_18f4d4a8-b2d2-4de8-a396-4c3e132baa47"
      unitRef="usd">0</neo:PaymentsOfPremiumsForCappedCallConfirmations>
    <neo:PaymentsOfPremiumsForCappedCallConfirmations
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfMzktNC0xLTEtMTI2NjI4_4b932962-1bd9-4794-92c8-39e2e7892d27"
      unitRef="usd">29291000</neo:PaymentsOfPremiumsForCappedCallConfirmations>
    <neo:ProceedsFromEquityOfferingNet
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDAtMi0xLTEtMTI2NjI4_f2ede77f-b3fa-4ceb-ac97-10f818187fa4"
      unitRef="usd">0</neo:ProceedsFromEquityOfferingNet>
    <neo:ProceedsFromEquityOfferingNet
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDAtNC0xLTEtMTI2NjI4_8cc45c25-194c-475e-a8f2-75216a97a816"
      unitRef="usd">408133000</neo:ProceedsFromEquityOfferingNet>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDEtMi0xLTEtMTI2NjI4_1d8614e2-c88c-4c45-a470-6efd7b887f48"
      unitRef="usd">10027000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDEtNC0xLTEtMTI2NjI4_dd066714-fc1d-49e0-9746-0a290592e34c"
      unitRef="usd">722825000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDMtMi0xLTEtMTI2NjI4_8253cc8e-4595-4a89-a973-4330aa468b10"
      unitRef="usd">-50701000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDMtNC0xLTEtMTI2NjI4_912b55cc-1e80-4442-8cab-cbe96a0ef423"
      unitRef="usd">93094000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDQtMi0xLTEtMTI2NjI4_149257a1-0249-4990-a37e-4e0a989ff346"
      unitRef="usd">316827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia78d78a3c9db493697ca176e09b7aa91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDQtNC0xLTEtMTI2NjI4_72310d58-c0a4-430a-9d68-c2bdec24fef0"
      unitRef="usd">250632000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDUtMi0xLTEtMTI2NjI4_008bde98-86b7-4964-bfd9-3536a4f2967f"
      unitRef="usd">266126000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOjg4MmU1YjQyNTNmNTRjYTNhMTE0MjFkOGZjYjI3YzIxL3RhYmxlcmFuZ2U6ODgyZTViNDI1M2Y1NGNhM2ExMTQyMWQ4ZmNiMjdjMjFfNDUtNC0xLTEtMTI2NjI4_87439082-f9a1-4149-987a-1e6519ded2db"
      unitRef="usd">343726000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMy0yLTEtMS0xMjY2Mjg_4668af27-050b-4e11-9ee0-11bc08e84cf2"
      unitRef="usd">266126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMy00LTEtMS0xMjY2Mjg_d0b0e35c-35aa-43eb-bcc1-fe0cc58caf23"
      unitRef="usd">340565000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfNS0yLTEtMS0xMjY2Mjg_dac8c76a-7bcc-4c98-af6d-640256727d60"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfNS00LTEtMS0xMjY2Mjg_f9c57355-5974-4053-bc38-9fb5b9aef921"
      unitRef="usd">3161000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfNi0yLTEtMS0xMjY2Mjg_0988d961-ca90-40d1-9e67-1957d31e9539"
      unitRef="usd">266126000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i634952822d8f47419d1fb60b6c946c77_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfNi00LTEtMS0xMjY2Mjg_b6359c02-3067-47c6-af5d-ff36e6fb0811"
      unitRef="usd">343726000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfOS0yLTEtMS0xMjY2Mjg_4b6d9236-6551-4139-882b-520aa054da84"
      unitRef="usd">2145000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfOS00LTEtMS0xMjY2Mjg_d96097d5-a66a-4642-9afd-34772908228a"
      unitRef="usd">1792000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTAtMi0xLTEtMTI2NjI4_e5fdccf4-31db-42d9-863e-cdba060aefb2"
      unitRef="usd">155000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTAtNC0xLTEtMTI2NjI4_a951b61f-5dd3-4977-9f48-09f1bbece95d"
      unitRef="usd">113000</us-gaap:IncomeTaxesPaidNet>
    <neo:FairValueOfCommonStockIssuedToFundAcquisition
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTItMi0xLTEtMTI2NjI4_b26ff0cd-4178-4c94-9ebf-97e79f3ae4c5"
      unitRef="usd">0</neo:FairValueOfCommonStockIssuedToFundAcquisition>
    <neo:FairValueOfCommonStockIssuedToFundAcquisition
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTItNC0xLTEtMTI2NjI4_d990d403-acd2-4884-aaa1-2327641bceca"
      unitRef="usd">29174000</neo:FairValueOfCommonStockIssuedToFundAcquisition>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTYtMi0xLTEtMTI2NjI4_29f3a57b-9667-4e55-ac79-6e08840c27a7"
      unitRef="usd">1144000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zMS9mcmFnOjIzY2U5MGY1YmJiYjRlYmRiODJiNzZlYjZhMDg5MWIyL3RhYmxlOmJjOGE2Y2RlZGYyYjRjOTM4OGI1OWMyYWJiYWFhN2VjL3RhYmxlcmFuZ2U6YmM4YTZjZGVkZjJiNGM5Mzg4YjU5YzJhYmJhYWE3ZWNfMTYtNC0xLTEtMTI2NjI4_48f8373e-434a-4111-bf3c-3c0470aa58f9"
      unitRef="usd">2184000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMzExNA_9d79862a-c8ff-4782-843f-367aa8fd6c34">Nature of the Business&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Nature of the Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NeoGenomics, Inc., a Nevada corporation (the &#x201c;Company,&#x201d; or &#x201c;NeoGenomics&#x201d;), and its subsidiaries, operate as a certified, high complexity clinical laboratory in accordance with the federal government&#x2019;s CLIA, as amended, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;COVID-19 Pandemic Update&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impact from the COVID-19 pandemic, including recent COVID-19 variants, and the related disruptions had a significant adverse impact on the Company&#x2019;s results of operations, volume growth rates and test volumes in 2020, 2021, and in the first three quarters of 2022. The full extent to which the COVID-19 outbreak will impact the Company&#x2019;s business, results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#x2019;s results of operations, financial condition, and cash flows may continue to be materially adversely affected, particularly if the pandemic continues to persist for a significant amount of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates that the cash on hand, marketable securities, and expected cash collections are sufficient to fund near-term capital and operating needs for at least the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of the first quarter 2021, due to the broad roll-out of the COVID-19 vaccine and a sharp decline in COVID-19 polymerase chain reaction (&#x201c;PCR&#x201d;) testing demand, the Company made the decision to exit COVID-19 PCR testing and the Company recorded a $6.1&#160;million expense related to the exit from COVID-19 PCR testing. This amount consisted of write-offs of $5.3&#160;million for all remaining COVID-19 PCR testing inventory recorded to cost of revenue and $0.8&#160;million for all remaining COVID-19 PCR testing laboratory equipment recorded to general and administrative expenses &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the Consolidated Statements of Operations for the nine months ended September 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. There were no COVID-19 PCR testing laboratory equipment or COVID-19 PCR testing inventory write-offs recorded for the three months ended &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the three and nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Coronavirus Aid, Relief and Economic Security Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Federal government passed legislation that the President of the United States signed into law on March 27, 2020, known as the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;). The CARES Act permits the deferral of payment of the employer portion of social security taxes between March 27, 2020 and December 31, 2020. Fifty percent of the deferred amount was due on December 31, 2021 and the remaining 50% is due on December 31, 2022. As of September 30, 2022 and December 31, 2021, the total accrued deferred social security taxes related to the CARES Act was $3.0&#160;million. This amount was recorded in accrued expenses and other liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <neo:PolymeraseChainReactionTestingExitCostsCOVID19
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMTkxMw_60d33c39-8e25-4e5b-9ad1-4890d4ff057a"
      unitRef="usd">6100000</neo:PolymeraseChainReactionTestingExitCostsCOVID19>
    <neo:PolymeraseChainReactionTestingWriteOffsCOVID19
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjAxMA_03342667-7368-4b87-8d66-e15d198520d5"
      unitRef="usd">5300000</neo:PolymeraseChainReactionTestingWriteOffsCOVID19>
    <neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19
      contextRef="i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjA5NA_bd637d32-4478-42b6-86fc-b2e0279d4466"
      unitRef="usd">800000</neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19>
    <neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjI5MA_3ead02cf-3aa4-4a83-b560-8b6522267ac7"
      unitRef="usd">0</neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19>
    <neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjI5MA_45391a91-6af9-4cae-b744-e28b3a732dd6"
      unitRef="usd">0</neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19>
    <neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjI5MA_e80ebe3b-55ac-4c9f-a620-1870a3a85fff"
      unitRef="usd">0</neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19>
    <neo:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjE5OTAyMzI1ODY3MA_292c1bd8-d095-4b1f-ba8c-2cc4abd239ec"
      unitRef="usd">3000000</neo:SocialSecurityTaxEmployerDeferralCARESAct>
    <neo:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF8zNy9mcmFnOjc5NDljYTNkNzYwNjQ1YzNiNGY4NmZlNWYwMDU1NTFlL3RleHRyZWdpb246Nzk0OWNhM2Q3NjA2NDVjM2I0Zjg2ZmU1ZjAwNTU1MWVfMjE5OTAyMzI1ODY3MA_607f5132-2b97-43d0-90c0-2a7d88108d26"
      unitRef="usd">3000000</neo:SocialSecurityTaxEmployerDeferralCARESAct>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTc_740e5b44-f9f9-44be-81f1-5413bf7fcb66">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with GAAP for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, except for new accounting standards discussed under Recent Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain information and footnote disclosures normally included in the Company&#x2019;s annual audited Consolidated Financial Statements and accompanying notes have been condensed or omitted in these accompanying interim Consolidated Financial Statements and footnotes. Accordingly, the accompanying interim unaudited Consolidated Financial Statements included herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations presented in this Quarterly Report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited Consolidated Financial Statements include all adjustments and accruals, consisting only of normal, recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#x2019;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owned 43,560 square feet of its Carlsbad, California facility. During the third quarter of 2021, the Company committed to selling this property and the associated land and concluded that these assets met the held for sale criteria. As of December 31, 2021, $10.1&#160;million was recorded as assets held for sale within current assets on the Consolidated Balance Sheets for this property and associated land and reflected its carrying value which was lower than its fair value less costs to sell. The Company sold this property and associated land for proceeds of $12.1&#160;million, net of closing costs, in the first quarter of 2022. For the nine months ended September 30, 2022, a net gain on the sale of this property and associated land of $2.0&#160;million is included in general and administrative expenses on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#x2019;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#x2019; data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June 30, 2022, the Company performed a qualitative assessment to determine whether it was more likely than not that the fair values of its reporting units were less than their carrying values. Such qualitative factors included macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. As a result of the qualitative assessment, the Company determined that there were indicators that it was more likely than not that the fair values of its reporting units were less than their carrying values. Accordingly, the Company performed a quantitative analysis and determined the reporting units&#x2019; fair values exceeded the reporting units&#x2019; carrying values and there was no impairment of the recorded goodwill as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist of payroll and payroll related costs for the Company&#x2019;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, gains or losses on disposals of assets, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three and nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2021-10&#x201d;). This update requires business entities to disclose information annually about certain government assistance they receive. Such annual disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this new accounting standard in its Annual Report on Form 10-K for the year ended December 31, 2022 and does not expect the adoption of this standard to have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-08&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating its adoption date of this standard and the impact of the standard on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-04&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LIBOR&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-01&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of September 30, 2022, there was no impact to the Company&#x2019;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTI_b76e01d7-63f4-4082-8860-7271efa7b592">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with GAAP for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, except for new accounting standards discussed under Recent Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTU_d044246a-c7b3-474a-837a-7372a03caaa9">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#x2019;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <neo:AssetsHeldForSalePolicyPolicyTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTM_1efc7e67-fe02-4915-ab57-adf76ab1ccd2">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.&lt;/span&gt;&lt;/div&gt;</neo:AssetsHeldForSalePolicyPolicyTextBlock>
    <neo:AssetHeldForSaleSquareFeetOfFacilityOwned
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMzg4Mg_2b82ad74-62cf-4bb5-b679-b3dfe8b76761"
      unitRef="sqft">43560</neo:AssetHeldForSaleSquareFeetOfFacilityOwned>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfNDExNA_b199ca71-5dd9-485d-a53b-a5778bfe8ca3"
      unitRef="usd">10100000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="i7fb987fb745a46ddaabee10f5edd1014_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfNDQwNQ_343d70f9-7434-4e1e-bace-5da052af4748"
      unitRef="usd">12100000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfNDU0Mg_4abaed85-0da1-43c0-8127-8ea1d272daf0"
      unitRef="usd">2000000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTg_368ae80a-ad61-4d23-9e80-ae13d1012d10">GoodwillThe Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#x2019;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#x2019; data.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="iad9898a18252459abeaaa2287043243d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfNjYzMg_3090e1a6-a522-4cba-ba49-022a4c3f3e40"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMjE5OTAyMzI3NzI1OA_c123767c-649c-4310-ae51-35ff6e786827">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist of payroll and payroll related costs for the Company&#x2019;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, gains or losses on disposals of assets, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services &lt;/span&gt;&lt;/div&gt;segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three and nine months ended September 30, 2022 and 2021.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80MC9mcmFnOjM3ZmFkMGU5ODRjMTQxMzI5ZDI5ZTU5MjYzNzUxNWI1L3RleHRyZWdpb246MzdmYWQwZTk4NGMxNDEzMjlkMjllNTkyNjM3NTE1YjVfMTEzNTA_2a5b053f-7e8d-4233-aea8-a9b2780d9d6c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2021-10&#x201d;). This update requires business entities to disclose information annually about certain government assistance they receive. Such annual disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this new accounting standard in its Annual Report on Form 10-K for the year ended December 31, 2022 and does not expect the adoption of this standard to have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-08&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating its adoption date of this standard and the impact of the standard on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-04&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LIBOR&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-01&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of September 30, 2022, there was no impact to the Company&#x2019;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTE3MjM_a5038404-4d6a-4410-aea9-defda5ea15e5">Acquisitions&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Trapelo Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 7, 2021 (the &#x201c;Trapelo Acquisition Date&#x201d;), the Company completed the acquisition of a 100% ownership interest in Intervention Insights, Inc. d/b/a Trapelo Health (&#x201c;Trapelo&#x201d;), an information technology company focused on precision oncology. The purchase price consisted of (i) cash consideration of $35.6&#160;million, which included a net adjustment of $0.6&#160;million for estimated cash on hand of Trapelo and estimated working capital adjustments on the Trapelo Acquisition Date, and (ii) equity consideration of $29.2&#160;million, consisting of 597,712 shares of the Company&#x2019;s common stock, par value $0.001 per share, valued at $48.81 per share. The Company acquired control of Trapelo on the Trapelo Acquisition Date; therefore, the fair value of the common stock issued as part of consideration was determined on the basis of the closing market price of the Company&#x2019;s common stock immediately prior to the Trapelo Acquisition Date. The Trapelo acquisition enhances the Company&#x2019;s ability to provide customers clinical decision support to help answer complex questions related to precision oncology biomarker testing and treatment options as part of the Company&#x2019;s comprehensive oncology offerings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Trapelo was determined to be a business combination and has been accounted for using the acquisition method. The purchase price and purchase price allocation were based upon management&#x2019;s best estimates and assumptions and were considered final as of March 31, 2022. The following table summarizes the purchase consideration recorded for the acquisition of Trapelo, the fair value of the net assets acquired and liabilities assumed, and the calculation of goodwill based on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the excess of the consideration transferred over the fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Per share value of common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of common stock at Trapelo Acquisition Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of the purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - marketing assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The identified developed technology and marketing intangible assets are being amortized over ten years and four years, respectively, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Trapelo acquisition is 9.8 years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The marketing intangible assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the marketing intangible assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the marketing intangible assets had the intangible assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#x2019;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The goodwill recognized, all of which was assigned to the Clinical Services segment, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. None of the goodwill resulting from the acquisition of Trapelo is expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations of Trapelo are included in the Company&#x2019;s unaudited Consolidated Financial Statements beginning on the Trapelo Acquisition Date. No pro forma information has been included relating to the Trapelo acquisition, as this acquisition was not deemed to be material to the Company&#x2019;s revenue or net loss on a pro forma basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Inivata Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021 (the &#x201c;Inivata Acquisition Date&#x201d;), the Company completed the acquisition of the remaining equity interests in Inivata Limited, a private limited company incorporated in England and Wales (&#x201c;Inivata&#x201d;). Inivata is a global, commercial stage, liquid biopsy platform company. The acquisition follows a $25.0&#160;million minority equity investment by the Company in Series C1 Preference Shares (the &#x201c;Preference Shares&#x201d; or &#x201c;previously-held equity interest&#x201d;) in Inivata in May 2020, at which time the Company also acquired a fixed price option to purchase the remainder of equity interests in Inivata for $390.0&#160;million (the &#x201c;Purchase Option&#x201d;). The Company and Inivata also entered into a line of credit agreement in the amount of $15.0&#160;million (the &#x201c;Line of Credit&#x201d;) in May 2020. In the first quarter of 2021, prior to the Inivata Acquisition Date, an observable transaction of an identical investment in Inivata Preference Shares occurred which resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Company recorded a net unrealized loss of $5.0&#160;million on investment in non-consolidated affiliate for this remeasurement for the three months ended March 31, 2021 in other expense (income), net on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Inivata acquisition adds liquid biopsy platform technology, including minimal residual disease testing capabilities, to the Company&#x2019;s comprehensive portfolio of oncology testing solutions. The purchase price consisted of cash consideration of $398.6&#160;million, which included a net adjustment of $8.6&#160;million for estimated cash on hand of Inivata and other adjustments on the Inivata Acquisition Date, and was funded through cash on hand and a private placement of equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the acquisition of the remaining equity interests in Inivata, the Company accounted for its previously-held equity interest and the Purchase Option in Inivata as equity securities without a readily determinable fair value. The equity interests were recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Therefore, the Company&#x2019;s acquisition of control of Inivata on the Inivata Acquisition Date was accounted for as a business combination achieved in stages under the acquisition method. Accordingly, the Company used a discounted cash flow to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#x2019;s previously-held equity interest and Purchase Option in Inivata. To determine the fair value of the previously-held equity interest, the fair value of Inivata&#x2019;s total equity was allocated to its various classes of equity based on the respective rights and privileges of each class of stock in liquidation. The business enterprise value and a Black-Scholes model were then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at the fair value at the Inivata Acquisition Date based on its settlement value. This resulted in fair values of $64.9 million in Preference Shares and a $74.3 million Purchase Option, immediately prior to the acquisition. On the Inivata Acquisition Date, the $10.3&#160;million outstanding under the Line of Credit extended by the Company to Inivata was effectively settled as part of the acquisition of Inivata at the $15.0&#160;million principal amount and was recorded as part of the consideration transferred in the acquisition. The Company recorded a gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#x2019;s Consolidated Statements of Operations of $109.3&#160;million for the year ended December 31, 2021 for the excess of the acquisition-date fair value of the Company&#x2019;s previously-held equity interest, Purchase Option, and Line of Credit over their carrying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The purchase price and purchase price allocation were based upon management&#x2019;s best estimates and assumptions and were considered final as of June 30, 2022. The following table summarizes the calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit, and the estimated fair value of the previously-held equity interest and Purchase Option, over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 18, 2021&lt;br/&gt;(as initially reported)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 18, 2021 &lt;br/&gt;(as adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value of business combination:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of Line of Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of previously-held equity interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of Purchase Option&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total fair value of business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;535,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allocation of the fair value business combination:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets - developed technology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;302,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets - trademarks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - trade name&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total fair value of business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;535,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangibles assets and related future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, we recorded a $4.3&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The identified developed technology intangible assets and the trademark intangible assets are both being amortized over fifteen years, and the trade name intangible asset is being amortized over five years, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Inivata acquisition is 14.9 years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The trademarks and trade name assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the trademarks and trade name assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the trademarks and trade name assets had the assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#x2019;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The goodwill recognized, of which $234.6&#160;million and $32.4&#160;million was assigned to the Clinical Services and Pharma Services segments, respectively, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of liquid biopsy technology for oncology testing. The recording of amortizable intangibles has given rise to a deferred tax liability upon the acquisition of Inivata which increased goodwill by $56.6 million. None of the goodwill resulting from the acquisition of Inivata is expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These unaudited pro forma results represent the combined results of operations of the Company and Inivata, on an unaudited pro forma basis, for the period in which the acquisition of Inivata occurred and the prior reporting period as though the companies had been combined as of the beginning of the earliest period presented. Therefore, the unaudited pro forma consolidated results have been prepared by adjusting the Company&#x2019;s historical results to include the acquisition of Inivata as if it occurred on January 1, 2020. These unaudited pro forma consolidated historical results exclude, $17.8&#160;million of measurement period adjustments recorded in the three months ended &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and $109.3&#160;million of gain on investment in and loan receivable from non-consolidated affiliate, net, recorded in the nine months ended &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTM1_8ed1afec-d1c8-4b9c-808a-a01b4e4bcd99"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMzQ1_df2a7b78-06fc-4768-83e4-514324e90b9f"
      unitRef="usd">35600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments
      contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMzg0_575382f9-7636-46ac-a2ea-7183f03ee0fe"
      unitRef="usd">600000</neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNTMz_7324f63f-82a4-45de-bfe4-1a0d32daf246"
      unitRef="usd">29200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNTUx_284ee773-fd5a-4625-ab90-1b9ed12d20a7"
      unitRef="shares">597712</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iff7308f890e64260ae7552498699b417_I20210407"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjAy_3f48ea66-1870-4fa8-a79d-113ebdbce6e0"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjI2_3567624f-4047-4117-909b-fbd5d4474146"
      unitRef="usdPerShare">48.81</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTE3MjQ_74c0742c-1004-478f-824a-457103f6afe3">The following table summarizes the purchase consideration recorded for the acquisition of Trapelo, the fair value of the net assets acquired and liabilities assumed, and the calculation of goodwill based on &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the excess of the consideration transferred over the fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Per share value of common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of common stock at Trapelo Acquisition Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of the purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - marketing assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The purchase price and purchase price allocation were based upon management&#x2019;s best estimates and assumptions and were considered final as of June 30, 2022. The following table summarizes the calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit, and the estimated fair value of the previously-held equity interest and Purchase Option, over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 18, 2021&lt;br/&gt;(as initially reported)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 18, 2021 &lt;br/&gt;(as adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value of business combination:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of Line of Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of previously-held equity interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of Purchase Option&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total fair value of business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;535,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allocation of the fair value business combination:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets - developed technology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;302,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets - trademarks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - trade name&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total fair value of business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;535,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangibles assets and related future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, we recorded a $4.3&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMi0yLTEtMS0xMjY2Mjg_0abe8c60-b779-45af-8000-ed3ea2f50936"
      unitRef="shares">597712</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMy0yLTEtMS0xMjY2Mjg_be2a8e7d-3509-4874-80f2-d51d74897b3a"
      unitRef="usdPerShare">48.81</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfNC0yLTEtMS0xMjY2Mjg_d8f241c3-2782-4340-afc8-05a5d01c2fe8"
      unitRef="usd">29174000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfNS0yLTEtMS0xMjY2Mjg_3f9e9b88-3567-4ffe-90cc-b829f55c0174"
      unitRef="usd">35591000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfNi0yLTEtMS0xMjY2Mjg_a36f864d-638d-428c-9b31-644b67e9db95"
      unitRef="usd">64765000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfOS0yLTEtMS0xMjY2Mjg_b98d1a6a-b888-4f23-a20e-6edbd370b948"
      unitRef="usd">713000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTAtMi0xLTEtMTI2NjI4_119507c9-7304-4320-b4f8-78fc9f84b2cc"
      unitRef="usd">282000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ib2c2a0a7992f4f9c87c6ec0df05f6881_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTEtMi0xLTEtMTI2NjI4_72b0e08f-9ad5-473c-bb8d-6d0b7037035d"
      unitRef="usd">549000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i47dac90fa672439484bfb0a011afa79b_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTItMi0xLTEtMTI2NjI4_446387b0-2302-4e60-ac18-814ee85a0440"
      unitRef="usd">19040000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTMtMi0xLTEtMTI2NjI4_f213a43d-bf49-41f0-a025-08fa0cdd376e"
      unitRef="usd">268000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTQtMi0xLTEtMTI2NjI4_ed18fd73-391e-489e-904f-2bed8da73648"
      unitRef="usd">20852000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTUtMi0xLTEtMTI2NjI4_cd141179-cf22-4b0d-970e-47b3273a91ef"
      unitRef="usd">751000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTYtMi0xLTEtMTI2NjI4_43e7b797-c19d-4b38-8378-1eb6de78cb00"
      unitRef="usd">20101000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTctMi0xLTEtMTI2NjI4_c423f751-5808-4a8a-89e1-ea91272b2560"
      unitRef="usd">44664000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjcxYjg2MTkxYTk2ZTQ1MmVhNDlhYTE5MTQxNzhlOGMxL3RhYmxlcmFuZ2U6NzFiODYxOTFhOTZlNDUyZWE0OWFhMTkxNDE3OGU4YzFfMTgtMi0xLTEtMTI2NjI4_cc69279f-2d70-4261-a0dc-6e8b6c4b4a16"
      unitRef="usd">64765000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2fb74da8b2fb46a5bb928c2ae920bddb_D20210407-20210407"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTk2NQ_978040dc-b765-4d28-8d0f-9206923f9a17">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i752263ab04214611a5770e4027948a06_D20210407-20210407"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTk3Mg_41a7fe8b-7f9a-49fb-a823-032f11269b63">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0254e4cf16114941859a750438514071_D20210407-20210407"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMjE0OA_06eb4398-b1dd-4f3d-8a79-515cafd71dbb">P9Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i23d019f81e5749f4a1f01a51d0b349d0_I20210407"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMzMwNQ_d5cec33f-c442-4f5a-b716-c1708eeb3a65"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="id9000f1ccba54fd19804e3f40e0611cb_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNDA5NA_14faea51-da3b-4c7c-bf89-b26707a22718"
      unitRef="usd">25000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i6a29368d78684750a6b47e75d93b5fe5_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNDM3OQ_c6ef601a-c985-48ff-81d1-bbf483e80191"
      unitRef="usd">390000000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNDQ5Mw_9a1b27f9-8754-45d6-b361-104c755e00f5"
      unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie866a05c754c4aea88ba72656f3dfaf1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNDg0Mg_a6db4fcc-a882-470b-ac6e-b310f5f2defd"
      unitRef="usd">-5000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNTI3OA_e2f5383c-b646-4858-ab6a-94097d3ee1f7"
      unitRef="usd">398600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNTMxNw_14e4ad8b-7023-48dd-978e-e1e903082a12"
      unitRef="usd">8600000</neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i447890f585a7488ca3884eedd5e3f87b_D20210930-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjkxOA_bd3909f1-1e30-4be8-843d-532a350a2212"
      unitRef="usd">64900000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue
      contextRef="i447890f585a7488ca3884eedd5e3f87b_D20210930-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjk0OA_b35a8e08-3934-47c7-8206-087f55da6737"
      unitRef="usd">74300000</neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue>
    <us-gaap:LineOfCredit
      contextRef="i42f304bd718a4345825da30d39801aa4_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNzA0Mw_fc0639c7-99eb-4d86-87ec-133a80d0c263"
      unitRef="usd">10300000</us-gaap:LineOfCredit>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNzE4Nw_9a1b27f9-8754-45d6-b361-104c755e00f5"
      unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i19602c53e9f24c5e9c34e6540ce4ce9a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNzQ1MA_c6cc9fc8-2b5e-4cdf-a343-08e9c4964770"
      unitRef="usd">109300000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMi0yLTEtMS0xMjY2Mjg_a5d79d72-b0b4-4831-9f13-b3e80dd10dcf"
      unitRef="usd">398594000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMi02LTEtMS0xMjY2Mjg_8d4d4842-9d95-40dc-8803-5d939f8a23b5"
      unitRef="usd">398594000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMy0yLTEtMS0xMjY2Mjg_55fbf7fd-3bfd-4a77-a3c9-f84021e8b136"
      unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMy02LTEtMS0xMjY2Mjg_9a7cccff-a635-41e3-a5de-8453c154d71a"
      unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNC0yLTEtMS0xMjY2Mjg_9fc70217-b722-4eb7-bc04-d67080eabaec"
      unitRef="usd">413594000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNC02LTEtMS0xMjY2Mjg_8b3b93b5-c2fb-49f5-9bba-4db2d21cf969"
      unitRef="usd">413594000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNS0yLTEtMS0xMjY2Mjg_a52fd8b9-f254-4717-8800-539f951cb68e"
      unitRef="usd">62919000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNS00LTEtMS0xMjY2Mjg_601344ff-fa5e-45bd-8282-30700aba0c7c"
      unitRef="usd">1987000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNS02LTEtMS0xMjY2Mjg_9956b854-d642-4089-a654-f6f81fffe603"
      unitRef="usd">64906000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue
      contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNi0yLTEtMS0xMjY2Mjg_55a8b881-904e-4b51-a560-478b4d252898"
      unitRef="usd">58537000</neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNi00LTEtMS0xMjY2Mjg_165cf1be-25fd-4724-a4fe-b4f924732a88"
      unitRef="usd">15763000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue>
    <neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNi02LTEtMS0xMjY2Mjg_eb0f76fb-1b05-48dc-b070-1b36a945bc91"
      unitRef="usd">74300000</neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="ia684065582284ea892447e0db574adc0_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNy0yLTEtMS0xMjY2Mjg_8fa03851-c9b1-49f2-806b-70bf1c81f80f"
      unitRef="usd">535050000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNy00LTEtMS0xMjY2Mjg_ec604ac7-84a2-4870-a4d9-71960b35518c"
      unitRef="usd">17750000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfNy02LTEtMS0xMjY2Mjg_8afba7f1-abc3-4e8f-a0ac-8f0417e231b2"
      unitRef="usd">552800000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTAtMi0xLTEtMTI2NjI4_4ea8a3c3-52f3-4949-9051-2b74685ea7f0"
      unitRef="usd">14068000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTAtNi0xLTEtMTI2NjI4_d0819efb-44d1-427d-9072-6e2074d1abe2"
      unitRef="usd">14068000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTEtMi0xLTEtMTI2NjI4_279f34c7-c4b9-4d42-9d3e-af1e480b9539"
      unitRef="usd">5366000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTEtNC0xLTEtMTI2NjI4_c957f9f1-5898-47e9-8002-962fd9292776"
      unitRef="usd">345000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTEtNi0xLTEtMTI2NjI4_bd51afbe-9179-4806-9e97-966ccf709923"
      unitRef="usd">5711000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTItMi0xLTEtMTI2NjI4_c9b3dc00-fc2b-46e3-9ff8-2f24d5cf06ef"
      unitRef="usd">1753000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTItNi0xLTEtMTI2NjI4_47013880-a382-4efe-b942-f53139cb2e5f"
      unitRef="usd">1753000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iddea112c263e4efd98f07f82c1942c43_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTMtMi0xLTEtMTI2NjI4_1fe5c121-1b0b-4b24-87a6-0f8b2a33db2c"
      unitRef="usd">302982000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="icc7e8245487f4f58b121fa84f4613dc4_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTMtNC0xLTEtMTI2NjI4_b96b3e66-7884-4149-95d1-ed104dd8b05d"
      unitRef="usd">-11796000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ifc78548fd43f4d83ac64d4a4b191d44e_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTMtNi0xLTEtMTI2NjI4_92a3edf6-d639-4c9e-8741-01747ad51e91"
      unitRef="usd">291186000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iec4e93a323ef4cc3a8b43b840cbbf66c_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTQtMi0xLTEtMTI2NjI4_0e7b5308-5f0a-4478-9c0e-99c0a4d7020f"
      unitRef="usd">31700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="ieb7a81052f8342aaaa4c62d41e183a9e_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTQtNC0xLTEtMTI2NjI4_29699294-4704-4542-aeef-935e31a4d649"
      unitRef="usd">-226000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8b166ff4628f47a6a659a300bfe3a6bd_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTQtNi0xLTEtMTI2NjI4_6c084a91-459a-49a7-b079-c8cb0c9a6a81"
      unitRef="usd">31474000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i57af656e837042e79c7838e6547334dc_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTUtMi0xLTEtMTI2NjI4_7790b956-99ec-46cc-82d5-474eb96e4ef8"
      unitRef="usd">2322000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="id7214014d96a45c489ea60bba444a28e_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTUtNC0xLTEtMTI2NjI4_59665c77-6453-414a-8374-df853c6081d1"
      unitRef="usd">253000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i865870f7a6e3486b94e11d31cbf92518_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTUtNi0xLTEtMTI2NjI4_77f6ecae-e88c-4a6c-a225-ef22d08817ab"
      unitRef="usd">2575000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTYtMi0xLTEtMTI2NjI4_1cd29656-b0ae-42ff-a98c-d9e021aeb13c"
      unitRef="usd">6240000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTYtNi0xLTEtMTI2NjI4_a8e9d0bd-d45e-498f-aa93-18609e48c0f8"
      unitRef="usd">6240000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTctMi0xLTEtMTI2NjI4_794d0b6a-dfd3-4487-a576-4bf838d18f85"
      unitRef="usd">364431000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTctNC0xLTEtMTI2NjI4_f9afad84-1f63-4d62-9af1-9195a79cd1a8"
      unitRef="usd">-11424000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTctNi0xLTEtMTI2NjI4_25fa4297-a069-46ef-941c-0e5b827c5c9a"
      unitRef="usd">353007000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTgtMi0xLTEtMTI2NjI4_8a604847-152c-4198-a2c1-d499fbb4b652"
      unitRef="usd">4241000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTgtNC0xLTEtMTI2NjI4_06a832bd-c1e6-4eec-b4be-e74392b5009b"
      unitRef="usd">-1650000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTgtNi0xLTEtMTI2NjI4_c3b702ad-f9cc-4b2a-ac18-e073396ab2d6"
      unitRef="usd">5891000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTktMi0xLTEtMTI2NjI4_12f2a622-781c-4900-acb1-aa2205990cc5"
      unitRef="usd">64680000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTktNC0xLTEtMTI2NjI4_dc2618dd-b0ba-4ed9-b897-9684b913d100"
      unitRef="usd">3686000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities
      contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTktNi0xLTEtMTMzNTUw_aa19667e-52b4-47c8-a58a-31567a652800"
      unitRef="usd">4349000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMTktNi0xLTEtMTI2NjI4_5d0b5a22-af7b-4d51-9c5a-418175303015"
      unitRef="usd">56645000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjAtMi0xLTEtMTI2NjI4_2d0f7ccb-fe39-4999-aa48-ae1d1261036f"
      unitRef="usd">4690000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjAtNi0xLTEtMTI2NjI4_64dbee58-a4c1-4140-8984-7a6540ce5a41"
      unitRef="usd">4690000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjEtMi0xLTEtMTI2NjI4_eb2a9b25-2ac1-4391-a739-4f04299498b2"
      unitRef="usd">290820000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjEtNC0xLTEtMTI2NjI4_ffe9ade8-164f-4f37-81f1-c2cbf8b6e922"
      unitRef="usd">-9388000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjEtNi0xLTEtMTMzNTUw_e4bbd36b-b17d-4d1b-8187-1d0b0228adb8"
      unitRef="usd">4349000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjEtNi0xLTEtMTI2NjI4_3c6c4f67-8c32-4c79-8969-3411acd2a551"
      unitRef="usd">285781000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjItMi0xLTEtMTI2NjI4_69875333-f0d5-46fe-bbd2-a84fc8677c6c"
      unitRef="usd">244230000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjItNC0xLTEtMTI2NjI4_9f5e12bb-8095-44f7-a0c4-462368d17969"
      unitRef="usd">27138000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjItNi0xLTEtMTMzNTUw_f7423bdb-3782-4f4b-8f45-45a43ae81e4b"
      unitRef="usd">-4349000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjItNi0xLTEtMTI2NjI4_f3a66e8d-4e86-4937-bb84-cbc63f70c928"
      unitRef="usd">267019000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i972519f375d24149b066529619e13c9d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjMtMi0xLTEtMTI2NjI4_75a6e17b-91b2-4217-af6e-42cda4d0d2cd"
      unitRef="usd">535050000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjMtNC0xLTEtMTI2NjI4_1dc67d84-9355-40ad-bafc-fd0f421509c3"
      unitRef="usd">17750000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjQ0NDFmZTAwYTkzNTRkYzNhNTk4N2E0M2QzY2M2OTEyL3RhYmxlcmFuZ2U6NDQ0MWZlMDBhOTM1NGRjM2E1OTg3YTQzZDNjYzY5MTJfMjMtNi0xLTEtMTI2NjI4_7c63fe5b-0242-4ff4-89ae-528683bfa9bd"
      unitRef="usd">552800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfNjU5NzA2OTc3ODkzMQ_c8d2244d-959c-4fc6-8199-cc50cb66f35c"
      unitRef="usd">-4300000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ieb7a81052f8342aaaa4c62d41e183a9e_D20210618-20210618"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfODkyNQ_6e290fb7-a61d-4007-b1bb-0cd437cb1d31">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icc7e8245487f4f58b121fa84f4613dc4_D20210618-20210618"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfODkyNQ_83a6c351-b08c-4275-a2c7-86deb47594ce">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id7214014d96a45c489ea60bba444a28e_D20210618-20210618"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfODk4OQ_f78f78b4-307a-4401-b338-d8cc4391dcec">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i39681a3fb607451684256d16e371d9c7_D20210618-20210618"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfOTE1MQ_dc4b29e5-e9b3-4fc4-b7ab-396fa1644354">P14Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie1bbf95ea8de4373bbdc6c8c9dfb2a77_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMjE5OTAyMzI2NzI4MA_1c47cc09-930f-4fba-8787-3651a6e70073"
      unitRef="usd">234600000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i5190e0e6e6094a9aba5a2f9550f41b08_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMjE5OTAyMzI2NzI5Ng_6abd8650-1aec-4291-a36a-dd5e4a350f86"
      unitRef="usd">32400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTA1MTQ_7bcd1d8b-0b1f-414d-a8a1-4179bff342f9"
      unitRef="usd">56600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="if0bbfe44413e450596641e770fb62e42_I20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTA1MTg_ee05f9dd-7418-4161-b00f-ea51358ec0a4"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTE3MjY_cc62615f-71f9-42d3-996a-6884b7543e5f">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjM4ZmQ5MDNhYWIxNTQwNjc5ZDQ4ZjhhY2VhYjJkYWQxL3RhYmxlcmFuZ2U6MzhmZDkwM2FhYjE1NDA2NzlkNDhmOGFjZWFiMmRhZDFfMi0yLTEtMS0xMjY2Mjg_89464edc-b8bc-4fcc-bc8d-47fe21c6164f"
      unitRef="usd">121340000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i42a24c5b482d4c868eb1ce13b760dbe9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjM4ZmQ5MDNhYWIxNTQwNjc5ZDQ4ZjhhY2VhYjJkYWQxL3RhYmxlcmFuZ2U6MzhmZDkwM2FhYjE1NDA2NzlkNDhmOGFjZWFiMmRhZDFfMi00LTEtMS0xMjY2Mjg_ad2a354a-2130-480d-88f5-20dcf49ceb17"
      unitRef="usd">358499000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjM4ZmQ5MDNhYWIxNTQwNjc5ZDQ4ZjhhY2VhYjJkYWQxL3RhYmxlcmFuZ2U6MzhmZDkwM2FhYjE1NDA2NzlkNDhmOGFjZWFiMmRhZDFfMy0yLTEtMS0xMjY2Mjg_61a95e3e-e5c6-4282-9729-7f5ce109858a"
      unitRef="usd">-37017000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i42a24c5b482d4c868eb1ce13b760dbe9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RhYmxlOjM4ZmQ5MDNhYWIxNTQwNjc5ZDQ4ZjhhY2VhYjJkYWQxL3RhYmxlcmFuZ2U6MzhmZDkwM2FhYjE1NDA2NzlkNDhmOGFjZWFiMmRhZDFfMy00LTEtMS0xMjY2Mjg_0da32486-dcf4-4ab5-becc-6bdffea1578e"
      unitRef="usd">-88134000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMjE5OTAyMzI2Nzc1Mg_46b327a8-b719-4d2c-bf67-442656971e47"
      unitRef="usd">17800000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <neo:GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate
      contextRef="i42a24c5b482d4c868eb1ce13b760dbe9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80My9mcmFnOjZhYTU5OTE0MGY3ZDQwMzQ4NGU4ZmE1MzhmNmM5ZmMzL3RleHRyZWdpb246NmFhNTk5MTQwZjdkNDAzNDg0ZThmYTUzOGY2YzlmYzNfMTE2NDM_51ba488c-f914-47da-b284-841e01dfb5b2"
      unitRef="usd">109300000</neo:GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNDIxNg_a0f5e073-d8c1-4a26-afed-cd37af61c4c1">Fair Value Measurements&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities.&#160;These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly.&#160;These are typically obtained from readily-available pricing sources for comparable instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs, where there is little or no market activity for the asset or liability.&#160;These inputs reflect the reporting entity&#x2019;s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets and Liabilities that are Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#x2019;s marketable securities accounted for as available-for-sale securities as of September 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had $0.7&#160;million and $0.6&#160;million of accrued interest receivable at September 30, 2022 and December 31, 2021, respectively, included in other current assets on its Consolidated Balance Sheets related to its marketable securities. Realized gains or losses on marketable securities for the three and nine months ended September 30, 2022 and September 30, 2021 were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at September 30, 2022 and December 31, 2021. &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the Company&#x2019;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of September 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the three and nine months ended September 30, 2022 and September 30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other liabilities, and other current assets and liabilities, are considered reasonable estimates of their respective fair values at September 30, 2022 and December 31, 2021 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, and long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and, as such, these are considered Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNDIxOA_af02a8e7-b99d-4e66-b5ef-ba6c9d9e1904">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#x2019;s marketable securities accounted for as available-for-sale securities as of September 30, 2022 and December 31, 2021.&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNC0yLTEtMS0xMjY2Mjg_c1c1f383-c277-4f0e-83ae-aca43ffbe8c4"
      unitRef="usd">52826000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNC00LTEtMS0xMjY2Mjg_4b55da8d-82bc-47d8-b148-0e0670d2a3f2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNC02LTEtMS0xMjY2Mjg_b6153226-bed7-42f4-927f-1e19e34b658f"
      unitRef="usd">889000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNC04LTEtMS0xMjY2Mjg_29bce335-564b-4ae4-b723-3085aafdd349"
      unitRef="usd">51937000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNi0yLTEtMS0xMjY2Mjg_8e5a3c65-ad85-4c2a-92d3-c8eab0778ded"
      unitRef="usd">8373000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNi00LTEtMS0xMjY2Mjg_f3e6dc69-4797-4913-9a44-a03c66b5175e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNi02LTEtMS0xMjY2Mjg_9d2bbe77-bb96-4409-9479-8ff4cd121de3"
      unitRef="usd">141000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNi04LTEtMS0xMjY2Mjg_098adc57-f04e-4db3-88cc-c0d2bcdfaf90"
      unitRef="usd">8232000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNy0yLTEtMS0xMjY2Mjg_fe81abb1-63e1-4b9c-98f7-bb5788b55d87"
      unitRef="usd">8890000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNy00LTEtMS0xMjY2Mjg_82c74d76-5497-44bb-8fc2-8904a799ab9a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNy02LTEtMS0xMjY2Mjg_c2a10525-26e4-4e50-b217-5d147b29717d"
      unitRef="usd">147000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfNy04LTEtMS0xMjY2Mjg_2f1230b4-8445-4e22-83d3-5c9fdf05d402"
      unitRef="usd">8743000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOC0yLTEtMS0xMjY2Mjg_dfd2f2dc-3baf-4c44-b8bf-c7f3ee50e409"
      unitRef="usd">12877000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOC00LTEtMS0xMjY2Mjg_fa1beaa3-657c-46db-8ee8-5ab26d955492"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOC02LTEtMS0xMjY2Mjg_5e48de74-cae0-42b4-bbba-cb8e67aff26e"
      unitRef="usd">1119000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOC04LTEtMS0xMjY2Mjg_01d8e009-8c27-4677-b11b-bb426e28e91f"
      unitRef="usd">11758000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOS0yLTEtMS0xMjY2Mjg_4462562a-94f3-4fa7-a2b0-f74d1666458a"
      unitRef="usd">6974000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOS00LTEtMS0xMjY2Mjg_b650549e-3087-433d-97ff-73862625776e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOS02LTEtMS0xMjY2Mjg_57f72003-ea31-4e52-a460-a88df3366814"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfOS04LTEtMS0xMjY2Mjg_a021f1a0-e24a-4601-8c98-a3f6573448d3"
      unitRef="usd">6945000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i449f2af14b0146a5a78576a510536145_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTAtMi0xLTEtMTI2NjI4_ad131a0d-8177-482e-b734-54a10f6c046f"
      unitRef="usd">30117000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i449f2af14b0146a5a78576a510536145_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTAtNC0xLTEtMTI2NjI4_16274a9f-aa16-4d1e-b148-bb8c4ebf22ea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i449f2af14b0146a5a78576a510536145_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTAtNi0xLTEtMTI2NjI4_5fb8b5d4-114b-4044-99fe-2f9bbde6613c"
      unitRef="usd">510000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i449f2af14b0146a5a78576a510536145_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTAtOC0xLTEtMTI2NjI4_286bda2c-1c82-44be-925a-86e41939d967"
      unitRef="usd">29607000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i45be316a68fd49828e355ae260885a25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTEtMi0xLTEtMTI2NjI4_c4fa156e-4caf-4f7b-bb28-3e0945907ad1"
      unitRef="usd">62725000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i45be316a68fd49828e355ae260885a25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTEtNC0xLTEtMTI2NjI4_c0caffa3-ac42-43b5-a6c2-57f252a344ae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i45be316a68fd49828e355ae260885a25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTEtNi0xLTEtMTI2NjI4_94572b87-41da-410b-a0f4-57dc8ccaa748"
      unitRef="usd">2533000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i45be316a68fd49828e355ae260885a25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTEtOC0xLTEtMTI2NjI4_4a3ffa55-2a39-4ad6-967f-4c1d1f8212cf"
      unitRef="usd">60192000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTItMi0xLTEtMTI2NjI4_bfce9b60-bf2b-49f1-997e-fb2a0ed61bb3"
      unitRef="usd">182782000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTItNC0xLTEtMTI2NjI4_028a3a99-6417-4ada-a5a6-bcb291fe5e16"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTItNi0xLTEtMTI2NjI4_d52dff00-6201-42e6-943f-ac73e250153f"
      unitRef="usd">5368000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmFjYTBkMGUxMmVkZDRkZGU4ZTY5ZDc2ZjE4OWNmZjBhL3RhYmxlcmFuZ2U6YWNhMGQwZTEyZWRkNGRkZThlNjlkNzZmMTg5Y2ZmMGFfMTItOC0xLTEtMTI2NjI4_a46a0ae1-e2b4-4595-8489-1ad9ad4aca8a"
      unitRef="usd">177414000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNC0yLTEtMS0xMjY2Mjg_92862a99-4079-402b-825a-46607af9b014"
      unitRef="usd">52791000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNC00LTEtMS0xMjY2Mjg_3a6dc5f9-5918-4fdf-bc3f-41c9e182502a"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNC02LTEtMS0xMjY2Mjg_eb568ef7-bdee-485b-abcc-6b2dd3840397"
      unitRef="usd">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNC04LTEtMS0xMjY2Mjg_96d02fc0-4a6b-4ae9-aafd-28c3cf118316"
      unitRef="usd">52664000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNS0yLTEtMS0xMjY2Mjg_bedf2389-8cf7-4f02-a9c3-7174f4e700c0"
      unitRef="usd">6175000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNS00LTEtMS0xMjY2Mjg_886df41c-a899-406e-9c4d-3e4c96a492db"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNS02LTEtMS0xMjY2Mjg_5ac1ab60-40c4-4fda-b442-f3a00220ec6c"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNS04LTEtMS0xMjY2Mjg_e3d3003f-7382-436f-9a66-c8fcbcda838b"
      unitRef="usd">6160000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i270d8802e355431a87805141beb22e21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNi0yLTEtMS0xMjY2Mjg_a27d917b-5205-4393-9f4e-f6e2997b35b3"
      unitRef="usd">17546000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i270d8802e355431a87805141beb22e21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNi00LTEtMS0xMjY2Mjg_385bd7d4-33bc-4161-93a1-5bbc486054be"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i270d8802e355431a87805141beb22e21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNi02LTEtMS0xMjY2Mjg_e5e79ffb-3a25-4098-ac1e-8e91af8bb739"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i270d8802e355431a87805141beb22e21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNi04LTEtMS0xMjY2Mjg_45d9baea-9bda-4350-a1bd-ab66c3a5d7d7"
      unitRef="usd">17530000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNy0yLTEtMS0xMjY2Mjg_eb6f6667-3ecb-45da-9307-39224f3969d0"
      unitRef="usd">12440000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNy00LTEtMS0xMjY2Mjg_36cf9660-2c27-4953-a6b8-4f8d3690e939"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNy02LTEtMS0xMjY2Mjg_1aee5ef4-9b45-443e-b7ab-fb97561d3f74"
      unitRef="usd">211000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfNy04LTEtMS0xMjY2Mjg_a7fa1e57-8b12-4038-a6b4-4c0491149639"
      unitRef="usd">12229000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i67a59efcaaa54315abd137625d2903be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOC0yLTEtMS0xMjY2Mjg_231a5a19-9214-48cb-ad68-34be3b7adf64"
      unitRef="usd">17694000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i67a59efcaaa54315abd137625d2903be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOC00LTEtMS0xMjY2Mjg_cfba5961-2103-4275-8d78-cac683200b49"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i67a59efcaaa54315abd137625d2903be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOC02LTEtMS0xMjY2Mjg_73755d9c-cefd-4e0b-9c63-6107db2490f2"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i67a59efcaaa54315abd137625d2903be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOC04LTEtMS0xMjY2Mjg_3e1c0673-9f18-4e3a-90ae-183baec86504"
      unitRef="usd">17690000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOS0yLTEtMS0xMjY2Mjg_454ea7e7-a434-4210-a232-64c8bfd4d411"
      unitRef="usd">27620000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOS00LTEtMS0xMjY2Mjg_0ad3f98a-32c5-47cb-afdd-d08622da1e7e"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOS02LTEtMS0xMjY2Mjg_9f835e02-fe8b-4ae2-a478-2cdbbaf77b85"
      unitRef="usd">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfOS04LTEtMS0xMjY2Mjg_194bdb2e-f3cd-4dbd-90e5-e3cbf4fbd475"
      unitRef="usd">27535000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i836abb9e08624532bd3983b006965c8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTAtMi0xLTEtMTI2NjI4_636c3c68-b83c-4aaa-9c2e-c909f32593bb"
      unitRef="usd">65198000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i836abb9e08624532bd3983b006965c8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTAtNC0xLTEtMTI2NjI4_a76ca4e3-713d-4cdb-9d88-134555d27ffc"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i836abb9e08624532bd3983b006965c8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTAtNi0xLTEtMTI2NjI4_aadb3a82-1b93-4e5c-9b03-277957fa285a"
      unitRef="usd">452000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i836abb9e08624532bd3983b006965c8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTAtOC0xLTEtMTI2NjI4_272ec6e8-2b82-4b30-b75c-d1d54090e1ac"
      unitRef="usd">64755000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTEtMi0xLTEtMTI2NjI4_33753d90-5831-444b-bd08-fe38129f93c8"
      unitRef="usd">199464000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTEtNC0xLTEtMTI2NjI4_80fdb4a6-b7bc-4791-ac62-2351baf06760"
      unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTEtNi0xLTEtMTI2NjI4_cc37d36f-e7c5-42ce-99a6-e81e2fe5b0bf"
      unitRef="usd">923000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4OTMyZmFhNWYwZTRmNjJiYTA0NDRjMWIyMjljMmUwL3RhYmxlcmFuZ2U6NDg5MzJmYWE1ZjBlNGY2MmJhMDQ0NGMxYjIyOWMyZTBfMTEtOC0xLTEtMTI2NjI4_5995788c-2839-45a3-954b-c7e23b776727"
      unitRef="usd">198563000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfMjU5Mw_2c5b26af-7eba-40d6-b7db-5fa5b7ff5a2d"
      unitRef="usd">700000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNzE0NjgyNTU4NDc5Mw_6db2b0bd-7821-4540-83cc-113b3ee59390"
      unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNDIxOQ_c73c4de1-a6ba-46ee-b6bf-f2b50e3aa304">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at September 30, 2022 and December 31, 2021. &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNC0yLTEtMS0xMjY2Mjg_cdc71392-5ce1-42ae-b926-b52cc85c40ed"
      unitRef="usd">36102000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNC00LTEtMS0xMjY2Mjg_28675706-d5d4-42c1-946e-5b524e717ffa"
      unitRef="usd">15835000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNC02LTEtMS0xMjY2Mjg_91adde8f-f3c9-4642-8c44-36c857c1c157"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ibbdaab51178b41529b740316e578e1d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNC04LTEtMS0xMjY2Mjg_68bae6fd-60e2-4d8b-8f70-7b1b13d8ab50"
      unitRef="usd">51937000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNi0yLTEtMS0xMjY2Mjg_04a13086-934b-41ed-a4fd-62e714a6b471"
      unitRef="usd">5704000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNi00LTEtMS0xMjY2Mjg_bc4c1059-335c-4793-a393-0c76dc042851"
      unitRef="usd">2528000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNi02LTEtMS0xMjY2Mjg_5725203d-a706-4f74-aca4-4beeae8c6870"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i18fb7d36fca64200a81888dd0251b185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNi04LTEtMS0xMjY2Mjg_f525a1b2-c561-454a-b10f-1a00a57c3b2c"
      unitRef="usd">8232000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNy0yLTEtMS0xMjY2Mjg_97ddbe84-6ba9-4135-8fbd-46e19fa87fdb"
      unitRef="usd">6419000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNy00LTEtMS0xMjY2Mjg_8a4cf146-7af2-4587-a911-e03a2507738b"
      unitRef="usd">2324000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNy02LTEtMS0xMjY2Mjg_84fe4a36-3749-4aff-a375-67b160382a67"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ie54101ba639b4d8da6ecd576e651fccd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfNy04LTEtMS0xMjY2Mjg_48001487-cb70-4f81-b45b-08364a25d3de"
      unitRef="usd">8743000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOC0yLTEtMS0xMjY2Mjg_81d72989-ebbf-404e-aa21-3b94670e2b04"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOC00LTEtMS0xMjY2Mjg_83a0560b-09ac-4e98-bd58-43137dedc5ce"
      unitRef="usd">11758000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOC02LTEtMS0xMjY2Mjg_e8201655-96af-49ec-bf46-f0e2d62abd99"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i766ee8715c984f5a91d4e9e5957aa027_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOC04LTEtMS0xMjY2Mjg_84bfe423-f191-44f1-aa50-3d623f9f8ee6"
      unitRef="usd">11758000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOS0yLTEtMS0xMjY2Mjg_241a486d-2497-4740-9b6e-511a2567328b"
      unitRef="usd">6945000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOS00LTEtMS0xMjY2Mjg_29a6030d-71b8-4b61-b3df-6526e911d1b8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOS02LTEtMS0xMjY2Mjg_1c4b06c7-4c4b-4292-a48d-64c08a45e579"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i8e89a70008f0452185c38f35f5c3160f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfOS04LTEtMS0xMjY2Mjg_074cc363-8c85-47d1-86f6-f10838ac1a77"
      unitRef="usd">6945000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i449f2af14b0146a5a78576a510536145_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTAtMi0xLTEtMTI2NjI4_5257eafd-6ed4-46f9-b437-9fc847991940"
      unitRef="usd">25052000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i449f2af14b0146a5a78576a510536145_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTAtNC0xLTEtMTI2NjI4_d51ade99-cc2c-425f-b30f-7fb844a07c26"
      unitRef="usd">4555000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i449f2af14b0146a5a78576a510536145_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTAtNi0xLTEtMTI2NjI4_34846408-cf93-497f-87ff-4c4dc4d48e9d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i449f2af14b0146a5a78576a510536145_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTAtOC0xLTEtMTI2NjI4_16f10b39-2c3b-49d4-b192-f67dad288334"
      unitRef="usd">29607000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i45be316a68fd49828e355ae260885a25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTEtMi0xLTEtMTI2NjI4_861137c6-9704-4020-8948-287e0e3cd416"
      unitRef="usd">31945000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i45be316a68fd49828e355ae260885a25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTEtNC0xLTEtMTI2NjI4_2d06f4ef-3957-4998-a7e3-3265699eeafc"
      unitRef="usd">28247000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i45be316a68fd49828e355ae260885a25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTEtNi0xLTEtMTI2NjI4_116abc53-317a-49ae-a7b6-e43d85b4a481"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i45be316a68fd49828e355ae260885a25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTEtOC0xLTEtMTI2NjI4_89af6f91-99dc-4bab-9747-44c0f8b903a7"
      unitRef="usd">60192000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTItMi0xLTEtMTI2NjI4_21cd9ee4-cacf-4280-af85-efc43e70cfc1"
      unitRef="usd">112167000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTItNC0xLTEtMTI2NjI4_bf79ca43-d845-4a75-8b98-24325b9b904c"
      unitRef="usd">65247000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTItNi0xLTEtMTI2NjI4_0f5c4778-21ba-456c-903b-c2df03556492"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOmJjZTEyMGFmY2ZjZjQ1MDk5NWM4Mjk4MDRhZjE3ODA2L3RhYmxlcmFuZ2U6YmNlMTIwYWZjZmNmNDUwOTk1YzgyOTgwNGFmMTc4MDZfMTItOC0xLTEtMTI2NjI4_354f6b4f-529e-4130-ab35-41cb1e373375"
      unitRef="usd">177414000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNC0yLTEtMS0xMjY2Mjg_3bf8f8f2-82f9-4c29-aaab-56710f28461d"
      unitRef="usd">22550000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNC00LTEtMS0xMjY2Mjg_3fbf498a-a0ed-47f0-b587-5f86ea6498f8"
      unitRef="usd">30114000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNC02LTEtMS0xMjY2Mjg_b0e66497-5274-49bf-bf10-36dad55fa7ff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ifdae249624a24acd9b708eff8cd37977_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNC04LTEtMS0xMjY2Mjg_a383d53c-ff42-4021-80bb-8cc0e797a435"
      unitRef="usd">52664000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNS0yLTEtMS0xMjY2Mjg_fb0d7e02-7380-470c-ad06-05be63a8bfa9"
      unitRef="usd">4150000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNS00LTEtMS0xMjY2Mjg_ce21ac4d-f9b8-4966-9b8a-fb497133323c"
      unitRef="usd">2010000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNS02LTEtMS0xMjY2Mjg_2c4f5c49-0e65-4174-a91e-fb97bdda1e77"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i06d8161afc2042ec9e387fdb20260efb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNS04LTEtMS0xMjY2Mjg_a2f524a4-3d68-4d9b-b146-8414a74559ec"
      unitRef="usd">6160000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i270d8802e355431a87805141beb22e21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNi0yLTEtMS0xMjY2Mjg_955128c6-69dd-4ad3-bd56-0997349faccf"
      unitRef="usd">14041000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i270d8802e355431a87805141beb22e21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNi00LTEtMS0xMjY2Mjg_fa9f9917-2df5-4d6f-83e1-a7e527373935"
      unitRef="usd">3489000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i270d8802e355431a87805141beb22e21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNi02LTEtMS0xMjY2Mjg_3c6aa5fc-d8d9-473b-a671-6454e0a83ec7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i270d8802e355431a87805141beb22e21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNi04LTEtMS0xMjY2Mjg_965464c7-3dce-41b6-b492-ce23e563e1b8"
      unitRef="usd">17530000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNy0yLTEtMS0xMjY2Mjg_4e402f4d-7e01-4deb-9f81-290b120632e3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNy00LTEtMS0xMjY2Mjg_c5d72f0a-64cd-43c2-b099-80111f224cc0"
      unitRef="usd">12229000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNy02LTEtMS0xMjY2Mjg_d5552e49-33cf-4f1f-aa52-18d8e491c218"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if0387bd97bb24097a69a3236c020cbf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfNy04LTEtMS0xMjY2Mjg_5bb54a98-c492-45eb-af74-85e94c11b141"
      unitRef="usd">12229000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i67a59efcaaa54315abd137625d2903be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOC0yLTEtMS0xMjY2Mjg_42f136dc-c86b-4234-aaf7-bc28067f106e"
      unitRef="usd">17690000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i67a59efcaaa54315abd137625d2903be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOC00LTEtMS0xMjY2Mjg_82dd2504-a762-4707-abf5-a0dbc6d980a2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i67a59efcaaa54315abd137625d2903be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOC02LTEtMS0xMjY2Mjg_cf2c0dff-6531-4015-86b1-d7fc26da7be7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i67a59efcaaa54315abd137625d2903be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOC04LTEtMS0xMjY2Mjg_ef5a2334-5b3f-4dac-8c84-28c04ffb2784"
      unitRef="usd">17690000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOS0yLTEtMS0xMjY2Mjg_07d2ce72-32a5-44ca-8d17-b24c98da6255"
      unitRef="usd">20868000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOS00LTEtMS0xMjY2Mjg_35c111a6-6ed8-42e0-a535-6fd9e9a87400"
      unitRef="usd">6667000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOS02LTEtMS0xMjY2Mjg_5340088d-8fe9-4977-94c2-1e5d9712e28e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i6004076cc7944a468953c8b1ff560f34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfOS04LTEtMS0xMjY2Mjg_b33674a3-049a-4d12-9d0b-657750f79dc7"
      unitRef="usd">27535000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i836abb9e08624532bd3983b006965c8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTAtMi0xLTEtMTI2NjI4_a1ca8097-e1f8-4f00-9fa7-92f583b72e61"
      unitRef="usd">25412000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i836abb9e08624532bd3983b006965c8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTAtNC0xLTEtMTI2NjI4_6d887b73-f66f-46b2-a3a7-eb2d6aad6966"
      unitRef="usd">39343000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i836abb9e08624532bd3983b006965c8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTAtNi0xLTEtMTI2NjI4_242dfc57-59a0-46fc-8aa9-7e158a483fe7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i836abb9e08624532bd3983b006965c8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTAtOC0xLTEtMTI2NjI4_5a722ed9-8482-4702-b8c4-05c12e5220df"
      unitRef="usd">64755000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTEtMi0xLTEtMTI2NjI4_8d691535-c54a-47e6-9531-bbc9f63c45f2"
      unitRef="usd">104711000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTEtNC0xLTEtMTI2NjI4_2ec68817-7ec4-4c33-882d-fe67c1fb51a8"
      unitRef="usd">93852000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTEtNi0xLTEtMTI2NjI4_0972d31c-3f66-4b87-bfe0-0252b6aacaaa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjljMWJiZjk3Zjg2MjQwZTY5NjE5OTZjOTE0ZWFlM2YxL3RhYmxlcmFuZ2U6OWMxYmJmOTdmODYyNDBlNjk2MTk5NmM5MTRlYWUzZjFfMTEtOC0xLTEtMTI2NjI4_bad522da-8592-4298-bae6-ef60a2304836"
      unitRef="usd">198563000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RleHRyZWdpb246ZGViNzQyOGExMGFkNGVlMDliOTZlZWRkMzE2ZjhhYjBfNDIxNQ_fe5ce4f8-c2a7-4aa5-bf3b-1ba2a68f4941">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the Company&#x2019;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of September 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i836132e570fa408799f2204a799b968a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNC0yLTEtMS0xMjY2Mjg_d49bc950-34fb-4ca8-8b23-9345594155e4"
      unitRef="usd">197901000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75847b6fd90245879f447b248c88a3c6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNC00LTEtMS0xMjY2Mjg_e2b55926-fd85-4837-bdeb-e4ab13b468c6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib63051c22ad4419daca3d275e18517da_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNC02LTEtMS0xMjY2Mjg_e15bd135-e19b-48b6-b0ec-9ae62aca550b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i743caf65823d4bd1958a8cbb299c0895_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNC04LTEtMS0xMjY2Mjg_82323a86-8248-4a2a-9fcb-c8d49eb833c5"
      unitRef="usd">197901000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i51799610f4064775a69dfb0cac87a703_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNi0yLTEtMS0xMjY2Mjg_aacd0840-b2f0-4195-a69d-b5e5a7ad1814"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if6bf0ff21f364dc0a684dbf075b53b37_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNi00LTEtMS0xMjY2Mjg_81fc82e1-971e-4ec4-bf20-927a6da3eef9"
      unitRef="usd">35899000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iae95464f5ee74284b6ae32d61d93ce73_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNi02LTEtMS0xMjY2Mjg_cc44c3bb-3730-4a26-aa0a-8ff181678258"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1af9878ff27e4d028b3550392083c7b2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfNi04LTEtMS0xMjY2Mjg_4a8af484-a95a-4ccb-a16a-d7af3bd94380"
      unitRef="usd">35899000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i79ea5826458e41d99aa352a497ffafd4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfOC0yLTEtMS0xMjY2Mjg_63a97300-fda6-4d45-b0ba-779472589bbf"
      unitRef="usd">51937000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i118589658cf34ed5b9ddf840fb4e46c8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfOC00LTEtMS0xMjY2Mjg_5bcbcdd6-0e39-4245-9a94-25657e0a72b0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i604eda05df5c4b31b29a38fc217c0cbb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfOC02LTEtMS0xMjY2Mjg_b49b4d31-de8b-40d9-909a-e6ae71590620"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i6936f18c703b4b55a0cdedf5a286c9e3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfOC04LTEtMS0xMjY2Mjg_ebcd697a-3006-4a0d-aec9-9608010a5d7e"
      unitRef="usd">51937000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i1bbc37daa8d04bef9ffd619049eca18d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTAtMi0xLTEtMTI2NjI4_f4e28cfc-fbdf-4205-9110-e93532613f82"
      unitRef="usd">8232000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ibf405aba888440c491e4e49e02bde83d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTAtNC0xLTEtMTI2NjI4_43ffc22a-f560-406d-adcd-c493206177e0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ie2698d44ba514d578ea6e059ae78c719_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTAtNi0xLTEtMTI2NjI4_f5ace403-1bf3-4b5f-a4a9-51cb50bd5549"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ibac99a06e90442119500a802935b5fc5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTAtOC0xLTEtMTI2NjI4_49da276a-1f68-48a9-a6d1-4161d0f59337"
      unitRef="usd">8232000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id067a8d27c5e4dde917550297727f471_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTEtMi0xLTEtMTI2NjI4_6344b2c6-7d37-47be-a6ed-766fa2b2194d"
      unitRef="usd">8743000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib8dbf4d41b6a462f9551daf656d6df24_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTEtNC0xLTEtMTI2NjI4_3afd3889-b45f-4a7d-ba62-5e222c1acc2c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i200b62a58197422faf0e93c36a17fcf2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTEtNi0xLTEtMTI2NjI4_bb165c3c-5417-46fb-bf7d-a535dd973ed7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id0f5e669517d4caf99147dede75e60cd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTEtOC0xLTEtMTI2NjI4_2d2e4e72-dcb4-4e6a-be03-ee1bca617318"
      unitRef="usd">8743000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ia425bc11b6e14936bb3bb334c3fcd38d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTItMi0xLTEtMTI2NjI4_bdc2603f-8da8-4984-a2ca-9b3b342ee504"
      unitRef="usd">11758000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib5eb1da66af64627bcc27ca09542053d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTItNC0xLTEtMTI2NjI4_798a94c9-9208-4e15-8370-6e47024c144e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib59406768d67448cb2b65eb67fed6dd0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTItNi0xLTEtMTI2NjI4_2d1d4efb-6a3f-4dcb-ab44-66edeaaf0e26"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i9dc03daff727488d8a6291b702771aaa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTItOC0xLTEtMTI2NjI4_3cb08f1a-48c4-4ccb-a9aa-93c6d61a760e"
      unitRef="usd">11758000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i3aa480d457354319b83badeb66ffb82a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTMtMi0xLTEtMTI2NjI4_7eb3afa4-d438-41bd-8dd4-a0a11659afe9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i9d0f765f52554a9c8dd28422846ea647_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTMtNC0xLTEtMTI2NjI4_ba74d2f1-975b-4e97-ba79-02a5f8251df5"
      unitRef="usd">6945000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i9e9885cc6a7e41a58d60dbb43b197069_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTMtNi0xLTEtMTI2NjI4_73a10434-c25d-4196-b289-55a8aa1beab8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="icf8cb448cee344b8bf8f9dd3f02aecf6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTMtOC0xLTEtMTI2NjI4_99dac6ba-9082-4958-9490-456240d72508"
      unitRef="usd">6945000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ie81bbebaf499410a8b2e96ff47a6f837_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTQtMi0xLTEtMTI2NjI4_4a61c0ac-f0c9-46c6-b14b-45bcb909d920"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ia10649a3764d48f99a112b7824cbe5ee_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTQtNC0xLTEtMTI2NjI4_e08b2b55-f262-4b87-b020-5dc2d9f6514a"
      unitRef="usd">29607000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iea910074ae8048cb9c2564fc116234c3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTQtNi0xLTEtMTI2NjI4_2042bedf-87a7-4e58-945a-1f570e63109a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ia2be2fd21f9148e0b393eeafdff75ecf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTQtOC0xLTEtMTI2NjI4_74275c9f-45ca-4a01-be18-adf9a4416a3e"
      unitRef="usd">29607000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ibf8ac5a2c2b446f397a0b928f822a84c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTUtMi0xLTEtMTI2NjI4_7573acfa-ff53-4a56-87c9-3651999196ed"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i3d7ac3af4f1f4aba835faf1dec1ae2d7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTUtNC0xLTEtMTI2NjI4_be2c7627-3abc-4634-9c6f-509dd096dacd"
      unitRef="usd">60192000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i7758f3fc5d2843889d3dccc581512940_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTUtNi0xLTEtMTI2NjI4_d92d1722-4fd6-4b13-a274-66a87cd4b936"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i18f5b2b00f414b6cb866b819f1811ee6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTUtOC0xLTEtMTI2NjI4_2b7e86a2-03df-47d0-bc57-fe97ce268578"
      unitRef="usd">60192000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecbb10c34a5e40a192afaea2596f4d4b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTYtMi0xLTEtMTI2NjI4_a04a4c75-77b9-43ad-b619-511d63f4a4b9"
      unitRef="usd">278571000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iea762de04e3247bd84d1cc134af37b04_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTYtNC0xLTEtMTI2NjI4_737e23f8-9a42-4981-8cd9-95ca0647fffe"
      unitRef="usd">132643000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3b3c9ac9f23540ddbfd3c2431b55c0cb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTYtNi0xLTEtMTI2NjI4_a8c00e2b-7ad4-4906-8f2b-96eb96e38d95"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iacdf3ffa20844c33b3b4b233621d3bda_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjVkZWFiYjRlNDRiNTRjYTFhMmIyYTE1YzRjNGFmNTZiL3RhYmxlcmFuZ2U6NWRlYWJiNGU0NGI1NGNhMWEyYjJhMTVjNGM0YWY1NmJfMTYtOC0xLTEtMTI2NjI4_c5ce32d9-9ca1-4865-95bf-9797364ca348"
      unitRef="usd">411214000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i12a6b55ac524499facd15cc496171051_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNC0yLTEtMS0xMjY2Mjg_18db9e58-4076-4098-b7ee-4309194d36f6"
      unitRef="usd">254157000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75652f68da664faa9631192fcc0b0756_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNC00LTEtMS0xMjY2Mjg_2ad6827f-377d-487d-a0b3-b8aea5713ad1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i542bc1cf4cff4dbf8c06c801299e4c0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNC02LTEtMS0xMjY2Mjg_27b190c8-fcd2-443f-9625-09302b9caf61"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i195050c8c9bc4002b86ccce162741c31_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNC04LTEtMS0xMjY2Mjg_2f848ced-e000-40ce-a2dc-e86f3a156b9b"
      unitRef="usd">254157000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if242353c50be44199306bd42b828c140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNi0yLTEtMS0xMjY2Mjg_a67f732f-08d1-49fb-b016-06c16ea96ec9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if8e94869d91d484ba640ce057070111e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNi00LTEtMS0xMjY2Mjg_d1377a5e-193c-4290-aed1-ec5b261a0b73"
      unitRef="usd">22491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic977ba257bc74ed0ac2c4dcf4afc8570_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNi02LTEtMS0xMjY2Mjg_b973be81-589e-4a52-8b5d-2303a838ac19"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9e8311a90b3b424cac6df4bef4c4fbdf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfNi04LTEtMS0xMjY2Mjg_059f7ce7-a248-4a6b-bb4a-cb38ddca349c"
      unitRef="usd">22491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i3004fdeeb1e74b4ca1d1b3699743ba6c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOC0yLTEtMS0xMjY2Mjg_625ba7ee-2123-4edc-bac6-d14e1064e6b5"
      unitRef="usd">52664000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i28d3e0ab7458409591d23b08216cb230_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOC00LTEtMS0xMjY2Mjg_79c5ce5f-3a25-4ae3-97a6-76a462e62b30"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i9a655c1539e343408dda30ab3e70fe06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOC02LTEtMS0xMjY2Mjg_adebf61b-0f7c-476b-8572-4ee9e5adbea5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i6b4e60329fa940689159d4dd319eb066_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOC04LTEtMS0xMjY2Mjg_ea5c0fd7-17c1-48f1-a745-9471f2019ba0"
      unitRef="usd">52664000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="idc756c44664b43f4b23fb38f1e93addd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOS0yLTEtMS0xMjY2Mjg_7b15da64-4807-43eb-ba98-40d2410e0750"
      unitRef="usd">6160000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i99e9f544c88447d2a59495913c96164d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOS00LTEtMS0xMjY2Mjg_056ad70f-411e-4d5a-a72b-9f789d7f59ac"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="idcc93136cd934c7ebd896d313b7290a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOS02LTEtMS0xMjY2Mjg_6e351b29-418f-416a-bb77-5ba471b2850f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i99c789341c8e4a58bd9ab39f1bf6644b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfOS04LTEtMS0xMjY2Mjg_ed12aedd-32c3-40a9-86a4-bbc5d8b7ef76"
      unitRef="usd">6160000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib5e98456b3d846289512b6de773624bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTAtMi0xLTEtMTI2NjI4_a2ac27cb-bfb5-4461-9856-82e7c633125a"
      unitRef="usd">17530000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iabe8bbfc732445e9aceeb47b5e0c3c5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTAtNC0xLTEtMTI2NjI4_056d8d3a-bfa0-438f-9a78-51ee1e815a78"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="idcc990a87d7a472183c3ef562e4fdfc4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTAtNi0xLTEtMTI2NjI4_c5576ac7-f9e6-40b0-ba1b-ad37a3d36244"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i5f5ddba725f1440e874eacac1370e4dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTAtOC0xLTEtMTI2NjI4_018ed82a-ce8e-4581-b2e4-95a8000efbaf"
      unitRef="usd">17530000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ibedaa1c912184478b0503bfd2e5d722b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTEtMi0xLTEtMTI2NjI4_7d7a8ec4-dbe2-45cc-9046-f659d1bfb81b"
      unitRef="usd">12229000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib2e72e0725a14c9ca1b8b6e1a39fc880_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTEtNC0xLTEtMTI2NjI4_75d684ae-1bc6-495a-83c8-e48d1c40f9f5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i4319725e3601450bad41434e87073ac6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTEtNi0xLTEtMTI2NjI4_b644bce8-2d87-497c-88ed-b39a55eaed83"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i4fbddcccd95b4981920388808f6beba8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTEtOC0xLTEtMTI2NjI4_ca55ee35-8e3d-4862-9d2c-7e44c1a0354f"
      unitRef="usd">12229000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i62f94087a2cb4149929f3d7ce3682734_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTItMi0xLTEtMTI2NjI4_38f26e58-8f0c-4dd4-be0b-728fbb92c47a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i105dd178cd01422fa6a4e525c0693dae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTItNC0xLTEtMTI2NjI4_13b6355c-f19b-42e8-9004-72c60c1fd426"
      unitRef="usd">17690000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i62854311ca47485eae6a22edb90202c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTItNi0xLTEtMTI2NjI4_29bec136-7073-47fc-95f0-6f7f21c093af"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ia6e5dd926f964588ba31f770c52749a9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTItOC0xLTEtMTI2NjI4_17dda7ac-271a-4fec-8ac0-ed222954d490"
      unitRef="usd">17690000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ia89899f69b9044c0a9086495bace3ae2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTMtMi0xLTEtMTI2NjI4_c53421b6-e931-487c-ba51-abe89f5c313f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i6f7167428b0340b584497251fb87718a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTMtNC0xLTEtMTI2NjI4_1e570515-8abe-4679-bfe3-e0adce8bdf8d"
      unitRef="usd">27535000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i321e7755d58a4125b1abe353704933f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTMtNi0xLTEtMTI2NjI4_46a1cdd5-6af7-4b43-9055-760532436d65"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i4822392b9ab44df6b413f0f3ac8e55be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTMtOC0xLTEtMTI2NjI4_3a77758e-7eaa-4daf-bb4f-19e3cfe57c6d"
      unitRef="usd">27535000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic0b09d8a7a9546a1bddda55ed781ae42_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTQtMi0xLTEtMTI2NjI4_2f0eb354-e4c9-4bf9-952a-18883e7a055d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ifb1d46b14a944988aae7942c987d7d5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTQtNC0xLTEtMTI2NjI4_98eb814d-b547-4a1e-8745-cddb07e62ef2"
      unitRef="usd">64755000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i4e4ee5f830e74fdc9b4bbb24f9d53418_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTQtNi0xLTEtMTI2NjI4_87b6f72e-1237-48f8-b671-7e0f6a731188"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i472970cdec304f53a5e8cd5cd075b4bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTQtOC0xLTEtMTI2NjI4_56774ec2-dad3-4394-84e5-fee14881d215"
      unitRef="usd">64755000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia93e0b2a1e3d464f8e6df2d0e9f52148_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTUtMi0xLTEtMTI2NjI4_d15e877c-008e-4a53-8143-121f19017520"
      unitRef="usd">342740000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib40d6f4a0a5143328f21dd179932836c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTUtNC0xLTEtMTI2NjI4_ff4a888b-8f7f-4f2f-aa7d-9ba4600cbcad"
      unitRef="usd">132471000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d9995d5167f4c7bb2a4f642fe88981d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTUtNi0xLTEtMTI2NjI4_a6cb99c5-42b4-4123-b127-3a32edcfddc5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i59e0361f10ac4f76b5eba47b82775cbb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF80Ni9mcmFnOmRlYjc0MjhhMTBhZDRlZTA5Yjk2ZWVkZDMxNmY4YWIwL3RhYmxlOjQ4NGRiNDZkNGFkYTRmNTg5OTdkYjIwZWQ2MDE1NjllL3RhYmxlcmFuZ2U6NDg0ZGI0NmQ0YWRhNGY1ODk5N2RiMjBlZDYwMTU2OWVfMTUtOC0xLTEtMTI2NjI4_99543ab2-9970-4e1b-9466-c8b7e41ab784"
      unitRef="usd">475211000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjI2_0edf7d94-71fb-4132-b688-2c300174f54e">Goodwill and Intangible Assets&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amounts of goodwill by segment at September 30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, we recorded a $4.3&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amortization expense within cost of revenue and general and administrative expense on the Consolidated Statement of Operations. The following table summarizes the amortization expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles included in cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles included in general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,649&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,911&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense related to amortizable intangible assets for each of the following periods as of September 30, 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjI3_5fb6ba84-d026-44aa-8d41-ce8dff5c8b53">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amounts of goodwill by segment at September 30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, we recorded a $4.3&#160;million decrease to goodwill and corresponding decrease to deferred income tax liabilities, net, on the Consolidated Balance Sheets to correct an immaterial error related to a prior period. The error was not material to any previously reported annual or interim consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i75670d9ce45547bc99a81d6754f3d28c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMS0xLTEtMS0xMjY2Mjg_7ea79b19-c5c4-446b-9439-333af23afce6"
      unitRef="usd">462603000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7ae39a4495a641b8aa5ccb48e1ae2a5b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMS0zLTEtMS0xMjY2Mjg_47d798e6-ff96-4311-9869-d0b1f1f7d9ec"
      unitRef="usd">64512000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMS01LTEtMS0xMzI0OTU_59e57e92-8b25-4ee1-884d-72c6536b5527"
      unitRef="usd">527115000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMi0xLTEtMS0xMjY2Mjg_14286854-8d6c-4d9f-88a3-2f6079972f3a"
      unitRef="usd">-3821000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMi0zLTEtMS0xMjY2Mjg_aa725a09-2f54-47e3-8137-6c4f2b723d67"
      unitRef="usd">-528000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMi01LTEtMS0xMzI0OTU_69eb0db8-fa6b-4bed-a0d9-270305a235ef"
      unitRef="usd">-4349000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="icb880a76146242968e6bfd45a3fcc254_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMy0xLTEtMS0xMjY2Mjg_3de8eeb3-e534-4e47-ae72-7ddc79c675ea"
      unitRef="usd">458782000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i98b823d3747b4ba79fe123db7bc136cb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMy0zLTEtMS0xMjY2Mjg_238ed0d5-c043-4eb8-85ae-559f7affec23"
      unitRef="usd">63984000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOmQyNTgzNTNiMzRlZjRjNjJhOTc1YTBkN2ExZTZhY2I0L3RhYmxlcmFuZ2U6ZDI1ODM1M2IzNGVmNGM2MmE5NzVhMGQ3YTFlNmFjYjRfMy01LTEtMS0xMzI0OTU_9f819c5a-8fcb-41ca-9f89-f51a90d3f6fb"
      unitRef="usd">522766000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i8a5deb5e1fe74f3abb44fdfda3d5722b_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfMTA5OTUxMTYzMDA4OQ_c8d2244d-959c-4fc6-8199-cc50cb66f35c"
      unitRef="usd">-4300000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjI5_e7c87311-23ef-4f96-81e4-3e355aba90b5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i549421f861aa49dc823adf1f4747dd6d_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjo2OTNiMWMwMGQwZjY0MWRiODIwM2Q0YTAxNmFkZTRmYl80_e07eb0e4-4f5a-4a85-a003-9b09b8c6ae32">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i79e1457052954b8b8b8d8d0bbe2ac708_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjo2OTNiMWMwMGQwZjY0MWRiODIwM2Q0YTAxNmFkZTRmYl85_d002fbe8-eb54-4616-8fcf-5d0c2d3cbe30">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3d4e012e5ff04c92ba9762ee777b5ee0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC00LTEtMS0xMjY2Mjg_8d1e48df-3383-49c5-8a69-a3d8b952192e"
      unitRef="usd">143101000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3d4e012e5ff04c92ba9762ee777b5ee0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC02LTEtMS0xMjY2Mjg_edd9b9fd-09fc-4897-a175-0f095037d05f"
      unitRef="usd">53172000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3d4e012e5ff04c92ba9762ee777b5ee0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNC04LTEtMS0xMjY2Mjg_6bf40eef-f768-49e8-b5fe-d6e22a7ae439"
      unitRef="usd">89929000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i797aec3fed494b6da15b5b1d78e7afaf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjo4Mzc5NzNiZTlhMGI0YThiOTgxODA0MzQ1N2IwNDE1YV80_e616d492-1a6a-42d1-9e24-e24ab0741b64">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie84a64cf52bf488aa8c4b5c32b37ab49_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjo4Mzc5NzNiZTlhMGI0YThiOTgxODA0MzQ1N2IwNDE1YV85_a387bf9e-d6e6-4a82-ba0a-5e8bac4da138">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idfd5d3b7d14541ccb4c98224679c859c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS00LTEtMS0xMjY2Mjg_a7b52449-cb4e-498f-ada4-ce5da131ec47"
      unitRef="usd">310226000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idfd5d3b7d14541ccb4c98224679c859c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS02LTEtMS0xMjY2Mjg_76afb3cc-98a0-41ca-b7fd-ade6334f5625"
      unitRef="usd">27787000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idfd5d3b7d14541ccb4c98224679c859c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNS04LTEtMS0xMjY2Mjg_da96f2af-70f4-4cb9-96a7-54299336fea4"
      unitRef="usd">282439000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1ac8a4996bb34043b19229ddcdd8fcf5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNi0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjpkYzdiZDA5ZjI2ZWI0ZTM4YjliOWM3Y2Q1OWFkNmI5YV80_f1440b6a-4dd7-4030-8a9b-82218aac7bde">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibfbdc2914bf44ebf9369d82276e58d62_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNi00LTEtMS0xMjY2Mjg_09bd4642-6e34-4921-8108-2d89c643bb6a"
      unitRef="usd">549000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibfbdc2914bf44ebf9369d82276e58d62_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNi02LTEtMS0xMjY2Mjg_f2f4926d-518e-4f42-81a1-d3246c973ff5"
      unitRef="usd">204000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibfbdc2914bf44ebf9369d82276e58d62_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNi04LTEtMS0xMjY2Mjg_6900a2ba-1c65-49eb-9aaf-9d687e5f8674"
      unitRef="usd">345000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i106e8545ca314dd797829120c72a1131_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNy0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoyMGY5M2Y4ODMwNzQ0ZDU4YjI2ZjcxZDA1NDFjZTRiN180_4bfc326d-3642-4380-b19f-51c75a84603d">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idede4c70818e4ec8b5e2e8f0405ddf00_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNy00LTEtMS0xMjY2Mjg_78140d47-27c4-45fe-b10b-fe1bb519ad9c"
      unitRef="usd">31473000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idede4c70818e4ec8b5e2e8f0405ddf00_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNy02LTEtMS0xMjY2Mjg_6fc05ee4-cb46-47f6-b6c0-6dea5ef31628"
      unitRef="usd">2699000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idede4c70818e4ec8b5e2e8f0405ddf00_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfNy04LTEtMS0xMjY2Mjg_075896ce-67ed-4c97-8df0-c25c16355e63"
      unitRef="usd">28774000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i361720e05c8e458d9eda92fc5388b6e8_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOC0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjpiNzZkYmQxN2E5MWM0NzVjODM0YzI0ZTdiNmUwNjk3Nl80_eec72bdb-be3e-4890-929a-c00b439b77ce">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6ef158959bfb4e7f9623bff4b4a573cb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOC00LTEtMS0xMjY2Mjg_b85a1b4e-3a96-4f1e-88fb-dca4f2b6ff2a"
      unitRef="usd">2584000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6ef158959bfb4e7f9623bff4b4a573cb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOC02LTEtMS0xMjY2Mjg_b387ee7c-6350-42c1-b2d7-0f193f711cdf"
      unitRef="usd">670000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6ef158959bfb4e7f9623bff4b4a573cb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOC04LTEtMS0xMjY2Mjg_967f00c5-cb8a-4610-8e1f-33eaeefc403f"
      unitRef="usd">1914000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib216f20bf24c458d809516016332ecd5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOS00LTEtMS0xMjY2Mjg_81c7ec18-9774-4c91-b80f-251feb06b136"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib216f20bf24c458d809516016332ecd5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfOS04LTEtMS0xMjY2Mjg_52ba6073-3ec3-41b2-9ba8-31d24e9d58d0"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfMTAtNC0xLTEtMTI2NjI4_c3eb874a-287a-4a90-9d14-689ca886e5cb"
      unitRef="usd">501380000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfMTAtNi0xLTEtMTI2NjI4_19831e19-4c00-4190-ba54-ab4ea64d2e8c"
      unitRef="usd">84532000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjg0NTRiMWFjNTZiNzQxM2M5NTlmNDc3NjYwYzdjMjFmL3RhYmxlcmFuZ2U6ODQ1NGIxYWM1NmI3NDEzYzk1OWY0Nzc2NjBjN2MyMWZfMTAtOC0xLTEtMTI2NjI4_4fa410fd-34d5-44db-85dc-03e1209c9dfa"
      unitRef="usd">416848000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ifd6c3992b5294ed89c00bb7e4387a2ff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjplNjdmNzExYjNhMWQ0M2UyYTU5YmZlYmQxOTRkMWM4Y180_e1f8fe5f-8e76-41c2-bb20-848909051ce4">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib759ebff98dd441ca6275338c855db76_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjplNjdmNzExYjNhMWQ0M2UyYTU5YmZlYmQxOTRkMWM4Y185_9bf72115-254f-4f84-aa0b-a29d33b3c48f">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id1e053abf65147d29a5dd6a6ac867b9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi00LTEtMS0xMjY2Mjg_5a663323-0c5a-4023-803e-9bd2444dd429"
      unitRef="usd">143101000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id1e053abf65147d29a5dd6a6ac867b9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi02LTEtMS0xMjY2Mjg_f565c846-81fd-4b91-aeb9-3b7f96faa918"
      unitRef="usd">45756000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id1e053abf65147d29a5dd6a6ac867b9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMi04LTEtMS0xMjY2Mjg_723b078d-5fce-415b-b4b6-a7de0cf247ac"
      unitRef="usd">97345000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="idd8360c0431e46e48e0c165b0287f029_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjphZDdkNzM2ODZlNzE0YmRkYWY4NmRjYmIxNjY1MTY1Ml80_cec7dbb9-a4a7-420b-84c5-ebdb69387e4e">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i19cd4a991b204018b122a75e5768a87f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy0yLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjphZDdkNzM2ODZlNzE0YmRkYWY4NmRjYmIxNjY1MTY1Ml85_e9d40ede-d6f6-4a5d-8bb0-7dc8242717cd">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6c8ecbf116e841a9b4dfffda832ac632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy00LTEtMS0xMjY2Mjg_9b8f6f67-6177-42dc-bc14-e246a79673ca"
      unitRef="usd">310226000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6c8ecbf116e841a9b4dfffda832ac632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy02LTEtMS0xMjY2Mjg_503f5d41-bd96-4935-b90f-2c6bb4d066b6"
      unitRef="usd">11798000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6c8ecbf116e841a9b4dfffda832ac632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfMy04LTEtMS0xMjY2Mjg_0815cad9-a58c-40bb-9b1b-294258c52e88"
      unitRef="usd">298428000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic0b5bb4b553741e0bed88b54c12490b9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNC0yLTEtMS0xMjY2Mjg_e5b8983c-9f5d-4e49-8f93-f273df680f16">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i240234cbd1b048a88a80ecfb7db9b243_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNC00LTEtMS0xMjY2Mjg_ff684808-741b-40ed-a010-2c09f7ab38e6"
      unitRef="usd">549000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i240234cbd1b048a88a80ecfb7db9b243_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNC02LTEtMS0xMjY2Mjg_8872021f-f05d-4231-8bc3-c76d74ad823c"
      unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i240234cbd1b048a88a80ecfb7db9b243_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNC04LTEtMS0xMjY2Mjg_e0f63a80-0e50-4fa9-8c3a-1a8ff4bba5d8"
      unitRef="usd">449000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if9cf7af964324575b1e90a208499969a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNS0yLTEtMS0xMjY2Mjg_6db8dd58-3658-4abb-9f1c-d7d9e4220962">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia2acb703fa2e4b3d8f2adf8f1ccf8251_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNS00LTEtMS0xMjY2Mjg_b853a09b-fe97-4b0b-8d4f-6d0c04ae42a8"
      unitRef="usd">31473000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia2acb703fa2e4b3d8f2adf8f1ccf8251_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNS02LTEtMS0xMjY2Mjg_bfb1825d-8294-4a08-8990-b7e73a146074"
      unitRef="usd">1125000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia2acb703fa2e4b3d8f2adf8f1ccf8251_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNS04LTEtMS0xMjY2Mjg_c9ce8b52-f493-4c3c-a595-b7a19c38d487"
      unitRef="usd">30348000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7474ff176c7846c0acef3250e51c454e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNi0yLTEtMS0xMjY2Mjg_9e686c45-ac4d-476d-82de-cb3cd1eb76d0">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1287835862df47c8bc96b7ec0def19bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNi00LTEtMS0xMjY2Mjg_79a4d75b-853e-429b-953f-29f8ff036777"
      unitRef="usd">2584000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1287835862df47c8bc96b7ec0def19bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNi02LTEtMS0xMjY2Mjg_5229b6d3-8ef7-4076-aed9-eb4de722e92f"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1287835862df47c8bc96b7ec0def19bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNi04LTEtMS0xMjY2Mjg_a93dc951-63cd-4ffc-9b4e-6bba0cce3d15"
      unitRef="usd">2308000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iad4649c38cd34257bb5c56cd8d83cd45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNy00LTEtMS0xMjY2Mjg_00d2dd70-2505-484b-b7f9-8084c4c02d44"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iad4649c38cd34257bb5c56cd8d83cd45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfNy04LTEtMS0xMjY2Mjg_d68ecf0b-01df-4287-b968-aea03623115a"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfOC00LTEtMS0xMjY2Mjg_69da2d62-ced3-41cf-8001-55ea1efbc8c7"
      unitRef="usd">501380000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfOC02LTEtMS0xMjY2Mjg_d7141966-60de-4576-acbc-0aa967c9a1b0"
      unitRef="usd">59055000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAzZGIxYWU5MzdlNjQ5NmFhODQxMTY2ODY3NGEzYjkzL3RhYmxlcmFuZ2U6MDNkYjFhZTkzN2U2NDk2YWE4NDExNjY4Njc0YTNiOTNfOC04LTEtMS0xMjY2Mjg_860d8373-f0e7-48c7-91ef-0a0ee6c7f6e5"
      unitRef="usd">442325000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <neo:ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjMw_ae767995-6430-4a17-a317-8bb6caa2b719">The following table summarizes the amortization expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles included in cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles included in general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,649&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,911&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</neo:ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i56e071a65fde4540a8f2f69263d43769_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMi0yLTEtMS0xMjY2Mjg_b37323cc-f092-4486-958f-61f78a22d09f"
      unitRef="usd">4853000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic77b4f7ab7454a149dc9bb68b7337a50_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMi00LTEtMS0xMjY2Mjg_8d22955b-c040-408a-9cf0-77ef5bbc2eb6"
      unitRef="usd">4825000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifac78e36d8f94115b39886bb71273081_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMi02LTEtMS0xMjY2Mjg_76a0af93-b8ab-475d-a2e0-f5b9b1fb06f6"
      unitRef="usd">14559000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4ac44e2ebca3469bb5add1f5bc673f54_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMi04LTEtMS0xMjY2Mjg_0758480a-f6f5-4827-ae18-31759da58a09"
      unitRef="usd">5554000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8950ddf7dc73426abd2e59bb9e3428cd_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMy0yLTEtMS0xMjY2Mjg_198f9bd3-4ded-4016-94bc-fa7888d518a4"
      unitRef="usd">3637000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2b5b9002c6c54807843802a2269d680c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMy00LTEtMS0xMjY2Mjg_3fd32613-fed4-42e7-af44-ba706dfeac85"
      unitRef="usd">3649000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i985788d5c071467d85f2f33e2f2e2fe3_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMy02LTEtMS0xMjY2Mjg_1dab857c-adfa-48e1-bacb-2c5aea07cce3"
      unitRef="usd">10911000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i613c8ef800af4acbb247578aff04da3d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfMy04LTEtMS0xMjY2Mjg_9fc73013-53bb-4cd8-8167-3c384627a6b4"
      unitRef="usd">9129000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfNC0yLTEtMS0xMjY2Mjg_4cf4d426-5767-41da-bace-c778d4f97764"
      unitRef="usd">8490000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfNC00LTEtMS0xMjY2Mjg_5103bfae-77bd-4c7b-acd6-e42bbb595df5"
      unitRef="usd">8474000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfNC02LTEtMS0xMjY2Mjg_225b3602-4347-445b-b40c-9cf5056da81b"
      unitRef="usd">25470000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjE0MDdiNDBhZjU4YTQ4MWQ5ZmEyODZlMzJjNDNhZmRkL3RhYmxlcmFuZ2U6MTQwN2I0MGFmNThhNDgxZDlmYTI4NmUzMmM0M2FmZGRfNC04LTEtMS0xMjY2Mjg_9fc79694-3a1b-40b5-9111-d7aaeb8c5cf1"
      unitRef="usd">14683000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RleHRyZWdpb246N2YzYWJkMmNmMzY4NDQ5YjlmMTcwZWY5OWE2Y2ZkZTdfNjI1_d8b48d99-6448-4fa1-8cf4-f10c782eaa1b">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense related to amortizable intangible assets for each of the following periods as of September 30, 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfMC0xLTEtMS0xMjY2Mjg_5700a991-6c3b-49ab-abd6-5ec70a02a8c5"
      unitRef="usd">8490000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfMS0xLTEtMS0xMjY2Mjg_a2296f66-9b90-4506-b113-99d5e038cf6e"
      unitRef="usd">33962000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfMi0xLTEtMS0xMjY2Mjg_cccac90e-9074-4adb-8034-d6d2be95741d"
      unitRef="usd">33961000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfMy0xLTEtMS0xMjY2Mjg_9186ff62-55f9-4fb5-af67-8aa61cd06da2"
      unitRef="usd">33858000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfNC0xLTEtMS0xMjY2Mjg_26268379-9692-42ba-884e-9a4e163e68f5"
      unitRef="usd">33547000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <neo:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfNi0xLTEtMS0xMjY2Mjg_6a2f56b1-a9d3-45b5-ab1f-cf347619db0b"
      unitRef="usd">259583000</neo:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81Mi9mcmFnOjdmM2FiZDJjZjM2ODQ0OWI5ZjE3MGVmOTlhNmNmZGU3L3RhYmxlOjAyZjNiZjkwY2Q5ZjQxM2Y4Y2Y3YTUzODRlMzEyOTdlL3RhYmxlcmFuZ2U6MDJmM2JmOTBjZDlmNDEzZjhjZjdhNTM4NGUzMTI5N2VfNy0xLTEtMS0xMjY2Mjg_146bc85a-32a6-44c6-9e62-aadf6398c749"
      unitRef="usd">403401000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTU0MQ_0b99d3cc-3c02-4dec-87fb-7c0a210a44fa">Debt&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;2028 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2021, the Company completed the sale of $345.0&#160;million of Convertible Senior Notes with a stated interest rate of 0.25% and a maturity date of January 15, 2028 (the &#x201c;2028 Convertible Notes&#x201d;), unless earlier converted, redeemed, or repurchased.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended June 30, 2022. Based on the terms of the 2028 Convertible Notes, the holders could not have converted all or a portion of their 2028 Convertible Notes in the third quarter of 2022. The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended September 30, 2022. Based on the terms of the 2028 Convertible Notes, the holders cannot convert all or a portion of their 2028 Convertible Notes in the fourth quarter of 2022. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $8.61 on September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized on the 2028 Convertible Notes includes $0.2&#160;million, $0.4&#160;million and $8,500 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2022. The interest expense recognized on the 2028 Convertible Notes includes $0.7&#160;million, $1.1&#160;million and $25,300 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2022. The interest expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized on the 2028 Convertible Notes includes $0.2&#160;million, $0.4&#160;million and $8,400 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2021. The interest expense recognized on the 2028 Convertible Notes includes $0.6&#160;million, $1.0&#160;million and $23,700 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2021. The effective interest rate on the 2028 Convertible Notes is 0.70%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of 0.25% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2022, the estimated fair values (Level 2) of the 0.25% Convertible Senior Notes due 2028 was $217.4&#160;million. At December 31, 2021, the estimated fair value (Level 2) of the 0.25% Convertible Senior Notes due 2028 was $297.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;2025 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2020, the Company completed the sale of $201.3&#160;million of Convertible Senior Notes with a stated interest rate of 1.25% and a maturity date of May 1, 2025 (the &#x201c;2025 Convertible Notes&#x201d;), unless earlier converted, redeemed, or repurchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended June 30, 2022. Based on the terms of the 2025 Convertible Notes, the holders could not have converted all or a portion of their 2025 Convertible Notes in the third quarter of 2022. The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended September 30, 2022. Based on the terms of the 2025 Convertible Notes, the holders cannot convert all or a portion of their 2025 Convertible Notes in the fourth quarter of 2022. The value of the 2025 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $8.61 on September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized on the 2025 Convertible Notes includes $0.6&#160;million, $0.3&#160;million and $37,200 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2022. The interest expense recognized on the 2025 Convertible Notes includes $1.9&#160;million, $0.9&#160;million and $0.1&#160;million for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2022. The interest expense recognized on the 2025 Convertible Notes includes $0.6&#160;million, $0.3&#160;million and $36,500 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2021. The interest expense recognized on the 2025 Convertible Notes includes $1.9&#160;million, $0.9&#160;million and $0.1&#160;million for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2021. The effective interest rate on the 2025 Convertible Notes is 1.96%, which includes the interest on the 2025 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2025 Convertible Notes bear interest at a rate of 1.25% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, which began on November 1, 2020.&lt;/span&gt;&lt;/div&gt;At September 30, 2022, the estimated fair values (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $171.1&#160;million. At December 31, 2021, the estimated fair value (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $238.9&#160;million.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2e078001d1454b3cbc7f7d7b83568f2e_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTA0_008ac48d-abed-477f-a424-e4d1217eeacc"
      unitRef="usd">345000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e078001d1454b3cbc7f7d7b83568f2e_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTY2_11476341-951e-40c4-b326-d7a007d96a59"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzg2_696b8471-2274-4743-b64f-0a7c467d2d10"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDU1_85743f2d-8a47-44c0-996a-546d1dfccd8f"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDcw_e83c119a-67a1-4f84-a049-8e774be41014"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNzk1_63573127-89bf-44b4-8107-7754152e2709"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjE5OTAyMzI2MTY1Nw_3e2252e6-5ec9-4140-8e44-786bc48a266b"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjE5OTAyMzI2MTY2MQ_563cd2a4-c376-4a41-a804-08c6b5d173c9"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i7e9577a5d34442988876254f1f4de500_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjM2NQ_aa42a5dc-cd0a-4115-bede-13b34ab4f703"
      unitRef="usdPerShare">8.61</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i09ab64c3de5a4744a9608181e3687f96_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTMwNg_e45575a9-f151-4957-be72-649981d8fb91"
      unitRef="usd">200000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i09ab64c3de5a4744a9608181e3687f96_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTMxMA_502ea91a-1d0d-415d-8088-a5bd0ac19c10"
      unitRef="usd">400000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i09ab64c3de5a4744a9608181e3687f96_D20220701-20220930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTMxNw_0d09b64a-4825-4898-a859-59dd9408b78f"
      unitRef="usd">8500</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTU2MA_e4efd3e0-8f81-41c0-9a4e-aa0c5f66e228"
      unitRef="usd">700000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTU2NA_be0bd2dc-f739-4672-88a3-12ef8f52f97d"
      unitRef="usd">1100000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTU3MQ_bca77a08-d949-4ac0-9a22-fea3f1841ef3"
      unitRef="usd">25300</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="ie2b7a7f93dbb4b1ca8195ad0d4023f57_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTgxMQ_383a40a6-c830-495a-9ec1-4dcdcaa75b59"
      unitRef="usd">200000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="ie2b7a7f93dbb4b1ca8195ad0d4023f57_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjM1MQ_3025c639-1e9a-4dc8-be27-c37c710c1d87"
      unitRef="usd">400000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="ie2b7a7f93dbb4b1ca8195ad0d4023f57_D20210701-20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTgyMg_896ba063-338c-4b58-98f4-05d9b50dc9fa"
      unitRef="usd">8400</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i6cf3c51ab90a4a2898937c535e682135_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjQ2OA_c1742ef6-8e0f-4f82-8ed2-c7b8f1dff48b"
      unitRef="usd">600000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i6cf3c51ab90a4a2898937c535e682135_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjQ4Mg_6528ea08-fe42-4def-92d3-7691324a0e32"
      unitRef="usd">1000000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i6cf3c51ab90a4a2898937c535e682135_D20210101-20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjQ5Ng_52122e2d-d31e-42c2-8ef5-34c48c65a120"
      unitRef="usd">23700</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i7841c499ba774fcaa4bc3d8111f44411_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjMwNg_58d5f3f8-6ace-4150-b40d-b167f97e1035"
      unitRef="number">0.0070</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e9577a5d34442988876254f1f4de500_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjQ4NQ_25b43761-d1a1-471d-aaff-fe081b95bb23"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e9577a5d34442988876254f1f4de500_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjY1MA_0bd62494-9e38-4e53-931b-9912ba2a18eb"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ibf48e559e728411498f7b81a86313e8e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjY5MQ_6dd907cd-5856-40ac-bad6-9a09b9b83787"
      unitRef="usd">217400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie5639e39468f41488a1252639d4ef0c1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTA5OTUxMTYzMzMyNQ_ace924fe-787a-47a6-a0f3-152de2d1fe57"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i766de052b6724a39ac4cff4bcdcc1a5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjc4NQ_a7b01116-be8a-47e8-8387-88be483955f7"
      unitRef="usd">297600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib8696c4831ac447f91dae99b16f092c2_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjg2OQ_2eaed371-8fdf-4005-abde-e07ac46a94e6"
      unitRef="usd">201300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib8696c4831ac447f91dae99b16f092c2_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMjkzMQ_6469d668-4f93-443b-b928-db947b998c9f"
      unitRef="rate">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzE0Nw_02dab045-44b8-4ee0-9855-6797ba44ced4"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzIxNg_7b2c8aba-3832-43fb-8a2e-9b219b8ecad3"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i90b7c04e82d44a5c98f077bce868a14c_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzIzMQ_3ff12317-df7c-43d2-b659-6663073aa477"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzU1NQ_d21353b4-63d6-4e7a-8e71-953e42954941"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzYyNA_4d769948-314b-4d52-a1c5-c557486e2e33"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ic1be8c04b2604bbbbfb1325911ab5351_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMzYzOQ_9c33464e-630f-43ae-85b9-d9f79078f646"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ied71922b6fb843699775ee25dc037112_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTA5OTUxMTYzMzg5NQ_ba67998c-a4f7-4a84-837b-6bbf7f3002be"
      unitRef="usdPerShare">8.61</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="ia865031156044a7dbb6c87daac4c70d7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDA1NQ_632b796d-dd55-4c6b-9570-2fb05ef1288f"
      unitRef="usd">600000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="ia865031156044a7dbb6c87daac4c70d7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDA1OQ_7732e983-07f1-42f0-bc8f-9211eac865e7"
      unitRef="usd">300000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="ia865031156044a7dbb6c87daac4c70d7_D20220701-20220930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDA2Ng_a5aa7a65-39c0-4635-860d-9fe20a105f22"
      unitRef="usd">37200</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDMwOQ_ce802196-674f-4bc0-94e7-c8d33ac2d4c4"
      unitRef="usd">1900000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDMxMw_19e8034b-29a2-4a89-80a9-26eb51d95748"
      unitRef="usd">900000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNDMyMA_76bcb89b-c42a-4c0c-909f-b9697590754a"
      unitRef="usd">100000</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i5ca9c808340f4bfcb031c666d2d97909_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjYyMg_4a230e5e-d82b-4978-ae12-dc6cb984735b"
      unitRef="usd">600000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i5ca9c808340f4bfcb031c666d2d97909_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjYzNg_89200620-b4a1-4005-9126-84c22a314f94"
      unitRef="usd">300000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i5ca9c808340f4bfcb031c666d2d97909_D20210701-20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjY1MA_bdfd6e5c-dd32-4b0e-8cf0-31cd544bdf3c"
      unitRef="usd">36500</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i1edd2c29bc214bb28b0e32e7fd84ca23_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjcxOA_1215688a-7c7c-49c2-bafa-3304576a225e"
      unitRef="usd">1900000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i1edd2c29bc214bb28b0e32e7fd84ca23_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3MjczMg_82bb63f1-4bf4-4525-9cb0-dc5c8c502caa"
      unitRef="usd">900000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i1edd2c29bc214bb28b0e32e7fd84ca23_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNjU5NzA2OTc3Mjc0Ng_4184032b-6e96-4f21-90e1-904fa8d23428"
      unitRef="usd">100000</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i83c0920a4d824897a44e365ebe3dee01_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTA1NQ_24327bcd-48b9-4e93-8440-a8491a1faa0f"
      unitRef="number">0.0196</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ied71922b6fb843699775ee25dc037112_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTIzNA_9116bc40-13b7-4610-b5dd-bdcbd00a3a28"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ied71922b6fb843699775ee25dc037112_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTQwMg_9d46d718-5706-417e-bd5a-9241f42db5a4"
      unitRef="rate">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5cc7c64aab7049d8bf4e97fd24d8055d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTQ0Mw_a9635228-8eb9-47cd-bc08-f9b71a2816a2"
      unitRef="usd">171100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8dfff7d2e5c04e57a4f8de1a51fac23f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfMTA5OTUxMTYzMzMzOA_796fd56f-465e-469f-8ab6-3e97e03d24a4"
      unitRef="rate">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i2582f1fdaa5d4fd58b8edb349ee79064_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF81OC9mcmFnOjJjMzA0MWVmY2Y1YzQ2ZDlhZGI0ZGM2ODE0NTc5YzExL3RleHRyZWdpb246MmMzMDQxZWZjZjVjNDZkOWFkYjRkYzY4MTQ1NzljMTFfNTUzNw_60803a75-8304-42d1-98ee-bb0ddca1a1e7"
      unitRef="usd">238900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjczNA_6668be74-a656-462f-85e1-a8ba0a7e56fb">Stock-Based Compensation&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded approximately $4.3 million and $5.2 million for stock-based compensation in general and administrative expenses &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the Consolidated Statements of Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the three months ended September 30, 2022 and 2021, respectively, and approximately $20.0 million and $12.4 million for the nine months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company&#x2019;s plans for the nine months ended September 30, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,961,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,849,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,247,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award granted during the nine months ended September 30, 2022 was estimated as of the grant date using a Black-Scholes model with the following assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 - 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 3.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, there was approximately $14.8 million of unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of approximately 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted stock activity under the Company&#x2019;s plans for the nine months ended September 30, 2022 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Restricted&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,477,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(311,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,022,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, there was approximately $19.8&#160;million of unrecognized stock-based compensation expense related to restricted stock that will be recognized over a weighted-average period of approximately 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Modification of Stock Option and Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2022, upon the Chief Legal Officer&#x2019;s departure from the Company and in accordance with the terms of the Chief Legal Officer&#x2019;s employment agreement, 41,487 previously granted time-based vesting stock option awards and 76,138 previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $2.2 million of incremental stock-based compensation which consisted of $0.3 million and $1.9 million for the acceleration of stock option awards and restricted stock &lt;/span&gt;&lt;/div&gt;awards, respectively, within general and administrative expenses on the Consolidated Statements of Operations for the nine months ended September 30, 2022. There were no such amounts for the three months ended September 30, 2022. In the first quarter of 2022, upon the Chief Executive Officer&#x2019;s departure from the Company and in accordance with the terms of the Chief Executive Officer&#x2019;s separation agreement, 237,960 previously granted time-based vesting stock option awards and 142,302 previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $5.9 million of incremental stock-based compensation which consisted of $2.3 million and $3.6 million for the acceleration of stock option awards and restricted stock awards, respectively, within general and administrative expenses on the Consolidated Statements of Operations for the nine months ended September 30, 2022. There were no such amounts for the three months ended September 30, 2022.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfNzM_b372c9c6-2549-48a1-9adf-0482b217daee"
      unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfODA_b52f60be-f358-482c-9a47-c71d3b59ac6f"
      unitRef="usd">5200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjY2_e8b6edc9-c709-44e8-894c-74c0167362e1"
      unitRef="usd">20000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjcz_27fe82bd-9c26-4b65-a721-653d46ba4fe6"
      unitRef="usd">12400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjczNQ_26b3606f-af08-4d35-ab9d-adef1d1b6823">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company&#x2019;s plans for the nine months ended September 30, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,961,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,849,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,247,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfMS0yLTEtMS0xMjY2Mjg_5e33e973-b164-4678-8691-bf4d951d279b"
      unitRef="shares">2961195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfMS00LTEtMS0xMjY2Mjg_1d9bec14-9fcd-42f0-a891-56643ef5ef2b"
      unitRef="usdPerShare">25.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfMi0yLTEtMS0xMjY2Mjg_c8ee9190-bf51-48f4-a3a9-857de6b5190f"
      unitRef="shares">3849603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfMi00LTEtMS0xMjY2Mjg_e583f629-c29d-447f-bb8c-5d7b1680609b"
      unitRef="usdPerShare">14.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNC0yLTEtMS0xMjY2Mjg_6d343e12-0280-4e26-bd9e-cc8a75862912"
      unitRef="shares">804555</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNC00LTEtMS0xMjY2Mjg_8cc03ed2-72d0-4c44-a546-125122ce9c46"
      unitRef="usdPerShare">11.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNS0yLTEtMS0xMjY2Mjg_aa1fe4c3-606d-4fdf-95c1-4321f9004832"
      unitRef="shares">1758886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNS00LTEtMS0xMjY2Mjg_464c54b3-07d4-4aae-a788-b909b49f4169"
      unitRef="usdPerShare">28.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNi0yLTEtMS0xMjY2Mjg_c08256d3-71dd-4fad-a57d-19a260fb31f0"
      unitRef="shares">4247357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNi00LTEtMS0xMjY2Mjg_f930fe95-3ad5-4ae3-b514-b824affdc778"
      unitRef="usdPerShare">17.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNy0yLTEtMS0xMjY2Mjg_41a3670d-a630-4323-8a2f-cf65aad12925"
      unitRef="shares">1019075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc0MTM3OWUwOWNiYjRiODg4NjM4ZDE1ZDQwZjA5Yjg0L3RhYmxlcmFuZ2U6NzQxMzc5ZTA5Y2JiNGI4ODg2MzhkMTVkNDBmMDliODRfNy00LTEtMS0xMjY2Mjg_b018aaf8-518d-4fde-a6f6-d38a036faf28"
      unitRef="usdPerShare">24.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjczNg_db61b4e9-0903-4528-bc17-328df55477fe">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award granted during the nine months ended September 30, 2022 was estimated as of the grant date using a Black-Scholes model with the following assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 - 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 3.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i23b5d383d9e84db6b635cdcd0c0f9d95_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMS0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoxMWU4YzU4NDYxY2Y0ZjA1YTQwZTAzODNlOGQxNTY1OV80_2f8c618f-85d6-4ceb-b2fb-14efb8154935">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i62713aa84dd049d68dc66b6a1fe200e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMS0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoxMWU4YzU4NDYxY2Y0ZjA1YTQwZTAzODNlOGQxNTY1OV85_37d3858b-495d-41c1-85f0-68b3586005fb">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i23b5d383d9e84db6b635cdcd0c0f9d95_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMi0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoyMzVlZDM0MTc3YWM0MGJlOTUxZjAyYTk2YjRjMTU3YV83MTQ2ODI1NTgwNTQ4_b90d5278-5591-439e-83b5-a29fe753c92b"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i62713aa84dd049d68dc66b6a1fe200e6_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMi0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjoyMzVlZDM0MTc3YWM0MGJlOTUxZjAyYTk2YjRjMTU3YV83MTQ2ODI1NTgwNTU0_00368dc2-f9ef-4c4b-88ad-6d9f9ce25e1c"
      unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i23b5d383d9e84db6b635cdcd0c0f9d95_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMy0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjozODBjZGEwOGQzMjc0M2Y2YWY4YTAwZDYwMDlkMmViN180_ba2aea4d-5846-4295-81d1-ca7fa69d8ea3"
      unitRef="number">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i62713aa84dd049d68dc66b6a1fe200e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfMy0xLTEtMS0xMjY2MjgvdGV4dHJlZ2lvbjozODBjZGEwOGQzMjc0M2Y2YWY4YTAwZDYwMDlkMmViN185_0988f48a-9cd4-49fe-a730-b377769c7624"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfNC0xLTEtMS0xMjY2Mjg_8c41a856-a597-42ef-af55-7f743d25f864"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjc2YjU1ZWEzMTAyNTRlM2ViNjQzYzllNWEyNjIxZDMyL3RhYmxlcmFuZ2U6NzZiNTVlYTMxMDI1NGUzZWI2NDNjOWU1YTI2MjFkMzJfNS0xLTEtMS0xMjY2Mjg_dbf00ba2-871c-4656-8251-7c95b8477762"
      unitRef="usdPerShare">6.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfNjc4_bc0bee19-0b62-45d7-b000-66f8cb6fcc4e"
      unitRef="usd">14800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfODI3_d597099b-7973-4fa5-a9fa-975da891fbfc">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjczMg_cad5753d-1824-4ed2-a38f-d38f0a4ea282">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted stock activity under the Company&#x2019;s plans for the nine months ended September 30, 2022 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Restricted&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,477,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(311,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,022,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id36af2f403f24cf7b4525fc88fa61cb6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMS0yLTEtMS0xMjY2Mjg_c456645c-1abb-4176-a34b-d1d2b9fe1785"
      unitRef="shares">851403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id36af2f403f24cf7b4525fc88fa61cb6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMS00LTEtMS0xMjY2Mjg_29180fcf-8b6c-4d7a-baf4-e41fcd760212"
      unitRef="usdPerShare">36.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMi0yLTEtMS0xMjY2Mjg_eb36217b-8864-4370-b371-fffe7a9087df"
      unitRef="shares">2477418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMi00LTEtMS0xMjY2Mjg_de029c86-626a-456b-b308-0f9a5edc7dd2"
      unitRef="usdPerShare">14.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMy0yLTEtMS0xMjY2Mjg_bc2feba8-9c89-49bc-84f4-cf472408c1a2"
      unitRef="shares">311055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfMy00LTEtMS0xMjY2Mjg_3f89c6ce-f3e6-4920-96f3-2bcdd6dbf60b"
      unitRef="usdPerShare">36.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfNC0yLTEtMS0xMjY2Mjg_8aad2480-c347-4bd2-8f8a-b12964d47519"
      unitRef="shares">1022904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfNC00LTEtMS0xMjY2Mjg_65f00ca4-28e0-4b1e-b676-66aa5bf37ba3"
      unitRef="usdPerShare">27.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9abed8a09c214319a4423cf3fb5ecb73_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfNS0yLTEtMS0xMjY2Mjg_78efc1a3-ac96-4a7d-85b1-012676b5b993"
      unitRef="shares">1994862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9abed8a09c214319a4423cf3fb5ecb73_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RhYmxlOjdjMzQ3YTAyZDgwMDQ2ZGE5NWM2Y2ZmNzM1YmVkZGQxL3RhYmxlcmFuZ2U6N2MzNDdhMDJkODAwNDZkYTk1YzZjZmY3MzViZWRkZDFfNS00LTEtMS0xMjY2Mjg_cd5414da-8b55-493a-8f26-a15f6f279ab1"
      unitRef="usdPerShare">13.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i9abed8a09c214319a4423cf3fb5ecb73_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTAwNw_7c247f69-ed7a-4fb1-a979-408d8fffa0f9"
      unitRef="usd">19800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTE1OQ_5106472c-5a69-488f-838e-9162bd1c46b8">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="idda8fd6e0a664803b84d581d6ad6b27a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTM5OA_4e388902-8cb7-4601-822a-59996ed851fe"
      unitRef="shares">41487</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="i7ae752c4884e4e67ad202713d68fe1b2_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTQ2Mw_d03f62c7-0c2e-4878-9d68-d9de9c5ad053"
      unitRef="shares">76138</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i79b69f5ad10b449dac5c4fc387dfccf0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTY2NA_f51f3ead-d8f7-4671-91ca-a8718b180e2f"
      unitRef="usd">2200000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i0739f9f5cb43425cb2d6fc5c3d1947da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTcyNg_52cf68ce-8395-4e6b-8543-27bca42b7ab6"
      unitRef="usd">300000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i90a3daea84f54e7bbfd7da40f557227c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMTczMw_a796d0f9-c880-47fc-abfe-e87465095a16"
      unitRef="usd">1900000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i403368f4b4754ed4b335bff0b80a92da_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfNjU5NzA2OTc2OTUyNQ_722f828a-0dcc-4f91-a96a-f5029bf1bd64"
      unitRef="usd">0</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="if65fbf7f2c924f07a648c17a334c7c42_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfNjU5NzA2OTc2OTUyNQ_a0869991-73a9-4bb5-aa37-79f029b65b3e"
      unitRef="usd">0</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="i402c8314c37b4397a60a9dc5100ead32_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjEzMg_20d8a466-5e76-4c2b-b364-38b4466c25dc"
      unitRef="shares">237960</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="i915d2ee33bfe41828d288f2c9e850276_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjE5Nw_848e59b5-bcd4-4de9-a123-86da5a312075"
      unitRef="shares">142302</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i2983b693db614e67a0385420d6fe04db_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjM5OA_9fc7a306-1719-4169-aede-31588d980ec1"
      unitRef="usd">5900000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i8422c990601641b9923d741a1879f6f6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjQ2MA_69c48160-1b60-4a3f-a63b-632535203990"
      unitRef="usd">2300000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="ie06ce2ae770d4cf98f1c70856a4ca493_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjQ2Nw_9549315e-a98e-419d-8caf-792c9de020c9"
      unitRef="usd">3600000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i403368f4b4754ed4b335bff0b80a92da_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjY4NQ_722f828a-0dcc-4f91-a96a-f5029bf1bd64"
      unitRef="usd">0</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="if65fbf7f2c924f07a648c17a334c7c42_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF82Ny9mcmFnOmQ0MTE0MDNiYzA0NzQ1ZWM4MzI2ZDYyZWFmNTg2MDY3L3RleHRyZWdpb246ZDQxMTQwM2JjMDQ3NDVlYzgzMjZkNjJlYWY1ODYwNjdfMjY4NQ_a0869991-73a9-4bb5-aa37-79f029b65b3e"
      unitRef="usd">0</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzI4Nw_f10c84fe-56cd-4875-8650-ff4bbe9124d6">Revenue Recognition&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s two reportable segments for which it recognizes revenue are (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience and other anticipated adjustments, including anticipated payer denials. Collection of consideration the Company expects to receive typically occurs within 90 to 120 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pharma Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Pharma Services segment generally enters into contracts with pharmaceutical customers as well as other CROs to provide research and clinical trial services ranging in duration from one month to several years.&#160;The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, and/or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is usually recognized over time based on the number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to the sponsor(s) at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics is the sale of de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts collected in advance of services being provided are deferred as contract liabilities on the Consolidated Balance Sheets. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. Contract assets are established for revenue recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets. All others are classified as non-current assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most contracts are terminable by the customers, either immediately or according to advance notice terms specified within the contracts.&#160;All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma capitalized commissions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma capitalized commissions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma capitalized commissions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized for the three and nine months ended September 30, 2022 related to Pharma contract liability balances outstanding at the beginning of the period was $0.7&#160;million and $4.8&#160;million, respectively. Revenue recognized for the three and nine months ended September 30, 2021 related to Pharma contract liability balances outstanding at the beginning of the period was $0.4 million and $4.2 million, respectively. Amortization of capitalized commissions for the three and nine months ended September 30, 2022 was $0.3&#160;million and $0.6&#160;million, respectively. Amortization of capitalized commissions for the three and nine months ended September 30, 2021 was $0.2 million and $0.9 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered various factors for both its Clinical Services and Pharma Services segments in determining appropriate levels of homogeneous data for its disaggregation of revenue; including the nature, amount, timing, and uncertainty of revenue and cash flows. Clinical Services categories align with the types of customers due to similarities of billing method, level of reimbursement, and timing of cash receipts. Unbilled amounts are accrued and allocated to payer categories based on historical experience. In future periods actual billings by payer category may differ from accrued amounts. Pharma Services relate to contracts with large pharmaceutical and biotech customers as well as other CROs. Because the nature, timing, and uncertainty of revenue and cash flows are similar and primarily driven by individual contract terms Pharma Services revenue is not further disaggregated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Client direct billing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Medicare and Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Self-Pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Clinical Services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNDc_b1b33c91-6dc9-481b-9797-74039dcd76ba"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzI5MA_e3645028-6a79-43b1-a420-74a414728921">Collection of consideration the Company expects to receive typically occurs within 90 to 120 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzI5MQ_87e9e30b-e2fe-45da-82f3-e9f49afa7081">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma capitalized commissions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma capitalized commissions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma capitalized commissions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMS0xLTEtMS0xMjY2Mjg_a1232c06-a07e-4974-be20-db3b03325dde"
      unitRef="usd">2679000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMS0zLTEtMS0xMjY2Mjg_837bb79b-622b-4658-8109-f6f5aca073c9"
      unitRef="usd">1738000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMi0xLTEtMS0xMjY2Mjg_c621cdf6-6e08-431e-bfd5-3624d70400d2"
      unitRef="usd">257000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMi0zLTEtMS0xMjY2Mjg_2a8474e3-a40b-4ba7-9d57-a9429606bf1d"
      unitRef="usd">236000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMy0xLTEtMS0xMjY2Mjg_2bf8351e-ddb0-4b1d-a213-d6ce408227ba"
      unitRef="usd">2936000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMy0zLTEtMS0xMjY2Mjg_957435f7-a0ef-4546-95d5-4d4ddfd83002"
      unitRef="usd">1974000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfNi0xLTEtMS0xMjY2Mjg_24b95e12-f5b9-4a05-9526-531fcc8c4df4"
      unitRef="usd">106000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfNi0zLTEtMS0xMjY2Mjg_36bec197-9658-4618-95e3-0a79673e1767"
      unitRef="usd">109000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfNy0xLTEtMS0xMjY2Mjg_90155ed4-4396-4e98-baf7-a985a169cce3"
      unitRef="usd">1527000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfNy0zLTEtMS0xMjY2Mjg_7e9961ce-e652-461d-9238-1ffcf5287dc8"
      unitRef="usd">882000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostGross
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfOC0xLTEtMS0xMjY2Mjg_9addba89-1209-49ec-91f8-2dc15064096b"
      unitRef="usd">1633000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfOC0zLTEtMS0xMjY2Mjg_d0bef946-da6f-463f-84f2-092bac80e9d2"
      unitRef="usd">991000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTEtMS0xLTEtMTI2NjI4_5925c5a6-7325-4abb-b8b6-7e4f01fe918b"
      unitRef="usd">6386000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTEtMy0xLTEtMTI2NjI4_7f1e0941-a161-42d5-b148-f8af0836a8e1"
      unitRef="usd">5192000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTItMS0xLTEtMTI2NjI4_d8ed20b7-f708-49a5-8bda-1caab30c1e5e"
      unitRef="usd">1128000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTItMy0xLTEtMTI2NjI4_6932a18e-948c-49e2-8ad6-2d4b5b138223"
      unitRef="usd">917000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i83580aae10c642e8968c0f73731cc216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTMtMS0xLTEtMTI2NjI4_2b82e3ae-ed91-4cbe-87b0-7d8061a082b3"
      unitRef="usd">7514000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic8321097bff14046a282e8abcc199611_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjQyZjg2ZjhmMGM5OTQ0NmJiMzdkN2NjZTNjZDBmMWQ1L3RhYmxlcmFuZ2U6NDJmODZmOGYwYzk5NDQ2YmIzN2Q3Y2NlM2NkMGYxZDVfMTMtMy0xLTEtMTI2NjI4_0bd2eb03-e80e-4359-aa8c-16d5623fe5a1"
      unitRef="usd">6109000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODA4Nw_4c3482fe-19b3-4a38-b250-2c2d29e4032a"
      unitRef="usd">700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODEwNw_4abca97f-d75f-4367-876c-cd44cea5a810"
      unitRef="usd">4800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNjU5NzA2OTc3NDA3Ng_21ab1910-e5d8-426b-afc3-9f4bb7998207"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODA0OA_6f25b2c8-1995-4145-8e39-d49defde65a5"
      unitRef="usd">4200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODEzMw_83f4c497-779e-49f1-b3fe-e72b8de92713"
      unitRef="usd">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzE0NjgyNTU4ODE0OA_44f44a2f-9872-4b00-8156-2797e4a4ef23"
      unitRef="usd">600000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNjU5NzA2OTc3NDA1Mw_f96c3b78-6524-4874-a003-fad8ffb3e7e2"
      unitRef="usd">200000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNjIxMQ_9a02ea77-f48a-4ae7-8047-62830b3e6a98"
      unitRef="usd">900000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RleHRyZWdpb246YWIxNTAwYTQ4MGZiNDhhMmJmNjY3YTM4NTVlZjNhOGVfNzI5NA_e8ae24e2-a348-4fc9-ac08-e521014ef6cb">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Client direct billing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Medicare and Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Self-Pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Clinical Services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i12404422705e4e5db442f2c6fa044950_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfMy0yLTEtMS0xMjY2Mjg_24304682-1d6e-4c0c-8213-5372b9e54b0b"
      unitRef="usd">73234000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0c4daaae4c144b64bf090d8b0ec28bde_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfMy00LTEtMS0xMjY2Mjg_e027b787-9be6-4430-b864-15b3cd2767fd"
      unitRef="usd">64195000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic2ce6ba5e4be4b41adb542d8cc8b71c4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfMy02LTEtMS0xMjY2Mjg_fb7815f0-6b3c-49cf-bcee-e240f348710a"
      unitRef="usd">208123000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2c9f8f865eca4dee9704f9ae41b2c4a2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfMy04LTEtMS0xMjY2Mjg_700053ce-3006-45f0-9faa-ecfb74d52e6d"
      unitRef="usd">188040000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2e4e564189e94f8da0931134c08f04e2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNC0yLTEtMS0xMjY2Mjg_91faad14-22ed-4494-9a4c-77f57124115b"
      unitRef="usd">17105000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9077f666a17a48f3b7bc80bc791c4661_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNC00LTEtMS0xMjY2Mjg_71e91d49-5b60-4894-9bc0-58ef5d25b46f"
      unitRef="usd">19539000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i11e2ed3be0744fb0a5fa17de9fd64cb8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNC02LTEtMS0xMjY2Mjg_7a8c9b94-7e1d-4555-bffa-ba4b5d1737c6"
      unitRef="usd">53904000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i518f32fbbb6149f08c71ce0cf09bfa3e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNC04LTEtMS0xMjY2Mjg_7dcebcf2-3acc-457e-b27c-9afb2ae05002"
      unitRef="usd">58642000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia6531ec4b2bd491d919cb52b975afca2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNS0yLTEtMS0xMjY2Mjg_57bafffd-3f40-40b4-9fa3-23081f161d00"
      unitRef="usd">15795000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idadb4a2ecea94787888cba5a2ec1fdf4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNS00LTEtMS0xMjY2Mjg_bc980fc7-6b6a-4e0a-b7d3-19f1c7cce5d5"
      unitRef="usd">18295000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3e676b3f14974a14b21ed4e1353a4970_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNS02LTEtMS0xMjY2Mjg_4fd13de7-0cf0-41dc-aa17-6582f2bce3de"
      unitRef="usd">48427000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0430c68b11e441a1932ef5b6bf20883e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNS04LTEtMS0xMjY2Mjg_caff1756-521d-403c-9852-9fa248a24886"
      unitRef="usd">52929000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1f4d4146b09f46f8bae21fa55af4e603_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNi0yLTEtMS0xMjY2Mjg_0ce6a544-111b-469e-83d6-3792e5e05d43"
      unitRef="usd">28000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i00c17f0a685d4b4bb4ac9262b0409185_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNi00LTEtMS0xMjY2Mjg_78bebe64-c325-45d8-ad58-4129ee3e5635"
      unitRef="usd">198000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4359f136a8724314ae74fdfcb5cf1ddb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNi02LTEtMS0xMjY2Mjg_93bdf433-ffe0-4d82-90d0-adf2c7da683d"
      unitRef="usd">134000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i31361b8430c34cb1a61a5212cab1d7e4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNi04LTEtMS0xMjY2Mjg_ca0b186b-e0fb-4e86-9a28-2bfded5ffbdd"
      unitRef="usd">508000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNy0yLTEtMS0xMjY2Mjg_a44b4c1e-e229-49df-8e1c-6e73403e0a03"
      unitRef="usd">106162000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNy00LTEtMS0xMjY2Mjg_c8f3eb1c-5124-4d24-bec1-fe45f8be22a5"
      unitRef="usd">102227000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNy02LTEtMS0xMjY2Mjg_274cba14-d15e-4db8-83f1-2b4d7a3779fb"
      unitRef="usd">310588000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfNy04LTEtMS0xMjY2Mjg_d19c27aa-f5e1-41de-92b9-54bc771684e5"
      unitRef="usd">300119000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOC0yLTEtMS0xMjY2Mjg_26ad7a9b-3abd-4d2d-8bd1-b1ed56faaef8"
      unitRef="usd">22620000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOC00LTEtMS0xMjY2Mjg_c4a1cd17-c9aa-437a-8500-89f0f47464f6"
      unitRef="usd">19113000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOC02LTEtMS0xMjY2Mjg_8c9fccee-5ba4-4ff5-b5d0-0103c72c6d50"
      unitRef="usd">60435000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOC04LTEtMS0xMjY2Mjg_de9685d5-ab68-4949-8872-7e5bdbc100ed"
      unitRef="usd">58478000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOS0yLTEtMS0xMjY2Mjg_b61adb8d-0238-4b5e-81db-80049c75101e"
      unitRef="usd">128782000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOS00LTEtMS0xMjY2Mjg_3e54f943-a372-4169-905c-80f1c987ba8c"
      unitRef="usd">121340000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOS02LTEtMS0xMjY2Mjg_7b844cd5-be92-4d24-9a15-83313d6cea25"
      unitRef="usd">371023000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83MC9mcmFnOmFiMTUwMGE0ODBmYjQ4YTJiZjY2N2EzODU1ZWYzYThlL3RhYmxlOjU3NjgxM2I4ZTk1MDQ4YzQ4ZDAzNDMyNTQxMWRhNmE2L3RhYmxlcmFuZ2U6NTc2ODEzYjhlOTUwNDhjNDhkMDM0MzI1NDExZGE2YTZfOS04LTEtMS0xMjY2Mjg_380756c7-621a-4848-a8a4-7cdb63bcbf2f"
      unitRef="usd">358597000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83My9mcmFnOjNkY2M0ZjAyNDFmZjQzNWQ5ZTg1M2M3NWQ0ZDFhOTg4L3RleHRyZWdpb246M2RjYzRmMDI0MWZmNDM1ZDllODUzYzc1ZDRkMWE5ODhfMjAzMA_ad89a897-5956-48ad-8412-cf22f337cd6e">Income Taxes&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of each interim period, management estimates the annual effective tax rate based on forecasted pre-tax results of the Company&#x2019;s global operations and applies such rate to its ordinary quarterly earnings to calculate income tax expense related to ordinary income. The tax effects of items significant, unusual and infrequent in nature are discretely calculated and recognized in the period during which they occur. These discrete items often relate to changes in tax laws, excess tax benefits/deficiencies related to share-based compensation or adjustments to previously reported tax expense/benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing available positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred income tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome. Cumulative loss in recent years is commonly defined as a three-year cumulative loss position. As of September 30, 2022, the Company&#x2019;s U.S. ongoing operations were in a three-year cumulative loss position. Management determined that sufficient objectively verifiable positive evidence did not exist to overcome the negative evidence of the Company&#x2019;s U.S. cumulative loss position. Accordingly, the Company&#x2019;s estimated annual effective tax rate applied to the Company&#x2019;s pre-tax loss for the three and nine months ended September 30, 2022, includes the unfavorable impact of a valuation allowance against the Company&#x2019;s deferred income tax assets expected to be created in 2022 for additional U.S. net operating loss and tax credit carryforwards.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjQxNg_49be0063-ba48-4edc-8881-aff14ba8a487">Net (Loss) Income Per Share&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company presents both basic earnings per share (&#x201c;EPS&#x201d;) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised and if the 2028 Convertible Notes and 2025 Convertible Notes were converted. The potential dilution from stock awards is accounted for using the treasury stock method based on the average market value of the Company&#x2019;s common stock. The potential dilution from conversion of the 2028 Convertible Notes and 2025 Convertible Notes is accounted for using the if-converted method, which requires that all of the shares of the Company&#x2019;s common stock issuable upon conversion of the 2028 Convertible Notes and the 2025 Convertible Notes will be included in the calculation of diluted EPS assuming conversion of the 2028 Convertible Notes and the 2025 Convertible Notes at the beginning of the reporting period (or at time of issuance, if later).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculations (in thousands, except net loss per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NET (LOSS) INCOME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the &#x201c;Capped Call Transactions&#x201d;) with option counterparties pursuant to capped call confirmations at a cost of approximately $29.3&#160;million. The potential effect of the Capped Call Transactions were excluded from the calculation of diluted net loss per share in the three and nine months ended September 30, 2022 as the Company&#x2019;s closing price on September 30, 2022 did not exceed the conversion price of $85.75 per share. The Capped Call Transactions are not reflected in diluted net loss per share as they are anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjQxOA_6acab686-e3ed-4191-a836-924ab66fdb55">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculations (in thousands, except net loss per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NET (LOSS) INCOME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMy0yLTEtMS0xMjY2Mjg_56157c20-520b-41c7-9b39-c7e3e2dd77c6"
      unitRef="usd">-36852000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMy00LTEtMS0xMjY2Mjg_f9ab7c1c-41f0-4d2e-81af-15716cf97d31"
      unitRef="usd">-20348000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMy02LTEtMS0xMjY2Mjg_febbc9f5-e29f-4652-93bf-ec99c5752559"
      unitRef="usd">-121563000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMy04LTEtMS0xMjY2Mjg_52338472-0085-456b-9de9-d4cbf2180cba"
      unitRef="usd">33412000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOC0yLTEtMS0xMjY2Mjg_476cc719-9464-4152-8de0-f086b107e42b"
      unitRef="shares">124425000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOC00LTEtMS0xMjY2Mjg_8e78f3c2-8247-43a6-931f-58a2cb8a9309"
      unitRef="shares">122559000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOC02LTEtMS0xMjY2Mjg_d75e4545-8430-44b1-8b9b-6caf4c71059d"
      unitRef="shares">124055000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOC04LTEtMS0xMjY2Mjg_3851f783-34d3-4dd5-906e-92d3ba189dbd"
      unitRef="shares">119087000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if4429118382147fe986ee5dbfc122521_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOS0yLTEtMS0xMjY2Mjg_bf9f1cfa-577f-4cfe-8e33-67e91edd777b"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i1c42bc6f38d647e19f5951ebd7219933_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOS00LTEtMS0xMjY2Mjg_5696d87e-d4c4-48c2-8225-367733f21f67"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i36c5815174fc465484a397d6b8310ed5_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOS02LTEtMS0xMjY2Mjg_931e6791-d834-4bee-bbf5-be8191807820"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2ee7ce21290e41ef94470a95e2d94830_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfOS04LTEtMS0xMjY2Mjg_8c4281ee-0439-486a-9bab-75afd9e4bb6a"
      unitRef="shares">2077000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if05bf8eb6bc645cd9e362b07a66b1d8c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTAtMi0xLTEtMTI2NjI4_afc8249a-45c1-4bf3-8ee1-b8e1d97ad410"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3db9446bf9344b45b0f702886c5f0051_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTAtNC0xLTEtMTI2NjI4_8c198c59-2c32-4f8f-8df0-73be464051c4"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic0be01a76b974be59aeb5242f03aeb9d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTAtNi0xLTEtMTI2NjI4_12019192-1ea0-4144-abca-ec9570387bc8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i69da659e90044db1a544a5bde21c110c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTAtOC0xLTEtMTI2NjI4_c1dbc5fd-cf82-419b-882f-5b2fc273cf98"
      unitRef="shares">192000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i5a46098d95ff4c398528d14d94cf1462_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTEtMi0xLTEtMTI2NjI4_13c93acc-2389-4352-9fab-311495639767"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i0f31d48f948140049d3ec9c0b3ce5eb3_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTEtNC0xLTEtMTI2NjI4_a1b9217e-0b0d-4879-bcdb-51ab7a670548"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i277bb1a3397c493eab6081211ecad60e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTEtNi0xLTEtMTI2NjI4_4e572bb9-077b-4e4f-9f77-ee629044a3e8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i3d2147cc98bb480fb457363bd7cdaef9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTEtOC0xLTEtMTI2NjI4_b914ab0e-20f7-40ca-9313-fc6499f8093a"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i1ce2989799cb43159de5d33b523a462c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTItMi0xLTEtMTI2NjI4_8b44a15e-880d-4e54-ba0d-7ed353e280b5"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i75ab618a9f5c4dd0a3656bbe96c190ad_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTItNC0xLTEtMTI2NjI4_43e7dc31-0100-40ee-a1a6-0836dfc2d780"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i242b0a5a38704451a6823784364be43c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTItNi0xLTEtMTI2NjI4_e4e8e4b8-07b4-43fd-a490-75e8f6489130"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i86ad372323184dde948139f6d77bc2bd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTItOC0xLTEtMTI2NjI4_eff263b6-46db-41f7-8196-98f5624a96d0"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTMtMi0xLTEtMTI2NjI4_fad47ad5-71d4-4e58-88a3-a745d3d0e173"
      unitRef="shares">124425000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTMtNC0xLTEtMTI2NjI4_decc7e11-bf97-4475-92ef-26d655c3e303"
      unitRef="shares">122559000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTMtNi0xLTEtMTI2NjI4_9b443f42-16ad-496c-9001-54bcd1aa5147"
      unitRef="shares">124055000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTMtOC0xLTEtMTI2NjI4_822030fd-234e-4cb4-903e-6fffb67c11b0"
      unitRef="shares">121356000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTUtMi0xLTEtMTI2NjI4_7e1c41ad-b1ba-4ec5-bdfa-9076e4dd6ee9"
      unitRef="usdPerShare">-0.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTUtNC0xLTEtMTI2NjI4_36b6883a-69e2-4421-887f-11b3ceb786aa"
      unitRef="usdPerShare">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTUtNi0xLTEtMTI2NjI4_4e30efea-d0d7-4be6-91db-c8a29db1d997"
      unitRef="usdPerShare">-0.98</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTUtOC0xLTEtMTI2NjI4_595c93a6-e4e7-4313-b172-039ef9452933"
      unitRef="usdPerShare">0.28</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTYtMi0xLTEtMTI2NjI4_50edaecc-0805-48d9-a37c-513083a8d8ef"
      unitRef="usdPerShare">-0.30</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTYtNC0xLTEtMTI2NjI4_cc005134-e69f-4e01-b6c8-2be21f69c921"
      unitRef="usdPerShare">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTYtNi0xLTEtMTI2NjI4_57668e3e-3f00-4e1d-9cbf-765d9100d486"
      unitRef="usdPerShare">-0.98</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjJkYmZlZDQzMjEzNjQ5NDY5MGQxZWQwMWRiZDVjNzNlL3RhYmxlcmFuZ2U6MmRiZmVkNDMyMTM2NDk0NjkwZDFlZDAxZGJkNWM3M2VfMTYtOC0xLTEtMTI2NjI4_75854070-f2a5-49e9-850c-15a708e89d5b"
      unitRef="usdPerShare">0.28</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjQxOQ_fb95adbf-9aed-43b1-a938-828697476fd2">The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3cf08791a42c4b12b704b3c8c21f8f15_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMi0yLTEtMS0xMjY2Mjg_970dc9fe-0cec-4d4a-b4ff-7f2ed88e5171"
      unitRef="shares">45000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i05e8201ba8544204b7f58c994e8ac179_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMi00LTEtMS0xMjY2Mjg_b15483d3-b0bf-4a8e-8768-6e7f1d61eb7a"
      unitRef="shares">1811000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i50746063c011499591f6bd542aedaab2_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMi02LTEtMS0xMjY2Mjg_bb6621bf-9ad9-48a7-9916-ad811aa196b9"
      unitRef="shares">272000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i72f0500c13d24ac7bcf932ec6cb56213_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMi04LTEtMS0xMjY2Mjg_36a56cb1-2df5-4b75-932e-624cbe3cea27"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i94151c90de104b8dbe11dec588578819_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMy0yLTEtMS0xMjY2Mjg_3836470d-c241-42e2-b8bc-36972c6929bc"
      unitRef="shares">295000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i96522c45dcd84160880608c828bd86b3_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMy00LTEtMS0xMjY2Mjg_c02ffcab-88cc-4e6f-80f6-b3c7efb62926"
      unitRef="shares">201000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic226270fce13411aaa7fde2cdeb1e234_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMy02LTEtMS0xMjY2Mjg_872c2580-a0fc-4b04-a124-e797948a29b8"
      unitRef="shares">266000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i953f791557df441a893456e3ce3c860a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfMy04LTEtMS0xMjY2Mjg_54332540-7736-4115-be46-e4e58f44b2d7"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i62cba84218e84f778d2010e7be8c7e0d_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNC0yLTEtMS0xMjY2Mjg_232ddc73-17ae-4cda-9123-2af7d0278138"
      unitRef="shares">5538000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6e5b26bbdce64c3ca2829078807c061f_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNC00LTEtMS0xMjY2Mjg_1bae88bf-8e4e-43dd-bdf6-f5a6c15f5841"
      unitRef="shares">5538000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia40344f3d7174e60be2e0dbaf9533460_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNC02LTEtMS0xMjY2Mjg_df112064-157a-4c8d-ae4d-f04a467530f8"
      unitRef="shares">5538000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9dd0bf6f3fb647c1a101a318ce23fbad_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNC04LTEtMS0xMjY2Mjg_3ce213f2-c072-4b9d-973a-ebf542e71f92"
      unitRef="shares">5538000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i98e63a0f57c2427c9d3b54f1c162de3c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNS0yLTEtMS0xMjY2Mjg_533444d7-873f-4370-8127-5349c2a919c3"
      unitRef="shares">5215000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4bbde1a0788e4d5e98970b3bd2cb180a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNS00LTEtMS0xMjY2Mjg_85e1aeb4-a219-4f5a-b2be-e84f7bc6ef6d"
      unitRef="shares">5215000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i346de9f05ee645788bff3412f862de33_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNS02LTEtMS0xMjY2Mjg_ae12d1fe-505a-4b50-8a0b-16ec9fb0a84d"
      unitRef="shares">5215000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i879e090b3f4e4e71bc92de7e2ad882b2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RhYmxlOjA2NGJmYjZjYTQ5YTRjNjU4ZjA5MmUwZTg3OWJmYjMyL3RhYmxlcmFuZ2U6MDY0YmZiNmNhNDlhNGM2NThmMDkyZTBlODc5YmZiMzJfNS04LTEtMS0xMjY2Mjg_8bfa0257-82d0-4e23-8bcb-62cf16fb303b"
      unitRef="shares">5101000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ib4d31e5c09604f229766351b8ba0d0fc_D20210111-20210111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjA3NA_e3f4de7e-c2e9-44da-a21d-9e7e1a4c993f"
      unitRef="usd">29300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i68c2a2f8b6bc4a8f9ea7991d94b969f2_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF83Ni9mcmFnOmY0M2Q0NTBkZjQ0ZTQwNDg4YzkzNzk5ZWFhZDU5MWMxL3RleHRyZWdpb246ZjQzZDQ1MGRmNDRlNDA0ODhjOTM3OTllYWFkNTkxYzFfMjI5OA_852d0a61-75a4-49fc-923f-262c8241ed12"
      unitRef="usdPerShare">85.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84Mi9mcmFnOmUwZGE3ZmU4ZDZiODQ3ZTY4MWJmY2EyMTdlZjA5ZTRkL3RleHRyZWdpb246ZTBkYTdmZThkNmI4NDdlNjgxYmZjYTIxN2VmMDllNGRfMjc2OQ_11e2d1a1-034a-40ff-b2bf-ebf2f06e7410">Commitments and Contingencies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceeding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2021, Natera, Inc. filed a patent infringement complaint against the Company&#x2019;s newly-acquired subsidiary Inivata Limited and its subsidiary Inivata, Inc. in United States District Court for the district of Delaware, alleging Inivata&#x2019;s InVisionFirst-Lung&#x2122; cancer diagnostic test of infringing two patents. The litigation is presently in the pleadings stage. The Company believes that it has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. At the time of filing, the outcome of this matter is not estimable or probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the assistance of outside counsel, the Company is voluntarily conducting an internal investigation that focuses on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#x201c;OIG&#x201d;) of the Company&#x2019;s internal investigation in November 2021. The Company&#x2019;s review of this matter is ongoing. The Company has a reserve of $11.2 million in other long-term liabilities as of September 30, 2022 and December 31, 2021 on the Consolidated Balance Sheets for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#x2019;s best estimate of the minimum probable loss associated with this matter. As a result of the ongoing investigation and interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. The Company was notified on June 30, 2022 that the Department of Justice (&#x201c;DOJ&#x201d;) will be participating in the investigation of this matter. At this time, the Company is unable to predict the duration, scope, result or related costs associated with any further investigation, including by the OIG, DOJ, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Any determination that the Company&#x2019;s operations or activities are not in compliance with existing laws or regulations, however, could result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, or other losses or conduct restrictions, which could be material to the Company&#x2019;s financial results or business operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="ie54a7a7e84624ef48b6fa7119e60f286_D20210120-20210120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84Mi9mcmFnOmUwZGE3ZmU4ZDZiODQ3ZTY4MWJmY2EyMTdlZjA5ZTRkL3RleHRyZWdpb246ZTBkYTdmZThkNmI4NDdlNjgxYmZjYTIxN2VmMDllNGRfMzY4_c3abcafd-7955-42f3-9a1c-bedd3ee638d2"
      unitRef="patent">2</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="idbe5ba6b460e48cea499cfd288684c3c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84Mi9mcmFnOmUwZGE3ZmU4ZDZiODQ3ZTY4MWJmY2EyMTdlZjA5ZTRkL3RleHRyZWdpb246ZTBkYTdmZThkNmI4NDdlNjgxYmZjYTIxN2VmMDllNGRfMTI2MQ_6d334721-3436-4a31-98fc-f244a48a6e30"
      unitRef="usd">11200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i72c663a25f6742dea0c2944423d3ba66_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84Mi9mcmFnOmUwZGE3ZmU4ZDZiODQ3ZTY4MWJmY2EyMTdlZjA5ZTRkL3RleHRyZWdpb246ZTBkYTdmZThkNmI4NDdlNjgxYmZjYTIxN2VmMDllNGRfMTI2MQ_91f7790a-807f-414c-ab3b-1d2cacdaf93c"
      unitRef="usd">11200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfMTU3Ng_2f974b07-e933-48d0-8bac-386d2d484fbd">Related Party Transactions&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2020, the Company formed a strategic alliance with Inivata and entered into a Strategic Alliance Agreement and Laboratory Services Agreement whereas Inivata, prior to the Inivata Acquisition Date, would render and perform certain laboratory testing which the Company made available to customers. In connection with this agreement, Inivata provided $0.8 million of testing services to the Company recorded in cost of revenue in the Consolidated Statements of Operations for the nine months ended September 30, 2021 through the Inivata Acquisition Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021, the Company completed its acquisition of all remaining equity interest in Inivata by exercising its Purchase Option. Beginning June 18, 2021, Inivata is a wholly-owned consolidated subsidiary of the Company. As of the Inivata Acquisition Date, Inivata&#x2019;s financial statement activity is being consolidated within the Company&#x2019;s unaudited Consolidated Financial Statements. For further details on the acquisition of Inivata, please refer to Note 3. Acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has Pharma Services contracts with CytomX Therapeutics, Inc., an entity with whom a director of the Company, Dr. Alison L. Hannah, was an officer at until September 2022, and the Company&#x2019;s former Chief Legal Officer, Halley E. &lt;/span&gt;&lt;/div&gt;Gilbert, is a director. In connection with these contracts, the Company recognized $0.1&#160;million and $0.5&#160;million of revenue in the Consolidated Statements of Operations for the three and nine months ended September 30, 2022, respectively. For the three and nine months ended September 30, 2021, the Company recognized revenue in the Consolidated Statements Operations of $0.2&#160;million and $0.4&#160;million, respectively.The Company has Pharma Services contracts with HOOKIPA Pharma, Inc., an entity with whom a director of the Company, Michael A. Kelly, is a director. In connection with these contracts, the Company recognized $0.3&#160;million of revenue in the Consolidated Statements of Operations for both the three and nine months ended September 30, 2022. For the three and nine months ended September 30, 2021, the Company recognized revenue in the Consolidated Statements of Operations of $0.2&#160;million and $0.4&#160;million, respectively.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i79ee0320473e4c25be7915c5434f0efe_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNDAw_719d581f-3d53-4067-9506-ab417609e459"
      unitRef="usd">800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i6eb774483c5d44a88b442c3a493331f4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc3MDI3Nw_805be543-9cdc-4b47-b368-bede53a39bba"
      unitRef="usd">100000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i3d2b85ad77a2443083ab566f9d503e37_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfMTM3Ng_6ebd5a5a-fa0d-480c-a755-5c4b6c553b78"
      unitRef="usd">500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i3640c3db5b114ab3997daf6009f1e121_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfMTUwMw_3770857d-3dff-439d-be35-70afd852504a"
      unitRef="usd">200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i9ce9041f492249c4a99391bfbb0cddc4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfMTUxMA_e96edfa9-f9b9-4cef-aafe-92559f9b8995"
      unitRef="usd">400000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i6637559ec6a04ab5b9435cf6158fd0c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc2OTk1NQ_e63a3af8-2e3d-4aa9-b4d3-4b723aa696a3"
      unitRef="usd">300000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i6f4bd7a8247d417ea28e862e1cf803db_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc2OTk1NQ_f64d7f96-5321-49f4-941f-421aea2be3d2"
      unitRef="usd">300000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i250039242aab493dabb7b5413e5f5a41_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc2OTk2OQ_8bbd2195-3f86-4b9a-8a68-e70e01b6b2a0"
      unitRef="usd">200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ieb967b231404449cb3a51eadf05ece29_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84NS9mcmFnOmQ2ZmM1NjA5ZTMzZTQ3YTlhNzJlNDcxMjMyYjQ5MmI1L3RleHRyZWdpb246ZDZmYzU2MDllMzNlNDdhOWE3MmU0NzEyMzJiNDkyYjVfNjU5NzA2OTc2OTk4Mw_099c6a2c-1055-409a-8a41-c7aefdd88db6"
      unitRef="usd">400000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTk1MQ_2e49ebd6-b2ac-462d-b243-f0efb4e10cd2">Segment Information&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under two reportable segments, (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology and oncology practices, hospital pathology labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and self-pay patients. The Pharma Services segment supports pharmaceutical firms&#x2019; drug development programs by assisting with various clinical trials and research as well as providing informatics related services often supporting pharmaceutical commercialization efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial information reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) includes revenues, cost of revenue, and gross profit for both reportable segments.&#160;Assets are not presented at the segment level as that information&#160;is not used by the CODM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the segment information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost of revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on investment in and loan receivable from non-consolidated affiliate, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Clinical Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 includes $4.3&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2022 include $12.8&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2021 include write-offs of $5.3&#160;million for COVID-19 PCR testing inventory and $5.0&#160;million of amortization of acquired Inivata developed technology intangible assets.&lt;/span&gt;&lt;/div&gt;(2) Pharma Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 include $0.6&#160;million of amortization of acquired Inivata developed technology intangible assets. Pharma Services cost of revenue for the nine months ended September 30, 2022 and September 30, 2021 includes $1.8&#160;million and $0.6&#160;million of amortization, respectively, of acquired Inivata developed technology intangible assets.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfNzE_022f5384-de9c-4d1c-84c2-20946c310f5c"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTk1Mg_2ed1f6d4-f978-41a3-a575-8fa0a905e01f">The following table summarizes the segment information (in thousands):&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost of revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on investment in and loan receivable from non-consolidated affiliate, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Clinical Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 includes $4.3&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2022 include $12.8&#160;million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for the nine months ended September 30, 2021 include write-offs of $5.3&#160;million for COVID-19 PCR testing inventory and $5.0&#160;million of amortization of acquired Inivata developed technology intangible assets.&lt;/span&gt;&lt;/div&gt;(2) Pharma Services cost of revenue for both the three months ended September 30, 2022 and September 30, 2021 include $0.6&#160;million of amortization of acquired Inivata developed technology intangible assets. Pharma Services cost of revenue for the nine months ended September 30, 2022 and September 30, 2021 includes $1.8&#160;million and $0.6&#160;million of amortization, respectively, of acquired Inivata developed technology intangible assets.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMy0yLTEtMS0xMjY2Mjg_463cf27a-25f2-4346-a1dd-9dd755c337f5"
      unitRef="usd">106162000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMy00LTEtMS0xMjY2Mjg_d12374ea-3485-4ddc-82ca-63e6af13108b"
      unitRef="usd">102227000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMy02LTEtMS0xMjY2Mjg_8300b3c7-cdbc-4bc3-b438-b21e12dcd446"
      unitRef="usd">310588000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMy04LTEtMS0xMjY2Mjg_49289a1a-5ea9-47bf-b8a9-06b69fb04c64"
      unitRef="usd">300119000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNC0yLTEtMS0xMjY2Mjg_9cdcc7fe-05f4-4cea-b489-245d6a9c061f"
      unitRef="usd">22620000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNC00LTEtMS0xMjY2Mjg_0f68ab0e-998f-4c30-bf31-26f7b7bdf7ab"
      unitRef="usd">19113000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNC02LTEtMS0xMjY2Mjg_a783dc9f-1e9f-4abb-a8fc-ba932fb1b1ce"
      unitRef="usd">60435000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNC04LTEtMS0xMjY2Mjg_d861f3ae-e615-442d-8197-7947b781715f"
      unitRef="usd">58478000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNS0yLTEtMS0xMjY2Mjg_29983672-5e6a-4ce3-b098-58c8a888079f"
      unitRef="usd">128782000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNS00LTEtMS0xMjY2Mjg_046c1b09-d37c-4f50-9163-f954aeef7284"
      unitRef="usd">121340000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNS02LTEtMS0xMjY2Mjg_b252c63e-81be-404b-a7d5-9cc2c186115d"
      unitRef="usd">371023000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfNS04LTEtMS0xMjY2Mjg_d0fbabcb-65b0-4359-b85e-0fb76997d5b7"
      unitRef="usd">358597000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOC0yLTEtMS0xMjY2Mjg_ff4ae6aa-669b-49a3-929d-44a03a2f5a1f"
      unitRef="usd">65261000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOC00LTEtMS0xMjY2Mjg_020bee0a-ffa4-4249-9db8-a9b35d50bc1d"
      unitRef="usd">59560000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOC02LTEtMS0xMjY2Mjg_167f1604-0e22-4780-bd9d-43e149bc9da1"
      unitRef="usd">197563000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOC04LTEtMS0xMjY2Mjg_e5d78ea9-38c4-4a00-aeba-d964a12fa5d7"
      unitRef="usd">178358000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOS0yLTEtMS0xMjY2Mjg_8bb532e5-d996-4193-b94e-64909359dee4"
      unitRef="usd">14628000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOS00LTEtMS0xMjY2Mjg_bc5916b9-44a5-40fe-857d-aaf4ef9782d5"
      unitRef="usd">14541000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOS02LTEtMS0xMjY2Mjg_f010d984-2210-4c56-9863-bbec58479618"
      unitRef="usd">42389000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfOS04LTEtMS0xMjY2Mjg_443983c4-6219-4c13-b155-1a5d0224cd29"
      unitRef="usd">38436000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTAtMi0xLTEtMTI2NjI4_761f5bcb-56c0-4148-92b0-c6231a42f09d"
      unitRef="usd">79889000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTAtNC0xLTEtMTI2NjI4_712ce54e-aa08-426f-94a4-bd5f1277a02b"
      unitRef="usd">74101000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTAtNi0xLTEtMTI2NjI4_7d4ff51f-4bbc-416c-a9bd-cb7199f4166e"
      unitRef="usd">239952000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTAtOC0xLTEtMTI2NjI4_35cf7e1a-bb11-4619-8a29-e33f3c348653"
      unitRef="usd">216794000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTMtMi0xLTEtMTI2NjI4_dba24db3-358b-43ba-9841-86cae43a64d6"
      unitRef="usd">40901000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTMtNC0xLTEtMTI2NjI4_f6cbb544-1771-4be9-8192-07b26d7eaab3"
      unitRef="usd">42667000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTMtNi0xLTEtMTI2NjI4_9860646f-5d11-4e38-a111-0edbd079f39e"
      unitRef="usd">113025000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTMtOC0xLTEtMTI2NjI4_c755e4f1-8cfc-432b-a275-a4ff62396a14"
      unitRef="usd">121761000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTQtMi0xLTEtMTI2NjI4_5b967ec8-844e-4e54-ad4a-75399efc812d"
      unitRef="usd">7992000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTQtNC0xLTEtMTI2NjI4_c1aea550-703b-48b9-8565-00bdfa3e3321"
      unitRef="usd">4572000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTQtNi0xLTEtMTI2NjI4_9eeef420-2535-4f35-a9ba-0fbc1ab3ad89"
      unitRef="usd">18046000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTQtOC0xLTEtMTI2NjI4_ef0f1856-760c-4fdb-b809-3ed0c27e3fb3"
      unitRef="usd">20042000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTUtMi0xLTEtMTI2NjI4_d3266411-5332-4a61-9893-443cdc8ea955"
      unitRef="usd">48893000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTUtNC0xLTEtMTI2NjI4_a9d19a5c-b027-4c41-9cfa-d0c9fa087027"
      unitRef="usd">47239000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTUtNi0xLTEtMTI2NjI4_fd8936fb-9dc8-4fcc-aa0e-770613f77a23"
      unitRef="usd">131071000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTUtOC0xLTEtMTI2NjI4_d0dad8e1-64ac-42dd-a96b-660d57d1babf"
      unitRef="usd">141803000</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTgtMi0xLTEtMTI2NjI4_6006fc89-f42b-4481-a350-5fdece3c9fec"
      unitRef="usd">64282000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTgtNC0xLTEtMTI2NjI4_264112a7-0f6d-45e0-a819-fd29e1675b29"
      unitRef="usd">63839000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTgtNi0xLTEtMTI2NjI4_ef7fcde3-cf32-4e20-812f-732fb144e95b"
      unitRef="usd">188481000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTgtOC0xLTEtMTI2NjI4_cdc869d5-bf22-4dc0-8208-1ece2e55f601"
      unitRef="usd">158953000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTktMi0xLTEtMTI2NjI4_a03d9e1f-282b-47e1-9e19-7c7d29e9c49c"
      unitRef="usd">7312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTktNC0xLTEtMTI2NjI4_9ef55631-eaec-4882-bef0-a8fddd09ff7d"
      unitRef="usd">7409000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTktNi0xLTEtMTI2NjI4_f3bbee5a-dd84-4875-b475-e7d37f4df3aa"
      unitRef="usd">23651000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMTktOC0xLTEtMTI2NjI4_a5689e21-c798-47a3-854c-3f634ff20db2"
      unitRef="usd">13360000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjAtMi0xLTEtMTI2NjI4_4b0270ff-2eb7-4add-beba-4dadd971a97e"
      unitRef="usd">16809000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjAtNC0xLTEtMTI2NjI4_79574a96-8dca-4087-9b00-504c3512b152"
      unitRef="usd">15704000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjAtNi0xLTEtMTI2NjI4_7ecb5b13-bb54-4c98-b246-17a150ffadc9"
      unitRef="usd">50179000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjAtOC0xLTEtMTI2NjI4_9c178638-e4fd-4979-98d3-1fe93c744d0f"
      unitRef="usd">46677000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OperatingExpenses
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjEtMi0xLTEtMTI2NjI4_0faf1ee1-f56a-43c1-912e-a90d0ffc29b3"
      unitRef="usd">88403000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjEtNC0xLTEtMTI2NjI4_b6a43f3b-de6c-4e61-845d-e72d461843b2"
      unitRef="usd">86952000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjEtNi0xLTEtMTI2NjI4_6c996615-8499-45de-bfa7-c1b1180e99e0"
      unitRef="usd">262311000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjEtOC0xLTEtMTI2NjI4_ec420888-774a-404d-93cc-7cd098b6ab30"
      unitRef="usd">218990000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjItMi0xLTEtMTI2NjI4_aa83a8df-a3d7-4062-bc17-a182d6eedd3c"
      unitRef="usd">-39510000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjItNC0xLTEtMTI2NjI4_01a41e6c-4045-43af-bc0f-05ee72cfb887"
      unitRef="usd">-39713000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjItNi0xLTEtMTI2NjI4_db33029c-e7b1-425d-bbbb-5504a19d0779"
      unitRef="usd">-131240000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjItOC0xLTEtMTI2NjI4_1635cf42-cf89-4c9e-b258-45d45d971193"
      unitRef="usd">-77187000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjMtMi0xLTEtMTI2NjI4_9d6774e7-83b2-446d-9007-68e8b98de745"
      unitRef="usd">139000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjMtNC0xLTEtMTI2NjI4_03b41ac8-ad15-42eb-aa04-3a4fdf257237"
      unitRef="usd">1296000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjMtNi0xLTEtMTI2NjI4_b90f45fb-bab3-4e35-bac5-f3451fdfd794"
      unitRef="usd">2366000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjMtOC0xLTEtMTI2NjI4_f2936577-5dd0-420d-988b-dd6c246f8193"
      unitRef="usd">3375000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjQtMi0xLTEtMTI2NjI4_1ce5b7ff-bd0b-427c-830e-b1870d0688b9"
      unitRef="usd">25000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjQtNC0xLTEtMTI2NjI4_d0048053-9c2a-41db-ab56-49cf11b6fb8a"
      unitRef="usd">89000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjQtNi0xLTEtMTI2NjI4_9ecff3c8-ec1e-41f4-bcc8-9288473a8ee6"
      unitRef="usd">-212000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjQtOC0xLTEtMTI2NjI4_f36bbc2b-5585-4680-9ef1-3add4c82eaa0"
      unitRef="usd">431000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnInvestments
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjUtMi0xLTEtMTI2NjI4_c628212c-1f95-481d-bd37-243754e88534"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjUtNC0xLTEtMTI2NjI4_8e0343e8-9324-4763-b8dc-35ac2f8cbef2"
      unitRef="usd">17750000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjUtNi0xLTEtMTI2NjI4_00a6af7b-9a19-4e54-b17a-f26d35e4305e"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjUtOC0xLTEtMTI2NjI4_5af65693-1464-4c6f-bc90-3fdfb17e5092"
      unitRef="usd">109260000</us-gaap:GainLossOnInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjgtMi0xLTEtMTI2NjI4_b8186eb3-7240-44ba-ac4e-01eaa3f3e34d"
      unitRef="usd">-39624000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjgtNC0xLTEtMTI2NjI4_a33d9137-4fd7-4785-bde2-1a10857cdf10"
      unitRef="usd">-23170000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjgtNi0xLTEtMTI2NjI4_fb00f796-f4b2-4996-a155-2d550f5a482c"
      unitRef="usd">-133818000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjgtOC0xLTEtMTI2NjI4_b1ddf957-6a0d-4767-932a-3ef1cef0e130"
      unitRef="usd">29129000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjktMi0xLTEtMTI2NjI4_47e61b3b-14fb-46d0-bac7-3005caed2c2a"
      unitRef="usd">-2772000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjktNC0xLTEtMTI2NjI4_b850c355-7850-45f8-949f-eeb98f6ea59b"
      unitRef="usd">-2822000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjktNi0xLTEtMTI2NjI4_21c4cf54-b642-4dca-840b-2a3189753bfd"
      unitRef="usd">-12255000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMjktOC0xLTEtMTI2NjI4_de7c8cb5-fa71-4f8e-a0c8-0eed7d3cdcb2"
      unitRef="usd">-4283000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMzAtMi0xLTEtMTI2NjI4_b9e9fb3c-79df-4e33-a3f4-8e22477d98e7"
      unitRef="usd">-36852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e804018c246429ebbc614cd307cfad5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMzAtNC0xLTEtMTI2NjI4_cf6744ce-f51b-412c-a6f2-7d982356ea74"
      unitRef="usd">-20348000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i975631ef90164404b70009f57bd9d5e0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMzAtNi0xLTEtMTI2NjI4_855d03a2-888b-412b-a77e-067705766df5"
      unitRef="usd">-121563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia126358383e44bd1b9fdd9b560c46a2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RhYmxlOjNkMWY4MDlkMmJiMjQ3ZTM5N2FlN2MwZDA2NzM1NDVkL3RhYmxlcmFuZ2U6M2QxZjgwOWQyYmIyNDdlMzk3YWU3YzBkMDY3MzU0NWRfMzAtOC0xLTEtMTI2NjI4_cb848e7f-9a0c-4703-85b4-166d2a03fc9e"
      unitRef="usd">33412000</us-gaap:NetIncomeLoss>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="i2639560cca8a4a08972d55827cb4627c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTEzMQ_1bb7898f-ff68-4a87-85ef-224f8b195eeb"
      unitRef="usd">4300000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="ib309ef6ef3b348c6802d707d98292e52_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTEzMQ_40291b43-93e6-4031-bb8c-f830b762796e"
      unitRef="usd">4300000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="i0833c6739bc34e8fb98d0012d57bbca2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTMxMw_8fedcc8c-9794-4883-b441-3f60b147c567"
      unitRef="usd">12800000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <us-gaap:InventoryWriteDown
      contextRef="i19908e283dc94d0d945d062e4df46a9a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTQ3Ng_6d47a5c0-aaa5-48ee-a8a1-8c15d63271e3"
      unitRef="usd">5300000</us-gaap:InventoryWriteDown>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="i0d2d45fade304e44806bc5487f10c762_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTUxOA_28bef9f5-6d55-4c40-84da-5c9d04dd9516"
      unitRef="usd">5000000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="i563f11e1511e41838ce4b805fcdc267a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTY3Mg_a35197d7-d68d-4a5d-8bf7-58b704e83fa9"
      unitRef="usd">600000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="ib4656829bc514b11b83bd81d1f88237c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTY3Mg_c002247e-69e3-4b91-985b-d954d797ee9d"
      unitRef="usd">600000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="i60bc548c06ef4128a5350dbb091d4f4b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfMTgxOQ_4bebb2be-9607-480d-874e-61d5f646b291"
      unitRef="usd">1800000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="iac5e97d9222c4e11860ce35bc66188a2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxMjk3MDAwOWJkZjRhNTQ5M2YzNmYwN2ExMzY5ZmE0L3NlYzpiMTI5NzAwMDliZGY0YTU0OTNmMzZmMDdhMTM2OWZhNF84OC9mcmFnOjVmOGZhN2QxMzM4OTQyYmM5ZGU4NzNkZTA1YTc0MzhmL3RleHRyZWdpb246NWY4ZmE3ZDEzMzg5NDJiYzlkZTg3M2RlMDVhNzQzOGZfOTg5NTYwNDY1MjE0Ng_80042df8-6b59-488d-b1d7-ca0a99296d4b"
      unitRef="usd">600000</neo:IntangibleAssetsAcquiredAmortizationExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %:%:%4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !6A6A5!XLI=.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OI\F*:.CFHGA2$%Q0O(5D=C=LTX1DI-VW-ZV[740?P&-F_GSS
M#4QKHC0AX4L*$1,YS%>C[_HL35RS/5&4 -GLT>M<ET1?FMN0O*;R3#N(VAST
M#D$TS0UX)&TU:9B 55R(3+762)-04T@GO#4+/GZF;H99 ]BAQYXR\)H#4]/$
M>!R[%BZ "4:8?/XNH%V(<_5/[-P!=DJ.V2VI81CJ837GR@X<WI^?7N=U*]=G
MTKW!\BL[2<>(:W:>_+:Z?]@\,B4:(2K.J^9V([B\%E+<?4RN/_PNPCY8MW7_
MV/@LJ%KX=1?J"U!+ P04    " !6A6A5F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M %:%:%41.>YET 4  ,,>   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9EK<^(V&(7_BH9V.KLS(=@RX;(ES!!ODC)-"!O2W=EV^D&Q!7C6MJ@L0_CW
M?66#G4WE%^I9OB2^G8,>ZW8L#39"?DN6G"OR$H5Q<ME8*K7ZT&HEWI)'+#D7
M*Q[#G;F0$5-P*A>M9"4Y\S-1%+:H975:$0OBQG"079O*X4"D*@QB/I4D2:.(
MR>T5#\7FLF$W]A<>@\52Z0NMX6#%%GS&U1^KJ82S5N'B!Q&/DT#$1/+Y96-D
M?W =J@79$Y\#ODE>'1.-\BS$-WTR]B\;EBX1#[FGM 6#?VON\C#43E".?W:F
MC>(WM?#U\=[])H,'F&>6<%>$7P)?+2\;O0;Q^9REH7H4F]_X#NA"^WDB3+*_
M9),_VVXWB)<F2D0[,90@"N+\/WO9O8A7 @ U"^A.0-\([*I?<'8")P/-2Y9A
M?62*#0=2;(C43X.;/LC>3:8&FB#6U3A3$NX&H%-#5ZRY)$V2+)GDR:"EP%/?
M:7D[_56NIQ7Z/KD7L5HFY#KVN?^]O@5E*0I$]P6ZHJCAC*_.B6.=$6I1:BB/
MB\LG8GU.K+9)_EUQG.+].)F?@[Z?OT;/B9+0Y/XVO:'<H6UVT/WP0[)B'K]L
M0$=+N%SSQO"7G^R.]:L)[P>9?0?;+F#;F/OPH_!2Z***/&U7W$2*RVVK^<F$
MA*IJ(ET42!?'(7U*F51<AEORR%="*A,>;J5D:GHI+JJJB=<I\#K'X4VY#(2O
M>R&!<<!8>;A3T>\J.QZJK\G9+3B[1[9,R6 *R6: ZGK$O>8L3(P5B<IJ O8*
MP!Y:J.M8!6I+;H*0DTD:/7-I L,]+,MN.A?=BXX)#I76A.L7</UCX![Y(M##
M*%3CA$7&-HK[3*X?;J\G#_=C=W9&QA/WW 2*6M0$M:UR.K6.01W'GI#0/)EN
MJ6=DIJ!/$B&)*])8R2W\]XW\!]PGGTW$N*@N\JL$81^#_,1>R-B'/AK, R_C
M1AKR <MNNTE[_:[3Z1EY47%=7EKRTF-X1[X/[LG9_H#<P7/D(3;7*V[9;_<M
M,N'BEL<B"KR$?&';,R,ZZE,7O0Q#-AH__H/NZC-HUD]B$QNQ<3L(XHK<;[E,
MS+"GR$)V&89L/,Z\A2TZ\52*=1![YHK&/6_NC*"G2$AV&9%L/-B\!9V*1+&0
M_!FLJL<IW-%Q^K8Q0^"ZNJ1E6K+QD).UUQ%\[E:#X0;OJ--_;P0[13JRRWAD
MXYGF3GA08].EB+'X<,"DV^DUK8YE&?E.$8[L,AW9>+1Y"A0$(S$G-GWW_)[,
MN)=*J$LC).[DBBB"J0D^K+UOY-W/UCFD)K)BDJQ9F')SW9XB.]EE>++QU .1
MUP_B!9EMHV<1&I$/QB8CUBF2$BV3$L6SS+X.R?6+MV3Q@E>&P@-&D]'LX\CX
MX8D+ZQ*6P8@>%8S<5$K]Z9)_KV0U"3-):EQL.>#XU;A$X^*JNIQE(*)'!:)Q
M#-_7^;*<_@9E>W C)^Y8Q7F*]$/+]$./2C_Z&PV2/(2!A9#&(>B SQV3T-I'
MGL?!"&S\W-)(?(H(1,L(1(^*0+.(A2&Y2A.XG9C;+>Y3^<F-Z^KRE<F''I5\
MKB,N%[ICWH*#6D(XB%8L-E<M;E@->HK@0\O@0_'<LJ_()8>*Q/!PFVJ\4\0?
M6L8?BB>7_4B;S^TS/;=#7L^6M,E#JB#.QGH*-1+_H&"S>P^YVT7FIK=0UD.;
M=AS+H1U[T%J;(,L,1(]:(G)A2)40]L:QSU_([]Q<CX=6BBS;ZG;MGF.$.$7>
MH67>H7A<V<^7-T&B0^U7#N$,6]<\8-=LVK3IV$;04R0@ITQ #AY<BD7-UZ0W
M<-$XQ!XPJUJUQ65U&<L,Y.")Y2WC;IVZFA*W^V1LL+BH+F.9?QP\K8P T,\A
M0V8<9 X85 ZKN.[_@K5>;1/J&2_;/4V(I]<D\QW#XFJQ0SO*]B5;Y>/Y]NX]
MTQ-F0D(^!ZEUWH413^8[IOF)$JMLT_%9*"6B['#)F<^E?@#NSX50^Q/] \6^
M]?!?4$L#!!0    ( %:%:%6ENSH+=0<  -8?   8    >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&ULK9G;;MLX$(9?A7"#H@6<F@<=V\1 FG2W!7H(FG;WFI'I
MF*@DNA*=-/OT.Y0<2Q8I.@%RT4:V9\A_>)AO2)W<J>I7O1)"HS]%7M:GDY76
MZ[>S69VM1,'K-VHM2OAEJ:J":_A8W<SJ=27XHG$J\AG%.)H57):3^4GSW64U
M/U$;G<M27%:HWA0%K^[?BUS=G4[(Y.&+[_)FI<T7L_G)FM^(*Z%_KB\K^#3;
MM;*0A2AKJ4I4B>7IY(R\/0^P<6@L_I'BKNX](Q/*M5*_S(=/B],)-HI$+C)M
MFN#PYU:<BSPW+8&.W]M&)[L^C6/_^:'UOYK@(9AK7HMSE?\K%WIU.DDF:"&6
M?)/K[^KNH]@&%)KV,I77S?_H;FN+)RC;U%H56V=04,BR_<O_; >BYT""$0>Z
M=:"/=6!;!]8$VBIKPKK@FL]/*G6'*F,-K9F'9FP:;XA&EF8:KW0%OTKPT_/S
M;U^OOGW^=''VX\,%>G_V^>SK^0=T]?'#AQ]7Z!C]O+I KXY>HR,D2_1CI38U
M+Q?UR4Q#S\9_EFU[>=_V0D=ZN1+K-XCA*:*84H?[N=_]0F3@3AIWLN\^@WAW
M0=-=T+1ICXT%O:DJ46K$ZUIH9SBM?^#V-UOK;;WFF3B=P-ZI174K)O.7+TB$
MW[F">Z;&]D)ENU"9K_7Y.:]7""8-9>9!_-[(6YY#[,ZHVZ:BIBFS_V_G-(H(
MC4YFM_UX;#-&HH3&.[,]I<%.:>!5^H57OX3FU[E M<@VE=12U%/$-5IR62&0
MO1$NT6VK84\-B>. ! /1#K,T"2/F%AWN1(=>T6=9IC8PFI#1,@%#"^JGJ!3:
M)32T%1"2ID.A+C-*&'8+C79"(Z_03^4MS+JJ8$Q=VB*K4\KB-!U(<UFQ-'0K
MBW?*8J^RRTJLN5QX-F-LCT@4$C(0Y["B+ S<XI*=N,0_OXTHM!+Y @$S40V;
MQR4QL3K' WFV!<$X')G5="<O]<K[IE>B DP<2F>IU7D<DN&VMHT2DJ1N@01W
M?,%>B3^4YODC)&Z;Z7<?8<:BX3BZ[!(2XF1$: ^$Y, ZA-JHTO=-MC2)<ET8
MQ:]@-R.UA'HCVQ2;G&NQ@#(!,G4F>5.(P&]'A(933)+&]8C@=)J&= HYH5Z+
MIDS)[U\[8R:.10'1),.8779I$(WL/-)QD'C9,_\&$4,4Y0W*!=1"J#)%S[%:
M'F_@@V>NJ*4G3=(@',JVS0@ /!T!!>F81OQ0^U1J7MY(@XI6Y&C.W3;4EQ
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MQ$ BZXNJ[FA1VK-^)C3<'+:9P]U.I F ]W,A]'/'7!_-UT+R%U!+ P04
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M![0MY)/&3A*[G_Q<A8(3M%X>Z%',92Y0&;^UA$'3ZZE]SJFC2P=P*KYYAG0
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M"=>-&HBCE!I9P<0Q@EW?2 L #F.U_5K68&/)J=V2'U#-IZ8SYB[E1)=LPMS
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M:#WVU@M.MM5<MR)<3(G5;2K^*0"5 /%\30A_6D@'[7\/_S]02P,$%     @
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MFI_KS=VL??68-[<M/ORN6_I_,[N[?_IEMUJW:KH(/JYVN]7B\.-]4]\TF^Z
M]N^WJ]7N],MERW]8;3X=8ES]'U!+ P04    " !6A6A5^/".'X4)  !<*P
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MW%?;(A<B&+KJLD9?Y$??W55X+SU%%AQ&06+DO2GFH*=8PS#VP_#%FLLW<A-
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MLWT0U:JY#?E8"5$MFX\+1C-6*P'Y_;RJQ-N#^H'N0NW9?P%02P,$%     @
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M_BLHS=147$5+%'V)-[%=)2E.QK/)Q&,ENP];^P!V@R3B9H,!NB4KOWZ_<PZ
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M;BR(:BUE/14%\[M3]4W/N1*=#D/SM?I5\DK:+I74H>M&G$B2X704: >CZ :
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M*8BFWINW%7V0=DJ2(7E_ZHL#1#I:$1611^<TQ1]1D:^@N:B\M4'$KJ20>/A
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MF5%[P+2E'%0*V>"7O'C DZWBPQS8'=>]"7E1@G:BQM5YBN2]TN0(?RSR=G?
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M]PPC9*;G("F:S1ITA7K[UT96M:6?C"SJ-V5.F1GW(X/HRL6G3(( 8 ,ZA:!
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MN93_4A<E_VX814==[/GC3B&5JF@!WF^*HO9?Z(#VA^1O_PM02P,$%     @
M5H5H5>TUK2,&"P  B"(  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
MU5IKC]LV%OTKA!L4$T SHY<M>YH,,$DWW0+)MMLD712+_4!+M$U$$A6*\L3]
M]7LNJ9=?,Y-M%]C]8DO4Y>5]GGM)Z<6]TI_JC1"&?2GRLGXYV1A3W5Q?U^E&
M%+R^4I4H\62E=,$-;O7ZNJZTX)F=5.37H>_/K@LNR\GM"SOVL[Y]H1J3RU+\
MK%G=% 77NU<B5_<O)\&D&_A%KC>&!JYO7U1\+=X+\['Z6>/NNN>2R4*4M50E
MTV+U<G(7W+R*B=X2_"K%?3VZ9J3)4JE/=/-C]G+BDT B%ZDA#AQ_6_%:Y#DQ
M@AB?6YZ3?DF:.+[NN+^QND.7):_%:Y7_0V9F\W(RG[!,K'B3FU_4_5]%J\^4
M^*4JK^TONW>T43QA:5,;5;23(4$A2_?/O[1V&$V8^V<FA.V$T,KM%K)2?L\-
MOWVAU3W31 UN=&%5M;,AG"S)*>^-QE.)>>;V#9>:_<KS1K!W@M>-%K"XJ5]<
M&S GDNNT9?3*,0K/,%JP=ZHTFYK]I<Q$MC__&D+UDH6=9*_"!QF^%]45BWR/
MA7X8/L OZC6-++_H<4V_EW6:*U*V9O^\6]9&(SC^=4IGQS(^S9(2YJ:N>"I>
M3I 1M=!;,;G]]IM@YG_W@,!Q+W#\$/>O<<U_Q(C9\:T=ES6%,N9EC-?,; 03
M7](-+]>"55JF D/<(,&:/&-+@6Q,!9(I8T %QI%;=0W\P'7%9<:,8K!H6:\$
M'K)<\J7,I=FQ"U"*+](XEL^9+.U*N"M36?&<&!2J-HQG6UX:8()J:@2[_@3F
MM!)1]TL-?,$'G)7.A,YW;FGN<GXIS+T09<>CXMI(6HJT5V[U8K (R[@15]92
MW$XW(MV4\G.#,&EJ815KR=EJL%V!+*64E(7\75B>(&9JQ=220H(O<]BWK!JL
MR<N,DOB(LBF/:*_8W7B1C12:ZW2S8QLX:$E*B=J 7B+W,PM,F5-)"\%RL15Y
M39P=,X\N[S<RW=A55U)#9'.O&(<JJ0+$PG;$8)""1"7:G(-T+-\5>TO<67##
M_MXH@UG6G;5U@\78UMRU]1DXES ZO&L]5X]=)P74_+!!YEA!S*XB0OA0+0VW
MP;C2JD"T\?S2H!2PS[2@XSMR\WCI/FP[&62Y5?E6ENLC23I%PAOV8V<E:$QA
MAG#Z?*!;FC? -:"SV6"UU@1>:U22?F2[\['J,2'M&IE$#AE2%28JN[LG6B.3
M^>Z2;[G,[7(D(RE8JT:GK7E252#:VW@"P#4VY3N5HQOV\3CD2!NA;6!J"PF0
MV. IV)6JRR%K9\JZ\TIV6K1!CS)+-=@2:U$IY""$)5^8W;??S,,@^0Y1<6]1
MI"DJYU'$*]$C([G#GE,I[/"HL4OU5CAG^%&*""00HEJ6KJFQW4%OS1:54JG3
MID"*E2E%Z9T+7LJ*MT/T.M'(6RVP CX-&^$M<6:_B+31FF1[Q6N8%=9AK\D_
MY:[#DYJE0I.7D9LEEI1#OH#A" <L0]TS7!)#KPU/&^2F0TRK3$V43E02O5LD
MY?6&B<^-!%,7%V.9.D# G#S?8]$9Z1*&NZPQ=[RTV2AX@A($$AB:L[.(2G"U
M4U@]" 'OU"-X';H@-)0+N'I?5H(E($\M5W)(.E*:8+H#$N>HUY!6Y9)6RF#@
MG!S&WE-#5+>U;&?Y#1X&C-=-18'8LT23JVT@P.XY$%]F)'TI1-;:!H*#3Y\#
MJ6HH (FO]<L(@5O@Z.+U##:V7$]["ES7HH1$E/V'_!U&'=<6EX]JWY 7@WM:
M@5*EM5HJS3MTHV>8ZM@6*J/"8<.Z,8CRW\6)I>J&,(^T,G A,DE;-Y-3=U(@
M);'^5M3/!Z''J59IM96$I4LJW9G _H*0&8M*G5U2@N]ZP2Q*0!&/@%U4K@WX
M>/4>YM,V<W9C;0<P_B-.6:D<6Q4;T:0TU'7MAW'%DQ>$8+^#6XI>Q6-KK6KT
M!R55*3N\1H;5)\;1<=:ME8:$[I&N3;X>$,^$AHN\KO,ZE9)[Y)8].FDCBB7<
MV[735HCOT<2YT<".!E>G*"\L'J(1PQ1X]*[7_C5U:C]8)3\.2OY RA\/OW6Z
MCY#Q38]S#EIOD+-@?8F(*DXK?W/>\<_8-/3FX0P7UH#A=[BZF,\7S^E1X"VB
MA/W&RT]HC99 HIK-O2B)>MJ+( Z>8RR,0G:'S$MW/=E\X8_)$B)+XHB]:TKI
MFE9'&6#])!F1>D& U8/ 2Z9S<FXAM-6VXH :-O,623Q0AR#%4#QUQKA<\O03
MK#;2$/X(@A'_:> _9^'"F_D)N.O*)G0KRRSTDG ZXNY-HP@+@,4B9!^4@1C/
M6# 'V3S<-]G4BV9S,EJ0)%X<Q,=!\G\4$,DB($WHYR*(K%H8G<WB_5B8>4$R
M95 LF)$7L'O;#X(@\:;Q;.1:D-%8Y)^*@C@>!4P8(*XP&(:+XQ@ C]EB% 3Q
M<S?DGPV"$(]#GT2=0X:09)@>>W\*-\_9 @RG(12*$8'3P>N+A1?# L]82*Z_
M6(21=?=B[DUGT5X;L.$9>^9?)=BQY+GMD4H[,.L'@"T )$U(.Y0"NS5T6PCS
M9.CQ,*^NA$7C?.<-_;;L"MYQ\:=6YZ'BKT5NAU'NSW9%5VC.QK!M>T87FJH\
M@\%=X^NV6J1.B>Z\;6T8%;/LG-Y'PP&[M[UV@=HH-&+C225HW ^N3I6 TX(O
M;6MG#SL:!$/?I'V%GYY2(GZ",7X37),MWPJD_4];4/>C'S9:->L-\GWK1EJ"
MT;T+UF- >#>H]?YI*! AGWT*]&#JS9$L8[ [51>F7N+'#( 9SGO*$W5A!FQ<
M@"P*XQ'9J;K0/6T+P<'MJ;H0#\C=_3]<&L*IYT]#%GO3Z3#U3&F 'XE5")WB
MH9H<5@8@5C!+< 4L(;JQU9Y<&/Z7PB"$1Z<^Q0.5T7@_#$Z4A-@+0!YZ?N"/
MG'!<&6+/CP,6>?%\,;CV=&GH'[MJ<'![NCCX1Y'P6('PO?EL#E%GL\&[9^H$
MPB;&CBQ:>%$\M$*'Y<+'O:V@B\B;3_>[A7'1> 2Q#KO;PPVH.QG[,UI>=U!)
MH%J,MN2/[*#W#P=.'KO]^:UT>X;4G4)U1S-GP_[U@<UNZ,1]V)2N&O(J>27Q
M%GZPYZFQS]S3HX#K2"( Y6)Q>/ON*_NO%EL/P_=T*T[P>DAYLAE/1H'Z,.P>
MP.UCL+L/M$^#W0.D?01X#Z#V#/*&"3(JL5UK!%B"8F/?Q1 _? KT_I<B*YP2
M+B9G(JM[>M:X .$8'?G![5='EH/KH\@ZW=C/CB'T3(<?G03;,TW^&,$?0_(#
MZ'XBDA^ ]R-8?H#>9\ \BK$GBOTVNN)D'R/B!,4>4/_!GOY:!"V'%SD6_8[.
M)O?/\FD3H.Q94F.(O#\D;^/0<ZV B\4_M8O^8^>S?U/E4 ^&(]J4:[VCH;[3
MME7+GJ,>)(PW' D.^Q^/E<*,GE1\YX:[/9/X4HFR.Q)RNYR1-;W1\,'FAQ[L
M4^Z_QJ&T4:7-*6S)9&%/Y]PY$S0?=EI[YU!?L0M@66-/41V_>MBFE[2E$/NG
MR3ROU?$Q=ZG*RZ<<=9=CW[2GW96&2EKF='QH>+F6=K-I67ALK51VC_VI,U^N
MRO5E;E]5MFO0.;(JR_:C 'M:C2R5*I,I$]ONU9_;Y57*T $D!)3016IZA[*O
MW&#>XWV9.]5NEVUJ4F"0_,0;/Q+8HSZ#CE>];OJ^9_OL&;U^'+W2O3KUVOEZ
M]'4 H&EMOX& )R@JW8<"_6C_F<6=^[I@('??: "LU[1+SL4*4_VK9#IAVGWW
MX&Z,JNRW!DMEC"KLY49PR$X$>+Y2,&E[0POT'Y_<_AM02P,$%     @ 5H5H
M5;"PR*:^!0  ' X  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK5=9
M;QLW$/XK R4($H"U]CX<VX"/'GEH:MAN^U#T@=JE)#:[I$)2EIU?WX]<659B
M60F"O.SRF/DX]Y!'*VT^V+D0CN[Z3MGCT=RYQ>%X;)NYZ+D]T NAL#/5IN<.
M4S,;VX41O U,?3=.HJ@8]URJT<E16+LT)T=ZZ3JIQ*4AN^Q[;N[/1*=7QZ-X
M]+!P)6=SYQ?&)T<+/A/7POVYN#28C3<HK>R%LE(K,F)Z/#J-#\\R3Q\(_I)B
M9;?&Y#69:/W!3]ZUQZ/("R0ZT3B/P/&[%>>BZSP0Q/BXQAQMCO2,V^,']%^"
M[M!EPJTXU]W?LG7SXU$UHE9,^;)S5WKUFUCKDWN\1G<V?&DUT.;IB)JE=;I?
M,T."7JKAS^_6=MABJ*)G&)(U0Q+D'@X*4EYPQT^.C%Z1\=1 \X.@:N"&<%)Y
MIUP[@UT)/G?RJ];M2G8=<=72.^6XFLE))^C46N'LT=CA#$\Y;M9X9P->\@Q>
M3;]KY>:6?E:M:#_G'T.VC8#)@X!GR5[ :[$XH#1BE$1)L@<OW2B<!KSTNQ2F
M"VF;3MNE$?3/Z<0Z@[#Y=Y<9AE.RW:?X5#JT"]Z(XQ%RQ0IS*T8GKU[$1?1V
MCP[91H=L'_IW.&TOWFYIOV*HF[F@J>Z0U%+-R'&_-62V_"0L.6PWW)A[O\M[
MO53@T5.:/:!.[LF*&=+;$7<$+SO13X39N#H<>R&:]6H<5F-Z+16P]=)BV[XY
MI'/H(AO> <'<R@8G7\XYLO5Q?J,=ML]XQU4C_%E/05]25B2LB%*,BHSE<8)!
MGI0LCG,Z;?]#&@9!7\=OZ'7*JL3_\Z3"-V-I5K_9AM^A"O#SBI65'Q4IJZLL
MX">L+(H >K$TP8HPFIM+T]+')3<.$+"81V"T$BB!C39(*N+T,CM(40VZSA>V
M5C0HQQ:L^M&\WGH@AS<76K4>?)L,94M@KR6I&MUCB=]1)_E$=M))81DIX1AI
M%20ZU\KJ3K;<@>%!T6M?<:S'"J<T\*(B"?=#:@E[ UX;B-P%+I!Q6AB)I07V
M=7L0XF<@6G%+2CO:\'IJ=0]Z<2OAZ>X>. MM/!!7:@D*<$GEJ7L<OR7=5"I(
MYS&LPX)WFCW8#EX^!*]GDM9SP,#NLTC^,L!VN/.TAS#R$P]MY5Q;1Z=-L^R7
M@Z[OT4G/0^$&SY4W ,CL7"XLE?03(:)>4IRE+(Y\X.48E#XNJIK528W@O$6C
M7 #G1C1SI3L]NZ<X&AC3.&))4A BLZQ*2JJ$92DJ+C<?A//"KW,SHSRK(6M&
M:9;3C>$M.CFZ_(#!LC(EA'L-$D1EF0T4])XC$G+LY(C/HHPH9G6</;)#AG<H
MZK"Q= +A<@LA7[U ,B1O*4Y9EI5?3H?4@Y)1S-(J\EHBN]*0$''!JJS:D8P_
MTKI9SLJ\P* NF3?%-UDWCEE95Y34%<N2ZCGKQE%$&?X[K1NS.,E]P*10<8=U
MDQ).9&E4_5CKYC6+<F^!+ ,Z)+@)Z=LO?#H-Y</Z8OQH7W&'VQUJPDJB[BCD
M!<R-E$#F";44H8K,A!*&#Q6%M[B"2-\5_5UJP[VK4%P_)*#'^P-9/WCJX%L:
MQTX1<0%=%T@C!LD4VACUPW5#^.O&<VUD9^>X"3C;MY4OV-][^#W[ 3Y /XX^
M"UXH+C>EQ_I:VRW;4'2?&!HN8U6>#O]D"&*6Y[5W*O[9-P-_W5N64E:DI?^&
M,$:2QU0C8.MU1/$]1R&#659'P[_T;2S),8@&@8LJ'>JZ=;(/4;#3D]M=8;WO
M@T ^*=/>Y8(W\Z=5>N@B".9PJ=CA%QGV!@;[Q/=7PK]7VL<&NU$,DY12].@B
M>#0;QL'%N1]7>>7'A1_G/@GG EUUZGMU@O3+O076>9E%R%.4H5T7OO'6C1V5
M;!;>);XOX9XT7-XWJYNGS^EPXW\D']Y-J$\SJ2QU8@K6Z*#,1V2&M\@P<7H1
M[O\3[5 VPW".YYLPG@#[4ZW=P\0?L'D0GOP/4$L#!!0    ( %:%:%621^A;
ML04  ($;   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;.59;6_;-A#^
M*X2;%BW@VI)LQTGS B3-ABU8NZ+9RX=A'VCI;!&E2)6DXKB_?G>4+-N9K"2M
MMZ7KEUB4[H[//3R2#\/CN38?; K@V$TFE3WII,[EK_I]&Z>0<=O3.2C\,M4F
MXPZ;9M:WN0&>>*=,]J,@V.]G7*C.Z;%_]\Z<'NO"2:'@G6&VR#)N%N<@]?RD
M$W:6+]Z+6>KH1?_T..<SN +W:_[.8*M?1TE$!LH*K9B!Z4GG+'QU/B1[;_";
M@+E=>V:4R43K#]3X,3GI! 0(),2.(G#\N8;7("4%0A@?JYB=NDMR7']>1O_>
MYXZY3+B%UUK^+A*7GG0..BR!*2^D>Z_G/T"5SXCBQ5I:_Y?-2]MHW&%Q89W.
M*F=$D E5_O*;BH<UAX-@BT-4.40>=]F11WG!'3\]-GK.#%EC-'KPJ7IO!"<4
M#<J5,_A5H)\[O8").^X[C$3M?EQYG9=>T1:O0_9&*Y=:]IU*(-GT[R."&D:T
MA'$>M0:\@KS'!D&714$4M<0;U&D-?+Q!2UKL0MA8:EL88'^<3:PS6 )_-B5;
MQAHVQZ)I\<KF/(:3#M:]!7,-G=-G3\+]X*@%Z;!&.FR+OG4 [O8BK@[8:ZVN
MP3@QD<"N0 EMV%OMP+*?%;ODJL"9QL+0$XM_70KHD>5<+5B,OQ(<)/ZMY1A
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M9X6GZFIR?7)Q<\;VR> O39NP=RV8R<JYKWSS3EU-Y@R(#)61(TA\K>F6C.%
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MJ*Y1Z'T$EKCDN*NXIOJ.RP-"ELZ6ID_[=1+DL+3L#]J62''V:VQS+;<.)\&
M3M6-TF$R6W1\8 >YWYVBTWC-$C^%G?+"0>D*QAA':0: :V[^VY^G8G6=A4#<
M0Y;[F=/'QA.]8*,G<+-"SH)**F/L86C>%?EQ(YL>G(>?9W<S3-+:<67O3<4-
M>1YJOYITK_L4)H=O$^A<D'V5QT \L/+?M]$HH-(J+4]:_WWQ$H>G@O]@V"=R
M1Y0JRS28:[,]+,YN/U)']J*\=:A=B_P_Q&Y;2JF'?LZ2YJ$!G=#,Z?A"?'PY
MN'":*UH- ZVWE5P[GY332%9&IG^XRF6-X1+B061'I@)/UW(8UFA8; 9)!)0#
MXTDTI%))18B25+8XN@_E@T)*;)D?!X4[;-']WF_ANI%>A=FA8TJQ=X)LR=?I
MG,R]T-N8#Y/CT_$H?IU/H(_F^1S_7OH:S(6A"J[SV>N7$^'SV3C?1->E\^C*
M19QNTV6#GQ/DV0#O*^?B[H83C#]0EO\!4$L#!!0    ( %:%:%6NZW%M]P4
M *\0   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;+586V_;-AC]*X1;
M% F@VI)L.<X5:-(,Z["F09UM#\,>:(FVB$BB2E)V\N]W/E*^I;:WMMN+3%'\
M#L]W)WVQ4/K1Y$)8]E06E;GLY-;69[V>27-1<M-5M:CP9:ITR2U>]:QG:BUX
MYH3*HA>'X;!7<EEUKB[<W+V^NE"-+60E[C4S35ER_7PM"K6X[$2=Y<1G.<LM
M3?2N+FH^$V-A?ZOO-=YZ*Y1,EJ(R4E5,B^EEYUUT=CV@]6[![U(LS,:8D283
MI1[IY4-VV0F)D"A$:@F!XV<N;D11$!!H?&DQ.ZLM27!SO$3_R>D.72;<B!M5
M_"$SFU]V1AV6B2EO"OM9+7X6K3X)X:6J,.[)%GYM/^RPM#%6E:TP&)2R\K_\
MJ;7#AL!HGT#<"L2.M]_(L7S/+;^ZT&K!-*T&&@V<JDX:Y&1%3AE;C:\2<O;J
M#GX_^E49<\P^5*DJ!;L7FHUSKL5%SV(#6M9+6[!K#Q;O 3ME'U5E<\-NJTQD
MV_(]$%NQBY?LKN.#@&-1=UD_#%@<QO$!O/Y*V[[#Z^_!N^6ZDM7,K)5D?[Z;
M&*L1''_MTM?##7;#4<*<F9JGXK*#C#!"ST7GZLVK:!B>'R [6)$='$+_5M=\
M-QA[R 6[467-JV?F]*BL81-E<XIWF3*QM%H-$>-$CMZ\&L5Q>'Y[/W:CZ/R8
M\2ICF2P:*S*&^2Z[=M(8,O&4%DTF@* LT"4O_$J7EQ"3AH%3[40GS_@VEQEV
M9!58%R!-DQ8L%R[)1/:6SX5&S6!54TY 2DU)O@2:HV<8RH^Q0"805"XG#/92
M95WV?LV1R@K5!^,7?$W.YMP"NBDRIM*TT4Q.&7(R?61\P75FP C6$$]"I](
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M0K:Y6#0+;ZIXF*^,1SKCWP)W,;;! -_7!K5J%R% =[N;_0]02P,$%     @
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M/,Y%& DN1(%1$D<\*TL:11&/X^I%J@O!<Q&QN,+?A.413Y.,925/BY+];*G
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MXJW&OO;\VAM#F*6XUJM:+W4AZU9<%(7IZE;7*_')5+K0RHE'\=/QFY,6I.F
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M/H9/A^W,*RWE\Q'4&=,&P349R)>N"^Y<0AFR-!V5U[]W$I:TY'MP/3RVWC+
M;+W,2ZL%.@)%V5/7E$Q:8]FE,H=4W[1K0^AFBY"SJW)OWH?J)^+1Z3&A6U9_
MR!+^Z?(T4:D5Q%C"ZDR=.I\LIU;L/CAI?DS]%! 0A2([%&?A5OLDC&V/GAQ[
MO_4$ I!2^,&RSGEYD2SAZ*NN(C&F@Y)VJ:UKPV)H!#I$:2@IU27F!@$)[&6,
MUAP]K.=*?Z6\R)Y&JDCPE/DG>7*(-4;RVN_O793@>R>/3(*FZ4E?/'P8F!)0
MQ\8()?#_A:N,?$ M0 =I#F8*JDM.F_D4G+GUNA\L3272  07G-30;!#ANUSW
M-7[B&U8:<,MK65TCT0]:*Z26MD^V?3U&Y_?4J"++I4#]'S K)'4X.6%\[!N]
MDLB;;]<:T3,@'EX2BJO2C4B12OR>@:&[]K7<4"D^@%NW<QX5]4PX+U.C GT-
MS%%$G0VQ1@$FW5HLD?1AU :5GZ3L'4I-M.Q?T<W'YY,@8]>BG_I#N6 RGZV9
M813L022J%N4^G#U+.'NV'RU5C<Q>,4\7)6)2TXR*7>E=Z-_X'55Y_M,OS#6I
M(2X8P^B]5,?'68>PDJ^1PS6QW?3UBN-TU\BM12W#R^/GV!/Y?!D=;7>F@9Z6
MLNHDC(Y@UW6'2*4F$^F!NYELE(1H+-:UJ<QJZWL.PZBVPR'B$=57K2JJ#FZI
MGL3_^WJBH:/*RIF8*;B#6 )4L JJ(.UI9@@(&SKQJ(R)^/ K\6DEF.C0)E/!
M2')/Q K%'V<*"D%R^#K4[2"5]_>I#.,4$:JP^.T>21\/=8SH71U@-SW20&5M
M$WCZV(0JE$JE/0Z9O=RDEXD.Y=C&(NZMIKZO;:U&ZN4PHV)KTU1FJ^[*$'.'
MX[-[U)Z$)U8U:>QYP]WN"!/DFUV%_CDVI_TK+KQY; ]]!J-F+A.U Z^DCE5<
M![.+/2#P,H' R[T@X&=I4,:]T[2Q$#_DS/M/%!]H?'GC1X%^#$CRO;^XOD0^
M<1TT?W']!4NF_/;QZ6PB?J2ZO.;$@>Y+TW 0.GKTJVET(<Z>S(\GX@<_5.IH
MK(:L=QEKH'>4(BDRY,*@SKKG) K_^>PU$0Y$^<GIZV,*1Z2YKN$V/0S87%]C
MJ7@^E3=AL#5 "%]IDL,Q Z']0FI/C,B>$6AB&V8Y*K9\OE(MDWR1B<'TB'6(
MO$3O0UZZ,]/.1VV[8^@MCZV\*2KNF!!^+LXVPC1<^$L_/POBP8^+81I&AZ#N
MQX>A7>M3.:=!$$KA1@FQ'\_W!R7J?$!>_5+MZ$*?BF+:"S8B[%1D=J0:Q8]V
MN!:EBM8KU ^!8$FUTG7-@;BD0B:-J4^?Q3$U3R_1XY(12\,3)=J.2AUR#JFY
M-=?V*&I87*A!:09**N:' R":,E!+G9LI--7<WA6FZ?LKJ*;T!D^*[B=0V#&B
M21<G#W' ! !I:44P1/#.DD?O RX2"45W)$R F%WZ.F__@=1+H-NPJMT5UH\Q
MAX;*4QU7@ZQ?+(75[KD1(&FI(OMKEP]SEKPT"%RJZOV4R:LZ6IA5KUU/&#+P
M;9#L!X2AX3;U8:/\*8'?1[1#!V+?[&S2(]E5-B%-V#=[!NS+L';)=X\U7S?&
M215)FI[]W(_M_0@ROO'.)ZY")@()$5"Q=_#9F8BX*(; R Z*;J#3_CJ.I]3^
M,L)[4^V1<BL>R8*?V^.^[O<9T4\L>%+'K&:CY_0LNW40X2!_$S@Z21Z[(_SL
MA^</">_U^WSVG"2]"*Y!!!T##\< -S51G!CZP663$T;$#4/[)(H;8RY1I0I1
M4RL"EZ,QF%Z%JT=NA.(1TX%I[B#=$CD#_D=A\##.S?,^.=Z?1I!,N$0AG!\[
M%>^&N'@7L'Q#ZL$R(Y%V:![(#"FFAC,U;#T5-[IC,EBNTUT8ART!U':7+T+D
M$9@B3!Z]E6"5]MWHKC,(4Q2=Y91)22:!9:_WH)I,?6':T,\>U(Y4M">(O@/:
M!+*C^62<=R;$'-YA< ^:AROKS);UP./N9KL[+(VSPYSP4&*7F]Z#\WN1GH5A
MSH"=P]2[2L,^]E_"C>A@_4$YFL?R)$*X)Y1>_RE(1R<"KX!69GL!??9X]G0"
M %HBJ5+(?R;&\)425P3TIV?'K\1[W] -Q@SO^ONI\1,H!28&/Z?YQ1T8)RXB
MC(OCX-&PVXTF'V380B]D+/^N@#6(\RA!ECK==_J+>^]98;X=+A]2!@ [L=9-
MZ+TQ9;H9\ >M5;DB+ADEZ>E:-W[V+9TO:A>=+=&_Y?>?["?Q7B@,4[BN\-&8
M;M9^1IF([Q\HI-!IUU_%1[H0QB;66Z^9GS]<?OR<Z00Z\.VM39JV,MQ-RPJG
MU;Z%W7G-OO WB;H$JCLDO9^* ]QA-!&?9MR"J:)"4[L,5SI1[0<8+P"CV;$,
M?*P$_MQX*?N,Q:DXG#YNN53]T^0QW&2$@I:13;DVJ)*OR9?9T(S;Y#0UF_!0
MI&O]L-'Z.009&T3IMS!MI;*K7CH'H%K0:)I[&DM-M*S0/?@;FD![.@B"6YEG
MS RH8T2?SCDUSD+'OMV+=(ZZM9TZVM\]CA>?N3'W<!+]Z87O1L98V<UB4,9?
MX6ZD+(_W*,,32.GCH=WC.]V'A5]HD%L-(X:^DK=S+7[G;F"0N),SYP CZ?YQ
M98@.W^30Y2S_%@K^'62:Q>+&W_^1HFN3+LI,7C6D&>##5_D9&.4.!85D5AT=
MTYYD/[Q$I;GBGY?RE5#=^M]@IJ?I%ZP7_H>;_7+_\]=?.!CHGF&)K;/IBV='
MPOJ?E/HOK6GX9YP+TZ*LY8]K)1'9M #OE\:T\0L12+_K/?\O4$L#!!0    (
M %:%:%44O9(SW0<  &(4   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;*U86V_C-A;^*X0;% Z@B76WG"8!DLRV.T6G#2;9W8?%/C 2;;,CB1J2BI/^
M^OT.)2MR)G8"[+[8%'GN_,[A(<\V2G\U:R$L>ZS*VIQ/UM8VI[.9R=>BXN9$
M-:+&RE+IBEM\ZM7,-%KPPC%5Y2ST_716<5E/+L[<W(V^.%.M+64M;C0S;55Q
M_70E2K4YGP23[<07N5I;FIA=G#5\)6Z%_4=SH_$U&Z04LA*UD:IF6BS/)Y?!
MZ55"]([@GU)LS&C,R)-[I;[2QZ?B?.*30:(4N24)''\/XEJ4)0F"&=]ZF9-!
M)3&.QUOI/SO?X<L]-^):E?^2A5V?3[()*\22MZ7]HC9_%[T_SL!<E<;]LDU'
M.X\G+&^-557/# LJ67?__+&/PX@A\_<PA#U#Z.SN%#DK/W+++\ZTVC!-U)!&
M ^>JXX9QLJ9-N;4:JQ)\]N(R_]9*(RE"ADWO^'TIS/'9S$(T$<SR7LQ5)R;<
M(V;!/JO:K@W[6UV(8I=_!I,&N\*M75?A08&WHCEAD>^QT _# _*BP<_(R8OV
MR+MJ#6:,8=>JNI<U[R!1%^S2&$!_% ;V[\M[8S7@\I_7XM"IB5]70RET:AJ>
MB_,)<L0(_2 F%S_^$*3^3P><B <GXD/2+VZ1DD5;"J:6[(O(U:J6?XF"?2I$
M;>52BMX;T[FC\4T>_B;YO2SAFS"TWE8O-ZAS[+#JN[5@2U4BAV6]8I9PTB<R
M3##,8KEI=;Y&@K <6)*%T%V0-0S5  78M:/CHUC#D3O-&]0&SZTMN=3L@9>M
M\Y%F:NP.[[SB8Z_*D5>\\\IS"\24\S)O2[Y5L5*JV,BR=/E;,$P2D7C,"1"]
MGEVCL?^U60I-VM2#T/^[<8Q;Q]*[NX,X9*Y@4TEFJ=9 @/&<=8UE#72;-=>"
M%4COXU-V6:FVMNSFU6"?LENB=4[EJJH@&Q4D_\HDC" ;S L_D\7<FP<ANQG4
M#/Z]B_^(Q=E)%K"?=T*SPPJ_]_I\Q,*%%\QC=E.VYI1=<[-F#9<N6'FI#&$M
M2KQD$; [97FY#V-'+(V]>9JP2R T'_9]/RI[74=L'D3L#]!I%%OL=CWL9YB%
M0V(YM,O:\GHE:>A(V ?48?U56#*R9TKBQ9M,A7A +!I$TXI\7:M2K9Y8L/#\
MV.\M*56]^F"%K@9;TJSW7XZ%OT1>Z'M9$K+KWI$Q"*?S)#AFO\. MR0$?L!^
MV>9+''MI&K\S]K^VM6!!YDIVP#X+;EHM*K($Z)(*Q:GX$P<:S9C1^ 7?+I+N
MMV4[?R[;>W!RQ*)%!JC$&/WX0Q8&X4\[H^WJKH+?()[^K^&^M"Q(/-_W!Z[M
M?S_]$N7[*@:R(H@.F+)=W96' ^-!(O_+IP]K419,8%/L$T%((*4MFV('T]!;
M! L6>(ML/@A$_!=^^D+:4"#^:)Q]Q)T@ M&<O)FGT< ^C[T(SG6;O'PS_+ _
M04[ZB8]1@/+A!L_.)4GH99#W?2J.9!_85PB-/1^(?SUV_>*K.3L-X:,7I2F+
MXF3@@;=!P&XT<DXCGE2?*;2- U\ ^Z/O]]O-'LQDLR^5*="1CWU" 9D&D+1(
MCP?!X2+P@BQ]6S3@5 BJ+Z83"#F(Z30,1\(P&:-VOE5PG"A6\THX4:$7A2$+
M1UZ'7C)/]M6>U OC[Q.BFWU'38H SC@*7"3B,!X9GT3(J?GKU2J&>)@Z#;PT
M\9]YIHF7+3#_4?2))FO@1Z =>=SECXZG4#6%[C0#?X2_E 'F*,_3)/72.#G^
MSM\7!J2+D>+!@'[^[4*Z0"T.L6$++\JRXUYWF &+V:B^DI4ABFP8^2R<>T&4
MD0J08CJ=>SY2_?^=E@2!<6UNNMK,G^MQHR6U=>436C?T4-3=*<89JDF](H Q
M%"-06((]?\3RT%7]V6II"IEWMPE0;M8R7U/C)W)NB*'1:BDI4)KZKP97,Y*B
MV+U@*U%3+17%B<OCPS:.+*/*HKMF>%ML8&Q7SCO]GVKY@.8)30RC+;-EIS,O
MN:Q<5YJC,.#^RJACYRB;KD;TR>W4D:DU!+:Z0]?[K7L];L4; $:?Q<D:7"VW
MQ1/4;7>1E5W[RETC:)P#SUEO!BC"A<X.=-XM64X<VLJ_'%Q.'/8^8L.HG8<X
MNY:Z8-]:KI$-I)0N7A[;B.<&GK.C^"3"+;0LR8Y"(,ITPL#-H<,FM2"'[8U"
MQ"!\3/:&WQXUU-ZV/[\&B%0I"^?"%2]YG0OTMX*\H^TC+3EJ/R)245BU1*)
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MEI=2XQ0E"1P_M!;P-^"5ALJMYP(9HX466%I@7S5'Y.*G)UHQ0U)9&G@=M7P
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MVJQ2Q6H?]AF.DE;3?PPM%(H23O,*7I )>0:!X\(Y1$X$][E\.E\*1,@I)FI
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MB$-"6"YP! ;C!?!\KK7;OG@#NZ%Z\A]02P,$%     @ 5H5H52YOO7_H P
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M)FX?)KB/)GXX/FOC@-V&P&:#[<<&#BLYO2>R:OWUZ<.81O3+FS_UP[.]ZLC
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MI"I_S.M*%=G M8'ZOF!,;AO:05FV!_\ 4$L#!!0    ( %:%:%6(P?8A8@,
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MO1M:Q4]Z_5*,!B_$<#!T>C;HO;UYM,E>"N?J:'//WOSMNG@I!M.CS?WOV_C
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MF"U_\]7=Z7OAS&6L18>D95 :@=(HE,:@-(ZBJ=*4T4$2O, U'S0\@-(R*(U
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M'8A*#%4K@P?$@Y?<-M8<.[.==OQ[KITT=%M6$.(EL:_O.3[G.KY)-E+=Z0+
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ME*]8I7ZYX:*DM;H4MU.Y$HPN6J>RF*(@B*8ES:O)[*S][K.8G?%U7>05^RR
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M<'.5WWWP@6ND:-W!:OU%\*BX"GG+@<')&RE:-WE[!WU_:7"8JY"I]:H@Z/.
MQ4I1%7%L,J1+ N0O"9Y.5LC4?0.DSZ0+4)<%:."1VDU6R#PR*[+JUR]6*U<>
MM: C_]G:3U;(/"DG,>GKD<5*S3%VI5#K)?+KY:=UE6?YBA8>PO)&&+SG1HK6
M':\68!0?%V%YZX'!R1LI6C=YNCA _N+@"81EJCU$26SL,YL9(:[5K,L"Y"\+
M!C"6*?X&8_E,NAU*71Q@?W$P@+&P>60^@1#VCX,V,^0ZMF(M[-A_L/9S%K:=
ME..PWP.TF2&$4@<X+9S8+YP7O"R9R'+%6BNZ8L(*<=2^]EC1N@/>ZVSCHV(M
M["T,!B=OI&C=Y.DJ ?NKA"<\%S!E/TKC?N/88@7C*'4T-[ N#_# UKN3M+!9
M!/1)RVO2!:AK!.RO$8:0EGEL/D$&95F,7%G4PH[])^L#A&5IIJ<D[ .S'*C5
M#+L2J'43']#-9LN>S&EVIY+G[[K[(PW>>?]'WQUK.<;'U7G'H[;>QXK6?5JH
M2P7RW-X[,:4?!TJ'^P\+33,41\BQJHDN$<A8O7=RN/=N,7'4,$27"62TUCNQ
M--5#:("T->@=QT.BQ9T\I_-.S',S2J/ F&2+F3H?.AJ69.^AM5\\+[A8<4%K
M3_/='V'HKALK6G>\6HS)<37?R:C-][&B=9.G"P7RW.8[L;3548SZ0FPS"V'J
M>,A%=)% QFJ_D\/M=XN)XV1#=*5 1FN_$TMC'86XWSBRF9'0\;8(T=).GM.
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M-OT7']> '?<Z8>_+FQV\VHR]AR%[N]-'8](<!#E0<!2-N_+,: +<_Y0=MX5
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ML=]'Y)X9Q"U%F""WWK#2>X-(S3<(W*!BFE+V"@)6/FC3\4_B9YH&%_K*G_1
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ME]>4AU&<OQ*&7^^OP<L7K\ +$*7@RY;M<P&9SZ=<1%E\UW191?3^&!'JB"@
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MPD!\OF:,/UT47W Z7KSX'U!+ P04    " !6A6A5:75,#9@#  "V$   &0
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MN1TD07=/WMV@RZ*[RK\GMR;E_V"%"8L51FUI!7+K<_B=*(.*4B04EQ']]/^
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MI+9:[;:]%Z=[X9!)L J8LYUD>Y^^MB&$!)+=5'F3V##SYS=C#V/&&\9_B Q
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M(VEC;']XOK\1=%V=#K]2(6A>7:X(3@@K!?+]!:7B<%-VT/P+P_1?4$L#!!0
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ME/B4)P!XOF#P;IG?)!T4Q\R3?P!02P,$%     @ 5H5H5?W PP]7!0  OB8
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ME4/_N1$&E</@N1&&E8,9NEN.W20NI(I.QX(?B-#62-,7)OO&&_/%<OVBK)3
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M^K1)GB?S%)=LG*>_)8MJ=3-P!VC!EO$VK1[RUY#M$K)JWCQ/R^8G>FW+.MX
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M[/#MDQR_Q,5SDI4H94L>ROCH<)T7[<,1VS=5OFF>G/>45U6^;EZN6+Q@15V
M_WV9Y]7;FSK _A&5H_\!4$L#!!0    ( %:%:%6%$VG 1P,  ,H4   -
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %:%:%41.>YET 4  ,,>   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !6A6A5I;LZ"W4'  #6'P  &               @($3#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 5H5H5?FZ/QOZ @  .0@
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M965T-RYX;6Q02P$"% ,4    " !6A6A55JNXCU,'  #8$0  &
M    @(&Q1   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M5H5H52>M3LT)$0  8S0  !@              ("!.DP  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( %:%:%4Q7W I/Q(  %0^   9
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M970Q-"YX;6Q02P$"% ,4    " !6A6A56A=$8<P,  !3)0  &0
M    @($JC0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M %:%:%6(K$I?4 4  *P,   9              " @2V:  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ 5H5H5:[K<6WW!0  KQ   !D
M             ("!M)\  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !6A6A5YYH!\.(&  #[#P  &0              @('BI0  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %:%:%4#E>;@3@0
M .D)   9              " @?NL  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ 5H5H59%,9IWF!@  ]0\  !D              ("!
M@+$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !6A6A5
M35C^(Z8.  #C*P  &0              @(&=N   >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %:%:%44O9(SW0<  &(4   9
M      " @7K'  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ 5H5H5;M:V["$!@  _!4  !D              ("!CL\  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !6A6A5STEUV>P%  !S#P
M&0              @(%)U@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( %:%:%5VL@M"7 0  -\*   9              " @6S<  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 5H5H58I+>F!S
M!   8 L  !D              ("!_^   'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !6A6A5+F^]?^@#  "4"@  &0
M@(&IY0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %:%
M:%6[Y4\-8@4  #<,   9              " @<CI  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ 5H5H5=DXVK>; P  P@\  !D
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M=#,S+GAM;%!+ 0(4 Q0    ( %:%:%7!OQ,A=@8  ,8H   9
M  " @4,: 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M5H5H5=&K:S@[!@  %R@  !D              ("!\" ! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !6A6A5MV/31%P,   VD0  &0
M            @(%B)P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( %:%:%63O1*.- 0  '46   9              " @?4S 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 5H5H515]"J*$!@
M:BP  !D              ("!8#@! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !6A6A5:75,#9@#  "V$   &0              @($;
M/P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %:%:%57
M-^E'E (  /$&   9              " @>I" 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ 5H5H5?I&( MF"0  (6\  !D
M     ("!M44! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %:%:%40B:'^Q0,  . ,   9              "
M@6MA 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 5H5H
M5; EJ)1> P  S0P  !D              ("!9V4! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " !6A6A598[!!NX$  #.(   &0
M        @('\: $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( %:%:%6:M15X*04  '(>   9              " @2%N 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 5H5H5?W PP]7!0  OB8
M !D              ("!@7,! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " !6A6A5/OE*]?@"  ! "P  &0              @($/>0$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( %:%:%6OT%8N
MK ,  'P2   9              " @3Y\ 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ 5H5H532L4W[1"0  KE(  !D
M ("!(8 ! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !6
MA6A5A1-IP$<#  #*%   #0              @ $IB@$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( %:%:%67BKL<P    !,"   +              "  9N-
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( %:%:%6 YRGJ9P0  %HC   /
M          "  82. 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !6A6A5
M?'[I&]0!  #&'P  &@              @ $8DP$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " !6A6A5*F32ILH!  ";'P  $P
M        @ $DE0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /0 ] *(0
(   ?EP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>346</ContextCount>
  <ElementCount>313</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NatureoftheBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossIncomePerShare</Role>
      <ShortName>Net (Loss) Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/Acquisitions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/RevenueRecognition</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Net (Loss) Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossIncomePerShareTables</Role>
      <ShortName>Net (Loss) Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/NetLossIncomePerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SegmentInformation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Nature of the Business - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NatureoftheBusinessNarrativeDetails</Role>
      <ShortName>Nature of the Business - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Acquisitions - Schedule of Provisional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails</Role>
      <ShortName>Acquisitions - Schedule of Provisional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Acquisitions - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/AcquisitionsProFormaInformationDetails</Role>
      <ShortName>Acquisitions - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Amortized Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Fair Value Measurements - Fair Value by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Goodwill and Intangible Assets - Estimated Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/Debt</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Revenue Recognition - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenue Recognition - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Net (Loss) Income Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Net (Loss) Income Per Share - Schedule of Antidilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails</Role>
      <ShortName>Net (Loss) Income Per Share - Schedule of Antidilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="neo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SegmentInformationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="neo-20220930.htm">neo-20220930.htm</File>
    <File>a09302022neo-ex311.htm</File>
    <File>a09302022neo-ex312.htm</File>
    <File>a09302022neo-ex321.htm</File>
    <File>a10-1retentionagreementcin.htm</File>
    <File>a10-2amendedemploymentagre.htm</File>
    <File>neo-20220930.xsd</File>
    <File>neo-20220930_cal.xml</File>
    <File>neo-20220930_def.xml</File>
    <File>neo-20220930_lab.xml</File>
    <File>neo-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1127">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "neo-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "contextCount": 346,
   "dts": {
    "calculationLink": {
     "local": [
      "neo-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "neo-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "neo-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "neo-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "neo-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "neo-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 494,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 29,
   "keyStandard": 284,
   "memberCustom": 19,
   "memberStandard": 35,
   "nsprefix": "neo",
   "nsuri": "http://neogenomics.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://neogenomics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Acquisitions",
     "role": "http://neogenomics.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "role": "http://neogenomics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Debt",
     "role": "http://neogenomics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Stock-Based Compensation",
     "role": "http://neogenomics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Revenue Recognition",
     "role": "http://neogenomics.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Income Taxes",
     "role": "http://neogenomics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Net (Loss) Income Per Share",
     "role": "http://neogenomics.com/role/NetLossIncomePerShare",
     "shortName": "Net (Loss) Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "role": "http://neogenomics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Related Party Transactions",
     "role": "http://neogenomics.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Segment Information",
     "role": "http://neogenomics.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Acquisitions (Tables)",
     "role": "http://neogenomics.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://neogenomics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://neogenomics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://neogenomics.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Net (Loss) Income Per Share (Tables)",
     "role": "http://neogenomics.com/role/NetLossIncomePerShareTables",
     "shortName": "Net (Loss) Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Segment Information (Tables)",
     "role": "http://neogenomics.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "neo:PolymeraseChainReactionTestingExitCostsCOVID19",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Nature of the Business - Narrative (Details)",
     "role": "http://neogenomics.com/role/NatureoftheBusinessNarrativeDetails",
     "shortName": "Nature of the Business - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "neo:PolymeraseChainReactionTestingWriteOffsCOVID19",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "neo:AssetHeldForSaleSquareFeetOfFacilityOwned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "neo:AssetHeldForSaleSquareFeetOfFacilityOwned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "iff7308f890e64260ae7552498699b417_I20210407",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Acquisitions - Schedule of Provisional Information (Details)",
     "role": "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
     "shortName": "Acquisitions - Schedule of Provisional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i0254e4cf16114941859a750438514071_D20210407-20210407",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Acquisitions - Pro Forma Information (Details)",
     "role": "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
     "shortName": "Acquisitions - Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "ia3189dabeae047b78cfbb5d2f4ffa661_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost (Details)",
     "role": "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails",
     "shortName": "Fair Value Measurements - Schedule of Amortized Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Fair Value Measurements - Fair Value by Contractual Maturity (Details)",
     "role": "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
     "shortName": "Fair Value Measurements - Fair Value by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis (Details)",
     "role": "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "iacdf3ffa20844c33b3b4b233621d3bda_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "ic8321097bff14046a282e8abcc199611_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Classes of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i56e071a65fde4540a8f2f69263d43769_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "neo:GainLossOnInvestmentAndLoanReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Goodwill and Intangible Assets - Estimated Amortization Expense (Details)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i2e078001d1454b3cbc7f7d7b83568f2e_I20210111",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Debt (Details)",
     "role": "http://neogenomics.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i2e078001d1454b3cbc7f7d7b83568f2e_I20210111",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "ic8321097bff14046a282e8abcc199611_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "ic8321097bff14046a282e8abcc199611_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails",
     "shortName": "Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "id36af2f403f24cf7b4525fc88fa61cb6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "id36af2f403f24cf7b4525fc88fa61cb6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Revenue Recognition - Narrative (Details)",
     "role": "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Revenue Recognition - Contract Assets and Liabilities (Details)",
     "role": "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails",
     "shortName": "Revenue Recognition - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i83580aae10c642e8968c0f73731cc216_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "role": "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i12404422705e4e5db442f2c6fa044950_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Net (Loss) Income Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)",
     "role": "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails",
     "shortName": "Net (Loss) Income Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME",
     "role": "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Net (Loss) Income Per Share - Schedule of Antidilutive Shares (Details)",
     "role": "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails",
     "shortName": "Net (Loss) Income Per Share - Schedule of Antidilutive Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "ib4d31e5c09604f229766351b8ba0d0fc_D20210111-20210111",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "ie54a7a7e84624ef48b6fa7119e60f286_D20210120-20210120",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://neogenomics.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "ie54a7a7e84624ef48b6fa7119e60f286_D20210120-20210120",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i79ee0320473e4c25be7915c5434f0efe_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Related Party Transactions (Details)",
     "role": "http://neogenomics.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i79ee0320473e4c25be7915c5434f0efe_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Segment Information (Details)",
     "role": "http://neogenomics.com/role/SegmentInformationDetails",
     "shortName": "Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i6e30f17ca1b1469d95e7b43f6888d02f_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i27adbda67be34d02b60f48394e1038b2_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i1dd080603fcd48d18c04d2943c42ebfc_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Nature of the Business",
     "role": "http://neogenomics.com/role/NatureoftheBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://neogenomics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20220930.htm",
      "contextRef": "i975631ef90164404b70009f57bd9d5e0_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 58,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt",
        "label": "Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt",
        "negatedTerseLabel": "Premiums paid for capped call confirmations"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_AssetHeldForSaleSquareFeetOfFacilityOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Held For Sale, Square Feet Of Facility Owned",
        "label": "Asset Held For Sale, Square Feet Of Facility Owned",
        "terseLabel": "Square feet owned (in sq ft)"
       }
      }
     },
     "localname": "AssetHeldForSaleSquareFeetOfFacilityOwned",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "neo_AssetsHeldForSalePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Held For Sale, Policy",
        "label": "Assets Held For Sale, Policy [Policy Text Block]",
        "terseLabel": "Assets Held for Sale"
       }
      }
     },
     "localname": "AssetsHeldForSalePolicyPolicyTextBlock",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other",
        "terseLabel": "Measurement period adjustments, other current assets"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities, Current",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities, Current",
        "terseLabel": "Measurement period adjustments, current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value",
        "terseLabel": "Measurement period adjustments, fair value of Purchase Option"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Assets Acquired and Liabilities Assumed, Net",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Measurement period adjustments, net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Deferred Income Tax Liabilities",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Measurement Period Adjustment, Deferred Income Tax Liabilities",
        "terseLabel": "Measurement period adjustments, deferred income tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentDeferredIncomeTaxLiabilities",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Step Acquisition, Purchase Option, Fair Value",
        "label": "Business Combination, Step Acquisition, Purchase Option, Fair Value",
        "terseLabel": "Fair value of purchase option"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionPurchaseOptionFairValue",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_COVID19PCRTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 PCR Testing",
        "label": "COVID-19 PCR Testing [Member]",
        "terseLabel": "COVID-19 PCR Testing"
       }
      }
     },
     "localname": "COVID19PCRTestingMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_CappedCallTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped Call Transactions",
        "label": "Capped Call Transactions [Member]",
        "terseLabel": "Capped Call Transactions"
       }
      }
     },
     "localname": "CappedCallTransactionsMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Acquired From Acquisition And Working Capital Adjustments",
        "label": "Cash Acquired From Acquisition And Working Capital Adjustments",
        "terseLabel": "Payments to acquire business, adjustments"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_ChiefLegalOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chief Legal Officer",
        "label": "Chief Legal Officer [Member]",
        "terseLabel": "Chief Legal Officer"
       }
      }
     },
     "localname": "ChiefLegalOfficerMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ClientDirectBillingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client Direct Billing [Member]",
        "label": "Client Direct Billing [Member]",
        "terseLabel": "Client direct billing"
       }
      }
     },
     "localname": "ClientDirectBillingMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Services [Member]",
        "label": "Clinical Services [Member]",
        "terseLabel": "Clinical Services"
       }
      }
     },
     "localname": "ClinicalServicesMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_CommercialInsuranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Insurance [Member]",
        "label": "Commercial Insurance [Member]",
        "terseLabel": "Commercial Insurance"
       }
      }
     },
     "localname": "CommercialInsuranceMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ContractualObligationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation.",
        "label": "Contractual Obligation [Line Items]",
        "terseLabel": "Contractual Obligation [Line Items]"
       }
      }
     },
     "localname": "ContractualObligationLineItems",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_ContractualObligationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation.",
        "label": "Contractual Obligation [Table]",
        "terseLabel": "Contractual Obligation [Table]"
       }
      }
     },
     "localname": "ContractualObligationTable",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_FairValueOfCommonStockIssuedToFundAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Common Stock Issued To Fund Acquisition",
        "label": "Fair Value Of Common Stock Issued To Fund Acquisition",
        "terseLabel": "Fair value of common stock issued to fund business acquisition"
       }
      }
     },
     "localname": "FairValueOfCommonStockIssuedToFundAcquisition",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_FederalHealthcareProgramRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Healthcare Program Revenue",
        "label": "Federal Healthcare Program Revenue [Member]",
        "terseLabel": "Federal Healthcare Program Revenue"
       }
      }
     },
     "localname": "FederalHealthcareProgramRevenueMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_GainLossOnInvestmentAndLoanReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Investment and Loan Receivable",
        "label": "Gain (Loss) On Investment and Loan Receivable",
        "negatedTerseLabel": "Gain on investment in and loan receivable from non-consolidated affiliate, net"
       }
      }
     },
     "localname": "GainLossOnInvestmentAndLoanReceivable",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Investment In And Loan Receivable From Non-Consolidated Affiliate, Net",
        "label": "Gain On Investment In And Loan Receivable From Non-Consolidated Affiliate, Net",
        "negatedTerseLabel": "Gain on investment in and loan receivable from non-consolidated affiliate, net"
       }
      }
     },
     "localname": "GainOnInvestmentInAndLoanReceivableFromNonConsolidatedAffiliateNet",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Investments And Loan Receivable From Non-Consolidated Affiliate",
        "label": "Gain On Investments And Loan Receivable From Non-Consolidated Affiliate",
        "terseLabel": "Gain on investment in and loan receivable from non-consolidated affiliate, net"
       }
      }
     },
     "localname": "GainOnInvestmentsAndLoanReceivableFromNonConsolidatedAffiliate",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_IncreaseDecreaseInPrepaidConstruction": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Construction",
        "label": "Increase (Decrease) in Prepaid Construction",
        "negatedLabel": "Prepaid lease asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidConstruction",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InivataMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inivata",
        "label": "Inivata [Member]",
        "terseLabel": "Inivata"
       }
      }
     },
     "localname": "InivataMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_IntangibleAssetsAcquiredAmortizationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets Acquired, Amortization Expense",
        "label": "Intangible Assets Acquired, Amortization Expense",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsAcquiredAmortizationExpense",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InterestExpenseDebtAccretionOfDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Accretion Of Debt Discount",
        "label": "Interest Expense, Debt, Accretion Of Debt Discount",
        "terseLabel": "Interest expense, accretion of debt discount"
       }
      }
     },
     "localname": "InterestExpenseDebtAccretionOfDebtDiscount",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Amortization Of Debt Issuance Costs",
        "label": "Interest Expense, Debt, Amortization Of Debt Issuance Costs",
        "terseLabel": "Interest expense, amortization of debt issuance costs"
       }
      }
     },
     "localname": "InterestExpenseDebtAmortizationOfDebtIssuanceCosts",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InterestExpenseDebtContractualCouponInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Contractual Coupon Interest",
        "label": "Interest Expense, Debt, Contractual Coupon Interest",
        "terseLabel": "Interest expense, contractual coupon interest"
       }
      }
     },
     "localname": "InterestExpenseDebtContractualCouponInterest",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_MedicareAndOtherGovernmentalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare And Other Governmental [Member]",
        "label": "Medicare And Other Governmental [Member]",
        "terseLabel": "Medicare and Medicaid"
       }
      }
     },
     "localname": "MedicareAndOtherGovernmentalMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_OnePointTwoFivePercentConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Five Percent Convertible Senior Notes",
        "label": "One Point Two Five Percent Convertible Senior Notes [Member]",
        "terseLabel": "1.25% Convertible Senior Notes"
       }
      }
     },
     "localname": "OnePointTwoFivePercentConvertibleSeniorNotesMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PatentInfringementComplaintMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement Complaint",
        "label": "Patent Infringement Complaint [Member]",
        "terseLabel": "Patent Infringement Complaint"
       }
      }
     },
     "localname": "PatentInfringementComplaintMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PaymentsOfPremiumsForCappedCallConfirmations": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Premiums For Capped Call Confirmations",
        "label": "Payments Of Premiums For Capped Call Confirmations",
        "negatedTerseLabel": "Premiums paid for capped call confirmations"
       }
      }
     },
     "localname": "PaymentsOfPremiumsForCappedCallConfirmations",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_PharmaServiceContractsWithCytomXTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Service Contracts with CytomX Therapeutics, Inc.",
        "label": "Pharma Service Contracts with CytomX Therapeutics, Inc. [Member]",
        "terseLabel": "Pharma Service Contracts with CytomX Therapeutics, Inc."
       }
      }
     },
     "localname": "PharmaServiceContractsWithCytomXTherapeuticsIncMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Services contracts with HOOKIPA Pharma, Inc",
        "label": "Pharma Services contracts with HOOKIPA Pharma, Inc [Member]",
        "terseLabel": "Pharma Services contracts with HOOKIPA Pharma, Inc"
       }
      }
     },
     "localname": "PharmaServicesContractsWithHOOKIPAPharmaIncMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PharmaServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Services [Member]",
        "label": "Pharma Services [Member]",
        "terseLabel": "Pharma Services"
       }
      }
     },
     "localname": "PharmaServicesMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PolymeraseChainReactionTestingExitCostsCOVID19": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Polymerase Chain Reaction Testing, Exit Costs, COVID-19",
        "label": "Polymerase Chain Reaction Testing, Exit Costs, COVID-19",
        "terseLabel": "PCR testing, amount recorded, COVID-19",
        "verboseLabel": "Write-off of COVID-19 PCR testing inventory and equipment"
       }
      }
     },
     "localname": "PolymeraseChainReactionTestingExitCostsCOVID19",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://neogenomics.com/role/NatureoftheBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19",
        "label": "Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19",
        "terseLabel": "PCR testing, general and administrative expenses, COVID-19"
       }
      }
     },
     "localname": "PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/NatureoftheBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_PolymeraseChainReactionTestingWriteOffsCOVID19": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Polymerase Chain Reaction Testing, Write-Offs, COVID-19",
        "label": "Polymerase Chain Reaction Testing, Write-Offs, COVID-19",
        "terseLabel": "PCR testing, write-offs, COVID-19"
       }
      }
     },
     "localname": "PolymeraseChainReactionTestingWriteOffsCOVID19",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/NatureoftheBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_ProceedsFromEquityOfferingNet": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Equity Offering, Net",
        "label": "Proceeds From Equity Offering, Net",
        "terseLabel": "Proceeds from equity offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromEquityOfferingNet",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_ReceivableWithImputedInterestNonConsolidatedAffiliates": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable With Imputed Interest, Non-Consolidated Affiliates",
        "label": "Receivable With Imputed Interest, Non-Consolidated Affiliates",
        "negatedTerseLabel": "Interest receivable on loan receivable from non-consolidated affiliate"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestNonConsolidatedAffiliates",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_RepaymentsOfEquipmentAndOtherFinanceObligation": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of Equipment and Other Finance Obligation",
        "label": "Repayments of Equipment and Other Finance Obligation",
        "negatedLabel": "Repayment of equipment financing obligations"
       }
      }
     },
     "localname": "RepaymentsOfEquipmentAndOtherFinanceObligation",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Intangible Asset Amortization Expense",
        "label": "Schedule of Intangible Asset Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "neo_SelfPayServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Self Pay Services [Member]",
        "label": "Self Pay Services [Member]",
        "terseLabel": "Self-Pay"
       }
      }
     },
     "localname": "SelfPayServicesMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Reduction in Options Outstanding, Weighted Average Exercise Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Reduction in Options Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardReductionInOptionsOutstandingWeightedAverageExercisePriceAbstract",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Reductions in Options Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Reductions in Options Outstanding [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardReductionsInOptionsOutstandingAbstract",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_SocialSecurityTaxEmployerDeferralCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Social Security Tax, Employer, Deferral, CARES Act",
        "label": "Social Security Tax, Employer, Deferral, CARES Act",
        "terseLabel": "COVID-19, deferred social security payroll tax"
       }
      }
     },
     "localname": "SocialSecurityTaxEmployerDeferralCARESAct",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/NatureoftheBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_StrategicAllianceWithInivataLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Alliance With Inivata Limited",
        "label": "Strategic Alliance With Inivata Limited [Member]",
        "terseLabel": "Strategic Alliance With Inivata Limited"
       }
      }
     },
     "localname": "StrategicAllianceWithInivataLimitedMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_TrapeloHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trapelo Health",
        "label": "Trapelo Health [Member]",
        "terseLabel": "Trapelo Health"
       }
      }
     },
     "localname": "TrapeloHealthMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_YankeeBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yankee Bonds",
        "label": "Yankee Bonds [Member]",
        "terseLabel": "Yankee bonds"
       }
      }
     },
     "localname": "YankeeBondsMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Two Five Percent Convertible Senior Notes",
        "label": "Zero Point Two Five Percent Convertible Senior Notes [Member]",
        "terseLabel": "0.25% Convertible Senior Notes"
       }
      }
     },
     "localname": "ZeroPointTwoFivePercentConvertibleSeniorNotesMember",
     "nsuri": "http://neogenomics.com/20220930",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r377",
      "r535",
      "r536",
      "r539",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Inivata Limited",
        "verboseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r103",
      "r293",
      "r298",
      "r304",
      "r479",
      "r480",
      "r483",
      "r484",
      "r542",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r103",
      "r293",
      "r298",
      "r304",
      "r479",
      "r480",
      "r483",
      "r484",
      "r542",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r0",
      "r107",
      "r117",
      "r124",
      "r215",
      "r425",
      "r426",
      "r427",
      "r439",
      "r440",
      "r487",
      "r489",
      "r491",
      "r492",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative-effect adjustment from change in accounting principle"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r0",
      "r107",
      "r117",
      "r124",
      "r215",
      "r425",
      "r426",
      "r427",
      "r439",
      "r440",
      "r487",
      "r489",
      "r491",
      "r492",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r0",
      "r107",
      "r117",
      "r124",
      "r215",
      "r425",
      "r426",
      "r427",
      "r439",
      "r440",
      "r487",
      "r489",
      "r491",
      "r492",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r283",
      "r285",
      "r286",
      "r287",
      "r310",
      "r341",
      "r380",
      "r382",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r576",
      "r632",
      "r634",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r283",
      "r285",
      "r286",
      "r287",
      "r310",
      "r341",
      "r380",
      "r382",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r576",
      "r632",
      "r634",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r188",
      "r285",
      "r286",
      "r357",
      "r361",
      "r578",
      "r631",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r188",
      "r285",
      "r286",
      "r357",
      "r361",
      "r578",
      "r631",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r273",
      "r283",
      "r285",
      "r286",
      "r287",
      "r310",
      "r341",
      "r369",
      "r380",
      "r382",
      "r415",
      "r416",
      "r417",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r576",
      "r632",
      "r634",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r273",
      "r283",
      "r285",
      "r286",
      "r287",
      "r310",
      "r341",
      "r369",
      "r380",
      "r382",
      "r415",
      "r416",
      "r417",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r576",
      "r632",
      "r634",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r104",
      "r105",
      "r106",
      "r110",
      "r111",
      "r114",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r146",
      "r218",
      "r219",
      "r440",
      "r488",
      "r491",
      "r492",
      "r493",
      "r522",
      "r530",
      "r531",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r104",
      "r105",
      "r106",
      "r110",
      "r111",
      "r114",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r146",
      "r218",
      "r219",
      "r440",
      "r488",
      "r491",
      "r492",
      "r493",
      "r522",
      "r530",
      "r531",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r1",
      "r104",
      "r106",
      "r110",
      "r111",
      "r114",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r122",
      "r123",
      "r146",
      "r218",
      "r219",
      "r440",
      "r488",
      "r491",
      "r492",
      "r493",
      "r522",
      "r530",
      "r531",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r193",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchaseProgramAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to adjust previously recorded stockholders' equity balances to the actual aggregate amounts paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.",
        "label": "Accelerated Share Repurchase Program, Adjustment",
        "terseLabel": "Incremental stock-based compensation for accelerated vesting"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseProgramAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r545"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r194",
      "r195"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "verboseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r48",
      "r49",
      "r50",
      "r619",
      "r640",
      "r644"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r57",
      "r58",
      "r59",
      "r104",
      "r105",
      "r106",
      "r482",
      "r531",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Amortization Period (years)",
        "verboseLabel": "Amortization period of acquired intangible assets (in years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r425",
      "r426",
      "r427",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForErrorCorrectionDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r119",
      "r120",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of error correction.",
        "label": "Error Correction, Type [Domain]",
        "terseLabel": "Error Correction, Type [Domain]"
       }
      }
     },
     "localname": "AdjustmentsForErrorCorrectionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "terseLabel": "ESPP expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r384",
      "r428",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense - options and restricted stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Stock issuance fees and expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net\u00a0cash\u00a0used in operating\u00a0activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AgencySecuritiesMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued by government sponsored entities.",
        "label": "Agency Securities [Member]",
        "terseLabel": "Agency bonds"
       }
      }
     },
     "localname": "AgencySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock compensation expense (gain)"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r73",
      "r89",
      "r330",
      "r517"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of convertible debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r67",
      "r89",
      "r330",
      "r519"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issue costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r89",
      "r252",
      "r260"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangibles",
        "verboseLabel": "Total amortization of intangibles"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r208",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r19",
      "r99",
      "r170",
      "r177",
      "r184",
      "r214",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r479",
      "r483",
      "r505",
      "r543",
      "r545",
      "r598",
      "r618"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r35",
      "r99",
      "r214",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r479",
      "r483",
      "r505",
      "r543",
      "r545"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r265",
      "r545"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r99",
      "r214",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r479",
      "r483",
      "r505",
      "r543"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r203",
      "r207",
      "r614"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Over Five Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r203",
      "r206",
      "r613"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Over One Year Through Five Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r203",
      "r205",
      "r612"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "One Year or Less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "verboseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r379",
      "r381",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r379",
      "r381",
      "r458",
      "r459",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Shares of common stock issued as consideration (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interests acquired (as a percent)"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill, tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Stock price per share on closing date (in dollars per share)",
        "verboseLabel": "Per share value of common stock issued as consideration (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r456",
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r456",
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r470",
      "r471",
      "r472"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r470",
      "r471"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Fair value of common stock at Trapelo Acquisition Date"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": {
     "auth_ref": [
      "r453",
      "r472"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination",
        "totalLabel": "Total fair value of business combination"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.",
        "label": "Business Combination, Consideration Transferred, Other",
        "terseLabel": "Fair value of Line of Credit",
        "verboseLabel": "Line of credit"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r465",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred",
        "terseLabel": "Measurement period adjustments, net assets acquired",
        "totalLabel": "Measurement period adjustments, net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to equity interests acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests",
        "terseLabel": "Measurement period adjustments, fair value of previously-held equity interest"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteMeasurementPeriodAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to financial assets acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets",
        "totalLabel": "Measurement period adjustments, total identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "terseLabel": "Measurement period adjustments, identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedTerseLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income tax liabilities",
        "verboseLabel": "Increase in goodwill from deferred income tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r460",
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r460",
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total purchase consideration"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Fair value of previously-held equity interest"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "terseLabel": "Gain on investment in and loan receivable from non-consolidated affiliate, net"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Abstract]",
        "terseLabel": "Capitalized Contract Cost [Abstract]"
       }
      }
     },
     "localname": "CapitalizedContractCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "totalLabel": "Total pharma capitalized commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetCurrent": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalizedContractCostGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.",
        "label": "Capitalized Contract Cost, Net, Current",
        "terseLabel": "Current pharma capitalized commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalizedContractCostGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Long-term pharma capitalized commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r14",
      "r91"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r85",
      "r91",
      "r96"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r85",
      "r509"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r602",
      "r623"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r288",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments an Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, (250,000,000 shares authorized; 126,562,037 and 124,107,500 shares issued and outstanding, respectively)"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r64",
      "r607",
      "r627"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "COMPREHENSIVE (LOSS) INCOME"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Contract Assets and Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r345",
      "r347",
      "r358"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "totalLabel": "Total pharma contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Contract with Customer, Asset, Net [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r345",
      "r347",
      "r358"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Current pharma contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r345",
      "r347",
      "r358"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term pharma contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r345",
      "r346",
      "r358"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total pharma contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r345",
      "r346",
      "r358"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current pharma contract liabilities",
        "verboseLabel": "Pharma contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r345",
      "r346",
      "r358"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term pharma contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Pharma contract liability, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r310",
      "r320",
      "r321",
      "r322",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r336",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debt Securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r578"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "COST OF REVENUE",
        "verboseLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Amortization of intangibles included in cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r324",
      "r331",
      "r332",
      "r334",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r98",
      "r103",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r336",
      "r337",
      "r338",
      "r339",
      "r520",
      "r599",
      "r600",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r309",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Convertible Notes, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days (in days)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Conversion price on applicable trading day (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days (in days)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r307",
      "r336",
      "r337",
      "r518",
      "r520",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r322",
      "r336",
      "r337",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r41",
      "r327",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Effective interest rate on Convertible Notes (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42",
      "r98",
      "r103",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r336",
      "r337",
      "r338",
      "r339",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r204",
      "r225",
      "r226",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Current",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "terseLabel": "Fair Value",
        "totalLabel": "Total",
        "verboseLabel": "Marketable securities, at fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r89",
      "r267"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology",
        "verboseLabel": "Developed Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r357",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r388",
      "r389",
      "r420",
      "r421",
      "r423",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r387",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r89",
      "r266",
      "r270"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain on sale of assets held for sale"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "NET (LOSS) INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net (Loss) Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation expense, weighted-average recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r57",
      "r58",
      "r59",
      "r104",
      "r105",
      "r106",
      "r111",
      "r120",
      "r123",
      "r149",
      "r215",
      "r343",
      "r344",
      "r425",
      "r426",
      "r427",
      "r439",
      "r440",
      "r491",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r531",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionOtherMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r119",
      "r120",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Error correction to previously issued financial statement classified as other.",
        "label": "Error Correction, Other [Member]",
        "terseLabel": "Error Correction, Other"
       }
      }
     },
     "localname": "ErrorCorrectionOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r119",
      "r120",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of error correction.",
        "label": "Error Correction, Type [Axis]",
        "terseLabel": "Error Correction, Type [Axis]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r497",
      "r498",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring and Nonrecurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r322",
      "r336",
      "r337",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r498",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r500",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r322",
      "r370",
      "r371",
      "r376",
      "r378",
      "r498",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r322",
      "r336",
      "r337",
      "r370",
      "r371",
      "r376",
      "r378",
      "r498",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r322",
      "r336",
      "r337",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r498",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r322",
      "r336",
      "r337",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of equipment financing obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r228",
      "r229",
      "r230",
      "r231",
      "r333",
      "r342",
      "r486",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets, useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r17",
      "r259"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r253",
      "r256",
      "r259",
      "r263",
      "r579",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r259",
      "r583"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r253",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r259",
      "r579"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangibles, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r72",
      "r89",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Gain on investment in and loan receivable from non-consolidated affiliate, net"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Gain on sale of property"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Amortization of intangibles included in general and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r16",
      "r237",
      "r238",
      "r245",
      "r249",
      "r545",
      "r597"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r239",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r238",
      "r245",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Adjustment"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r244",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "negatedTerseLabel": "Measurement period adjustments, goodwill",
        "terseLabel": "Measurement period adjustments, goodwill"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r69",
      "r99",
      "r170",
      "r176",
      "r180",
      "r183",
      "r186",
      "r214",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r505"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "GROSS PROFIT"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r170",
      "r176",
      "r180",
      "r183",
      "r186",
      "r596",
      "r604",
      "r610",
      "r629"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) income before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r60",
      "r65",
      "r110",
      "r114",
      "r115",
      "r117",
      "r118",
      "r131",
      "r140",
      "r141",
      "r493",
      "r603",
      "r605",
      "r608",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net income (loss) per share (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r60",
      "r65",
      "r110",
      "r114",
      "r115",
      "r117",
      "r118",
      "r131",
      "r140",
      "r141",
      "r142",
      "r493",
      "r608",
      "r624",
      "r626",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net income (loss) per share (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r271",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r436",
      "r437",
      "r438",
      "r444",
      "r446",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r122",
      "r123",
      "r168",
      "r435",
      "r445",
      "r447",
      "r630"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "verboseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid, net"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable, operating lease liabilities, deferred taxes, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r136",
      "r137",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Dilutive effect of Convertible Notes (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r142",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options and restricted stock awards (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r255",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Trademark - Indefinite lived"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r255",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Total cost of intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r251",
      "r257"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r61",
      "r164",
      "r516",
      "r519",
      "r609"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net",
        "verboseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r84",
      "r86",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r32",
      "r545"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Write off of COVID-19 PCR testing inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r99",
      "r178",
      "r214",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r480",
      "r483",
      "r484",
      "r505",
      "r543",
      "r544"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r99",
      "r214",
      "r505",
      "r545",
      "r601",
      "r621"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r40",
      "r99",
      "r214",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r480",
      "r483",
      "r484",
      "r505",
      "r543",
      "r544",
      "r545"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r22",
      "r23",
      "r99",
      "r214",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r480",
      "r483",
      "r484",
      "r505",
      "r543",
      "r544"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r22",
      "r600",
      "r617"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Amount outstanding under line of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r37",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r280",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r282",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.",
        "label": "Marketing-Related Intangible Assets [Member]",
        "terseLabel": "Marketing Assets"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r4",
      "r51",
      "r54",
      "r59",
      "r63",
      "r90",
      "r99",
      "r110",
      "r114",
      "r115",
      "r117",
      "r118",
      "r122",
      "r123",
      "r138",
      "r170",
      "r176",
      "r180",
      "r183",
      "r186",
      "r214",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r493",
      "r505",
      "r606",
      "r625"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "NET (LOSS) INCOME",
        "totalLabel": "NET (LOSS) INCOME",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r114",
      "r115",
      "r117",
      "r118",
      "r127",
      "r128",
      "r139",
      "r142",
      "r170",
      "r176",
      "r180",
      "r183",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "NET (LOSS) INCOME"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r2",
      "r108",
      "r109",
      "r112",
      "r113",
      "r124",
      "r125",
      "r126",
      "r197",
      "r198",
      "r216",
      "r217",
      "r441",
      "r442",
      "r443",
      "r490",
      "r494",
      "r495",
      "r496",
      "r506",
      "r507",
      "r508",
      "r523",
      "r524",
      "r528",
      "r532",
      "r580",
      "r581",
      "r582",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestInVariableInterestEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).",
        "label": "Noncontrolling Interest in Variable Interest Entity",
        "terseLabel": "Investment in minority interest"
       }
      }
     },
     "localname": "NoncontrollingInterestInVariableInterestEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r170",
      "r176",
      "r180",
      "r183",
      "r186"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r5",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NatureoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r34",
      "r545"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "OTHER COMPREHENSIVE LOSS:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r52",
      "r55",
      "r477",
      "r478",
      "r481"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized loss on marketable securities, net of tax",
        "verboseLabel": "Net unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other adjustments"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "terseLabel": "Consideration paid to other shareholders"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r76",
      "r79",
      "r199"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      },
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedNetLabel": "Business acquisitions, net of cash acquired",
        "terseLabel": "Plus: Cash paid at closing",
        "verboseLabel": "Cash consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r79",
      "r535"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.",
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "negatedTerseLabel": "Loan receivable from non-consolidated affiliate"
       }
      }
     },
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r8",
      "r33",
      "r233",
      "r234"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r76",
      "r77",
      "r199"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from assets held for sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.",
        "label": "Proceeds from Sale of Property Held-for-sale",
        "terseLabel": "Proceeds from sale of property"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyHeldForSale",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r269",
      "r545",
      "r615",
      "r622"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment (net of accumulated depreciation of $125,018 and $109,952, respectively)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r377",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r377",
      "r535",
      "r536",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Payments to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r377",
      "r535",
      "r539",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r533",
      "r534",
      "r536",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r432",
      "r577",
      "r651"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r18",
      "r96",
      "r646"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r344",
      "r545",
      "r620",
      "r639",
      "r644"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r104",
      "r105",
      "r106",
      "r111",
      "r120",
      "r123",
      "r215",
      "r425",
      "r426",
      "r427",
      "r439",
      "r440",
      "r491",
      "r635",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r161",
      "r162",
      "r175",
      "r181",
      "r182",
      "r188",
      "r189",
      "r191",
      "r356",
      "r357",
      "r578"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total net revenue",
        "verboseLabel": "Total Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r360",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r68",
      "r296",
      "r298",
      "r299",
      "r303",
      "r304",
      "r305",
      "r645"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "terseLabel": "Revenue payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r458",
      "r459",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r131",
      "r135",
      "r140",
      "r142",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r253",
      "r258",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Classes of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r537",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r170",
      "r173",
      "r179",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r170",
      "r173",
      "r179",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r383",
      "r385",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r392",
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Each Stock Option Award Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r157",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r191",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r275",
      "r276",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r159",
      "r160",
      "r170",
      "r174",
      "r180",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing",
        "verboseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses and Sales and Marketing Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Restricted Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Weighted average fair value/share at grant date (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (%)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (%)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (%)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, ending balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "verboseLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award",
        "verboseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number",
        "terseLabel": "Accelerated vesting (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r3",
      "r157",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r191",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r272",
      "r275",
      "r276",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r45",
      "r57",
      "r58",
      "r59",
      "r104",
      "r105",
      "r106",
      "r111",
      "r120",
      "r123",
      "r149",
      "r215",
      "r343",
      "r344",
      "r425",
      "r426",
      "r427",
      "r439",
      "r440",
      "r491",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r531",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r149",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r24",
      "r25",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r24",
      "r25",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock issuance ESPP Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock - public offering, net of underwriting discounts &amp; private placement, net of private placement fees (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r24",
      "r25",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted stock, net of forfeitures (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r343",
      "r344",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock for stock options (in shares)",
        "verboseLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r45",
      "r343",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock for acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r24",
      "r25",
      "r343",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issuance ESPP Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r343",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock - public offering, net of underwriting discounts &amp; private placement, net of private placement fees"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted stock, net of forfeitures"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r343",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r29",
      "r30",
      "r99",
      "r196",
      "r214",
      "r505",
      "r545"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r333",
      "r342",
      "r486",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r102",
      "r370",
      "r378",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Net unrealized loss"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r130",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Diluted weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r127",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Basic weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomePerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r127",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL121698322-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=SL65897772-128472"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r652": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r653": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r654": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r655": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r656": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r657": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r658": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r659": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r660": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r661": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r662": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r663": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r664": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001077183-22-000173-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001077183-22-000173-xbrl.zip
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M,[GU3L6* GP?UUY-X1/P0.D>G_+8BPF/OJ!1?8;71?R+*Q?_!U!+ P04
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M(TN2FL+99(Z^S'>ZC*/79T-W4DM%@J6RK7!/\!(&M[I4!F_3=OL/I.IJ(K5
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MAT0LM!3M&1@N;UTVI1DJSY6V129M93P "7;^E^=N#H/!&@8V!XH'.U5SN'E
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M@>@[<+QMQ_OL_*I,^@CZ[^<7O3)R" "G.#B3\:L<NWBLQS2"LAN6T$0KK(6
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M9Y;H(H3;BGXS*A0M*+E<"E"(WF!(%I)(-B>KRQ(JQ2(8Q.(%74+2@D/2Y)*
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MN2P&])(&J7VJ,BV=Y9TT*7@H!NM .04RP3A$H=P22&;KA .*WC'VVZ0QGGQ
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MDV3_3!*"MC%J_J,AZ9*R;D5&<D4M6[.N=H;$TE!D)FDMDTDFEBZFQ.$1BF!
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M<\YH#&7G)1*T@6XVIQ3[;:*[30%PB3*#C1(P,-7T'I%< )5"G=*66S'ULCD
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MV)BR64*]F=46X* 4Z6QR'FP2F*AH9009F<  W0HMG,<XQV)B(@ZAO3;>JES
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M:=!@!:PFI5%(18=LFG2N<U-E0B^#P2QRG;E8C&M1,G0%K":E8&TJ.AF. X)
M0%7WBM4N<5! UBNI38OR<RM@-2DK6&N$D3&!G&*G*"'XXJ*7Z*V6FCRM:'CS
M0\SF;]\PNYB C-6!= #K"\A:WTXJH_BW#%1$:L$\XZ7%ZX]FL6<VQ=G:3,*H
M:)T"U $3I%KK(^649"L*RB\M1);(I,UP2R-O@TW@M:R3GSAZD!F)@U-IBP@J
MG:U %,((:"I>5XG5JQ BNL)T!<S"Z657RSA&6Z(';4-PSA IDY/0CBU9\TG:
M"B$W2XN8KQNAI316 *#+,=KD7<;J^YS(KD6ITA54&I0I]3JQ#Q((V2OPP2$
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MCRC3"/O_(NQ/#FI-R*>CX<L1'CVCUS0X^5KA[J;HNU.)72HJ4ZP#9H$HD@H
MH'36+$\[E9N4JGD[O;91;NQ"U0<[KOZ(W *1T$J TP1)F4AU&D(RH*$(*FTJ
M\OJ,^FQS\E,V>J<?>,P/:HU-1GS"RUY:Z_=[M2C^B][D8'/0>XT3?-([ZO'%
MLV+B7V@+8^K#(^^W@UPKI<=MX@,;TTY=1A)N*3H'X'4R&9BQ^;J98JIUJ;76
MLD"+DL4W+-[90?XI1Z='>%Y=KYJQ$9\QKKA_>#H9'OWO[@';L&/BL#6--P=I
M&3._.JOH#6;G4 %HX35&8VT)V0A-VK4HG[:"77N28]J"2#I'$Z4$C#H$E[%8
M(4*1)%6;BB&M8->>T8.0* A@;QJ4@I  0]!!QA*C2#FG-M6J7<&N1=S.:F=,
MH&11L+4S,8 VJ5AI?,DB+0&W^X*XQQ_)^U\[._^S^73M[(ROB[HIJM!*7F<+
MQ.S0*W 9I"-4GKQ5)%/Q0K>JJ/L*<NW@=,H(H8,"A1@Y:LT8HXL&I"93#,(2
M<+H5Y!K&YR@&ZZ+2$@0 $[JHT4C"7.>'U,)2[>=S*\@UC,O)$(0GY75. ;+(
M 4P6[%@A%[ 8VK06;0';75P\^H_!R?@$^SNC.A!(_SZI0X+<E@\>O//GYKH,
M3Q\^VZ7QY.O;U3<?2_=Z;^^/:#P\&7$_GGT]8%,U;7SNO7[P*_]U/A]#JN!8
MY"$RIM"P+RW:%N%0:AL*PE]UE.C]->/):9^Q<]0;= ^H]_)@<E_ZX\D_WO3R
MY."^%.+_NS,][\&OXV,<//@UCN[QU6>?SV[R^:UP])+O%H<3#M#N:[Y9?84N
M]GLO!_?KW!@:W?GR[;[Y1A.,?;JX) Y'W"?=-.SW\7A,]R\^_"/WQL=]/+W?
M&S FJ3N]Z!\?/\#P Z9S=ABQYP^9/N_L\/L>N2O.>F7"?3_)%T\^/WQW>NC>
M)']^+/B[07SYL+@K+X_=F]Y[=''"N6"X!^Y,K^.WJEWVSSOZSB<O_KZO.GEX
M4COF/\7TOW\<8\ZL"/=%1TYO\_XY]Z:=<47_?TEL%\>Y&</1_8L'%(9JM^!1
MKW]Z___LLM*..]OTIO-L>(2#__/+F.U_=\S@+F<GCGOOZ+YTW.73KV_.WI!Q
M^X^I?"Z@J&I__;&]N;NQWGF^N[:[\?R+:&E*:Y]O//SCV>;NYL;SSMKV>F?C
M?Q_^:VW[\4;GX<[6UN;SYYL[V]<$O/T;S9G=2ZEKO=0+'!\P>B;#P2^=];L/
M[W:48,O2>%D\VGFVU?F5;>5@.-@^.>*;I,ZY27U&I:;TG+&Z;FXAI 6HE:FJ
MY2S&Q1RRH2N7K74&6+UMIM[]]6&:3@>LA=#OG$^RT'^>QO7AZR?JV>L]O762
M#S=>[S\.ASM'FV^W#E_IK?6U-SLO_OO5_N&S@^W=W\V6VGNW?;3W9EMMO-UZ
MMV?VCS;$$[W=WWMWW-O:W33;[];>;*WW>_N/]\3>[A]B9W?[:.O=_M'6>C[8
MVMU2.R_V#[8?^;=/U/[IWHMD]W>W8/]P^V#_\-5;OO;=]N,MM;_;[^^L_S=?
M]^QPZ^A9?^O%[V+KQ=[K_/A/R/_Z[_Z^ZK^.A\?]K7<'1UOJT='.[@:W<TOL
MO=OO[[SX [:.]NI]3O<?__%V?_WWM_M]#]MK?\DBK$W@NL2A6Q=$SMWHK>X:
M5+H6VXW"Q3L/I.C^/O57[V7P99._> ,?PEUO]/?8=W-7@[J6>?\FKZ'N@O'?
MXC6^Y"(N/( Z?EM]P(>VI4_E\ZX9'E]?:U_PC>O-QQWU)8T5GV@L?*JQTM0W
MN7EE_?V$V1F-^AR&' ]'DSN=,N3 9\(/>#NY7WIO*7<GHY-VZO.C7GS\A]U6
MW KUY]$6G\NZ>[J]GF#O79^?4:_?>%-U>VOWU9N=]<WS:_[D9YG!_NY0L\X?
M[K_8>[/W;N]T_W!3;+\[.-SA[U-[L,MM?_?[VYW=-=CJ^S=/=M<F6\_%VR>[
M&Z?;AWNG.VM_,==,X!UV@T+L0G&A&Y,VW>0%<*"C8U3ESH/_^L_@P/[CBV;A
M'.ES!O$U7<^G0/[,]4Q)WN]_K#W;W7CV9*_S;./ISK/=SM,_GCW_8VU[M[.[
MTV&.L,M$H"-U9^=91YJ?\L^=G4>=W7]M=#Z@#Y?48>WA;CTL@X:/NNCOZ=NY
M\>,NN)I*G/W2&]18\#ZH*2N<<T^=.>GAJ#,YH,Z_+_2R<Q8$=3@VHCP/]_UT
M^KR-LU#L8WN0^9?N$3_SH%[6S7C:/24<=6G02OOPW?Z>WV7M+Q6M"E'9;@S!
M=CFR5-W@ WM]0"FQ[BSE'!-@.IZ<A>Y:_-*I_?ZIGG>^QH"_";,K?M B?O!C
M1G4>5+YF*GLU4?EE>E"P/VXS/]@[_%WN';YD7L#G/-XPV^L;S ]>J?T7W+[U
M/PS?P^P=;6CV]Y_P@^/>]OJ?/>8-@FW$F[W=5\PCF!_L[O?WUU^]V>;OS#-Z
M>[O<UD=7\@.?C4S68-?FP#&#B6%J/;I)6%W(.D2/Y_P EIH?[#Y;VWZ^.64!
M324("^8#DTM-O" $930\ZOS7?THK_G'QFO-OX%D_94K#T73%XOT3]D:C>E;%
M;6W;M_Z]N'>Y\Z S&796?3FCOOS>QEXC$=A077TX/#KJC>OH3.=1CUD86VHF
M?O=ODK2?#0[6IYT]K)5^^+MY^.G6[N]_::V+1>.Z L!U09K4K6L!NPB0- ;C
M#=HZ[">[VG!G7SO[MHC\L_]!,W'C2'M&+WOCZHLFVWSDUJ$M_66%Q:"4ZR;*
MF:,^QEW4";K<C1 9<1Y\OO-@>V/G\<;VSM;FP^>_=#:W'][]H9SO(FS93QMO
M,4VF\N\,2V=T*?<.CCOC8TIUP#QW>H-.;S+NI(-IMN+G!KW69QG5Z6M][&KF
M&RP[?==H_SW!LO)W@PPSCY:EN2N$GOEM]5WOKC>R^RUW!7?7BQ\([>T71H<Y
M+NJ,A_U>G@X._^-O0J;SI,LG<CZ[S8+BIANW]YL#=C/'YYYF.LGEX?!D,!F=
M/ASFCY.#_ JISO68T/%H^+K>IZ59P;.LP/[CS7?[A_]]M'VT"3N[6V^WU_.K
MO1<;<G]]\W3K<,ULKV_*K1?/>MN/]S[-"KS:.^3V'.VIO<.79NO=AMA6SP[V
M=O]\M77(UZZ_$EN'[%,>;XK]JT<-K"8LT=FN]EIW 0F[&&+L>@J!]34!A.IB
MZ#5FG&U2X&J$SR,M\)FU%I];ZUF^TW)K[2Z^W3R?U):FFMOBX&#>ZKCUJ3JJ
MK$$BZY\@P^J8LNZ&*&Q7A.1J]30=O;CSP$%7^>"T]7^KDM=S336P;:9?^FJ
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MK?W#WW?>%"_PTKS RZ:UX@5NQECN C]SX09^%=_;WE3CJ HF%)6CJ!P/J'+
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MG[C(])G.!JS,V>VF\U%->_6-*F@2K"'7[9]'3)[?/B?%3Y/ OTT _V&.]ZQ
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M8\D1Q3B!^J H,L831(DST40=K,K)OU2T,5FDDVF#U(?)SBB+\W$OSJ];?[,
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MEL9X7[>NZ7AA/(V".R2],HCS2)%.08/VXK!()"E*>*Z&PI1ID#U6H-Q,U:5
M>7507O2MX.23E!)%0C.4'48ZV(A BL+;X#CST\)&^M[G0ZMSK32OCEPIIO?$
M'&*OCRVP5D68&2XKRVAXZO9T7?KE\YG@_NJ.CY]/1O#H%Q[_LC75OS5=UU>-
M:ARS24UH3GY6 B.K=4"!@DDMB3"&XTK+U/?V^A<'66,!79>660"]:D OZ)K*
MLV1EM CTS8@X=@%9(1@R7 1"2)2$@:X@VJ11H85/KP2?KRD+<Q7EN&Y5T&&=
M^:\NA::$7BZ3[?ZXIA ?LQ9+DY!,3B#.@/*T8Q() C:UXOG,SVUL:M'&F"V[
M(->J:[<4Y#=(\RG(7R[R%_0<2:-37 6DJ+"Y:I-%6E*/0B*,&C!J.!. ?-6F
M;.GU-Q^LQ,GZ%9]X->B_1^,X/&E2^8E;"?:A:U/<?9!/ZO1YT*]&DPN\C&*_
M.QBV^H-QO$>7WW)"M7)GX%R"V]&-2UG;96RDUY1^<$S[A'%$5C$/&ZGRR C)
M$%6):4,%ESIWZ&*\+7$Y:7Z\.*[1!UAPO'P<+W;:$TE8+!R2)&C <>!(1VZ1
MH%0*CZEGAF<<TS;7==G"Y9BYG,7..YS5'.M7CFX:$>M7Z'L9]'U-2J4AW-B@
M/0J2Y9*M$@-]8X5<THYAB06V<F-3X397]ZYW4TYB&POG)<?[%3@O!\Z+%9@M
M$TP(,*A\9(BK:)$.FB"BDV"!8YF, 3C3-M7W-JI6=P[;/!6KQ/P],4??=DP1
M""RTNGT_.(FML?UR6=<L_KYU43CG@MRMY'AHOUPZ0NO$LC_5MC_!F*ZIX$&H
M]]I8Y%2RB%-,D TV(6:U2X)SZ[2:UBRZ?[/=XO1K+)CK4C<+F%<(YL5:J52I
M0'/]G9#;?6"#D9.6(VMYM#)AYRK7GP#;L4E@?E+NL6FML96??C]U>[HV]]B5
M:D3%D%X&MUW3:I=B9L"&3HA*31'GB2-C@D9":>V$<$['W&J7MXDL&0J/%\>U
M^<4*CE>"X\4BJ2*2I*1$(8"BP@UER.!<\]@X2K4F,F!=X1C?OU]V24RX1V)"
M?3K**@*4'S?K+2$OH1#>,@COFLQ*GCR+&%L4"6@OG%N/-&,<L42CLO">I&)C
M4PK5%J:N#A;-:"I;<-\4;:?@?NFX7U1T3.!41(J" O!S%BP8+/!/$TSR)$7C
M9,ZH5KQ-95WQE WKO/H=_:OI.M!T_F_Z.=.0ENN[J241X!&V*KOSXS^6W6 )
M6F#9 ^K; ZY)2U4L!,\X058HAKA-#,%ZUBAA[+7!B7O+-C85IZ#[U=42I#%Y
MJ87>"KT]L+);Z*U.>EM0<9-E#D<"*JZV >A-).3 I$4^*,:<,XKC'-PF25O@
MNH)5FY=\>[VGK\ED]'QP<M(=YW8!TP9(&88P]-CW@)G6+YW!.+8(^>=2G7VW
MN,:/K9GYU9>C0WT9=7_M=WO_;V,\G,3%]*;S.=SJA^>79[#0R2WHY.TU1WS4
MFJK(;=1<(AZD0YH$CH(TP3+@DD!P7DI7>.11K<^[;()E?2YU?5ZSW5D;'(4%
M:3!!7,+&IRU.B &;D"@5\3;>N#Z?0$V'@_' ?SP>]  4H__[?S0EZK>J,<WX
M[*$+.S3Z&JM6.$+WT_S:LTN@_/E?":W&]$#ZR"#?%-9/N_6/[]'EZS@\.+;#
M6(OML-MY<1UM#OK52GYMA_O#@W%NI?JG[4WBQ:UG=@,N1'H+(O7CO2M$"M?K
MQ=_?G+W[*YP"G<IWAQ[&\!'OO]R#^8!GVWYS\NZP=W+T >9B>_?L'<Q99_OH
M2^>PE_8.W_]-># Z$8U<DAST!)*085$CZX,!\4>1M/[^IGO#*OHY!UM916NY
MBARGS&(1L]T*JTC1@&P"E9-33S0C%/,(QBM^AJ\Q71=>:)W:8>M3EF^[]<N-
M*V^4!3]: 755*VRT-1D?#X9 P^%V?I"R$A]@)7[=^SL+7<B@D,(JMX&W# $)
M)>0I=BI8)5P4W^&S:U?5,JBLK*IU6E4*>TI-,H@;B><E,;5 3./@@5Z(\6"M
M4(';H-OE_[\%RTV76LN>+X'?6DU9EON3\6AL^UF=+>NRJ>NR<_CV;XRYXS$1
MA*G/FZ\'*]I'B8S!C&NL*%:N.6RW.QI-"M,U>T51[J@*FB.K,M-A G\Q8Y#$
M+H'X8_18;6P2*MM"TC9FZA9,E]WB3='C"K6MPT+\L/MWB-$Z001R46O$I3)(
M"PW:7 K&^>B]T_:NU+:\956HK?DK*@6;#'84!9XW2TH<LEB#:6 )U<YK8DC,
MU,;;!*NVN(L2UZW$7Q'=X()@VBUX[S3"1S_%WMG%$6#H?JKWH.7>Z=9-.U2]
M?83'=4_X6((XZJL">\Y6E=OLFSVPQ&W<C92N'K2"AAU#D"+W(52@,%'8IQ@-
M8"D*T,DEJ$S295995)36ON)#H9U'23OU%:TMM%,7[2R<GQ.60E*<(B=!C^'2
M): =%9'E6H+<6&19/09EID&T\Y1J4VS!D/-TVU[KU'8#ZO9;WIYVQ[972E.L
M@<IT(;[7(+W=_O.I["Y16@F'K8_?KBG=*IRF4@0)QEJE5AF)M"<!R:@LA?\)
M:S._M8G@;2;O78&G5*EH+*3K4D<*I%<+Z<6*6AKKR#5'AM.LLE",K%(>.9Y"
ML!)CK64%:<K:DNH&0?HIU0+=\GYR,NGE&)O6H"JPY0<GI\-X'/NC[J?8Z@U&
M#UZY8OWX[N8XECIUF!$\)ORUP'P7(JU*]3R_+-!I=<%7(-5.'.^G0_NET&!]
M-/AQ4;,)1M/@.4,N<(.X5A89*BWRG%/OA),.TZJ9,%ZTW1;22-;(6U0 ?G^-
MIBZ %PS?"<.+]2@H :R"%H-C!%5&*(%<8AC^$LEZRV@@>F-3LD4EYD$0_*0<
M+Y?TEQ!3UW=_KG3YDS;/'E1=>1/'%D84=NRP#],VNB31[:E BX92&[L=;EU3
MQSQHI0.H)-8FBCC),4#$6\0CC<9:'+PT8*@QV>;7')+?GN&*TZ6YJ*Y=1RFH
M7BVJ%[OG  M+T%(0T+5&G&>[PQ*&,,/2*<:]#]-BH?J:H+X' ?53JA-ZFQI9
MHWIS0N]YNO]4:\K<^?$;O2<\P-G:Y=3FG6KY%N:OC_FOZ4OCM$@F6(U@PU:(
MI^R"=X$CCF%OM]IXGDAVO&-"VT;?V_%^5X T/(JI\-P3X[FZ#AP+SRV7YZ[Q
MR@EOM,%(@:P0ITPBC8'G6)").*ZH5:HZ8,2Z355= 9G-*Z+U=$K%5A'W-:O%
M]91:G$[BKPSF/0PFKA?/E\13W4_JGY_'LN$LH1;M5C^4[6>9V\\U795TX"$1
M&9&U#M1LJR0";5H@"=L1I8[@P%C>?I00;:'K:LA2'Y[6HX9M(=9"K ]8!;<0
MZ]*)=4&OC\)B*T@ O9X[Q#G7".3(D:<62V-),%QD8M72M)6J*W#PX8FU4OS_
M-;9PTWG6Z*5Z<Y>NY2,L^N$,CIO_XX;_VOPVV?067UL=BFE5WS#&UO@XMJS/
MX86V?P:3U>H/QG"#\:!Z9]*WD]#-Q_C/!_UJ<JLS_1?=ONW[+M@!52&PJBCG
ML]:-CSN[*6//5#9]3@>C*@CXUV'LV9R7^]OG;A@?SZGETA=G<L<77[$.1C$9
MW_R5I4\MP;>:6W$ET_C2SSS:BH0<H4;!,(P+*1?M,BPQF;"RA$F3;"X@NS'_
MTO'PHL;A^XC<,-J/R"9XP%]M[[,]&VW\ZYMY..GVYP/B=#KO5Z?LYJ6Z^@6[
M,*L+%3FK6>WL[+_<Z>SO[3X_:+=V.\^?/1S$;CGBY_N=@_U7N]M;ASO;K8-#
M^+6WTSD\:.V_:.V_WGFS=;@+'VC\4_S2[0,?#"9PC3!JM^(7'X%/3^-PFGS?
M EJP_VS^4YS3V=W&6K'_!2=5.PZ,N6=/1_'7^1^_A>[HM&?/?NWVJSM77_KM
MQ [? Q)G1)91>&6WJ>XW??L"H,_P%*0SA]/LSK.WGU5O7=E!I^]Q_$Q(>>/;
M^!FY\;WO79;09X:)G[KL]]]CFJ_/8#5EZS/8I<VLOM5EU[KGP(]W^$MNTAO=
MF^9>3SOEGB85PSX\'H*ZN >?.QZU=OH!U, #V 3BB8-=@.'V+?R\/XSX>FQS
MUH%7;CME2X#,*B?DQUOP;4!32Y."M5@:M&H'O<QI6&XGB'699%('+SVI&2O+
M<N7+<JU[:=R2^3L[AZTW.W_N=-[NW.=(^"X.OX;,QT^ICRMJX/%3B"IS^?-+
M\Z$[MMR1H!]'UOTME]%S>"F/!;3TX:>N7^R"?.^4V<8]\EI66[OEL]WAD-(Q
M;&*2,3''N/928QIR\P*CJ:%1T+^WJ^@/A0FZ71C(F_@I]B?QQ7!PDEN5Y2'\
MU1T?/Y^,8#[B<+?O>Y,\CUNC483_A75)^3_;Z\X/,/]S<G2X]>7HPW\^[!]^
M)$=?__AR1#O'[U["7;Z^_=KY\/YL?_O/CYT/NV?G!Y@G.V=[7W>_[GW8.^L<
M>OKNPQ_BZ*OG^R_A3ML?Z?Y+&.-7N.;AV[.K!YA'A]/OP?=)!\;5V>Y]Z'Q]
MS^$;'_</CZI#S[WM%_"L_TE[9[/#RP,,<W%$]SZ\_]M8ZCU/%IG(*.*46V2Y
MP$@:XK&T+AGK-S8)EFTB[QT6TKS$_\)<CY2YJ&1&2.R]U99;K(VB00A-E7=<
MPL^*N<B<N4AAKJ8SU]=%YG(X1(H134$BKI1#A@:,E% LX$"9#R$S%VW34N"V
M,-?:,!?6C'FIF'&>\:B3,SI@3("^E'/>SG4N4G2N-6$N<I6Y.$O*&^%!TW(Y
MTPU^&.H)TEYQ&T,$D<J-349P6]26\5:8JS#7TIDKT,!%LB$RS"/G&DOG!=<J
M$>R5I#.=BQ2=:TV8BUUE+JTQPTHX1*0!:Q%L1V0=_-"1\815\F H G-AW";$
M-(BY'D>1J5LB]O6Q!03<Z*Q;USHR]?.5D"P1$HF 'YQHIGWD3F.1?/!4*EN\
M6^O$5^>A^9?YBKB@%(_(2.P1C\DA%RA'@N!(HR8!6[&Q26E;TL5B4:5,]Z-!
MNN-22$W!I!*$.T*<9BZ ^$G2FK+B#5H[I"]X@X1+A!*N$ \,D.Y"0LYBC PH
MH#9ZJT$[V=@D!A035I#^>)$N<65R>"QCXH1J*YC P3EL2.")N^(]63.D+WA/
M I<!!)F086"(<*\3F!_2(4D$9D09AW7<V)2XS5EIO?&(D6Z]B$8%0RGU/!*B
M0<6+L"2\E$1K6[P-ZX;T!6^#H"I1&@PR5&- .F/(^B11TI80:K# GF]L"MWF
MM276EM*0=P3LM.Q-/XY;PRE\?LK=4$LYL[5F,QD93D1Y2QSAT@0CHG*<):FU
M#IBFXHM8*S8[6/1%^$"<23PAK#Q!'%8S K-4(S!.K&,.J"[BW!51M]7]"["L
MJO[7 _3?>,(DP:+&'!/M*9><FNA V2'<!P9+*MD@BAMCS4ABP8VA0F)1@''#
M(H^(!VF099HBH35HNT$[FW*=)DK:C-_;8UE(XC&2A%%",A*3P41RCKFK2FDD
MH5PP041</"!K1A(+'A 3DA())^2$%(@++I#A%J-,#C):D[P NX@ITL;TWL[.
M0A*/D20LH9()S33L,]Q5FFD(QN6(V5R*+!;GR9J1Q(+S!#,509>PB&&*$6=6
MYMZF"NG@&?P!\HZ@2< :: NS;N6&YP.9KWY14< #9(V5:ZS1-1Y7\97KLXF?
M[Q\<YAI:/\HH7K,^EVO@;WL^&(WWT\O!(%1U.&?!5P>#7BC[7&W[W#4);#%P
M9X7PR AJ$?=.P5_:(LQ<#CU51 JZL:E,6^LF120^\<:U:^ ;*X!>": 77&",
M"9&(24@P!8"6@2 7HD(1[!-%39!1:@ T;X-Q4@#]> %=NQ^K 'HE@%YT5SG,
M); P\H( H T6R%DM4 @.!Y$T)3E1DS+3ABV\(/KQ(KIVIU-!]$H0O>!;8L%;
M3@ELT2E00#1QR!"A$0N@7EFJ13 ,$$UD6QG>($0WS7VTI*IP983K/,*GX*9Z
M^6;_X*#U^LW^B]W#XJ-:F8_JY7 P&KT>#M*:-#1?BPUR_YI8K\14]$'!WBB]
M0SQ8A@RHNXBGR&!O9$'HM+')=5N;N@YHB\;;0 37[I0J"%X.@A>]4#A2:AU#
MDC,P6K7QR'$J4+1,I6S1<HX!P:H-=FM!\.-%<.U>J(+@Y2!XP>VD;?(V<(N2
MM 1Q3"URT0J$/?=>8LU#R/'6C+2Q*H[D1PSAVMU.!<++@?!B IB+RG(!F 7"
M!0B+@+3@&CF<8O32B.1S4C<G;8V;I$<_KKKUUP-P_S0.[3AW1HQ?3F-_%$>_
M+KU^?6,].6602Q_DDZJX_C+V 5V]ENV'E@TGW7YW-!Y6/4&+MVQUWK*I$+;Z
M8>L;$>Q,^:YL_;55FIMM^]\T5O8<:RJ-0A;GCO5.4 0*/4:4&&I]HI[ZL+$I
M>9O6EBU9M/<&PKI^%UJ!]0IA?78%UL0S*@3#B'EE$%CB&&F)%?)*I$B!K ,#
ME5ZRMBY^M<<,Z_K]:@76JX-UY^INK0PL66>K.ORY_!I)R$8BD!1>&*FRTSQ;
MZEJWN2[.MD>,Z_J=;077*\3UU>W: #L'S 5*Q(:,:]BN'5=(4VV$P(EY'@'7
M0K>->(0>N/7P%KR)HVB'_KAR%X3X*?8&IR>Q/RZ5GU=8;6DJ J"I[0L!%(ZJ
MG:-V%ST%0A"">01EHSHET%@@&Y1%"E01F0P/FK&-3=5FY-Z.@E(/LKF87D)Q
MI(+I56'ZJMX1>-(V6H\,+-U<+$T@%Y-'+.6"SM( 59.,:8[O[24HF&XNII=0
MRZA@>D687O 16!.5E@XC::T%6T('9(AEB$4@;6>!IAG->6!M*>[M(BB@;BZH
MEU![J(!Z5:"^NE%[0T'Q\@:Q'"(+ZI9"+J6(A'>)45#"&.$YRJ[-9),ZK#RI
M:((#6.*CRCEP8H<?8P[:*6$$*W,-',1>+Q<^ZX>]^>P7:JJ=FO86_0)*6Z5Q
MTL@2R7)?&(L<=?!#*>D"I19> FJ2;7U_(Z(<2307T;4[!@JB5X3HJ\J&H($:
M[B524V7#4@ SQXB8P'GP'D=2G4:T%6Y2VGE!=-/= @71JT'T@D_ V$1=HA3A
M[!C@P4;D(M>(*&6]I"&XG"@K<)NHLD<_8D37[A,HB%X1HA<< IIYFJ)!6,0<
M,>! _P[<(Y*$54X8ZC7?V.2R+55=98>;%C"P)DV;!@L9//<)&/AQE9/'R5RU
M^PO.$ZMF?#4JA%4?8?UQ3?B LQ0',"4\2Q14$,^038DC$84WAH#5B,7&9HY<
MO'^.X9VPLD8'%D\5_+6[%@KXEPO^J]J*XS;$0")*,J<CR&21)I8C[[1,W(%I
MB2F 7]91FK* _W&!OW8O1 '_4L&_X'S@7K) P51),K=("2PBJP1'.D5*A$F:
M,+NQ225M,U)71$)!_R-!?^T>BX+^Y:+_ZM8?,;<@KH1\XJ#W*]CUM9,816$3
M:'$I6I5R$5O=-J:NT(7EHO\I5 Y]E0N'OGBSO]?:?[WS9NMP=[]SL)26T^M(
M7[^LUF\Q@@>&OVXDLMV^'YS$5X-1H;(:J>SMH@N#"^<HE0)IZ7)2M<7(2F V
M;%SD409L1=C89*8MR"*3_;.V+F_K>K3R9#F@!O=%X8 'XH"KZHQ-TH7( [*6
M!,2)B,A1Z9  Q32&P#45IN( 11;=F(4#GBP'U.#%*!SP,!RPX-# %&OG%$.2
M899[OE)D03= V!&*F66)YDS(7/*47M,]OI# DR6!&IP9A00>B 2N*@(,6#R*
MD)",E2+ +#*>..0DQXY&8BR.&YM*M8E>#,!H& <\A4*JNX##81R-YU$8[58_
MEM(-JXNWF,__>7A8(: [$-#1HC>"Q)"DCPSI[%/E+"KD6-!(!(,CET**%+(6
M4C*W'S%,:X^,6(!I42)JQ/!"ID6T7IIH$*,IY+@(@G3"&!%B%,MJH<U=M<&.
M,+*@^/&BN/80AX+B):)XP1^0C! @FYR-'7,3(X"R$5@C!J:=T6#98>$W-FF;
MR8+B1XSBVD,5"HJ7B>*%O9B'*!BU()R@<K==@AP8\DC%9"7W3-!@-S99FRG1
M(!0_KF"$&WJ@C(_CL/5+MW)M_?/^!OSZIGJM./+@BH\QBZ$SZ ^^]346@_YG
M",A?DR%AN.%)<Q0",XA';Y$UC"/CE0/UD.1.3*!&+++/G;V):WIN\,@!6W^6
M0P%LK8"]JC'@D*+,6=4L!8YXH RPRB6R8,(S'G#TQFQLZD4'7 %L8P';C"/]
M MPZ@;M@L'NA;:2Y@#%6&G$/?SEG*!+. VHCIT2J')-<.AZM&WQ7?!I?8+M,
MV"XT-9*,.F\5(L$3Q!ELM4[:A(C7DDE,A99R8Y.SQ22B!]EPG\*I^DO;[;<
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M<3(42XV29@SQJ AR0E@D$_%*2)L4X0W<:)]$<$,GC@'*PPAC^1I#JS<8C5J
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M\^+A_%';^Q G?C"-H0J0JX/DG]H"I#/1:R<%&*HIB$"* $D2^(S4QJ!B6F9
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MKBXH,4G",,5!*DP@DG-@A?) -6HG'.51Q&[%U<TH(9DW39H6I:TWF$[/2B^
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M':(M59/\M_W;#M-L/OWP;#:=X:C<M#HT<V42QE\[[:&95B5FN-9@N9,@@K*
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MF*B@8FN;$]&-'M35ORL.5SM5.W4X7JY D:KQLBOQLB5$1:9$H(%"8$Z#D%(
M6J4A"!E=4#89PSH4+S>B)NRJS.2OUH?E5/[\I_%IL4$5F)YN8](N"$S-BX?S
M1VWO0YSXP32&JBBM#I)?M!4ECI'F((L@I18@@HQ@0BI;%X1PRE$29 %DJOM"
MZPXU,'V$5<(GY>\+&HK?S]F76PJ\A:NGP8<8X*\X&5?BM:27MYMC$&^XMPR(
M+J.RF)* F52#C=P1&Q*35EZF4]7+G["7?]6*OGL$].KJMW/U!9JDICE/YJB
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M,L>X!HLNE5FH""9G?!!1<9<L2FYL%].\ZMWK0W*6=._*<>[GXPL:8QF738I
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M9&%V0^9@C4"M-;SQ'9;%F3FV?P]1$CFH! __U!@+]E7I@B1Z<N!T2$^YT52
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M&HC@I\4K^+Z9V&M@8G_"W(X'!\T&=PQ@S84["P_/3D6J);-*$3B/B+ LE$0
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MX>^"D^/@^?'1N^,_#U[LG[Q\$;PZ.-H_>GZP_V?P[@3^</CRZ.3=MJ_DM^E
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MY?GCF6P2KO^X_=H;:D[<6!KFAQY=D0#CJ7B)[(:C!ZI7<3XV)CB$Y\[+X.4
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M2 ?!("F9C$A>1;+-4O<5T=TC-B- 5"$P916OTT/#$#DREW,QTL8ZJ5VSU \
MT@*S=[9TN[0$B4L7E-9<><F=BC;(9JG[C.N.[ /H,(,#AEXC@Q@#0V&0)8M9
MA>1!.=Y#2_T0 K4V+]JN>.=1QNT=*_2.ILS]N?YJ?; SG6_5/6G'SM[6VI G
MU$X:T(Z@./L>46F)X&W.F!-<U4EH^35ZX3AL7Q ::!3Z,A7@+"<T#!)H%GA
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MN+8A_=#PI3.Q-:SW%^N$OCQC <GQ&I'ARZS70(Y"&%F#+9M-7RF8=T(R.,A
M*;-Z.B4#FL]O=-TZKRTGHP3WV&SZ \ YEF$@<Y(B>P&.>%!>$6%..5M-,3>;
MOG)@[X@9%J35T>?BL4>LV54%"R0<PY0] @B#BGIHTUM(QI/)]' RQ:-ELGLV
M6??**?\<1HTRR@!@LO(6>?#292<E.HC-XUD=$OSS@H@,;17&C"QGK0H):E-\
MG^B9*E,:[[WPAE);OGD .%?)8E28(8L,-<6GTAFS*) 62#*UB(S5 WLW(H-D
MM$9:IC!$!D8!\]%DIKE/B7N3,!:P&SX4?NE<8 WK_<6ZM=IEE:.N05<U7TI2
M*<:HG=!">F@;2U8+YN=M>O(R"2LE@YP,@R 40VGKQA(LMCU!\.KF-I8TG/<7
MY\)E'63@/(. 8&)PQ@0G?#T'7!"UD(S5 WLW.T:PY Q*QE7-S&\39R%JRS)Y
M&TD:IZWKH4U_"#$9.Y,CW/\1,1:7/1<FTT13MJC\(U6Z*$V.Z^'4M<YG5X\F
MAX]J[\TF^Z.TN'(I&_:NB?_G>Q6X&VF:>V,@*(8@>%1EWD_ L5 $9B24VIN:
M)?'*1P7.XXMFSW$T_0_N']/3T2SN3V;'4VKD?W/D_Z:KWB 'A&@ULS9X!@H3
M"T;41.XB&57F\<776]N0U@VU%3>D8=\$@NYXG:OQ9^//&PH'L$8FXD!*@@W)
M01(QBL*G6=G KYQ.MO'GK?!G-]6*LB15=LPCU'AF)YB+]415'9$;L,7;K;NR
ME1R:Y9/+-?YL_-GX\\M%AZ"BQ^BS5!IX2B$G%24H$;2N9U7?,'\VD?'ZU-EQ
M/5WDG&1@%A,4ZN2&N5S^Z0V%\G_EDM<W'2K5J+-19Z/.TPBUF++*&25W %$5
M)@T0I%)&BJ1"NG*FC.9ZW@I_=G3;J&.9-%1?,Z)@X(PN7F?(S%MOE8&("MS:
M!@@QE +N 7_.!=^?CNJZ0?F=1G]OG%5JZ_B@H"4N_EW'^&A\C/-:_E)N.ZO4
M*4Y KEM=L'0XF8WJ/8^FM%]N_IM^_C!*1[MG./KLP=/:\D^/8"AU.S[Z^B.?
MU2Q27<VX?3J0M4R2?^SA18-]]G-W>E::0WQ'+$P)WS/,I;"/</\#GLS6?OJB
M3@>C,3O7AG=6?7>N]O;"VF\]VW[Q;&M[\^635\/!RZTGZU\V1@\+O+WS[-5@
M9WOP9'OKU?9O+Y\^WGGV=/#\Y=;CK2<O'_\V>+53/MA\MK7SJN\U^=?Q&(_3
MZ(C2_UXT L_A=&$!Z@8(M Z$C &D,DY)$RD+S!J,H_#5,;9W/#L:Y9.UK[PW
M9:M4EIF#3Y ##W7W1?+!)Y$DZOK>.:M\PON<QDI+[>/AC!Z=_?%S&LT.]_'D
MT6@\K_#\H9\/</JN(..4)"HJSK'8O*"+RY\ L\X7H#E=P#K]YM/+Z_-+YSAY
M<4VZ=6>_?IFOBVM><U)=Z\EO%5;H=2OD#RBL<M *NUJ%]5=Z[26+NI<&;'S'
MK5)T[KU@TK/@T#MR\3O4.N>,IQ3I(-!TH,1P4%QT\843=\467(7YW;]&X\'1
M[N2XO"/-_O<*R^#?,3RN[*KV?##\1G_3_D!<)4;@TAH_N&:3K=FNTVRJ-=OW
M-5LWC.>ZP4O7:I'>$?OST1C'\X2X"^WHT0]-(W,CS;K,VUL)5[*$#VV;Y!.<
M[0[H_XY'?^-^X=!KHO*JH=7M'??K'0\A'/>2T^HF8SH9'.#T/1T-\O$/.K#N
M>]KSGB[CW<_E."'1!*TQ:@G@?<:8A(X1O!%6<"WFRW%"2"6^O1Q7:?SQ.-5?
MSSZ1^0-=GOL=ME[\,=IZ^O;]UHOG[]_L_'&PM?-.;^^D]V_V7GYX^_IWN?GT
MF=C:V]_O+,\]?<??OGC)MPY^YV]>ESJ]>".VG[[76_*/T>;>K_MOG[[YL+GS
M9RGG?_+6$WXR7YI[Q4M;O)&;>^_^$BX%7]._ +>F_/".!4O$0'$O/"1ELEG;
MD!J&0O<I.42CJ493W]SYJ8V6V;AZ>B!D1&^4$%[F&'G@Y>(/IJE[%X!U:PS%
MSS.4Q&2<M)DI:Q,#5T\_YT&QX)!06Z$PB7N<JJHQU#UE* TR1!$SQ)PAA>PB
M-]%Q(;TGB)P:0_64H62'H6P0GD?'<DR2 :C,O)&:U9@T&7S$;!I#-8;J1]V^
M9ZKG-==E7$<?8GF9#,[$4F%AI 4159OJ]9JFH$-3V=5#*Q*C,L+*5"\20YDB
M(V>R0J%-\*&/4[U+)+NS:*=26/HVL[4[KWOG0UMC:*=CWJWER1*DTBIJ'@A
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ME@10/0F43-!K&UH.C5DZ;T>;#_07ZM(E11R#!>V >^U%DBKP,@\T,939X1U
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M&%8GXP")B1#+[*;X.:S,7QTC<$E$X-GGFPLN;SCO+\Y!"5] 3LIP 9H'3"!
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M&C\'N#>Z14WJD_>'35(PG/''C::N [;W#=A&4%"B>B$*X%)[+X-4(9IH$%E
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M&DMK+)UP+V_&E9!&&)$ ?&3>YABMEXJ&TF'J^CC)&DMG"$O'1F:MLD"$8YX
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M;FC ).]J7M#I_5L$M'9M;A %V5S?4C%:JD,DTDA%@+I O(N*6$>MM]X(74*
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MGV5<$0.!<R<89 O3<"V?*A>U:SE]^2BU0S[FJ)(,),:2.N)I(B9D2O!I10F
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M$_:ZI3WT8RWM$V__K5O:R1WZW.8@_'OQG&O\>C!^G=Z)7\C__]K=_+AR@C[
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MU!2Y5B>XT[8.A]#K$B%GO2JK$NLF'<_4XWQKSC4 "/!9]_/CRW<0[^1[0T0
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M/'F'?Q2&"B^L1(I1@;AU#CGMX,_($R8I&J(AXI ;3#=S]@U /1: NLOER U
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M;A^D]J>MD_;61QNTL=HH)(R08)@V(,T)13Y1FA@#^Y2Q0FO0T!BV,CYR&(%
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MJ7AZZX>,:!3__.;/=^4W\O./!7I"-R=]0@L^WVS]4NZ&7W,@4&'IX3!3JRX
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MPYLHYN5B:(2<A4SNU/J?E2@;?;UW?;T$>F>T',+5^&W)-5=^[Y5/Z_C#"]C
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MH<>%V0_=K/6X\Y7OD1IME#'><4:$"5$$QIR@S'))[VBM1X.-=XR-.\O9#^V
M]1 1D=8Y#HJ"(V?A-Q4#$RQ2C9UHIGV>A]4K 9$/T=8DX7D(V#(II'/12$\,
MMJ')?CQ2JU_*?G 65?",(*"W&!A1C,@2*Q'63(;D:5"Z6=[U3*R><NJP%99I
M!1&P #70E"G-F>0N<N:;[,=CM?I%7Q]YU)$[C;!R''&6 K+<8*1$U$ER;0AK
MK/Z96+V6-C!%&65$@Z^/><:#F22#4LY3%YKLQR.U^J7L!Z@SE<Q)Q&7(I:N2
M0IH8B8Q.0E)NC0QK:?6WM/9C_;,>,=S94:2WF ^^0?6&QXZ5]W5(::T-%7#N
MG@U]LPGP]@"RO9P"239P98- B@2>4R ::6T9LHJ+P *.1+%;.ZST6M;TB*:+
MGC$\W-<!IPT\W <\+.5*0)!>14*02T8ASI5 AL:$J Q2",_ .;!;.^BT@8<G
M!P_W=3AJ P_W @^+[,$X#E204T0@HD;<2(\,AK$4W/E K!6$JUL[)+6!AR<'
M#_=UL&H##_<!#TO9%PV(#M%C0)3QB+AW'."!121![9U4GA"'JT*13,A' 0^W
M4B3JJJG:YAG-,ZY9).I)) :K"D6#.&G]T!N.QS^VNJ7V9>LPCJK<X%VD V^\
M)'3MQ'CU,JVKNKC>-..;5:G_C*/BZ6\WDYF9W.KBU&>E67\=#?NOX9W=P10$
MN0L*:\LIU="BHM1ULVI>@1M><05>\?=RTE)%XCF!B,,19Q&/7B 7D@5RH63D
M(<@8S8M7>)/A&U2?7K\5[ U$/76(NF$VM8&HAX*HI<0IDP[\"K-(FD@1YY0@
MK55"$/(P'YW2TMH,463Y<,4&HM;)C!N(NM6,;@-1#P91R_L!&8XI6A1P4/GT
M9XD,"0YY;:D)C@1C5(8HHQN(:B!JW?+)%R/4#9/*M &F^P6FI;2Q,"*?2B)1
MY#%7UR0, CU%$68FGTLNJ&$L Q-=!J9'OU]QK8%FMF+OME-SER1-;[Q>>>T$
M>77$7M7%]4;LQY>:FY\=;-#[6NC]?CDY)W ,-GJ/L,8"<1T,LDQY) C#$!#K
MH&.Z<7)N_398-"#UU$'J89-S#4C= *26TG/>Y\/;&4=1FH1XA#%STFM$7<S5
MSHPWE-PX/=> 5 -2SRL]UX#434!JB4DI*75D$;&4-ZI'$I#Q+B$E13"@(H%K
M>>,$70-2#4@]AP1= TTW@*:E%)T26G"@NBA1"T&>B09I@3TBPBJLHP9?XVXG
M17?;FVI_*KNQX=_0_?)JUKC.M _:[U_]+WPX:TK]1I31Y*69(4QW$.)@\A*9
M EE5']SHIU>G_2F/O?W'S/7TTW0\Z:;C^[=W.F?OM<1N@7R<M^5W_B"&:2_N
MIBTPXU ?C':V5?[-5]^;AA@J2^\?3B?%PG?3&SL:@)S',\S9@U;]TAOZSX_3
MQ'OQ/W\=?_@W'#J(-N'Z$S!STO[MKWYG^Z]>9WL+[VX??-K=:[/=O5[O_;^_
M?N[L??[Z_N37U/[T]NONVX_)&6$#D 5C8T"<.8*L81IIJJ517,D4: 7+@)4Q
M;.4E\$2K)*(R@:;$K:)6&I)G!)E5Q!-+7K0BX.9AUL;1-+YXM7<06VG8ZPV/
M0/"MP^$$5+IK>ZW9J,TV<A_%46S%>N!:"4:N-8%;P4S]M%>&+Y]X%RY/+K=<
M]'8ZCOGV[FAV6M[1<-H+\%7+PNO1Z<M_Z [@NN$4E#V,?WRY9.KG+"U_60NC
M-.B<[=7ZS^FF$F CA\-Q-U_S<A1SZ[_$GX^Z87(P\X=S-U;P\Q*?W6+=>)B[
M>>$M<W;N09QQ]$!F3M6"@.9^'HS.P&T_(C>*]C.R"1K[TO:.[/'XQ4_G^M3O
M#M""#!^L^WJA]VIE[SMO=G][T]EM[[Q^M]':Z;S>O HN/VB#=_?>O&OM[;9>
M[W;>[?ZQL[VU]V:[]>M.9ZOS>F?KC]:[/?B@_::S]V[=>_+#=&"GH0M(\.,J
M#5RPTPK;I;;*26:<9H$3JYT&N I"!IWK]Q!^N8ZM?.RE> C,)9.),W,O6T]
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M=7)&!XP)P)=RSEMZV?:A!KG6#+F6Z@UKAK%C7B$?7#Y,P3/D.-/(T;RM._C
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MTD-S;QQ_=4^?&D/UYCQSY]K%D%=L!+/5^,\A+VI>JZOZU!A;[^[<BRSU)UZ
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MB4(:#8*#LN+:B/U\).RJ:BO<B0J;)0> DV["CU4Y.(67YL48*'G1 LO\C01
M//<=I>##SU'%@!-YP:J[LQ$?U.=E@=.M2H*R;@H2E0^Q.1_B:CY)%X=6Z//8
M,0+;-0WP!9G!$I<;IL49<S*'.VY*. 6^/7_'Q(ZU)RI;LE<I/65+]MN6S&4(
MF>.DD>4$AILA[E$0>D:<<MNPF&6&7I"DF672I9E6H. .E"W90F&2LB7[8DOF
M+N"-33,+(M_(7.PXCN!OS/(\PTX]S\P\YH9V@AW'C@X.C#(FJR]H3^W)R_9&
M*2NR%U9D+D,:6VF:15Y@^,Q,\<PRP--+9C@\LQ*>F=PB;-I(M^Q-W;>U>]"T
M>UBF)30)TT5:S N>Y:K4:K]30V 495GIWP0_E>';G.'[L> RX(#[5NS$AN5F
ML>'ZJ8EMXH'AF*:7,)[:B<VP33P(YFO&5:W&0:CT<V=HE$H_JTK/7[<3>F;B
M0 @4P%\,U\M"(W*CS. \CL+,Y\R+8E3IT%8J?: J_=R)$J72SZO2L[NT;25N
MDF$5%EAHP\5;OD/7C V;.58(S';B+'WUSK)UVWM*%[72Z1W6Z>?#>E4ZO06=
MGDLYI#Q(PB3V0+("RW"SD!O,3$+#Y#P-4B=)$[P5S]7M\"FX[PK59:VK;L[Y
M2'O=[Q2D/$<-RHJ9(4&(-PZP*RW'V&I&>>:G)6QW+H/SRR/S9D^FSN'L#,^7
MDP%U4/C?S[ ?_'FRH, FXE$6.XD11&F&@'V.P9S,-4)NVVX0I%'(\2(07P\7
MW)+ZV'.LIVK1"Q]T*4NJ+.E^I,*4)7TV2SJ7 $LR/W#=A!N99\6&BYW%S,]L
M VVH[7@^9P%"GYJZXVZN(D!9TL=5)!VM&3U4&_I\N4=E0Y_/ALYZHZ'GI:;#
M;"-$N%FPH;'!@H ;IA\$IA?X?IKA10ZVI0.W7\R(*@NJ+.A^6-"7+$M3=O/9
M[.9<5C>)0Q<"]<R(F)D8;F Z1NC%KF&!Q;29Z61)Q"&*=W1W8R!\+VD[*2?\
MVPB!L.!_T_SFW5_ACV;* U9=Y06].P0MD2\TT&"]B::-V'_']2C/[L1'>9'R
M8O3&B,C ;E1=_9[WD+[:YE_>#LLZ1Y:\J7B?C?(;_A8783CTZUF*L)KC . F
M6>W&MV4;8Z.-T4[A,YR8=LFKFSR!D9.R'FEEIE7\AA=CCKJO 0>OM=$UA_\J
MSK4!C'M=:QQHGL(/AR,^B'FE.::NH7]&F&=S'UN8'N^/4WC%+VN8-C!L$=JQ
MA(7,9688!5BF'=I!$KL^_/E0?.TUIJW@)=Y$P(JK'$3OI*[YJ#Y)_ACG%4]/
M!B7PYT\JN%WKE@)_/XU>G__]V]W_^U<ZC&W7/P?#!^]W_M_[#W]^^?/*.W__
M?_-__]F'WUPY7^QO_2_O_WE]_N<__H3QLR_?X9E__,>*XR",PLS(,C\T7!8&
M8+)X9MBVFX6Q%7F<QVMM8+%C1CSS>>;$$&$G?FC::6!2]!W9W+,?RD<K+C\#
MEUW3CJS8=8S(X;[AFHYEQ'&8&%GHF'$ RA?Y8,'<WKPSOV2; @/61T$ Z\(Z
MO*!_2QYI9T5^PT8,F'O#^^40/AGQY+H >WAU!Q:DX:S&B+6]%0T8VJX"K-^#
MIDO:J+5,E!DZ3N('3A0GCLO##&^M,TT+[%00QPFS'PI?E?!N5GB__/QR^Y\P
MXVF2@+1&0>0:;A@Z1NRZEN%DOAE;;I!X/EY)9O?F\WE[(JSMAJK=5OF(&V66
MU3C4.J)K19$9<CMTTB1R4S.-7(CA?9N[:0:!0\0>"AR\^<(06,>HK.[^A7-Z
M7]X62DH72^D_G/.K__BI&S O,0W&&.)8<FZ GV,986)YJ>_8@<6=5^^\!29V
M6DA1;$XO_GGVWK B[>OI-Y##&E&7"8R6^$%.V5I6+;53U\M8RAW3A; R-/TX
M\=PPR"PS >N_LF@HJ[81>?G]Y\7)?^PPYEF4>88/3K#A)JYIA&[*#"^)4M.%
MF-^S?)27^1[H9S-J;>Q)H1R^-A%=;&SB"DQ_<L3AWE]GB"&$V('0QG=2-[,M
MYCJQ&R>9:899%J:QEW'7$9H)OP&%0;UPN96FX(XYCI?!G@;>N)>FL*?928;W
M;83+WI,ZB(T;F&$8>*Z3>*'EQ($3N)EOV5D6!;/OR?PH#LTT<>*(N>"'AVX2
M15;$DS2PP=5/(7RU?]56XOD+QKB+:?%8&CY,DZ_7#.S7%@/JM<RZYSN997'+
M@S]<*W3"A+NP("]+TL3V Z8BK>V:=5C=U7^8XUE1D 9&ZH<IQ-->:H1Q%AA>
M& >P^89.QJ+UXFG7]WR(G6''MMP8I#MTXC2T4BL+0]M169,7X7)BFEB7Q0T_
MXH[AQI%E1*$7&[!KNVD0!9Q'8#[,WOSMJEL,45:Q7BM'TYM,!$+8ANYG8OH\
M<RT[9)[CF6D<FY$%.Z<;JRA[NR)]]?/B'_]Q8Q['=LR-R#<#B%],,%R!"Q)N
MI5[FNWYL1Q9$V0\&V>L&)RSQ.!C,"+;<!'9R*_3-A#M>G/B^%89,!2=;%8:+
M[_#]=YCW^W];7_[[P83 -C1-UTZST/!C+\+T2VK$%FQP"3-9%-D1!+[Q8EMW
MKVG3P0[50YZ@P]V_TY\6MSSLMFK3P4TG<)$>IFOW G3XYZ.!VSP=73<GN9T?
MRC,W<_(3%M=E?SQ:_I-.$)1P!/?8_H$T.=*..1/K=?[$Z9+,QY8=4?E.G&;@
MR+B1DSE^9@;,<OPH8^Y_\ YQ^:/KJEG"D%UQ(ZXX^V&P#%;XAO5OV5W]ZK?I
M:!%"13DCSQ*$WQV:S76'$,W./UQ\^G!^\>7L]%+7SLY/>TLE:E=F_.7D_.33
MAR\?SK\36'OP]E)[?W9Y^OOEY=G%N79R_A[^._G\[\NS2^WBH_;Q[/SD_/3L
MY+-V>G'^_NQ[\\RW#Y>_?_Y.CUQ\_?#M!+^XG%N[6.&[O\;5;^\6R=8*Y%GT
MXWM'7D-2@U?WGU#["S,4S\<W&O%-/H+7)2OHZSDO/_&B'.1)#;)7)#U=8_"V
M&Y8RV$VK82D0AK37%<]XA29T5(*AA+7FZ9CU^W=@*LG70T&PS;=?68676IV6
M UC>'7UHO=7 'X0E]AN;K-WF$-KFHUJKQW&=ISFK<E@DC"1'Z<ZJ&4-^=<MG
M/QG//5..*[WSZL[T9N:5%_!E7FO_&+,*Q 5F]HW#DD>_:KE85<6O\GI4,5@2
M.K67'T[A(WP"\Z;#,="GYN 07XQQ@0-P=8&C9?(#?]Z''P*YX*/O,- YJU/V
MAW9)WWYAU0\^TCY_/M5>-RNF[^6\?@6W)N5BXO7=("[[+6$^7,AGEAN)CO!9
M]I:E[UZK<8;P4^F8MO!59K]MU;E749")&<AP>8NL3_,Z&==UXY:R@O7O:F!Z
M?5V.^ZD6H^2P%.4+?(7_C@OAK)+8(U/'!1NG.8K':?=VMX]YP8HDQ[.?$7Q
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M7'@]DE_B'B-2NT+FQ(:;5_5('G#](78\&ANSLV++Y3\9F"JNT]OG$L] ^G*
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M^"?8TCY.7G@>0TR95'0,*0UP<V @C^WE"YO>EO9D@[(,0"1]\L\KV&O'PHM
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M%3<UY<P$WIBJ:K;=N!6VR;EGF?&ZEF52[>PF_F7[=DH 0I X:MRO1GU :L&
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M]1?->YU3HJD[B6D'TQLH*;Q93WS1%'_JD\-5+<6SD 8UN$F@3=\?VEY!0:=
M'8A1"(>ZW?)T<I6/ZI8*>UB>>]].^7WB<M,;]VQIE K&"@Z!(= 4&K1P%>T1
M_W1D(3*XL^>*700"(2@(5Z>+_LFE-2'BNJF%I<]U3_O;7>=P?.IZW>GW4?98
ME!8.L BETKO'Y *SX0KG@ D3>=":3\.$U&5)Y?_@^=1YW.<][=NB4L6Z T)"
M[0:=E#,6ZU#))TL%'LM-<X(KX;(0PB3!*]0HS3Y!&P8-2P6">HN'P<:B_)NJ
M#@OL8FAI3;>18N6@2.()LBPZL3UI >#[=XLMS,)J3$(_[22FJ2BYJ<K,^QRO
M%9. O0).H*O_99OY7\+50U+_?W4*,+_()A"DV"6=0A,<]'?.!GNV8M&/T. 0
M-<TMT\4A0FW?"REH0*;J45LUTA:)-#=WZ9-B#(J$FR;F2<?(DKOW0&SE/>:I
M5 :JFVXN+* BAI_Y0%326:&I?7D_F=ZD-'B !S?-_M6_:YIQ@'T@N.5M,0N@
M1XU!+,L:##-"(5D@[+3#T> $+\*K:<B429/0!-NO+;/NE^6/QI+1RSK7H4V*
MD.1G=[(I)J$FY[FNHZ*]$ED<+]7MRS]*,)HE^JC+V4^5<[8UX;,O$9.;;IFB
MVBE9/3S5Z2WP_LEFM5U,LB]H6??4,C)3(6N+(@!B<MV5S4[%EC@JQ'L:R1)/
M75(H;W-O$127%4,?DHDZFQS,-JG:B^:49\^6.57C?=N]1)+D0G3]@T\BX2T;
M(">"<6QP$.@2L&Z!O+S*HB!TKDFU]&0,0EUK0+8G V73-V=0<?3?3^?:LEH$
MN&576G:.EZ<0)694:0I!D G?:S1S211Y\+EH$<0:<&$2)8)4ZPZU@'S:Q2*$
MB'GHT"N!\M6QC4TCC_##DNNRQ+X2@H]$PT.H?_2_#0BD:(0A(W8K\<R$HX/B
M-(.MT?7R*,09L"LN;Z>6]7IL<@4+$:(N9:DV*Z8 &.\A*%W$(.8@LWI7_3)F
M_:;ZK.[ZIQ.8N_D>O :X; ZBOAL&=:C75@+,V\H&-J0QFH)#+:C7D,Z9J"J0
MKK[C/W-9]XTDH5/=17B"C8T4&\P#<(_P 2$X$CD)(! Y=XN6=5RP&Y;WFQKW
MAL[WT/@^%*D=MC!B>YC#B1GG(][8DDD[WU((%KI7C@OA%J!NQ&%,JW91X9#&
MN"?AK;H"8E J,C@Y>2$*K:>J.;M .!*>\[ILFI,[V#!=GZP!D,$QY [>F*%6
MU,Z$TRZT8 XNIM8;&+J&\?5*$*=M_-!URJ9 O"=OFJE:I99KX3RTE).PJ1<B
M()G(G9#MYL*4B9Q2N31L"0:IU4*\U![&I,2."7#J$B),70TQ<3EDB\:4&].8
M30%Y2S=)U+=4^8N*12A\%+)BN 5CBIAU<B%ET9@PK-0746+;0# '>*FPVJ:+
M-UU5O*F*-P^Z>+/C Z^ 1-L%*)Z&I6V@Q:4!;+UH-O$KA(LD>Y870>7J2[%L
M*12;N;U/P-F*.U=$J2D!W8H+%!8#W':]<FH3[V 8+VF]E<@)9+?K!E*VO2RH
M<QE+LPM.T&1A,^VC<2_EA5/BWP1!RSN_%"^F\$)TS^'VT4)LCJHQ7PL?5D2W
MZ+Z2S[ "1.PAA:CGS:G">X$.>,F0GA_Q?'//5BDR9Q+DL*9ET#$MJ!9B2J-C
M+=VZ-KZD!&XC[[,HAPM0WOO4SU?_R/O]NMO,/.5G3H5X8A[DEC1)ZP?OF< K
MKP0< 7DJ\)XLIX:W*VJA;]JISB'RN19WQ%R6X^:O]*EVRC%1UY??3/Z):_H7
M(E?<J[O7=%'$!!6@R4:V,$#=HLBNK]LXU1,H '*UIF""AK.-W]C>*!OSR6-K
M03^F89E;G5S>L2W2Y%.-UZ+#^DSO]E W63"9'1 L@DB2CM5&LO9<WE_6P6;0
M3F7N4/O61=!<7JIR^NW+I 6ZE)@*;0A05;G(C.D-SK]L\ASQJTJ0'6B V;@F
M9RE;J"38O$!DD&<;.,LEI30M=R<5-),"&I(N.AOZ]D5$\LWIYT*B)*33K#GV
MH"L -5A[17E/NK]'1AW4/8C5ESFOI^\KD6(L)!!=O!)[8Z?7V&8C^R(1TF9$
M16:[HU12"6=4L&O>X^;>UB:PJ1GL)D $FBBL6S9'T,@XIEPF;V] %!>:46C.
MFD-<3 2+*&QRZ*O+C9;5\EHBTG9XL/F"G'C*?U#TFFEX5R4V8=*=E12!R1O1
M8.WR6@O"VZ?N"&,\[-H48=O$83*?W!=9%LLJRN6I&]W\*TDR2?2(NV*FN3VY
M[J#FU.2(>RLU(!/ %BJOS&\MOV9BU7*):)_*)2Z)Q:2 >[='?B<4A/^6XKKF
M5E5D5[2TN#<@J .Z'RSE0T[U2%-8#:+SB,)A 1DK+CQ&3^FW+K35S)F5.!40
M3:I-SW/3/HWSDJ^5LYK;%T79()X?@2N#*ZOQ=@UX"C^9X'K48T1=T&Y8TJ2%
MD%LZ8:MCN[-V3>6A!):;EVEW:D28YGLPS!.G&*%Z1&X.4R'-$Z# >//IY-V#
M/$W[D^XCSG_,W/,P6KI,T+-4HF#0XF!8+FY'HLN<4>?HKL9;(+JX:*(0@W9N
MH,/FK%HZ-M>E3#&BP1R*:YZ!]#=W6EU@S<OU&'8@L'0B\0CVJV!I*=+R#<2&
M--4ZN4'B&HX^HGV!S1$9&2JNE?>3L/J:\O)U<[<2H\(LGDHZ[YO33/5$]Q[=
MX>%H(0K2,/C 2@N(,RI,>%4#35P'7%R)?S4GIWA/%A/'A.+^/PKJ"M&_UMS[
M(&\!^)=H 9R2&,)B:2.GFM*7K)Y@AK=$1_S'B9FB9SA>\8D-X;!CT24.'1]+
MOH$DX 9O+A&=Z#+?ADMHP;6;I8C-2/RPNUFTO[PN;[4_QGGRH]\YX6QNXFB:
M&26P8E/6(IRC"3AE=PWXTWPP1-RN[M#MZ4-GV+H%;.RA@]9:N@4,H;_1U<C-
ML<9454G<)R "=+P%.'F7:GD]>TED.TB=7(.>8"4+H<0TV532*E&3+D)TP4*)
MI\S%!3X"D!MMTYSUF!X*L?/ UHJAFDN6)Q!DRU7N*'.3WO+<Y!JNBF6_4AE-
ME=%\0D9SM^ HODW.>2Z&S1U/;?CRG<#=*8N)/LD7W*IJ[4.!H<E\P1!N,Z>=
M&[_6'L%:$3??W^*%  ^ZTY/F=5%:**.H6K:M=]J1+B&TXH/FIHH.N2GA O]$
MS9%HCP4?-5M%VX<NQF]-,::'#4*!&=;\3?.7MVE>#_OL[DU>T'SI1V^GZ8>F
MYP:/T,#KEU)( BF^GEBEGBDLTZB"_]+FS?+K'GWUVRB=_XXVEFCIUV;/>N1W
MGK/\I??]\K[)6G;/-ETU6359VUQ-9G\C?1 Z 6J'ROE_7CFO)MX -:^\L8<_
M-6O:UHNM<5;WA-IMWX29HMD'BP%;PRO7?L^R3%S4JP6/1KM&@?"A'= 4-AQW
MJ.4;TQ&3YH$M>XHR+ZT4)Q@U/MH7VK J3!Z5VS0Y?L.1O%NP6<!>"0-Z>"O0
M9J4%'QOA+"542JB>5Z@>L+^8*[JB/B-#SC!).,^R^U:-W;<[Y:N<3X*B583F
MH24O%1C[X3%6EB136T!9NGYC.Z2-5J(L!7N+][^-40*_)8KL-"7^HB1+29:2
M+"592K*49"G)>IJ/F='_/=K';,]8MNUHGI94/S7K;&YT*CZBVCPXEP6'LRA;
MAM-;D,3'LW=1U_O:^G7F1&H=RS##MD=9A@6LWP_E]^VU=7^QF.^=>BOQ6$4\
MK)ZEQ$.)QS+Q<'N!$@\E'LO$P^QYQRD>QY"?_$27& JD6162;528G%!%9"K6
M?Q[!BI1@*<':O&!Y/4<)EA*LS0M6M+8/>0R"M>WDY$LXF+)FN+BB'NNB[EY2
M]1PQF!KCL,;84! FS*2SX\KR232,2A3!05[@A=F40G_I#6G_]APW>JR7O._;
MBA*/%4CFV3U?B8<2CV7B8?9")1Y*/)9M+NYC(^5]%X\-Q2S[X8]]6X+<I$Z1
MUK:GZHQ12<?R,T95H*"DXQ[I<)5T*.E8EEL^UIWEJ#)C N65[K)BU0\"?5=1
MR]I%XL[:^^R!1"U*/%81#UME3)5XW&<]'GF(J\3C.,3CD>5N^RX>FTR)V=Z.
M.V+?RQ'K:^7<J?Y+!RX'5C'CAX\-:PZZ8D8)UE/I&5AKGWLJP5*"M8)@F<IB
M*<%ZGO;%1W:W'K1@'4-WTF=L3A*P\RWT[$M'9@>F7:\=L-N_KANR';1F*:%Z
MNE#92JB44&U:J+R>JX1*"=5&A<JV>IX2JF/K2CI#<%2\<4ZF+W6\O>"EX[;]
MTQY3U6TIZ5A^(J2D0TG'/;;CD7EH)1U'(1WKEJ(<B'0<0UKO@NX#E:Z7]CHO
MDG+ ?WV\#W;4=1=T:9S]]CA++Y2$K!+CFCU[[1!72<812,;Z\9N2CN.1#K ;
MUM'9C6/(?GW"VZ/+0LN+&UZ/L*%57(&.]W\SO.\YX?D-W=Q)9Z]%61A)]U90
MEF5Y/X>_JK39%EVV PEPE(2L8GHMM^>O;GN5:!R/:"CCH23DX9*>-<XT#T0T
M'G#<FCO&P9GA]^/3J2<?^Z1BP8L_>0SIX]=8%OJK)M+&6LRSLN+:B/U\9!.2
M*HZY;R,)57&,$JK-AC91SU1"M:M"M8\2Y?B/2%2N1@$E3D<G3F'/WC!6_=Y+
MU#$DQ<^$.PE^)+B4!7_L?4C'G7FPUSEI/I#$@Y*,U23#49*A)&.1]Z8D0TG&
MXDCQ"'>38TC@G?.1]KK?2>+M2/@BB/+& ;%)RS'6/S2T.+0<C!VN<[R\<2KM
MHV(JL=R"P?<?WS:NQ'(GQ/*@4D&(8_#H Y GT4>)HA+%*5)':X/@'[DTDB/]
MVPC+6.%_T_SFW5_ACV9*<G4&^L9O$-EVFOW_'=>C/+L3'^5%RHO1&T,\MO6U
MV:+JJ\O[C4[ ZX7>"G-X.RSK'!&8WE2\3W<2OD6I,9R>A3^?E0-6<QP!-_5?
MM6>9]VJ$.RWKD59F6L5O>#'F6E96VNB:PW\5Y]H ?G]=:QPXG&J7?#CB@YA7
MFF/JFFW:-M5$SWUL8=32'Z<PQU_<7J3!I/M %WH8/@B;#W1X:3WD"=*J?Z?C
M+-B@!#+]24A6]._DCW%>P;O/BOR&C5ASR1!\,N+)=0$TNKJ#UXU8<96CTK*Z
MYJ.ZIRU;5@$$>'!5D^ECF6D[_QV97Y>\WK-,CSAU6^4C;I195N-(\":G?1-.
M]O3BGV?O#2O2OIY^@\%J KO%@OEB5%9WO=;4S!J6 :NN\J(QMS[(J/P$E<7?
MO/EX..06:@ ?H7K2TK]>LVK @/+539[ .PJ(QR6CZI930WA1F=;:$(08%HUE
M_Q42$![H]\O;6GO]"W8-C*[+,4PLK7]M[_4EF]ON2V*#@77VV;#F;YJ_O&VJ
ME_*"9DL_>CM-O05VA0RR^/KM;9Z.KM'V]TRR_TW:1+Y9?MVCKV9V2_D=FKYH
MZ==FSWKD=T[H/NJ7]TT6(O;(4W-5<U5S57/=F[D&YFJC/I#VWJ?L]N(P[9Y%
M+0^ K54(D.#N7+U,(!8LI,!W\JV_""_OP[R7=\RT.4<'>$72K*@42VGTJ$=7
MS@CL-ITQT%DE._7@:H^*9)8BV5HD^T4[O8;8<J4#3$6V2:9N=;(='W&4Y5*6
M2UFN'27;0LMU+#4[,D?XYEE/_5888S,"J6:H9JAFJ&:XX1EN\C;(G;^6NSU6
M:LZ2GJ/*>1W*+2SFV![95BM4^.4I1<V[78-AF;YN^>LVT&VF=EO)W+'*G*W;
M]B,O'U0RIV3N$4MS],A9]S;TW9.XE4HM][9_R.F%"B5-V:/CL$>6J7OAR\B[
MDKDCE3G3U"WK9>[I4#)WG#('9L[U]U_D#MWQ>AG7^,4=KPT=!.U'[F^FBORE
M6\'V3TUL6_?M=:^VW\PU"XI)*V\X$?@XCF+23C/)T3USW?R?XM&6%2GLO8P:
MO;A7H,1C!9+YX-BOG5%5.KQ=)GFA[@;K)ID4D[9L:/7(4YOA;O/(.=:]\!B0
M9+^7(]9OBB5?XF#F";@G>Y_*7''M.ZTREAWJ0?C((IIG0W39"0D^<B'>-SFV
M=,==-\.U+@V4*"M1?O9U![KK;MH@[Y@@'_:9E+_V5=<'<B;UTF;NF&W<'ADX
M)[!TTUXW*E4^Y^$+\9[)L1?J7O3(8O!]V:J5*!^#*%NV[MK^84OR83N=QUT(
M-0>^^Q+0EX)H*4_*BF!#WP"Q>26@:;_-I&B78'E*Y,X%^,#;3S!+3-N"%)HA
M*F<+W)D72<59#1_]$C1@T2T2;5EI$ ']1=?N.*N,$@3'P+_UM+D.SB5(N8@;
MNBJX;#,-9Q8<US)[WC)TW-MK7H Y& P9 KJ.2GIWS083)-*\('C8GG8F7T$?
M+5] Q;,^C(]PK^VL\!<,5L^NN#8N\I$VK. W6@J/PROK$0@)O\H3^&T^B,=5
MS0>\&,&/\E%.F,<".Y8!%2J@$+L!J4*P4P2(A87]?! 7=N=D:18+=I/<]Z:Y
M;_?,9<Q?A>\-DVA6^0#Q>,L,^%?^%\;18ARXN*KWC0/WV:<&1%G:*:+BIZJL
M:^UK578O*-R/I<Z#<;= ST-V5Y5]@4[<_)U@QCFZ"/5(P!*#0,#_$.=1X6I=
M&["\&/&"%8F@3LJ'%4_R%B"ZSV*D:UG=:?R/<3Y$;4;9 YW& 3M?9RS)^Z#E
M'$;M? S"? 5/PX<@:+%4_WH\'/;I2?'./D@Q/(O_2,IQE8-"B$D+I'2<KA3;
M"H@W+*M1.T%4 J!P4>,CL3 D/%TNQ)*<KMT+$!UY'I.]!45&:,W.#R6DLCGY
M"8MA$QF/EO]D#HCGA:3&\:?)T?WSNFIF,P1&&3'PZX?!,ICL&]:_97?UJ]^F
M-0/40@[N68*&N[/\.<@A6O[YAXM/'\XOOIR=7NK:V?GI<N'8E1E_.3D_^?3A
MRX?S[__[/Z%M!6\OM?=GEZ>_7UZ>79QK)^?OX;^3S_^^/+O4+CYJ'\_.3\Y/
MSTX^:Z<7Y^_/OC?/?/MP^?OG[_3(Q=</WT[PB\NYM8L5OOMK7 &C%XC)4JOX
M0L+\'<Q TO7?DAF;B%;DBHS\D(R\-N C\%'J&?CU_4-;=\*>9^T/VKKM^6JN
MSS!7U[2?8:ZA[1PY7?=IKJZUF@P\'A5\F\B!6\<%M[Q=(T&X,[C@^TJ;9\ %
M?]'4_FJKGKU#9DN P N2X+LM'4_%!.XN^-@(]R1DX*,EW)%"=&]''0\*.'D[
MBGB$)#L"K.G%"Y])$^\NWO2Z<JDFN=>35#-\KAENNRWL)8H1[@=,WNAD_-Z#
M-_J:]]WH>_^%OO:O,XGV+5:V[5#QVHH<WTLPKA77YGNZ[;],7;T2NF,5.B_2
M/?^1364[)'3[6OFX(I>BWB,K5W>I]''%M1X[^JXR2N^L* "K],CVF1VR2DKJ
M]DKJ@E!WO/U'?3[PO= R#P&)_E&;X;;3E2\6V"]!0]VCL-YY2EA_H&A.JRJX
MJ_NVPD7;?2YY[KK9"L6E+7/)7#MPW$%HM&<-'(];/EQ;=\)U;P!06KQE+CFA
M[CHOH\B*2^L$)@> 0[F=P.2>B"S8\12( *2<:339*9"@V=J< TTM[3PPQ8H+
M#R(]7'L/WC-D"B7+1R++KFZ9CSS#WA=9/O#\:G"TZ55EZY2M6V/AMA/ID7?@
M.*9*F(]$F"U?#R+WL(7YP'=NR^P]$JIQ[[?NPVKD6%+M/(MM46M,^\M3DQ ;
M+%/?D7Z@5<MM[9[YO$<&AT<RJV?M#,EV98P]89W;"W:&=7M",K/G[0S)%C7X
M-#]N9NW1$YOVE=08:@PUQOUC');[N;B/^%,'1NW%FXC5&&J,O1WC&*YM7-J:
MJ_HKCK6_PC7UZ+%G@SN41%1"MU="9^N^_S)9496Y7IE+K]V>-0=7=_!):V60
MCM @69:CF_;+W&2CI.YHI<ZV].  P$4.?1\,>O;Q[8.'E3U;JZ-5M5>L7I>H
M1]&ZQ5:J!V;;X9;N!8I).\ZDP%V[Q/=0&I64@*SD+8:ZZ:I^PQWGDFT"EY2Q
MW7$NO;;,GKFZ3W\HAO;X.D*O.N?CJJU$5>(_VH4.]3!Z)/;=OA3B*UD^$ED.
M=-LY\-;F T]).KV7.:MX>1=&V3IEZ]8)FAU+-X,#[WU7PGPDPNQ:>F@>N!=Z
MX#OWZZ#GJ\/$0SQ,_#1UHSG=.[XK!?G[T=KEA*KW<WV213M#LET98T]8Y_6<
MG6'=GI LVNG>S]]&+.[S=Q);'/YHQA*; ;E>/BQ4CF#@#O8FFJ;Z?\?U*,_N
MQ$=YD0(3WA@1O6BC%/=ZX8- Z_9]0.O60Q>H:<^"#Q^M,.D%?2ZSR)!:5E8:
MR/*U-KKF\!]>VCXHZ69R/G\SN8:7X6JL6/"QI>5%TA^G\(I?W)ZCP5KZ0"Y\
M%1N40)T_V:CY=_+'.*]@[+,BOV$CIJ4PEWXYA$]&/+DN@#17=S#<B!57.0B2
MQNJ:C^J>MMIJ<"$%WK#^T#HF$[;L7KC[,^Z0^+;*1]PHLZS&L7[Q.@3' 4\O
M_GGVWK B[>OI-Y@A:%)Q!3^&-X[*ZHX8"+\QGV/)T_<*'+?N.R^J^S,U?5O1
M?+/G/XL>K;*6E?7^P558'6M NM)9E@[OK(<\03'HW^G;5IUPH:9LWPT1NTM9
M4/:$C7@ZQQ(@9\5!%]*6.4+&D* KL>GVFA<PZF#(D):CDL:HV8!K0YANF=;P
M"L&Y894#B6!]6@HOAB>O89(PU)#=566_3Z^4?S=(A>5T:_H&A]V8H'Z'P>8I
M0>_(\@H^_V/,*G G\?NNU*4/F?2)]99KQ"'Y3XBPLZH<++3X-)N*:[?X1U%J
M]3BY[HS3>>$TAQ[:A1JBK<?/_1/O!7F,1\LRJS6*ZNDG%/',&I*NI%,T*QY%
M3W_V42E04[H@Y4E(8,J%[M''9C.6V[/_\L@%S,X )CJO=1M2(IK4JAJ\LK^Q
M(U(EY@'\*2NBTQN(JW@E_(5/O. 5$XL]20?@.=:CBOP-[<//(2_J3F'^?JQV
M>DUL>DU<K@D86=2Y,)D+^*U-6VR4WW)<P:]Y,L9Q="U&,UE<Z6!A"U8D\,GU
M&":.(@M/@KN &@._&PC)G,B>3N\!%P@D;69RH%9U612\KR.0W2W'.=5 O#+Y
M8<2TJZ&^POQIS)[V+Y#>?@TZT.^7"4R7S :O:_@25E]+OP6FR)*\#\XD+%NN
M7]?.ON/\*@8O'R>C<25V$'@XY<.*)SF]0I]6KV43G]G?0"NO'N; JDJT"V[&
M"LLAZ\105( 9MW6+!D-9B3:M(4Z!8 U]-JSYF^8O;].\'O;9W9N\H)G0C]Y*
M.HBDSYL%7C\IG/CZ[6V>CJXQ4],S*5O3Y/OEF^77/?IJYN!#?&>;/2>REGYM
M]A[[G1.ZC_KE?9,->Y:U_%LU5S57-===FZOG/&[4 Z*KO=I\'CBOW:]C@\7U
M$O<L:WE)@K5K) A70HG[3E'/%Q'L?)@/=HZ9-N<8!ZY(FL>KQ?:J%59;]>M?
M1#A=CF&0M)ZK2'F,!'0.S]:H-=IMZ< LP"HGCJLL^-@(9RG"/8)POVBGUZRX
M6@DW7A%OMNIL=>(=)7V4.5/F3)FSO2'>0G.VU[6T#Y[AF_>GSY^C^NNAW^U+
M^\1JM%V]>V+MY;]01?IJZ_9=W0X?"<RP,[T32I*5)+_S'3U<NW]72;*2Y)V3
M9-==MYEMS\1XI6:VC8CTSO%V_6L/M\#;%Z##LS0L*/-X#.;1"D/=#==M7M\S
M$ZE$^2A$V0OUR#OPW5Z)\C&(LAWIGOU(J-9]D>0C]ENML/=(D-6#=ESW^GJT
MU19\LI&KNP\4WF3%@#[J/1)8;M_U0XG'"B3S[+5MJQ*/G;M7=Q?'.$QU,=>^
M$D"IR_&(A^OV'HD%I\3CL,98"WYFKYHD)^WTOY@]=ZHU?&7\!OW!GOJFI1[;
MB//)2ZE_>:[?]Q>W,Q$(%E;MV=6U7V;P5@H^TOK8; W_Q/Z[L@9J8 <Q-033
M\W;W>>P8'?<)U23C0)QF>)C4UZK\+T]&VBD;L?Y=/=)>8[?H#>O#G!,VI/;*
M855>56SPJ^C_A,&M[N P&+9PXK^F6TX+X/;I=<XS[4/3?*I=9%F>\(K:KNL)
MZ %A$ZS2JK@6_T0G/_!NE+,^\ %[]X%R\9W&VI;OE5E,* .6V?.Z:R<F '61
MM+Q([FA^#$AR-08*(VK @(T0OD#"8DQQL=/;*GJS6_23.4V4XN_:O0";*><!
M5MH>2NS$Z?Q0=F":DY^PN"[[X]'RG\P5MKV0ECO!-#FZ?UY7DVK<*V[$P,H?
M!LM@LF]8_Y;=U:]^F[9D8,;DX)XE:+@[RY\KX:/EGW^X^/3A_.++V>FEKIV=
MGRYO.MZ5&7\Y.3_Y].'+A_/O__L_H6T%;R^U]V>7I[]?7IY=G&LGY^_AOY//
M_[X\N]0N/FH?S\Y/SD_/3CYKIQ?G[\^^-\]\^W#Y^^?O],C%UP_?3O"+R[FU
MBQ6^^VM< :,7B,GA[6)VU#$]Z^#W/'$7:ZUGLXM973/63*2!K,#%?*_8$/8$
M[>^<]4?76CV.ZSS-82M$(*[K/+D6=KF%NVC@.3@8TG0.\(7(0SM>.R_X05$6
M1L)J&'T)Q,"$AFBW@RX@D9A#"R1#PPY <1!X8-EHS3I9DO ^KUK,#OJ!5@Y;
MD(&* Q?S!'=7\1V[955::^-A*9:Y9$>D'XOO/O,KF(K\7*I2C> &0!C8CF&?
M^/ 3YX[;.8[8I<LZ>^B*/--7PQ! -(>)N,(>^XO?"[K;W2I^CC>]O4Z!0J#G
MHJ,3->5](#Y//4+VD0_1!:L 1R7J/EISB$L0\$+Z*1,'K>,/(6'@"P2%>S*C
M9ARQO-B<([8))TR?1NZ"4:8!-.#;8!VODWP<:YJ#\S[.$QV_U>"#=LOOLZQI
MQY\LGW#'-%@HV)BDP[D98>P\3+9LD=:.KME(*Y-D7#UH3P\) .@;2!*KP)8C
M+=X+L"2T!/L+_S.UHK2SHE8/A'2@< AI(:VEY]"HH+:#D0 #QD=,(E?B5MG]
M#+5ME">$>D90/\U>\B"8D Y2G8.#2:A!I 8L1K:@O'.04IJJWOVT'@^'?53^
MUZ!T5VBD91!9CD>PP?#&(+)"XECA.BO\>XT01S@K-&+5,K*,.!OL$QK/TH7,
MV;D&IVR(/RGPMWN/T@-6T'H<-L7A((D<^UR#7FB%:JY'+0/[--<]DP%[-;HJ
ME)Z#0J)1*#T*I4>A]"A8B^T23L%:*%B++1-/H?0H<Z;,V2X13IDSA=*S?LBV
M+,VM.IZW>,?QOC37K;CP0'<LA=*C1/D@1-DU%4R/$N4#$.774;#ZI>5[)L,'
MV>N\*E^MGK-3C'T)(BB$'F49'[UPV]%]3T'T*%D^ %FV'-WQ327+2I8/0)9-
MW8X.W"X?L^<:!+T=M%0O[[[N-4[/BBM60#U/IZ&W-CSK#F('/&N =]SRX??6
MW3R5?.P>,,0NCG&H^N(J?5'RL91FCMIO=\@&[1Y8SW(DA,40$;O>X$B]NUF?
MC=;%>EFUGY?:&]O6;PD#L$9G7M. V_;(WS6H!JR> C7XO^."MVVWVL,K[X ]
M6&;/>138PZ.Q'KK-\%F?)]2/.04M\-P4VKMFW7]Q( 78SGR(';GWDR?-"1%
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M$_SB<F[MR]&.]F0WN6^W_,3 JH!5.R/$%X)Y.1,[RN<2YOF-)SR_(?N65>4
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MD6CJ<FI-L$,BN^$A(-] :]'V^+8R@/SV2@MQJEN?V93>_<#9R+KG;.AXEC<
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MGRI3"4<+*!>55I :I$][@+> ?-M:%2$8$HB_-X"_S&S:>V:S,H=^Y,5Q*(,
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M:V3H/J;\5VS[Y O!TA(REA>U>+JLUO3'^Z:7.$@!H3A2C5CXS)CY0&T;N^8
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MP8SG#IR) 91EA,(X"RY')!C<8(Z]B/@*PSI2%D]-RAM.<7^"YJGDQ$L$+@F
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M3#0(SFI32YMI>J(IY'EX3JK!&12MB[RV CPD3=J.7KN38<LMPFY;^STFI/5
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M(K<433/GZGY85]=ZD@U.'%.BD!89(>/15V2!!A]*4<%+,L8[(\T5KB%E)O;
MFPT%U(XZYW#JL;:#L\5R=H+S3KE7XZX$2\R9#-(95N\=-Q ,%D C$MH4DA/-
MSST\@*?/L5ZN7\X8#SQ!HI^@0K(0HC9@531):>%#:%V/OP:L02G75HRYM4@:
MBV<G:^3:^M4%90I60DZ%QLX\*0AO-1CAF'!<<&E:EPZNAVQ0*G8?[-E02+T2
MZ,)Q_C;R.B>GD(.,7I*CH#R-.D?@UGJAF3?%-_?F'@+4ZV@O%K(+=6@D6VVM
M68G::QEJNY5D,!N;9'.??0U<0U>TF[%FG;6RE81VLU*N+>-(X\LY( 2LG3I%
MI/]I\K5Y$DGPF&+,K7>%UX0V=&6[ P9M**<U4S7GK]<?,2SP[W_Z_U!+ P04
M    " !7A6A5)(K2V4Y@   M.P0 %    &YE;RTR,#(R,#DS,%]D968N>&UL
M[+U;=ULYDB[XWK\B)^=U4(G[I59GG^5;5GD=I^VQ756GYX4K  0L=E*DFZ2<
M=O_Z"5"BKI1$:F.3%.6ZV+K0>W^(^ !$! (1__Z_OAV/?OJ*T]EP,O[U9_$7
M_O-/.$Z3/!Q__O7G?WSZC?F?_]=__-N__?O_Q=C_>?[AS4\O)^GD&,?SGUY,
M$>:8?_IS.#_ZZ5\99W_\5*:3XY_^-9G^,?P*C/W'XA^]F'SY/AU^/IK_)+F4
MUW\[_:O,#FP4FEEED>G@@848!5/)6:EE1*O#__/YKR"E%-9Q!D"?U24X%C7G
MS!3IM7$R.IT6#QT-QW_\M?X1888_T>#&L\6WO_Y\-)]_^>LOO_SYYY]_^1:G
MH[],II]_D9RK7Y:?_OGLX]]N?/Y/M?BT""'\LOCM^4=GPU4?I,>*7_[/[V\^
MIB,\!C8<S^8P3A<OH-?G^?D_O(S&_'+Z2_KH;/C7V>+?OYDDF"_4<^\0?KKU
M$_4[MOP8JS]B0C(E_O)MEG_^CW_[Z:=3R<$T32<C_(#EI[,O__'A]4VDP_'\
MESP\_N7L,[_ :$2(%T^8?_^"O_X\&QY_&>'R9T=3++>B7PZY@C(5SO]=G_9+
M9TQ'!&2:3B(R^BF.*\$;8ESU].Z8SY_%,A8X&<T;(K[Y[*9X)\<P;"G@&X]N
M@';Q(':,QQ&G+:%>>>XEG$N0UQ&.<?(9QY/C89K])4V.?UF@>_'N[<=W;UZ_
M?/;IU<N/G^C/WU^]_?3QW6_OWK_Z\.S3:_KM_9#IP:RNLSPHOH"VQD,OX25B
M#,?#NM:\H6_/GES!M46.W^8XSIA__FF8?_UYF)-/P67IA#8Z< ##3<'HHRY1
M1!"#-9Y?Q[ <Q6B2KKQN5-?/R;G"1Q!QM/CIX&3&/@-\&7R<TU96=S4:-KZF
M+V<#8[SQ$")#K6C#L8 L2&N8QOIC'B%IN$F7V9)^!69Q09BS5_Q2M?(+CN:S
MY4\6>EKHZ'84I[IY^+@^X%<<G^!OM"^_F(SG4TCS?]%V_>)D-I\<X_3U.(U.
MZD[_;#9#^E_^!-\&I 8P40#3,GCZHW 6@A>L6.TDF)QT;CWP!\"\*ID+WCZ;
M+F5T-ND?N"I44Z8I1^:3[:KFE"(TQI]_FDPS3G_]F7=ETXO);/ZN_&TRR;-G
MX_P1IU^'"6<?)Z,\" C*0!8L2RQ,&VD(6=0L)>=M\"BXXHU)<SN:1\^-1H*^
M20'1E0)_FTYFL_?321G.!P HO$Z.QN4LTQP]@P*!V:(-<3&I +FQSB^]_M$K
M^:&BO*E5V56K[\B4)0]C_/G5MR]D<^'L69PM5J0! 5"\.,V,RHIIGX!Y&3G+
MT4! '0(M1XUU?"N81Z_Q-F*^J7_5>5;CF)"-:*UYEH])JA75?/@5SW .@$MN
ML[%,04A,:R%8!&Y8P6"%25!0R=8S_6Y(V^="(^5=7P0:2KZ'Y?X#SI >>$3X
M7I*],II\J;-A"4XIY%(%QPRX.@-29H U)F-23FC("Q&M%X<[ 1T**=I)O8>]
MXB..1M4L'>??8?H'7AK\P!E07AC%("G:Q<B'8Y%,$F8UT+9&.QEZU=IENA7-
MH9"AD;Q[V#5NC'>@I';18F!!.UJMO)#,9T5[I54E88PF^A4AEK;6PJ'HO9MT
M;ZI;-U,WN:;DH;XAZW7@2K Q"L64#^2-!+)@O=2*QNMR(),V"Y[Z4O@%C,,Q
M#!\HVAZT_7H\QRG.SG>=&%6,-F;F?/4[)3@&V9#?J5%"QL"5;FT"7H/PZ+7<
M1:0W-6PZS^?Y$4[?3L:3J^1;HN,ZT+8B-<N..T*7$@LN(\M2% <E.)]<ZZE]
M)Z)'K_^& K])!_M0.HQQ,O@;2:,N.N_&K\=?B:%US&1PO)G ^ ,F''Z%.,*!
MELYK*)%YL$#[#P*+WB0&*EBEL@PR70L,WSB-6/MECU;9_8CSIKY=]P5^N=4L
M0]##\0F1\FPOFHQGS[%,IGCZN4_P#6>OOI%90^\?CF'Z?2$B8G.JP>O)PD9=
M+G #R;W.JAAF))FCY*+0T#@7K&0PRF?I@BW--XO>AO-HN;AOJK[)8M^&Q03Y
M;!5]CF.L 56!H%7TCI'!7,/D AE$\H^X#8F[)'5TNA<&WH!R(.SI)N*;F@]=
M-?\6YY>LY8P*,+A(-.35-RJ<121/R_N4R0D+4%QK:^4*@$>OY8>+<T78L?-)
MXRN8CFF5F;W'Z<<CF.*Y1PTY1P=*LH1(RXW*P$!;P7QQ)44+*JK6\_HV+(]>
MY4V$O$+[G:/.]^]7!/DYS(9I@7L 8#'[:!E/-M-*E#D#&P@OAJ!#\<#1;MW<
MN )Q^UQIH]R-#8F'*Z:'TXNUX+X<CD[FF$\!*UXLVIQ9<L4RG>FK"+K0XN>T
MS,&0;=XZ]V5CD$^)2P]63@\''__"FL6,^=E7 O@9WYY4H;TK"VRS=R?SFN*[
M2-A92D=$6V(-SQ?#:46..I-OAY$5(;-&X<"%UGO5IA@?_1[6JU)6+$E;8]%B
M%1WD@DI@\<S'>L(3A65>A$+@E0N>)ED6K:.N&P'</G_Z5?@#V;6YLGK8[6X!
M>WD)O8QYP+VQTJ;"I.9X>J,B:$7N7 $-/'JI5.O3V@TA/DUV-5%8'P?_RY7[
MTR)\*1*Y^2IJYBQY_CKZR()"PP!*4$D6KILG?UQ%T) =EVZO]+YC=1#CJD7C
MI].["']-H\D,\Z\_SZ<G>/%#LJKPV_S5:/'"7W^>X>?Z13,F/#^9D4QFLX^G
MSYT]^S:<#5!K]$A#,**F+%F16-0JL21E#-%HFU+K)( [ 37DR1TWBN[@S0,4
M?1MG.@N\AWWG#,O+Q0J[%IC!M;M-S7*!+@%IN7?<=B?K#IUW5]2--*"N4NY=
M]8 N!0_D_D&AM= JQ4(@)PV]-AR#-J)Y#'8+*K]RK6UW&M]$N TU78\S7] /
MAPE&RWL(OR^,J %M@5S+(%CVOM[(]8KYFIV4LQ#1R>R$OQ9U6WD<O/KI.W!,
M'R[N25-9-;RX4Q&])SOR&*[A*>A (Q'1^7J;R$!B/@1)R")PAXC ]1JZ6_7L
MQZJYSG*Z==;]^R_71$&&Y!^-[XA^_/3NQ?_^^[LW+U]]^/CJ__W'ZT__>156
MI[NB*Q[>WYW1^T9R[>ZH4S$8*0('!)V%!K*_ _W$1JLE&G7KW=$5[VE^AS0J
MGJ, R80FGU '<A'!6L$J2.T5D+O0.CVR_1W2U^,T19CA2SS]^_7XXWR2_CB:
MC(CDLU?_?3*<?_\P&8U^FTS_A&D>>)L$<.N9R$K4.1,8>$^S!Y(AB]>5HGLX
MC=D$XEY$/3?AQHK8>6\JZ>'>Z,U0AG$1,<C ?'*9%FGN&!2>&2?/VAJ>K ^^
M]<38?72I5[5=MQX[R;P/7^'&4 =1H+0:"4P2BO94LHX#H62I:,A16E]DZ^CV
M310'3H-N4F\81JPVUK/\7R>GZ9"S3Y-G.2\$#:/W,,ROQR_@RW .HZ54ZJG@
M^Y-I.J*OWY47,!K-/N"H5ASZ-'DQ&7_%Z7P81R3$.!^$$)TNFKB,DH8D@F;
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M]F0X;@AU-V9D;ZI?GV+-]+;=A6PU[ !<6!-8B5(P;85@$(-E5@H4Q<F4;.N
MR5[0[!XC=&]9MH&Z>F#72_Q*]M87S)\P'8TGH\GG[Q_J/9ME&4VN F&H!XE0
MVT-E)9FO[>552(I#0I5#ZRO@]T#:OL74JTHG_>FCAUH[O\/T#ZQ'%Q]P47[W
MACQ.468=I#>),V-JE)FC9;6^*Q/1*6%$L(*WCJFMA^RPR=.#=GI8<LC'RWA,
M4,\Y30,LQB1FO95,Q^19#)JS;+277H4L9>L=ZSJ&P^9%)XGW8$$O\-2Q+?%H
M8X&[0BA D<?)/0V.*\%X]K8HDZU2K6^;7<?P!!CP4(FW+H]]Z6!R<:6M)GLL
M>H5$Y0VB9#'5=&P7R74L@3,E@C0\9%O*6FU4[BM/>LO[#]K/;B;X+9!A&89:
M U7+@MBW(ME!$>PFFKI']1W$W+J0\>WH("DEG 8&M4>M)HW1BA4ERT)(E;B/
M3JSE?^R9\N\J:KU%W6\BW1XLP=47G-].YN^G0S)7OC_',<D[#>G+93\/HY(O
MNC#:[&I7AUK!RJK,I+$Z)*ME2:VSV#<&N>5RUHVT.]FF:GKP3,]<GO<PG7]?
MI,U!.ML_+__F=")IK6FOS$Q96>K^69A/))Q:B3L 3:?H6K=K6Q_=05LA/2NK
MA\)UE_$L-\PU$/44S[^)9C<A^[[T=P=-.@B_AYUK!3+E%!:I(Y,AUQIIRC"/
M@;QKH6S@.3K$UAV>MT6'>T+KNV/#)C)O;+.>I]2>[KK+7=#2ANL@*F:2</7L
M/))?3>/E@1LMLP9AUDKZN<=>7?WV[<<PNNIDTE2@/9@5YSVJEKOBQ]-LU%.3
MO!"7BTV$*R59[UHA&><(]>XXF@3&.]TZ<>!.0$_">&BGDAX*F)YA.9L+ZX#I
MR52X F3'/:*[*^HZ!3I+N0>;X"HH\K2R2\1K::0E;UTH!D"$%]FGH'0,4MC'
MI_)U>T'WK/%-A-NZ703]<)A@]!&G7X?I/)Z>T3DCM&8A>G':;C(@UTQHY[7F
M1N;K+3U7=X-8^?3M[^L=Q#UI*JO&"9WOCV!Z#-?P!! B<F>9<C5.8FJ-QD"\
M3,I'D[5#G]:II;+JV8]5<YWE=.NLZZM3V=($F935ER_;-#!;]RUM^YH]:&S7
MVIVACCQY+K6-6BMMH,0LC$B!%Q?)C!X\Y(4]=D&+*=H,1K'B:E%?33P+!0,+
M.@>C _<9ME#K_1S/GG3D\,I%0!$93ZI> @Z)A221)K4GD=B2./95<^R@.G)L
MPJZ>.G)LHLH>'-N["_[3_E"$#+34QQK,=R6R &!8UB5JR840N:^Z X^ATT)C
M^CQ0\#W>:FO1 PF#2D48SH*MU[L<1C+WE63&\RR24JK(+=1'/)#&5BT8MVVE
M]I YME%306,E<LX- U$[/Y>:,*6-8U*CMSQ%!]?M^J?<Z[$+PWI32X^]T38H
M9:R!^[H<U\Q_IJ-.+$93_U 9 X\6W(]:TSM9KAZ@H![.B#< + :N. ':<R8A
MDQ-=M&4Q1T'NM-!.>BEB;+TH;8+O:?)H,[7TV/>L30VI:[OX ()%EVE<O%;V
MI[6V-M:5AKGDK/2A.!=;'TWW.J##)NF.%-]#W[8F];G!9P(:#,,B: P^"Q8+
MK?#H2C!@%7*SA1)XC[W,>F..]JO&AGWA;BGRW6&.W5H0/"0>K..LD!G+=!"6
MA4P#S#J&8&/F7%_+*ERW(GM[L = SOU4;,/V<AW+TUN7"]DM+"M-(B43AX$T
MA0&YZ=:E@ K6.8\\E/X #1G6@P)Z:/>VK:*D6B430TW,BIYIA>35^^29T#S0
MF$OQN:\:5T^J/NW^F)A-J-!'6[H-W#T:U^@DTP!OLUO^CJ/\?CJ<3#]-+CU.
M# 28[+Q!!@& :6LB(PN[YB9R S+[E/T6;-'6PSILKN^4!%MJEO?@ZNJ+P.QX
M$?;_"J-%;RY1DK&U@;,T]9J9E((%F2.+H6C%47NG]KFX_LT1'3:]=Z7ZECW[
MVMOR+TYHBH_GIV)81(D'/L1L30V#U++(&@PP*/2'R+)4J7NRR;;NG]W$>0!L
MW3MU;JF%X,.GXLWA">VY\B(P-*;6:(F6U9YB-%#O)3D2VIG6-5'Z'=$!\'H/
M5=^R(6$?PZ,Y_P6G\^_O1T"#/-UMOM09/5!D+:429,UWJE5=9:&]9E$MU'A1
M5#$\MR[YLI6!_>!YCT3HHY%BVYWJHI+/;"!1@[6*/(-:2U"'*G8#F@7T/"DN
MK<JM[YGW-IC#IO4.%+ZE?I$/GK#72U(M]J9/1S!>-I\;^(S@I 5F;)VX4!+I
M@+21@A.D&^M2V4(PI+\!'C;E]X08?72E;#G:Q>C>3L;ILITV2!@=E&P9)J[)
M RGD?-2$H^"=41(<2K_/,9*5@_I!]YX(L*4FFQWVL-_H$>-4/W8V.E-H^MK$
MBC3D6]>N4H TE2'503HO)&XA1ZW=@ Z;VCM2_):Z:CYXXIX-24@G!49D@:.J
M;1,-\Z4$VINT#$)!EFZ?_<RG0.!MJKAU9\RV\_'2$,\"0P,%9"YEVFF$K=GR
M BV+FKP+Y5VVJHC:TGGK8>N;. ^ H7NGSC[Z;_80N[S<ECFB<RDJQ[)&DGO=
M1;R-FGDRC*!(EZS:0LBCX8@.@-=[J/H5S-[YX>'O"+.3Z:)ZR7N<#B?Y8AXO
M>Y O/HS7.I%[F3W7/#!GJRM@8F'11-I]@D?(1FH5Q)86Z <.X0 X_IA(L(+\
M>W4:N1SHM2%&T"D+4DNRB_PN[1@8<$S%B+98-(YOX1))XU$= /7WE (K6+Y7
M)Y,7(9U+OSL]@(U9Y90*,L]K.F,RGD%)AF%T.@038H;6/8^V,[(?;.^3"BL8
M_^##R2WL9^L(!N>#Z$+V]'\68A&DI,B9SSDR)S$J 4I+GG9OWJPWF /@_][(
M<B-BK)@:>W78N1B/3B($R9FQJ;97D+$6*#",%S0B0+:A><'&QD,X 'KO@W)7
MD+7SD>3R;'1Y6^AB2E[,N]F DWGE30:26*UC0,)C@6PKAD9Y*UP,OK1NF[<6
ML ,B5GM%K*!+Y^.]\Z/T(J)2O@:T@R*+.Q)OO2!+)-6$;!!.6]_Z).X TQ\>
M),X5>MW5^=82_ZW+&R_*F5HU+!0M:J)H9MYER8KF22JA<H8M'-BV&,H!L6X?
ME+VB?E+WDO@;%WMW019)3E1TT=!J2@MIX)B9+8Y[%)%[WWI;VQ1C0]H!+9W;
M)UNO2EE5:/"G*H \_VL:36:8?_UY/CW!BQ].QG/\-G\U6C@8O_X\.RU*W$/-
MRD5A<0>Y\)0-*SQGIH,3M,#SVDT@"FZSBUZFGI:_:U >3P.&3=1_?P7+C=70
M8^W*R[#.KG*>5<->!V!/[1CN!;>;%@U-5+D&/;KK82>$R9J@*&V8,8GL10O
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M%_S81/1]Y'=,9O-WY2.,SL/Z463IA);,VDP.K1*VAO6!)>=E5H)S[5H?U]\
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MUB7<]F'<CVCN[0/Y]W B;\3<1S5[KP86[A<$5]S&"($9CJ[6QO(LQGHU%[@
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M )BV]0B_PK/.NU"D@.37ZNEX3^FB5>\^&*.JB7 ;M]H[PS-[-LY+!BX/#]8
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M@*>@A<"DU9'I+H;"GL>?WE:HJ(!)7>D=>Z?4^J_++QYFZ=__[?\!4$L#!!0
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MWH\,C=E1*0,J;6H"G53,J]EUHU*5,K6AWR_5V+44&XAT73 >@H.MY!D/);O
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M#*WA/."6U"A;CV^C+C#Z3L!:X[;/$OB]5!H8K4&IML<%98#!\76?T:.DP]Z
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MH<DURQ+NMSR&9P7&MEC6XGM:+@?_'"QW"R,>Y+ZW'1:E,Y:VE<!;,&QJ@4_
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M^=S4( 6,SDI?21.J+_2B2HNE"5BJPO:'*A?F\U,B,HR)H!$4@E"(2"0@"86
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M<?58EDF\^"X+GB_E\G)>&9:_29-'4AN2SYIU[V3S^^LBYW(:)9*%.,U@$-$
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M3RUVC+ZJ"]W5!;U;EY_G3T5AKKO2!"F2<0;3, XA0D1 2B,.!<,Q(S+((KL
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M4Z@BG HEXS1B5OEF'?L=VWKR:3&_@[JC!_!X3XL'JA>,NIK?;.,[X&S-6HV
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M2ZEMEGS^59I[J<7\5MN6FH)_TZ:IO%)J>7[UZ^6'D$SC+$ H%A&,N& 0I8I
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MU_5=5WR3O^2;U[T=K^(LY8@I*#$-]:,L8YA%*H$JC$B<\I2'U.G<\G*3ID8
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M"UV8@ZBW@KI72_'V%ZU/SA.4Q%F:IC +4L-I(8493O0?*DR"6 8L"\G\J3S
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MU\Z )_JJS5F #?UIWS?(?AJZ27,P<(<^;*U ;(P&VNH9:.PVJIN5Y9H_C>U
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M++H6E_H6K86E_MMN47GN[J-PAJ6+#3G8?MRWT%DKTD[30&\\-1$H%0B(-0E
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M2:G@3!MS&_*-B> W8R2HK70<[N>PM!OM Q$:>;"[@N,N<G?9?5^2=F=:F%;
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MR%BPCKS2:,PV6XG:/+"W_ 9\KNBFA/SV&MVXQY+T ,U72(E+T]-&EO0 Y23
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MR7G- ;Y(:7Z.>744C8OEY1FT"5HD"O"AD.,.RCH%+M.WQBLNBI92FJ?R*+M
M;R^"A^F;<3A('D][.T.5HH@X:[5WIE2O<BX^8$):?\3I.[SF1G,NC).@@R:7
MPC@*+M KL%'$9'U46CR5Y-UI"WV"GF%Z<AP.:LUDWX'1>S/]2E3/YM^)A1%#
MCU'7AA+9,:(]$>U"Y'J17&1F@K'IJ4*477!S\_W#-.HX'$YVEFT'N'@_Q[,P
MSJ^_G>%T@9?@ECER6;(";FOEKK<%0DX!5(K.I"#0F-:^^8.$#-/,XW!(V5_:
M'4!F+9:_XB1?;+KO9LOW84[![ZOQXFRV")._S&?G9U=%>]Q&;Q#!!%[SGMR
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MVT<5'8#J\E#_??A>3_0O$YB1H;=195!8YVUD:\$[+D&R;!"Y4:RY]7J8DF[
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M\6J#JT9"[P ^?YG/%HOW\UD9+T<A('<J69)#G<S#T$$HP8,I2A/ND_2A==.
M&Z_OY'"I#4!V%6L'U6A7[0PN9E=>MT0G@B4K5H&668)R*8 3D4&..GA4WI/9
M;(R/1XGIY/BH#5K:B+P':X)3XF12ZT+R*85_E8OE^"M>\#4*3#"3M0$9:@*!
M7$2@"$!#06]XS5.B;#ZFYFF2AG5W&BG^KO%IJ(4.0/6!=$($?"%^7I$_-YFM
M:HHNF9$2F9#>@@ZVKK:4(2!CH'7*"36%W<V/!)XD:%@_YS" :J>!#N#T$2>3
MZO)/\V]A_D^\(:R1U4$ZKB6$)&FGU@4ADLL&1@7:NFFW1M>\2/]1:H;UAPX#
MI$:R[P!%]^0SDD+96#.97JU&K'(!+DOR!XPL"6/4T;4^;+I'Q+!>T6$PLY^D
M>W*HK^_-C6SQ)L8Z ,%YBA(]10=.*$GRL=E3N) Y:UT3_@ 9G53,-':B=Q1S
M!TAY,R4#A8NKG35&67OJ9+"NYA)$L!"R5I 4BI#1,ZG:UW'<(F'8:SZ-$;*/
M>'O8<NI%W'>SZ>PVT"^Y8<K3UBD49,ML;>R4P-N,D 4O-A1O76I]</TT1<-V
M.&YM7=H)?WLH^364IOAY-0)EWW/-OX3QM)K'D^F;Z5=:#ZM:HFE^.PO3#YAP
M_'5UP%-[YZA0(KA@ NVR&" ZG2#(.DD^"R_2G>.*!P\Z-WK9L)/_&D'E,*+=
M%RV?&DZQOMQ7+\]3QM-S6@D7&^]LNO@%RVR.5\TJ<?'Z&_E_I+[Q-,R_KR1;
M^\;5DYC9*A"XM,@CP9S*LFC0@GQ^BB%)(HS5KG1!2Y>%]:;U;?L#LK,1G'WG
M<.Y-[5WX9Q<L7IC]7W"*-<//,2@9G06*2NJ9#T<(D0)89GQB-@D5K3H(>N^1
MLEDZDSTKZ.TG[PX<MW>XO!&39)2A#L,CS+,:O18&$2D6=BYE"I-]*,T+#&\1
ML!E$GLL)_^ZR[<">7'8\N;RY>)4O"3E'&Z2 A$AV4>9ZV\QP<,66%$V04;8V
M*(_1LAE<GLO!?1.)=V!2?KPI$X>_A,4XK:_$AE![Y$0#+-4&.CHS",83>^B]
M\L4%AJW;:V])XK '<6UPL;7GM+N2G@L&7XTGYQ2%K!F4K!@T.4.RQ8#*]%4,
MJI"-MDIDKRG^:5T!MS61PY[?#8?#G175 1+_@>//7XCX%U^)H<_X[KQ6'9^4
M>]<DKZ3)HRFQ'C85S6CCJ(.)@\0(A8NLD-M@?>O]=5L:-[.'SZ4>ZJ :>D8(
M7%G[42XH.18'+M:SSL@-..Y+;5!AO:,%G9O?S]R*P&'WXL-B94=@;J^X?E%Y
MT]3?ND7.G#;"I )",=IDBK?@E:0PNP056'1"RM;U#UN2..SNW ,RFRCOF;4
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M^:(]6E)2)F<I2HDR@0HDG%BP0$PY1TV\,7Z(:=*WB!BX_&I_Q3[>+7L'*7<
MDT=&?UXP(XSTLL0,SO,Z504IL'7% $E,B)R1EE7K7>I)@@:NFFH.GW;2[P%*
M/Q[F><%8)%-<:'V0]@T%JT*0R )GP+4/T3&A/;9.46U,W+!A_P$@=A"M= "W
MN_,\+[CPG#&O7 !7:M>9D@7%&I*#CR@Y<\Z%YC7M#U,R;).$]D!J(.\!4;.8
M+T<OUPNAMB@J!=-RG=4]*2_R[&REE^HX<NL#3\6!4,:#8E)!E&1T'3*L539%
M;S9NBUYX SOTW35N-J6ED^/0W6.R@PB]<Q!=-C;V/CG4"<CE$Z!2)C?010LN
M.BFR#DF$C3IO[ FC(0.UPVA_"VCMH(K.P?4B_^_S]6WO"^LK$XM1(0G,1A)=
M/7X*SE0_D1=>A+4W)AH?TEK=H:M?P.V"B6VLV3X*ZL"I>J >/TJ6(P\"N,((
MRC,-P1@.(7BFG RHW<'FRK[=JB?YX0_C&J8G=Q-P!Q"Y>PK^9GH__?]A-IG\
M.IO_'N9Y1&CG)!8'/)-;J'2H*X#\1162]A)M*>H =P*W(;&3/.:.B+A_"^M@
MZND ??<+TK6-B)[LJDLV@S+,0B@L ]/:&<V2<=ZUMD\[W1<XY+RNPZG\KOW:
M2_X[ ^ALM<_24IDO&^US=P4TBAR%44@L)$Y6O9!!]\0;I*)"CL*X(EK7$=ZG
M8MB0[ZA VD\#@R.IMF&Z]O86GV:/Y'(O95GOQ+X_GZ<O]/5)>1DFD\4'7*7E
M/LU>SJ9?<;X<DW/Q"N-RY'VTJBA:0RA($-PK",QKB$QG)G0(N-'0IP.1-ZPO
M=@R,]J+;?IIRK62\GBU\L\9VO1N\/CV;S+XCKL>E7\CA_21,R9/Q/"3. P1;
MK_#F[, '68"3\$60$5EJWNIX-U*'3=<>W?(>6)<]>(H/L_GW,#G'1[D<>:TU
M\1,A!O*_%7<(7C$.GL6B7%:^^'@<P#Y-Z+ ]=3N :T,]]@O6]9K\@(OE?)SJ
M==SZ:R^J2%<%NB3>@N/E.?W.2!>9O/;$H4DD6%\*.%;OY4:9N'51^N93TO<F
M>MBVOQV ^$#Z[1?0JU6[$;]!U=;(Z &+L,2OJC,B/<66*0:7 N8@FX?U>](\
M;"?B#N!\&.WVB^;U\EW]\&25_E^\_H;S-%Y@'G&!R5D2KY%V=7$B@)?2 46U
M.@@K1<JMI^)M3^6P#9$[0&PK#?:+T=6:?)C![)@.17DP.M,B1&-JYRT/I60I
ML^(F'Z#[PI9$#MOCN .$-M)?OP!=+\%W^/OJ1XM1G?]<K." Z*NCHQDY[>3R
MV*P#ZBR)JR-M_'<H&[CI<0=8W$=5_0)PM<*NF4J:UYD<$;(+B<Q^-"2WK"$C
M\\:;6%AJ/>EM(\(&;JC< ?SV4%2_Z%NOJ1>)!+A8Y9@IU),ZUBZ(4 O 016=
M@*29(#)4=?BY"ZSU18V-B1NX3W,'*-Q38?TB<;6\;O'EF;$HHP<?=01%YAR\
MMPE0:*&E#=**(P'Q'FT#]RWM (?[J:L#&&YRPG:#]_IGF":L0]$7(^>ERCX*
MX,07\6HC1.439&%XD"DKEUJ'U_O0NQE<_Q#'2T=3:S^GHQNQ7+>-7TCVJS8>
M.%VLM/_P <9\]GD>3C_@>FWC1YQ_'2=<+_L/F&:?IZLWC+3/VC)GR/\N"(H5
M#MXY22(34CGE!-KF]ZB&876S]?.'..]Z#F!Z+KM'%5.\*Z8?BF*ULXZ4(9ZS
MHGC"^ PJ(D*,6D"QB$X:S,JVSD,<FJ?-5M$?XL"M*WATL%P.UETO:%9BS!:L
MR:2:+"*$F! PD8H*.A;X0>:!#M9^\0]Q@-<%''9>%E]Q'F<'F9J67-*$MTS+
M.-?)7A33!R$=(%.)%VL,F@ZFIOTA3N1V%WP7N+E?".]-4"&P"$9)<J RDC 8
M)A!8-"^*\0.<^.YV$>&/<5ZVEP+VK!]_/=UO/O(35?#%8S35;B9M'7%1'(0<
M$DA#MM6F(B([2,GL#O<0_CAG7;NKH"F0CC3GXL7'O_[Z]N0?'V_SL-]DBZMG
M'G26Q<.4M^]N^3(LOOPZF?V^N&IDR&1(I'X+6D56+WUJ\#$Y,"PD&[@)K'FN
MY2EZ&K@]]9GOY[.O8Y+<+]__1F'0F^G)Y=SY%VDY_KKR]AX:Y'8EE>*%8B5P
M2"P+VK:C!<]E!%E289XS9]4!_*4&E'=RYW-?I#W@5!U;K1T$MW=<2>ZQU'LU
MVO%"6T#M-AHT>06)4_SABFV?N.EHR,H0"'C:L]]"'5UX]K=21S7O,TWC"=YB
MZM-L0QE?R5,EA5+Z!(6EVI^;)PA2"I"^MDP20F;1NJKD$'P,>S^U VP/#HX.
MS.TKI#>G\4JJ(Q&=$D9PT"$:4+9.C'6& ];YK89'$SDV!O;-]P]K;(='PZR1
M:CJ U8O3.N;B/U>TUZD'%-9_KM=F7RP6N*Q=HK1RQFK07N7J%C%PUD30T7#-
MHF")MV[L]S1%P]K"[J#74'T=@/'A$]91L%:00YXAN3K]DL=,2PH52#32F%"X
M$\W;MC](R;"7\+L#7P-U=0"Z*^F\K4FOU]\J(S@2 D,..0-*)D$)LN4ND;O"
MLBD*D['%-A]P]A AP]Z0[PYR^RNK \3=-MJU0<6K\2+-SJ?+]W,\'9^?CI*7
MGJ$SY"(K<I9E<!"%YU PB"2S5Z+YE),?$C7LY??ND-A6B=VA\M?Q-)"(IY_7
M)8(F&TGO1"@Q8&VP[\&+HB!Z)Y4/FJ7F,W2?HF?8.^R=8W$/U0T(P]K^I]8]
MG$S?3+_B6KQOIB^F^>TL3$G(./Y:^T#6KC_O9M.7L^EB-AGG6E+ZHI3QA**O
MJH&1-404CQZ$K&UM4[T50!^ +,*2A.OMO#L'>0]V<=J?DF'OI7<#T0'4.GR)
M<F7ZFK=_C)=?WIR>G2^K?&FAD!0>8W4Q<LES;:R%J+BK(W0\,1I2G9M:2K!1
MIKLE]@_B=[>W#WLSO2O,'D%]P^/T4O+7]6;DPYS-UE=;3LHZB<!'SB!ZR05X
M7X_WDQ%UTBH%=#I%GKF4);1NS_0T1</>3^\&IP=07S^87+,2)G^9S\[/WLW6
MWO7J? 'SU?'"7<[#9&30,>.5!U:;12M+,@S"2= N%^&X2BZW#MQW)'7@J^W=
MP?@8&A\>WW5S>3^;?#\EAA;X\@OQ\P%)=,3;)]I:2*ROOXV7*]?]Y<G?W[SB
M?B2$Q546%V/@H**@!5R2AH#T@63%,ELV\ FV>^O -]^[0>>!]=7%X?NJ,/VA
M ]V+,IFKRIE1T%)K91UP7R=31U9K_NB/B-'83#]CA[EXL EQ ]^2[P:QA]5J
M!YFJ^X6J5UQ>7#*ZEI_)R3)%2U$Z!LHD T[7ECTY(SGJ%#7ZUGC=G+J!K]-W
M!]@#Z;5+Q+Y(JUSQXCK.'"G+<U:27'2,&E3P#ER)"HP)/EAE4?+6->B;T-7;
MF(4VF/@A]/94T+Z.YH%@5Y-P4_I'M&1'ECL?6+VY46S-J<4$T90,+#"10Q8^
ML]8EFT\2U-L8AB,!;5>5#(JPZA7?9^7]',_".-?<V')^OO*11V@M16?D C,O
M*#H3J9!;41(P9[FP/@97^ ;!RT8OZVU(0E,$'4;DG=JI"[9>75!T<=#_8KH>
MIWM1W92,0OI_ IOJL3\:2[Y&2B"17(YBDG.V=2O-W2CM;<S!D2Q;<R5V"M9+
M5^%]^%[]A$L&KVM5QB&.)RL_>92*4D(X"SX7 XHB*[+P2@ JI^EC+C&W'NRW
M%\&]C3PXLO?76J4=Q"*;U_./E,I&2*>@EHH29RB(,ZD@H>;!&JPCQP:[:#;L
M9M_!K8@#*7)WB,YH/1X2HNL*@LV%2YYSL9DG<$X4(!%H"(%GT XU%N^BT*V+
MEMI0WLD,\B/=DSRD6CNPM[2%7'9$JGTCY_CB:QA/5D4OL_G',,'K'B^K665:
M)"%IX0/WG+SW7 ?=!IG!T39BC$S6E]:HW9+$+N]:'A1%L^.I=/@3RBLNY[.$
MF!>U-JLR14[0;V%9^?I^4A[G>)2YR"78.J-,!5!<LEJ-+2#7]I+!9 S-NX3N
M2&J7%RN/"N0CJ+A'$TQ\DR"7W^O4LB4Q75N0G*V.PC1ZYH)%BC]UJADX X$)
M!Z%X)E1A6'CK6J?-J>O2Y1W4\+919!=YA;MK\:30)[FF]+Y>7N?3FHLD701O
M!46:SM?Y>BJ"\Q1U%F&9*:TS]C^F:MCD5@^@;*NX'NWE+^>+\12)E\6JYV"5
M^,5/\DA%)25/%+@J5WES"6(6'HRR7"COM2NMCRVWH6_8!%8/\#R4,O>UFO3V
MQFC]];S>*YA^II5P6N\7K.H:5B.AWX?YRG$) H,7]?2V]CE40E/XZI4$H5)6
M:)#X;WUDL 5YPUYKZ@JK;5793U"UN9#)R58:C5+ 776R,]+VP6P$X4B\WKML
M5.M!()M3-^SUI@Z@>B!%]IM]O;I6N*%P.29RM$4FG\?RV@; @RL)(7DO2PC>
M)=<Z#="&\F&CK&-G7P^IUH&ODW[ LXO]Y*1<!8:71WEKOO$D3L:?UWTKHN3*
M:&7 N%JVG01Y02)R2#+&8#!RKS>Y.KK=6[O,I1X4$[.C**B[D/YRY XMZ]GI
MZ6S=6W?DB'"I@@29(Y*_72R$$AQXK9,.N<@BFJ>;?D14EUG18T#R,&KK(9Z_
MP1!)[2N2!QTGN#J;*):S(LF-#JQVJ8BRUDUD YB5,5:)8'/SB.AQ<KK,< Z%
MO7U4-?#6^_[*KE]T0UG\.IN_#&=GF%^&R80X*^/YZ5IN(^$RA7"F *+RM5[1
M0[1<@$S<^A29<_)'';*W?6>72<MC;;L'4\[P8?:*O1M+:-U;_J00+23#VDE"
ML>"Y)/]!1&/)B7 67+VO@CH:(RGFNS=__6&P/?62+G..1T-7,_%WL'-N+LM1
MT=EIS14$'0HHY%@OW(O:!4^(7*Q%V[K9\.;4=9E9/.:^>B!%=I"NJ6S5_^I:
M^QHFN+JS1!(;IV6UYXLO%%#=_N#&;ZX'2=VO?TV3\[RZVIR^A.EG_$#6^36M
MXIJ"B*5XA@$B>1VT'V"!*&,"K05&1,<9MFX]?%P.AW4-#I;^Z1@FSWT1C7Q0
MRN@ZP-/K#,I$69GEX(SD+J#4TK4>4[(7P</Z)WU"?"LE[CE_B"0P;W/VN2?+
MR681ZTV)D *HP@S$Z!P4+R+3,:486I>:'AZW!_-B>L7M%DKL9 #;7@Q?G]XE
MZ7D1LO:T))%[92$Z(8!'[7-4U@;?NM-3$\*'/3KM$\4[*;6#^/""K[O<4*PQ
MGW\GSV@]MC@ZBFV+-(!&ICH?CX$W]5M6F.+2&FT.@=0?$C;LX=, @'D LFVU
MUP$D;XOLW6R:SN=5'2,732G96G!6DH.#JVOA1@,6KY"\FSILOC$*'Z-EV".F
MX8'71$==M [;SW<)1F>C-9*3[14HRW5MEFZA:*F%3RXPJ7O:PH<]GAH>M\?3
M=@<Y@8_G9V>3E:L4)I>NTIMIF5T<C5P)-*>H,]H(5J9Z_UL4"(S<)YVS0JZ1
M!='Z2O^&I W;S_E@GN8A%-/!QGW97?I]&-?:Z!&S4904ZZU!%FFAH@.?44!A
MOLA@:]:[M==XAX2!Y[4>0LWW.C_L+O,N(%,[]7T*WW!QR8%61284$5ABY$'$
M>EXK+)GWHG/QWJ$WK7,Z]ZD8^ +[48"SE^0[P,ZE9*KW25]>%RY/\P.G8K49
M\V2V.)_CE?@D=]JS8D!H1MMYM@:<=*+VKA A<"<Q'2*JW8?F81O''S3U<C15
M#EQ9]&L8SU=Q^:V*O%JFAWE];61UF6G=!'\DDHY&>0,\F+HF.0?/@@;!C<DH
MF1'J3@>;!ZL]MGKI\%F5XV%A=@S%=&$L5]VF5BW,\GA)\EJ\60?M^9?SY;O9
M\C]PY4.,-).>&5X@9:?)@6 4P!O/(?NH%<NNV-#>*&Y&V_!)EZ/C\J#J:P;+
M?_WYGD;>T@>K'ZU^4O_5!RP_U;__]N'-U?-IV7W&Z>QTG!9_)G=D_?1WM8$#
MSLKRR]5-S]L4+\:GY![]P.H]])2?KRFZ2^O%PVXA9C?J\-N2=(3Y3WNVM)]_
M#M.+D6C7LWHJUJ?Y_0WBK\:EA<G5]GR]*2.JH+21% 0$4\.!6%N[!7"6G$/4
M'E&TGL/8A/"]!P+L0\3UVOU$ROQE4@OF ]-HHDX@/'G$*CLR]UEF8"YQ*UT*
MAK6^Y]":AV&W]>/C^=XX@2$QT:FM_7A^>AKFWV?EX_CS=%S&J78A6;>.I.WL
M/8DHU>++[<WOA@]N89%WX:&1D;Y^S<M5_=BB=G"9SV?SES-2<+I=_:D]9\;1
MKNQ+'0&82R*/,3HH*:Q2,XJWGXF[!7W[5QK_?D/J\]F4ODP7RW>:+]Y_U9AT
M]3MC6F0$I<7UDA)"N:)=@F!BH?4=%'V5+"C#LQ.2D9O=^CRE!=W#FM:#H?!^
M#?*15=RIU;P1!^YB&V_]\Q86\'%Z&MFY2T^7XN)(>^/%IKGJ#73CW==-89W+
MD@L'PBD)*F$"VA(5;=5&<YZT-;9UB?5V%.YKZQYXVT,.@F3"U](V\%+6&N+D
M(.J0@*F0#4-$*5MW$-B,LF'MU0'1=-=B'4!1G=JDJ^S5;Q@J<RNKO(-Q>O@Y
M+:S4!A0V,E=7;[K6]8T-,*5H.'K03&A0SFIP@D((:[+7-O$H1.MK3D_1LZ\I
M>NC9U\"F=<*\XAZ,0 *VT99V>R&@6!8,9J.R:GVT_R1!PQJ>9KBX:V;:*:%3
MZ_*7V2S_/IY,PK3.D"8_K][IOFB?N+V->>II+2S-QM0VLC>7[WMQ_WT/Y(&3
M3X9\W00R% :J% M.:=I[+&UTSJHH96L#M!6!>P_CWN1EUZO#,L-UG7[KK*ES
M+R*#4+?BZ(2)*JWV]R'$T8G-.ARV[DWA/IS>.K5JJX8=VYNOZSX?>]JI^^]O
M9)#J@Q] !QHEI34<I*_]AZS@$!D78.O5,:V-#;IUJY2'*=E[MOJMI][(+1@O
MI-4UF1 =*!_K56M5NRS9[ SGA=O6Z:-'2!G6:#30_[WAY@U$WJD96)WS_Q(6
MF"E,K".^UHW-=DAZ/_R@)DGN#6AL9#S6/2^N0".049"M.63)$OG%)H K2!XR
M%]*P;))BK;MXWJ9@;V-QA=I58<>5\"[:L:XFGW_\0NMJ)=ZK#JY7"*\) &=%
M'3_(20!"(+@D'"15R^^X%[RY@[(GR<,:GSWP<\_H'%%UG1JG#_@5I^=8QUM_
MGHYW-$P//*2%4?H1;8T,TL5K+CJ*K5#UC_'RR\OSQ7)VBO/K]BI1!,>+ :^3
M!Z4B?:42 Y:,QL"<]+)U%X,-2=O_2MR3K[D&O Z1"^5H2X^9U^GEM<.,#I!S
MLB8%5ESSDM9-:1O6*!T"0_<OQ1U 2YV:I1OEXSO8HYO_NH4A>I2:1A;HZOD/
M.=6L-BZT$9+!U?%$( >8]K> *G*9K<?F*=8GR&EV(>,A7Y\Q7X)%VC\CTN+0
MLMY_LQFX2MPR8ITH/3RKG5B45IAX]&+&OAKHU'+4J1FSQ6+-YGN<K_RW70H\
M'WQ.DQ+/'U/8*M0*\^EX^GEQ^9+K;<@9822%YICK#J%"AA!0@(PA\Y""M['U
MR?%CM.QK4>X^]QK,CDDFG<X0;6;DG1=%WKE"2$)XAIXIVH@/S&0GMJ0)#NX:
MDC:"[]2*U!L:X^4JW O3O.ZZ2+^U8[7B4T]K85$VIK:17;GQOA=WWO? ;F4"
M5R+Z #S6:322W-&0O 5NM2XLE9"P]3K<BL"][[YL\K(;JR-&XZ50Y/C7"CEE
M L0Z?4]ZRRMD0K*MAX9O1^' ][,.AJU[EUX.I[=.K=J-"5'?/\W#=!'2KD6&
MCSZJ3>)G$SJ;I7\>?MDUQK1/ C-"0:[J-6@)H10)*;.B+2\"8^N[&3^B:?^$
MS\//?PCW1J .V5 0$)D#Q:0'+VM78:LS\X1<PUH'H%N0-W3:IR%V[N=[#J.D
M3HW31_Q<;?&-1@2[')'=?TB3X[$?T-;(%%V\Y@.>S>:KNY]7 7_QI<[K \MS
MG:?"2+U>:!!)1DY1.:;0O(7.([3LW37HSG,?K/VP6=!V*H$S3NQFXMDC:I %
M5<J!PI+<>H[O!F0-W.VE!3;N=0IJK(Q>3<M&5[@.?AUM@&MI_5Q/\YEQGI0!
MQ@A+M$-I\+0'@K5UOJ-Q%IMG8XYY/>V7L!@O3LH=#7Q?_WGC3J?2M(Q4 5'O
MY]-BE5!G98&(*(0IUN32^@QQ,\J>T16S;9!T[\)&>S5UT'WC;PL\*:\7RS'Y
M)K@8Q6Q3H=@4@M!DL4OPX P/]8(+Q<HQ"R-;+[7;% S;2>-H8-I#[ ,W"5J7
MW?X5)_G7V?QCF.##RX"CC48;)!:X)>%8 2$36T5D)H*40O+P@YUQ\[<-VSOT
MX* YD-@[L#Y/%'9?_FC-X<A++D2I]>*^#CUQU@%96@1Z)AG5E+(,K2]N;DS<
ML&-MCF:S#J.L#E#X$2?TH\]_P2G.0V7O13X=3\=59,OQ5URU-EI<.,0WUAI+
MF4>4!4KR#%2@!1<+L>ICX=8B;?BR=39^-TJ'G4ES-'P>08T=@/6)3@</;PDV
M>N-KW5C&RE\JL@Z.(I$*6WR61&)J#=-M:1QV^,S1 'I0U76:/[G9 .)3H UC
MW[84%P]IW9SB(=J&:5'!,U,<HP8IDR.E*]H\1:BS/'7FAD 65.MF/,=M4?$Q
M?<%\/J$ Z*(\^S\QO\FDP7$9X_JMB]5K"<%$QMMQB./)JG4A_>S\%/-*5S?N
M^3!3LG$1O*FS*Y.K6482&$E-)"=2X:EUS-J8A6?5]&(;?-[;H@=4?0=[]Z6D
M;XB5MH%?Z\'0C?.A&[FDG"Q+5D%,2-&<<@&"HVB.N<B43R8)W7KKWI+$8=,U
M1T3N(577Z=;]8%>4G??PIYYVL!XN!]S5G^[8@<*@C*5V[8D4 )/W%FM@883T
M(1;A0_-R]*-T<EE;Z L)YY,I6?'S^7S=:OC=;#J__':5*[]CJS-S+-8F1LSZ
M6._D*G#:>["%:>>*4+FTKH5I07?/?6&V0-FC?6&.I=(.MM]U8^R587@Y"8O%
MRNGXY?OEC:CS,/FMME >+[^_"DN\PRN6J,G)\)"9(5?#Y00^UTX64DH,AO[7
M?#CW/O0.NS$?#+9'4V$'</WQ$EVOR2O^5#:)/)L,1J^\85L@R!0 4_%1NN P
MMX;HMC0.>U(SH#7=0U6=NH=/M++:V4G\\3,/W(3K@ [C=NV2C Q:)K)0#"L:
MI<W@7:+]E9 3,T,F8^LLT%%;<5UG BY?>Z,BU6KDN9C:.YWB-(6UYZ7)($.D
MF+X6I[K#)73ND?.<FFQM@YK'<S/[::2#G?.:E;LR(S%><7?'.?!2>"_).1"6
M1">BA-5M^Z(X&N.UDJ9U!ZH=R!S6K1L"C(?1X,!%-(^R]^*T5M.N)T%<'%C>
MC;ETJ+,="G"2*$E510A(GD-FTG.6(DH;?[#+[D?!L"[<X2%X1/UT9"IG=;3(
M>(EOQU_QGF1_/:^3A7[,NRR<,<MC'?&IB/=<[_$Z"4E[EF4TV?GF%1$-Z1^V
MCN?XQO7H.N\TDGFX@]W.0<R3CSM<Q[T#ABYW^J8Q[4KTVA/V? !5(E]?T@\V
M.EVR0%9:MYUKVW?OVKQ?MVB[*<J5@$_.UI4?Z\%YW^^:>;+R.11RAJ.N(_.R
M!F<T!_3"A^BSU:)U-GM_JKOJOK<-BAYW#X^BP([VZ9L<7W05?/%[F.?79)AF
MWQ%7G+\_GZ<O]!OO)V%:TU)K%=<3]+/K8I=K47C/(GDL!2(S99V,BC(7$#HR
M+J,66;=N^WU =H8-D0X,\B%4W@'Z;W;;?'C%OYC/:^W>ZF3@E^\/"^S6Q43G
M"F. (9 %**R06D(!EJ/D0M-?H;6CVIB%8:.PAB@?4K6=^J/WFY?N[(L^^JC#
M-%D]H ^Z:9O,H(.*TCHPLC;6+0G)QBD*2IQ&[Z3FF9G&2_M(K58??/8J*7%=
M*7?7RU'6H%&<@519@.)8AU,I!M9(F6.*(L3V#92V)G/H3ASMD76_8=!A==?'
M'AT^?Y[CYXM1M1=BO<,4\22M$1X*9Y&$2/R$.G(QH8LN25U*\_X,&Q$VK-=X
M# BVUT^GV^>#33)WWD&?>MK!6GH>,I?S6$-'(XN*: /(Y.H]*,O %^X@!*.4
M2EYE;+TR#]78\SIRNON&6H:1R.:^&D_.E_?*R54H%/I$ TK7HMT@+3@M19U1
M%%T(2)ZE;"R"'4GMM"GH-AAZ/-P]G-(ZV":OV7PQ78YS96G\%3_6.J'518?7
MW]+DG);Y>B\X/3N_'/W^>--4XX(F2A44AV2SM?+@F5VU,XR>8;0ZMJXV;L_%
MP&F;PR)Z$%5WNCW?;XBV^TG+8X\Z3..V ^[*C[;HLL@-DZ% R+;.B>$&@HP1
M,HNFF,1X5JUK.@_6ONTZGWGG#3=D_,OWBQ_>S-3[4)@1]48V67DTM 0S+<:,
MD=,B#$:;PYFWK4CMM,W;-AAZ(@E],*5U:JC>U4IRG)7E%[R\_?4NS-?-!%[A
M,HPG.\43&SRU25RQ+?6-+-G)_'.87E0,4"R[F$W&^?)FWOL;S)S4XH,P3>,P
M^4B?K-.[UYT)E>36B7ISKL@Z+;26'O((J<ABT/.0>.LI TT(WZ<H[/UL\IV"
M_;# EU_">/H!UTU;/^&B+K?7W\;+U52QER=_?_.*^Y'(G!:U\9"2H!46A0(7
M-0<IE4@I,Y>8_P$6MW_KL!;N^-BZ611V0/T,7([X-&?_(&^5['^YXDPGG5WR
M"+Z.(J^W9B&:;(&[;+R2),N[2>4=D'?WK</&!STC;R_]=(V\'[7RN6*80C3/
MR;>Q67I0)@1PW 7(5H5D'5.FY+T!N2$QPQ[,]HS30VASZ#KNV4J"ZXC^^Z?P
M[:(F8_YJ14N8O'SQX?7'%R12E:-13D9@M0&R<HR#"]% =+QHIH(S16\ T8U?
M.&PMZ[ P/(Q6.HU2-FOFO'N\LMWSC]>>^I QS%8=P8K5P8O H:3$":4U&\?I
MVZB2$49E:^_ZX<^B._55T]$;/4<__I]S6OZ_(BYIX8:T.K0^^7V*F192X)X,
M-VB1,X7[F5P.9S(P6K 8D^/>IPW,V\8O?$8]I[?!Q[V.K\V%W\$)R+U6MN]F
MRSJIY*2\&B_.9HLP^<M\=G[V\GQ>=3%2W*F<?0%6IY(H[9!V 2<!G6"6(;,H
MFG=_WXK"9]2R>A<L'D%M'8#R_7R6$/.BGL54YDX*?7*&\^7W&QR/K L*@[+
M@B9_01>*L6*L?WC&3*( 2[9.16]$V#-J@+T/!-LKJ0/D_84BI5H!<C*]S5*M
MY%[60MNSZA6/O.-!V,3(&>;$E1%DY$M)@%SJJ%3F4C1O@+T19<^H^_4^V#N
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M%U7-FLIMZ.8C7\+\--RAWP?.([,&I*VQJ<YD,3VM@21=U%E9=.E'=PT>>_;
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M?X7Q[SG=.YNSI$ I&P;<>K(<AA:<*P:\%<G8R$S UGA[@IQQ=\=V@[I6"NL
M>Z]G\Z^S.2Y7WN<]9H*)6EF*4+B5')3+""[$7-G2BD>6F&Z]S^I)@L9=[=H-
M_MHIK0,$MLB"WCQB)I08C>80%0_D:60-CM6&HI +,\()45J''$T9&#<:[B0C
M/1HB.C"'GW)8WICTR3><G%6!_C*;?\2S_,/KZ\]_K#=MG<0XOUA--EZMVGJ5
MRVR>3\[.9O^DTZ?^IZ^)C\FROK]?S36K*\Z9+@Z,ITA/9>=(/UZ E%%XGYE/
M+C:VD\-P=OQ/.CM"=]8]CCKH%;XKASM2BO'B_.*LCK?X=4Y,_H4T@V=53+_2
ME7TICD_XQVDH-K&4!=3$":ATF<<-D#0%LB8$[5-SI[P%X<=_N;2QC<.CH(.+
M95>FJ[7?8EIDF9VR$.LD#)5UW41G)3#FC*/0)UG3NO"F">'C9H"/'_J[HV#\
M04.;78F/W8)7-QUB]CG339>1:>*9"<!(@;TI,6IAI4*C#NHQ/4/PN*GH?A!_
M.*UW<,@_X_7]R.-)H7\_[-Z=LI*-,9DD'F*L/>@!G!<(7NF(QGLLNO4\]U:T
MCYL:/Q;@#X2%8RK9OO[#\/WU;+HJ]+S L]]Q647VO7'E]F9?-E@!]PZ\'J*.
M.S&62':*4.T(6HD1JK1!B,FQF IAO7F/]''4<9O '3*6(=E$P862%I"N&C#:
M2A]*%-FV[F'Y,]1Q;X.WX>JXMU%N!T[%8P6=+$1C7$((22E0+.HZ$)'$RJ/F
M=%?)]FF0%U['O14P-JSCWD9+'8"MZ2-;X<5'GA1(5TKEG8,7EOZ12O(Z<N==
MZ]>@EU_'O16@AJSCWD:['2#[B<)@[X5)WC)P2I*;SSE%F2(ST,R@-<9FBC/_
M7<<],$(VK^/>1EW=U7$GP6,N)@ OM>W;:0.NJ SH4*:4?=#^N0#GI==Q[P*;
M_87=P1'U2(&P88+IR#A8G34HS0-XF1,4G9RF/Y,>_UW'?<"CJ8&:.@#;@T7"
MA2-&8A^"\'2T)E4 ;8ZU2LK9$%3FL3747G@=]SY VUM%'<#LX1)A[Z3D3-3]
M,J[F];VO;8D(F1>ZOCWC9$G_KN,^&-#V5U('2'NJ+-@G4[QUF4+Y*"_+/5&B
M@,2=T(A!B^8K>_X<==Q[W:.-%-8!]IXN"=:"%R>0@?&)W%!17S$9.O)%8XR<
MG-'L6@^+_+/4<>]WZK526@<(;/OP64<QJE R!"/K>#V*KC$;"UK[P&-RR%/K
MSH-_UW&WSDB/AH@.S.'N>_N->==W^?7#*_WN;Y/EE\GTW33_5\;YM<1.R;P9
M#Y9!X"6!,DX W481G&6VNCTIQ=;^Z7X4'_\3S(Y0>Z; ;D"]'Q'*5^4EQ.RG
M+_/9Q><OOTR^K?B^*4LX%3P5'JT':Q4Q+M% "#("CYFI9!E+K+F#W(KXXS_L
M#XO]MF@X-C.H[*XY_Y2G=QAG2CC.I -CZF"8P"2@)OL7QCF;F.<EB#'-X"GB
M7U*-]<',H!D:.C"#_4IM,WF:%%USR#HP4%X%N@3IMQX=CTRS(LJ_"ZP[A/OA
MM-[ILJL'"RXOU7*EB-F-(E:2;UQ<NMF7#59<N@.OAR@N9=P6RY&#0!]!:2'
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M;SWH>C/*NDTDMX)?<_4TFVP]R%5[$N/%^<7J]>7D?#9?3OZU4N:IKNM"E#+
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M(,82C\1 K6VH7C/]!H+F%I(+P@9G?6P^"F%CXL;M+1L!AGMI9^22QRL/^7K
M3ZB<K5H:+O#L]>SBZVQZ]3.G3!'UAB6PI;[ZV&S!U[D-NO@@O&+1^SO;>QXL
M=MSF.\?M%&L/ID%EWA^63F*<Y\OA85=],ZNHW[+HI%824O!D(4P&< $U1,^U
M4]SX*-QN2'KD&S?"D3MZ'+60=X<H^F$*W>H<7BPN<!ISG>=:!<B-E13).\W(
M1B+3X")YHUIES[D,.7*V(YJ>_N:-4.6/'U4-Y=^=FW4[1_33Q9Q\Q\M"A-.Z
MFADIE 'R%1UQY1-@80)DU&ACEBAEZ]&FFU&V68Z8'0_L!E1,=W"[?IX[S4%[
M;:6$O.KD0A<!3:U!#:I8ID/$YBVUCY"R&:!>P*O#+J)OAJ"VC?>KM. K7&0*
M?L_K2;WZP+<XOYP\O7M/_H8?W*)=?Q<>&G7R__R/"T+9=?<VEIB=\G2&Y#J^
MUO(,KC %0M7-@CZ4S%H7-_](0;O=.Q^_D-'=$^H)R73Z^;+LX-7WFY]YC]]7
MK:7_Q'FZ?"X6LEC/;2(OT=3:@Y@!,]E&D62'K B7#&LLBF;$C_MZN@>F'E_-
M<TAU=G!97E)^U<R#1JC@F(&<9!VJ8"Q@S @V,%2"_HZ%UA5$/Q#0RW:>@X+@
M[@CPG372 9QV%]P-V]/T_@RGMWI<HU.*D><!A97Z^$%R#3QZR$99[6RTVC<_
M(0?@8UQP[P&KNV?EV#KN .<?*$Z:3^I,LY5/==5Z7W0TM:,MR;I?M!0%7NH
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M,):DHRQRM!0!LW[&@NW$8><W0F/\MC*?X<'TYS"U]7A"$RE$1SKS&,8"RJ
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M9I.KZI&/[Q(4NRAOUE:2'9PN3QS'-VGTA'7 .!/@L0X;]RJ0$04/'*4+1OK
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M%@  83$P+3%R971E;G1I;VYA9W)E96UE;G1C:6XN:'1M4$L! A0#%     @
M5X5H5?LM5L3="   )30  !X              ( !D"0  &$Q,"TR86UE;F1E
M9&5M<&QO>6UE;G1A9W)E+FAT;5!+ 0(4 Q0    ( %>%:%5[2-O@7Z(" /#<
M(0 0              "  :DM  !N96\M,C R,C Y,S N:'1M4$L! A0#%
M  @ 5X5H57PUG'LV#P  V)T  !               ( !-M " &YE;RTR,#(R
M,#DS,"YX<V102P$"% ,4    " !7A6A5B61 CQ@E  !*>@$ %
M    @ &:WP( ;F5O+3(P,C(P.3,P7V-A;"YX;6Q02P$"% ,4    " !7A6A5
M)(K2V4Y@   M.P0 %               @ 'D! , ;F5O+3(P,C(P.3,P7V1E
M9BYX;6Q02P$"% ,4    " !7A6A5JCP9"J_K  #]T0D %
M@ %D90, ;F5O+3(P,C(P.3,P7VQA8BYX;6Q02P$"% ,4    " !7A6A5_D@=
MB7F4  "5OP8 %               @ %%400 ;F5O+3(P,C(P.3,P7W!R92YX
8;6Q02P4&      L "P#H @  \.4$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
